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Preamble 
This appendix provides further methodological detail and more detailed results for “Global, regional, 
and national comparative risk assessment of 84 behavioural, environmental and occupational, and 
metabolic risks or clusters of risks, 1990-2017: a systematic analysis for the Global Burden of Disease 
Study 2017.” This study complies with the Guidelines for Accurate and Transparent Health Estimates 
Reporting (GATHER) recommendations. It includes detailed tables and information on data in an effort 
to maximise transparency in our estimation processes and provide a comprehensive description of 
analytical steps. We intend this appendix to be a living document, to be updated with each iteration of 
the Global Burden of Disease Study. 
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Section 1: GBD overview 
Section 1.1: Locations of the Analysis 
The locations included in Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017) 
have been arranged into a set of hierarchical categories composed of seven super-regions and a further 
nested set of 21 regions containing 195 countries and territories. The locations for which GBD estimated 
global, regional, and national risk exposure, relative risk, theoretical minimum-risk exposure level 
(TMREL), and population attributable fractions (PAFs), have not expanded following GBD 2015. 
Subnational estimation in GBD 2017 includes Brazil, China, India, Indonesia, Japan, Kenya, Mexico, South 
Africa, Sweden, the United Kingdom, and the United States, and new subnational assessments at the 
administrative one level for Ethiopia, Iran, Norway, and Russia and by Maori ethnicity for New Zealand. 
For this publication, we present subnational estimates in figures only for all subnational countries with 
the exception of the new assessments, which will be reported in separate publications. Select 
subnational estimates are also included in supplementary results appendix. Combined, there are a total 
of 390 locations at the first subnational unit level. Included in subnational Level 1 locations are countries 
that have been subdivided into the first subnational level, such as states or provinces, for the GBD 
analysis; subnational Level 2 only applies to India, England, and Russia. For this paper, we present data 
at the national and territory level. 
Section 1.2: Time Period of the Analysis 
A complete set of risk-specific exposure, relative risk, TMREL, and PAFs were computed for the years 
1990-2017. All GBD 2017 results and online data visualisations are available at 
http://vizhub.healthdata.org/gbd-compare with access to results for all GBD metrics. 
Section 1.3: Statement of GATHER Compliance 
This study complies with the Guidelines for Accurate and Transparent Health Estimates Reporting 
(GATHER) recommendations. We have documented the steps involved in our analytical procedures and 
detailed the data sources used. See Appendix Table 1 for the GATHER checklist. 
The GATHER recommendations may be found here: http://gather-statement.org/ 
Section 1.4: GBD risk factor hierarchy 
In this analysis, we focus on three groups of risk factors: behavioural, environmental and occupational, 
and metabolic. The GBD 2017 risk factors hierarchy and Levels are summarised in Appendix Table 2.  
The GBD risk list continues to evolve to reflect the policy relevance, public health, and medical care 
importance of major risk factors. The risk factors list expanded following feedback from GBD 2013 and 
input from GBD 2015 collaborators. Three risks were added to the list for GBD 2017. 
Section 1.5: List of abbreviations 
APCSC: Asia-Pacific Cohort Studies Collaboration 
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BMI: body-mass index 
BMD: bone mineral density 
CKD: chronic kidney disease 
COD: causes of death 
CODEm: cause of death ensemble modelling 
COPD: chronic obstructive pulmonary disease 
CSA: childhood sexual abuse 
CSMR: cause-specific mortality rate 
CRA: comparative risk assessment 
CVD: cardiovascular disease 
DALY: disability-adjusted life-year 
DHS: Demographic and Health Survey 
DRI: data representativeness index 
EMR: excess mortality rate 
FAO: Food and Agriculture Organization 
FPG: fasting plasma glucose 
GATHER: Guidelines for Accurate and Transparent Health Estimates Reporting 
GBD: Global Burden of Disease 
GoF: goodness of fit 
ID: Iron deficiency 
IDA: Iron deficiency anaemia 
IER: integrated exposure response 
IHD: ischemic heart disease 
ILO: International Labour Organization 
IPV: intimate partner violence 
JMP: Joint Monitoring Project 
LDI: lag distributed income per capita 
LMIC: Low and Middle-Income Countries 
LRI: lower respiratory infection 
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MCMC: Markov Chain Monte Carlo simulations 
MDG: Millennium Development Goal 
MICS: Multiple Indicator Cluster Surveys 
MoM: method of moments 
NCD: non-communicable disease 
OER: observed-to-expected ratio 
PAF: population attributable fraction 
PDF: probability density function 
PM2.5: particulate matter <2.5 µm in diameter 
PSC: Prospective Cohort Study 
RCT: randomised controlled trial 
REDCap : Research Electronic Data Capture 
RMSE: root mean square error 
RR: relative risk 
SBP: systolic blood pressure 
SD: standard deviation 
SDG: sustainable development goal 
SDI: Socio-demographic Index 
SEER: Surveillance, Epidemiology, and End Results Program 
SEV: summary exposure value 
SIR: smoking impact ratio 
SSB: sugar-sweetened beverages 
ST-GPR: spatiotemporal Gaussian process regression 
TB: tuberculosis 
TMREL: theoretical minimum-risk exposure level 
TSNA: tobacco-specific nitrosamines 
UI: uncertainty interval 
WCRF: World Cancer Research Fund 
WHO: World Health Organization 
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YLD: years lived with disability 
YLL: years of life lost 
Section 1.6: GBD results overview 
Results from the Global Burden of Disease Study (GBD 2017) are now measured in terabytes. Results are 
available in an interactive data downloading tool on the Global Health Data exchange (GHDx). Data and 
underlying code used for this analysis will be made publicly available pending manuscript acceptance. 
The current version of the data download tool is available in the GHDx and contains core summary 
results for the GBD 2017: http://ghdx.healthdata.org/gbd-results-tool. The core summary results include 
deaths, YLLs, years lived with disability (YLDs), and disability-adjusted life-years (DALYs). The GHDx 
includes data for causes, risks, cause-risk attribution, aetiologies, and impairments. 
In the GBD 2017 version, the GHDx tool also contains measures such as prevalence and incidence as well 
as rate of change data. Data above a certain size cannot be viewed online but can be downloaded. 
Depending on the size of the download, users may need to enter an email address; a download location 
will be sent to them when the files are prepared. 
Section 1.7: Data input sources overview 
GBD 2017 incorporated a large number and wide variety of input sources to estimate mortality, causes 
of death and illness, and risk factors for 195 countries and territories from 1990-2017. These input 
sources are accessible through an interactive citation tool available in the GHDx. 
Users can retrieve citations for a specific GBD component, cause or risk, and location by choosing from 
the available selection boxes. They can then view and access GHDx records for input sources and export 
a CSV file that includes the GHDx metadata, citations, and information about where the data were used 
in GBD. Additional metadata for each input source are available through the citation tool, as required by 
the GATHER statement. 
The citation tool is accessible through the GHDx at http://ghdx.healthdata.org/gbd-2016/data-input-
sources. 
Section 1.8: Funding Sources 
Research reported in this publication was supported by the Bill & Melinda Gates Foundation, the 
National Institute on Aging of the National Institutes of Health (award P30AG047845), and the National 
Institute of Mental Health of the National Institutes of Health (award R01MH110163). The content is 
solely the responsibility of the authors and does not necessarily represent the official views of the Bill & 
Melinda Gates Foundation or the National Institutes of Health. 
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Section 2: Risk factor estimation 
Section 2.1: Overview 
The comparative risk assessment (CRA) conceptual framework was developed by Murray and Lopez,1 
who established a causal web of hierarchically organised risks or causes that contribute to health 
outcomes, which allows for quantification of risks or causes at any Level in the framework. In GBD 2017, 
as in previous iterations of the GBD study, we evaluated a set of behavioural, environmental and 
occupational, and metabolic risks, where risk-outcome pairs were included based on evidence rules (see 
Section 2.2.1). These risks were organised in four hierarchical Levels, where Level 1 represents the 
overarching categories (behavioural, environmental and occupational, and metabolic) nested within 
Level 1 risks; Level 2 contains both single risks and risk clusters (such as child and maternal 
malnutrition); Level 3 contains the disaggregated single risks from within Level 2 risk clusters (such as 
low birthweight and short gestation); and Level 4 details risks with the most granular disaggregation, 
such as for specific occupational carcinogens, the subcomponents of child growth failure (stunting, 
wasting, underweight), and suboptimal breastfeeding (discontinued and non-exclusive breastfeeding). 
At each level of risk, we evaluated whether risk combinations were additive, multiplicative, or shared 
common pathways for intervention. This approach allows the quantification of the proportion of risk-
attributable burden shared with another risk or combination of risks and the measurement of potential 
overlaps between behavioural, environmental and occupational, and metabolic risks.  To date in the 
GBD we have not quantified the contribution of other classes of risk factors illustrated in Appendix Table 
3. We do provide some insights into the potential magnitude of distal social, cultural, and economic
factors through an analysis of the relationship between risk exposures and development measured using
the Socio-demographic Index (SDI) (see Appendix Section 2.9).
Two types of risk assessments are possible within the CRA framework: attributable burden and 
avoidable burden. Attributable burden is the reduction in current disease burden that would have been 
possible if past population exposure had shifted to an alternative or counterfactual distribution of risk 
exposure. Avoidable burden is the potential reduction in future disease burden that could be achieved 
by changing the current distribution of exposure to a counterfactual distribution of exposure. Murray 
and Lopez identified four types of counterfactual exposure distributions: (1) theoretical minimum risk; 
(2) plausible minimum risk; (3) feasible minimum risk; and (4) cost-effective minimum risk.2 The
theoretical minimum risk level (TMREL) is the level of risk exposure that minimises risk at the population
level, or the level of risk that captures the maximum attributable burden. Other possible forms of risk
quantification include plausible minimum risk – which reflects the distribution of risk that is conceivably
possible and would minimise population-level risk if achieved – while feasible minimum risk describes
the lowest risk distribution that has been attained within a population, and the cost-effective minimum
risk is the lowest risk distribution for a population that can be attained in a cost-effective manner.
Because no robust set of forecasts for all components of GBD is available, in this study we focus on
quantifying attributable burden using the theoretical minimum risk counterfactual distribution.
Appendix Table 3 shows the eight possible types of risk quantification within the CRA framework, with
the hatched box representing the type of CRA currently undertaken by the GBD study. As per the
definition of avoidable burden, risk reversibility would be incorporated into this type of assessment, as it
would involve reducing risk to the counterfactual for the index year, given a history of past risk
exposure. Given the focus in this study on attributable burden, risk reversibility is not a criteria used in
estimation here.
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In general, this analysis follows the CRA methods used since GBD 2015.3 The methods described here 
provide a high-level overview of the analytical logic with a focus on areas of notable change from the 
methods employed in GBD 2015. Here we aim to provide sufficient detail on the methodology and 
overall structure of the estimation process. This study complies with the GATHER recommendations 
proposed by the World Health Organization (WHO) and others, which include recommendations on 
documentation of data sources, estimation methods, and statistical analysis (Appendix Table 1).4 
Section 2.2: Step 1. Effect size estimation 
Section 2.2.1: Collate relative risk data 
Criteria for inclusion of risk-outcome pairs 
In this study, as in GBD 2016, we have included risk-outcome pairs that we have assessed as meeting the 
World Cancer Research Fund (WCRF) grades of convincing or probable evidence.5 In this framework, 
convincing evidence consists of biologically plausible associations between exposure and disease 
established from multiple epidemiological studies in different populations. Evidentiary studies must be 
substantial, include prospective observational studies, and where relevant, randomised controlled trials 
(RCTs) of sufficient size, duration, and quality, and showing consistent effects. Probable evidence is 
similarly based on epidemiological studies with consistent associations between exposure and disease, 
but for which shortcomings in the evidence exist, such as insufficient trials (or prospective observational 
studies) available.  
The World Cancer Research Fund grading system 
Convincing evidence 
Evidence based on epidemiological studies showing consistent associations between exposure and 
disease, with little or no evidence to the contrary. The available evidence is based on a substantial 
number of studies including prospective observational studies and where relevant, randomised 
controlled trials of sufficient size, duration, and quality showing consistent effects. The association 
should be biologically plausible.  
Probable evidence  
Evidence based on epidemiological studies showing fairly consistent associations between exposure and 
disease, but for which there are perceived shortcomings in the available evidence or some evidence to 
the contrary, which precludes a more definite judgment. Shortcomings in the evidence may be any of 
the following: insufficient duration of trials (or studies); insufficient trials (or studies) available; 
inadequate sample sizes; or incomplete follow-up. Laboratory evidence is usually supportive. The 
association should be biologically plausible.  
Possible evidence  
Evidence based mainly on findings from case-control and cross-sectional studies. Insufficient 
randomised controlled trials, observational studies, or non-randomised controlled trials are available. 
Evidence based on non-epidemiological studies, such as clinical and laboratory investigations, is 
supportive. More trials are needed to support the tentative associations, which should be biologically 
plausible.  
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Insufficient evidence  
Evidence based on findings of a few studies which are suggestive, but insufficient to establish an 
association between exposure and disease. Little or no evidence is available from randomised controlled 
trials. More well designed research is needed to support the tentative association. 
Causal criteria 
As in GBD 2015 and 2016, to be more objective, consistent, and transparent in our evaluation of the 
causal relationship, we summarized epidemiologic evidence supporting causality for each risk-outcome 
pair (Appendix Table 4 and Appendix Table 5). For each pair, we collected data on the following 
domains:      
Domains Description 
RCTs of disease endpoint Number of independent RCTs evaluating the effect of the risk on the disease 
endpoint 
Percent of independent RCTs showing significant effect in the opposite direction  
Percent of independent RCTs showing no effect   
Prospective observational 
studies of disease 
endpoint 
Number of independent prospective observational studies evaluating the 
association of the risk with the disease endpoint 
 
Percent of independent prospective observational studies with significant 
association in the opposite direction  
Strength Lower Limit of relative risk (RR) in observational studies> 1.5 (Yes/No) 
Dose response Evidence of the dose-response relationship between the risk and the outcome 
(Yes/No) 
Biologic plausibility Potential biologic mechanism that could explain the effect of the risk on the 
disease endpoint (Yes/No) 
Analogy Evidence on the relationship between the risk factor and a disease endpoint from 
the same category (Yes/No) 
For risk-outcome pairs with less than five prospective studies, we summarized evidence from case-
control studies as well including (a) the number of independent case-control studies evaluating the 
association of the risk with the disease endpoint and (b) percent of independent case control studies 
with significant association in the opposite direction.       
Section 2.2.2: Determine relative risks 
Effect size estimation  
The relative risk by level of exposure, or by cause, for mortality or morbidity can be found in published 
and unpublished primary studies or in secondary studies that summarize relative risks. In Step 1a of the 
analytical process (Appendix Figure 1), we collated information from randomised controlled trials, 
cohort, pooled cohort, and case-control studies, and in Step 1b, used these data to determine the 
relative risk for the risk-outcome pairs included in GBD 2017 (Appendix Table 6). For most risks, data 
from pooled cohorts, or meta-analyses of cohorts, were used; in the case of the risk of cataracts from 
household air pollution, cohort data were not available, and instead we used case-control data. We 
estimated relative risks of mortality and morbidity for 65 risk factors for which we determined 
attributable burden using relative risk and exposure. We incorporated relative risks from studies that 
controlled for confounding but not for factors along the causal pathway between exposure and 
22
outcome. For risk-outcome pairs with evidence available for only one of mortality or morbidity, we 
generally assumed that the estimated relative risks applied equally to both. Given evidence of 
statistically different relative risks for mortality and morbidity, we incorporated different relative risks 
for each. We did not find that relative risks were consistently higher or lower for mortality compared 
with morbidity. Details and citation information for the data sources used for relative risks are provided 
in searchable form through a new web-tool (http://ghdx.healthdata.org/). Available data sources for 
determining relative risks varied across risks. Details on how relative risks were calculated for each risk 
can be found in Appendix Section 4: Risk-specific estimates.  
For all outcomes related to unsafe sex, the relative risk and exposure framework was not used to 
estimate attributable burden. For unsafe sex and HIV, we used a direct attribution approach to address 
the lack of data on unsafe sexual practices in most populations. The proportion of HIV attributable to 
unsafe sex was modelled directly using DisMod-MR 2.1 from data on the fraction of cases identified as 
being through sexual transmission, intravenous drug use, or blood transfusion.  
For risks estimated from a continuous exposure distribution where the effect size was reported by 
categories in pooled or meta-analysis studies, we converted those categories to relative risk per unit 
increase in exposure. This implies a linear increase in the log of the relative risk and exposure; various 
studies have suggested this is a reasonable approximation of the dose-response curve for many risks. An 
example of this is high systolic blood pressure, where data from the Prospective Cohort Study (PSC) and 
the Asia-Pacific Cohort Studies Collaboration (APCSC) were well-described by a linear increase in the 
logarithm of the relative risk by a 10-unit increase in high systolic blood pressure. This approximately 
log-linear relationship suggests that the proportional difference in the age-specific risk of stroke death 
associated with a given absolute difference in exposure is about the same at all levels of risk. Many 
meta-analyses convert relative risks to per unit increase for convenience, particularly when studies 
choose different categories that could not otherwise be compared. The log-linear approximation 
appears plausible6 even where there is limited consensus on the appropriate TMREL. Where there were 
insufficient samples in the primary studies at high levels of exposure to inform the shape of the tail of 
the distribution, we applied a cap to the maximum relative risk using the midpoint of the last category 
for which a relative risk was reported.  
Section 2.3: Step 2. Exposure estimation 
Section 2.3.1: Collate exposure data 
Systematic reviews 
For GBD 2017, we conducted systematic literature reviews for 23 risks. For other risk factors, only a 
small fraction of the existing data appears in the published literature and other sources predominate 
such as survey data and satellite data. Data were systematically screened from household surveys 
archived in the Global Health Data Exchange (ghdx.healthdata.org), including Demographic and Health 
Surveys, Multiple Indicator Cluster Surveys, Living Standards Measurement Surveys, and Reproductive 
Health Surveys. Other national health surveys were identified based on survey series that had yielded 
usable data for past rounds of GBD, sources suggested to us by in-country collaborators, and surveys 
identified in major multinational survey data catalogues, such as the International Household Survey 
Network and the WHO Central Data Catalog, as well as through country Ministry of Health and Central 
Statistical Office websites.  Citations for all data sources used for risk factor estimation in GBD 2017 are 
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provided in searchable form through a web-tool (http://ghdx.healthdata.org/). A description of the 
search terms employed for risk-specific systematic reviews are detailed by cause in Appendix Section 4. 
Information on systematic reviews were managed using Research Electronic Data Capture (REDCap) 
electronic data capture tools hosted at the University of Washington.7 REDCap is a secure, web-based 
application designed to support data capture for research studies, providing 1) an intuitive interface for 
validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated 
export procedures for seamless data downloads to common statistical packages; and 4) procedures for 
importing data from external sources 
Search terms 
Search terms for updates of systematic reviews for GBD 2017 are shown by risk in Appendix Section 4. 
Survey data preparation 
For GBD 2017, survey data constitutes a substantial part of the underlying data used in the estimation 
process. During extraction, we concentrate on demographic variables (such as location, gender, age), 
survey design variables (such as sampling strategy and sampling weights), and the variables used to 
define the population estimate (such a prevalence or a proportion) and a measure of uncertainty 
(standard error, confidence interval or sample size and number of cases).  
Section 2.3.2: 2b. Adjust exposure data 
A number of adjustments were applied to extracted exposure sources in order to make the data more 
consistent and suitable for modelling. Commonly applied adjustments included age-sex splitting, adding 
study-level covariates, and bias correction. Age-sex splitting was applied to literature data reported by 
age or sex but not by age and sex assuring that the total number of cases remained as reported. If a 
source did not report sample size by age or sex, we applied the age-sex distribution of the population for 
the same location and year to the reported total sample size. We relied on the metaregression 
component of DisMod-MR 2.1 for most of the bias correction of data for variations in study attributes 
such as case definitions and measurement method. DisMod-MR 2.1 calculates a single adjustment that 
is applied regardless of age, sex, or location. If enough data were available to differentiate these 
adjustments by age, sex, or location, or if detailed survey data were available to make more precise 
adjustments between different thresholds on a biochemical measure, we applied bias corrections to the 
data before entry into DisMod-MR 2.1.  
Section 2.3.3: 2c. Estimate exposure 
Mean exposure estimation 
In Step 2a of the estimation process, we used systematic literature reviews to identify risk factor 
exposure studies published or identified since GBD 2016 and combined these with existing data from 
household and health examination surveys, census, morbidity, or satellite imagery and ground sensor 
data (used for estimation of PM2.5 [particulate matter <2.5 µm in diameter]). Certain risks, such as diet 
and alcohol consumption, also incorporated administrative record systems. Data sources used in 
estimating risk factor exposure can be accessed through the data source tool at 
http://ghdx.healthdata.org/. 
Once data were collected and compiled, step 2b of the analytical flowchart describes the adjustments 
applied, where necessary, to correct for bias. Examples of these adjustments include: use of urban 
studies for lead; crosswalks between different measurements, methods, and definitions, such as for self-
24
report of obesity and glycated haemoglobin (HbA1C) for diabetes; and age-sex splitting of data, such as 
for fasting plasma glucose, cholesterol, and systolic blood pressure that may be reported from broad 
age-groups.  
For the GBD, we developed two modelling approaches, a Bayesian meta-regression model (DisMod-MR 
2.1) and a spatiotemporal Gaussian process regression model (ST-GPR), to pool data from different 
sources, control and adjust for bias in data, and incorporate other types of information such as country-
level covariates. DisMod-MR 2.1 and ST-GPR are mixed effect models that borrow information across 
age, time, and locations to synthesise multiple data sources into unified estimates of levels and trends. A 
detailed description of the likelihood used for estimation, and a full description of improvements made 
for DisMod-MR 2.1, are detailed by Vos and colleagues8 with additional detail in the appendix to that 
paper. The ST-GPR model has three main hyper-parameters that control for smoothing across time, age, 
and location. Values for these hyper-parameters were selected based on cross-validation. Cross-
validation tests were conducted for different combinations of the hyper-parameters for three types of 
models: one data-sparse model, one data-moderate model, and one data-dense model. In each test, 
20% of the data were held out and the performance of each combination of hyper-parameters 
evaluated on the held out data. For each hyper-parameter combination, 10 cross-validation tests were 
conducted. The performance of each model in predicting the withheld 20% of the data was evaluated 
using a combined measure based on root mean square error (RMSE) and uncertainty interval coverage. 
A detailed description of the ST-GPR process regression can be found below in Appendix Section 2.3.3. 
The main difference between these methods is their power to include unstructured types of data by sex 
and age group and in their degree of flexibility. Step 2c in Appendix Figure 1 outlines the use of DisMod-
MR 2.1 for 10 risk factors where data were available by different age intervals or mixed sex groups; 
DisMod-MR 2.1 is the preferred tool in these cases because of its ability to integrate over age and adjust 
for different exposure definitions in the data; however, the use of Bayesian Markov Chain Monte Carlo 
(MCMC) simulations with large volumes of data renders the analysis computationally intensive and
reduces the number of iterations that are possible. If large volumes of standard age-group data are
available – as is generally the case for metabolic risks – using ST-GPR becomes the preferred approach.
In some cases, we adapted our methods of modelling exposure to risks where necessary to account for 
complexities in the risk-outcome relationship or the need for particular handling of data, for example, 
dietary risks and ambient air pollution (see Appendix Section 4 for more detail). A complete list of risks 
and the analytical method used is reported in Appendix Table 2. Additional details for adjustments or 
adaptations to particular risk models are located in Appendix Section 4. 
DisMod-MR 2.1 Estimation 
DisMod-MR 2.1 description 
Until GBD 2010, nonfatal estimates in burden of disease assessments were based on a single data source 
on prevalence, incidence, remission or a mortality risk selected by the researcher as most relevant to a 
particular location and time. For GBD 2010, we set a more ambitious goal: to evaluate all available 
information on a disease that passes a minimum quality standard. That required a different analytical 
tool that would be able to pool disparate information presented in varying age groupings and from data 
sources using different methods. The DisMod-MR 1.0 tool used in GBD 2010 evaluated and pooled all 
available data, adjusted data for systematic bias associated with methods that varied from the reference 
and produced estimates by world regions with uncertainty intervals using Bayesian statistical methods. 
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For GBD 2013, the improved DisMod-MR 2.0 had increased computational speed allowing computations 
that were consistent between all disease parameters at the country rather than region Level. The 
hundred-fold increase in speed of DisMod-MR 2.0 was partly due to a more efficient rewrite of the code 
in C++ but also by changing to a model specification using log rates rather than a negative binomial 
model used in DisMod-MR 1.0. In cross-validation tests, the log rates specification worked as well or 
better than the negative binomial specification.9 For GBD 2015, we rewrote the ‘wrapper’ code that 
organizes the flow of data and settings at each level of the analytical cascade. The sequence of 
estimation occurs at five Levels: global, super-region, region, country and, where applicable, subnational 
location. The super-region priors are generated at the global Level with mixed-effects, nonlinear 
regression using all available data; the super-region fit, in turn, informs the region fit, and so on down 
the cascade. The wrapper gives analysts the choice to branch the cascade in terms of time and sex at 
different levels depending on data density. The default used in most models is to branch by sex after the 
global fit but to retain all years of data until the lowest Level in the cascade. Appendix Figure 2 
summarizes the DisMod-MR process. 
In updating the ‘wrapper,’ we consolidated the code base into a single language, Python, to make the 
code more transparent and efficient and to better deal with subnational estimation. The computational 
engine is limited to three levels of random effects; we differentiate estimates at the super-region, region 
and country Level. In GBD 2013, the subnational units of China, the UK and Mexico were treated as 
‘countries’ such that a random effect was estimated for every location with contributing data. However, 
the lack of a hierarchy between country and subnational units meant that the fit to country data 
contributed as much to the estimation of a subnational unit as the fits for all other countries in the 
region. We found inconsistency between the country fit and the aggregation of subnational estimates 
when the country’s epidemiology varied from the average of the region. Adding an additional level of 
random effects required a prohibitively comprehensive rewrite of the underlying DisMod-MR engine. 
Instead, we added a fifth layer to the cascade, with subnational estimation informed by the country fit 
and country covariates, plus an adjustment based on the average of the residuals between the 
subnational location’s available data and its prior. This mimicked the impact of a random effect on 
estimates between subnationals.  
In GBD 2015, we also improved how country covariates differentiate nonfatal estimates for diseases 
with sparse data. The coefficients for country covariates are re-estimated at each Level of the cascade. 
For a given location, country coefficients are calculated using both data and prior information available 
for that location. In the absence of data, the coefficient of its parent location is used, in order to utilize 
the predictive power of our covariates in data sparse situations.  
For GBD 2016, the computational engine (DisMod-MR 2.1) remained substantively unchanged from GBD 
2015. We changed the prediction year set to generate fits for the years 1990, 1995, 2000, 2005, 2010, 
and 2016. We updated the age prediction sets to include age groups 80-84, 85-89, 90-94, and 95+, to 
comply with changes across all functional areas of the GBD. We also expanded the set of locations 
where subnational units are modelled; the set now includes: Brazil, China, England, India, Indonesia, 
Japan, Kenya, Mexico, Saudi Arabia, South Africa, Sweden, and the United States. 
In GBD 2017, we continued to use DisMod-MR 2.1, as there were no substantial changes. Updates to 
computation include extending the terminal prediction year to 2017 and additional subnational units in 
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Ethiopia, Iran, New Zealand, Norway, and Russia. Saudi Arabia was also modelled only at the national 
level in 2017. 
The flowchart for the DisMod-MR 2.1 process can be found in Appendix Figure 2. 
DisMod-MR 2.1 likelihood estimation 
Analysts have the choice of using a Gaussian, log-Gaussian, Laplace or Log-Laplace likelihood function in 
DisMod-MR 2.1. The default log-Gaussian equation for the data likelihood is: 








where, yj is a ‘measurement value’ (i.e., data point); Φ denotes all model random variables; ηj is the 
offset value, eta, for a particular ‘integrand’ (prevalence, incidence, remission, excess mortality rate, 
with-condition mortality rate, cause-specific mortality rate, relative risk or standardized mortality ratio) 
and aj is the adjusted measurement for data point j, defined by: 
𝑎𝑎𝑗𝑗 = 𝑒𝑒(−𝑢𝑢𝑗𝑗−𝑐𝑐𝑗𝑗)𝑦𝑦𝑗𝑗 
where uj is the total ‘area effect’ (i.e., the sum of the random effects at three Levels of the cascade: 
super-region, region and country) and cj is the total covariate effect (i.e., the mean combined fixed 
effects for sex, study level and country level covariates), defined by: 




with standard deviation 




where k denotes the mean value of each data point in relation to a covariate (also called x-covariate); I(j) 
denotes a data point for a particular integrand, j; βI(j),k is the multiplier of the kth x-covariate for the ith 
integrand; 𝑋𝑋�𝑘𝑘,𝑗𝑗 is the covariate value corresponding to the data point j for covariate k; l denotes the 
standard deviation of each data point in relation to a covariate (also called z-covariate); ζI(j),k is the 
multiplier of the lth z-covariate for the ith integrand; and δj is the standard deviation for adjusted 
measurement j, defined by: 
𝛿𝛿𝑗𝑗 = 𝑙𝑙𝑙𝑙𝑙𝑙�𝑦𝑦𝑗𝑗 + 𝑒𝑒(−𝑢𝑢𝑗𝑗−𝑐𝑐𝑗𝑗)𝜂𝜂𝑗𝑗 + 𝑐𝑐𝑗𝑗� − 𝑙𝑙𝑙𝑙𝑙𝑙�𝑦𝑦𝑗𝑗 + 𝑒𝑒(−𝑢𝑢𝑗𝑗−𝑐𝑐𝑗𝑗)𝜂𝜂𝑗𝑗� 
Where mj denotes the model for the jth measurement, not counting effects or measurement noise and 







where A(j) is the lower bound of the age range for a data point; B(j) is the upper bound of the age range 
for a data point; and Ij denotes the function of age corresponding to the integrand for data point j. 
Spatiotemporal Gaussian process regression 
Spatiotemporal Gaussian process regression (ST-GPR) has been used for risk factors where the data 
density is sufficient to estimate a very flexible time trend. The flowchart showing the analytic steps can 
be found in Appendix Figure 3. The approach is a stochastic modelling technique that is designed to 
detect signals amidst noisy data. It also serves as a powerful tool for interpolating non-linear trends.10,11 
Unlike classical linear models that assume that the trend underlying data follows a definitive functional 
form, GPR assumes that the specific trend of interest follows a Gaussian Process, which is defined by a 
mean function 𝑚𝑚(∙) and a covariance function 𝐶𝐶𝑙𝑙𝐶𝐶(∙). For example, let 𝑝𝑝𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡 be the exposure, in 
normal, log, or logit space, observed in country c, for age group a, and sex s at time 𝑡𝑡:  
�𝑝𝑝𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡� = 𝑙𝑙𝑐𝑐,𝑎𝑎,𝑠𝑠(𝑡𝑡) + 𝜖𝜖𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡 
where 
𝜖𝜖𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡 ~ 𝑁𝑁𝑙𝑙𝑁𝑁𝑚𝑚𝑎𝑎𝑙𝑙�0,𝜎𝜎𝑝𝑝  2 �, 
𝑙𝑙𝑐𝑐,𝑎𝑎,𝑠𝑠(𝑡𝑡) ~ 𝐺𝐺𝐺𝐺 �𝑚𝑚𝑐𝑐,𝑎𝑎,𝑠𝑠(𝑡𝑡),𝐶𝐶𝑙𝑙𝐶𝐶 �𝑙𝑙𝑐𝑐,𝑎𝑎,𝑠𝑠(𝑡𝑡)��. 
The derivation of the mean and covariance functions, 𝑚𝑚𝑐𝑐,𝑎𝑎,𝑠𝑠(𝑡𝑡) and 𝐶𝐶𝑙𝑙𝐶𝐶 �𝑙𝑙𝑐𝑐,𝑎𝑎,𝑠𝑠(𝑡𝑡)�, along with a more 
detailed description of the error variance (𝜎𝜎𝑝𝑝 2 ), is described below.  
Estimating mean functions 
We estimated mean functions using a two-step approach. To be more specific, 𝑚𝑚𝑐𝑐,𝑎𝑎,𝑠𝑠(𝑡𝑡) can be 
expressed, depending on the exposure transformation, as: 
𝑙𝑙𝑙𝑙𝑙𝑙�𝑝𝑝𝑐𝑐,𝑎𝑎,𝑠𝑠(𝑡𝑡)� = 𝑋𝑋𝑐𝑐,𝑎𝑎,𝑠𝑠𝛽𝛽 + ℎ(𝑁𝑁𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡) 
𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑡𝑡�𝑝𝑝𝑐𝑐,𝑎𝑎,𝑠𝑠(𝑡𝑡)� = 𝑋𝑋𝑐𝑐,𝑎𝑎,𝑠𝑠𝛽𝛽 + ℎ(𝑁𝑁𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡) 
𝑝𝑝𝑐𝑐,𝑎𝑎,𝑠𝑠(𝑡𝑡) = 𝑋𝑋𝑐𝑐,𝑎𝑎,𝑠𝑠𝛽𝛽 + ℎ(𝑁𝑁𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡) 
where 𝑋𝑋𝛽𝛽 is the summation of the components of a hierarchical mixed-effects linear regression, 
including the intercept and the product of covariates with their corresponding fixed effect coefficients. 
Some models were run as hierarchical mixed-effects linear regressions, with random effects on the 
levels of the geographic hierarchy. For most mixed-effects models, random effects were only used in the 
fit, not in the prediction. The second part of the equation, ℎ(𝑁𝑁𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡), is a smoothing function for the 
residuals, 𝑁𝑁𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡, derived from the linear model.3 Descriptions of exposure transformations and which 
covariates were used in linear models can be found in Appendix Section 4, which described the risk-
specific estimation approaches. Some models used a custom stage-1 estimate – these risks will have 
detailed information on their mixed-effect estimation process in the risk-specific appendix sections.   
While the linear component captures the general trend in exposures over time, much of the data 
varaibility may still not be adequately accounted for. To address this, we fit a locally weighted 
polynomial regression (LOESS) function ℎ(𝑁𝑁𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡) to systematically estimate this residual variability by 
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borrowing strength across time, age, and space patterns (the spatiotemporal component of ST-GPR).12,13 
The time adjustment parameter, defined by 𝜆𝜆 , aims to borrow strength from neighboring time points 
(i.e. the exposure in this year is highly correlated with exposure in the previous year but less so further 
back in time). The age adjustment parameter, defined by ω, borrows strength from data in neighboring 
age groups. The space adjustment parameter, defined by 𝜉𝜉, aims to borrow strength across the 
hierarchy of geographical locations. This year, we further combined the spatial and temporal weights 
into a single space-time weight, to allow the amount of spatial weight given to a particular point 𝑁𝑁𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡 
to fluctuate given the data availability at each time t and location-level l  in the location hierarchy. 
Let 𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡 be the final weight assigned to observation 𝑁𝑁𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡 with reference to a focal observation 
𝑁𝑁𝑐𝑐0,𝑎𝑎0,𝑠𝑠0,𝑡𝑡0 . We first generated a temporal weight 𝑡𝑡.𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡 for smoothing over time, which was based on 
the scaled distance along the time dimension of the two observations14: 
𝑡𝑡.𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡 =  
1
𝑒𝑒𝜆𝜆|𝑡𝑡−𝑡𝑡0|
Next, we generated a spatial weight to smooth over geography. Specifically, we defined a geospatial 
relationship by categorizing data based on the GBD location hierarchy (Appendix Table 7).  
In previous GBD iterations, a vector of spatial weights corresponding to each level of the location 
hierarchy was derived as [𝜉𝜉, 𝜉𝜉 ∗ (1 − 𝜉𝜉)𝑛𝑛1−1, . . . , 𝜉𝜉 ∗ (1 − 𝜉𝜉)𝑛𝑛𝑖𝑖−1, (1 − 𝜉𝜉)𝑛𝑛𝑖𝑖], where ni, designated the 
number of location levels in between the given location and the global level and ζ was typically between 
.7 - .99. Under the previous spatial weighting system,  all country datapoints would receive a weight of ζ, 
all regional datapoints a weight of ζ *(1- ζ), etc, no matter how much data was available in the country 
compared to the region. For example, if there was only a single datapoint for a given country and ζ was 
set to .7 , that lone datapoint would receive 70% of the spatial weight. 
This year, we reformulated zeta to act as a scalar on a given datapoint given its proximity to the target 
location:  
𝑡𝑡.𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡 =   𝜁𝜁|𝑐𝑐−𝑐𝑐0|  
For example, estimating a country would use the following weighting scheme: 
• Country data: 𝜁𝜁0 = 1
• Regional data not from the country being estimated: 𝜁𝜁1
• Data from other regions in the same super region: 𝜉𝜉2
• Global data from other super regions: 𝜁𝜁3
Under the new spatial weighting specification, typical values of ζ range from [.001, .2], where ζ can be 
interpreted as the amount to downweight regional datapoints compared to country datapoints for a 
given estimating country. For example, for a given datapoint 𝑁𝑁𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡 and ζ = .01, a datapoint not within 
country c but within the same region r as  𝑁𝑁𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡  would be assigned 
1
100
 the weight of a datapoint within 
the country. 
The spatial and temporal weights were then multiplied and summed across each level of the location 
hierarchy, and normalized for each time period t . This allows the space-time weight to implicitly take 
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into account the amount of data available at the country vs. region vs super-region level and attribute 
spatial weight accordingly.  
Given a normalization constant, 
𝐾𝐾𝑖𝑖 = �𝑠𝑠.𝑤𝑤𝑐𝑐,𝑡𝑡 ∗ 𝑡𝑡.𝑤𝑤𝑐𝑐.𝑡𝑡
𝑐𝑐𝑐𝑐𝑐𝑐
+ �𝑠𝑠.𝑤𝑤𝑐𝑐,𝑡𝑡 ∗ 𝑡𝑡.𝑤𝑤𝑐𝑐.𝑡𝑡
𝑐𝑐𝑐𝑐𝑐𝑐
+ � 𝑠𝑠.𝑤𝑤𝑐𝑐,𝑡𝑡 ∗ 𝑡𝑡.𝑤𝑤𝑐𝑐.𝑡𝑡
𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐




Finally, we calculated the weight 𝑤𝑤’’𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡 to smooth over age, which is based on a distance along the 
age dimension of two observations. For a point between the age 𝑎𝑎 of the observation 𝑁𝑁𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡 and a focal 
observation 𝑁𝑁𝑐𝑐0,𝑎𝑎0,𝑠𝑠0,𝑡𝑡0, the weight is defined as follows: 
𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡′′ =  
1
𝑒𝑒𝜔𝜔|𝑎𝑎−𝑎𝑎0|
The final weights would then be computed by simply multiplying the space-time weights and age 
weights and normalizing so all weights for a given time period t sum to 1.  A full derivation of weights for 
each category follow, assuming the location being estimated was a country, follows:  
1) If the observation 𝑁𝑁𝑐𝑐,𝑡𝑡 belongs to the same country 𝑐𝑐0 of the focal observation 𝑁𝑁𝑐𝑐0,𝑡𝑡0: 
𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡 =  
(𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡′ 𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡′′ )
∑ (𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡′ 𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡′′ )𝑐𝑐=𝑐𝑐0
 ∀𝑐𝑐 = 𝑐𝑐0 
2) If the observation  𝑁𝑁𝑐𝑐,𝑡𝑡 belongs to a different country than the focal observation 𝑁𝑁𝑐𝑐0,𝑡𝑡0, but both 
belong to the same region R:
𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡 =  
(𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡′ 𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡′′ )
∑ (𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡′ 𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡′′ )𝑐𝑐≠𝑐𝑐0
  ∀𝑐𝑐 ≠ 𝑐𝑐0 ∩  𝑅𝑅[𝑐𝑐] = 𝑅𝑅[𝑐𝑐0] 
3) If the observation 𝑁𝑁𝑐𝑐,𝑡𝑡  belongs to the same super region SR but to a both different country 𝑐𝑐0
and region 𝑅𝑅[𝑐𝑐0] than the focal observation 𝑁𝑁𝑐𝑐0,𝑡𝑡0:
𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡 =  
(𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡′ 𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡′′ )
∑ (𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡′ 𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡′′ )𝑐𝑐≠𝑐𝑐0
  ∀𝑐𝑐 ≠ 𝑐𝑐0 ∩  𝑅𝑅[𝑐𝑐] ≠ 𝑅𝑅[𝑐𝑐0] ∩  𝑆𝑆𝑅𝑅[𝑐𝑐] = 𝑆𝑆𝑅𝑅[𝑐𝑐0] 
4) If the observation 𝑁𝑁𝑐𝑐,𝑡𝑡  is from a different super region than the focal observation 𝑁𝑁𝑐𝑐0,𝑡𝑡0(ie. all 
other data currently not receiving a weight):
𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡 =  
 (𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡′ 𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡′′ )
∑ (𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡′ 𝑤𝑤𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡′′ )𝑐𝑐≠𝑐𝑐0
  ∀𝑐𝑐 ≠ 𝑐𝑐0 ∩  𝑅𝑅[𝑐𝑐] ≠ 𝑅𝑅[𝑐𝑐0] ∩  𝑆𝑆𝑅𝑅[𝑐𝑐] ≠ 𝑆𝑆𝑅𝑅[𝑐𝑐0] 
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Observations could be downweighted by a factor of 0.1, usually because they were not geographically 
representative at the unit of estimation. Details of reasons for downweighting can be found in risk-
specific modeling summaries. The final weights were then normalized such that the sum of weights 
across age, time, and geographic hierarchy for a reference group was 1. 
Estimating error variance 
𝜎𝜎𝑝𝑝 2  represents the error variance in normal or transformed space including sampling variance of the 
estimates and prediction error from any crosswalks performed. First, variance was systematically 
imputed if the data extraction did not include any measure of uncertainty. When some sample sizes for 
data were available, missing sample sizes were imputed as the 5th percentile of available sample sizes. 
Missing variances were then calculated as 𝜎𝜎𝑝𝑝 2 =
𝑝𝑝∗(1−𝑝𝑝)
𝑛𝑛
 for proportions or were predicted from the 
mean using a regression for continuous values. When sample sizes were entirely missing and could not 
be imputed, the 95th percentile of available variances at the most granular geographic level (ie, first 
country, then region, etc.) were used to impute missing variances. For proportions where p*n or (1-p)*n 
is < 20, variance was replaced using the Wilson Interval Score method. 
Next, if the exposure was modelled as a log transformation, the error variance was transformed into log-
space using the delta method approximation as follows,  




where 𝜎𝜎𝑝𝑝′   2 represents the error variance in normal space. If the exposure was modelled as a logit 
transformation, the error variance was transformed into logit-space using the delta method 
approximation as follows, 
𝜎𝜎𝑝𝑝 2 ≅  
𝜎𝜎𝑝𝑝′2
(𝑝𝑝𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡 ∗ (1 − 𝑝𝑝𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡))2
 
Finally, prior to GPR, an approximation of non-sampling variance was added to the error variance. 
Calculations of non-sampling variance were performed on normal-space variances. Non-sampling 
variance was calculated as the variance of inverse-variance weighted residuals from the space-time 
estimate at a given location level hierarchy. If there were fewer than 10 data points at a given level of 
the location hierarchy the non-sampling variance was replaced with that of the next highest geography 
level with more than 10 data points. 
Estimating the covariance function 
The final input into GPR is the covariance function, which defines the shape and distribution of the 
trends. Here, we have chosen the Matern-Euclidian covariance function, which offers the flexibility to 
model a wide spectrum of trends with varying degrees of smoothness. The function is defined as 
follows:  












where 𝑑𝑑(∙)is a distance function; 𝜎𝜎2, 𝜈𝜈, 𝑙𝑙, and 𝐾𝐾𝑣𝑣 are hyperparameters of the covariance function—
specifically 𝜎𝜎2 is the marginal variance, 𝜈𝜈 is the smoothness parameter that defines the differentiability 
of the function, 𝑙𝑙 is the length scale, which roughly defines the distance between which two points 
become uncorrelated, and 𝐾𝐾𝑣𝑣 is the Bessel function. We approximated 𝜎𝜎2 by taking the normalized 
median absolute deviation 𝑀𝑀𝑀𝑀𝑀𝑀𝑁𝑁(𝑁𝑁𝑐𝑐′) of the difference  which is the normalized absolute deviation of 
the difference of the first-stage linear regression estimate from the second-stage spatiotemporal 
smoothing step for each country. We then took the mean of these country-level MADN estimates for all 
countries with 10+ country-years of data, to ensure that differences between first- and second-stage 
estimates had sufficient data to truly convey meaningful information on model uncertainty. We used the 
parameter specifications 𝐶𝐶 = 2 for all models. The scale parameter 𝑙𝑙 used for each risk is reported in 
Appendix Section 4. 
Prediction using GPR 
We integrated over 𝑙𝑙𝑐𝑐,𝑡𝑡(𝑡𝑡∗) to predict a full time series for country 𝑐𝑐, age a, sex s, and the prediction 
time 𝑡𝑡∗:  
𝑝𝑝𝑐𝑐,𝑎𝑎,𝑠𝑠(𝑡𝑡∗) ~ 𝑁𝑁�𝑚𝑚𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡(𝑡𝑡∗),𝜎𝜎𝑝𝑝2𝐼𝐼 + 𝐶𝐶𝑙𝑙𝐶𝐶 �𝑙𝑙𝑐𝑐,𝑎𝑎,𝑠𝑠,𝑡𝑡(𝑡𝑡∗)�� 
Random draws of 1000 samples were obtained from the distributions above for every country for a 
given indicator. The final estimated mean for each country was the mean of the draws. In addition, 95% 
uncertainty intervals were calculated by taking the 2.5 and 97.5 percentile of the sample distribution. 
The linear modelling process was implemented using the lmer4 package in R, and the ST-GPR analysis 
was implemented through the PyMC2 package in Python.  
Subnational Scaling and Aggregation 
To ensure internal consistency of the estimates between countries and their respective subnational 
locations, national estimates were either created by population-weighted aggregation or subnational 
estimates were adjusted by population-weighted scaling to the national estimates, depending on the 
data coverage of a given country compared to that of its subnational locations. For example, if there was 
better data coverage at the national level, relative to its corresponding subnational locations, for a given 
country and risk across age, sex, and time, estimates were rescaled to be consistent with the national 
level. Conversely, if there was better data coverage at the subnational level, estimates for its parent 
country were generated through population-weighted aggregation of subnational estimates. 
This GBD iteration, we incorporated an option to scale estimates within logit space. Scaling in logit space 
ensures that subnational estimates of proportion models will not exceed one after being rescaled to the 
national estimate.   
Fitting a distribution to exposure data 
The most informative data describing the distribution of risk factors within a population come from 
individual-level data; additional sources of data include reported means and variances. In cases when a 
risk factor also defines a disease or disease severity cut-off, such as haemoglobin level and mild, 
moderate, or severe anaemia or diabetes and fasting plasma glucose, the prevalence of disease is also 
frequently reported. To model the distribution of any particular risk factor, we seek a family of 
probability density functions (PDFs), a fitting method, and a model selection criterion. To make use of 
the most commonly available data describing most populations, we used the method of moments 
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(MoM); the first two empirical moments from a population, the mean and variance, were used to 
determine the parameters of two-parameter probability distribution families (PDF) describing the 
distribution of risk within any population. Exceptions to this rule are justified by context. We used the 
Kolmogorov-Smirnov15 (KS) test to measure the goodness of fit (GoF), comparing the distance between 
the empirical and ensemble distributions, but in some cases, the GoF was based on the prediction error 
for the prevalence of disease.  
We used an ensemble technique in which a model selection algorithm is used to choose the best model 
for each continuous risk factor.15 We drew the initial set of candidate models from commonly used PDF 
families, including both right-skewed and left-skewed distributions. These included: beta, exponential, 
gamma, gumbel, inverse gamma, inverse Weibull, log-logistic, lognormal, mirrored gamma, mirrored 
gumbel, normal, and Weibull. We fitted each PDF candidate family to each dataset using the MoM, and 
used the KS test as the measure of GoF. Preliminary analysis showed that the GoF ranking of PDF 
families varied across datasets for any particular risk factor and that combining the predictions of 
differently fitted PDF families could dramatically improve the GoF for each dataset. Therefore, we 
developed a new model for prediction using the ensemble of candidate models, which is a weighted 
linear combination of all candidate models, {𝑓𝑓}, where a set of weights {𝑤𝑤} is chosen such that 
∑ 𝑤𝑤𝑖𝑖 = 1𝑖𝑖 , and the values of the weights were determined by a second GoF criterion with its own 
validation process. For each risk, we pooled all available microdata and performed Nelder-Mead 
numeric optimisation across demographics subsets of data to derive a set of distribution-specific 
weights such that the average KS statistic across data sets is minimised. The details can be summarised 
by 1) the summary statistics for each dataset; 2) a table showing the KS statistic for each candidate 
model; and 3) the weights defining the final ensemble model for each dataset. We then averaged across 
demographic subsets and data sets to determine the final weights for modelling the distribution of any 
particular risk factor. 
Section 2.4: Step 3. TMREL 
In this and all previous GBD studies, the counterfactual level of risk exposure used is the risk exposure 
that is both theoretically possible and minimizes risk in the exposed population that consequently 
captures the maximum population attributable burden.2 For each risk evaluated in GBD 2017, Step 4 of 
the analytical flowchart describes the use of the best available epidemiological evidence from published 
and unpublished relative risks by level of exposure and the lowest observed level of exposure from 
cohorts, used to select a single level of risk exposure that minimises risk from all causes of DALYs 
combined to establish the TMREL. In principle, the TMREL for a given risk may vary by age, sex, and 
location if supported by clear evidence. Based on the available evidence, the TMREL itself can be 
uncertain, which is reflected in the 95% uncertainty intervals (UIs) in Appendix Table 6. An estimation of 
uncertainty was derived by resampling from a uniform distribution of TMRELs where evidence 
supporting the selection of the TMREL was uncertain (for example, elevated systolic blood pressure or 
cholesterol).  
Section 2.5: Step 4. Estimate population attributable fractions 
Risks are categorised on the basis of how exposure was measured: dichotomous, polytomous, and 
continuous. High low-density lipoprotein (LDL) cholesterol is an example of a risk measured on a 
continuous scale. The population attributable fraction (PAF), which represents the proportion of risk 
33
that would be reduced in a given year if the exposure to a risk factor in the past were reduced to an 
ideal exposure scenario, is defined for a continuous risk factor as:16 
𝐺𝐺𝑀𝑀𝑃𝑃𝑗𝑗𝑗𝑗𝑎𝑎𝑠𝑠𝑗𝑗𝑡𝑡 =  
∫ 𝑅𝑅𝑅𝑅𝑗𝑗𝑗𝑗𝑎𝑎𝑠𝑠𝑗𝑗(𝑥𝑥)𝐺𝐺𝑗𝑗𝑎𝑎𝑠𝑠𝑗𝑗𝑡𝑡(𝑥𝑥)𝑑𝑑𝑥𝑥
𝑢𝑢




Where 𝐺𝐺𝑀𝑀𝑃𝑃𝑗𝑗𝑗𝑗𝑎𝑎𝑠𝑠𝑗𝑗𝑡𝑡 is the population attributable fraction for cause 𝑙𝑙 due to risk factor 𝑗𝑗 for age group 𝑎𝑎, 
sex 𝑠𝑠, location 𝑙𝑙, and year 𝑡𝑡. 𝑅𝑅𝑅𝑅𝑗𝑗𝑗𝑗𝑎𝑎𝑠𝑠𝑗𝑗(𝑥𝑥) is the relative risk as a function of exposure level 𝑥𝑥 for risk 
factor 𝑗𝑗 for cause 𝑙𝑙, age group 𝑎𝑎, sex 𝑠𝑠, and location 𝑙𝑙 with the lowest level of observed exposure as 𝑙𝑙 
and the highest as 𝑢𝑢; 𝐺𝐺𝑗𝑗𝑎𝑎𝑠𝑠𝑗𝑗𝑡𝑡(𝑥𝑥) is the distribution of exposure at 𝑥𝑥 for age group 𝑎𝑎, sex 𝑠𝑠, location 𝑙𝑙, and 
year 𝑡𝑡; 𝑇𝑇𝑀𝑀𝑅𝑅𝑇𝑇𝑇𝑇𝑗𝑗𝑎𝑎𝑠𝑠 is the TMREL for risk factor j, age group a, and sex s.  
The 𝐺𝐺𝑀𝑀𝑃𝑃𝑗𝑗𝑗𝑗𝑎𝑎𝑠𝑠𝑗𝑗𝑡𝑡 for dichotomous and polytomous risk factors for every country is defined as: 
𝐺𝐺𝑀𝑀𝑃𝑃𝑗𝑗𝑗𝑗𝑎𝑎𝑠𝑠𝑗𝑗𝑡𝑡 =  
∑ 𝑅𝑅𝑅𝑅𝑗𝑗𝑗𝑗𝑎𝑎𝑠𝑠𝑡𝑡(𝑥𝑥)𝐺𝐺𝑗𝑗𝑎𝑎𝑠𝑠𝑗𝑗𝑡𝑡(𝑥𝑥)𝑢𝑢𝑥𝑥=1 −  𝑅𝑅𝑅𝑅𝑗𝑗𝑗𝑗𝑎𝑎𝑠𝑠𝑗𝑗(𝑇𝑇𝑀𝑀𝑅𝑅𝑇𝑇𝑗𝑗𝑎𝑎𝑠𝑠)
∑ 𝑅𝑅𝑅𝑅𝑗𝑗𝑗𝑗𝑎𝑎𝑠𝑠(𝑥𝑥)𝐺𝐺𝑗𝑗𝑎𝑎𝑠𝑠𝑗𝑗𝑡𝑡(𝑥𝑥)𝑢𝑢𝑥𝑥=1
Where 𝐺𝐺𝑀𝑀𝑃𝑃𝑗𝑗𝑗𝑗𝑎𝑎𝑠𝑠𝑗𝑗𝑡𝑡 is the population attributable fraction for cause 𝑙𝑙 due to risk factor 𝑗𝑗 for age group 𝑎𝑎, 
sex 𝑠𝑠, location 𝑙𝑙, and year 𝑡𝑡. 𝑅𝑅𝑅𝑅𝑗𝑗𝑗𝑗𝑎𝑎𝑠𝑠𝑗𝑗(𝑥𝑥) is the relative risk as a function of exposure level 𝑥𝑥 for risk 
factor 𝑗𝑗 for cause 𝑙𝑙, age group 𝑎𝑎, sex 𝑠𝑠, and location 𝑙𝑙 on a plausible range of exposure levels from l to u 
𝐺𝐺𝑗𝑗𝑎𝑎𝑠𝑠𝑗𝑗𝑡𝑡(𝑥𝑥) is the proportion of population in risk group  (prevalence),  for age group 𝑎𝑎, sex 𝑠𝑠, location 𝑙𝑙, 
and year 𝑡𝑡; 𝑇𝑇𝑀𝑀𝑅𝑅𝑇𝑇𝑇𝑇𝑗𝑗𝑎𝑎𝑠𝑠 is the TMREL for risk factor j, age group a, and sex s. 
Section 2.6: Step 5. Estimate summary exposure values 
Summary exposure value (SEV), is the relative risk-weighted prevalence of exposure, a univariate 
measure of risk-weighted exposure, taking the value zero when no excess risk for a population exists 
and the value one when the population is at the highest level of risk. We report SEVs on a scale from 0% 
to 100% where a decline in SEV indicates reduced exposure to a given risk factor and an increase in SEV 
indicates increased exposure. 
We first calculate risk, 𝑁𝑁, and cause, 𝑐𝑐, specific SEVs using the following equation, 





for each most-detailed age, sex, location, year, and outcome. 𝐺𝐺𝑀𝑀𝑃𝑃 is the YLL (expect for occupational 
noise, bullying victimization, and occupational ergonomic factors which are YLD only and thus use the 
YLD) PAF. 𝑅𝑅𝑅𝑅𝑚𝑚𝑎𝑎𝑥𝑥 for categorical risks is the RR at the highest category of exposure. For continuous risks, 
this is   
𝑅𝑅𝑅𝑅𝑚𝑚𝑎𝑎𝑥𝑥 = 𝑅𝑅𝑅𝑅
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇−1𝑠𝑠𝑠𝑠𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑠𝑠𝑒𝑒𝑒𝑒𝑒𝑒





otherwise, and for custom modelled risks like ambient particulate matter pollution, household air 
pollution from solid fuels (HAP), alcohol, smoking, bullying, and activity, the modeller provides draws of 
𝑅𝑅𝑅𝑅𝑚𝑚𝑎𝑎𝑥𝑥. Generally, RRs do not vary across time and space, however, there are exceptions – an example 
being those risks such as second-hand smoke (SHS) or HAP where the RR is based on the integrated 
exposure response [IER], curve) and in these cases the RR is averaged across location and year to ensure 
no time or space variation. If the PAF is negative, signifying a protective effect for that outcome, the PAF 
is set to 0 and the SEV is then also 0 as the SEV univariate and constrained to be a value between 0 and 
1. Once we have a set of risk cause specific SEVs at the most-detailed risk, cause, age, sex, location for all
years, we average across causes to produce the final risk specific 𝑆𝑆𝑇𝑇𝑆𝑆𝑟𝑟,






Section 2.7: Step 6. Mediation 
Section 2.7.1: Summary 
The portion of the burden of disease that is attributable to various combinations of risk factors or to all 
risk factors combined has been a topic of broad interest.17 Assumptions about how one risk factor is 
mediated through other risk factors are needed in order to estimate the joint risk factor burden for 
combinations of metabolic risks and behavioural or environmental risks. To accomplish this, in Step 6 of 
the estimation process, for every two risk factors for an outcome, we estimated the fraction of risk that 
was mediated through the other risk. This resulted in a matrix of parameters containing each possible 
pairing of risk factors included in the GBD 2017. Using this matrix, we computed the aggregated burden 
of disease at each level of the GBD 2017 hierarchy and for all risk factors using the following formula: 







where 𝐽𝐽 is a set of risk factors for the aggregation; 𝐺𝐺𝑀𝑀𝑃𝑃𝑗𝑗𝑗𝑗𝑎𝑎𝑠𝑠𝑗𝑗𝑡𝑡 is the PAF for risk 𝑗𝑗 for age group 𝑎𝑎, sex 𝑠𝑠, 
location 𝑙𝑙, and year 𝑡𝑡; and 𝑀𝑀𝑃𝑃𝑗𝑗𝑖𝑖𝑗𝑗 is the mediation factor for risk 𝑗𝑗 mediated through 𝑙𝑙 for cause 𝑙𝑙. 
Mediation factors can be found in Appendix Table 8. 
Section 2.7.2: Additional detail 
In GBD 2010, we only aggregated the burden of risk factors for some clusters of risks including access to 
improved water and sanitation, child and maternal malnutrition, tobacco smoking, alcohol use, dietary 
risk factors, occupational risk factors, and sexual abuse and violence. We did not aggregate air pollution 
and metabolic risk factors.  For GBD 2013, GBD 2015, GBD 2016, and GBD 2017, we aggregated all risk 
factors into three large categories:  behavioural, environmental and occupational, and metabolic risks -- 
as well as aggregating all GBD risk factors into a single attributable fraction for each diseases and 
eventually for all-causes of burden. 
Aggregating risk factors at different levels share three essential challenges: 
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1. Risk factor coexistence or aggregation: for example, metabolic risk factors often occur together
or high-risk behaviours are related such as drug abuse and unsafe sex.
2. Mediation: a risk factor may effect another risk factor that lies in the physiological pathway to a
disease outcome. It can be inside a cluster of risk factors such as the effect of obesity through an
increase in fasting plasma glucose (FPG) and later cardiovascular disease outcomes, or between
clusters of risk factors such as the effect of fibre on cholesterol.
3. The formula to calculate the aggregated PAF.
The aggregation method is conceptually applicable to other aggregations such as socioeconomic factors, 
education, homelessness and refugee status that are being considered for inclusion in future GBD 
iterations. In the next section, we explain our approach to deal with these challenges.  
There are three patterns of associations between risk factors to take into consideration. The first 
concerns confounding; risk B affects risk A and outcome C (Pattern 1 in Patterns of associations between 
risk factors). In these cases, the relative risk (RR) for A should be adjusted for B, for example, the fruit RR 
is adjusted for smoking. If part of the effect of A is through B, a mediator, we do not adjust the effect of 
A for B. For example, we do not adjust the RR of body-mass index (BMI) for cholesterol as cholesterol 
lies in the biological pathway between BMI and cardiovascular outcomes (Pattern 2 in in Patterns of 
associations between risk factors). The third pattern occurs when risks A and B are proxies of a third 
variable Z and aggregation aims to estimate the total effect of a latent variable Z, on C. An example is 
child growth failure, which is measured by stunting, wasting, and underweight as proxies.
Patterns of associations between risk factors 
Pattern 1 
Pattern 2 Pattern 3 
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Section 2.7.3: Calculating burden of multiple risk factors 
Validation studies have reported congruency between the true risk associated with multiple risk factors 
affecting the same outcome and a multiplicative aggregation of the population attributable fractions of 
the individual risk factors (formula below).18   
𝐺𝐺𝑀𝑀𝑃𝑃1..𝑖𝑖 = 1 −  �(1 −  𝐺𝐺𝑀𝑀𝑃𝑃𝑖𝑖) 
𝑛𝑛
𝑖𝑖=1
Where PAF is the population attributable fraction and i is each individual risk factor. The same validation 
studies also found that the overestimation from ignoring the covariance between risk factors is small. 
This was important to note as there are few data sources from which we can draw information on 
covariance.  
We endeavoured to evaluate RRs that were controlled for confounders. However, as we had to rely on 
the literature for many RRs we did not always have full control over the choice of confounders 
controlled for in each study. 
Section 2.7.4: Adjusting for mediation 
When aggregating the effects of multiple risk factors, we included a mediation factor if a part of the 
effect of one risk factor was included in the effect estimated for in the mediator. First, we prepared a list 
of possible mediations especially between behavioural risks and metabolic risk factors with 
cardiometabolic outcomes. We did not assume any mediation effect between risk factors for cancers. 
Danaei and colleagues assumed that part of the effect of BMI on ischemic heart disease (IHD) is through 
high systolic blood pressure (SBP), cholesterol and FPG.19 The proportion of the BMI effect that can be 
explained by other metabolic risk factors is the amount of mediation. The difference between the crude 
RR of BMI on IHD with the RR adjusted for SBP, FPG, and cholesterol reflects the amount of BMI effect 
on IHD that is mediated and already included in SBP, FPG, and cholesterol: 
𝑀𝑀𝑃𝑃 =  
𝑅𝑅𝑅𝑅𝑐𝑐𝑟𝑟𝑢𝑢𝑐𝑐𝑒𝑒 − 𝑅𝑅𝑅𝑅𝑎𝑎𝑐𝑐𝑗𝑗𝑢𝑢𝑠𝑠𝑡𝑡𝑒𝑒𝑐𝑐
𝑅𝑅𝑅𝑅𝑐𝑐𝑟𝑟𝑢𝑢𝑐𝑐𝑒𝑒 − 1
We used this approach for estimating mediation factors to adjust PAFs before aggregation. 
𝑀𝑀𝑃𝑃 =  
𝑅𝑅𝑐𝑐+ − 𝑅𝑅𝑎𝑎+ 
𝑅𝑅𝑐𝑐+ −  𝑅𝑅𝑐𝑐−
 
So: 𝑅𝑅𝑎𝑎+ = 𝑅𝑅𝑐𝑐+ −𝑀𝑀𝑃𝑃 ∗ (𝑅𝑅𝑐𝑐+ −  𝑅𝑅𝑐𝑐−) 
𝐺𝐺𝑀𝑀𝑃𝑃𝑐𝑐 =
𝑝𝑝 ∗ ( 𝑅𝑅𝑐𝑐+ −  𝑅𝑅𝑐𝑐−)
𝑝𝑝 ∗  𝑅𝑅𝑐𝑐+ + (1 − 𝑝𝑝) ∗ 𝑅𝑅𝑐𝑐− 
=  
𝑝𝑝 ∗ ( 𝑅𝑅𝑐𝑐+ −  𝑅𝑅𝑐𝑐−)
𝑅𝑅𝑇𝑇
If 𝑅𝑅𝑐𝑐+: crude risk of outcome in exposed population 
 𝑅𝑅𝑐𝑐−: crude risk of outcome in non-exposed population 
 𝑅𝑅𝑎𝑎+: adjusted risk of outcome in exposed population 
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 𝑅𝑅𝑎𝑎−: adjusted risk of outcome in non-exposed population 
𝑅𝑅𝑇𝑇 is the overall rate of the outcome in the population. Since we are interested in the part which is from 
BMI but through cholesterol, the total risk in the population will be the same for the adjusted RR, so the 










=  𝐺𝐺𝑀𝑀𝑃𝑃𝑐𝑐 ∗ ( 1 −𝑀𝑀𝑃𝑃)  
So for aggregating the PAF of multiple risk factors, we first calculated the part of the effect of every risk 
factor that is not mediated and then aggregated these assuming they are independent. 
Therefore the aggregated PAF would be: 
If MF is mediation factor of R2 through R1: 
𝐺𝐺𝑀𝑀𝑃𝑃1,2 = 1 − (1 −  𝐺𝐺𝑀𝑀𝑃𝑃1) ∗ �1 − 𝐺𝐺𝑀𝑀𝑃𝑃2 ∗ ( 1 −𝑀𝑀𝑃𝑃2/1�) 
and a generalization for multiple pathways of R1 through other RFs: 







For every risk factor outcome pair, the matrix of possible mediations was calculated and used. 
Section 2.7.5: Calculating mediation factor 
1 – Comparing crude RR versus mediator-adjusted RR 
The best example is the mediation of BMI through SBP, FPG, and cholesterol reported by Danaei et al.19 
In their meta-analysis, they report the adjusted and unadjusted RR of BMI on IHD and stroke based on 
combined data from individual cohorts. They calculated the mediation factor using the equation below, 
and we used it directly as mediation factor in risk factor aggregation. Using individual level data from 
cohort studies, we estimated the mediation factor for other metabolic risk factors and some dietary 
risks. 
𝑀𝑀𝑃𝑃 =  
𝑅𝑅𝑅𝑅𝑐𝑐𝑟𝑟𝑢𝑢𝑐𝑐𝑒𝑒 − 𝑅𝑅𝑅𝑅𝑎𝑎𝑐𝑐𝑗𝑗𝑢𝑢𝑠𝑠𝑡𝑡𝑒𝑒𝑐𝑐
𝑅𝑅𝑅𝑅𝑐𝑐𝑟𝑟𝑢𝑢𝑐𝑐𝑒𝑒 − 1
2 – Estimating the mediation factor by pathway of the effect 
For many other risk factors, there are no data available to use the first method. Instead, we searched 
studies to estimate the effect of the risk factor on the mediator and finally the expected increase in IHD 
risk. We pooled available studies to calculate the unit increase in the mediator per unit increase in the 
risk factor to calculate the size of the IHD RR.  
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Example of pathway between fruit, high systolic blood pressure, and cardiovascular diseases 
We have RRs for the effect of A on C and B on C in GBD from a meta-analysis of studies in the literature. 
The effect of A on B was estimated by analysis of diet trials. 
𝑅𝑅𝑅𝑅𝐴𝐴𝐵𝐵𝑐𝑐 =  𝑅𝑅𝑅𝑅𝐵𝐵𝑐𝑐∆𝐴𝐴𝐴𝐴  
𝑅𝑅𝑅𝑅𝐴𝐴𝐵𝐵𝑐𝑐  is expected effect of A through B on C 
𝑅𝑅𝑅𝑅𝐵𝐵𝑐𝑐  is relative risk of each unit increase in mediator on outcome C 
∆𝐴𝐴𝐵𝐵 is change in mediator level B per each unit change in A 
If 𝑅𝑅𝑅𝑅𝐴𝐴𝐵𝐵 is the overall effect of A on B then: 
The mediation factor would be 
𝑀𝑀𝑃𝑃 =  
𝑅𝑅𝑅𝑅𝐴𝐴𝐵𝐵𝑐𝑐 − 1 
𝑅𝑅𝑅𝑅𝐴𝐴𝐵𝐵 − 1
We kept uncertainty of each parameter by generating and following 1000 draws of the estimates to 
calculate 1000 draws of the posterior distribution of the mediation factor. We did not include risk-
mediator pairs if the mediation factor was not significant at 5% level (more than 50 out of 1000 draws 
were negative). We truncated the mediation factor distribution at 1 where the whole effect of the risk 
factor on the outcome would be assumed to be through the mediator pathway. 
Some mediation factors equal 1 where the whole effect was calculated through other risk factor, e.g. 
the effect of salt through SBP, or when we assumed other risk factors are sources of the exposure, for 
example, fibre is provided by consuming fruit, vegetable, and whole grains and all the beneficial effect of 
milk on colorectal cancer is mediated through calcium. 
Dietary risk factors 
For each dietary risk factor, we searched for randomised trials evaluating the effect of the diet 
component on metabolic risk factors and estimated the change in a given mediator per unit change in 
the diet component. Only salt outcomes, with the exception of stomach cancer, are mediated through 
BMI – all other dietary risk factors have their relative risk applied directly. 
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Physical activity 
We found cohort studies on the effect of physical activity on FPG. The data was more on the effect of 
physical activity on diabetes incidence, so we calculated the shift in FPG using the provided RR value. We 
used this to calculate the mediated part of effect of physical activity on cardiovascular disease (CVD).20–
26
Air pollution 
We considered mediation for particulate matter pollution, but the evidence was not strong enough to 
justify inclusion of PM2.5 on SBP, FPG, or cholesterol. There are two cohort studies which have published 
findings of increased risk of hypertension due to long-term exposure to ambient PM2.5 and several 
studies which have found elevated SPB due to household solid fuel use. We found time series studies 
with different PM2.5 lag (by day) that show very short-term and confounded effects. We decided to re-
examine these outcomes when more evidence becomes available. 
Assumed mediations 
For the risk factors with PAFs of 100% such as FPG and diabetes, impaired kidney function and chronic 
kidney disease, SBP and hypertensive heart disease, alcohol and alcohol use disorders, child 
underweight and protein-energy malnutrition, and child wasting and protein-energy malnutrition, and 
drug use and drug use disorders, no mediation is needed.  
Section 2.7.6: Piecewise aggregation (Pattern 3) 
There are three anthropometric indicators that are highly correlated: child underweight, stunting, and 
wasting, as demonstrated in Venn diagram demonstrating the correlation between child underweight, 
stunting, and wasting. Available RRs for each indicator are not adjusted for the other two because there 
is a high correlation between these indicators and also interaction where the majority of the burden 
occurs. Estimating the total burden due to childe growth failure, a latent variable, is difficult. The three 
anthropometric indicators are not independent, so the covariance between them should be considered. 
This was the main reason that GBD 2010 only included child underweight. If covariance between these 
indicators is significant (as is shown in the Figure below), aggregating these indicators assuming 
independence would overestimate the total burden significantly.   
To use the best available data, we adjusted observed RRs reported by Olofin et al for underweight, 
stunting and wasting by simulating the joint distribution of the three indicators using the distribution of 
each indicator and covariance between indicators in the countries included in the meta-analysis 
(extracted from Demographic and Health Survey (DHS) micro-data).27  Based on the analysis done by 
McDonald et al, we assumed there is an interaction between the three indicators, and extracted the 
interaction terms from the corresponding analysis.28 We calculated the adjusted RRs by minimizing the 
error between observed crude RRs (from meta-analysis) and expected crude RRs derived from adjusted 
RRs.  
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Venn diagram demonstrating the correlation between child underweight, stunting, and wasting 
After adjusting for the three risk factors, we calculated the PAFs and aggregated underweight, stunting 
and wasting burden. 
Section 2.7.7: Uncertainty of aggregated and mediated PAFs 
We generated 1000 draws of posterior distribution of mediation factor calculated by different methods 
to use beside draws of other inputs to the PAF aggregation. 
Section 2.7.8: Important assumptions in aggregating risk factors and including mediation 
1 – The mediation factors or PAF adjustments are similar across countries, age, sex, and years. While it is 
quite likely that the size of mediation is different in different populations, there is little data to inform 
the covariance between different risk factors or the mediation factor amount by age and countries. For 
example, in some countries, the size of the mediated BMI-IHD PAF through cholesterol, calculated by 
the mediation factor, was even bigger than the total burden of cholesterol, indicating that less effect of 
BMI is mediated through cholesterol and mediation factors are not similar across countries. 
2 – For many risk-mediator-outcome pairs, there are no data available, so we assumed the mediation is 
zero. 
3 – Since the covariance between undernutrition indicators is different by location (and across time, 
results were not reported), and there is an interaction between these indicators, the total burden might 
be underestimated. 
4 – It is assumed that there is no significant covariance between PAFs, which might not be true between 
some risk factors such as between metabolic risk factors. While this overestimation is controlled by 
using adjusted RRs, using crude RRs for BMI and other metabolic risk factors may cause significant 
overestimation of aggregated metabolic risks burden. 
Section 2.8: Step 7. Estimate attributable burden 
Four key components are included in estimation of the burden attributable to a given risk factor: the 
metric of burden being assessed (the number of deaths, years of life lost [YLLs], years lived with 
disability [YLDs], or DALYs [the sum of YLLs and YLDs]); the exposure levels for a risk factor; the relative 
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risk of a given outcome due to exposure; and the counterfactual level of risk factor exposure. Estimates 





where 𝑀𝑀𝐴𝐴𝑗𝑗𝑎𝑎𝑠𝑠𝑗𝑗𝑡𝑡 is the attributable burden for risk factor 𝑗𝑗 for age group 𝑎𝑎, sex 𝑠𝑠, location 𝑙𝑙, and year 𝑡𝑡; 
𝑀𝑀𝑀𝑀𝑇𝑇𝐷𝐷𝑗𝑗𝑗𝑗𝑎𝑎𝑠𝑠𝑗𝑗𝑡𝑡 is total DALYs for cause 𝑙𝑙 (of 𝑤𝑤 relevant outcomes for risk factor 𝑗𝑗) for age group 𝑎𝑎, sex 𝑠𝑠, 
location 𝑙𝑙, and year 𝑡𝑡; 𝐺𝐺𝑀𝑀𝑃𝑃𝑗𝑗𝑗𝑗𝑎𝑎𝑠𝑠𝑗𝑗𝑡𝑡 is the population attributable fraction (PAF) for cause 𝑙𝑙 due to risk 
factor 𝑗𝑗 for age group 𝑎𝑎, sex 𝑠𝑠, location 𝑙𝑙, and year 𝑡𝑡. The proportion of deaths, YLLs, or YLDs 
attributable to a given risk factor or risk factor cluster were analogously computed by sequentially 
substituting each metric in place of DALYs in the equation above. 
Section 2.9: Decomposition analysis of deaths and DALYs 
We conducted a decomposition analysis of changes in DALYs from 2007 to 2017, decomposing changes 
in all-age cause-specific DALYs attributable to all risk factors and individual risk factors due to changes in 
population growth, population age structure, exposure to the given risk for a disease, and risk-deleted 
death and DALY rates. In this case, risk-deleted rates are the rates after removing the effect of a risk 
factor or combination of risk factors; in other words, observed DALY rates multiplied by one minus the 
PAF for the risk or set of risks. Our decomposition analyses draw from methods developed by Das 
Gupta29 to provide a computationally tractable solution to isolating drivers of burden changes whereby 
all combinations of possible pathways are averaged across factors. Attributable burden is determined, 
following the methods of Das Gupta, as a product of three factors such that: 
𝑇𝑇𝑎𝑎𝑠𝑠𝑗𝑗𝑡𝑡 =  (𝑀𝑀𝑎𝑎𝑠𝑠𝑗𝑗𝑡𝑡  𝐴𝐴𝑎𝑎𝑠𝑠𝑗𝑗𝑡𝑡 𝐶𝐶𝑎𝑎𝑠𝑠𝑗𝑗𝑡𝑡) 
where 𝑇𝑇𝑎𝑎𝑠𝑠𝑗𝑗𝑡𝑡 represents the attributable burden at year 𝑡𝑡; 𝑀𝑀𝑠𝑠𝑗𝑗𝑡𝑡is the age-specific population size for a 
given age group 𝑎𝑎, sex 𝑠𝑠 and location 𝑙𝑙 at year 𝑡𝑡; 𝐴𝐴𝑎𝑎𝑠𝑠𝑗𝑗𝑡𝑡 is the underlying rate of the outcome unrelated 
to the risk factor or observed rate, multiplied by 1 − 𝐺𝐺𝑀𝑀𝑃𝑃 for a given age group 𝑎𝑎, sex 𝑠𝑠 and location 𝑙𝑙 
at year 𝑡𝑡; and where 𝐶𝐶𝑎𝑎𝑠𝑠𝑗𝑗𝑡𝑡 is the ratio of attributable burden to the underlying rate, which reflects the 
risk exposure effect for a given age group 𝑎𝑎, sex 𝑠𝑠, and location 𝑙𝑙 at year 𝑡𝑡 defined as 𝐺𝐺𝑀𝑀𝑃𝑃/(1 − 𝐺𝐺𝑀𝑀𝑃𝑃) 
in the case of decomposing attributable burden to a risk. Risk exposure effects for individual risk factors 
are scaled such that they sum to the all risk exposure effect by location, age, sex, and cause accounting 
for mediation. This allows for aggregation of risks; the exposure for all risks for a disease can be split into 
exposure to metabolic, behavioural, and environmental risks. The contribution of each factor to total 
change in attributable burden was determined by changing the level of one factor from time t0 to t1 – 
here 2007 to 2017 – with all other factors held constant. Thus, the effect of any of the three factors, for 
example 𝑀𝑀𝑎𝑎𝑠𝑠𝑗𝑗𝑡𝑡on the change of attributable burden between 2007 (𝑀𝑀07) and 2017 (𝑀𝑀17) is calculated as: 







Where 𝑇𝑇𝐴𝐴 is the proportion of change due to factor 𝑀𝑀, and the subscripts for each factor in the equation 
denote the year for each estimate. Since the effect depends on the order of entry of the factor, we 
calculated the average of all combinations of the three factors.29 The proportion of change due to 
factor𝑀𝑀𝑠𝑠𝑗𝑗𝑡𝑡, the age-specific population size for a given age group 𝑎𝑎, sex 𝑠𝑠 and location 𝑙𝑙 at year 𝑡𝑡, is 
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then further split, setting change in population growth equal to the percent change in all-age population 
from time t0 to t1 and change in population age structure to the residual, giving four factors. 
This three factor decomposition method does not work for risks where the PAF, by definition, is 100% 
(such as high fasting plasma glucose and diabetes type 2) or where the PAF is directly estimated (such as 
for unsafe sex and HIV). In the cases of  child underweight and protein-energy malnutrition, child 
wasting and protein-energy malnutrition, short gestation for birth weight and neonatal preterm birth 
complications, low birth weight for gestation and neonatal preterm birth complications, iron deficiency 
and iron-deficiency anaemia, alcohol use and liver cancer due to alcohol use, alcohol use and cirrhosis 
and other chronic liver diseases due to alcohol use, alcohol use and alcohol use disorders, alcohol use 
and alcoholic cardiomyopathy, drug use and drug use disorders, occupational particulate matter, gases, 
and fumes and other pneumoconiosis, occupational particulate matter, gases, and fumes and coal 
workers pneumoconiosis, occupational exposure to asbestos and asbestosis, and occupational exposure 
to silica and silicosis, we used a two factor decomposition method, which examines the contribution of 
population, ageing, and risk exposure. Effectively, we assume trends in these cases are driven by 
exposure, not change in the risk-deleted rates. Conversely, for unsafe sex and sexually transmitted 
diseases excluding HIV, we used a two-factor decomposition method, which examines the contribution 
of population, ageing, and risk-deleted death and DALY rates, assuming trends in these cases are driven 
by risk-deleted rates, not change in exposure. For high fasting plasma glucose and diabetes mellitus type 
1 and 2, high fasting plasma glucose and chronic kidney disease due to diabetes mellitus type 1 and 2, 
high systolic blood pressure and hypertensive heart disease, high systolic blood pressure and chronic 
kidney disease due to hypertension, and impaired kidney function and chronic kidney disease, we used 
GBD estimates of Summary Exposure Values (SEVs) for the given risk and the case-fatality rate 
decompose trends into the contribution of the three factors. Similarly, for unsafe sex and cervical 
cancer, we used GBD estimates of the incidence of cervical cancer and the case-fatality rate to 
decompose trends into the contribution of the three factors. For unsafe sex and HIV, we used spectrum 
counterfactual and CD4 risk-weighted prevalence. 
Section 2.10: SDI Analysis 
Section 2.10.1: Development of SDI 
The Socio-demographic Index (SDI) is a composite indicator of development status strongly correlated 
with health outcomes. In short, it is the geometric mean of 0 to 1 indices of total fertility rate under the 
age of 25 (TFU25), mean education for those aged 15 and older (EDU15+), and lag distributed income (LDI) 
per capita. 
Section 2.10.2: Development of revised SDI indicator 
SDI was originally constructed for GBD 2015 using the Human Development Index (HDI) methodology, 
wherein a 0 to 1 index value was determined for each of the original three covariate inputs (total fertility 
rate in ages 15 to 49, EDU15+, and LDI per capita) using the observed minima and maxima over the 
estimation period to set the scales.  
In response to feedback from collaborators and the evolution of the GBD, we have refined the indicator 
with each GBD cycle. For GBD 2017, in conjunction with our expanded estimation of age-specific fertility, 
we chose to replace the total fertility rate as one of the three component indices with the total fertility 
rate under 25 (TFU25). The TFU25 provides a better measure of women’s status in society, as it focuses 
on ages where childbearing disrupts the pursuit of education and entrance into the workforce. 
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During GBD 2016, we moved from using relative index scales to absolute scales to enhance the stability 
of SDI’s interpretation over time, as we noticed that the measure was highly sensitive to the addition of 
subnational units that tended to stretch the empirical minima and maxima. We selected the minima and 
maxima of the scales by examining the relationships each of the inputs had with life expectancy at birth 
and under-5 mortality and identifying points of limiting returns at both high and low values, if they 
occurred prior to theoretical limits (e.g., a TFU25 of 0). 
Thus, an index score of 0 represents the minimum level of each covariate input past which selected health 
outcomes can get no worse, while an index score of 1 represents the maximum level of each covariate 
input past which selected health outcomes cease to improve. As a composite, a location with an SDI of 0 
would have a theoretical minimum level of development relevant to these health outcomes, while a 
location with an SDI of 1 would have a theoretical maximum level of development relevant to these health 
outcomes.  
We summarize the final scales for GBD 2017 in the table below. 
Input Lower Bound Upper Bound 
TFU25 0 3 
LDI per capita 250 USD (5.5 log USD)b 60,000 USD (11.0 log USD) 
EDU15+ 0 years 17 years 
b The minimum for the LDI scale was originally set at the theoretical limit of 0 USD, as we did not observe an asymptotic 
relationship between log(LDI) and E0 or 5q0 at lower values of log(LDI). Empirically, however, we also did not observe an LDI 
below 350 USD (5.86 log USD) for the estimation period 1970-2016. In log-space, this meant that approximately half of our 
scale was not being utilized, compressing the observed variation in LDI and diminishing its meaningful contribution to SDI. 
Accordingly, we set the lower limit on LDI to 250 USD (5.52 log USD) to ensure we were fully utilizing the range of the scale to 
capture its variation across space and time, as is the case with the other two inputs. 
Using scales described above, we computed the index scores underlying SDI as follows: 
𝐼𝐼𝑐𝑐𝑙𝑙𝐶𝐶 =
(𝐶𝐶𝑙𝑙𝐶𝐶 − 𝐶𝐶𝑙𝑙𝑗𝑗𝑤𝑤)
(𝐶𝐶ℎ𝑖𝑖𝑗𝑗ℎ − 𝐶𝐶𝑙𝑙𝑗𝑗𝑤𝑤)�  
Where 𝐼𝐼𝑐𝑐𝑙𝑙𝐶𝐶 – the index for covariate C, location l, and year y – is equal to the difference between the value 
of that covariate in that location-year and the lower bound of the covariate divided by the difference 
between the upper and lower bounds for that covariate. If the values of input covariates fell outside the 
upper or lower bounds (e.g. LDI per capita greater than 60,000 USD), they were mapped to the respective 
upper or lower bounds. We also note that the index value for TFU25 was computed as 1 − 𝐼𝐼𝑇𝑇𝑀𝑀𝑇𝑇25𝑙𝑙𝐶𝐶, as 
lower TFU25s correspond to higher levels of development, and thus higher index scores. For GBD 2017 
we expanded the computation of SDI to 890 national and subnational locations spanning the time period 
1950-2017.  
The composite Socio-Demographic Index is the geometric mean of these three indices for a given location-
year. The cut-off values used to determine quintiles for analysis were then computed using country-level 
estimates of SDI for the year 2017, excluding countries with populations less than 1 million. 
Example calculation 
Below we present an example calculation of SDI for “Country X”: 
𝑇𝑇𝑃𝑃𝑇𝑇25 = 1.09;  𝑀𝑀𝑒𝑒𝑎𝑎𝑀𝑀 𝑒𝑒𝑑𝑑𝑢𝑢𝑐𝑐 𝑦𝑦𝑁𝑁𝑠𝑠 𝑝𝑝𝑐𝑐 = 8.23;  𝑙𝑙𝑀𝑀𝑇𝑇𝑀𝑀𝐼𝐼 = 9.60 
44
𝐼𝐼𝑇𝑇𝑀𝑀𝑇𝑇25 = 1 −  
1.09 − 0
3 − 0
=  .637 
𝐼𝐼𝑇𝑇𝑐𝑐𝑢𝑢𝑐𝑐 =  
8.23− 0 
17− 0




=  .744 
𝑆𝑆𝑀𝑀𝐼𝐼 =  �𝐼𝐼𝑇𝑇𝑀𝑀𝑇𝑇25 ∗ 𝐼𝐼𝑇𝑇𝑐𝑐𝑢𝑢𝑐𝑐 ∗ 𝐼𝐼𝑙𝑙𝑛𝑛𝐿𝐿𝑙𝑙𝐼𝐼




=  .741 
𝑆𝑆𝑀𝑀𝐼𝐼 =  �𝐼𝐼𝑇𝑇𝑀𝑀𝑐𝑐 ∗ 𝐼𝐼𝑇𝑇𝑐𝑐𝑢𝑢𝑐𝑐 ∗ 𝐼𝐼𝑙𝑙𝑛𝑛𝐿𝐿𝑙𝑙𝐼𝐼
3 =  √. 855 ∗ .543 ∗  .7413 =  .701 
SDI grouping by location can be found in Appendix Table 9, and SDI values can be found in Appendix 
Table 10.  
Section 2.11: Epidemiological Transition 
Section 2.11.1: Derivation of expected SEVs 
In order to evaluate the average relationship between SDI attributable burden, we first quantified that 
between SDI and population-level exposure.  Using the “gam” package in R, we fit a generalized additive 
model (GAM) with a loess smoother on SDI by age and sex group. For age a, sex s¸and risk r. 
𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑡𝑡(𝑆𝑆𝑇𝑇𝑆𝑆𝑎𝑎𝑠𝑠𝑟𝑟) =  𝛽𝛽0 +  𝑠𝑠(𝑆𝑆𝑀𝑀𝐼𝐼) + 𝜖𝜖 
Inputs to this model were age-sex specific SEVs for all most-detailed risks in the GBD risk hierarchy 
corresponding to all national GBD locations and years between 1990 and 2017. The span for the loess 
term was set at a default of .7, and the model was fit on the middle 95% of the data to mitigate the 
impact of compositional bias evident in outliers very close to zero or one. Expected age and sex 
proportions of the population on the basis of SDI produced through an analogous modelling framework 
were used to generate age and sex aggregates of expected exposure. 
Section 2.11.2: Calculating attributable burden 
Borrowing from forecasting methods, we generated an estimated expected risk-specific 𝐺𝐺𝑀𝑀𝑃𝑃 by back-
transforming the expected 𝑆𝑆𝑇𝑇𝑆𝑆 to 𝐺𝐺𝑀𝑀𝑃𝑃, rearranging the formula for 𝑆𝑆𝑇𝑇𝑆𝑆 described in further detail in 
the appendix to solve to 𝐺𝐺𝑀𝑀𝑃𝑃 for a given age 𝑎𝑎, sex 𝑠𝑠, cause 𝑐𝑐, risk 𝑁𝑁, and SDI 𝑑𝑑, 
𝐺𝐺𝑀𝑀𝑃𝑃𝑎𝑎𝑠𝑠𝑐𝑐𝑟𝑟𝑐𝑐 = 1 −  
1
𝑆𝑆𝑇𝑇𝑆𝑆𝑎𝑎𝑠𝑠𝑟𝑟𝑐𝑐  ×  (𝑅𝑅𝑅𝑅𝑎𝑎𝑠𝑠𝑐𝑐𝑟𝑟𝑚𝑚𝑎𝑎𝑥𝑥 − 1) + 1
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As 𝐺𝐺𝑀𝑀𝑃𝑃 estimates are derived directly from the 𝑆𝑆𝑇𝑇𝑆𝑆 which is not cause specific, but averaged 
across causes, we then calculated a correction factor 𝐶𝐶𝑃𝑃 by comparing in logit space the empirical 𝐺𝐺𝑀𝑀𝑃𝑃 
to the 𝑆𝑆𝑇𝑇𝑆𝑆 derived estimate 𝐺𝐺𝑀𝑀𝑃𝑃, 
𝐶𝐶𝑃𝑃𝑎𝑎𝑠𝑠𝑐𝑐𝑟𝑟 = 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑡𝑡�𝐺𝐺𝑀𝑀𝑃𝑃𝑎𝑎𝑠𝑠𝑐𝑐𝑟𝑟𝑙𝑙𝐶𝐶� − 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑡𝑡(𝐺𝐺𝑀𝑀𝑃𝑃𝑎𝑎𝑠𝑠𝑐𝑐𝑟𝑟𝑙𝑙𝐶𝐶) 
and apply the correction factor to the estimated expected 𝐺𝐺𝑀𝑀𝑃𝑃 to derived an adjusted expected 
estimated 𝐺𝐺𝑀𝑀𝑃𝑃 
𝐺𝐺𝑀𝑀𝑃𝑃𝑎𝑎𝑠𝑠𝑐𝑐𝑟𝑟𝑐𝑐 = 𝑒𝑒𝑥𝑥𝑝𝑝𝑙𝑙𝑡𝑡(𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑡𝑡(𝐺𝐺𝑀𝑀𝑃𝑃𝑎𝑎𝑠𝑠𝑐𝑐𝑟𝑟𝑐𝑐) + 𝐶𝐶𝑃𝑃𝑎𝑎𝑠𝑠𝑐𝑐𝑟𝑟) 
for all most-detailed risks in the hierarchy, excluding unsafe sex and occupational injuries, by age, sex, 
cause, and SDI, adding in risk-outcome 
To estimate expected risk-attributable burden, we draw from the CRA methods (see Appendix 
Section 2.6), first calculating the joint adjusted expected 𝐺𝐺𝑀𝑀𝑃𝑃 for all risks for a cause using mediation 
factors. We then draw from the methods for observed risk-attributable burden calculation, using 
expected YLLs, deaths, and YLDs (see Appendix Section 2.7) to generate expected burden for a given SDI, 
not location year.  
𝑀𝑀𝐴𝐴𝑟𝑟𝑎𝑎𝑠𝑠𝑐𝑐𝑐𝑐 = �𝑀𝑀𝑀𝑀𝑇𝑇𝐷𝐷𝑎𝑎𝑠𝑠𝑐𝑐𝑐𝑐𝐺𝐺𝑀𝑀𝑃𝑃𝑟𝑟𝑎𝑎𝑠𝑠𝑐𝑐𝑐𝑐 
where 𝑀𝑀𝐴𝐴𝑟𝑟𝑎𝑎𝑠𝑠𝑐𝑐𝑐𝑐 is the expected attributable burden; 𝑀𝑀𝑀𝑀𝑇𝑇𝐷𝐷𝑎𝑎𝑠𝑠𝑐𝑐𝑐𝑐 is expected total; 𝐺𝐺𝑀𝑀𝑃𝑃𝑎𝑎𝑠𝑠𝑐𝑐𝑟𝑟𝑐𝑐 is the expected 
PAF. The proportion of expected deaths, YLLs, or YLDs attributable to a given risk factor or risk factor 
cluster were analogously computed by sequentially substituting each measure in place of expected 
DALYs in the equation above. Comparisons of observed to expected attributable burden were made to 
identify locations exhibiting exceptional deviations relative to what would be expected based on their 
development status. 
Section 2.12: Additional Methods Information 
Section 2.12.1: Risk-specific comparisons to other estimates 
Low birth weight / Short Gestation:  
GBD 2017 estimates of total preterm birth prevalence are generally in line with country-specific 
reports30 as well as the most recent global analysis completed by Blencowe and colleagues.31 GBD 2017 
estimates of preterm birth prevalence in 2010 are very similar, 11.3% (95% UI: 11.1% to 11.5%) versus 
11.1% of live births, compared to estimates by Blencowe and colleagues. Close agreement is not 
surprising as most of the same data sources were used as data inputs to our modelling process, although 
the GBD analysis included almost eight times as many data points. Most reports, like GBD 2017, have 
assessed temporal trends in preterm birth in many locations to be either static or increasing. Compared 
to UNICEF estimates of low birth weight,32 GBD 2017 estimates of global birth prevalence of 14.4% 
(14.0% to 14.8%) are similar but slightly lower than the estimate of 15.5% birth prevalence globally. The 
geographic variation in low birth weight largely mirrors that of the UNICEF report. 
Chewing Tobacco 
In GBD 2016, we estimated age-sex specific and aggregate current smokeless tobacco use prevalence for 
all countries and territories from 1990-2016 using all available data. The estimated prevalence was then 
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attributed to either all chewing tobacco, or all snus/snuff by country, based on input from smokeless 
tobacco experts.  
For GBD 2017, we have changed the exposure definition from current smokeless tobacco use to current 
chewing tobacco use, based on the strength of evidence supporting the health effects of chewing 
tobacco use. By estimating chewing tobacco exposure in all countries and territories, burden is now 
estimated for locations previously classified as predominantly snus/snuff, but still have non-negligible 
use of chewing tobacco. 
We compared GBD estimates to recent research by Siddiqi et al.33 on smokeless tobacco prevalence, 
risk, and burden in 2015. Our methods differed from Siddiqi on some key points: 
Prevalence estimation: We estimated both age-sex specific and aggregate current smokeless 
tobacco use prevalence for all countries and territories included in GBD from 1990-2017 using 
all available data. Siddiqi et al. used only the single most recent survey available containing data 
on smokeless tobacco use among adults.  
Relative risks and attributable burden: GBD excluded hospital-based case-control studies, while 
Siddiqi included them. GBD calculated relative risks for chewing tobacco (and by sex for oral 
cancer only), while Siddiqi calculated separate relative risks by geography, and then pooled 
these to produce global relative risks. Siddiqi used country- or region-specific relative risks 
where available, and in the absence of region-specific relative risks assigned global relative risks 
in countries predominantly using products with moderate to high pH and tobacco-specific 
nitrosamine (TSNA) levels.  
The main differences in attributable burden come from the relative risk exclusion criteria. GBD’s 
exclusion of hospital-based led to very different relative risk outputs: we found significant relative risks 
for oral cancer and oesophageal cancer. Siddiqi found significant relative risks for oral, pharyngeal, and 
oesophageal cancers and ischemic heart disease, resulting in higher levels of global burden. 
Smoking 
We compared GBD estimates to the most recent report on the global tobacco epidemic published by 
WHO30. Overall, we found marked similarities in estimates. Among the 142 countries and territories 
included in the WHO report and estimated in GBD, the correlation coefficient for current smoking 
prevalence estimates among females was 0.91 and among males was 0.85. In cases where estimates 
diverge, discordance can be attributed to differing modelling methods or data sources. GBD uses ST-GPR 
to estimate smoking prevalence, whereas WHO uses Bayesian meta-regression (DisMod MR). 
Additionally, the WHO model was fit on 1,175 country-year data sources, whereas the GBD model was 
fit on 2,870 country-year data sources. There are no comparable global estimates of the burden of 
disease attributable to smoking, as GBD 2015 estimates of attributable burden were used in the most 
recent WHO report. 
Ambient air pollution 
In the past few years, other researchers have estimated the burden of disease due to air pollution using 
different data and methods. Other sources of estimates have been compared to those of the GBD. Since 
their introduction in GBD 2010, satellite-based estimates of PM2.5 and the Integrated Exposure Response 
(IER), have been widely adopted. Recent estimates from WHO31 of 3·0 million deaths in 2012 used a 
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similar exposure estimate model as that presented here, but an earlier (GBD 2013) version of the 
integrated exposure response (IER) and somewhat different baseline disease burden estimates. 
Lelieveld and colleagues32 analysed source sector contributions to air pollution and the resulting disease 
burden in 2010 and estimated the burden in 2050. These estimates used an older (GBD 2010) IER. 
Furthermore, the coarse spatial resolution (∼100 × 100 km) of the exposure estimates introduced errors 
via spatial misalignment between exposure and population density compared with our estimates. Silva 
et al. estimated 2.23 million deaths/year due to anthropogenic PM2.5 and 493 thousand deaths per year 
due to ozone,33 while Butt et al. estimated 12.4% global attributable deaths due to PM2.5 in the year 
2009,34 both using versions of the IER. 
In GBD 2017, we added Type 2 diabetes as an outcome of ambient particulate matter pollution 
estimating 184 thousand attributable deaths and 10.5 million attributable DALYs globally in the year 
2017. An independent group of researchers recently published work estimating the 2016 burden of 
diabetes attributable to ambient PM2.5.35 Using GBD 2015 PM2.5 exposure estimates, GBD 2016 diabetes 
burden, and generating their own IER the team estimated 206 thousand attributable deaths and 8.23 
million attributable DALYs globally for the year 2016. 
Occupational 
Takala and colleagues36 reported 2.3 million deaths attributable to occupational injury/illness in 2011. In 
the closest comparison year of 2007, GBD estimated nearly 1.1 million deaths. This discrepancy is largely 
driven by the cause-outcome pairs that GBD currently has the evidence to include based on the criteria 
of the CRA framework. For example, 45% of Takala’s reported burden is driven by occupational 
circulatory disease (35%) and occupational communicable disease (10%). Circulatory diseases are linked 
to occupational risks like shift work and lack of control, but the GBD approach currently has insufficient 
evidence to estimate the variability in exposure to these factors on a global scale. Additionally, the use 
of a CRA approach in GBD estimates requires careful consideration of proposed counterfactual in order 
to derive the TMREL for a given risk. The TMREL for something like occupational lack of control is a 
challenging concept, and as such, these risks are still being reviewed for possible inclusion in future 
iterations of the GBD. 
Takala also reports higher burden from occupational cancer based on the inclusion of carcinogens that 
are currently still out of the scope of GBD. For example, the authors use attributable fractions derived 
from Rushton and colleagues to attribute pairs like breast cancer and shift work or skin cancer and solar 
radiation. These carcinogens, which form a large part of the cancer burden in Takala/Rushton are 
currently not included in the GBD based on limited exposure data across the time/space that GBD 
estimates38. 
In terms of fatal occupational injuries, Takala reported 353 000 deaths in 2011. The GBD 2017 
estimate for deaths attributable to occupation was approximately 348 000 deaths for 2007. The 
figures are very similar but the GBD estimates are slightly lower, again due to the selection of risk-cause 
pairs. The ILO estimation strategy includes some kinds of injuries, such as deaths due to intentional 
violence that the GBD does not attribute to occupation.  
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Child growth failure (stunting, wasting, and underweight)  
UNICEF et al estimate lower proportion of stunting (height-for-age z-score < -2 standard deviations 
below the reference median) in children under five in 2017 than GBD 2017.37 The geographic patterns 
generally agree in identifying sub-Saharan Africa and South Asia as the regions with the largest burden 
of stunting (prevalence and magnitude, estimated as number of stunted children in UNICEF et al, and as 
DALYs in GBD 2017), with additional high prevalence in Oceania (excluding Australia and New Zealand) 
and moderate prevalence in Latin America and the Caribbean. While UNICEF et al estimates highlight 
minimal or lack of progress in reducing stunting since 2000 in Africa and Oceania, GBD 2017 estimates 
show moderate decline in sub-Saharan Africa and North Africa and the Middle East, and a small decline 
in Oceania (compared to UNICEF et al’s rise in stunting prevalence in Oceania). GBD 2017 estimates 
show a downward trend in the prevalence of underweight (weight-for-age z-score < -2 standard 
deviations below the reference median) among children under 5 in 2016, driven largely by populations 
in sub-Saharan Africa and South Asia, a trend also reflected in the UNICEF et al estimates.  
Impaired Kidney Function  
Recently published estimates from a meta-analysis of global data on exposure to impaired kidney 
function indicate prevalence of chronic kidney disease (CKD) stages 1-5 to be 13.4% (11.7-15.1%). (ref) 
These estimates are similar to the current GBD 2017 exposure estimates across all four levels of 
impaired kidney function, which indicate a prevalence for individuals over the age of 25 of 14.0% (13.0-
15.1%). 
Household Air Pollution 
WHO estimated 4.3 million deaths and 146.5 million DALYs attributable to exposure to household air 
pollution globally in 2012, as compared to GBD 2017 estimates for the year 2017 of 1.6 million deaths 
and 59 million DALYs. Differences in attributable burden arise between the WHO estimates and GBD 
2016 for a number of reasons. First, the IER curve was used for all outcomes (LRI, IHD, cerebrovascular 
stroke, COPD, Type II Diabetes, and lung cancer) except cataracts in our analysis, while WHO adapted 
relative risks for COPD based on a meta-analysis of published RR estimates. The excess relative risks for 
COPD used by WHO are larger than the excess relative risks used in GBD, resulting in a larger PAF. 
Additionally, this was the first year we included Type II Diabetes as an outcome of particulate matter 
pollution, including household exposure to solid fuel. WHO has not included this as an outcome in their 
estimates.  Finally, WHO only estimates LRI deaths in children aged 0-4, while we estimate respiratory 
infections and pneumonia at all ages.  
Additionally, by adapting the new proportional PAF approach for particulate matter pollution, beginning 
in GBD 2017 we are taking into account ambient pollution in the counterfactual of household. This has 
reduced burden estimates from previously published numbers, which we believe more accurately 
reflects the exposure-outcome relationship.  
Another difference from the WHO estimates is the use of a database which maps solid cooking fuel use 
to PM2.5 exposure, allowing us to model differences in exposure level and relative risk by location, while 
WHO relies on global relative risks. We also adjust this household PM2.5 exposure by ambient air 
pollution levels since personal PM2.5 exposure captures all sources of exposure. WHO makes no 
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adjustments for ambient air pollution exposure. In addition to the differences in data sources, we 
estimated the burden of cataract attributable to household air pollution (HAP) only in women while 
WHO estimated for both sexes.  
Below is a comparison between the WHO38 and GBD 2017 of the number of DALYs attributed to HAP 
contributed by each cause (GBD 2017 on right): 
• 48,500,000-Pneumonia/LRI 25,400,000-Lower respiratory infections 
• 36,900,000-Stroke 8,010,000-stroke 
• 30,500,000-Ischaemic heart disease 9,170,000-IHD 
• 22,100,000-COPD 11,700,000-COPD 
• 6,720,000-Lung cancer 1,780,000-Lung cancer 
• 1,670,000-Cataract 1,230,000-Cataract 
• 0-Type 2 diabetes 830,000-Type 2 diabetes 
Breastfeeding
Globally, WHO estimates that 40% of infants under six months of age are exclusively breastfed, which is 
consistent with the GBD 2017 estimate (40.3%). A recent WHO study estimates 73.3% continued 
breastfeeding at one year of age globally, where the GBD 2017 estimate of continued breastfeeding 
between 6 and 11 months is 88% (we expect our estimates to be higher, as our estimates measure 
breastfeeding for any infants age 6-11 months, while the WHO estimates focus on breastfeeding status 
at the age of 1 year).39 CDC reports 25% of mothers in the United States exclusively breastfeed their 
child through 6 months of age, while GBD 2017 estimates that 42% of infants 0-5 months are exclusively 
breastfed (this difference is again explained by our estimates focusing on all infants 0-5 months, while 
the CDC reports infants who complete 6 full months of exclusive breastfeeding). Additionally, CDC 
reports 34% of mothers in the U.S. continue to breastfeed at 12 months of age. GBD estimates 44% of 
mothers in the U.S. continue to breastfeed from 6 to 11 months of age. Finally, in India, WHO and 
UNICEF estimate 55% exclusive breastfeeding in the first six months of life, comparable to the GBD 2017 
estimate of 55%. 
WaSH 
The Joint Monitoring Project40 (JMP), which is led by WHO and UNICEF, estimates water, sanitation, and 
handwashing access throughout the world. Globally, JMP estimates that 91% of population had access 
to an improved water source in 2015, while GBD estimates 88% of the population have access to 
improved water. Additionally, JMP reported the global prevalence of households with piped water 
connection to be 57% in 2015, while GBD reports piped prevalence of 53% for that year. JMP reported 
68% of population had access to improved sanitation in 2015, whereas GBD estimates improved 
sanitation prevalence of 74%. The slight discrepancies in these estimates at the global level can be 
largely attributed to differences in input data. The JMP relies almost exclusively on large-scale 
household surveys (DHS and Multiple Indicator Cluster Surveys [MICS]), while GBD estimates 
incorporate exposure data from smaller, yet still nationally representative, survey series such as 
Reproductive Health Survey and various country specific surveys. Due to the relative dearth of data 
regarding access to a handwashing facility, the JMP only generates handwashing estimates for a select 
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number of countries (mostly sub-Saharan Africa) where those data are actually collected. However, we 
model and predict handwashing facility prevalence for all locations, even in the absence of data, and 
estimates that 67% of the globe has access to a handwashing facility. 
Lead 
The most recent external estimates for the burden of lead exposure were conducted by WHO in 2004 
and provided disaggregated average exposures for children and adults in different regions of the 
world.41 The GBD 2017 exposure estimates for the early 2000s are generally higher than these 
estimates, as we have observed higher estimates of exposure in GBD 2017 with changes in model 
covariates and covariate effects. The WHO study calculated a global burden attributable to lead 
exposure of 13 million DALYs, which includes 229 000 deaths. GBD 2017 estimates global burden 
attributable to lead exposure to be 24.4 million DALYs, including approximately 1.05 million deaths.  
In addition to differences in overall attributable burden, the breakdown of burden from intellectual 
disability and cardiovascular disease is very different. Both attribute 2% to 3% of global CVD to lead 
exposure, but our estimates of CVD burden in 2007 are higher than WHO’s (such that we estimate 18.1 
million DALYs from CVD due to lead in 2007 compared to their estimate of 3.1 million). Additionally, our 
methodology for intellectual disability differs substantially from theirs. In the WHO study, they used a 
higher disability weight of 0.361 for intellectual disability, whereas we currently use weights ranging 
from 0.01 to 0.2 (depending on the severity). However, WHO’s estimates of intelligence quotient (IQ) 
shift from lead exposure are much lower than ours, since recent studies have provided better evidence 
for notable effects of lead on IQ at low levels of exposure. Still, due to differences in our estimates of the 
underlying burden of intellectual disability, our estimate of 2.67 million DALYs from intellectual disability 
attributable to lead exposure in 2007 is much smaller than their estimate of 9.8 million.  
Intimate partner violence 
WHO reports a global lifetime prevalence of physical and/or sexual intimate partner violence among 
ever-partnered women of 30.0% (27.8-32.2).(ref) For GBD 2017, the estimated all-age global exposure 
for intimate partner violence (IPV) in 2017 is 19.7% (16.1-24.3) among all women, which is a smaller 
estimate than the WHO estimate because WHO estimates are among only ever-partnered women, while 
the estimates used for GBD risk factor exposure are among all women. After making an adjustment 
using our model for the proportion of women who have ever been partnered, we estimate global 
lifetime IPV exposure as 32.5% (25.9-40.9) among ever-partnered women – an estimate that agrees with 
the WHO report. The regional distribution reported by WHO is in agreement with the distribution by 
GBD super-region; highest prevalence of IPV in North Africa and Middle East; South Asia; and sub-
Saharan Africa and lower prevalence in Southeast Asia, East Asia, and Oceania; Central Europe, Eastern 
Europe, and Central Asia; high-income; and Latin American and Caribbean. 
Iron deficiency 
Iron deficiency (ID) was the fourth ranked level 3 risk factor in 1990, decreasing to sixth in 2017 after 
increasing 15.23% over that time period in terms of attributable YLDs, almost all of which was YLDs due 
to dietary iron deficiency (IDA). We have not identified any other global, systematic analyses of ID as a 
risk factor for increased disease burden so we are not able to compare our estimates of ID-attributable 
health loss. There are a number of other studies that have evaluated the prevalence of ID and IDA, 
however.42 The most comprehensive meta-analysis from Low and Middle-Income Countries (LMIC) 
estimated a much lower prevalence of ID/IDA than we have for GBD 2017. There are three aspects that 
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make a direct comparison with GBD 2017 difficult. First, the study by Petry and colleagues likely 
underestimated ID/IDA somewhat by applying a single cut-off for diagnosing ID of <12 grams per 
decilitre of plasma ferritin concentration, especially with the acknowledged limitation of not being able 
to fully account for the effect of inflammation in many of its component studies. Second, Petry and 
colleagues did not distinguish aetiologies of ID/IDA whereas GBD does distinguish many causes of 
anaemia (e.g. hookworm, gastritis) that can manifest as ID. Third, whereas Petry and colleagues made 
direct estimation of ID/IDA from serum measurements, the GBD approach for estimating ID/IDA is 
indirect and therefore does not have a directly comparable case definition. We began by first estimating 
overall anaemia then, after reassigning large portions to >25 other underlying causes, used fixed 
proportion redistribution methods to estimate IDA. The risk exposure for ID was then estimated as a 
counterfactual haemoglobin concentration in the absence of all the “other” causes rather than an 
explicit prevalence value. Unless all possible causes of anaemia are included, the GBD approach has 
potential to overestimate the proportion of anaemia to be redistributed to ID/IDA in places where other 
causes are important. We have begun work to address this in GBD 2017 by adding Cirrhosis, Crohn’s 
Disease, Ulcerative Colitis, and others as causes of anaemia, but there are still a number of others (e.g. 
cancers, alpha thalassemia, intestinal infections, and other nutritional deficiencies) that have yet to be 
included. 
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Section 4: Risk-specific estimation 
The risk-specific modelling write-ups follow the order of the risk factor hierarchy for GBD 2017. In some 
cases, multiple risk factors are addressed in a single write-up, for example child underweight, wasting, 
and stunting are all included in a single detailed write-up.  
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Input data & methodological summary 
Exposure 
Case definition 
For GBD 2017, exposure to unsafe water was defined based on reported primary water source used by 
the household and use of household water treatment (HWT) to improve the quality of drinking water 
before consumption. Water sources were defined as “improved” based on the JMP designation,1 which 
includes piped water as improved water, and households with access to piped water connection to the 
house, yard, or plot were defined as having access to piped water supply. Solar treatment, chlorine 
treatment, boiling, or the use of filters were all established as effective point-of-use household water 
treatments based on effect sizes calculated from network meta-analysis. 
Input data 
The search for usable household surveys and censuses was conducted using the Global Health Data 
Exchange (GHDx) database. HWT input data is primarily limited to two large survey series (DHS and 
MICS) due to data availability. Water source data includes censuses and nationally representative 
surveys such as DHS, MICS, AIS, and WHS. For each survey, household sample weights were multiplied 
by the number of household members to produce a weighting scheme that estimates proportion of 
individuals, not proportion of households, exposed to a given indicator. Surveys and censuses were then 
tabulated to the two water source and two water treatment categories of interest for each location. 
Modelling 
Water source data is modelled using an ordinal framework, with two distinct models: prevalence of 
piped water and proportion of improved water (excluding piped) within the non-piped population. Both 
models produce results for each unique location, year combination. This ordinal framework allows us to 
estimate the category with the most data (piped water prevalence) and leverage that estimate to 
58
anchor the estimates for improved and unimproved water categories. The results of the improved 
proportion model are multiplied by the piped water prevalence to calculate improved water prevalence. 
The sum of improved and piped water prevalence are subtracted from 1 to yield unimproved water 
prevalence.  
HWT categories are estimated in a similar ordinal framework, by modelling prevalence of individuals 
using no water treatment methods and proportions of households that boil/filter water within the 
population of households that engage in treatment methods. The prevalence of individuals that 
boil/filter drinking water is calculated by multiplying the proportion that boil/filter modelled previously 
times prevalence of any water treatment (estimated by subtracting prevalence of no treatment from 1). 
The prevalence of individuals that treat their water using solar/chlorine methods was estimated by 
subtracting the sum of prevalence of no treatment estimates and prevalence of filter/boil treatment 
from 1. By year and location, each of the above categories are modelled using a 3-step modelling 
scheme of mixed effect linear regression followed by spatio-temporal Gaussian process regression (ST-
GPR), which produces full time series estimates for each GBD 2017 location. Socio-demographic index 
(SDI), a composite metric combining education per capita, income per capita, and fertility, was set as a 
fixed effect in the linear regression since it proved to be a significant predictor. Random effects were set 
at GBD 2017 region and super-region levels to fit the models but were not used in the predictions. 
The process of vetting and validating models was accomplished primarily through an examination of ST-
GPR scatter plots by GBD 2017 location from 1990-2017. Any unfitting data points were re-inspected for 
error at the level of extraction and survey implementation, and subsequently excluded from analysis if 
deemed appropriate. In addition to SDI, a number of different potential fixed effects were considered, 
including lag-distributed income and urbanicity, but SDI proved to be the strongest predictor of the 
unsafe water categories. Uncertainty in the estimates was initially formed based on standard deviation 
by survey, then propagated through ST-GPR modelling by means of confidence intervals around each 
data point that reflect the point-estimate specific variance. 
Once models are vetted, full time series outputs from ST-GPR modelling are then converted from 
proportion to prevalence by year and geography and then rescaled to form 9 mutually exclusive 




Unimproved, no HWT 
Proportion of individuals that primarily use unimproved source, and do not 
use any HWT to purify their drinking water. 
Unimproved, chlorine/solar Proportion of individuals that primarily use unimproved source, and solar or 
chlorine treatment to purify their drinking water. 
 
Unimproved, boil/filter 
Proportion of individuals that primarily use unimproved source, and boil or 
filter to purify their drinking water.  
 
Improved water except piped, 
no HWT 
Proportion of individuals that primarily use improved sources other than 
piped water supply, and do not use any HWT to purify their drinking water.  
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Improved water except piped, 
chlorine/solar 
Proportion of individuals that primarily use improved sources other than 
piped water supply, and use solar or chlorine treatment to purify their 
drinking water.  
Improved water except piped,  
boil/filter 
Proportion of individuals that primarily use improved sources other than 
piped water supply, and boil/filter their drinking water.  
 
Basic piped water, no HWT 
Proportion of individuals that primarily use basic piped water supply, and do 
not use any HWT to purify their drinking water 
Basic piped water, 
chlorine/solar 
Proportion of individuals that primarily use basic piped water supply, and use 
solar or chlorine water treatment to purify their drinking water.  
 
Basic piped water, boil/filter 
Proportion of individuals that primarily use basic piped water supply, and boil 
or filter to purify their drinking water 
High-quality (HQ) piped water, 
boil/filter 
Proportion of individuals that primarily use basic piped water supply, and boil 
or filter to purify their drinking water 
 
We modelled the microbiological quality of piped water sources primarily using data a review by Bain et 
al.1 that measured proportion of piped water sources contaminated with fecal indicators. We use the 
value generated from this model to split the prevalence of piped water into basic piped water and high 
quality piped water by location, year, age, and sex. 
A substantial limitation in our analysis is the paucity of data on HWT and piped water quality. The 
inclusion of more location-specific data on water treatment utilisation at the household level can greatly 
improve our estimates in future iterations. 
Theoretical minimum-risk exposure level 
The theoretical minimum-risk exposure level for unsafe water is defined as all households have access to 
high quality piped water that has been boiled or filtered before drinking. 
Relative risks 
For GBD 2017, unsafe water was paired with one outcome-diarrheal diseases-given evidence provided 
by relative risk studies. A meta-analysis by Wolf et al.3 provided the bulk of the relative risk evidence for 
the relationship between unsafe water and diarrheal diseases. This meta-analysis was updated through 
a literature review that searched for related intervention studies post-2014 conducted in PubMed. 
Search terms used were identical to those provided by Wolf et al.3 Relative risk values for water-source 
interventions and point-of-use treatment interventions were calculated using network meta-analysis 
approach so as to include studies that differ in control groups within the same analysis. This analysis 
produced distinct relative risks for each water source and water treatment category. The combined 
effect of a source intervention and point-of-use intervention was assumed to be multiplicative in order 
to match GBD 2017 exposure definitions. Please refer to appendix tables for more information on 




1. "Improved and Unimproved Water Sources and Sanitation Facilities."WHO / UNICEF Joint 
Monitoring Programme: Wat/san Categories. The WHO/UNICEF, n.d. Web. 08 June 2016 
2. Bain, R., Cronk, R., Wright, J., Yang, H., Slaymaker, T., & Bartram, J. (2014). Fecal Contamination 
of Drinking-Water in Low- and Middle-Income Countries: A Systematic Review and Meta-
Analysis. PLoS Medicine, 11(5). doi:10.1371/journal.pmed.1001644 
3. Wolf, Jennyfer, Annette Prüss-Ustün, Oliver Cumming, Jamie Bartram, Sophie Bonjour, Sandy 
Cairncross, Thomas Clasen, John M. Colford, Valerie Curtis, Jennifer De France, Lorna Fewtrell, 
Matthew C. Freeman, Bruce Gordon, Paul R. Hunter, Aurelie Jeandron, Richard B. Johnston, 
Daniel Mäusezahl, Colin Mathers, Maria Neira, and Julian P. T. Higgins. "Systematic Review: 
Assessing the Impact of Drinking Water and Sanitation on Diarrhoeal Disease in Low- and 
Middle-income Settings: Systematic Review and Meta-regression." Trop Med Int Health Tropical 
Medicine & International Health 19.8 (2014): 928-42. Web. 
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Input data & methodological summary 
Exposure 
Case definition 
Exposure to unsafe sanitation is defined based on the primary toilet type used by households. Improved 
facilities are defined as such based on JMP designation (WHO). Sewer connection toilets included flush 
toilets or any toilet with connection to the sewer or septic tank. 
Input data 
The search for usable household surveys and censuses was conducted using the Global Health Data 
Exchange (GHDx) database. For each survey, household sample weights were multiplied by the number 
of household members to produce a weighting scheme that estimates proportion of individuals, not 
proportion of households, exposed to a given indicator. Surveys and censuses were then tabulated to 
two sanitation categories, sewer connection and improved sanitation, for each location. Data in 
tabulated form was lower priority to add to models and was only updated when time permitted. 
Modeling 
A change made for GBD 2017 was to model sanitation categories in an ordinal framework instead of 
independent models. Two distinct indicators were estimated: the prevalence of individuals using sewer 
connection or septic tank facilities and the proportion of individuals with improved sanitation within the 
population not connected to sewer or septic tank. This ordinal framework allows us to estimate the 
category with the most data (sewer connection/septic tank prevalence) and leverage that estimate to 
anchor the estimates for improved and unimproved sanitation categories. The results of the improved 
proportion model are multiplied by the sewer connection/septic tank prevalence to calculate improved 
sanitation prevalence. The sum of improved and sewer connection/septic tank prevalence are 
subtracted from 1 to yield unimproved sanitation prevalence.  
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The two indicators were modeled using a 3-step modeling scheme of mixed effect linear regression 
followed by spatio-temporal Gaussian process regression (ST-GPR), which produced full time series 
estimates for each GBD 2017 location. Socio-demographic index (SDI), a composite metric combining 
education per capita, income per capita, and fertility, was set as a fixed effect in the linear regression 
since it proved to be a significant predictor. Random effects were set at GBD 2017 region and super-
region levels to fit the models but were not used in the predictions. 
The process of vetting and validating models was accomplished primarily through an examination of ST-
GPR scatter plots by GBD 2017 location from 1990-2017. Any unfitting data points were re-inspected for 
error at the level of extraction and survey implementation, and subsequently excluded from analysis if 
deemed appropriate. In addition to SDI, a number of different potential fixed effects were considered, 
including lag-distributed income and urbanicity, but SDI proved to be the strongest predictor of unsafe 
sanitation in terms of magnitude of the coefficient. Uncertainty in the estimates was initially 
constructed based on standard deviation around each survey mean, then propagated through ST-GPR 
modeling by incorporating the variance of each data point in the Gaussian process regression step. A 
data point with high variance, for example, would contribute relatively less influence to the model than 
a data point with lower variance. 
Once models are vetted, full time series outputs from ST-GPR modeling are then converted from 
proportion to prevalence by year and geography and then rescaled to form three mutually exclusive 
categories that sum up to 1. The table below provides the final result of this rescaling. 
Category Definition 
Unimproved sanitation Proportion of individuals that use unimproved sanitation 
facilities.  
Improved sanitation Proportion of individuals with access to improved 
sanitation facilities, excluding sewer connection or septic 
tank.  
Sanitation facilities with sewer connection or 
septic tank 
Proportion of individuals with access to toilet facilities with 
sewer connection or septic tank. 
Theoretical minimum-risk exposure level 
The theoretical minimum-risk exposure level for unsafe sanitation was defined as all individuals have 
access to a sanitation facility with sewer connection. 
Relative risks 
For GBD 2017, unsafe sanitation was only paired with one outcome, diarrheal diseases. A meta-analysis 
by Wolf et al. 2014 provides the bulk of the relative risk evidence for the relationship between unsafe 
sanitation and diarrheal diseases. This meta-analysis was updated through a literature review that 
searched for related intervention studies post-2014 conducted in PubMed. Search terms used were 
identical to those provided by Wolf et al. 2014. Please refer to appendix tables for more information on 
relative risk values and citations. 
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Input data & methodological summary 
Exposure 
Case definition 
Unsafe hygiene is defined as lack of access to a handwashing station with available soap and water. We 
estimated the burden of unsafe hygiene in both developed and developing settings. 
Input data 
Since water and soap availability data are very limited, only country-specific Demographic Health 
Surveys (DHS) and Malaria Indicator Survey Series (MICS) conducted after 2006 were included as input 
data. 
Modelling strategy 
By year and location, proportion of households with handwashing facility is modelled using a 3-step 
modelling scheme of mixed effect linear regression followed by spatio-temporal Gaussian process 
regression (ST-GPR), which outputs full time series estimates for each GBD 2017 location. Socio-
demographic index (SDI), a composite index that include income per capita, education, and fertility, was 
set as a fixed effect in the linear regression since it proved to have significant coefficient. Random 
effects were set at GBD 2017 region and super-region levels to fit the model but were not used in the 
predictions. 
The process of vetting and validating models was accomplished primarily through an examination of ST-
GPR scatter plots by GBD 2016 location from 1990-2016. Any data points lacking face validity were re-
inspected for error at the level of extraction and survey implementation, and subsequently excluded 
from analysis if deemed appropriate. In addition to SDI, a number of different potential fixed effects 
65
were considered, including lag-distributed income and urbanicity. However, SDI proved to be the 
strongest predictor. 
A considerable limitation for when estimating handwashing practices for over 190 independent 
locations around the world was data sparseness. Even when data were published on handwashing 
prevalence, the definition was often altered from the GBD 2017 standard definition or it may only have 
pertained to certain populations (such as hospital patients) and lacked representativeness at the 
geographic scale we required. The incorporation of questions about soap and water availability in DHS 
and MICS added much-needed information but there remains a large data gap to be filled if we are to 
become more certain in handwashing access estimates. 
Theoretical minimum-risk exposure level 
The theoretical minimum-risk exposure level for unsafe hygiene is defined as all individuals with access 
to handwashing facility after any contact with excreta, including children’s excreta. 
Relative risks 
A meta-analysis by Cairncross et al.1 provide relative risk values describing the relationship between lack 
of facility access and diarrheal diseases. A meta-analysis by Rabie and Curtis2 provided relative risk 
evidence for the relationship between lack of facility access and lower respiratory infection. Please refer 
to appendix tables for more information on relative risk values and citations. 
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Input data and modeling strategy 
Exposure 
Definition 
Exposure to ambient air pollution is defined as the population-weighted annual average mass 
concentration of particles with an aerodynamic diameter less than 2.5 micrometers (PM2.5) in a 
cubic meter of air. This measurement is reported in µg/m3. 
Input Data 
The data used to estimate exposure to ambient air pollution is drawn from multiple sources, 
including satellite observations of aerosols in the atmosphere, ground measurements, chemical 
transport model simulations, population estimates, and land-use data.  
The following details the updates in methodology and input data used in GBD 2017. 
PM2.5 ground measurement database 
Updates of ground measurements used for GBD 2017 include using more recent data than that used  
previously and the addition of data from new locations. The data from the 2018 update of the WHO 
Global Ambient Air Quality Database include monitor-specific measurements of concentrations of 
PM10 and PM2.5 from 9,960 ground monitors (up from 6,003 in GBD 2016) from 108 countries. The 
majority of measurements were recorded in 2016 (as there is a lag in reporting measurements, little 
data from 2017 were available). Annual averages were excluded if they were based on less than 75% 
coverage within a year. Collection year ranged from 2008 to 2017 in data used. If information on 
coverage was not available then data were included unless they were already sufficient data within a 
country (monitor density greater than 0.1). 
For locations measuring only PM10, PM2.5 measurements were estimated from PM10. This was 
performed using a hierarchy of conversion factors (PM2.5/PM10 ratios): (i) for any location a ‘local’ 
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conversation factor was used, constructed as the ratio of the average measurements (of PM2.5 and 
PM10) from within 50km and within the same country, if such were available’ (ii) if there was not 
sufficient local information to construct a conversion factor then a country-wide conversion factor 
was used; and (iii) if there was no appropriate information within a country then a regional factor 
was used. In each case, to avoid the possible effects of outliers in the measured data (both PM2.5 
and PM10), extreme values of the ratios were excluded (defined as being greater/lesser than the 95 
and 5% quantiles of the empirical distributions of conversion factors) of the latter two cases for the 
country measurements were available, for both metrics. As in the GBD 2013 and GBD 2015/GBD 
2016 databases, in addition to values of PM2.5 and whether they were direct measurement or 
converted from PM10, the database also included additional information, where available,  related to 
the ground measurements such as monitor geo coordinates and monitor site type.  
Satellite-based estimates 
The updated satellite-based estimates for years 1998-2016 are described in detail in van Donkelaar 
et al. 2016.1 These estimates were available at 0.1o×0.1o resolution (~11 x 11 km resolution at the 
equator) and combine aerosol optical depth retrievals from multiple satellites with the GEOS Chem 
chemical transport model and land use information.  
Population data  
A comprehensive set of population data on a high-resolution grid was obtained from the Gridded 
Population of the World (GPW) database. These estimates are adjusted to match UN2015 
Population Prosepectus. These data are provided on a 0.0417o×0.0417o resolution. Aggregation to 
each 0.1o×0.1o grid cell comprised of summing the central 3 × 3 population cells. As this resulted in a 
resolution higher than necessary, it was repeated four times, each offset by one cell in a North, 
South, East and West direction. The average of the resulting five quantities was used as the 
estimated population for each grid cell. Population estimates for 2000, 2005, 2010, 2015 and 2020 
were available from GPW version 4 revision 10. Populations for 2016 and 2017 were obtained by 
interpolation using natural splines with knots placed at 2000, 2005, 2010, 2015 and 2020. This was 
performed for each grid cell.  
Chemical transport model simulations 
Estimates of the sum of particulate sulfate, nitrate, ammonium and organic carbon and the 
compositional concentrations of mineral dust simulated using the GEOS Chem chemical transport 
model, and a measure combining elevation and the distance to the nearest urban land surface (as 
described in van Donkelaar et al. 20161) were available for 2000 to 2016 for each 0.1o×0.1o grid cell. 
These were not included within the GBD 2013 analysis. 
Modelling strategy 
Significant advances have been made in the methodology used to estimate exposure to ambient 
particulate matter pollution since GBD 2013. The following is a summary of the modelling approach,  
known as the Data Integration Model for Air Quality (DIMAQ) used in GBD 2015, 2016, and 2017; 
further details can be found in Shaddick et al. (2017). 2 
In GBD 2010 and GBD 2013 exposure estimates were obtained using a single global function to 
calibrate available ground measurements to a ‘fused’ estimate of PM2.5; the mean of satellite-based 
estimates and those from the TM5 chemical transport model, calculated for each 0.1o×0.1o grid cell. 
This was recognised to represent a trade-off between accuracy and computationally efficiency when 
utilising all the available data sources. In particular, the GBD 2013 exposure estimates were known 
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to underestimate ground measurements in specific locations (see discussion in Brauer et al., 20133). 
This underestimation was largely due to the use of a single, global, calibration function, whereas in 
reality the relationship between ground measurements and other variables will vary spatially.  
In GBD 2015 and GBD 2016, coefficients in the calibration model were estimated for each country. 
Where data were insufficient within a country, information can be `borrowed’ from a higher 
aggregation (region) and if enough information is still not available from an even higher level (super-
region). Individual country level estimates were therefore based on a combination of information 
from the country, its region and super-region.  This was implemented within a Bayesian Hierarchical 
modelling (BHM) framework. BHMs provide an extremely useful and flexible framework in which to 
model complex relationships and dependencies in data. Uncertainty can also be propagated through 
the model allowing uncertainty arising from different components, both data sources and models, to 
be incorporated within estimates of uncertainty associated with the final estimates.  The results of 
the modelling comprise a posterior distribution for each grid cell, rather than just a single point 
estimate, allowing a variety of summaries to be calculated. The primary outputs here are the median 
and 95% credible intervals for each grid cell. Based on the availability of ground measurement data, 
modelling and evaluation was focused on the year 2016.  
The GBD 2017 model was updated to also include within country calibration variation. 4 The model 
used for GBD2017, henceforth referred to as DIMAQ2, provides a number of substantial 
improvements over the initial formulation of DIMAQ.  In DIMAQ, ground measurements from 
different years were all assumed to have been made in the primary year of interest (i.e. 2014 for 
GBD2015 before extrapolation) and then regressed against values from other inputs (e.g. satellites 
etc.) made in that year. In the presence of changes over time therefore, and particularly in areas 
where no recent measurements were available, there was the possibility of mismatches between 
the ground measurements and other variables. In DIMAQ2, ground measurements and matched 
with other inputs (over time) and the possibility of the (global level) coefficients  being allowed to 
vary over time, subject to smoothing that is induced by a second-order random walk process. In 
addition, the manner in which spatial variation can be incorporated within the model has developed: 
where there is sufficient data, the calibration equations can now vary (smoothly) both within and 
between countries, achieved by allowing the coefficients to follow (smooth) Gaussian processes. 
Where there is insufficient data within a country, to produce accurate equations, as before 
information is borrowed from lower down the hierarchy and it is supplemented with information 
from the wider region.   
DIMAQ2 is used for all regions except for the North Africa-Middle East and Sub-Saharan super-
regions and remote islands where there is insufficient data to allow the extra complexities of the 
new model to be implemented. In the North Africa-Middle East and Sub-Saharan super-regions a 
simplified version of DIMAQ2 is used in which the temporal component is dropped, and for remote 
islands the original DIMAQ is used.  
Due to both the complexity of the models and the size of the data, notably the number of spatial 
predictions that are required, recently developed techniques that perform ‘approximate’ Bayesian 
inference based on integrated nested Laplace approximations (INLA) were used.5 Computation was 
performed using the R interface to the INLA computational engine (R-INLA). Fitting the models and 
performing predictions for each of the ca. 1.4 million grid cells required the use of a high 
performance computing cluster (HPC) making use of high memory nodes.  
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Model evaluation 
Model development and comparison was performed using within- and out-of-sample assessment. In 
the evaluation, cross validation was performed using 25 combinations of training (80%) and 
validation (20%) datasets.  Validation sets were obtained by taking a stratified random sample, using 
sampling probabilities based on the cross-tabulation of PM2.5 categories (0-24.9, 25-49.9, 50-74.9, 
75-99.9, 100+ µg/m3) and super-regions, resulting in them having the same distribution of PM2.5 
concentrations and super-regions as the overall set of sites.  The following metrics were calculated
for each training/evaluation set combination: for model fit - R2 and deviance information criteria
(DIC, a measure of model fit for Bayesian models); for predictive accuracy - root mean squared error
(RMSE) and population weighted root mean squared error (PwRMSE).
All modelling was performed on the log-scale. The choice of which variables were included in the 
model was made based on their contribution to model fit and predictive ability. The following is a list 
variables and model structures that were included in DIMAQ. 
Continuous explanatory variables: 
o (SAT) Estimate of PM2.5 (in μgm-3) from satellite remote sensing on the log-scale.
o (POP) Estimate of population for the same year as SAT on the log-scale.
o (SNAOC) Estimate of the sum of sulfate, nitrate, ammonium and organic carbon
simulated using the GEOS Chem chemical transport model.
o (DST) Estimate of compositional concentrations of mineral dust simulated using the
GEOS Chem chemical transport model.
o (EDxDU) The log of the elevation difference between the elevation at the ground
measurement location and the mean elevation within the GEOS Chem simulation
grid cell multiplied by the inverse distance to the nearest urban land surface.
Discrete explanatory variables: 
o (LOC) Binary variable indicating whether exact location of ground measurement is
known.
o (TYPE) Binary variable indicating whether exact type of ground monitor is known.
o (CONV) Binary variable indicating whether ground measurement is PM2.5 or
converted from PM10.
Random Effects: 
o Grid cell random effects on the intercept to allow for multiple ground monitors in a
grid cell.
o Country-region-super-region hierarchical random effects for the intercept.
o Country-region-super-region hierarchical random effects for the coefficient
associated with SAT .
o Country-region-super-region hierarchical random effects for the coefficient
associated with the difference between estimates from CTM and SAT.
o Country-region-super-region hierarchical random effects for the coefficient
associated with POP.
o Country level random effects for population uses a neighbourhood structure
allowing specific borrowing of information from neighbouring countries.
o Within a region, country level effects of SAT and the difference between SAT AND
CTM are assumed to be independent and identically distributed.
o Within a super-region, region level random effects are assumed to be independent
and identically distributed.
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o Super-region random effects are assumed to be independent and identically
distributed.
Interactions: 
o Interactions between the binary variables and the effects of SAT and CTM.
In addition, DIMAQ2 includes 
o Smoothed, spatially varying, random-effects for the intercept
o Smoothed, spatially varying, random-effects for the coefficient of coefficient
associated with SAT
o Smoothed, temporally varying, random-effect for the intercept
Results 
The final model contained the following variables: SAT, POP, SNAOC, DST, EDxDU, LOC, TYPE, and 
CONV, together with interactions between SAT and each of LOC, TYPE and CONV. The model 
structure contained grid cell random effects on the intercept to allow for multiple ground monitors 
in a grid cell, country-region-super-region hierarchical random effects for intercepts and SAT and 
country level random effects for population using a neighbourhood structure allowing specific 
borrowing of information from neighbouring countries together with region-super-region 
hierarchical random effects for POP. Notably, and as in GBD 2015 and GBD 2016, based on the 
evaluation of candidate models, including estimates from the TM5 chemical transport model (CTM) 
used in GBD 2013 did not improve the predictive ability of the model and was therefore not 
included. 
Compared to the model used in GBD2013, DIMAQ showed improved predictions of ground 
measurements in all super regions with improvements in both within-sample fit; with a global 
population-weighted RMSE of 12.1 µg/m3 compared to 23.1 µg/m3 when using the GBD 2013 
approach.1 Using the larger database available for GBD2017, with potentially more variability in 
measurements, DIMAQ2 shows an additional improvement on DIMAQ: overall population-weighted 
RMSE reduced from 9.32 to 8.11 (12.12 to 11.17 when using all data, irrespective of within-year 
coverage). Reductions by super-region can be seen in Figure 1. Reductions can be seen in all super-
regions with particular improvement in the Southeast Asia, East Asia and Oceania super-region 
which is based largely on a substantial increase in accuracy in China, PwRMSE 6 vs 9 µg/m3 
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Figure 1: Summary measures of predictive ability, globally and by super-region. Dots denote the median values of 
population weighted root mean squared error (µg/m3) from 25 validation sets with vertical lines showing the range of 
values over those sets.  
Estimates for other years 
In contrast to the method used previously, where estimates (of PM2.5) were extrapolated to produce 
estimates for the year of interest (e.g. 2017 where data was available up to and including 2016) due 
to the extra complexity of the smooth spatial processes in DIMAQ2 this would not be possible in any 
straightforward manner. With DIMAQ2 it is the input variables that are extrapolated; this allows 
estimates for 2017 to be produced in the same way as other years and crucially, allows measures of 
uncertainty to be produced within the BHM framework rather than by using post-hoc 
approximations.  
Satellite estimates and quantities estimated using the GEOS-Chem model were available for 1990, 
1995, 2000, 2005, 2010-2016. Estimates of these input variables for 2017 were produced by 
extrapolating, on a cell-by-cell basis, using natural splines. Population estimates for 2000, 2005, 
2010, 2015 and 2020 were availalble from GPW version 4. For 1990 and 1995 data were extracted 
from GPW version 3, as in GBD2013.2 As with populations for 2015, values for each cell for 2011-
2017 were obtained by interpolation using natural splines with knots placed at 2000, 2005, 2010, 
2015 and 2020. 
These were used as inputs to DIMAQ, enabling estimates of exposures to be obtained for each of 
these years respectively. For 2017, estimates of exposures were obtained from predictions from 
locally-varying regression models.6 For each cell a model was fit to the values within that cell over 
time, with a constraint placed on the rate of change between 2016 and 2017 to avoid unrealistic 
and/or unjustified extrapolation of trends. Measures of uncertainty were obtained by repeating the 
procedure for the limits of the 95% credible intervals, again on a cell-by-cell basis.  
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Population-weighted exposure generation 
To generate a distribution of the population-weighted ambient particulate matter, we took a 
weighted sampling strategy, taking samples from all grid cells in a given location. For example, for a 
country with n grid cells, we randomly sampled 1000 values from the n (grid cells) x 1000 (samples) 
where the probability of being sampled was proportional to the population of that grid cell.  
Theoretical minimum-risk exposure level 
The TMREL was assigned a uniform distribution with lower/upper bounds given by the average of 
the minimum and 5th percentiles of outdoor air pollution cohort studies exposure distributions 
conducted in North America, with the assumption that current evidence was insufficient to precisely 
characterise the shape of the concentration-response function below the 5th percentile of the 
exposure distributions. The TMREL was defined as a uniform distribution rather than a fixed value in 
order to represent the uncertainty regarding the level at which the scientific evidence was 
consistent with adverse effects of exposure. The specific outdoor air pollution cohort studies 
selected for this averaging were based on the criteria that their 5th percentiles were less than that of 
the American Cancer Society Cancer Prevention II (CPSII) cohort’s 5th percentile of 8.2 based on 
Turner et al. (2016).7 This criterion was selected since GBD 2010 used the minimum, 5.8, and 5th 
percentile solely from the CPS II cohort. The resulting lower/upper bounds of the distribution for 
GBD 2017 were 2.4 and 5.9. This has not changed since GBD 2015. 
Relative risks and population attributable fractions 
We estimated the Ambient Air Pollution-attributable burden of disease based on the relation of 
long-term exposure to PM2.5 with Ischemic Heart Disease, stroke (ischemic and hemorrhagic), 
COPD, lung cancer and acute lower respiratory infection. These were also the pollutant-outcome 
pairs used to estimate the Ambient Air Pollution attributable burden since GBD 2010. For GBD 2017 
we also added Type II Diabetes as an outcome of ambient air pollution. We used results from all 
cohort studies published as of July 2018 that reported cause-specific relative risk estimates based on 
measured or modelled PM2.5 and that adjusted for potential confounding due to other major risk 
factors such as tobacco smoking using data for each study participant.  
Bowe et al. recently published work that assembled the evidence for the relationship between 
particulate matter and diabetes to generate IER curves and attributable burden estimates based on 
methodologies similar to those of the GBD. 8  
When generating the IER for Type II Diabetes, we included all eight of the studies summarized by 
Bowe et al. in addition to six other cohorts. Resulting attributable burden estimates were 
remarkably similar to GBD 2017 results. All citations for studies used in the fitting of the IER curve 
can be found using the GBD 17 Data Input Sources Tool.  
Integrated exposure response function 
The Integrated Exposure Response Function (IER) was created to ascertain the shape of the dose 
response curve for a variety of health outcomes across a wide range of exposure to PM2.5. The IER 
model is fit by integrating RR information from studies of outdoor air pollution (OAP), Second hand 
tobacco smoke (SHS), Household Air Pollution (HAP), and Active Smoking (AS). Because OAP studies 
are often performed at the lower end of the ambient air pollution range, incorporating other 
exposures to particulate matter enables RR estimation across the global range of exposure. These 
methods have been described in detail elsewhere.9,10 
Notable changes for GBD 2017 include added studies for OAP, SHS, and HAP, updated literature 
reviews for AS studies, and more informative priors to stabilize the shape of the IER curves.  
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• We added all newly published cohorts of long-term exposure to Ambient PM2.5 and
incidence or mortality due to IHD, stroke, COPD, lung cancer, and LRI. One notable addition
was the China Male Cohort which included mortality due to IHD, Stroke, COPD, Lung Cancer,
and Diabetes (unpublished analysis).11 This study represented a higher exposure range than
most of our previously incorporated studies with 5th and 95th percentile of 15.5 and 77.1
micrograms/m3. For Type II Diabetes, the new outcome included in GBD 2017, we included
all cohorts which measured long-term PM2.5 exposure and incident diabetes or mortality
due to diabetes.
• We did not change the SHS input studies with the exception of including all studies from a
recent meta-analysis examining the relationship between SHS and Type II Diabetes.12  We
also added seven studies found from a systematic review examining SHS exposure and
COPD. We had previously not included SHS in the formation of this curve.
• We added four cohort studies of HAP and any of our measured outcomes. Previously we
have only included which measured levels of PM2.5 exposure. To incorporate cohort studies
with binary exposure data (presence or absence of solid-fuel use for cooking) we used the
PM2.5 mapping function (see Household Air Pollution Appendix for more details) to obtain a
PM2.5 level attributed to solid fuel use for cooking for the location-year of the study
(ExpHAP). We also used the OAP exposure model to obtain an OAP PM2.5 level for the
location-year (ExpOAP). The study RR was used to inform the curve on the range of ExpOAP to
(ExpOAP + ExpHAP).
• For all outcomes, we used updated systematic reviews of the literature performed by the
GBD smoking team for studies examining cigarettes smoked per day and the six IER
outcomes to inform the high exposure range of the curve. The smoking team found that the
process of systematic review and inclusion of all acceptable studies led to lower relative
risks.
• To help obtain more reasonable curve fits, we added more informative priors to two of
three IER function parameters in the MCMC Bayesian fitting process.
Limitations 
It is important to recognize the inherent limitations of the IER approach. The use of various sources 
to construct a risk curve assumes an equitoxicity of particles, consistent with evaluations by US EPA 
and WHO. However, current evidence suggests there are differences in health impact by source, 
size, and chemical composition. This is seen when comparing studies of ambient and household 
particulate matter. As this body of evidence grows, we will continue to re-examine our strategy for 
the integrated exposure-response curve. For now, the IER is a practical solution to fill gaps in the 
literature where we do not have sufficient evidence such as household air pollution exposures and 
ambient in highly polluted areas. 
Additionally, currently the exposure concentrations used for both SHS and AS data points when 
fitting the IER are contrasted with the TMREL and do not take into account ambient particulate 
matter pollution. In future iterations of fitting the curve, we will test alternate approaches, including 
a similar approach to HAP, allowing each data point to inform the curve on the range of ExpOAP to 
(ExpOAP + ExpAS/SHS). 
Relative risk and proportional PAF approach 
For GBD 2017 we developed a new approach to use the IER for obtaining PAFs for both OAP and 
HAP. Previously, relative risks for both exposures were obtained from the IER as a function of 
exposure and relative to the same TMREL. In reality, were a country to reduce only one of these risk 
factors, the other would remain. We failed to consider the joint effects of particulate matter from 
outdoor exposure and burning solid fuels for cooking. 
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In GBD 2017, relative risks were still estimated from the output of the IER curve. Everyone is 
exposed to some level of OAP, but only a proportion of the population in each location-year use 
solid cooking fuel and are exposed to HAP. For the proportion of the population not exposed to HAP 
the relative risk was obtained by RROAP =  IER(z = ExpOAP) and used to calculate the PAF for each 
location based on the population-weighted exposure.  
For the proportion of the population exposed to both OAP and HAP, we calculated a joint relative 
risk from the IER by RROAP+HAP =  IER(z = ExpOAP+ExpHAP). This joint relative risk is used to calculate a 
joint PAF for each location. PAF calculation is detailed in the methods appendix. For each location, 
we proportioned the joint PAF based on the proportion of exposure due to OAP and HAP 
respectively. See the table below for equations used to calculate proportional PAFs. 
PAF Population  not exposed to HAP Population exposed to HAP 
OAP PAFOAP (ExpOAP/(ExpOAP+ExpHAP))*PAFOAP+HAP 
HAP 0 (ExpHAP/(ExpOAP+ExpHAP))*PAFOAP+HAP 
Generally, as expected, this new strategy led to lower PAFs for both ambient and household 
particulate matter pollution.  
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Input Data & Methodological Summary 
Exposure 
Case definition 
Exposure to household air pollution from solid fuels (HAP) is defined as the proportion of households 
using solid cooking fuels. The definition of solid fuel in our analysis includes coal, wood, charcoal, dung, 
and agricultural residues.  
Input data 
Data were extracted from the standard multi-country survey series such as Demographic and Health 
Surveys (DHS), Living Standards Measurement Surveys (LSMS), Multiple Indicator Cluster Surveys (MICS), 
and World Health Surveys (WHS), as well as country-specific survey series such as Kenya Welfare 
Monitoring Survey and South Africa General Household Survey. To fill the gaps of data in surveys and 
censuses, we also downloaded and updated HAP estimates from WHO Energy Database and extracted 
from literature through systematic review. Each nationally or sub-nationally representative data point 
provided an estimate for the percentage of households using solid cooking fuels. Estimates for the usage 
of solid fuels for non-cooking purpose were excluded, i.e. primary fuels for lighting. The database, with 
estimates from 1980 to 2017, contained about 680 studies from 150 countries. As updates to systematic 
reviews are performed on an ongoing schedule across all GBD causes and risk factors, an update for 
household air pollution will be performed in the next 1-2 iterations. 
Modelling strategy  
Household air pollution was modelled at household level using a three-step modelling strategy that uses 
linear regression, spatiotemporal regression and Gaussian Process Regression (GPR). The first step is a 
mixed-effect linear regression of logit-transformed proportion of households using solid cooking fuels. 
The linear model contains maternal education, proportion of population living in urban areas, and 
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lagged-distributed income as covariates and has nested random effect by GBD region, and GBD super 
region respectively. The full ST-GPR process is specified elsewhere this appendix. No substantial 
modelling changes were made in this round compared to GBD 2016. 
Theoretical minimum-risk exposure level 
For cataract, the TMREL is defined as no households using solid cooking fuel. For outcomes that utilise 
evidence based on the Integrated Exposure Response (IER), the TMREL is defined as uniform distribution 
between 2.4 and 5.9 ug/m3.  
Relative risks 
In addition to the previously included outcomes of lower respiratory infections (LRI), stroke, Ischemic 
Heart Disease (IHD), Chronic Obstructive Pulmonary Disease (COPD), lung cancer, and cataract, in GBD 
2017 we added Type II Diabetes as a new outcome of household air pollution. The relative risk for 
cataracts was extracted from a meta-analysis and is 2.47 with 95% (1.61, 3.73).1 GBD currently only 
estimates cataracts as an outcome for females. 
In GBD 2017, we adopted a new approach for risk attribution using the Integrated Exposure-Response 
Function (IER). Updates to the IER and the new joint-estimation PAF approach is described in the 
Ambient Particulate Matter appendix.  
PM2.5 mapping value  
In order to use the IER curve, we must estimate the exposure to particulate matter with diameter of less 
than 2.5 micrometers (PM2.5). Since GBD 2015 we have been using a mapping model relying on a 
database of now almost 90 studies which measures PM2.5 exposure in households using solid cooking 
fuel. Using socio-demographic index and study-level factors as covariates, we predict exposure for all 
location-years.  
In GBD 2017, we updated the model to estimate the individual exposure to PM2.5 over and above 
ambient levels due to the use of solid cooking fuel. We did this by subtracting off the estimated ambient 
level PM2.5 for the location-year of each study in the database before inputting them into the model. By 
doing this we have independent estimates for PM2.5 exposure due to ambient and household solid fuel 
use. 
These exposures are cross-walked to values for men, women, and children by generating the ratio of 
each group’s mean exposure to the overall mean personal exposure. The resulting location, year, sex, 
and age specific PM2.5 exposure values are used as inputs in the IER and attributable burden calculation 
process.  
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Ambient Ozone Pollution Capstone Appendix 
Flowchart 
Input data and methodological summary 
Exposure 
Case definition 
For GBD 2017, exposure to ozone pollution is defined as the seasonal (6 month period with highest 
mean) 8 hour daily maximum ozone concentrations, measured in ppb. This was an update from the 
previous exposure metric in accordance with an update of the American Cancer Society Cancer 
Prevention Study II (ACS CPS-II).1
Input data 
Previously, exposure estimates were based on a chemical transport model with no measurement 
database or evaluation. In GBD 2017, exposure estimates incorporated a new comprehensive ozone 
measurement database (TOAR).2 This enabled a continent-specific weighted blend of 6 chemical 
transport models with grid cell level bias correction. The use of ground measurements also enabled the 
incorporation of error estimation, where previously we had assumed a +/- 6% error. The output of this 
model is a global raster of ozone exposure which is a summary for the years 2008-2014.3  
Modelling strategy for trends 
To estimate ozone concentrations over time, we used the trend from the former GBD model for 1990, 
2000, and 2010 and cubic splines for 1995, 2005, and 2011, after applying an adjustment for the 
difference in trends between the previous (1 hour daily maximum) and current (8 hour daily maximum 
metrics. Annualised rate of change was used to predict for the years 2012-2017.  
Theoretical minimum-risk exposure level 
The TMREL of ozone was updated this year based on the exposure distribution from the updated ACS 
CPS-II study.1 A uniform distribution was drawn around the minimum and 5th percentile values 
experienced by the cohort, defined as ~U(29.1, 35.7), in ppb.  
79
Relative risks 
Since the inclusion of ozone in GBD 2010 the relative risk of ozone exposure for respiratory COPD 
mortality has been defined to be 1.029, 95% C.I. (1.01-1.048) per 10 ppb of ozone exposure. Note that 
this comes from one study that looked at all respiratory mortality.4 For GBD 2017, we performed a 
literature review and included five cohorts from Canada, the UK, and the US which all measured COPD 
mortality. For cohorts with multiple analyses we chose the most recent analysis. We found a resulting 
relative risk of 1.06, 95% C.I. (1.02, 1.10). 
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Input data & methodological summary 
Exposure 
Case definition 
Radon is a radioactive gas that is produced as a byproduct of the decay chain of uranium, occurring 
naturally within the Earth’s crust. Some fraction of this natural radon production escapes into the 
atmosphere, where it forms at low concentration unless build-up is caused by enclosed spaces like 
homes, mines, or caves. Radon exposure is expressed as average daily exposure to indoor air radon gas 
levels measured in Becquerels (disintegrations per second) per cubic meter (Bq/m3). 
Input data 
Exposure to radon is determined using values curated by an expert group. These values are taken from a 
variety of sources including literature, government agencies, and monitoring stations. Their 
methodology is then inspected to determine if they are robust enough to be considered as country-level 
averages. 76 data points were added for GBD 2017 including several from a study which reports on 
subnational variation in India. Before modelling, a crosswalk is performed from studies measuring 
geometric to arithmetic mean.  
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Modelling strategy 
Because radon is naturally occurring and is not considered to have much temporal fluctuation,1 we 
shifted from a spatio-temporal GPR model to a mixed effects linear model. The model included nested 
random effects on super-region, region, and location (most detailed) and one fixed effect covariate, 
long-term mean temperature as a proxy for adequate building ventilation.  
We did not have the microdata necessary to use ensemble modelling to inform our radon exposure 
distribution, so for GBD 2017 we continued to assume a lognormal distribution. Arithmetic mean 
exposure estimates obtained were used to fit the lognormal distribution before applying relative risks. 
Theoretical minimum-risk exposure level 
The TMREL was also taken directly from literature values that were not updated for GBD 2017. Given 
that radon is naturally occurring, zero exposure would be impossible. As such, we continue to use a 
TMREL of 10 Bq/m3, which is equivalent to the outdoor concentration of radon.2  
Relative risks 
The relative risk for radon exposure was extracted from literature values – a 2005 meta-analysis of case-
control studies showing the association of radon with lung cancer.3 This value was used in GBD 2010 and 
has not been changed since. 
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Lead Exposure Capstone Appendix 
Flowchart 
Definitions 
Exposure to lead is defined in two different ways according to the currently known pathways of health 
loss. Acute lead exposure, relevant to disease burden through IQ loss in children, is measured as the 
micrograms of lead per deciliter of blood (µg/dL). Long-term lead exposure, relevant to disease burden 
in adults given the manifestation of health impact through increased systolic blood pressure and hence a 
decline of cardiovascular health, is measured as the accumulation of lead in the bone as micrograms of 
lead per gram of bone (µg/g). 
Input Data 
The input data for lead exposure is primarily extracted from literature regarding blood lead, in addition 
to a few blood lead surveys. Blood lead values are derived from studies that take blood samples and 
analyze them using various techniques to determine the level of lead present. Our literature review 
resulted in 3,183 usable data points from 554 different studies, which span the years 1970 to 2017. The 
database of literature values was modelled for data-sparse countries using spatio-temporal Gaussian 
process regression (ST-GPR). These values were used as blood lead exposure estimates. The second 
pathway of burden is related to bone lead exposure, which was estimated by calculating a cumulative 
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blood lead index for cohorts using estimated blood lead over their lifetime. The cumulative blood lead 
index is then used to estimate bone lead using a scalar defined in literature.1 
Exposure Modeling 
The methodology to estimate lead exposure last underwent significant change in GBD 2013. Global 
exposure had been previously modelled using age-integrating Bayesian hierarchal modelling (DisMod-
MR). The modelling process was updated for GBD 2013 by shifting to spatial-temporal GPR 
methodology. This allowed for estimates of all country-age-sex-year groups for single years instead of 
five year periods. This approach improved the granularity of estimates for bone lead, which requires 
back-estimation of previous blood lead to calculate a cumulative blood lead index.  
For GBD 2017, the spatio-temporal Gaussian process regression modelling methodology was updated as 
detailed in the appendix specific to this analytical technique, which is common to a variety of risk 
factors. In order to predict blood lead in country-years with insufficient data, covariates that have been 
produced across time and space relevant to this analysis were used. For blood lead exposure, the 
covariates determined to have predictive ability were the socio-demographic index (SDI), the proportion 
of a location’s population living in urban settings (logit transformed), the combined number of 2 and 4-
wheel vehicles per capita, and a covariate indicating whether leaded gasoline had been phased out in a 
given country-year (smoothed over the first 5 years of phase-out to reflect its gradual implementation). 
ST-GPR was used to produce estimates of mean and standard deviation of blood lead for all age groups, 
for both sexes, and for all GBD locations from 1970 to 2017. 
In earlier iterations of GBD, the distribution of lead exposure was assumed to be log-normal. Since GBD 
2016, ensemble modelling techniques were used to find an optimal global distribution by fitting a 
variety of distributions to the available blood lead microdata. This was a common update for all 
continuous risk factors. The ST-GPR estimates of mean and standard deviation blood lead were used 
with the global distribution shape to determine distributions for blood lead exposure. 
To calculate blood lead over the lifetime of a given cohort, blood lead was assumed to grow linearly 
from 2.0 ug/dL in 1920 (see TMREL) to the value for that cohort in 1970. Using the exposure 
distributions of blood lead over time and space, cohorts were constructed such that lifetime blood lead 
could be expressed as a curve over each year of life. The area under this curve was the cumulative blood 
lead index, which could be used to estimate bone lead in a given year with the aforementioned scalar. 
Estimating Attributable Burden 
Assessment of risk-outcome pairs 
We included outcomes based on the strength of available evidence supporting a causal relationship. 
Blood lead level (a measure of acute lead exposure) is paired with idiopathic developmental intellectual 
disability as modeled through the impact of blood lead levels on IQ in children. Bone lead level (a 
measure of cumulative lead exposure) is paired with systolic blood pressure as an outcome, and 
subsequently to all cardiovascular outcomes to which systolic blood pressure is paired, which includes 
rheumatic heart disease, ischemic heart disease, ischemic stroke, intracerebral hemorrhage, 
hypertensive heart disease, other cardiomyopathy, atrial fibrillation and flutter, aortic aneurysm, 
peripheral artery disease, endocarditis, other cardiovascular and circulatory diseases, chronic kidney 
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disease due to hypertension, chronic kidney disease due to glomerulonephritis, and chronic kidney 
disease due to other and unspecified causes. 
Theoretical minimum-risk exposure level
In previous iterations of GBD, the TMREL was taken from literature estimates of pre-industrial blood 
lead in humans.2 That value was estimated at 2.0 ug/dL. The decision was made that the TMREL of blood 
lead could not be 0 given the ambient sources of lead that would be impossible to eliminate.3  
However, average blood lead exposures in a number of countries have fallen below 2.0 ug/dL in the past 
few years, suggesting that the TMREL ought to be lowered. Unfortunately, we were not able to find 
literature with statistically significant estimates for relative risk at such low levels of blood lead 
exposure. As a result, we have continued to use a TMREL of 2.0 ug/dL for GBD 2017. 
Relative Risks
Because the relative risk of IQ loss from lead exposure is specific to children, in GBD 2015 no burden of 
lead via IQ loss was estimated in the population aged 15 and above. To better account for the continued 
burden of past lead exposure on IQ in older age groups, since GBD 2016 we have constructed cohorts 
from the entire population. Estimates of a cohort’s lead exposure in early childhood (at 24 months of 
age) were used to determine past IQ loss, and thus calculate burden via the impact on concurrent IQ in 
the older population. 
Blood lead relative risks were previously taken from a 2005 pooled analysis that was first incorporated in 
GBD 2010.4 For GBD 2017, blood lead relative risks have been updated with a 2013 re-analysis of the 
findings of that 2005 paper, providing slightly adjusted relative risk estimates specific to exposure at 24 
months of age.5 The bone lead relative risks were taken from a 2008 meta-analysis that was updated for 
GBD 2010.6 
Population Attributable Fraction 
We used the standard GBD population attributable fraction (PAF) equation to calculate PAFs for bone 
lead exposure and each of its paired outcomes using exposure estimates and relative risks. We used a 
similar approach for estimating PAFs for the burden of intellectual disability attributable to blood lead, 
which uses the estimated distribution of intellectual disability and the modeled shifts in IQ due to blood 
lead levels to determine the PAF.  
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Occupational Risk Factors Capstone Appendix 
Exposure definitions 
The following definitions were used for occupational risk factor exposures. All exposures were estimated 
for ages 15 and older. 
Occupational Asbestos Cumulative lifetime exposure to occupational 
asbestos, using mesothelioma death rate as an 
analogue 
Occupational Asthmagens Proportion of the working population exposed to 
asthmagens, based on population distributions across 
nine occupational categories 
Occupational Carcinogens (arsenic, 
benzene, beryllium, cadmium, chromium, 
diesel engine exhaust, formaldehyde, nickel, 
polycyclic aromatic hydrocarbons, silica, 
sulfuric acid, and trichloroethylene) 
Proportion of the population that was ever 
occupationally exposed to carcinogens at high or low 
exposure levels, based on population distributions 
across seventeen economic activities 
Occupational Ergonomic Factors Proportion of the working population exposed to low 
back pain-inducing work, based on population 
distributions across nine occupational categories 
Occupational Injuries Proportion of injuries in the working-age population 
attributable to occupational work, based on fatal 
injury rates in seventeen economic activities 
Occupational Noise Proportion of the population occupationally exposed 
to 85+ decibels of noise, based on population 
distributions across seventeen economic activities 
Occupational Particulates Proportion of the population occupationally exposed 
to particulates, based on population distributions 
across seventeen economic activities 
Economic activities and occupations were coded according to the following categories: 
Economic Activities Occupations 
Agriculture, hunting, forestry Legislators, senior officials, and managers 
Fishing Professionals 
Mining and Quarrying Technicians and associate professionals 
Manufacturing Clerks 
Electricity, gas, and water Service workers and shop/market sales workers 
Construction Skilled agricultural and fishery workers 
Wholesale and retail trade/repair Plant and machine operators and assemblers 
Hospitality Craft and related workers 
87
Transport, storage, and communication Elementary occupations 
Financial intermediation 
Real estate/renting 
Public administration/defense; compulsory social 
security 
Education 
Health and social work 





Primary inputs were obtained from the ILO,1-4 and included raw data on economic activity proportions, 
occupation proportions, fatal injury rates, and employment to population ratio estimates. A systematic 
web review was conducted in order to collect the underlying microdata from the ILO’s estimates to aid 
in re-extraction at greater levels of granularity. Where freely available, survey datasets were 
downloaded from the survey organisations in question. Other datasets were obtained through 
submission of requests to agencies and through the GBD collaborator network. Microdata was tabulated 
in order to create survey-weighted estimates of economic activities and occupations for the GBD 
geographies and years. Various classification systems were crosswalked to ISIC Rev.3 (for economic 
activities) and ISCO 1988 (for occupations). Subnational estimates for UK and China were added to the 
datasets for economic activities and occupations.5,6  
For occupational asbestos, primary inputs were obtained through GBD 2017 cause of death estimates 
and published studies.7,13,14  
Uncertainty for inputs where microdata was unavailable was generated by fitting a Loess curve to the 
data and determining the standard deviation of the data from the fitted curve.  
Modelling strategies 
A Spatio-temporal Gaussian process regression (ST-GPR) was used to generate estimates for all years 
and locations for the primary inputs. Study level covariates used in the prior model were education in 
years per capita, geological covariates (for mining models), the proportion of the population living with 
access to a coastline (for fishing models), the IHME socio-demographic index (SDI), the mean 
temperature/latitude (for agriculture models), and the proportion of the population living in urban 
areas. Space-time parameters were chosen by maximising out-of-sample cross-validation and 
minimising RMSE. For economic activity and occupation proportions, estimates from ST-GPR were then 
re-scaled to sum to 1 across categories by dividing each estimate by the sum of all the estimates. 
The following sections describe the modelling approaches for each occupational risk’s exposure 
prevalence. 
Occupational carcinogens, occupational noise, and occupational particulates 
Prevalence of exposure to these risks was determined using the following equation: 
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EAP = economically active population 
EA = economic activity 
a = age 
c = country 
d = duration 
l = level of exposure 
r = risk 
s = sex 
y =year 
Exposure rate was provided by expert group recommendations and literature8-11 (see table 1). The 
CAREX database was used in order to quantify the association between exposure by industry/carcinogen 
to SDI across all the countries in the database. This effect was used to predict exposure in countries that 
were not included in CAREX. Duration was considered for occupational carcinogens through application 
of occupational turnover factors12 and for occupational noise and particulates by calculating cumulative 
exposure as the average exposure over the lifetime (the past 50 years) for each age/sex cohort. 
Occupational ergonomic factors and occupational asthmagens 
Prevalence of exposure to these risks was determined using the following equation: 




EAP = economically active population 
OCC = occupation 
c = country 
a = age 
r = risk 
s = sex 
y = year 
Occupational injuries 
Occupational injury counts were estimated using the following equation: 
𝑂𝑂𝑃𝑃𝑃𝑃𝐸𝐸𝐸𝐸𝑃𝑃𝑃𝑃𝑃𝑃𝑜𝑜𝑃𝑃𝑃𝑃𝑃𝑃 𝑜𝑜𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑃𝑃𝑃𝑃𝑖𝑖𝐸𝐸𝑃𝑃𝑃𝑃𝑃𝑃𝐸𝐸𝑐𝑐,𝑦𝑦,𝑎𝑎,𝑠𝑠




EAP = economically active population 
EA = economic activity 
c = country 
a = age 
y = year 
s = sex 
Occupational asbestos 
Prevalence of exposure to asbestos was estimated using the asbestos impact ratio (AIR), which is 
equivalent to the excess deaths due to mesothelioma observed in a population divided by excess deaths 
due to mesothelioma in a population heavily exposed to asbestos. Formally, this is defined using the 
following equation: 
𝐸𝐸𝐼𝐼𝐴𝐴 =  




Mort = Mortality rate due to mesothelioma 
Mort* = Mortality rate due to mesothelioma in 
population highly exposed to asbestos 
N = Mortality rate due to mesothelioma in 
population not exposed to asbestos 
c = country 
y = year 
s = sex 
Mortality rate due to mesothelioma was estimated from GBD 2017 causes of death.7 Mortality rate due 
to mesothelioma in populations not exposed to asbestos was calculated using the model in Lin et al.,13 
while the mortality rate due to high exposure to asbestos was estimated in Goodman et al.14 Asbestos 
exposure prevalence created using the AIR was used to estimate PAFs for all asbestos-associated causes 
except for mesothelioma. Custom PAFs were calculated for mesothelioma by using the ratio of the 
excess mortality with respect to an unexposed population (Mort – N) divided by the mortality rate in the 
population in question (Mort). This calculation assumes that all mesothelioma is a product of 
occupational asbestos exposure and could potentially over-estimate burden due to occupational 
asbestos exposure in populations with high non-occupational asbestos exposure. 
Theoretical minimum-risk exposure level 
For all occupational risks, with the exception of occupational asbestos, the theoretical minimum-risk 
exposure level was assumed to be no exposure to that risk. 
Relative risk 
Relative risks were obtained for all occupational risks by conducting a systematic review of published 
meta-analysis. The estimates used, as well as the associated studies, are reported by category group in 
appendix table 5.  
PAFs 
For all occupational risks, with the exception of injuries (outlined below) and mesothelioma (outlined 
above), PAFs were calculated using the prevalences estimated above, using the PAF formula in outlined 
in the GBD 2017 methods appendix.  
Occupational injuries PAF 
The PAFs for occupational injuries were calculated using the following formula: 
𝑃𝑃𝐸𝐸𝑃𝑃𝑐𝑐,𝑦𝑦,𝑎𝑎,𝑠𝑠 =  
𝑂𝑂𝑃𝑃𝑃𝑃𝐸𝐸𝐸𝐸𝑃𝑃𝑃𝑃𝑃𝑃𝑜𝑜𝑃𝑃𝑃𝑃𝑃𝑃 𝑜𝑜𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑃𝑃𝑃𝑃𝑖𝑖𝐸𝐸𝑃𝑃𝑃𝑃𝑃𝑃𝐸𝐸𝑐𝑐,𝑦𝑦,𝑎𝑎,𝑠𝑠 − 𝑇𝑇𝑀𝑀𝐴𝐴𝐸𝐸𝑇𝑇
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑃𝑃𝑃𝑃𝑖𝑖𝐸𝐸𝑃𝑃𝑃𝑃𝑃𝑃𝐸𝐸𝑐𝑐,𝑦𝑦,𝑎𝑎,𝑠𝑠
where: 
c = country 
y = year 
a = age 
s = sex 
Fatal injury totals were obtained from GBD 2017 causes of death.7 
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Suboptimal Breastfeeding Capstone Appendix 
Flowchart 
Definitions 
Exposure to suboptimal breastfeeding is composed of 2 distinct categories: non-exclusive breastfeeding 
and discontinued breastfeeding.  
Non-exclusive breastfeeding is defined as the proportion of children under 6 months of age who are not 
exclusively breastfed. We then parse those not exclusively breastfed into 3 categories – predominant, 
partial, and no breastfeeding. Exclusive breastfeeding is defined as the proportion of children who 
receive no other food or drink except breast milk (allowing for ORS, drops, or syrups containing vitamins, 
minerals, or medicines). Predominant breastfeeding is the proportion of children whose predominant 
source of nourishment is breastmilk but also receive other liquids. Partial breastfeeding refers to those 
infants who receive breastmilk as well as food and liquids, including non-human milk and formula. No 
breastfeeding refers to infants who do not receive breast milk as a source of nourishment. 
Discontinued breastfeeding is defined as the proportion of children between 6 to 23 months who 
receive no breast milk as a source of nourishment.  
Input Data 
We made substantial exposure data updates for GBD 2017, including extracting identified surveys not 
included in previous rounds and re-extracting all surveys for new GBD 2017 subnational locations. We 
searched the Global Health Data Exchange (GHDx) database for sources using the keyword 
“Breastfeeding.” Of 2,026 potential sources identified, we extracted 1,081 unique country-years of data 
(2,262 unique geography-years, including subnational geographies) that met our inclusion criteria. The 
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data used in the analysis consists mostly of processed individual-level microdata from surveys; in the 
cases where microdata was unavailable, we used reported tabulated data from survey reports and 
scientific literature. Data used to categorize type of non-exclusive breastfeeding (predominant, partial, 
and none) come from surveys with 24-hour dietary logs based on maternal recall.  
Exposure Modelling 
Using the processed microdata and tabulated data from reports, we generated a complete time series 
from 1980 to 2017 for the prevalence of breastfeeding patterns for children 0 to 5 months and 6 to 23 
months using a three-step spatio-temporal Gaussian process regression modelling process.  
First, we estimated a robust linear regression using each geography’s sociodemographic index as a 
covariate. The following linear model was used for the estimation of breastfeeding indicators:  
𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙�𝑃𝑃𝑥𝑥,𝑐𝑐,𝑡𝑡� = 𝛽𝛽0 +  𝛽𝛽1𝑆𝑆𝑆𝑆𝑆𝑆c,t +  𝛼𝛼𝑐𝑐 +  𝛾𝛾𝑅𝑅[𝑐𝑐] +  ωSR[c] +  𝜀𝜀𝑐𝑐,𝑡𝑡 
where 𝑃𝑃𝑥𝑥,𝑐𝑐,𝑡𝑡 is prevalence for breastfeeding category x in country 𝑐𝑐 and year 𝑙𝑙; 𝑆𝑆𝑆𝑆𝑆𝑆𝑐𝑐,𝑡𝑡 is value of the 
Sociodemographic Index for country 𝑐𝑐 and year 𝑙𝑙;  𝛼𝛼𝑐𝑐, 𝛾𝛾𝑅𝑅[𝑐𝑐], and ωSR[c] are country, region, and super-
region random intercepts, respectively. 
We then followed this with a spatio-temporal regression that uses the residuals of the predictions from 
the linear regression to perform a locally-weighted regression that provides a greater weighting factor 
to those nearer in space and time. The predicted residuals from this step are then added to those 
created in the linear regression step.  
Finally, we run a Gaussian process regression that incorporates the variance of the input data as well as 
the variance of the model predictions. It uses predictions from the spatio-temporal regression as the 
mean function and generates draws from a multinomial distribution (based on the data uncertainty in 
the prior) to generate the final prevalence estimates and their confidence intervals. 
We estimated six models to produce each of our categories: the proportion of currently breastfeeding 
infants 0-5 months of age, the ratio of infants exclusively breastfed to breastfed infants 0-5 months of 
age, the ratio of infants predominantly breastfed to breastfed infants 0-5 months of age, the ratio of 
infants partially breastfed to breastfed infants 0-5 months of age, the proportion of currently 
breastfeeding infants 6-11 months of age, and the proportion of currently breastfeeding infants 12-23 
months of age. We convert the ratios of exclusive, predominant, and partial breastfeeding to the total 
category prevalence proportions by multiplying each ratio by the estimates of any breastfeeding among 
infants aged 0-5 months. This ensures that these categories sum correctly to the “any breastfeeding 0-5 
months” envelope. We calculate the proportion of infants receiving no breastmilk 0-5 months of age by 
subtracting the estimates of current breastfeeding from 1. We perform the same operation to estimate 
discontinued breastfeeding in the 6-11 months and 12-23 months categories.  
93
Estimating Attributable Burden 
Assessment of risk-outcome pairs 
We included outcomes based on the strength of available evidence supporting a causal relationship. 
Studies evaluating the causal evidence for our risk-outcome pairs came primarily from articles found in a 
review published by the World Health Organization.1 Non-exclusive breastfeeding was paired with 
diarrhea and lower-respiratory infection as diseases outcomes. Discontinued breastfeeding was paired 
with diarrhea as an outcome.  
Theoretical minimum-risk exposure level
For non-exclusive breastfeeding, those children that received no source of nourishment other than 
breastmilk (“exclusively breastfed”) were considered to be at the lowest risk of any of the disease 
outcomes. For discontinued breastfeeding, we assumed that children aged 6 to 23 months who received 
any breastmilk as a source of nourishment to be at the lowest risk of disease outcome. 
Relative Risks 
We estimate relative risks for both non-exclusive and discontinued breastfeeding in a meta-analysis 
using relative risks from studies compiled in a published review by the World Health Organization.1
Population Attributable Fraction 
We use the standard GBD population attributable fraction (PAF) equation to calculate PAFs for non-
exclusive breastfeeding and discontinued breastfeeding and each of their paired outcomes using 
exposure estimates and relative risks.  
References 
1. Horta, B., Voctora, C. (2013) Short-term effects of breastfeeding: a systematic review on the
benefits of breastfeeding on diarrhoea and pneumonia mortality. The World Health Organization.
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Published literature and reports
WHO Global Database on Child
 Growth and Malnutrition
ST-GPR linear mixed effects model x 3:
1. Mean
2. Prevalence < -2
3. Prevalence < -3
Location-level Covariates:
1. Socio-demographic Index (SDI)
2. Logit-Sanitation (prop. with access)
 Mean, Prevalence < -2, < -3 of
 HAZ, WAZ, WHZ by geography-
year-age-sex
Calculate PAFs using 




fractions by risk, 
cause, age, sex, 
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A published pooled cohort analysis 
(Olofin et al, 2013)
Calculate the effect of each 
of the three undernutrition 
indicators adjusted for the 
effect of the other two
Adjusted relative 




fractions by risk 
aggregate, cause, 
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geography
Deaths, YLLs, YLDs, 
and DALYs 
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risk by age, sex, 
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Deaths, YLLs, YLDs, 
DALYs for each 
disease and injury 




Calculate height-for-age (HAZ), weight-
for-age (WAZ), weight-for-height (WHZ) 
z-score for children 0-59 months using 
WHO Child Growth Standards (2006)
Collapse into geography-
year-age-sex mean, SD
Extract four Z-score based values for 
height-for-age (HAZ), weight-for-age 
(WAZ), weight-for-height (WHZ) 
1. mean Z score
2. prevalence of <-1
3. prevalence of <-2
4. prevalence of <-3
Ensemble distributions fit using 










Integrate at -1 SD, -2 SD, 
and -3 SD thresholds (mild, 
moderate, and severe)
Prevalence of mild 
(TMREL), moderate, and 
severe stunting, 
underweight, and wasting
Optimize SD on Mean, 
Prevalence of < -2, < -3
Mean, SD by 
geography-year-
age-sex
Crosswalk tabulated 1978 NCHS growth 
standard data to equivalent WHO 2006 
growth standard values (<-2 only) 
Linear regression of <-2 prevalence 
versus mean Z score  predict mean Z 
score value for all location-age-sex-year 
where not published
Age- and sex-splitting of aggregate data 
into GBD age/sex groups based on 
microdata age/sex pattern
Input data & methodological summary 
Exposure 
Case definition 
Child growth failure is estimated using three indicators, stunting, wasting, and underweight, all of which 
all of which are based on categorical definitions using the WHO 2006 growth standards for children 0-59 
months. Definitions are based on Z scores from the growth standards, which were derived from an 
international reference population. Mild, moderate, and severe categorical prevalences were estimated 
for each of the three indicators. 
Input data 
There are three main inputs for the GBD child growth failure models: microdata from population surveys 
and tabulated data from reports, published literature, and the WHO Global Database on Child Growth 
and Malnutrition.1 The primary data additions in GBD 2017 for child growth failure were from population 
surveys that include anthropometry. Population surveys include a variety of multi-country and country-
specific survey series such as Multiple Indicator Cluster Surveys (MICS), Demographic and Health Surveys 
(DHS), Living Standards Measurement Surveys (LSMS), and the China Health and Nutrition Survey (CHNS), 
as well as other one time country specific surveys such as the Indonesia Family Life Survey and the Brazil 
National Demographic and Health Survey of Children and Women. These microdata contain information 
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about each individual child’s age (from which age in weeks and age in months are calculated), as well as 
height and/or weight. From that information, a height-for-age z-score (HAZ), weight-for-age z-score 
(WAZ), and weight-for-height z-score (WHZ) are calculated using the WHO 2006 Child Growth Standards 
and the LMS method.2  
All available data from the WHO Global Database on Child Growth and Malnutrition was extracted for 
GBD 2016 – much of which is from published studies. Exclusions included examination date prior to 1985, 
non-population representative studies, and those based on self-report. A systematic literature review was 
last completed in GBD 2010. We looked for four metrics from all sources with tabulated data: mean Z 
score, prevalence <-1 Z score (mild), prevalence <-2 Z score (moderate), and prevalence <-3 Z score 
(severe). All data for each metric was extracted for each of stunting (height-for-age Z score; HAZ), wasting 
(weight-for-height Z score; WHZ), and underweight (weight-for-age Z score; WAZ).  
To maximise internal-consistency and comprehensiveness of the modelling dataset, we performed three 
data transformations. First, any data that were reported using the National Center for Health Statistics 
(NCHS) 1978 growth standards were crosswalked to corresponding values on the WHO 2006 Growth 
Standards curves based on a study that evaluated growth standard concordance.3 Crosswalks from 1978 
to 2006 growth standards were performed only on <-2 (i.e. moderate) prevalence data as that is where 
the concordance was most consistent. Second, for any study that lacked a measure of mean Z score for 
any of stunting, wasting, or underweight, we predicted a mean value for that study based on an ordinary-
least squares regression of mean Z score versus <-2 prevalence for that metric from all sources where 
both were available. Third, any data that was presented as both sexes combined or for 0-59 months 
combined, we used the age and sex pattern from all data sources that included that detail to split into 
corresponding and age- and sex-specific data. All data was uploaded to a database and all inputs are 
catalogued in the Global Health Data Exchange (http://ghdx.healthdata.org). A representative dataset 
coverage map for moderate stunting is shown below.  




The following three-step modelling process was applied to each of stunting, wasting, and underweight. 
First, all microdata was fit using an ensemble modelling process, a modelling framework developed for 
GBD 2016 that is described elsewhere in this appendix. A series of 12 individual distributions (normal, log 
normal, log logistic, exponential, gamma, mirror gamma, inverse gamma, gumbel, mirror gumbel, 
Weibull, inverse Weibull, and beta) were fit to the entire set of microdata (approximately 2.5 million 
individual z-scores) at the individual survey level. A weighting algorithm combined each distribution to 
find the optimal combination of these distributions for each survey, minimising the absolute prediction 
error across the entire distribution. Ensemble weights for each survey were then averaged across all 
surveys to produce a single set of global weights of the ensemble distributions. Weights were different 
for each sex, but invariant across geography, time, and age group. All component distributions that were 
used to derive weights were parameterised using “method of moments,” meaning that each 
corresponding probability density function (PDF) could be described as a function of the mean and 
variance of the quantity of interest.  
Second, models were developed for mean Z scores and prevalence of moderate and severe growth 
failure. Individual level microdata were collapsed to calculate three metrics: mean z-score, moderate 
prevalence, and severe prevalence. These data were combined with that derived from literature, GHDx 
review, and the WHO Global Database on Child Growth and Malnutrition. Each of the three metrics was 
then modelled using spatiotemporal Gaussian process regression (ST-GPR), a common modelling 
framework used across GBD, generating estimates for each age-group, sex, year, and location. Location-
level covariates used in all models included Socio-demographic Index (SDI) and logit-transformed 
proportion of households with improved sanitation.  
Third, we combined estimates of mean, prevalence (moderate and severe) with ensemble weights in an 
optimisation framework in order to derive the variance that would best correspond to the predicted 
mean and prevalence. This variance was then paired with the mean and, using the method of moments 
equation for each of the component distributions of the ensemble, PDF of the distribution of Z-scores 
were calculated for each location, year, age-group, and sex.  PDFs were integrated to determine the 
prevalence between -1 and -2 Z scores (mild), between -2 and -3 Z scores (moderate), and below -3 Z 
scores (severe). These were categorical exposures used for subsequent attributable risk analysis.  
Ad-hoc data exclusions were limited. In some cases, we identified surveys with evidence of data entry 
issues (e.g. weights entered in a mixture of pounds and kilograms) that could not be corrected and these 
data were outliered. We initially ran all models with the complete dataset. Data plausibility inspection 
began with examination of time trends in stunting. If a given datum was judged to have led to a change in 
the prevalence of moderate stunting in 1-4 year olds of 50% or greater in 5 years or fewer, and was 
inconsistent with data prior to and after that year (a change considered implausible), we outliered the 
offending datum and reran the model. We then further visually-inspected the results of moderate 
stunting, wasting, and underweight in parallel to look for location-age-sex-years where the results were 
not internally-consistent (e.g. stunting and wasting decreasing, underweight rapidly increasing). This 
inspection revealed very few inconsistent data.  
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Improvements from GBD 2015 to GBD 2016/ 2017 
In GBD 2017, the primary changes from GBD 2016 were the 1) addition of a significant volume of new 
survey data, 2) crosswalking instead of down-weighting data based on NCHS 1978 growth standard, 3) 
utilisation of updated versions of location-level covariates, and 4) utilisation of an updated version of the 
ST-GPR modelling framework that empirically derives many of the modelling parameters.  
There are several important differences from the GBD 2015 analysis. First, our systematic data searching 
efforts led to an approximately 30% increase in the number of data sources since GBD 2015, including a 
significant increase in data sources for Oceania, Latin America, and South Asia. Most notable was the 
increase in data for India through our collaboration with the India Council for Medical Research (ICMR) 
and Public Health Foundation of India (PHFI). Second, while GBD 2015 also used ST-GPR to model growth 
failure, models were completed for a single 0-5 age group, followed by application of a pooled uniform 
age-sex split which resulted in the implicit assumption that the age pattern of growth failure is invariant 
over time and geography. GBD 2016 estimates, owing to smaller sample sizes in younger age groups, do 
have wider uncertainty in those age groups. Third, GBD 2015, like all analyses of growth failure before it, 
assumed that high-income countries had zero prevalence of child growth failure. We suspended this 
assumption in GBD 2016 as it is not accurate and instead made explicit estimates of growth failure in all 
locations. Fourth, GBD 2015 did not use an ensemble approach or estimate the entire distribution of Z 
scores. Fifth, we changed the name of this risk factor category changed from childhood undernutrition to 
child growth failure to more explicitly identify the specific aspects of childhood undernutrition that are 
covered by the three component indicators.  
Theoretical minimum-risk exposure level 
Theoretical minimum risk exposure level (TMREL) for underweight, stunting, and wasting was assigned to 
be greater than or equal to -1 SD of the WHO 2006 standard weight-for-age, height-for-age, and weight-
for-height curves respectively. This has not changed since GBD 2010. 
Relative risks 
The final list of outcomes paired with child growth failure risks included lower respiratory infections (LRI), 
diarrhea, measles, and protein energy malnutrition (PEM) as shown in Table 1. These were derived from a 
pooled cohort analysis by Olofin and colleagues.5  
There is a high degree of correlation between stunting, wasting, and underweight. Failing to account for 
their covariance and assuming independence would overestimate the total burden significantly. This is 
the main reason that GBD 2010 only included childhood underweight. In GBD 2013, a method was 
developed to adjust observed RRs of Olofin and colleagues by simulating the joint distribution of the 
three indicators using the distribution of each indicator and covariance between indicators in the 
countries included in the meta-analysis (extracted from Demographic and Health Survey (DHS) micro-
data).4 Based on the analysis done by McDonald and colleagues, we assumed there is an interaction 
between the three indicators, and extracted the interaction terms from the corresponding analysis. We 
calculated the adjusted RRs by minimising the error between observed crude RRs (from meta-analysis) 
and expected crude RRs derived from adjusted RRs.   
Of historical note, URI and otitis media were included as outcomes in the GBD 2013 risk analysis, based 
on the “analogy” causal criterion, assuming there is similar pathway as LRI outcome. However, closer 
review for GBD 2015 did not find sufficient evidence to support their inclusion and they were excluded, a 
decision that was carried forward into GBD 2016. We also attributed 100% of PEM to childhood wasting 
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and underweight but not stunting. To build on the existing literature base for GBD on risk-outcome pairs, 
a literature search was conducted for GBD 2017 searching for case-control studies published after 
January 1st, 1985; this search did not return any sources that were appropriate for this work.  
Table 1: Adjusted RRs for each risk-outcome pair for child growth failure 
Outcome Stunting Wasting Underweight 
Diarrhea 
<-1:   1.111 (1.023-1.273) 
<-2:   1.222 (1.067-1.5) 
<-3:   1.851 (1.28-2.699) 
<-1:   6.601 (2.158-11.243) 
<-2:   23.261 (9.02-35.845) 
<-3:   105.759 (42.198-157.813) 
<-1:   1.088 (1.046-1.134) 
<-2:   1.23 (1.163-1.314) 
<-3:   2.332 (2.076-2.802) 
Lower respiratory 
infections (LRI) 
<-1:   1.125 (0.998-1.655) 
<-2:   1.318 (1.014-2.165) 
<-3:   2.355 (1.15-5.114) 
<-1:   5.941 (1.972-11.992) 
<-2:   20.455 (70.84-37.929) 
<-3:   47.67 (15.923-94.874) 
<-1:   1.145 (1.044-1.364) 
<-2:   1.365 (1.215-1.755) 
<-3:   2.593 (1.908-4.39) 
Measles 
<-1:   1.103 (0.861-1.719) 
<-2:   1.54 (1.029-3.222) 
<-3:   2.487 (1.129-6.528) 
<-1:   1.833 (0.569-8.965) 
<-2:   8.477 (1.33-42.777) 
<-3:   37.936 (5.088-199.126) 
<-1:   0.995 (0.5-1.726) 
<-2:   2.458 (1.26-5.118) 
<-3:   5.668 (1.767-12.414) 
Protein-energy 
malnutrition 0% PAF 100% PAF 100% PAF 
References 
1 WHO | WHO Global Database on Child Growth and Malnutrition. WHO. 
http://www.who.int/nutgrowthdb/en/ (accessed July 30, 2018). 
2 Wang Y, Chen H-J. Use of Percentiles and Z-Scores in Anthropometry. In: Preedy VR, ed. Handbook of 
Anthropometry. New York, NY: Springer New York, 2012: 29–48. 
3 Uribe Á, Cecilia M, López Gaviria A, Estrada Restrepo A. Concordance between Z scores from WHO 2006 
and the NCHS 1978 growth standards of children younger than five. Antioquia-Colombia. Perspectivas 
en Nutrición Humana 2008; 10: 177–87. 
4 McDonald CM, Olofin I, Flaxman S, et al. The effect of multiple anthropometric deficits on child 
mortality: meta-analysis of individual data in 10 prospective studies from developing countries. Am J 
Clin Nutr 2013; 97: 896–901. 
5 Olofin I, McDonald CM, Ezzati M, et al. Associations of Suboptimal Growth with All-Cause and Cause-
Specific Mortality in Children under Five Years: A Pooled Analysis of Ten Prospective Studies. PLOS ONE 
2013; 8: e64636. 
99
Low Birth Weight and Short Gestation Capstone Appendix 
Flowchart  
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Input data and methodological summary 
The “Low Birth Weight and Short Gestation” (LBWSG) risk factor and its child risks “Low Birth Weight for 
Gestation” and “Short Gestation for Birth Weight” first were included as risk factors in GBD 2016.  
Although low birth weight for gestation and short gestation for birth weight are separate risk factors, 
the exposures and relative risks for both are estimated jointly through the low birth weight and short 
gestation parent risk factor. As of GBD 2017, LBWSG are the only risk factors estimated jointly.  
Case definition 
The meaning of the “low birth weight” and “short gestation” in GBD have subtle definitional differences 
compared to other usages of “low birth weight” and “short gestation” in literature. The term “low birth 
weight” has historically been used to refer to birth weight (BW) less than 2500 grams. However, because 
the goal of the GBD risk factors analysis is to quantify the entirety of attributable burden due to each 
risk factor, the GBD definition of “low birth weight” therefore refers to all birth weight below the 
Theoretical Minimum Risk Exposure Level (TMREL) for birth weight. Likewise, new-borns have been 
typically been classified into gestational age (GA) categories of “extremely preterm” (<28 weeks of 
gestation), “very preterm” (28-<32 weeks of gestation), and “moderate to late preterm” (32-<37 weeks 
of gestation). “Short gestation” in GBD refers to all gestational ages below the gestational age TMREL. 
Exposures and relative risks for the GBD Low birth weight and short gestation risk factors are divided 
into joint 500-gram birth weight and 2-week gestational age combinations. The lowest risk overall 500-
gram/2-week bin is the overall TMREL. The univariate TMRELs vary with GA and BW. The lowest risk GA 
varies by BW category and the lowest risk BWs vary with GA category. The latter are used to quantify 
univariate attributable risk. Under this framework, all attributable burden under the joint TMREL is 
referred to jointly as burden of LBWSG. All attributable burden to BWs under the TMREL for each GA 
category are, on aggregate, “low birth weight” and all attributable burden to GAs under the TMREL for 
each BW category are, on aggregate, “short gestation.” Each combination of 500-grams and 2-wks is 
associated with a relative risk for mortality by neonatal period (early and late neonatal) and by the 
causes listed in Table 2 and described below, and relative to the joint TMREL. 
Exposure 
Input data 
To model the joint distribution of exposure of low birth weight and short gestation for each location, 
year, and sex estimated in GBD 2017, three types of information are used: 
- Distribution of gestational age for each location, year, and sex
- Distribution of birth weight for each location, year, and sex
- Copula family and parameters, specifying correlation between gestational age and birth weight
distributions
Modelling strategy  
Distributions of birth weight & gestational age 
To model the joint distribution of birth weight and gestational age for every location-sex-year, ensemble 
model methods standard to GBD risk factors (described elsewhere in the methods appendix), are first 
used to create separate distributions of birth weight and gestational age for every location-sex-year. 
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Microdata is the most ideal data source for modelling distributions; however, microdata is not widely 
available for birth weight and is more scarce for gestational age. Categorical prevalence data is much 
more readily available, and from a wider range of locations and years, for low birth weight (<2500g), 
extremely preterm (<28 weeks of gestation), very preterm (28-32 weeks of gestation), moderate to late 
preterm (32-37 weeks of gestation), and preterm birth (<37 weeks of gestation). From GBD 2010 to GBD 
2015, this categorical data has been used model birth prevalence of preterm birth by gestational age 
(<28 weeks, 28-<32 weeks, and 32-<37 weeks) and low birth weight (<2500g) for every location, sex, and 
year estimated in GBD. Starting in GBD 2016 with the introduction of the LBWSG risk factors, the full 
distributions at birth have been modelled for gestational age and birth weight for all GBD locations, 
estimation years, and both sexes. The gestational age and birth weight distributions are then aggregated 
into the categorical estimates of <28 weeks, 28-<32 weeks, 32-<37 weeks gestation, and <2500 g birth 
weight.  
Ensemble model methods standard to GBD are used to model the distribution at birth of gestational age 
and birth weight. Gestational age ensemble distribution models use the prevalence of <37 weeks 
gestation, the prevalence of <28 weeks gestation, and mean gestational age per each location-year-sex 
as inputs into the model. Birth weight distribution models use the prevalence of <2500 grams birth 
weight and mean birth weight per each location-year-sex. Prevalence of <37 weeks gestation and of 
<2500 grams birth weight was estimated for all location-year-sexes using STGPR modelling processes 
standard to GBD.  
Low birth weight (<2500 grams) data was extracted from literature, vital registration systems, and 
surveys. DHS survey data were observed to have high missingness; to correct for the missingness, birth 
weight was imputed using the Amelia package in R.  Birth weight was predicted using standard Amelia 
imputation methods from the following variables also in the DHS surveys: urbanicity, sex, birthweight 
recorded on card, birth order, maternal education, paternal education, child age, child weight, child 
height, mother’s age at birth, mother’s weight, shared toilet facility, and household water treated. Data 
counts for categorical prevalence models are listed in Table 1.   
Table 1: Data Counts for Categorical Prevalence Models 
<28 weeks <37 weeks <2500 grams 
Site-years (total) 1872 2420 2980 
Number of GBD regions with data (out of 
21 regions) 14 21 21 
Number of GBD super-regions with data 
(out of 7 super-regions) 6 7 7 
Global ensemble weights for gestational age were derived by using a 3 million sample of all available 
microdata in Table 2 to select the ensemble weights. Of the exponential, gamma, inverse gamma, 
Weibull, log normal, and normal distributions, the three distribution families that received the highest 
weights were the Weibull (87%), normal (4%), and inverse gamma (4%) distributions. Global ensemble 
weights for birth weight were derived using a 3 million sample of all available microdata in Table 2, in 
addition to birth weight microdata available primarily through the DHS and MICS surveys. Of the 
exponential, gamma, inverse gamma, Weibull, log normal, and normal distributions, the three 
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distribution families that received the highest weights were the log normal (38%), normal (32%), and 
Weibull (20%) distributions. 
Ordinary least squares was used to model mean gestational age for all location-year-sexes by regressing 
mean gestational age on prevalence of <37 weeks gestation per location-year. All available microdata 
(Table 2) was used to fit the model. OLS was also used to model mean birth weight by regressing 
prevalence of <2500 g birth weight per location-year. All available joint microdata (Table 2), as well as 
additional birth weight microdata extracted primarily through DHS and MICS surveys, was used to fit the 
model. As estimates of prevalence of <37 weeks gestation and prevalence of <2500g birth weight are 
available for all location-year-sexes through STGPR models, mean gestational age and mean birth weight 
were predicted for all location-year-sexes.  
Copula optimisation 
In order to model the joint distribution of gestational age and birth weight from separate distributions, 
information is needed about the correlation between the two distributions. Distributions of gestational 
age and birth weight are not independent; the Spearman correlation for each country where joint 
microdata was available (Table 2), pooling across all years of data available, ranged from 0.25-0.49. The 
overall Spearman correlation was 0.38, pooling across all countries in the dataset.  
Table 3: Summary of Data Inputs 
















BRA 2016 2,854,380 Microdata 0.37 Yes Yes No 
ECU 2003-2015 2,473,039 Microdata 0.34 Yes Yes No 
ESP 1990-2014 8,537,220 Microdata 0.42 Yes Yes No 
JPN 1995-2015 23,644,506 Tabulations 0.41 No No Yes 
MEX 2008-2012 10,256,117 Microdata 0.35 Yes Yes No 
NOR 1990-2014 1,489,210 Microdata 0.44 Yes Yes Yes 
NZL 1990-2016 1,600,501 Microdata 0.25 Yes Yes Yes 
SGP 1993-2015 972,775 Tabulations 0.41 No No Yes 
TWN 1998-2002 1,331,760 Tabulations 0.38 No No Yes 
URY 1996-2014 698,622 Microdata 0.49 Yes Yes No 
USA 1990-2014 81,929,879 Microdata 0.38 Yes Yes Yes 
* Pooled across all year and sexes, excluding data missing year of birth, gestational age, or birth weight
Copula modelling is used to model joint distributions between the birth weight and gestational age 
marginal distributions. The Copula and VineCopula packages in R were used to select the optimal copula 
family and copula parameters to model the joint distribution, using joint microdata from the country-
years in Table 2. The copula family selected from the microdata was “Survival BB8”, with theta 
parameter set to 1.75 and delta parameter set to 1.   
The joint distribution of birth weight and gestational age per location-year-sex was modelled using the 
global copula family and parameters selected and the location-year-sex gestational age and birth weight 
distributions. The joint distribution was simulated 100 times to capture uncertainty. Each simulation 
consisted of 100,000 simulated joint birth weight and gestational age data points. Each joint distribution 
103
was divided into 500g by 2wk bins to match the categorical bins of the relative risk surface. Birth 
prevalence was then calculated for each 500g by 2wk bin. 
Estimating Early Neonatal Prevalence & Late Neonatal Prevalence from Birth Cohorts 
Early neonatal prevalence and late neonatal prevalence was estimated using life table approaches for 
each 500g & 2wk bin. Using the all-cause early neonatal mortality rate for each location-year-sex, births 
per location-year-sex-bin, and the relative risks for each location-year-sex-bin in the early neonatal 
period, the all-cause early neonatal mortality rate was calculated for each location-year-sex-bin. The 
early neonatal mortality rate per bin was used to calculate the number of survivors at 7 days and 
prevalence in the early neonatal period. Using the same process, the all-cause late neonatal mortality 
rate for each location-year-sex was paired with the number of survivors at 7 days and late neonatal 
relative risks per bin to calculate late neonatal prevalence and survivors at 28 days.  
Relative risks & theoretical minimum-risk exposure level 
Causes 
The available data for deriving relative risk was only for all-cause mortality. The exception was the USA 
linked infant birth-death cohort data, which contained 3-digit ICD causes of death, but also had nearly 
30% of deaths coded to causes that are ill-defined, or intermediate, in the GBD cause classification 
system. For GBD 2017, like in GBD 2016, we analysed the relative risk of all-cause mortality across all 
available sources and selected outcomes based on criteria of biologic plausibility. Some causes, most 
notably congenital birth defects, haemoglobinopathies, malaria, and HIV/AIDS, were excluded based on 
the criteria that reverse causality could not be excluded. The final list of outcomes included in 
calculating the attributable burden for LBW/SG are in Table 3.  
Table 3: Cause list of outcomes for low birth weight and short gestation 
Cause ID Cause name 
302 Diarrheal diseases 
322 Lower respiratory infections 
328 Upper respiratory infections 
329 Otitis media 
333 Pneumococcal meningitis 
334 H influenzae type B meningitis 
335 Meningococcal meningitis 
336 Other meningitis 
337 Encephalitis 
381 Neonatal preterm birth complications 
382 Neonatal encephalopathy due to birth asphyxia and trauma 
383 Neonatal sepsis and other neonatal infections 
384 Hemolytic disease and other neonatal jaundice 
385 Other neonatal disorders 
686 Sudden infant death syndrome 
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Input data 
In the Norway, New Zealand, and US Linked Birth/Death Cohort microdata datasets, live births are 
reported with gestational age, birth weight, and an indicator of death at 7 days and 28 days. For this 
analysis, gestational age was grouped into two-week categories, and birth weight was grouped into 500-
gram categories. The Taiwan, Japan, and Singapore datasets were prepared in tabulations of joint 500-
gram and two-week categories. 
Modelling strategy  
For each location, data was pooled across years, and the risk of all-cause mortality at the early neonatal 
period and late neonatal period at joint birth weight and gestational age combinations was calculated. In 
all datasets except for the United States, sex-specific data were combined to maximise sample size. The 
United States analyses were sex-specific. To calculate relative risk at each 500g and 2wk combination, 
logistic regression was first used to calculate mortality odds for each joint 2-week gestational age and 
500-gram birth weight category. Mortality odds were smoothed with Gaussian Process Regression, with
the independent distributions of mortality odds by birth weight and mortality odds by gestational age
serving as priors in the regression.
A pooled country analysis1 of mortality risk in the early neonatal period and late neonatal period by SGA 
category in developing countries in Asia and Sub-Saharan Africa were also converted into 500-gram and 
2-week bin mortality odds surfaces. The relative risk surfaces produced from microdata and the Asia and
Africa surfaces produced from the pooled country analysis were meta-analyzed, resulting in a meta-
analysed mortality odds surface for each location. The meta-analysed mortality odds surface for each
location was smoothed using Gaussian Process Regression and then converted into mortality risk. To
calculate mortality relative risks, the risk of each joint 2-week gestational age and 500-gram birth weight
category were divided by the risk of mortality in the joint gestational age and birth weight category with
the lowest mortality risk.
For each of the country-derived relative risk surfaces, the 500 g and 2-week gestational age joint bin 
with the lowest risk was identified. This bin differed within each country dataset. To identify the 
universal 500 g and 2-week gestational age category that would serve as the universal TMREL for our 
analysis, we chose the bins that was identified to be the TMREL in each country dataset to contribute to 
the universal TMREL. Therefore, the joint categories that served as our universal TMREL for the LBWSG 
risk factor were “38-40 weeks of gestation and 3500-4000 grams", "38-40 weeks of gestation and 4000-
4500 grams", and "40-42 weeks of gestation and 4000-4500 grams". As the joint TMREL, all three 
categories were assigned to a relative risk equal to 1.   
PAF calculations 
The total PAF for the low birth weight and short gestation joint risk factor is calculated by summing the 
PAF calculated from each 500g x 2wk category, with the lowest risk category among all the 500g x 2wk 
categories serving as the TMREL. The equation for calculating PAF for each 500g x 2wk category is: 
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To calculate the overall PAF for the short gestation for birth weight risk factor, PAF was once again 
calculated for each joint 500-gram and 2-week category. Unlike the joint PAF calculation, which used 
only one TMREL for all 500-gram and 2-week categories, the joint 500-gram and 2-week category with 
the lowest risk for each 500-gram birth weight grouping served as the TMREL for that 500-gram birth 
weight grouping. For example, the [3000, 3500) gram birth weight grouping contains five joint 
categories: [34, 36) weeks and [3000, 3500) grams; [36, 37) weeks and [3000, 3500) grams; [37, 38) 
weeks and [3000, 3500) grams; [38, 40) weeks and [3000, 3500) grams; and [40, 42) weeks and [3000, 
3500) grams. The [40, 42) weeks and [3000, 3500) grams joint category has the lowest risk, and so it 
serves as the TMREL for the [3000, 3500) gram birth weight grouping. In the Relative Risk surface 
figures, a birth weight grouping is one “column” of the birth weight and gestational age matrix. 
The overall PAF for the short gestation for birth weight risk factor was then calculated for all the joint 
500-gram and 2-week categories using the formula below:
The same methodology was applied to calculate the total PAF for the low birth weight for gestation risk 
factor, using two-week gestational age categories (each “row” of the matrix) instead of 500-gram birth 
weight categories. For example, the [24, 26) weeks gestational age grouping contains three joint 
categories: [0, 500) grams and [24, 26) weeks; [500, 1000) grams and [24, 26) weeks; and [1000, 1500) 
grams and [24, 26) weeks. The [1000, 1500) grams and [24, 26) weeks joint category has the lowest risk, 
and so it serves as the TMREL for the [24, 26) weeks gestational age grouping. 
After the short gestation for birth weight PAF and low birth weight for gestational age PAF were 
calculated, they were then scaled so that the sum of the short gestation for birth weight PAF and low 
birth weight for gestation PAF equal the low birth weight and short gestation parent PAF calculated for 
each location/year/sex/age group. 
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Iron Deficiency Capstone Appendix 
Flowchart 
Input data & methodological summary 
Exposure 
Case definition 
For GBD 2017, as with GBD 2016, the anemia model has two main steps: estimation of the anemia 
envelope and causal attribution. Our analytic strategy began with calculation of an anemia envelope – a 
determination of mean hemoglobin, as well as a sum total of anemia prevalence, by severity for each 
country, age group, and both sexes for each year from 1990 through 2017. The envelope approach 
avoids double-counting while capturing potentially different disease profiles within each population 
group. We defined a population group as a specific geography, sex, age-group, and year. 
Input data 
Iron-deficiency anemia (IDA) estimates include acute and chronic hemorrhagic states for which 
supplementation may be helpful, but poor nutritional intake is not the only underlying problem. A few 
causes in this category – hookworm, schistosomiasis, upper gastrointestinal bleeding, and gynecologic 
diseases – were considered separately from IDA in GBD 2016 because there was enough data from GBD 
prevalence estimation processes to do so. Distribution of anemia burden to IDA only after assignment to 
“known” causes avoided double counting of these cases. In GBD 2017, we redefined the iron deficiency 
risk factor to encompass all causes of anemia that would respond to iron supplementation. 
For our nonfatal anemia estimates, the envelope approach to the anemia impairment utilises data from 
a variety of sources. Population-based surveys of hemoglobin concentration were the primary input to 
our analytic dataset. Examples include the Demographic and Health Survey (DHS) and Multiple Indicator 
Cluster Survey (MICS) series, along with other national and subnational surveys that completed 
hemoglobin testing. We supplemented with pertinent sources downloaded from the WHO Vitamin and 
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Mineral Nutrition Information System (VMNIS) available at 
http://www.who.int/vmnis/database/anaemia/countries/en/. A full source list is available elsewhere in 
this appendix. Most used a HemoCue test, adjusted for altitude, and excluded those with terminal or 
acute medical conditions.  Inclusion, exclusion and diagnostic criteria for other studies were similar and 
can be found in each study. 
Modelling strategy  
For GBD 2017, we estimated the mean hemoglobin in g/dL among pregnant women aged 15 to 49 years 
of age and the implied mean hemoglobin among pregnant women in the absence of iron deficiency 
anemia, as the risk exposure for maternal iron deficiency anemia.  
Theoretical minimum-risk exposure level 
The implied mean hemoglobin in the absence of iron deficiency anemia is the theoretical minimum risk 
exposure level. This was calculated by adding the iron responsive hemoglobin shift back onto the 
observed hemoglobin concentration for each demographic. For example, if the observed hemoglobin 
concentration among 30-34 year old pregnant women in Ethiopia was 132.9 g/L, and the shift was 1.6 
g/L in that demographic, then the counterfactual was 134.5 g/L. The GBD 2017 anemia modelling 
strategy provides details on how the iron deficiency shifts were calculated. 
Relative risk 
We attribute 100% of iron-deficiency anemia to iron deficiency. The other outcomes used in GBD 2016 
are maternal hemorrhage, maternal sepsis and other maternal infections. In GBD 2017 we added the 
following additional maternal outcomes: maternal hypertensive disorders, maternal obstructed labor an 
uterine rupture, maternal abortion and miscarriage, ectopic pregnancy, indirect maternal deaths, late 
maternal deaths, maternal deaths aggravated by HIV/AIDS, and other maternal disorders. For these 
additional maternal outcomes, we assigned the same relative risk as that used for the maternal 
outcomes from 2016. Sources of evidence for these relative risks are unchanged from GBD 2013. 
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Input data & methodological summary 
Exposure 
Case definition 
For GBD 2017, vitamin A deficiency is defined as serum retinol <70 µmol/L. We examined vitamin A 
deficiency as a risk factor in children aged 6 months to 5 years. 
To ensure we were using as much information as possible, and therefore maximize the data basis of our 
estimates, we modeled Vitamin A deficiency sequentially. The first step was to estimate the coverage of 
Vitamin A supplementation. Although the typical metric on which supplementation is tracked is 2+ 
doses of Vitamin A in the previous 12 months for children under 5 years, most existing health surveys do 
not routinely provide sufficient information to calculate it. Our case definition for the supplementation 
model was therefore the proportion of children 6-59 months of age who received at least one dose of 
Vitamin A in the previous 6 months. Supplementation estimates were then used as a location-level 
covariate to guide exposure models of overall Vitamin A deficiency. 
Input data 
For GBD 2017, we used data from the WHO Vitamin and Mineral Nutrition Information System, health 
surveys such as DHS and MICS, and studies identified through literature review. This included updating 
the dataset to include all ages and all studies available in VMNIS as of April 2018. A separate systematic 
review was last conducted for GBD 2013. The PubMed search terms were: ((vitamin A 
deficiency[Title/Abstract] AND prevalence[Title/Abstract]) AND (“2009”[Date – Publication] : 
“2013”[Date – Publication])). The table below shows the number of data points included in the final 
datasets. Exclusion criteria were: 
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1. Studies that were not population-based, e.g., hospital or clinic-based studies




Table 1. Geographic representation of datasets used for three stages of Vitamin A deficiency risk factor 
burden estimation (number of data points per geography) 
Geography Supplementation (proportion) Deficiency (prevalence) 
Global 900 1540 
East Asia 12 27 
Southeast Asia 102 212 
Oceania 24 54 
Central Asia 51 66 
Central Europe 2 13 
Eastern Europe 3 
Australasia 1 
Western Europe 38 
Southern Latin America 16 
High-income North America 33 
Caribbean 17 34 
Andean Latin America 25 70 
Central Latin America 33 212 
Tropical Latin America 1 52 
North Africa and Middle East 49 148 
South Asia 61 96 
Central Sub-Saharan Africa 60 8 
Eastern Sub-Saharan Africa 182 220 
Southern Sub-Saharan Africa 49 57 
Western Sub-Saharan Africa 232 180 
Modeling strategy 
All Vitamin A deficiency estimates were made using DisMod-MR 2.1. As described above, we first 
estimated Vitamin A supplementation coverage. Although all data was from ages 6-59 months, we 
assumed no difference in age pattern of supplementation coverage and used the natural log of lag-
distributed income per capita (LN-LDI) as a location-level covariate to inform estimates where data was 
absent. DHS and MICS data was cross-walked to the reference data source, which came from UNICEF 
(http://data.worldbank.org/indicator/SN.ITK.VITA.ZS). 
Table 2: Covariate effects for Vitamin A supplementation model 
Measure Covariate Type Value Exponentiated 
Prevalence MICS Study-level 
-0.6
(-0.76 — -0.45) 
0.55 
(0.47 — 0.64) 
Prevalence DHS Study-level 
-0.09
(-0.2 — 0.025) 
0.91 
(0.82 — 1.03) 
Prevalence LDI (I$ per capita) Country-level 
0.013 
(0.00033 — 0.042) 
1.01 
(1.00 — 1.04) 
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Second, we estimated the age- and sex-specific prevalence of Vitamin A deficiency (serum retinol < 0.7 
µmol/L). WHO VMNIS was the primary data source for this model and was supplemented with data from 
DHS and other health surveys where testing was performed. We assumed the following in our model: no 
excess mortality, birth prevalence is possible, incidence is decreasing after age 5 and remission is 
increasing after age 5. Data from subnational locations was crosswalked to the reference data sources of 
nationally-representative data. Females were found to have 1.09 times higher Vitamin A deficiency, 
although the uncertainty in that ratio ranged from 0.97 to 1.24. Location-level covariates were used for 
Vitamin A supplementation coverage from the above model as well as GBD 2016 Socio-demographic 
Index (SDI) numbers.  
Table 3: Covariate effects for Vitamin A deficiency model 
Measure Covariate Type Value Exponentiated 
Prevalence Sex Study-level (x-cov) 
-0.0091
( -0.088 — 0.065)
0.99 
(0.92 — 1.07) 
Prevalence Subnational Study-level (x-cov) 
-0.28
( -0.44 — -0.1)
0.76 
(0.64 — 0.90) 
Prevalence 




( -0.1 — -0.00071)
0.97 






( -3 — -2.92)
0.051  
(0.050 — 0.054) 
Prevalence vegetables unadjusted(g) Country-level 
-1.36
( -1.53 — -1.12)
0.26 
(0.22 — 0.33) 
Theoretical minimum-risk exposure level 
The theoretical minimum risk exposure is that the prevalence of vitamin A deficiency is zero. 
Relative risks 
The relative risks were updated in GBD 2017 to reflect studies included in the most recently published 
systematic review by Imdad and colleagues.1 The overall estimation strategy has not changed. For each 
trial identified by the systematic review, we adjusted the relative risk for the background prevalence of 
Vitamin A deficiency in 1-4 years from the GBD 2017 model described above. This adjustment assumes 
the effect of supplementation is observed only in the fraction of the trial population that are Vitamin A 
deficient. Many studies evaluate either incidence or mortality. A subset of studies evaluated both 
incidence and cause-specific mortality as outcomes for the same cause. We found no statistical 
difference between the effect sizes of incidence and mortality in any of these studies so pooled all 
incidence and mortality observations as independent observations prior to meta-analysis. We then 
performed a fixed effects meta-analysis of all adjusted RRs to determine final outcomes to be included 
in GBD risk factor attribution estimates. Forest plots are shown in Figures 1-5; Final RRs are shown in 
Table 4. Three outcomes – diarrhea, lower respiratory infections (LRI), and measles – were found to be 
statistically significant after adjustment, pooling, and meta-analysis. Meningitis was non-significant. 
Malaria was significant, but only a single study was identified that evaluated this outcomes, which does 
not meet GBD causal criteria.  
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Table 4: Pooled relative risks for risk-outcome pairs included in GBD 2017 
Cause GBD 2016 RR GBD 2017 RR Include in GBD 2017 
Diarrhea 1.6 (1.21 - 2.02) 2.35 (2.17 - 2.54) Yes 
Measles 2.4 (1.61 - 3.48) 2.76 (2.01 - 3.78) Yes 
Lower Respiratory Infections (LRI) 1.23 (1.03 - 1.48) Yes 
Meningitis 3.2 (0.69 - 14.75) No (not significant) 
Malaria 3.65 (2.23 - 5.97) No (only one study) 
Figure 1: Forest plot of RR of diarrhea in Vitamin A deficiency 
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Figure 2: Forest plot of RR of measles in Vitamin A deficiency 
Figure 3: Forest plot of RR of LRI in Vitamin A deficiency 
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Figure 4: Forest plot of RR of meningitis in Vitamin A deficiency 
Figure 5: Forest plot of RR of malaria in Vitamin A deficiency 
References 
1. Imdad A, Ahmed Z, Bhutta ZA. Vitamin A supplementation for the prevention of morbidity and
mortality in infants one to six months of age. Cochrane Database of Systematic Reviews 2016; Sep
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Zinc Deficiency Capstone Appendix 
Input data & methodological summary 
Exposure 
Case definition 
Exposure to zinc deficiency is defined as consumption of less than 2.5 milligrams of zinc per day among 
children between the ages of 1 and 4 years old. 
Input data 
We used dietary data from nationally and sub-nationally representative nutrition surveys and United 
Nations FAO Supply and Utilization Accounts to estimate the mean intake of zinc at the population level. 
Modelling strategy 
For GBD 2016, we first used a spatio-temporal Gaussian process regression (ST-GPR) framework to 
estimate the mean intake of zinc by age, sex, country, and year. To assist with estimation for locations 
and years without data, we used the lag-distributed income of that location-year as a covariate. We 
considered data from 24-hour diet recall as the gold standard, and adjusted data from other sources to 
the gold standard method. Using the method described in the dietary risks section, we characterised the 
distribution of zinc intake for children between ages of 1 and 4 years old and estimate the proportion of 
the children with intake of less than 2.5 milligrams of zinc per day.    
Relative risk 
Relative risks used for zinc deficiency is based on the results of randomised trials that measured the 
effect of zinc supplementation.  
Theoretical minimum-risk exposure level 
The theoretical minimum-risk exposure level for proportion zinc deficient is zero percent deficient.  
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Smoking Capstone Appendix 
Flowchart 
We made significant changes to the methods used to estimate smoking attributable burden in GBD 
2017. In previous iterations of the GBD, we have used the Peto-Lopez (Smoking Impact Ratio) method to 
estimate burden attributable to cancers and chronic respiratory diseases. Although this method 
provides robust estimates of the burden of cancers and chronic respiratory diseases related to tobacco, 
it is not fully consistent with the GBD approach of estimating exposure independently of the outcomes 
affected by exposure. For cardiovascular diseases and all other smoking attributable health outcomes, 
we used five-year lagged daily smoking prevalence as the exposure. With a growing body of evidence on 
the association between smoking and several types of cancers and with cardiovascular disease, coupled 
with good estimates of the distribution of cumulative smoking exposure, direct estimation of 
attributable burden is possible. In GBD 2017, we have transitioned to using continuous measures of 
exposure that incorporate dose-response effects among daily, occasional, and former smokers for all 
health outcomes except fractures. 
Current and former smoking prevalence 
We estimated the prevalence of current smoking and the prevalence of former smoking using data from 
cross-sectional nationally representative household surveys. We defined current smokers as individuals 
who currently use any smoked tobacco product on a daily or occasional basis. We defined former 
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smokers as individuals who quit using all smoked tobacco products for at least 6 months, where 
possible, or according to the definition used by the survey. Prior to modelling a complete time series for 
all demographic groups, we made adjustments for alternative case definitions as well as for data 
reported in non-standard age or sex groups. We modelled current and former prevalence using 
spatiotemporal Gaussian process regression.  
Data extraction 
We extracted primary data from individual-level microdata and survey report tabulations. We extracted 
data on current, former, and/or ever smoked tobacco use reported as any combination of frequency of 
use (daily, occasional, and unspecified, which includes both daily and occasional smokers) and type of 
smoked tobacco used (all smoked tobacco, cigarettes, hookah, and other smoked tobacco products such 
as cigars or pipes), resulting in 36 possible combinations. Other variants of tobacco products, for 
example hand-rolled cigarettes, were grouped into the four type categories listed above based on 
product similarities. Only smoked tobacco products are included, smoked drugs are estimated 
separately as part of the drug use risk factor. 
For microdata, we extracted relevant demographic information, including age, sex, location, and year, as 
well as survey metadata, including survey weights, primary sampling units, and strata. This information 
allowed us to tabulate individual-level data in the standard GBD five-year age-sex groups and produce 
accurate estimates of uncertainty. For survey report tabulations, we extracted data at the most granular 
age-sex group provided. 
Crosswalk 
Our GBD smoking case definitions were current smoking of any tobacco product and former smoking of 
any tobacco product. All other data points were adjusted to be consistent with either of these 
definitions. Some sources contained information on more than one case definition and these sources 
were used to develop the adjustment coefficient to transform alternative case definitions to the GBD 
case definition. The adjustment coefficient was the beta value derived from a linear model with one 
predictor and no intercept. 
We generated separate crosswalk coefficients for the 10-14 age group and the 15-19 age group, as we 
found the relationships between case definitions differed strongly in the younger age groups compared 
to the 20+ age groups. To account for this, we attempted to generate a global crosswalk coefficient for 
both the 10-14 and 15-19 age groups, using the same regression as above. Due to data limitations, none 
of the crosswalk coefficients met the criteria outlined above, so no data covering youths under 20 years 
old were crosswalked. In other words, all data from these age groups that appear in the model were 
asked according to our case definition in the survey. 
We propagated uncertainty at the survey level from the crosswalk by incorporating both the variance of 
the errors and the variance of the adjustment coefficients.  
For each source that needed adjusting, we assigned space weights based on GBD region and super 
region to the sources containing more than one case definition. Data from the same region receiving a 
full weight of 1, and data from the same super-region received a weight of ½. We explored using a time 
weight, to control for possible changes in the relationship between smokeless tobacco use behaviours 
over time. We found incorporating temporal information did not significantly change the estimated 
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coefficients but did undercut sample sizes, and chose to exclude the time weight. Crosswalk coefficients 
generated from fewer than 20 data sources were dropped 
Age and sex splitting  
We split data reported in broader age groups than the GBD 5-year age groups or as both sexes 
combined by adapting the method reported in Ng et al. 
(http://jamanetwork.com/journals/jama/fullarticle/1812960) to split using a sex- geography- time 
specific reference age pattern. We separated the data into two sets: a training dataset, with data 
already falling into GBD sex-specific 5-year age groups, and a split dataset, which reported data in 
aggregated age or sex groups. We then used spatiotemporal Gaussian Process Regression (ST-GPR) to 
estimate sex-geography-time specific age patterns using data in the training dataset. The estimated age 
patterns were used to split each source in the split dataset.  
The ST-GPR model used to estimate the age patterns for age-sex splitting used an age weight parameter 
value that minimises the effect of any age smoothing. This parameter choice allows the estimated age 
pattern to be driven by data, rather than being enforced by any smoothing parameters of the model. 
Because these age-sex split data points will be incorporated in the final ST-GPR exposure model, we do 
not want to doubly enforce a modelled age pattern for a given sex-location-year on a given aggregate 
data point.  
Smoking prevalence modelling 
We used ST-GPR to model current and former smoking prevalence. Full details on the ST-GPR method 
are reported elsewhere in the Appendix. Briefly, the mean function input to GPR is a complete time 
series of estimates generated from a mixed effects hierarchical linear model plus weighted residuals 
smoothed across time, space and age. The linear model formula for current smoking, fit separately by 
sex using restricted maximum likelihood in R, is: 




Where 𝐶𝐶𝐶𝐶𝐶𝐶𝑔𝑔,𝑡𝑡 is the tobacco consumption covariate by geography 𝑙𝑙 and time 𝑙𝑙, described above, 𝐼𝐼𝐴𝐴[𝑎𝑎] is 
a dummy variable indicating specific age group 𝐴𝐴 that the prevalence point 𝑝𝑝𝑔𝑔,𝑎𝑎,𝑡𝑡 captures, and 
𝛼𝛼𝑠𝑠,𝛼𝛼𝑟𝑟 , and 𝛼𝛼𝑔𝑔 are super region, region, and geography random intercepts, respectively. Random effects 
were used in model fitting but not in prediction.  
The linear model formula for former smoking is:  




Where 𝐶𝐶𝑃𝑃𝑙𝑙𝐶𝐶ℎ𝑎𝑎𝑎𝑎𝑙𝑙𝑎𝑎𝐴𝐴[𝑎𝑎],𝑔𝑔,𝑡𝑡 is the percent change in current smoking prevalence from the previous year, 
and 𝐶𝐶𝐶𝐶𝐶𝐶𝐴𝐴[𝑎𝑎],𝑔𝑔,𝑡𝑡 is the current smoking prevalence by specific age group 𝐴𝐴, geography 𝑙𝑙, and time 𝑙𝑙 that 
point 𝑝𝑝𝑔𝑔,𝑎𝑎,𝑡𝑡 captures, both derived from the current smoking ST-GPR model defined above.  
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Exposure among current and former smokers 
We estimated exposure among current smokers for two continuous indicators: cigarettes per smoker 
per day and pack-years. Pack-years incorporates aspects of both duration and amount. One pack-year 
represents the equivalent of smoking one pack of cigarettes (assuming a 20 cigarette pack) per day for 
one year. Since the pack-years indicator collapses duration and intensity into a single dimension, one 
pack-year of exposure can reflect smoking 40 cigarettes per day for six months or smoking 10 cigarettes 
per day for two years. 
To produce these indicators, we simulated individual smoking histories based on distributions of age of 
initiation and amount smoked. We informed the simulation with cross-sectional survey data capturing 
these indicators, modelled at the mean level for all locations, years, ages, and sexes using 
spatiotemporal Gaussian process regression. We rescaled estimates of cigarettes per smoker per day to 
an envelope of cigarette consumption based on supply-side data. We estimated pack-years of exposure 
by summing samples from age- and time-specific distributions of cigarettes per smoker for a birth cohort 
in order to capture both age trends and time trends and avoid the common assumption that the amount 
someone currently smokes is the amount they have smoked since they began smoking. All distributions 
were age-, sex-, and region- specific ensemble distributions, which were found to outperform any single 
distribution. 
We estimated exposure among former smokers using years since cessation. We utilised spatiotemporal 
Gaussian process regression to model mean age of cessation using cross-sectional survey data capturing 
age of cessation. Using these estimates, we generated ensemble distributions of years since cessation 
for every location, year, age group, and sex. 
Risk-outcome pairs 
We included the following risk-outcome pairs based on evidence supporting a causal relationship: 
tuberculosis, lower respiratory tract infections, esophageal cancer, stomach cancer, bladder cancer, liver 
cancer, laryngeal cancer, lung cancer, breast cancer, cervical cancer, colorectal cancer, lip and oral 
cancer, nasopharyngeal cancer, other pharyngeal cancer, pancreatic cancer, kidney cancer, leukemia, 
ischemic heart disease, ischemic stroke, hemorrhagic stroke, subarachnoid hemorrhage, atrial 
fibrillation and flutter, aortic aneurysm, peripheral arterial disease, chronic obstructive pulmonary 
disease, other chronic respiratory diseases, asthma, peptic ulcer disease, gallbladder and biliary tract 
diseases, Alzheimer disease and other dementias, Parkinson disease (protective), multiple sclerosis, 
type-II diabetes, rheumatoid arthritis, low back pain, cataracts, macular degeneration, and fracture. 
Dose-response risk curves 
We conducted systematic literature reviews for all risk-outcome pairs identified as being caused by 
smoking. We extracted effect sizes by cigarettes per smoker per day, pack-years, and years since 
quitting from cohort and case-control studies. We synthesised these data to produce non-linear dose 
response curves using a Bayesian meta-regression model. For outcomes with significant differences in 
effect size by sex or age, we produced sex- or age-specific risk curves. 
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We estimate risk curves of former smokers compared to never smokers taking into account the rate of 
risk reduction among former smokers seen in the cohort and case-control studies, and the cumulative 
exposure among former smokers within each age, sex, location and year group.  
PAF calculation 
We estimated population attributable fractions based on the following equation: 
𝐶𝐶𝐴𝐴𝑃𝑃 =
𝑝𝑝(𝑎𝑎) + 𝑝𝑝(𝑓𝑓)∫ exp(𝑥𝑥) ∗ 𝑟𝑟𝑟𝑟(𝑥𝑥) + 𝑝𝑝(𝑃𝑃)∫ exp(𝑦𝑦) ∗ 𝑟𝑟𝑟𝑟(𝑦𝑦) − 1
𝑝𝑝(𝑎𝑎) + 𝑝𝑝(𝑓𝑓)∫ exp(𝑥𝑥) ∗ 𝑟𝑟𝑟𝑟(𝑥𝑥) + 𝑝𝑝(𝑃𝑃)∫ exp(𝑦𝑦) ∗ 𝑟𝑟𝑟𝑟(𝑦𝑦)
where 𝑝𝑝(𝑎𝑎) is the prevalence of never smokers, 𝑝𝑝(𝑓𝑓) is the prevalence of former smokers, 𝑝𝑝(𝑃𝑃) is the 
prevalence of current smokers, exp(𝑥𝑥) is a distribution of years since quitting among former smokers, 
𝑟𝑟𝑟𝑟(𝑥𝑥) is the relative risk for years since quitting, exp(𝑦𝑦) is a distribution of cigarettes per smoker per 
day or pack-years, and 𝑟𝑟𝑟𝑟(𝑦𝑦) is the relative risk for cigarettes per smoker per day or pack-years. 
We used pack-years as the exposure definition for cancers and chronic respiratory diseases, and 
cigarettes per smoker per day for cardiovascular diseases and all other health outcomes. 
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We define secondhand smoke exposure as current exposure to secondhand tobacco smoke at home, at 
work, or in other public places. We use household composition as a proxy for non-occupational 
secondhand smoke exposure and make the assumption that all persons living with a daily smoker are 
exposed to tobacco smoke. We use surveys to estimate the proportion of individuals exposed to 
secondhand smoke at work. We only consider non-smokers to be exposed to secondhand smoke. Non-
smokers are defined as all persons who are not daily smokers. Ex-smokers and occasional smokers are 
considered non-smokers in this analysis. Exposure is evaluated for both children and adults. 
Input data 
To calculate the proportion of non-smokers who live with at least one smoker, we used unit record data 
on household composition, which included the ages and sexes of all persons living in the same 
household. Our sources included representative major survey series with a household composition 
module, including the Demographic Health Surveys (DHS), the Multiple Indicator Cluster Surveys (MICS), 
and the Living Standards Measurement Surveys (LSMS); and national and subnational censuses, which 
included those captured in the IPUMS project and identified using the Global Health Data Exchange 
catalog (GHDx). 
To calculate the proportion of individuals exposed to secondhand smoke at work, by age and sex, we 
used cross-sectional surveys that ask respondents about self-reported occupational secondhand smoke 
exposure. Sources include the Global Adult Tobacco Surveys, Eurobarometer Surveys, and WHO STEPS 
Surveys. We identified sources using the GHDx. 
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Estimates of primary smoking prevalence in each location were also used in our calculations. Further 
details on the estimation of primary smoking prevalence can be found in the Smoking methods 
appendix. 
Modelling strategy  
We estimated the probability that each person is living with a smoker and is also a non-smoker 
themselves using set theory. First, household composition data were used at the individual level to 
capture the ages and sexes of each person in the household. Second, we analyzed surveys with both 
household composition data and tobacco use questions and determined that the distribution of 
household size, mean age of the household members, and the age distribution were not significantly 
different between households with and without a self-reported smoker. Since we did not find that 
household composition varied between smokers and non-smokers, we then used the GBD 2017 primary 
smoking prevalence model to calculate the probability that each household member is a smoker. Next, 
we used the probability of the union of sets on each individual household member to calculate the 
overall probability that at least one of the other household members was a smoker. We incorporated 
occupational exposure by modelling prevalence of current exposure to secondhand smoke at work, by 
age, sex, location, and year, using ST-GPR. In order to avoid double counting we calculated the 
probability that an individual is exposed through either non-occupational exposure or occupational 
exposure, given their age, sex, and household composition. Finally, we multiplied this probability of 
exposure by the probability that the individual is not a smoker themselves (i.e. 1 minus primary smoking 
prevalence for that person’s location, year, age, and sex). We then collapse these individual-level 
probabilities to produce average probabilities of exposure by location, year, age, and sex.  
These probabilities were modelled in the GBD ST-GPR framework, which generates exposure estimates 
from a mixed effects hierarchical linear model plus weighted residuals smoothed across time, space, and 
age. The linear model formula was fit separately by sex using restricted maximum likelihood in R. 
We used the sex-specific overall smoking prevalence for adults (age 15 and older) as a country-level 
covariate in the model. The overall male adult daily smoking prevalence was used as the covariate for 
females of all ages and for males under age 15. The overall female adult daily smoking prevalence was 
used as the covariate for males age 15 and older. This was a modelling change from GBD 2015, in which 
we used the male age-standardised smoking prevalence for the adult female and children under 15 
model, and the female age-standardised smoking prevalence for the adult male model.  
All input data points from the probability calculation had a measure of uncertainty (variance and sample 
size) coming from the uncertainty of the primary smoking prevalence model and the sample size from 
the unit record data going into the modelling process. Geographic random effects were used in model 
fitting but were not used in prediction. 
Theoretical minimum-risk exposure level 
The theoretical minimum-risk exposure level for secondhand smoke is zero exposure among non-
smokers, meaning that non-smokers would not live with any primary smokers. 
Relative risks 
For children ages 0-14, we estimated the burden of otitis media attributable to secondhand smoke 
exposure. For all ages we estimated the burden of lower respiratory infections (LRI), and for adults 
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greater or equal to 25 years of age we estimated the burden of lung cancer, chronic obstructive 
pulmonary disease (COPD), ischemic heart disease, and cerebrovascular disease attributable to 
secondhand smoke exposure, breast cancer, and type-II diabetes.  
For lung cancer, ischemic heart disease, cerebrovascular disease, and LRI, we used country-specific 
relative risks created using integrated exposure response curves (IER) for PM2.5 air pollution. The 
relative risks for otitis media, breast cancer, and diabetes are derived from published meta-analyses. 
We used the standard GBD population attributable fraction (PAF) equation to estimate burden based on 
exposure and relative risks. 
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Chewing Tobacco Capstone Appendix 
Flowchart 
Chewing tobacco exposure by age, sex, country, and time
Systematic Literature 
Review
Chewing Tobacco: Data and Model Flow Chart
Survey Reports
Survey Microdata
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In GBD 2016, we estimated age-sex specific current smokeless tobacco use prevalence for all countries 
and territories from 1990-2016 using all available data. The estimated prevalence was then attributed to 
either all chewing tobacco, or all snus/snuff by country, based on input from smokeless tobacco experts. 
For GBD 2017, we have changed the exposure definition from current smokeless tobacco use to current 
chewing tobacco use, based on the strength of evidence supporting the health effects of chewing 
tobacco use. By estimating chewing tobacco exposure in all countries and territories, burden is now 
estimated for locations previously classified as predominantly snus/snuff, but still have non-negligible 
use of chewing tobacco. 
Input data 
Inclusion criteria 
We included sources that reported primary chewing tobacco use among respondents over age 10. To be 
eligible for inclusion, sources had to be representative for their level of estimation (ie. National sources 
needed to be nationally representative, subnational sources subnationally representative). We included 
only self-reported chewing tobacco use data and excluded data from questions asking about others’ 




We searched the Global Health Data Exchange (GHDx) database for primary data sources with the 
keyword “Tobacco Use” on January 1, 2018 to ensure all available data sources were captured. Of the 
3,318 sources identified in the GHDx, 1,578 country-year sources met inclusion criteria and were 
included. 
In addition to the primary data sources identified through the GHDx, we performed a systematic 
literature search on PubMed. The search was conducted on January 19, 2017 and returned 5982 hits, of 
which 267 were eligible for inclusion. Of these 267 sources, 200 had already been identified in the 
GHDx, so the Pubmed search yielded 67 additional sources overall. The search string is shown below: 
("smokeless tobacco"[tiab] OR "Tobacco, Smokeless"[Mesh] OR bajjar[tiab] OR ("betel quid"[tiab] AND 
tobacco[tiab]) OR "chewing tobacco"[tiab] OR chimó[tiab] OR snuff[tiab] OR snuif[tiab] OR dip[tiab] OR 
dohra[tiab] OR gudakhu[tiab] OR gul[tiab] OR gutka[tiab] OR gutkha[tiab] OR "hnat hsey"[tiab] OR 
iq’mik[tiab] OR khaini[tiab] OR kharra[tiab] OR khiwam[tiab] OR khimam[tiab] OR kiwam[tiab] OR 
kimam[tiab] OR "lal dant manjan"[tiab] OR ("loose leaf"[tiab] AND (chew[tiab] OR tobacco[tiab])) OR 
mainpuri[tiab] OR maras[tiab] OR mawa[tiab] OR mshri[tiab] OR naffa[tiab] OR nas[Supplementary 
Concept] OR ((nas[tiab] OR nass[tiab]) AND tobacco[tiab]) OR naswar[tiab] OR nasway[tiab] OR 
nasvay[tiab] OR neffa[tiab] OR ((pan[tiab] OR paan[tiab]) AND tobacco[tiab]) OR (plug[tiab] AND 
tobacco[tiab]) OR (rapé[tiab] AND tobacco[tiab]) OR ((red[tiab] OR tobacco[tiab]) AND 
(toothpowder[tiab] OR toothpaste[tiab])) OR shammah[tiab] OR snus[tiab] OR taaba[tiab] OR 
tapkeer[tiab] OR tawa[tiab] OR tombol[tiab] OR toombak[tiab] OR tuibur[tiab] OR "tobacco water"[tiab] 
OR (twist[tiab] AND tobacco[tiab]) OR zarda[tiab]) AND Humans[Mesh] AND English[Language] NOT 
Case Reports[ptyp] 
Prevalence data preprocessing 
Data extraction 
We extracted primary data from individual-level microdata and survey report tabulations. We extracted 
data on current, former, and/or ever chewing tobacco use as well as frequency of use (daily, occasional, 
and unspecified, which includes both daily and occasional smokers). Products that do not include 
tobacco, such as betel quid without tobacco, were excluded or estimated separately as part of the drug 
use risk factor, if applicable.  
For microdata, we extracted relevant demographic information, including age, sex, location, and year, as 
well as survey metadata, including survey weights, primary sampling units, and strata. This information 
allowed us to tabulate individual-level data in the standard GBD five-year age-sex groups and produce 
accurate estimates of uncertainty. For survey report tabulations, we extracted data at the most granular 
age-sex group provided. 
Crosswalk 
Our GBD chewing tobacco case definition is current use of chewing tobacco. All other data points 
measuring other types of chewing tobacco prevalence were adjusted to be consistent with this 
definition. Some sources contained information on more than one case definition and these sources 
were used to develop the adjustment coefficient to transform alternative case definitions to the GBD 
case definition. The adjustment coefficient was the beta value derived from a linear model with one 
predictor and no intercept. 
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We generated separate crosswalk coefficients for the 10-14 age group and the 15-19 age group, as we 
found the relationships between case definitions differed strongly in the younger age groups compared 
to the 20+ age groups. To account for this, we attempted to generate a global crosswalk coefficient for 
both the 10-14 and 15-19 age groups, using the same regression as above. Due to data limitations, none 
of the crosswalk coefficients met the criteria outlined above, so no data covering youths under 20 years 
old were crosswalked. In other words, all data from these age groups that appear in the model were 
asked according to our case definition in the survey. 
We propagated uncertainty at the survey level from the crosswalk by incorporating both the variance of 
the errors and the variance of the adjustment coefficients.  
For each source that needed adjusting, we assigned space weights based on GBD region and 
superregion to the sources containing more than one case definition. Data from the same region 
receiving a full weight of 1, and data from the same super-region received a weight of ½. We explored 
using a time weight, to control for possible changes in the relationship between chewing tobacco use 
behaviors over time. We found incorporating temporal information did not significantly change the 
estimated coefficients but did undercut sample sizes, and chose to exclude the time weight. Crosswalk 
coefficients generated from fewer than 20 data sources were dropped. 
Age and sex splitting  
We split data reported in broader age groups than the GBD 5-year age groups or as both sexes 
combined by adapting the method reported in Ng et al. 
(http://jamanetwork.com/journals/jama/fullarticle/1812960) to split using a sex- geography- time 
specific reference age pattern. We separated the data into two sets: a training dataset, with data 
already falling into GBD sex-specific 5-year age groups, and a split dataset, which reported data in 
aggregated age or sex groups. We then used spatiotemporal Gaussian Process Regression (ST-GPR) to 
estimate sex-geography-time specific age patterns using data in the training dataset. The estimated age 
patterns were then used to split each source in the split dataset.  
The ST-GPR model used to estimate the age patterns for age-sex splitting used an age weight parameter 
value that minimizes the effect of any age smoothing. This parameter choice allows the estimated age 
pattern to be driven by data, rather than being enforced by any smoothing parameters of the model. 
Because these age-sex split data points will be incorporated in the final ST-GPR exposure model, we do 
not want to doubly enforce a modelled age pattern for a given sex-location-year on a given aggregate 
data point.  
Chewing tobacco prevalence modelling 
We used ST-GPR to model chewing tobacco prevalence. Full details on the ST-GPR method are reported 
elsewhere in the Appendix. Briefly, the mean function input to GPR is a complete time series of 
estimates generated from a mixed effects hierarchical linear model plus weighted residuals smoothed 
across time, space and age. The linear model formula for chewing tobacco, fit separately by sex using 
restricted maximum likelihood in R, is: 





Where 𝐼𝐼𝐴𝐴[𝑎𝑎] is a dummy variable indicating specific age group 𝐴𝐴 that the prevalence point 𝑝𝑝𝑔𝑔,𝑎𝑎,𝑡𝑡 
captures, and 𝛼𝛼𝑠𝑠,𝛼𝛼𝑟𝑟, and 𝛼𝛼𝑔𝑔 are super region, region, and geography random intercepts, respectively. 
Random effects were used in model fitting but not in prediction.  
The hyperparameters for ST-GPR were as follows: age weight = 0.87 for data density below 10 and 1.48 
for data density above 10, time weight of 0.04, space weight of 0.01 for data density below 10 and 0.005 
for data density above 10, and scale = 20. Amplitude was calculated at the region level. 
Hyperparameters were decided based on a random grid search evaluated on out of sample RMSE 
performed on direct smoking data, but due to computational time was not able to be applied to the 
chewing tobacco data.   
Estimating attributable burden 
Assessment of risk-outcome pairs 
We included outcomes based on the strength of available evidence supporting a causal relationship. 
There was sufficient evidence to include oral cancer and oesophageal cancer as health outcomes caused 
by chewing tobacco use. Appendix Table 4 reports the strength of evidence for included outcomes. 
Relative risk 
Relative risk estimates were derived from prospective cohort studies and population-based case-control 
studies. Sources used in relative risk estimation are reported in Appendix Table 4. 
Appendix Table 6a reports relative risk estimates and uncertainty for the two outcomes included in the 
analysis, by sex. We extracted the underlying effect size estimates from prospective cohort studies and 
population-based case-control studies identified by performing a systematic literature review as well as 
by reviewing the underlying studies included in published meta-analyses. We did not include hospital-
based case control studies due to concerns over representativeness. We only included sources that 
adequately adjusted for major confounders, especially smoking status. Summary effect size estimates 
were calculated in R, using the ‘metafor’ package. We performed a random effects meta-analysis using 
the DerSimonian and Laird method, which does not assume a true effect size but considers each input 
study as selected from a random sample of all possible sets of studies for the outcome of interest. The 
random-effects method allows for more variation between the studies, and incorporates this variance 
into the estimation process. We used an inverse-variance weighting method to determine component 
study weights. We found significantly different relative risks for oral cancer for males and females, and 
estimated relative risks separately by sex for oral cancer alone.  
Theoretical minimum risk exposure level 
The theoretical minimum risk exposure level is that everyone in the population has been a lifelong non-
user of chewing tobacco.  
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Alcohol Use Capstone Appendix 
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Input data & methodological summary 
Exposure 
Case definition 
We defined exposure as the grams per day of pure alcohol consumed amongst drinkers. We constructed 
this exposure using the indicators outlined below: 
1. Current drinkers, defined as the proportion of individuals who have consumed at least one
alcoholic beverage (or some approximation) in a 12-month period.
2. Lifetime abstainers, defined as the proportion of individuals who have never consumed an
alcoholic beverage.
3. Alcohol consumption (in grams per day), defined as grams of alcohol consumed by current
drinkers, per day, over a 12-month period.
4. Alcohol liters per capita stock, defined in liters per capita of pure alcohol, over a 12-month
period.
We also used three additional indicators to adjust alcohol exposure estimates to account for different 
types of bias: 
1. Number of tourists within a location, defined as the total amount of visitors to a location within
a 12 month period.
2. Tourists’ duration of stay, defined as the number of days resided in a hosting country.
128
3. Unrecorded alcohol stock, defined as a percentage of the total alcohol stock produced outside
established markets.
Input data 
A systematic review of the literature was performed to extract data on our primary indicators. The 
Global Health Exchange (GHDx), IHME’s online database of health-related data, was searched for 
population survey data containing participant-level information from which we could formulate the 
required alcohol use indicators on current drinkers, lifetime abstainers, alcohol consumption, and binge 
drinkers. Data-sources were included if they captured a sample representative of the geographic 
location under study. We documented relevant survey variables from each data-source in a spreadsheet 
and extracted using STATA 13.1 and R 3.3 . A total of 2,821 potential data-sources were available in the 
GHDx across countries with subnational locations, out of which 191 data-sources (corresponding 88,734 
tabulated data-points by location/year/sex/age) were included across the four indicators mentioned 
above.  
Within the grams per day, current drinkers, and abstainers model, we had a large amount of data on 
male drinking but not female drinking. To ensure a balanced dataset between sexes for use within 
DisMod MR 2.1, we imputed for missing sex observations within locations where data existed on male 
drinking but not female drinking. We used the following models to do so: 
For grams per day: 
𝑦𝑦𝑖𝑖  ~ 𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺(𝜇𝜇,𝜙𝜙) 
𝜇𝜇 = 𝑙𝑙𝑙𝑙𝑙𝑙−1(1 +  𝑆𝑆𝑆𝑆𝑆𝑆 + 𝑠𝑠𝑠𝑠𝑠𝑠 + 𝐺𝐺𝑙𝑙𝑠𝑠 +  𝑠𝑠𝑠𝑠𝑠𝑠 ∗ 𝐺𝐺𝑙𝑙𝑠𝑠 + (1 + 𝑠𝑠𝑠𝑠𝑠𝑠|𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑠𝑠𝑠𝑠𝑙𝑙𝑟𝑟𝑙𝑙𝑟𝑟) + (1 + 𝑠𝑠𝑠𝑠𝑠𝑠|𝑠𝑠𝑠𝑠𝑙𝑙𝑟𝑟𝑙𝑙𝑟𝑟) 
Where y is average amount of grams per day within a demographic, 𝜇𝜇 a parameter for the mean of the 
average amounts, and 𝜙𝜙 is a dispersion parameter 
For current drinking and abstention: 
𝑦𝑦𝑖𝑖  ~ 𝐵𝐵𝑟𝑟𝑟𝑟𝑙𝑙𝐺𝐺𝑟𝑟𝐺𝐺𝑙𝑙(𝜋𝜋𝑖𝑖,𝑟𝑟) 
𝜋𝜋𝑖𝑖 ~ 𝐵𝐵𝑠𝑠𝐵𝐵𝐺𝐺(𝜇𝜇𝑖𝑖,𝜃𝜃𝑖𝑖 ) 
𝜇𝜇𝑖𝑖 = 𝑐𝑐𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙−1(1 +  𝑆𝑆𝑆𝑆𝑆𝑆 + 𝑠𝑠𝑠𝑠𝑠𝑠 + 𝐺𝐺𝑙𝑙𝑠𝑠 +  𝑠𝑠𝑠𝑠𝑠𝑠 ∗ 𝐺𝐺𝑙𝑙𝑠𝑠 + (1 + 𝑠𝑠𝑠𝑠𝑠𝑠|𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑠𝑠𝑠𝑠𝑙𝑙𝑟𝑟𝑙𝑙𝑟𝑟) + (1 + 𝑠𝑠𝑠𝑠𝑠𝑠|𝑠𝑠𝑠𝑠𝑙𝑙𝑟𝑟𝑙𝑙𝑟𝑟) 
We then sampled 1000 draws from the above estimator for both sex = male & sex = female, with all 
other variables fixed by demographic unit. For sampling draws, we assumed the parameters were 
Gaussian multivariately distributed. For each demographic unit with only male observations, we 
multiplied male data by the ratio between the draws with sex = male & sex = female to impute for 
female observations. 
To generate estimates of alcohol consumption in liters per capita (LPC), we obtained data from 
FAOSTAT, and WHO GISAH database.1,2 To provide more stable time trends in the model, we 
transformed FAO sales data (which calculates stock based on primary inputs) to a lagged five-year 
average. Given WHO uses FAO data in locations where WHO could not find data using their own 
methods, we removed FAO data in the locations where WHO used FAO data in place of their own. To 
correct for bias in the underlying data sources, we adjusted the input data (crosswalked), by running a 
mixed effect model on the log average of the data with dummy variables for the data series, as well as 
random effects on super region, region, country, and time. We adjusted the data points using the 
following equation: 
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𝐿𝐿𝑙𝑙𝑙𝑙 𝐴𝐴𝐴𝐴𝑠𝑠𝑠𝑠𝐺𝐺𝑙𝑙𝑠𝑠 𝑆𝑆𝐺𝐺𝐵𝐵𝐺𝐺 = 𝑆𝑆 + (𝑆𝑆𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑅𝑅𝑠𝑠𝑙𝑙𝑟𝑟𝑙𝑙𝑟𝑟 |𝑆𝑆,𝑅𝑅𝑠𝑠𝑙𝑙𝑟𝑟𝑙𝑙𝑟𝑟 | 𝑆𝑆,𝐶𝐶𝑙𝑙𝑠𝑠𝑟𝑟𝐵𝐵𝑠𝑠𝑦𝑦 |𝑆𝑆,𝑌𝑌𝑠𝑠𝐺𝐺𝑠𝑠| 𝑆𝑆) 
𝑇𝑇𝑠𝑠𝐺𝐺𝑟𝑟𝑠𝑠𝑇𝑇𝑙𝑙𝑠𝑠𝐺𝐺𝑠𝑠𝑇𝑇 𝑇𝑇𝐺𝐺𝐵𝐵𝐺𝐺 =  𝑇𝑇𝐺𝐺𝐵𝐵𝐺𝐺 ∗  𝑠𝑠𝛽𝛽1�+ 𝛽𝛽3�  
where: 
𝑆𝑆 𝑟𝑟𝑠𝑠 𝐺𝐺 𝑇𝑇𝑠𝑠𝐺𝐺𝐺𝐺𝑦𝑦 𝐴𝐴𝐺𝐺𝑠𝑠𝑟𝑟𝐺𝐺𝑣𝑣𝑙𝑙𝑠𝑠 𝑇𝑇𝑙𝑙𝑠𝑠 𝐺𝐺 𝑇𝑇𝐺𝐺𝐵𝐵𝐺𝐺 𝑠𝑠𝑙𝑙𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠 
None of the data sources on liters per capita provided estimates of uncertainty, which is a component 
required for our eventual modelling strategy. To generate uncertainty, we ran a Loess model on the 
adjusted data points and the standard deviation between the difference of the Loess smoothed model 
and the adjusted data points across a five-year span was used as the standard deviation of the data. 
(i.e., if the total stock changes more variably in a narrow time frame, we believe the data to be more 
uncertain). 
We obtained data on the number of tourists and their duration of stay from the UNWTO.3 We applied a 
crosswalk across different tourist categories, similar to the one used for the liters per capita data, to 
arrive at a consistent definition (i.e. visitors to a country). 
We obtained estimates on unrecorded alcohol stock from six published papers,4-9 consisting of 166 
locations. 
Modelling strategy 
While population-based surveys provide accurate estimates of the prevalence of lifetime abstainers and 
current drinkers, they typically underestimate real alcohol consumption levels.10-12 As a result, we 
considered the liter per capita input to be a better estimate of overall volume of consumption. Per 
capita consumption, however, does not provide age- and sex-specific consumption estimates needed to 
compute alcohol-attributable burden of disease. Therefore, we use the age-sex pattern of consumption 
among drinkers modelled from the population survey data and the overall volume of consumption from 
FAO and GISAH to determine the total amount of alcohol consumed within a location. In the paragraphs 
we outline how we estimated each primary input in the alcohol exposure model, as well as how we 
combined these inputs to arrive at our final estimate of grams per day of pure alcohol. We estimated all 
models below using 1,000 draws. 
For data obtained through surveys, we used DisMod-MR 2.1 to construct estimates for each 
country/year/age/sex. We chose to use DisMod due to its ability to leverage information across the 
heterogeneous age groups reported in the surveys, through age-integration, as well as the model’s 
ability to leverage information available from data in nearby locations or time-periods.13  
We modelled the alcohol liters per capita data, as well as the total number of tourists, using a spatio-
temporal Gaussian process regression (ST-GPR). We chose parameters, as well as our final model, using 
out-of-sample 10-fold cross validation. 
Given the heterogeneous nature of the estimates on unrecorded consumption, as well as the wide 
variation across countries and time-periods, we took 1,000 draws from the uniform distribution of the 
lowest and highest estimates available for a given country. We did this to incorporate the diffuse 
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uncertainty within the unrecorded estimates reported. We used these 1,000 draws in the above 
equation. We adjusted LPC only for countries where estimates were available.  
We adjusted the alcohol LPC for unrecorded consumption using the following equation: 
𝐴𝐴𝑙𝑙𝑐𝑐𝑙𝑙ℎ𝑙𝑙𝑙𝑙 𝐿𝐿𝐿𝐿𝐶𝐶 = 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴ℎ𝐴𝐴𝐴𝐴 𝐿𝐿𝐿𝐿𝐿𝐿
(1−% 𝑈𝑈𝑈𝑈𝑈𝑈𝑈𝑈𝐴𝐴𝐴𝐴𝑈𝑈𝑈𝑈𝑈𝑈𝑈𝑈)
We then adjusted the estimates for alcohol LPC for tourist consumption by adding in the per capita rate 
of consumption abroad and subtracting the per capita rate of tourist consumption domestically.   
𝐴𝐴𝑙𝑙𝑐𝑐𝑙𝑙ℎ𝑙𝑙𝑙𝑙 𝐿𝐿𝐿𝐿𝐶𝐶𝑈𝑈 = 𝑈𝑈𝑟𝑟𝐺𝐺𝑇𝑇𝑈𝑈𝑠𝑠𝑠𝑠𝐵𝐵𝑠𝑠𝑇𝑇 𝐴𝐴𝑙𝑙𝑐𝑐𝑙𝑙ℎ𝑙𝑙𝑙𝑙 𝐿𝐿𝐿𝐿𝐶𝐶𝑈𝑈 + 𝐴𝐴𝑙𝑙𝑐𝑐𝑙𝑙ℎ𝑙𝑙𝑙𝑙 𝐿𝐿𝐿𝐿𝐶𝐶 𝐷𝐷𝐴𝐴𝐷𝐷𝑈𝑈𝐷𝐷𝐷𝐷𝑖𝑖𝐴𝐴 𝐴𝐴𝐴𝐴𝑈𝑈𝐷𝐷𝑐𝑐𝐷𝐷𝑐𝑐𝐷𝐷𝑖𝑖𝐴𝐴𝑈𝑈 𝑎𝑎𝑎𝑎𝑈𝑈𝐴𝐴𝑎𝑎𝑈𝑈
− 𝐴𝐴𝑙𝑙𝑐𝑐𝑙𝑙ℎ𝑙𝑙𝑙𝑙 𝐿𝐿𝐿𝐿𝐶𝐶 𝑇𝑇𝐴𝐴𝑐𝑐𝑈𝑈𝑖𝑖𝐷𝐷𝐷𝐷 𝐴𝐴𝐴𝐴𝑈𝑈𝐷𝐷𝑐𝑐𝐷𝐷𝑐𝑐𝐷𝐷𝑖𝑖𝐴𝐴𝑈𝑈 𝑈𝑈𝐴𝐴𝐷𝐷𝑈𝑈𝐷𝐷𝐷𝐷𝑖𝑖𝐴𝐴𝑎𝑎𝐴𝐴𝐴𝐴𝑑𝑑 
𝐴𝐴𝑙𝑙𝑐𝑐𝑙𝑙ℎ𝑙𝑙𝑙𝑙 𝐿𝐿𝐿𝐿𝐶𝐶 𝑖𝑖 =
∑ 𝑇𝑇𝐴𝐴𝑐𝑐𝑈𝑈𝑖𝑖𝐷𝐷𝐷𝐷 𝐿𝐿𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝑎𝑎𝐷𝐷𝑖𝑖𝐴𝐴𝑈𝑈 𝑙𝑙 ∗ 𝐿𝐿𝑈𝑈𝐴𝐴𝑐𝑐𝐴𝐴𝑈𝑈𝐷𝐷𝑖𝑖𝐴𝐴𝑈𝑈 𝐴𝐴𝑜𝑜 𝐷𝐷𝐴𝐴𝑐𝑐𝑈𝑈𝑖𝑖𝐷𝐷𝐷𝐷𝐷𝐷 𝑖𝑖,𝑙𝑙 ∗ 𝑈𝑈𝑈𝑈𝑎𝑎𝑈𝑈𝑈𝑈𝑐𝑐𝐷𝐷𝐷𝐷𝑈𝑈𝑈𝑈 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴ℎ𝐴𝐴𝐴𝐴 𝐿𝐿𝐿𝐿𝐿𝐿 𝑙𝑙 ∗ 
𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 𝑙𝑙𝐴𝐴𝑙𝑙𝐴𝐴𝑙𝑙ℎ 𝑜𝑜𝑜𝑜 𝑠𝑠𝑙𝑙𝐴𝐴𝑠𝑠 𝑖𝑖,𝑙𝑙
365  ∗  𝑙𝑙
𝐿𝐿𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝑎𝑎𝐷𝐷𝑖𝑖𝐴𝐴𝑈𝑈 𝑑𝑑
where: 
𝑙𝑙 𝑟𝑟𝑠𝑠 𝐵𝐵ℎ𝑠𝑠 𝑠𝑠𝑠𝑠𝐵𝐵 𝑙𝑙𝑇𝑇 𝐺𝐺𝑙𝑙𝑙𝑙 𝑙𝑙𝑙𝑙𝑐𝑐𝐺𝐺𝐵𝐵𝑟𝑟𝑙𝑙𝑟𝑟𝑠𝑠, 𝑟𝑟 𝑟𝑟𝑠𝑠 𝑠𝑠𝑟𝑟𝐵𝐵ℎ𝑠𝑠𝑠𝑠 Domestic consumption abroad 𝑙𝑙𝑠𝑠 Tourist consumption domestically, 
𝐺𝐺𝑟𝑟𝑇𝑇 𝑇𝑇 𝑟𝑟𝑠𝑠 𝐺𝐺 𝑇𝑇𝑙𝑙𝐺𝐺𝑠𝑠𝑠𝑠𝐵𝐵𝑟𝑟𝑐𝑐 𝑙𝑙𝑙𝑙𝑐𝑐𝐺𝐺𝐵𝐵𝑟𝑟𝑙𝑙𝑟𝑟 
After adjusting alcohol LPC by tourist consumption and unrecorded consumption for all location/years 
reported, sex-specific and age-specific estimates were generated by incorporating estimates modelled in 
DisMod for percentage of current drinkers within a location/year/sex/age, as well as consumption 
trends modelled in the DisMod g/day model. We do this by first making sure the sum of percent current 
drinkers and percent abstainers sum to one for a given location/year/age/sex. We then calculate the 
proportion of total consumption for a given location/year by age and sex, using the estimates of alcohol 
consumed per day, the population size, and the percentage of current drinkers. Lastly, we then multiply 
this proportion of total stock for a given location/year/sex/age by the total stock for a given 
location/year to calculate the consumption in terms of liter per capita for a given location/year/sex/age. 
We then convert these estimates to be in terms of grams/per day. The following equations describe 
these calculations: 
 % 𝐶𝐶𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑟𝑟𝐵𝐵 𝑇𝑇𝑠𝑠𝑟𝑟𝑟𝑟𝑑𝑑𝑠𝑠𝑠𝑠𝑠𝑠 𝐴𝐴,𝑑𝑑,𝐷𝐷,𝑎𝑎 =  
 % 𝐶𝐶𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑟𝑟𝐵𝐵 𝑇𝑇𝑠𝑠𝑟𝑟𝑟𝑟𝑑𝑑𝑠𝑠𝑠𝑠𝑠𝑠 𝐴𝐴,𝑑𝑑,𝐷𝐷,𝑎𝑎
 % 𝐶𝐶𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑟𝑟𝐵𝐵 𝑇𝑇𝑠𝑠𝑟𝑟𝑟𝑟𝑑𝑑𝑠𝑠𝑠𝑠𝑠𝑠 𝐴𝐴,𝑑𝑑,𝐷𝐷,𝑎𝑎 + % 𝐴𝐴𝑣𝑣𝑠𝑠𝐵𝐵𝐺𝐺𝑟𝑟𝑟𝑟𝑠𝑠𝑠𝑠𝑠𝑠𝐴𝐴,𝑑𝑑,𝐷𝐷,𝑎𝑎
𝐿𝐿𝑠𝑠𝑙𝑙𝑠𝑠𝑙𝑙𝑠𝑠𝐵𝐵𝑟𝑟𝑙𝑙𝑟𝑟 𝑙𝑙𝑇𝑇 𝐵𝐵𝑙𝑙𝐵𝐵𝐺𝐺𝑙𝑙 𝑐𝑐𝑙𝑙𝑟𝑟𝑠𝑠𝑠𝑠𝐺𝐺𝑠𝑠𝐵𝐵𝑟𝑟𝑙𝑙𝑟𝑟 𝐴𝐴,𝑑𝑑,𝐷𝐷,𝑎𝑎
=  
𝐴𝐴𝑙𝑙𝑐𝑐𝑙𝑙ℎ𝑙𝑙𝑙𝑙  𝑙𝑙/𝑇𝑇𝐺𝐺𝑦𝑦  𝐴𝐴,𝑑𝑑,𝐷𝐷,𝑎𝑎 ∗  𝐿𝐿𝑙𝑙𝑠𝑠𝑠𝑠𝑙𝑙𝐺𝐺𝐵𝐵𝑟𝑟𝑙𝑙𝑟𝑟 𝐴𝐴,𝑑𝑑,𝐷𝐷,𝑎𝑎 ∗  % 𝐶𝐶𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑟𝑟𝐵𝐵 𝑇𝑇𝑠𝑠𝑟𝑟𝑟𝑟𝑑𝑑𝑠𝑠𝑠𝑠𝑠𝑠 𝐴𝐴,𝑑𝑑,𝐷𝐷,𝑎𝑎
∑ 𝐴𝐴𝑙𝑙𝑐𝑐𝑙𝑙ℎ𝑙𝑙𝑙𝑙  𝑙𝑙/𝑇𝑇𝐺𝐺𝑦𝑦 𝐴𝐴,𝑑𝑑,𝐷𝐷,𝑎𝑎  ∗  𝐿𝐿𝑙𝑙𝑠𝑠𝑠𝑠𝑙𝑙𝐺𝐺𝐵𝐵𝑟𝑟𝑙𝑙𝑟𝑟 𝐴𝐴,𝑑𝑑,𝐷𝐷,𝑎𝑎 ∗  % 𝐶𝐶𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑟𝑟𝐵𝐵 𝑇𝑇𝑠𝑠𝑟𝑟𝑟𝑟𝑑𝑑𝑠𝑠𝑠𝑠𝑠𝑠 𝐴𝐴,𝑑𝑑,𝐷𝐷,𝑎𝑎 𝐷𝐷,𝑎𝑎
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𝐴𝐴𝑙𝑙𝑐𝑐𝑙𝑙ℎ𝑙𝑙𝑙𝑙 𝐿𝐿𝐿𝐿𝐶𝐶 𝐴𝐴,𝑑𝑑,𝐷𝐷,𝑎𝑎 =  
𝐴𝐴𝑙𝑙𝑐𝑐𝑙𝑙ℎ𝑙𝑙𝑙𝑙 𝐿𝐿𝐿𝐿𝐶𝐶 𝐴𝐴,𝑑𝑑  ∗  𝐿𝐿𝑙𝑙𝑠𝑠𝑠𝑠𝑙𝑙𝐺𝐺𝐵𝐵𝑟𝑟𝑙𝑙𝑟𝑟 𝐴𝐴,𝑑𝑑  ∗  𝐿𝐿𝑠𝑠𝑙𝑙𝑠𝑠𝑙𝑙𝑠𝑠𝐵𝐵𝑟𝑟𝑙𝑙𝑟𝑟 𝑙𝑙𝑇𝑇 𝐵𝐵𝑙𝑙𝐵𝐵𝐺𝐺𝑙𝑙 𝑐𝑐𝑙𝑙𝑟𝑟𝑠𝑠𝑠𝑠𝐺𝐺𝑠𝑠𝐵𝐵𝑟𝑟𝑙𝑙𝑟𝑟 𝐴𝐴,𝑑𝑑,𝐷𝐷,𝑎𝑎
 % 𝐶𝐶𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑟𝑟𝐵𝐵 𝑇𝑇𝑠𝑠𝑟𝑟𝑟𝑟𝑑𝑑𝑠𝑠𝑠𝑠𝑠𝑠 𝐴𝐴,𝑑𝑑,𝐷𝐷,𝑎𝑎 ∗ 𝐿𝐿𝑙𝑙𝑠𝑠𝑠𝑠𝑙𝑙𝐺𝐺𝐵𝐵𝑟𝑟𝑙𝑙𝑟𝑟 𝐴𝐴,𝑑𝑑,𝐷𝐷,𝑎𝑎




𝑙𝑙 𝑟𝑟𝑠𝑠 𝐺𝐺 𝑙𝑙𝑙𝑙𝑐𝑐𝐺𝐺𝐵𝐵𝑟𝑟𝑙𝑙𝑟𝑟,𝑦𝑦 𝑟𝑟𝑠𝑠 𝐺𝐺 𝑦𝑦𝑠𝑠𝐺𝐺𝑠𝑠, 𝑠𝑠 𝑟𝑟𝑠𝑠 𝐺𝐺 𝑠𝑠𝑠𝑠𝑠𝑠,𝐺𝐺𝑟𝑟𝑇𝑇 𝐺𝐺 𝑟𝑟𝑠𝑠 𝐺𝐺𝑟𝑟 𝐺𝐺𝑙𝑙𝑠𝑠 𝑙𝑙𝑠𝑠𝑙𝑙𝑠𝑠𝑠𝑠. 
We then used the gamma distribution to estimate individual level variation within location, year, sex, 
age drinking populations, following the recommendations of other published alcohol studies.7,8 We 
chose parameters of the gamma distribution based on the mean and standard deviation of the 1,000 
draws of alcohol g/day exposure for a given population. 
Theoretical minimum-risk exposure level 
We calculated TMREL by first calculating the overall risk attributable to alcohol. We did this by weighting 
each relative risk curve by the share of overall DALYs for a given cause. We then took the minimum of 
this overall-risk curve as the TMREL of alcohol-use. More formally,  
𝑇𝑇𝑇𝑇𝑅𝑅𝑇𝑇𝐿𝐿 = 𝐺𝐺𝑠𝑠𝑙𝑙𝐺𝐺𝑟𝑟𝑟𝑟 𝐺𝐺𝐴𝐴𝑠𝑠𝑠𝑠𝐺𝐺𝑙𝑙𝑠𝑠 𝑙𝑙𝐴𝐴𝑠𝑠𝑠𝑠𝐺𝐺𝑙𝑙𝑙𝑙 𝑠𝑠𝑟𝑟𝑠𝑠𝑑𝑑𝜔𝜔(𝑙𝑙/𝑇𝑇𝐺𝐺𝑦𝑦) 







 𝜔𝜔 𝑟𝑟𝑠𝑠 𝐵𝐵ℎ𝑠𝑠 𝑠𝑠𝑠𝑠𝐵𝐵 𝑙𝑙𝑇𝑇 𝑐𝑐𝐺𝐺𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝐺𝐺𝑠𝑠𝑠𝑠𝑙𝑙𝑐𝑐𝑟𝑟𝐺𝐺𝐵𝐵𝑠𝑠𝑇𝑇 𝑤𝑤𝑟𝑟𝐵𝐵ℎ 𝐺𝐺𝑙𝑙𝑐𝑐𝑙𝑙ℎ𝑙𝑙𝑙𝑙, 𝑟𝑟 𝑟𝑟𝑠𝑠 𝐺𝐺 𝑙𝑙𝑟𝑟𝐴𝐴𝑠𝑠𝑟𝑟 𝑐𝑐𝐺𝐺𝑠𝑠𝑠𝑠𝑠𝑠 𝑇𝑇𝑠𝑠𝑙𝑙𝐺𝐺 𝐵𝐵ℎ𝐺𝐺𝐵𝐵 𝑠𝑠𝑠𝑠𝐵𝐵,  
𝑆𝑆𝐴𝐴𝐿𝐿𝑌𝑌 𝑟𝑟𝑠𝑠 𝐵𝐵ℎ𝑠𝑠 𝑙𝑙𝑙𝑙𝑙𝑙𝑣𝑣𝐺𝐺𝑙𝑙 𝑆𝑆𝐴𝐴𝐿𝐿𝑌𝑌 𝑠𝑠𝐺𝐺𝐵𝐵𝑠𝑠 𝑟𝑟𝑟𝑟 2010,𝐺𝐺𝑟𝑟𝑇𝑇 𝑅𝑅𝑅𝑅 𝑟𝑟𝑠𝑠 𝐵𝐵ℎ𝑠𝑠 𝑇𝑇𝑙𝑙𝑠𝑠𝑠𝑠 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑙𝑙𝑟𝑟𝑠𝑠𝑠𝑠 𝑐𝑐𝑠𝑠𝑠𝑠𝐴𝐴𝑠𝑠 𝑇𝑇𝑙𝑙𝑠𝑠 𝐺𝐺 𝑙𝑙𝑟𝑟𝐴𝐴𝑠𝑠𝑟𝑟 𝑐𝑐𝐺𝐺𝑠𝑠𝑠𝑠𝑠𝑠  
𝐺𝐺𝑟𝑟𝑇𝑇 𝑠𝑠𝑠𝑠𝑠𝑠𝑙𝑙𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑙𝑙𝑠𝑠𝐴𝐴𝑠𝑠𝑙𝑙 𝑟𝑟𝑟𝑟 𝑙𝑙𝑠𝑠𝐺𝐺𝐺𝐺𝑠𝑠 𝑠𝑠𝑠𝑠𝑠𝑠 𝑇𝑇𝐺𝐺𝑦𝑦. 
In other words, we chose TMREL as being the exposure that minimises your risk of suffering burden 
from any given cause related to alcohol. We weight the risk for a particular cause in our aggregation by 
the proportion of DALYs due to that cause. (e.g. since more observed people die from IHD, we weight 
the risk for IHD more in the above calculation of average risk compared to, say, diabetes, even if both 
have the same relative risk for a given level of consumption) 
Relative risks 
For GBD 2016, we performed a systematic literature review of all cohort and case-control studies 
reporting a relative risk, hazard ratio, or odds ratio for any risk-outcome pairs studied in GBD 2016. 
Studies were included if they reported a categorical or continuous dose for alcohol consumption, as well 
as uncertainty measures for their outcomes, and the population under study was representative. 
Relative risk estimates by dose can be found in Appendix Table 6c. 
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We then used these studies to calculate a dose-response, modelled using DisMod ODE. We chose 
DisMod ODE rather than a conventional mixed effect meta-regression because of its ability to estimate 
nonparametric splines over doses (i.e. for most alcohol causes, there is a non-linear relationship with 
different doses) and incorporate heterogeneous doses through dose-integration (i.e. most studies 
report doses categorically in wide ranges. DisMod ODE estimates specific doses when categories overlap 
across studies, through an integration step.) We used the results of the meta-regression to estimate a 
non-parametric curve for all doses between 0-150 g/day and their corresponding relative risks. For all 
causes, we assumed the relative risk was the same for all-ages and sexes, with the exception of ischemic 
heart disease, ischemic stroke, hemorrhagic stroke, and diabetes, which we estimated by sex.  
Regarding injuries outcomes, we constructed relative risks based on chronic exposure rather than acute, 
which has a weaker relationship to the outcome, though still significant.15,16,18-21 We decided to use 
chronic exposure given the lack of available data on acute exposure, as well as, the lack of cohort studies 
using acute exposure as a metric. Further, using chronic exposure allowed us to construct relative risks 
curves for unintentional injuries, interpersonal violence, motor vehicle accidents, and self-harm using 
the same method as reported above.  
In the case of motor vehicle accidents, we adjusted the PAF to account for victims of drunk drivers that 
are involved in accidents. Using data from the Fatality Analysis Reporting System in the US,17 we 
calculated the average number of fatalities in a car crash involving alcohol, as well as the percentage of 
those fatalities distributed by age and sex (figures 1 and 2). We aggregated FARS data across the years 
1985-2015, given there was little variation in the data temporally and the number of cases in old age 
groups had too much variance when constructing estimates by year. To adjust PAFs, we multiplied 
attributable deaths by the average number of fatalities from FARS and redistributed the PAF amongst 
each population, based on the probability of being a victim to a certain drunk driver by age and sex, 
based on the FARS data. The following equation describes this process: 
𝐴𝐴𝑇𝑇𝑈𝑈𝑠𝑠𝑠𝑠𝐵𝐵𝑠𝑠𝑇𝑇 𝐿𝐿𝐴𝐴𝑃𝑃𝑖𝑖 =
∑ 𝐿𝐿𝐴𝐴𝑃𝑃𝑈𝑈 ∗ 𝑆𝑆𝐴𝐴𝐿𝐿𝑌𝑌𝑈𝑈 ∗ 𝐴𝐴𝐴𝐴𝑙𝑙 𝑃𝑃𝐺𝐺𝐵𝐵𝐺𝐺𝑙𝑙𝑟𝑟𝐵𝐵𝑟𝑟𝑠𝑠𝑠𝑠𝑈𝑈𝑈𝑈 ∗  𝐿𝐿(𝑟𝑟 𝑟𝑟𝑠𝑠 𝐺𝐺 𝐴𝐴𝑟𝑟𝑐𝑐𝐵𝐵𝑟𝑟𝐺𝐺)𝑈𝑈
𝑆𝑆𝐴𝐴𝐿𝐿𝑌𝑌𝑖𝑖
where: 
𝑟𝑟 𝑟𝑟𝑠𝑠 𝐺𝐺 𝑠𝑠𝑙𝑙𝑠𝑠𝑠𝑠𝑙𝑙𝐺𝐺𝐵𝐵𝑟𝑟𝑙𝑙𝑟𝑟 𝑣𝑣𝑦𝑦 𝑙𝑙𝑙𝑙𝑐𝑐𝐺𝐺𝐵𝐵𝑟𝑟𝑙𝑙𝑟𝑟,𝑦𝑦𝑠𝑠𝐺𝐺𝑠𝑠,𝐺𝐺𝑙𝑙𝑠𝑠, 𝑠𝑠𝑠𝑠𝑠𝑠 𝐺𝐺𝑟𝑟𝑇𝑇  
𝑇𝑇 𝑟𝑟𝑠𝑠 𝐵𝐵ℎ𝑠𝑠 𝑠𝑠𝑠𝑠𝐵𝐵 𝑙𝑙𝑇𝑇 𝐺𝐺𝑙𝑙𝑙𝑙 𝐺𝐺𝑙𝑙𝑠𝑠 𝐺𝐺𝑟𝑟𝑇𝑇 𝑠𝑠𝑠𝑠𝑠𝑠 𝑠𝑠𝑠𝑠𝑠𝑠𝑙𝑙𝑠𝑠𝑠𝑠𝑇𝑇 𝑙𝑙𝑠𝑠𝑙𝑙𝑠𝑠𝑠𝑠𝑠𝑠 𝑤𝑤𝑟𝑟𝐵𝐵ℎ𝑟𝑟𝑟𝑟 𝐵𝐵ℎ𝐺𝐺𝐵𝐵 𝑙𝑙𝑙𝑙𝑐𝑐𝐺𝐺𝐵𝐵𝑟𝑟𝑙𝑙𝑟𝑟 𝐺𝐺𝑟𝑟𝑇𝑇 𝑦𝑦𝑠𝑠𝐺𝐺𝑠𝑠. 
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Figure 1 
Population attributable fraction 
For all causes, we defined PAF as: 
𝐿𝐿𝐴𝐴𝑃𝑃(𝑠𝑠) =  
𝐿𝐿𝐴𝐴+∫ 𝐿𝐿(𝑥𝑥)
150
0  ∗ 𝑅𝑅𝑅𝑅𝐶𝐶(𝑥𝑥) 𝑈𝑈𝑥𝑥 − 1
𝐿𝐿𝐴𝐴+∫ 𝐿𝐿(𝑥𝑥)
150
0  ∗ 𝑅𝑅𝑅𝑅𝐶𝐶(𝑥𝑥) 𝑈𝑈𝑥𝑥
𝐿𝐿(𝑠𝑠) = 𝐿𝐿𝐿𝐿 ∗ Γ(𝒑𝒑) 
where: 
𝐿𝐿𝐿𝐿  𝑟𝑟𝑠𝑠 𝐵𝐵ℎ𝑠𝑠 𝑠𝑠𝑠𝑠𝑠𝑠𝐴𝐴𝐺𝐺𝑙𝑙𝑠𝑠𝑟𝑟𝑐𝑐𝑠𝑠 𝑙𝑙𝑇𝑇 𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑟𝑟𝐵𝐵 𝑇𝑇𝑠𝑠𝑟𝑟𝑟𝑟𝑑𝑑𝑠𝑠𝑠𝑠𝑠𝑠,𝐿𝐿𝑎𝑎  𝑟𝑟𝑠𝑠 𝐵𝐵ℎ𝑠𝑠 𝑠𝑠𝑠𝑠𝑠𝑠𝐴𝐴𝐺𝐺𝑙𝑙𝑠𝑠𝑟𝑟𝑐𝑐𝑠𝑠 𝑙𝑙𝑇𝑇 𝐺𝐺𝑣𝑣𝑠𝑠𝐵𝐵𝐺𝐺𝑟𝑟𝑟𝑟𝑠𝑠𝑠𝑠𝑠𝑠,𝑅𝑅𝑅𝑅𝐴𝐴(𝑠𝑠) 𝑟𝑟𝑠𝑠 𝐵𝐵ℎ𝑠𝑠 𝑠𝑠𝑠𝑠𝑙𝑙𝐺𝐺𝐵𝐵𝑟𝑟𝐴𝐴𝑠𝑠  
𝑠𝑠𝑟𝑟𝑠𝑠𝑑𝑑 𝑇𝑇𝑠𝑠𝑟𝑟𝑐𝑐𝐵𝐵𝑟𝑟𝑙𝑙𝑟𝑟 𝑇𝑇𝑙𝑙𝑠𝑠 𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑟𝑟𝐵𝐵 𝑇𝑇𝑠𝑠𝑟𝑟𝑟𝑟𝑑𝑑𝑠𝑠𝑠𝑠𝑠𝑠, 𝐺𝐺𝑟𝑟𝑇𝑇 𝒑𝒑 𝐺𝐺𝑠𝑠𝑠𝑠 𝑠𝑠𝐺𝐺𝑠𝑠𝐺𝐺𝐺𝐺𝑠𝑠𝐵𝐵𝑠𝑠𝑠𝑠𝑠𝑠 𝑇𝑇𝑠𝑠𝐵𝐵𝑠𝑠𝑠𝑠𝐺𝐺𝑟𝑟𝑟𝑟𝑠𝑠𝑇𝑇 𝑣𝑣𝑦𝑦 𝐵𝐵ℎ𝑠𝑠 𝐺𝐺𝑠𝑠𝐺𝐺𝑟𝑟 𝐺𝐺𝑟𝑟𝑇𝑇 𝑠𝑠𝑇𝑇 𝑙𝑙𝑇𝑇 𝑠𝑠𝑠𝑠𝑠𝑠𝑙𝑙𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 
We performed the above equation for 1,000 draws of the exposure and relative risk models. We then 
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Input data & methodological summary 
Exposure 
Case definition 
Injecting drug users (IDU) are at high risk from blood-borne infections, including human 
immunodeficiency virus (HIV) and Hepatitis B and C viruses (HBV and HCV, respectively), through the use 
of shared needles and injection equipment. In GBD 2010, based on the available epidemiological 
literature and the availability of exposure estimates1,2 we measure the burden of disease attributable to 
HIV, HBV and HCV due to injecting drug use. An injecting drug user was defined as a current or recent 
user aged 15-64 years old. 
Input data 
The major burden of mortality from viral hepatitis is due to cirrhosis and liver cancer resulting from 
chronic hepatitis infection. Cirrhosis mortality was modelled with vital registration data using CODEm. 
Etiologic proportion models, estimated using DisMod-MR 2.1, were used to split the overarching 
cirrhosis mortality estimates into cases of cirrhosis attributable to hepatitis B, hepatitis C, alcohol, and 
other causes.1-4   
Liver cancer mortality was modelled using cancer registry data. The incidence numbers were 
transformed into mortality estimates using mortality to incidence ratios. The mortality estimates from 
cancer registries were then combined with vital registration system data as input data into CODEm, 
which produced the final mortality estimates for liver cancer. As with cirrhosis mortality, etiologic 
137
proportions for liver cancer due to hepatitis B, and C, alcohol, and other causes were generated using 
DisMod-MR 2.1.  
To estimate the burden of HIV cases attributable to IDU, we extracted data on the proportion of notified 
HIV cases by transmission route – sexual intercourse, injecting drug use, commercial sex work and other 
-- from a number of agencies that conduct surveillance of HIV across the globe.6-13  
The prevalence of current injecting drug use was estimated using data from a 2008 review conducted by 
the Reference Group to the UN on HIV and injecting drug use,15 and a new review currently being 
conducted by international collaborations and experts. The reviews used a multistage process of 
systematic review adhering to international guidelines. It involved multiple stages of peer and expert 
review, with searches of the peer-reviewed literature in addition to an extensive review of online grey 
literature databases in the drug and alcohol and HIV fields. Additional data on the age and sex 
distribution of injecting drug use were sourced for this modelling exercise. 
In order to generate a pooled incidence rate/absolute relative risk for viral hepatitis among people who 
inject drugs, we conducted a meta-analysis of longitudinal epidemiological studies that reported a 
hepatitis B16-20 or hepatitis C16-31 incidence rate among PWID. We calculated confidence intervals for the 
incidence rate (where no CI was reported) from a Poisson distribution around the number of cases. 
We excluded studies that focused on non-representative subgroups, such as recent injectors or 
adolescents or because hepatitis incidence is far higher in those groups than for all people who inject 
drugs (e.g. Larney et al.32) We did not vary incidence among active injectors according the availability of 
blood borne virus prevention strategies (e.g. NSPs, opioid substitution therapy) because too few studies 
have examined different levels of incidence according to variable coverage, and we were not able to 
estimate coverage by country over time. In any case, in most countries, coverage of virus prevention 
strategies remains very low among people who inject drugs,33 and would have been negligible in most 
countries until recent years. 
Modelling strategy  
As part of the GBD 2017 study, we measured the burden of hepatitis B and hepatitis C (including 
attributable cirrhosis and liver cancer) and HIV at the country, regional, and global level for each age-sex 
group for the years 1990 to 2017. For HIV, hepatitis B and hepatitis C, disease-specific natural history 
models were used to estimate deaths and YLDs, because the three-state model in DisMod-MR 
2.1(susceptible, cases, dead) did not capture the complexity of the disease processes.  
Mortality estimation  
Mortality due to overall acute hepatitis was modelled with vital registration data using the Cause of 
Death Ensemble Modelling tool (CODEm), an analytical tool that tests the predictive power of hundreds 
of models to estimate trends in causes of death.5 Due to poor coverage of cause of death data for each 
of the acute hepatitis varieties, four natural history models for hepatitis B and C were used to estimate 
mortality by deriving incidence from measurements of seroprevalence and then multiplying incidence by 
case fatality to estimate the number of deaths. These four models were then squeezed so as to fit the 
parent cause of death model. 
We estimated HIV mortality using a modified UNAIDS Spectrum model.2 This is a compartmental HIV 
progression model estimates age-specific incidence, prevalence and death rates using methods 
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described elsewhere.2 This modelling approach was adapted according to epidemic type, including 
concentrated and generalized epidemics. For concentrated epidemics, the Spectrum models were 
corrected for misclassification of HIV deaths and then calibrated to align with vital registration data. For 
generalised HIV epidemics, we minimised a loss function to select epidemic curves that were most 
consistent with the prevalence and all-cause mortality data.2  
Estimation of Years Lived with Disability 
For non-fatal estimation, we estimated the incidence of hepatitis B and C using seroprevalence data in 
DisMod-MR 2.1. For both hepatitis B and C, we use data on the seroprevalence of the hepatitis surface 
antigen (a marker of chronic infection in hepatitis B and a marker of ever-infection in hepatitis C), excess 
mortality, and remission, to estimate incidence of both hepatitis infections. Incidence of cirrhosis was 
also estimated in DisMod using cirrhosis hospital data and cause-specific mortality rate (CSMR) data.  
Incidence of liver cancer was derived by dividing mortality by the mortality to incidence ratios, which 
were then used to predict liver cancer survival. Finally, we estimated prevalence as a function of 
incidence and survival by splitting prevalence into four phases. Each phase had different disability 
weights, which were used to generate YLDs for that phase.   
Finally, incidence of HIV was also estimated using the UNAIDS Spectrum modelling approach described 
above in the mortality estimation section.  
Burden of HIV attributable to injecting drug use 
We then estimated the proportion of HIV cases attributable to three transmission categories (sex, IDU 
and other) for all country-time periods using DisMod-MR 2.1. The only covariate used in the model was 
one that added variance to the data points derived from data sources that attributed a portion of HIV 
cases to “unknown” transmission sources. We scaled the proportions from each of the three 
transmission models (sex, IDU and other) to ensure that they fit the total HIV transmission envelope by 
country, year, age and sex.  
Burden of hepatitis B and hepatitis C attributable to injecting drug use 
To estimate the relative contribution of IDU to hepatitis B and C disease burden at the country, regional 
and global level, we used a cohort method. We re-calibrated individuals according to history of injecting 
drug use, and their accumulated risk of incident hepatitis B and C due to IDU. We made use of data on 
prevalence of current injecting drug use, pooled in DisMod-MR 2.1; a meta-analysis of incidence rates of 
hepatitis B and hepatitis C among people who inject drugs; and estimates of population-level incidence 
of hepatitis B and C between 1990 and 2017. We used back extrapolations to estimate incidence before 
1990. These steps are detailed below. 
To estimate the lifetime risk of being infected with hepatitis B or C, we undertook a cohort analysis for 
each country, year, age, and sex category and estimated the probability of an individual having been 
infected in each preceding year. One of the main inputs to this cohort method was the probability of 
having injected drugs in a specific age cohort in a given calendar year.  For example, for a cohort of 40-
year-olds in 2015, the relevant probability in 2005 is the estimated prevalence of injecting drug use 
among 30-year-olds. 
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In addition to a global time series of estimated prevalence of injecting drug use, we also used the 
incidence of hepatitis B or C and the sero-conversion rate of hepatitis B and hepatitis C among people 
who inject drugs for each age-sex-country-year from 1960 to 2013 by 5-year age groups.  
1. Incidence rate of Hepatitis B and C in the general population
We modelled the annual incidence rate of hepatitis B and hepatitis C using sero-prevalence data in 
DisMod-MR 2.1. We assumed a low remission (mean 0.015 and standard error 0.0075)14 in the hepatitis 
B model to reflect the small proportion of cases who spontaneously clear the infection. We assumed 
zero remission for hepatitis C. 
2. Prevalence of ever-injecting drug use
DisMod-MR 2.1 was used to estimate the prevalence of injecting drug use with year as a covariate to 
estimate the trends over time. DisMod makes an average estimate of the change in drug use over the 
time period from 1990-2017 and we took draws from a normal distribution of the coefficient to project 
IDU prevalence backward in time to 1960 from baseline level in 1990.   
3. Pooled seroconversion hazard of hepatitis C and hepatitis B among people who ever
injected drugs
This pooled sero-conversion hazard for both hepatitis C and hepatitis B was derived from a meta-
analysis of longitudinal epidemiologic studies described above in the input data section.  
Theoretical minimum-risk exposure level 
The theoretical minimum-risk exposure level is defined as zero exposure to injecting drug use. 
Relative risks 
For drug use, there were not substantial changes made to the effect sizes from GBD 2015. We used a 
pooled absolute risk of Hepatitis C and Hepatitis B among those who have ever used injecting drugs.  
In addition to assessing IDU as a risk factor for blood-borne infections, the broader category of mental 
and substance use disorders is assessed as risk factors for suicide. The suicide burden attributable to 
mental and substance use disorders is estimated by comparing the current health status with a 
theoretical-minimum-risk exposure defined as the counterfactual status of the absence of mental and 
substance use disorders (Ferrari, Norman et al 2014). 
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Input data & methodological summary 
Exposure 
Case definition 
For GBD 2017, risk factors associated with diet include: diet low in fruits, vegetables, legumes, whole 
grains, nuts and seeds, fiber, seafood omega-3 fatty acids, polyunsaturated fatty acids, calcium, milk; 
and diet high in red meat, processed meat, sugar sweetened beverages, trans fatty acids, and sodium. 
Exposure to a diet low in fruits is defined as average daily consumption of less than 250 grams per day of 
fruits (fresh, frozen, cooked, canned, or dried, excluding fruit juices and salted or pickled fruits). 
Exposure to diet low in vegetables is defined as average daily consumption of less than 360 grams per 
day of vegetables (fresh, frozen, cooked, canned or dried vegetables excluding legumes and salted or 
pickled vegetables, juices, nuts and seeds, and starchy vegetables such as potatoes or corn). Exposure to 
a diet low in legumes is defined as average daily consumption of less than 60 grams per day of legumes. 
Exposure to diet low in whole grains is defined as average daily consumption of less than 125 grams per 
day of whole grains (bran, germ, and endosperm in their natural proportion) from breakfast cereals, 
bread, rice, pasta, biscuits, muffins, tortillas, pancakes and other sources. Exposure to diet low in nuts 
and seeds is defined as average daily consumption of less than 20.5 grams per day of nuts and seeds. 
Exposure to diet low in milk is defined as average daily consumption of less than 435 grams per day of 
milk including non-fat, low-fat, and full-fat milk, excluding soy milk and other plant derivatives. Exposure 
to diet low in calcium is defined as average daily consumption of less than 1.15 grams per day of calcium 
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from all sources, including milk, yogurt, and cheese. Exposure to diet low in fiber is defined as average 
daily consumption of less 23.5 grams per day of than fiber from all sources including fruits, vegetables, 
grains, legumes and pulses. Exposure to diet low in seafood omega-3 fatty acids is defined as average 
daily consumption of less than 250 milligrams per day of eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA). Exposure to diet low in polyunsaturated fatty acids is defined as average 
daily consumption of less than 11% of total energy intake from polyunsaturated fatty acids. This 
represents a change from the last round of GBD where the burden associated with a diet low in 
polyunsaturated fatty acids was estimated as a replacement for consumption of saturated fatty acids. 
Exposure to diet high in red meat is defined as average daily consumption of greater than 22.5 grams 
per day of red meat (beef, pork, lamb, and goat but excluding poultry, fish, eggs, and all processed 
meats). Exposure to diet high in processed meat is defined as average daily consumption of greater than 
2 grams of meat preserved by smoking, curing, salting, or addition of chemical preservatives. Exposure 
to diet high in sugar sweetened beverages is defined as average daily consumption of greater than 2.5 
grams per day of beverages with ≥50 kcal per 226.8 gram serving, including carbonated beverages, 
sodas, energy drinks, fruit drinks, but excluding 100% fruit and vegetable juices. Exposure to diet high in 
trans-fatty acids is defined as average daily consumption of greater than 0.5% of trans fat from all 
sources, mainly partially hydrogenated vegetable oils and ruminant products. Exposure to diet high in 
sodium is defined as average 24 hour urinary sodium greater than 3 grams per day.  
Input data 
We used dietary data from multiple sources including nationally and sub-nationally representative 
nutrition surveys, household budget surveys, accounts of national sales, and United Nations FAO Food 
Balance Sheets and Supply and Utilization Accounts. A specific improvement for this round was a novel 
approach we developed that allows the incorporation of FAO-based data to assist with our estimation of 
whole grains consumption. This is a powerful development as it dramatically increases our data 
coverage across countries and through time. This was achieved through separate estimation of total 
grain and refined grain availability. With whole grains and refined grains representing the entirety of all 
grain available, we were then able to calculate the availability of whole grains by difference. 
Additionally, for sodium and trans-fatty acids, we used data on 24-hour urinary sodium and availability 
of hydrogenated vegetable oil in packaged foods, respectively. Polyunsaturated and trans-fatty acids 
were modelled as a percent of total dietary energy. We modelled missing country-year data from FAO 
using a space-time Gaussian process regression and lag-distributed country income as the covariate. For 
each dietary factor, we estimated the global age pattern of consumption based on nutrition surveys (i.e., 
24-hour diet recall) and applied that age pattern to the FAO data. Substantive changes in input data
compared to GBD 2015 are as follows: (a) re-extracting data from all nutrition surveys and standardising
the definition of dietary components across sources; (b) incorporating data gathered through a
systematic review of literature for each of our dietary risk factors; (c) using sales data for fruit,
vegetables, legumes, processed meats, red meats, sugar-sweetened beverages, and milk.
Modelling strategy 
We used a spatio-temporal Gaussian process regression (ST-GPR) framework to estimate the intake of 
each dietary factor by age, sex, country, and year. In GBD 2017, for all dietary factors other than sodium, 
we considered data from 24-hour diet recall as the gold standard, and cross-walked other methods of 
assessment to the gold standard method. For sodium, the 24-hour urinary sodium was considered as the 
145
gold standard. To estimate the 24-hour urinary sodium based on dietary sodium, we performed a 
crosswalk adjustment between these two types of data.  
Table 1 summarises the study-level and country-level covariates used in modelling of each dietary 
factor.  
Table 1. Types of data sources (other than 24-hour dietary recall) and covariates used in modelling of each dietary 
factor.    
Data Sources Country level covariate 
Sales FFQ1 HBS2 FAO 
Diet low in fruits 
    
Lag-distributed income, total available 
kilocalories per person per day 
Diet low in vegetables 
    
Lag-distributed income, total available 
kilocalories per person per day 
Diet low in legumes 
 -   Lag-distributed income, total available 
kilocalories per person per day 
Diet low in whole grains -  -  Lag-distributed income 
Diet low in nuts and seeds - -   Lag-distributed income, total available 
kilocalories per person per day 
Diet low in milk 
    
Lag-distributed income, total available 
kilocalories per person per day 
Diet high in red meat 
    
Lag-distributed income, total available 
kilocalories per person per day 
Diet high in processed meat    - Lag-distributed income 
Diet high in sugar-sweetened 
beverages    - 
National availability of sugar (grams/person/day), 
Lag-distributed income, total available 
kilocalories per person per day 
Diet low in fiber -  -  Lag-distributed income, total available 
kilocalories per person per day 
Diet suboptimal in calcium -  -  Lag-distributed income, total available 
kilocalories per person per day 
Diet low in seafood omega-3 fatty 
acids - - - 
 
Lag-distributed income 
Diet low in polyunsaturated fatty acids -  -  Lag-distributed income, total available 
kilocalories per person per day 
Diet high in trans fatty acids   - - - 
Diet high in sodium3 - - - - - 
1 Food Frequency Questionnaire  
2 Household Budge Survey 
3 For sodium, we used data from the 24-hour urinary sodium and 24-hour dietary recall.  
To characterise the distribution of each dietary factor at population level, we use an ensemble approach 
that separately fit 12 distributions for individual level microdata to specific to each data source’s 
sampled population. The respective goodness of fit of each family was assessed and a weighting scheme 
was determined to optimise overall fit to the unique distribution of each risk factor. A global mean of 
the weights for each risk factor’s data sources was created.  We then determined the standard deviation 
of each population’s consumption through a linear regression that captured the relationship between 
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the standard deviation and mean of intake in nationally representative nutrition surveys using 24-hour 
diet recalls:  
𝑙𝑙𝑙𝑙 (𝑆𝑆𝑆𝑆𝑆𝑆𝑙𝑙𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 𝑆𝑆𝑑𝑑𝑑𝑑𝑑𝑑𝑆𝑆𝑆𝑆𝑑𝑑𝑑𝑑𝑙𝑙)  =  𝛽𝛽0  + 𝛽𝛽1  ×  𝑙𝑙𝑙𝑙 (𝑀𝑀𝑑𝑑𝑆𝑆𝑙𝑙𝑖𝑖) 
Then we applied the coefficients of this regression to the outputs of our ST-GPR model to calculate the 
standard deviation of intake by age, sex, year, and country. We also quantified the within person 
variation in consumption of each dietary component and adjusted the standard deviations accordingly. 
Theoretical minimum-risk exposure level 
In GBD 2016, to estimate the TMREL for each dietary factor, we first calculated the level of intake 
associated with the lowest risk of mortality from each disease endpoint based on the studies included in 
the meta-analyses of the dietary relative risks. Then, we calculated the TMREL as the weighted average 
of these numbers using the global number of deaths from each of outcome as the weight (Table 2). 
Table 2. Theoretical minimum-risk exposure level for dietary factors GBD 2017.  




Whole grains 100-150 gr/day
Nuts 16-25 gr/day
Red meats 18-27 gr/day
Processed meats 0-4 gr/day
Milk 350-520 gr/day
Sugar sweetened beverages 0-5 gr/day
Polyunsaturated fatty acids 9-13% of total daily energy
Seafood omega-3 fatty acids 200-300 mg/day
Trans fatty acids 0-1% of total daily energy
Dietary fiber 19-28 gr/day
Dietary calcium 1.0-1.3 gr/day 
Relative risk 
In GBD 2016, we measured the health effects of a diet high in sugar-sweetened beverages (SSBs) 
through how it changes a population’s body-mass index (BMI). All attributed disease burden was then 
solely through the health outcomes associated with a high BMI. Given the more recent publication of 
dose-response meta-analyses that quantifies the direct effects of SSB consumption on incidence of and 
mortality from disease endpoints (i.e., ischemic heart disease, and type-2 diabetes), we have updated 
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our approach to reflect the best available evidence. In GBD 2017, consistent with other dietary risks, we 
have estimated the health effects of SSBs on morbidity and mortality from disease endpoints. 
Considering that the relative risks included in these new meta-analyses were mostly adjusted for BMI, 
our estimated disease burden reflects the burden of disease attributable to SSB consumption 
independent of its effect on BMI.    
We obtained the relative risk of each disease endpoint per serving of the dietary components from 
recent dose-response meta-analyses of prospective observational studies, and where available 
randomised controlled trials. Considering the well-established age trend of the relative risks of 
metabolic risk factors for cardiovascular disease and diabetes, we conducted a literature review to 
identify the most important metabolic mediators for each dietary factor and used the age trend of the 
relative risk of that mediator(s) and the disease endpoint to estimate the age-specific relative risk for 
each dietary factors (Table 3).  












Diet low in fruits     
Diet low in vegetables     
Diet low in legumes     
Diet low in whole grains    - 
Diet low in nuts and seeds     
Diet high in red meats  -  - 
Diet high in processed meats  -   
Diet low in fiber -  - - 
Diet low in seafood omega-3 fatty acids  - -  
Diet low in polyunsaturated fatty acids -   - 
Diet high in trans fatty acids   - - 
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Surveys e.g. DHS, GENACIS, 




level microdata from WHO 
multi-country study on 
women’s health & domestic 
violence
DisMod – MR 2.1:
 (1) Exposure to lifetime IPV 
(2) Exposure to IPV in the 
past 12 months
Zero prevalence of intimate partner 
violence
Published paper reporting relative 









fractions by risk, 
cause, age, sex, 
and geography
Exposure to IPV 
in the past 12 
months by age, 
year, geography
Published statistics and police reports of 
“solved” homicides perpetrated by intimate 
partner
DisMod-MR 2.1: Calculate IPV-
homicide PAFS directly as fraction of 
solved homicides attributable to an 
intimate partner
Calculate PAFs using 
exposure, relative risks, 
and TMREL
Systematic review of 
published IPV prevalence 
literature
Meta-analysis of cohort studies: 
incidence rate ratio (IRR) of HIV
Calculate PAFs using cumulative exposure and 
associated cumulative HIV risk in order to 






Annual incidence rate of HIV 
from SPECTRUM model
Adjustment to data points 
from sources where 
population is only ever 
partnered or currently 
partnered women by 
multiplying by age-specific 
fraction of women in a 
relationship
DisMod – MR 2.1:





fractions by risk 
aggregate, cause, 
age, sex, and 
geography
Deaths, YLLs, YLDs, 
and DALYs 
attributable to each 
risk by age, sex, 
year, geography
Deaths, YLLs, YLDs, 
DALYs for each 
disease and injury 







Relative risk for 
depression
Proportion of HIV due to sex and not 
commercial sex work, from unsafe sex 
risk factor modeling
Exposure to 
lifetime IPV by 
age, year, and 
geography
Input data & methodological summary 
Exposure 
Case definition 
The case definition for intimate partner violence (IPV) is ever experienced one or more acts of physical 
and/or sexual violence by a current or former intimate partner since the age of 15 years. Estimated in 
females only because evidence of risk-outcomes for males does not meet our criteria. 
• Physical violence is defined as: ‘being slapped or having something thrown at you that could
hurt you, being pushed or shoved, being hit with a fist or something else that could hurt, being
kicked, dragged, or beaten up, being choked or burnt on purpose, and/or being threatened with
or actually having a gun, knife, or other weapon used on you.’
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• Sexual violence is defined as: ‘being physically forced to have intercourse when you did not
want to, having sexual intercourse because you were afraid of what your partner might do,
and/or being forced to do something that you found humiliating or degrading’ (the definition of
humiliating and degrading may vary across studies depending on the regional and cultural
setting).
• Intimate partner is defined as: ‘a partner to whom you are married or with whom you cohabit.’
In countries where people date, dating partners will also be considered (a partner with whom
you have an intimate (sexual) relationship with but are not married to or cohabiting).
Input data 
No systematic review of the literature was completed for GBD 2017. However, a systematic review of 
the intimate partner violence prevalence literature was conducted in PubMed for anything published 
between January 2016 and January 2017 for the GBD 2016 cycle. The following search terms were used 
to conduct the systematic review:  
((("health surveys"[MeSH Terms] AND prevalence[Title/Abstract]) OR ("sentinel surveillance"[MeSH 
Terms] AND prevalence[Title/Abstract]) OR ("prevalence"[Title/Abstract] AND cross sectional 
studies[MeSH Terms])) AND (abuse, sexual[MeSH Terms] OR domestic violence[MeSH Terms] OR abuse, 
partner[MeSH Terms] OR abuse, spousal[MeSH Terms] OR rape[MeSH Terms]) NOT 
("comment"[Publication Type] OR "letter"[Publication Type] OR "editorial"[Publication Type])) 
We get the proportion of solved homicides that were perpetrated by an intimate partner from crime 
statistics and police reports. 
In GBD 2015, an updated systematic review was done for IPV homicide sources in PubMed through April 
2016. The query used for this Pubmed search was:  
((IPV[All Fields] OR ("intimate partner violence"[MeSH Terms] OR ("intimate"[All Fields] AND 
"partner"[All Fields] AND "violence"[All Fields]) OR "intimate partner violence"[All Fields])) AND 
(("homicide"[MeSH Terms] OR "homicide"[All Fields]) OR femicide[All Fields])) AND 
("2013/01/01"[PDAT] : "3000/12/31"[PDAT]) 
These literature sources were supplemented with sources from the GHDx that were tagged with 
Intimate partner violence AND Homicide. 
Modelling strategy  
We use three distinct approaches to estimate burden attributable to IPV, including 1) the traditional 
exposure and relative risk (RR) to percent attributable fraction (PAF) method for depression and 
abortion; 2) the direct PAF approach for estimating the proportion of homicides that are perpetrated by 
an intimate partner; and 3) a cumulative risk approach for estimating the burden of HIV/AIDS 
attributable to IPV.  
Estimating attributable burden to IPV for depression, suicide and abortion  
We first adjusted data with variable recall periods (previous 12 months versus lifetime), type of violence 
(sexual, physical, or both) and severity (severe only versus all levels). To convert data to our reference 
definition of ever having experienced any physical or sexual IPV, we used data from the WHO Multi-
country Study on Women’s Health and Domestic Violence against Women to construct crosswalk 
150
regressions. The dependent variable in each of these regressions was ever any IPV (reference), while the 
key independent variable was one of the 11 alternative metrics of IPV that were represented in our 
dataset:  
1. Physical IPV in the past 12 months
2. Sexual IPV in the past 12 months
3. Severe IPV in the past 12 months
4. Severe physical IPV in the past 12 months
5. Severe sexual IPV in the past 12 months
6. Any IPV (physical and/or sexual) in the past 12 months
7. Ever any physical IPV
8. Ever any sexual IPV
9. Ever any severe IPV
10. Ever severe physical IPV
11. Ever severe sexual IPV
For alternate metrics 1-6 we included a series of age dummies: 
𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑡𝑡(𝑅𝑅𝑅𝑅𝑅𝑅𝑎𝑎𝑎𝑎𝑎𝑎) = 𝛽𝛽0 +  𝛽𝛽1𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑡𝑡(𝐴𝐴𝐴𝐴𝐴𝐴𝑎𝑎𝑎𝑎𝑎𝑎) + 𝛽𝛽2𝐼𝐼𝑎𝑎 +  𝜀𝜀
For alternate metrics 7-11, we ran the following regression: 
𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑡𝑡(𝑅𝑅𝑅𝑅𝑅𝑅𝑎𝑎𝑎𝑎) = 𝛽𝛽0 +  𝛽𝛽1𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑡𝑡(𝐴𝐴𝐴𝐴𝐴𝐴𝑎𝑎𝑎𝑎) +  𝜀𝜀 
where REF is the reference metric of IPV prevalence, ALT is the alternate metric of IPV prevalence, Ia 
refers to the complete set of age-group indicators, a refers to an age-group, i refers to a country, and t 
refers to year. We included age-group indicators in the first six regressions because we expected the 
prevalence of recent IPV to vary by age. Using the intercepts, coefficients, and variance-covariance 
matrix from each of these eleven regressions, we were able to convert all of the alternate metrics of IPV 
prevalence in our dataset to estimates of “ever any IPV.” We eliminated observations based on 
alternate metrics of IPV which came from studies that also provided estimates of IPV based on the 
reference definition.  
After applying crosswalks to the alternate metrics of IPV in the manner described above, we made an 
additional adjustment to the subset of our data that was based on only ever-partnered, currently 
partnered women currently married women or ever married women. To adjust these values so that they 
reflected IPV prevalence in the entire female population, regardless of partnered status, we multiplied 
estimates from these studies by the age-specific fraction of women who had ever been partnered. An 
updated time series was generated in GBD 2015 using MICS and DHS data in a single parameter DisMod 
model to reflect the most recent data on proportion of women that have ever been partnered.  
After these pre-DisMod crosswalks and adjustments, a single-parameter prevalence model was run in 
DisMod-MR 2.1 with age mesh points at 0 14 15 20 30 40 50 60 80 & 100. A study-level fixed effect on 
integrand variance (z-cov) to indicate whether a study was nationally representative or not was used to 
account for the heterogeneity introduced by studies that are not generalizable to the entire population. 
This covariate was first tested as an x-cov and the coefficient indicated no systematic bias. 
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In addition to the lifetime exposure model as described, a 12-month exposure model was also run in 
DisMod-MR 2.1, with data collected and processed analogously. This 12-month exposure model was 
used for the IPV-abortion PAF calculation to match the exposure definition in the risk evidence. 
Direct PAF for female homicides 
The burden of homicides attributable to intimate partner violence was modelled as a direct PAF. 
Input data fed into a single-parameter proportion DisMod-MR 2.1 model, which had age mesh points at 
0 10 20 45 & 100. The model had a study-level covariate for sources just including police reported 
homicides. We also included a study-level fixed effect on integrand variance (z-cov) to indicate whether 
a study was nationally representative or not. This covariate was first tested as an x-cov and the 
coefficient indicated no systematic bias. 
In GBD 2015, we added prevalence of binge drinking to the model as a country-level covariate, but it 
was dropped for GBD 2016 because it produced a non-significant coefficient.  
Cumulative risk approach for PAF of HIV/AIDS due to IPV 
The third and final modelling approach that we used to assess burden attributable to intimate partner 
violence was a cumulative risk approach to measure the burden of HIV/AIDS attributable to IPV.  
The approach itself remained the same in GBD 2017, but included updated intimate partner violence 
exposure numbers from the DisMod-MR 2.1 model described above, as well as revised HIV incidence 
numbers. 
From two cohort studies (Jewkes et al, Lancet 2010 & Kouyoumdijian, et al AIDS 2013) we pooled 
incidence rate ratio (IRR) of HIV incidence with a random effects model. As we measure burden based 
on deaths and prevalence, we needed to quantify attributable fractions for prevalence and death rather 
than incidence. To get a PAF for prevalence we needed to consider the history of exposure to IPV and 
the accumulated associated risk of incident HIV due to IPV, relative to the overall risk of HIV at the 
population level. The ratio of cumulative IPV-attributable HIV incidence to total HIV incidence was an 
approximation of the relevant PAF for HIV prevalence and we assumed this PAF can also be applied to 
mortality.  
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑙𝑙𝐶𝐶𝑡𝑡𝑙𝑙𝐶𝐶𝐶𝐶 𝐻𝐻𝐼𝐼𝐻𝐻 𝑙𝑙𝑖𝑖𝑖𝑖𝑙𝑙𝑖𝑖𝐶𝐶𝑖𝑖𝑖𝑖𝐶𝐶 𝑖𝑖𝐶𝐶𝐶𝐶 𝑡𝑡𝑙𝑙 𝐼𝐼𝐼𝐼𝐻𝐻
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑙𝑙𝐶𝐶𝑡𝑡𝑙𝑙𝐶𝐶𝐶𝐶 𝐻𝐻𝐼𝐼𝐻𝐻 𝑙𝑙𝑖𝑖𝑖𝑖𝑙𝑙𝑖𝑖𝐶𝐶𝑖𝑖𝑖𝑖𝐶𝐶 𝑙𝑙𝐶𝐶𝐶𝐶𝑜𝑜𝐶𝐶𝑙𝑙𝑙𝑙
=
1 −∏ �1 − 𝐼𝐼𝐴𝐴𝑅𝑅𝑎𝑎𝑎𝑎 ∗ 𝐼𝐼𝑎𝑎𝑎𝑎�𝑎𝑎=𝑛𝑛𝑎𝑎=𝑜𝑜
1 −∏ (1 − 𝐼𝐼𝑎𝑎𝑎𝑎)𝑎𝑎=𝑛𝑛𝑎𝑎=𝑜𝑜
Where: 
 I = annual incidence rate of HIV 
a = age (15-95) 
 y = year (1980-2016) 
𝐼𝐼𝐴𝐴𝑅𝑅𝐻𝐻𝐻𝐻𝐻𝐻 𝑎𝑎𝑛𝑛𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖𝑛𝑛𝑖𝑖𝑖𝑖  = 
[𝑃𝑃𝑃𝑃𝑖𝑖𝑃𝑃𝑎𝑎𝑃𝑃𝑖𝑖𝑛𝑛𝑖𝑖𝑖𝑖 𝑜𝑜𝑜𝑜 𝐻𝐻𝑃𝑃𝐻𝐻]𝑎𝑎𝑎𝑎∗ (𝐻𝐻𝐼𝐼𝐼𝐼−1)
[𝑃𝑃𝑃𝑃𝑖𝑖𝑃𝑃𝑎𝑎𝑃𝑃𝑖𝑖𝑛𝑛𝑖𝑖𝑖𝑖 𝑜𝑜𝑜𝑜 𝐻𝐻𝑃𝑃𝐻𝐻]𝑎𝑎𝑎𝑎∗ (𝐻𝐻𝐼𝐼𝐼𝐼−1)+1
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Theoretical minimum-risk exposure level 
The theoretical minimum-risk exposure level is zero exposure to intimate partner violence, as defined 
above.  
Relative risks 
We estimate burden attributable to IPV for abortion, depressive disorders, interpersonal violence (i.e. 
homicide) and HIV incidence. For GBD 2016, we completed a systematic review of the literature for 
papers reporting relative risk of IPV and our outcomes. Suicide, which was modelled as an outcome of 
IPV for GBD 2015, was removed from the analysis based on the availability of relative risk literature 
using suicide and not attempted suicide as the outcome definition. For GBD 2017, we used the same 
causal evidence for relative risk as was used for GBD 2016. 
For HIV, we use a pooled IRR of 1.59 (95% CI 1.3-1.94) from a random effects inverse variance weighted 
meta-analysis of the two available prospective studies as of date. 
The relative risks for depressive disorders and suicide come came from a systematic review of 
longitudinal studies assessing intimate partner violence and incident diagnosed major depression. A 
random effects inverse variance weighted meta-analysis produced a pooled relative risk and 95% 
confidence interval of 1.44 (1.09, 1.92). 
For the relative risk for IPV-abortion, we also performed a random effects, inverse variance meta-
analysis, which produced a pooled relative risk and 95% confidence interval of 1.91 (1.15, 3.16). An 
important methodological note with IPV-abortion is that we must apply the pooled relative risk for 
abortion to the current prevalence of IPV (in the previous 12 months), rather than lifetime prevalence. 
This is because the case definition for the relative risk component studies was physical or sexual IPV in 
the past year.  




Chowdhary 2008  
Suglia 2011  
Overall 
Q=2.22, p=0.53, I2=0%
Lipsky 2009  
Ouellet-Morin 2015  
    ES (95% CI)          % Weight
   0.88  (  0.26,  3.00)      5.4
   1.09  (  0.60,  1.90)     24.3
   1.44  (  1.09,  1.92)    100.0
   1.59  (  0.98,  2.58)     34.5
   1.72  (  1.07,  2.77)     35.7
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Meta-analysis for IPV-abortion: 









Leung 2002  
Romito 2009 old  
    ES (95% CI)          % Weight
   0.61  (  0.13,  2.84)      8.3
   1.22  (  0.99,  1.51)     34.2
   1.91  (  1.15,  3.16)    100.0
   2.01  (  1.58,  2.55)     33.7
   4.83  (  2.18, 10.67)     19.2








    ES (95% CI)          % Weight
   1.51  (  1.04,  2.21)     27.7
   1.59  (  1.30,  1.94)    100.0
   1.62  (  1.28,  2.04)     72.3
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Childhood Sexual Abuse Capstone Appendix 
Flowchart 
Household surveys e.g. GENACIS, 
CDC Reproductive Health 
surveys, BRFSS
DisMod – MR 2.1: 
Separate models for 
male and females
Zero exposure to childhood 
sexual abuse
Cohort studies meta-analysis of relative risks
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fractions by risk 
aggregate, cause, 
age, sex, and 
geography
Exposures by 
risk, age, sex, 
year, and 
geography
Deaths, YLLs, YLDs, 
and DALYs 
attributable to 
each risk by age, 
sex, year, 
geography
Calculate PAFs using 
exposure, relative risks, 
and TMREL












Deaths, YLLs, YLDs, 
DALYs for each 
disease and injury 
by age, sex, year, 
geography
X-COVS
 intercourse CSA; contact AND non-
contact CSA; age over 15; age under 
15; restricted perpetrator
Z-COVS
Study population school; non-
representativeness
Input data & methodological summary 
Exposure 
Case definition 
The case definition for childhood sexual abuse (CSA) is ever having had the experience of intercourse or 
other contact abuse (i.e. fondling and other sexual touching) when aged 15 years or younger, and the 
perpetrator or partner was greater than five years older than the victim. 
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Input data 
Currently, we use self-reported survey data to measure CSA prevalence, not data from Child Protection 
Services (CPS) or other crime data. The reliability and comprehensiveness of CPS and crime statistics 
varies too much geographically to warrant inclusion.  
Although no systematic review of the literature was completed for GBD 2017, an updated systematic 
review of CSA prevalence literature was conducted for sources published between August 2015 and 
January 2017 during the GBD 2016 cycle. The following search terms were used:  
(((("health surveys"[MeSH Terms] AND prevalence[Title/Abstract]) OR ("sentinel surveillance"[MeSH 
Terms] AND prevalence[Title/Abstract]) OR ("prevalence"[Title/Abstract] AND cross sectional 
studies[MeSH Terms])) AND (("child abuse"[MeSH Terms] OR "child abuse, sexual"[MeSH Terms]) OR 
("sex offenses"[MeSH Terms] OR "child abuse, sexual"[MeSH Terms]) OR (child*[Title/Abstract] AND 
sexual[Title/Abstract] AND abuse[Title/Abstract]))) NOT ("comment"[Publication Type] OR 
"letter"[Publication Type] OR "editorial"[Publication Type])) 
We supplemented with data from relevant national health surveys and violence-specific surveys. Several 
survey series used include the United States Behavioral Risk Factor Surveillance System, the CDC 
Reproductive Health Surveys, Brazil National Alcohol and Drug Survey, and the Gender, Alcohol, and 
Culture International Study (GENACIS).  
A number of study level covariates were also extracted that were used in the modelling process to 
adjust for heterogeneous definitions across sources. All crosswalks and adjustments were done in 
DisMod-MR 2.1. 
Modelling strategy  
CSA prevalence was modeled as a single parameter prevalence model in DisMod-MR 2.1. CSA exposure 
is modeled separately for males and females because we observe little correlation between the 
prevalence of child abuse among females and males, and modeling both sexes together causes 
unreasonable estimates in countries where we only have data for one sex. 
Three study-level covariates were used for alternate definitions of the violence. 
• Study asked only about intercourse CSA
• Study asked about contact and non-contact CSA
• Study placed restrictions on the relationship between the perpetrator and the victim (e.g. only
asked about CSA committed by a father)
We also included study-level fixed effects for varying age thresholds across studies. 
• Study asked about recall for events before ages above 15 years (versus reference age threshold
of 15)
• Study asked about recall for events before ages less than 15 years (versus reference age
threshold of 15)
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Two study-level covariate fixed effects on variance (z-cov) were also included in both the male and 
female models, including an indicator that the survey was not nationally representative, as well as 
whether the survey was administered in schools. These study-level covariates were tested as x-covs first, 
but we did not find coefficients which would indicate systematic bias. We have not included any 
national-level covariates to date due to lack of knowledge about a covariate (for which we have a time 
series for all GBD locations) that predicts CSA prevalence. 
Theoretical minimum-risk exposure level 
The theoretical minimum risk exposure level is zero exposure to contact childhood sexual abuse. 
Relative risks 
We estimate burden attributable to CSA for the following health outcomes: unipolar depressive 
disorders (major depressive disorder and dysthymia) and alcohol use disorders.  
In GBD 2015, we used one twin study that compared adverse outcome risks in same-sex discordant 
pairs.1 This study was deemed reliable given that environmental and contextual factors are inherently 
controlled for when comparing between twins, avoiding potential confounding. However, to add to the 
strength of the evidence for GBD 2016, we performed a systematic review and a random effects meta-
analysis to produce relative risks for depressive disorders and alcohol use disorders. In a departure from 
GBD 2015, suicide was not used as an outcome for CSA. This decision was based on the evidence 
available for the relative risk of suicide given exposure to CSA – not enough studies used suicide as an 
outcome, but instead used attempted suicide. For GBD 2017, we used the same causal evidence as was 
used for GBD 2016. 
The pooled relative risk figures and 95% confidence intervals were 1.63 (1.41, 1.89) for depressive 
disorders and 1.54 (1.19, 1.99) for alcohol use disorders. The resulting forest plots are as follows: 
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Input data & methodological summary 
Exposure 
Case definition 
Bullying victimisation is commonly conceptualised as the intentional and repeated harm of a less 
powerful individual by peers.1 This differentiates bullying victimisation from disagreements, conflicts, or 
playful teasing. The case definition of bullying victimisation in the GBD context is ‘bullying victimisation 
of children and adolescents attending school by peers.’ This definition includes the global concept of 
bullying victimisation which incorporates combined estimates of subtypes such as physical, verbal, 
relational, and cyberbullying victimisation. It excludes abuse/harassment by siblings, intimate partners, 
and adults (e.g. teachers). While bullying can be experienced as either a victim or perpetrator, 
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perpetration (i.e. those who bully others) is not included in this definition although some victims will 
also be perpetrators. 
Input data 
In order for a study to be included, it must report the prevalence of bullying victimisation and 1) have 
been published since 1980, 2) ask participants about bullying victimisation in the previous year or more 
recently, 3) use an appropriate frequency threshold to define bullying victimisation (approximating at 
least once a week or greater than ‘occasionally’), 4) be representative of the general population rather 
than a special population (e.g. ethnic minorities), and 5) report prevalence for bullying victimisation 
overall rather than a subtype e.g. physical bullying victimisation.  
Included studies were sourced from a systematic review of three electronic databases (PubMed, 
EMBASE, and PsycINFO), covering the period 1980 to 2017. No restriction was set on the language of 
publication. GhDx was also used to source microdata from survey series meeting the above inclusion 
criteria. Estimates from the Global School-based Student Health Survey (GSHS), the Health Behavior in 
School-aged Children (HBSC), and the National Crime Victimization Survey – School Crime Supplement 
(NCVS-SCS) were extracted and included in the dataset. 
Modelling strategy  
Bullying victimisation prevalence was modelled as a single parameter prevalence model in DisMod-MR 
2.1. We assumed no prevalence prior to 5 years or after 20 years of age. Four study-level covariates 
were included and are shown in the table below, along with their respective levels. Crosswalks for two 
of the covariates (low bullying frequency and no bullying definition presented) were calculated using 
within-study pairs of reference and non-reference estimates (n = 9 pairs and n = 3 pairs, respectively). 
Covariate name Reference Non-reference Exponentiated beta 
Low bullying 
frequency 
Optimal frequency threshold 
used e.g. ‘frequently’ 
Sub-optimal frequency 
threshold used e.g. 
‘sometimes + frequently’ 
3.35 (3.35 – 3.35) 




Definition of bullying 
victimisation presented to 
participants 
No definition of bullying 
victimisation presented to 
participants or not specified 
1.12 (1.12 – 1.12) 
(n = 3 pairs) 
Recall 1 year Asked about bullying 
victimisation more recently 
than in the past year 
Asked about bullying 
victimisation in the past year 
1.47 (1.30 – 1.68) 
Single school 
sample 
Sample was a household 
survey or multi-school survey 
Sample was from a single 
school 
1.21 (1.01 – 2.12) 
Adjustment for years of schooling 
In order to better represent the prevalence of bullying victimisation, prevalence estimates were 
adjusted for the proportion of children and adolescents attending school by ages 5-9, 10-14, and 15-19 
years by sex, location, and year. Data on the proportion of children and adolescents attending school 
was sourced from the online database (http://data.uis.unesco.org/) published by the United Nations 
Educational, Scientific, and Culture Organization (UNESCO). The data covered 18,441 country-years for 
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age groups 6-11, 12-14, and 15-17 years by sex. This data was modelled in ST-GPR, with average years of 
education as a country-level covariate, to predict the proportion of children and adolescents attending 
school by these age groups. This gave estimates of the proportion of children and adolescents attending 
school by age, sex, year, and location. 
Theoretical minimum-risk exposure level 
The theoretical minimum risk exposure level was assumed to be zero exposure to bullying victimisation. 
Relative risks (RRs) 
We estimate burden attributable to bullying victimisation for major depressive disorder and anxiety 
disorders. Data on the association between bullying victimisation and self-harm was also reviewed but 
not included due to variation in the definition of ‘self-harm’ and only one study looking at suicide. 
Input data for RRs 
Studies reporting the prospective longitudinal association between these outcomes and bullying 
victimisation were sourced from a systematic review of three electronic databases (PubMed, EMBASE, 
and PsycINFO), covering the period 1980 to 2017. No restriction was set on the language of publication. 
Studies had to report RRs, ORs, or sufficient data to calculate RRs (i.e. exposed/non-exposed cases/non-
cases). 
Meta-analysis 
The smaller number of estimates for anxiety disorders (n = 6) led to the decision to combine the major 
depressive disorder and anxiety disorders RR data into a single dataset. This was considered reasonable 
as the pooled RRs for major depressive disorder and anxiety disorders were effectively equal following 
an adjustment for low frequency bullying threshold studies (1.82, 95% CI: 1.62-2.04 vs 1.74, 95% CI: 
1.43-2.11, respectively).  
Meta-analysis of bullying victimisation and major depressive disorder/anxiety disorders 
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Meta-regression 
A meta-regression was conducted to determine the impact of follow-up time on the relationship 
between bullying victimisation and major depressive disorder/anxiety disorders. 
Prior to this, an initial meta-regression revealed studies with a low bullying frequency threshold 
reported significantly lower RRs than studies utilising the optimal threshold. Six studies reported RRs for 
both low and optimal bullying frequency threshold and we determined that the within-study ratios from 
these studies would better inform an adjustment than between-study comparisons estimated as a 
covariate. These ratios were pooled and then applied to the low bullying frequency threshold estimates 
(i.e. suboptimal estimates) prior to analysis. This process could not be done for the other characteristics 
(i.e. symptoms vs diagnosis or no control vs control for outcome as baseline) as there were no within-
study comparisons available. In the final meta-regression, these were instead controlled for using 
covariates. 
In the final meta-regression, estimates with a follow-up time of 25 years or more were excluded due to 
only data from a single cohort being available to inform the effect of follow-up time after this period. In 
total, 19 studies were included in the analyses.2-20 While the meta-regression demonstrated a waning 
effect of time, this was not statistically significant (p = 0.093). However, the model still predicted 
plausible estimates of RR over time that matched our strong prior that the effect size would have to 
diminish over time. Time was also significant in a parsimonious model that did not include the non-
significant covariates (p = 0.042).  
PAF calculations 
For bullying victimisation, the PAF calculations could not be determined by current prevalence and a 
single value for RR. This is due to the waning effect on outcomes over time (as demonstrated in the 
meta-regression) and because prevalence estimates were from surveys of young people reporting 
current bullying victimisation rather than estimates of past exposure at the time the outcomes occur 
(i.e. retrospective estimates). 
A cohort method was subsequently developed to address this issue. The following steps are conducted 
for each point of estimation (i.e. by age, sex, location, and year), hereafter referred to as a ‘cohort’: 
1. Pull current and past bullying victimisation prevalence for the cohort from the DisMod-MR 2.1
exposure model.
2. Adjust each bullying victimisation prevalence estimate for the proportion of  the cohort
attending school in that year.
3. Divide the cohort into proportions based on time since first exposed to bullying victimisation.
This equates to the incidence of bullying victimisation and is estimated using the following
formula:




where I represents incidence, P represents prevalence, r represents the estimate of persistence, and k represents the 
time between the incidence estimate and the earliest possible time of exposure in the cohort. Ik  requires I0 through 
to Ik-1 to first be calculated and so we complete this process by first estimating I0, then I1, and so on until we have 
estimated incidence for the latest possible year of exposure for this cohort. The persistence estimate is based on a 
separate meta-regression of seven studies.11,21-26 
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4. We Map RRs to the proportions of the cohort based on the time between the point of
estimation and when they were first exposed to bullying victimisation and estimate PAFs via the
following formula:
 𝑷𝑷𝑷𝑷𝑷𝑷 =  
∑(𝒑𝒑𝒕𝒕 × 𝑹𝑹𝑹𝑹𝒕𝒕) +  ∑𝒑𝒑𝒏𝒏𝒏𝒏 𝒆𝒆𝒆𝒆𝒑𝒑𝒏𝒏𝒆𝒆𝒆𝒆𝒓𝒓𝒆𝒆 − 𝟏𝟏
∑(𝒑𝒑𝒕𝒕 × 𝑹𝑹𝑹𝑹𝒕𝒕) + ∑𝒑𝒑𝒏𝒏𝒏𝒏 𝒆𝒆𝒆𝒆𝒑𝒑𝒏𝒏𝒆𝒆𝒆𝒆𝒓𝒓𝒆𝒆
where t is the time since first exposed to bullying victimisation, p is the proportion of the cohort first exposed to 
bullying victimisation at time t or the proportion not exposed to bullying victimisation, and RR is the relative risk for 
depressive and anxiety disorders given t.  
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Input data & methodological summary 
Case definition and summary of GBD approach 
Unsafe sex is defined as the risk of disease due to sexual transmission. The outcomes associated with 
unsafe sex that we estimate for GBD include HIV, cervical cancer, and all sexually transmitted diseases 
(STDs) except for those in neonates from vertical transmission, including HIV, opthalmia neonatorum 
and neonatal syphilis. We assume 100% of cervical cancer and STDs are attributable to unsafe sex and 
model the proportion of HIV incidence occurring through sexual transmission to estimate the 
attributable burden for HIV due to unsafe sex. 
Input data 
To be used in our models, sources must report HIV cases attributable to various modes of transmission. 
We screened all UNAIDS country progress reports and searched government epidemiological 
surveillance records for these data. The primary data sources we used were UNAIDS, the European CDC, 
and the US CDC.  
We excluded all extractions where the “other” category for HIV transmissions accounted for greater 
than 25 percent of all cases. We believe that such high proportions raise concerns about the quality of 
reporting.  
Modelling strategy  
We model the proportion of HIV cases attributable to unsafe sex. To do this we collect and clean data, 
run three DisMod models (HIV attributable to sex, HIV attributable to injection drug use, HIV 
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attributable to other routes of transmission), adjust results of the three DisMod models to sum to one, 
and prepare PAFs. 
All of the DisMod models included a study-level covariate fixed effect on integrand variance (z-cov) for 
sources that include cases of unknown transmission in their “other” category. We assumed that the 
inclusion of unknown cases in the other category would impact the uncertainty around the point 
estimates. No country level covariates were included in the models. We tested an injection drug use 
covariate, an opioid use covariate in the proportion HIV due to drug use model, but found no significant 
coefficients so excluded them from the final model. 
A new approach was introduced for GBD 2016, and used again for GBD 2017, to inform an age-pattern 
in these HIV transmission models. All-age data points represent the majority of the available data, so we 
derived an age-pattern for the HIV-IDU transmission model from the age-pattern present in the GBD 
2017 population attributable fraction for hepatitis B attributable to intravenous drug use. Assuming the 
proportion of HIV due to other is constant over time, the age-pattern for the proportion of HIV due to 
sex was set to be the complement to 1 of the age-pattern for the proportion of HIV due to IDU. The all-
age data were split according to these age-patterns, and the three HIV transmission DisMod models 
were run on the age-split data. Additional priors were set to inform an age-pattern: zero proportion HIV 
transmission due to IDU before age 15, zero proportion HIV transmission due to sex before age 10, and 
100% transmission due to other before age 10. The results from these HIV transmission models were 
adjusted to sum to 100% for a given country-year-age-sex group at each of 1,000 draws. 
Squeezed global HIV transmission models by age (females, 2016): 
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Theoretical minimum-risk exposure level 
The theoretical minimum level used for unsafe sex is the absence of disease transmission due to sexual 
contact.  
Population attributable fraction calculations 
The outcomes associated with unsafe sex that we report on include HIV, cervical cancer, and all sexually 
transmitted diseases (STDs) except for those in neonates from vertical transmission, including HIV, 
opthalmia neonatorum and neonatal syphilis.  
Based on evidence in the literature, we attribute 100% of cervical cancer to unsafe sex. These sources 
state that HPV infection is necessary for cervical cancer to develop and that HPV is only spread through 
sexual contact. The proportion of STDs attributable to unsafe sex is also 100%.  
For HIV, the results from the single parameter proportion DisMod model for HIV transmission due to sex 
were used directly as the population attributable fraction.  
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Input data and methodological summary 
Exposure 
Case definition 
We measure physical activity performed by adults greater than or equal to 25 years of age, for durations 
of at least ten minutes at a time, across all domains of life (leisure/recreation, work/household and 
transport). We use frequency, duration and intensity of activity to calculate total metabolic equivalent-
minutes per week.  MET (Metabolic Equivalent) is the ratio of the working metabolic rate to the resting 
metabolic rate.  One MET is equivalent to 1 kcal/kg/hour and is equal to the energy cost of sitting quietly.  
A MET is also defined as the oxygen uptake in ml/kg/min with one MET equal to the oxygen cost of sitting 
quietly, around 3.5 ml/kl/min. 
Input data 
We included surveys of the general adult population that captured self-reported physical activity in all 
domains of life (leisure/recreation, work/household and transport), where random sampling was used. 
Data were primarily derived from two standardised questionnaires: The Global Physical Activity 
Questionnaire (GPAQ) and the International Physical Activity Questionnaire (IPAQ), although we included 
other survey instruments that asked about intensity, frequency and duration of physical activities 
performed across all activity domains.   
Due to a lack of a consistent relationship on the individual level between activity performed in each 
domain and total activity, we were not able to use studies that included only recreational/leisure 
activities.  
Physical activity level is categorised by total MET-minutes per week using four categories based on 
rounded values closest to the quartiles of the global distribution of total MET-minutes/week.  The lower 
limit for the Level 1 category (600 MET-min/week) is the recommended minimum amount of physical 
activity to get any health benefit. We used four categories with higher thresholds rather than the GPAQ 
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and IPAQ recommended 3 categories to better capture any additional protective effects from higher 
activity levels.   
• Level 0: < 600 MET-min/week (inactive)
• Level 1: 600-3999 MET-min/week (low-active)
• Level 2: 4000-7,999  MET-min/week (moderately-active)
• Level 3: ≥ 8,000 MET-min/week (highly active)
The GHDx was used to locate all surveys that use the GPAQ or IPAQ questionnaire. Although there were 
many other surveys that focused specifically on leisure activity, we were unable to use these sources 
because they did not comprise all three domains (work, transport and leisure). In addition, we excluded 
any surveys that did not report frequency, duration, and intensity of activity.  
Modelling strategy  
DisMod modelling  
For this round of the GBD, we have chosen to separately model all of the GPAQ data separately from the 
IPAQ data. We then estimated the proportion of each country/year/age/sex subpopulation in each of the 
above four activity levels using 12 separate Dismod models (one for each data source). We use six 
categories of physical activity prevalence rather than four to accommodate the different MET-
minute/week cutoffs presented in tabulated data sources where individual unit record data was not 
available. Since the accepted threshold/definition for inactivity is consistently <600 MET-minutes/week, 
the vast majority of tabulated data was broken down into proportion inactive (model A) and proportion 
low, moderate or highly active (model B). 
Label MET-min/week Name of sequelae in online visualisation tool 
A inactive <600 Physical inactivity and low physical activity, inactive 
B low/moderately/highly 
active 
≥600 Physical inactivity and low physical activity, 
low/moderately/highly active 
C low active 600-3999 Physical inactivity and low physical activity, low active 
D moderately/highly 
active 
>4000 Physical inactivity and low physical activity, 
moderately/highly active 
E moderately active 4000-7999 Physical inactivity and low physical activity, 
moderately active 
F highly active ≥8,000 Physical inactivity and low physical activity, highly 
active 
These models have mesh points at 0 15 25 35 45 55 65 75 85 100, and a study-level fixed effect on 
integrand variance (Z-cov) for whether a study was nationally representative or not, to account for the 
heterogeneity introduced boy studies that are not generalizable to the entire population.  They also have 
national level fixed effects on prevalence of obesity.  
After DisMod, we rescale each of the 6 models specific to each data source so that the proportions sum 
to one. Since we have the most data for models A and B, we rescale the sum of the proportion in each 
category to be equal to one.  Next we rescale the sum of model C and D to be equal to the rescaled value 
from model B. Then we rescale the sum of models E and F to be equal to the rescaled value from model 
D. After these three rescales we are left with a proportion for each of the four categories that all sum to
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1. Scaled results for each data source are then hybridised to produce only one set of results for the
prevalence of the four categories of physical activity.
Similar to the previous round, we have directly estimated total MET-minutes per week globally. Although, 
this year we made use of two specific machine learning algorithms (Random Forest & XGBoost) that were 
trained using data that could characterise the relationship between total MET-mins/week and each of the 
categorical prevalences of physical activity. This resulted in country-year-age-sex specific estimates of 
total physical activity in the form of MET-minutes per week.  
Utilising microdata on total MET-mins per week from individual-level surveys, we characterised the 
distribution of activity level at the population level. We then used an ensemble approach to distribution 
fitting, borrowing characteristics from individual distributions to tailor a unique distribution to fit the data 
using a weighting scheme. We characterised the standard deviation of each population’s activity through 
a linear regression that captured the relationship between standard deviation and mean activity levels in 
nationally representative IPAQ surveys: 
𝑙𝑙𝑙𝑙 (𝑆𝑆𝑆𝑆𝑆𝑆𝑙𝑙𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 𝑆𝑆𝑑𝑑𝑑𝑑𝑑𝑑𝑆𝑆𝑆𝑆𝑑𝑑𝑑𝑑𝑙𝑙)  =  𝛽𝛽0  + 𝛽𝛽1  ×  𝑙𝑙𝑙𝑙 (𝑀𝑀𝑑𝑑𝑆𝑆𝑙𝑙𝑖𝑖) 
We then applied the coefficients of this regression to the outputs of our estimate of total MET-minutes 
per week regression outputs to calculate the standard deviation by country, year, age, and sex. 
Theoretical minimum-risk exposure level 
The theoretical minimum-risk exposure level for physical inactivity is 3000-4500 MET-min per week, 
which was calculated as the exposure at which minimal deaths across outcomes occurred.3  
Relative risks 
We used a recently published dose-response meta-analysis of prospective cohort studies to estimate the 
effect size of the change in physical activity level on breast cancer, colon cancer, diabetes, ischemic heart 
disease and ischemic stroke.3 
References 
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2005;17:2008.
2. World Health Organization. Global Physical Activity Questionnaire (GPAQ) Analysis Guide. 2011.
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Case definition 
High fasting plasma glucose (FPG) is measured as the mean FPG in a population, where FPG is a 
continuous exposure in units of mmol/L. 
Data seeking 
Exposure 
We did not conduct a systematic review for FPG in GBD 2017. However, we included data sources found 
in the systematic review for diabetes. Please see the diabetes mellitus appendix in Global, regional, and 
national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 
countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 for more 
information on data sources found through those efforts. 
Data inputs 
Data inputs come from 3 sources: 
• Estimates of mean FPG in a representative population
• Individual-level data of fasting plasma glucose measured from surveys
• Estimates of diabetes prevalence in a representative population
Data sources that did not report mean FPG or prevalence of diabetes are excluded from analysis. When 
a study reported both mean fasting plasma glucose (FPG) and prevalence of diabetes, we use the mean 
FPG for exposure estimates. Where possible, individual-level data supersede any data described in a 
study. Individual-level data are aggregated to produce estimates for each 5-year age group, sex, 
location, and year of a survey. 
Data processing  
We perform several processing steps to the data in order to address sampling and measurement 
inconsistencies that will ensure the data are comparable. 
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1. Small sample size
Estimates in a sex and age group with a sample size <30 persons is considered a small sample
size. In order to avoid small sample size problems that may bias estimates, data are collapsed
into the next age group in the same study till the sample size reach at least 30 persons. The
intent of collapsing the data is to preserve as much granularity between age groups as possible.
If the entire study sample consists of <30 persons and did not include a population-weight, the
study is excluded from the modelling process.
2. Time, Age, and Sex Splitting
For more details on how datapoints on mean FPG was processed, please see the diabetes
mellitus appendix in Global, regional, and national incidence, prevalence, and years lived with
disability for 354 diseases and injuries for 195 countries, 1990–2017: a systematic analysis for
the Global Burden of Disease Study 2017.
3. Crosswalks
We predicted mean FPG from diabetes prevalence using an ensemble distribution. We
characterized the distribution of FPG using individual-level data. Details on the ensemble
distribution can be found elsewhere in the Appendix. Before predicting mean FPG from
prevalence of diabetes, we ensured that the prevalence of diabetes was based on the reference
case definition: fasting plasma glucose (FPG) >126 mg/dL (7 mmol/L) or on treatment. For more
details on how the case-definition crosswalk is conducted, please see the diabetes mellitus
appendix in Global, regional, and national incidence, prevalence, and years lived with disability
for 354 diseases and injuries for 195 countries, 1990–2017: a systematic analysis for the Global
Burden of Disease Study 2017.
Exposure modelling 
Exposure estimates are produced for every year between 1980 to 2017 for each national and 
subnational location, sex, and for each 5-year age group starting from 25 years. As in GBD 2016, we used 
a Spatio-Temporal Gaussian Process Regression (ST-GPR) framework to model the mean fasting plasma 
glucose at the location-, year-, age-, and sex- level. Updates to the ST-GR modelling framework for GBD 
2017 are detailed elsewhere in the Appendix.  
Fasting plasma glucose is frequently tested or reported in surveys aiming at assessing the prevalence of 
diabetes mellitus. In these surveys, the case definition of diabetes may include both a glucose test and 
questions about treatment for diabetes. People with positive history of diabetes treatment may be 
excluded from the FPG test. Thus, the mean FPG in these surveys would not represent the mean FPG in 
the entire population. To address this limitation, using the data from the surveys reporting mean FPG in 
the entire population, we estimated a regression-based correction factor and adjusted the mean FPG to 
account for diabetics in the population. We also use an ensemble distribution to characterize the 
distribution of FPG in the population and estimate the standard deviation based on mean FPG and 
prevalence of diabetics from the non-fatal diabetes mellitus model. 
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To inform our estimates in data-sparse countries, we systematically tested a range of covariates and 
selected two covariates based on AIC and adjusted R2. These included prevalence of obesity and lag-
distributed income per capita (LDI). 
Mean FPG iss estimated using a mixed-effects linear regression, run separately by sex: 
logit�FPGc,a,t� =  β0 + β1log (LDI)c,t+ β2poverweightc,a,t + �βkIA[a]
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k=2
+ αs + αr + αc + ϵc,a,t
where log (LDI)c,t is the log of the lag-distributed income, poverweightc,a,t is the prevalence of 
overweight, IA[a] is an indicator variable for a fixed effect on a given 5-year age group, and αs αr αc are 
random effects at the super-region, region, and country level, respectively. The estimates were then 
propagated through the ST-GPR framework to obtain 1000 draws for each location, year, age, and sex.  
Theoretical minimum-risk exposure level 
The theoretical minimum-risk exposure level (TMREL) for FPG is 4.5-5.4 mmol/L. This was calculated by 
taking the person-year weighted average of the levels of FPG that were associated with the lowest risk 
of mortality in the pooled analyses of prospective cohort studies.1   
Relative risks 
We estimate 15 outcomes due to high fasting plasma glucose (continuous risk) or diabetes (categorical 
risk). 
Risk Outcome 
Fasting plasma glucose Ischemic heart disease 
Fasting plasma glucose Ischemic stroke 
Fasting plasma glucose Subarachnoid hemorrhage 
Fasting plasma glucose Intracerebral hemorrhage 
Fasting plasma glucose Peripheral vascular disease 
Fasting plasma glucose Type 1 diabetes 
Fasting plasma glucose Type 2 diabetes 
Diabetes mellitus Drug-resistant tuberculosis 
Diabetes mellitus Drug-susceptible tuberculosis 
Diabetes mellitus Multidrug-resistant tuberculosis 
without extensive drug resistance 
Diabetes mellitus Extensively drug-resistant 
tuberculosis 
Diabetes mellitus Liver cancer due to NASH 
Diabetes mellitus Liver cancer due to other causes 
Diabetes mellitus Pancreatic cancer 
Diabetes mellitus Ovarian cancer 
Diabetes mellitus Colorectal cancer 
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Diabetes mellitus Bladder cancer 
Diabetes mellitus Lung cancer 
Diabetes mellitus Breast cancer 
Diabetes mellitus Glaucoma 
Diabetes mellitus Cataracts 
Diabetes mellitus Dementia 
Relative risks for High Fasting Plasma Glucose (continuous risk) 
In GBD 2017, diabetes was further split into diabetes type 1 and diabetes type 2, and hemorrhagic 
stroke was further split into subarachnoid hemorrhage and intracerebral hemorrhage. 
Relative risks (RR) were obtained from dose-response meta-analysis of prospective cohort studies. 
Please see the citation list for a full list of studies that are utilized. For cardiovascular outcomes, we 
estimated age-specific RRs using DisMod-MR 2.1 with log (RR) as the dependent variable and median 
age at event as the independent variable with an intercept at age 110. Morbidity and mortality directly 
caused by diabetes type 1 and diabetes type 2 is considered directly attributable to FPG.  
Relative risks for Diabetes mellitus (Categorical risk) 
Relative risks were obtained from meta-analysis of cohort studies. Please see the citation list for a full 
list of studies that are utilized. 
References 
1 . Singh GM, Danaei G, Farzadfar F, et al. The age-specific quantitative effects of metabolic risk factors 
on cardiovascular diseases and diabetes: a pooled analysis. PloS One 2013; 8: e65174. 
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High LDL Cholesterol Capstone Appendix 
Flowchart 
Input Data & Methodological Summary 
Exposure 
Case Definition 
In the GBD 2016 study, we estimated burden attributable to total cholesterol. For GBD 2017, we 
modelled blood concentration of low-density lipoprotein (LDL) in units of mmol/L. 
Input Data 
We utilized data on blood low-density lipoprotein from literature and from household survey microdata 
and reports. Please see the appendix for a full list of included sources. For the GBD 2016 study, we 
carried out an updated systematic review for total cholesterol (TC), drawing from the GHDx and Medline 
via PubMed. For GBD 2017, we reviewed all data sources in our database that reported data on total 
cholesterol and re-extracted LDL data when it was available. Data on high-density lipoprotein (HDL) and 
triglycerides (TGL) were also extracted when available. 
Inclusion Criteria  
Studies were included if they were population-based and measured total low-density lipoprotein using a 
blood test or calculated using the Friedewald equation.  We assumed the data is representative of the 
location if the geography was not related to the diseases and if it is not an outlier compared to other 
data in the country or region. 
Outliers 
Data was utilized in the modeling process unless an assessment of data strongly suggested that the data 
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was biased. A candidate source was excluded if the quality of study did not warrant a valid estimate 
because of selection (non-representative populations) or if the study did not provide methodological 
details for evaluation. In a small number of cases, data point was considered to be an outlier candidate if 
the level was implausibly low or high based on expert judgement and other country data. 
Data Extraction 
Where possible, individual level data on LDL estimates were extracted from survey microdata and these 
were collapsed across demographic groupings to produce mean estimates in the standard GBD 5-year 
age-sex groups. If microdata were unavailable, information from survey reports or from literature were 
extracted along with any available measure of uncertainty including standard error, uncertainty 
intervals, and sample size.  Standard deviations were also extracted. Where LDL was reported split out 
by groups other than age, sex, location, and year (eg, by diabetes status), a weighted mean was 
calculated. 
Lipid crosswalk 
Total cholesterol consists of three major components: LDL, HDL, and triglycerides. LDL is often calculated 
for an individual using the Friedewald equation, shown below: 




We utilized this relationship at the individual level to impute the mean LDL for a study population when 
only data on total cholesterol, HDL, and TGL were available. Because studies report different 
combinations of TC, HDL, and TGL, we constructed a single regression to utilize al available data to 
evaluate the relationship between each lipid and LDL at the population level. We used the following 
regression:  
𝐿𝐿𝐷𝐷𝐿𝐿 = 𝑖𝑖𝑖𝑖𝑑𝑑𝑡𝑡𝑡𝑡𝛽𝛽1𝑇𝑇𝑇𝑇 − �𝑖𝑖𝑖𝑖𝑑𝑑ℎ𝑑𝑑𝑑𝑑𝛽𝛽2𝐻𝐻𝐷𝐷𝐿𝐿 + 𝑖𝑖𝑖𝑖𝑑𝑑𝑡𝑡𝑡𝑡𝑑𝑑𝛽𝛽3𝑇𝑇𝑇𝑇𝐿𝐿� + �𝛼𝛼𝑑𝑑𝐼𝐼𝑑𝑑 
Where 𝑖𝑖𝑖𝑖𝑑𝑑𝑡𝑡𝑡𝑡 ,  𝑖𝑖𝑖𝑖𝑑𝑑ℎ𝑑𝑑𝑑𝑑 , and 𝑖𝑖𝑖𝑖𝑑𝑑𝑡𝑡𝑡𝑡𝑑𝑑 are indicator variables for whether data is available for a given lipid, 𝐼𝐼𝑑𝑑 
is an indicator variable a given set of available lipids 𝑙𝑙. 𝛼𝛼𝑑𝑑  is a unique intercept for each set of available 
lipids. For example, for sources that only reported TC and HDL, 𝛼𝛼𝑑𝑑=𝑇𝑇𝑇𝑇,𝐻𝐻𝐻𝐻𝐻𝐻 should account for the missing 
lipid data, ie, TGL. The form of this regression allows us to estimate the betas for each lipid using all 
available data. As a sensitivity analysis, we also ran separate regressions for each set of available lipids 
and found that the single regression method had much lower root-mean squared error. A comparison of 
the observed vs predicted LDL for each set of available lipids is shown in Figure 1. We found almost no 
relationship between LDL and HDL or TGL when TC was not available, so only studies that reported TC 
were crosswalked to LDL. 
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Figure 1.  Results of the lipid crosswalk using a single regression method 
Incorporating United States prevalence data 
Survey reports and literature often report information only about the prevalence, but not the level, of 
hypercholesterolemia in the population studied.  These sources were not used to model LDL, with the 
exception of data from the Behavioral Risk Factors Surveillance System (BRFSS) because of the 
availability of a similarly structured exam survey covering the identical population (NHANES).  BRFSS is a 
telephone survey conducted in the United States for all counties.  It collects self-reported diagnosis of 
hypercholesterolemia.  These self-reported values of prevalence of raised total cholesterol in each age 
group, sex, US state, and year were used to predict a mean total cholesterol for the same strata with a 
regression using data from the National Health and Nutrition Examination Survey, a nationally 
representative health examination survey of the US adult population. The regression was: 
TCl,a,t,s =  β0 + β1prevl,a,t,s 
where TCl,a,t,s is the location, age, time, and sex specific mean total cholesterol and prevl,a,t,s is 
the location, age, time, and sex specific prevalence of raised total cholesterol.  The coefficients 
for both models are reported in Table 1.   
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Table 2.  Coefficients in the sex-specific US states TC prediction models 
Term Male model Female model 
Intercept 4.23 4.36 
Prevalence 6.25 5.22 
Out of sample RMSE was used to quantify the predictive validity of the model. The regression was 
repeated 10 times for each sex, each time randomly holding out 20% of the data. The RMSEs from each 
holdout analysis were averaged to get the average out of sample RMSE. The results of this holdout 
analysis are reported in Table 2. Total cholesterol estimates were crosswalked to LDL using the lipid 
crosswalk reported above.  
Table 3. Out of sample RMSEs of the sex-specific US states TC prediction models 
Male model Female model 
Out of sample RMSE 0.21 mmol/L 0.20 mmol/L 
Age and Sex Splitting 
Prior to modeling, data provided in age groups wider than the GBD 5-year age groups were processed 
using the approach outlined in Ng et al.2 Briefly, age-sex patterns were identified using person-level 
microdata (58 sources), and estimate age-sex specific levels of total cholesterol from aggregated results 
reported in published literature or survey reports. In order to incorporate uncertainty into this process 
and borrow strength across age groups when constructing the age-sex pattern, we used a model with 
auto-regression on the change in mean LDL over age groups: 
𝜇𝜇𝑎𝑎 = 𝜇𝜇𝑎𝑎−1 + 𝜔𝜔𝑎𝑎 
𝜔𝜔𝑎𝑎~𝑁𝑁(𝜔𝜔𝑎𝑎−1, 𝜏𝜏) 
Where 𝜇𝜇𝑎𝑎 is the mean predicted value for age group a, 𝜇𝜇𝑎𝑎−1 is the mean predicted value for the age 
group previous to age group a,   𝜔𝜔𝑎𝑎 is the difference in mean between age group a and age group a-1, 
𝜔𝜔𝑎𝑎−1 is the difference between age group a-1 and age group a-2, and 𝜏𝜏 is a user-input prior on how 
quickly the mean LDL changes for each unit increase in age. We used a 𝜏𝜏 of 0.09 mmol/L for this model. 
Draws of the age-sex pattern were combined with draws of the input data needing to be split in order to 
calculate the new variance of age-sex split data points. 
Modeling 
Exposure estimates were produced from 1980 to 2017 for each national and subnational location, sex, 
and for each 5-year age group starting from 25+. As in GBD 2016, we used a Spatio-Temporal Gaussian 
Process Regression (ST-GPR) framework to model the mean LDL at the location-, year-, age-, sex- level. 
Updates to the ST-GR modeling framework for GBD 2017 are detailed in the appendix.  
Covariate selection 
The first step of the ST-GPR framework requires the creation of a linear model for predicting LDL the 
location-, year-, age-, sex- level.  Covariates for this model were selected in two stages. First a list of 
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variables with an expected causal relationship with LDL was created based on significant association 
found within high-quality prospective cohort studies reported in the published scientific literature.  The 
second stage in covariate selection was to test the predictive validity of every possible combination of 
covariates in the linear model, given the covariates selected above.  This was done separately for each 
sex.  Predictive validity was measured with out of sample root-mean-squared error.  
In GBD 2016, the linear model with the lowest root-mean squared error for each sex was then used in 
the ST-GPR model. In GBD 2017, we used an ensemble model of the 50 models with the lowest root-
mean squared error for each sex. This allows us to utilize covariate information from many plausible 
linear mixed-effects models. The 50 models were each used to predict the mean LDL for every age, sex, 
location, and year, and the inverse-RMSE-weighted average of this set of 50 predictions was used as the 
linear prior. The relative weight in ‘draws’ contributed by each covariate is plotted by sex in Figure 2. 
Figure 2.  Results of the ensemble linear model covariate selection 
Methodological updates to ST-GPR are reported above. The result of the ST-GPR model are estimates of 
the mean LDL for each age, sex, location, and year. 
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Estimate of standard deviation 
The standard deviation of LDL within a population was estimated for each national and 
subnational location, sex, and 5-year age group starting from age 25 using the standard 
deviation from person-level and some tabulated data sources.  Person-level microdata 
accounted for 3009 of the total 4001 rows of data on standard deviation.  The remaining 992 
rows came from tabulated data.  Tabulated data was only used to model standard deviation if it 
was sex and 5-year age group specific and reported a population standard deviation LDL.  The 
LDL standard deviation function was estimated using a linear regression: 




where mean_LDLc,a,t,s is the country, age, time, and sex specific mean LDL estimate from ST-GPR, and 
IA[a] is a dummy variable for a fixed effect on a given 5-year age group,. 
Distribution shape modelling 
The shape of the distribution of LDL was estimated using all available person-level microdata sources, 
which was a subset of the input data into the modelling process.  The distribution shape modelling 
framework for GBD 2017 is detailed in the appendix.  Briefly, an ensemble distribution created from a 
weighted average of distribution families was fit for each individual microdata source, separately by sex. 
The weights for the distribution families for each individual source were then averaged and weighted to 
create a global ensemble distribution for each sex. 
Theoretical minimum-risk exposure level 
A Meta-analysis of randomized trials has shown that outcomes can be improved even at low levels of 
LDL-cholesterol, below 1.3 mmol/l.3 Recent studies of PCSK-9 inhibitors support these results.4 We 
therefore used a TMREL with a uniform distribution between 0.7-1.3 mmol/l. 
Relative risks 
After a systematic search, we were unable to find relative risks for LDL that were reported by age and 
level of LDL. Given this evidence that the relative risks for LDL and TC are very similar5 and the strong 
linear correlation between TC and LDL at the individual level, we used relative risks reported for TC to 
approximate the relative risks for LDL. We used Dismod-MR 2.1 to pool effect sizes from included 
studies and generate a dose-response curve for each of the outcomes associated with LDL. The tool 
enabled us to incorporate random effects across studies and include data with different age ranges. RRs 
were used universally for all countries and produce RRs with uncertainty and covariance across ages, 
taking into account the uncertainty of the data points. As in GBD 2016, RRs for IHD and ischemic stroke 
are obtained from meta-regressions of pooled epidemiological studies: the Asia Pacific Cohort Studies 
Collaboration (APCSC) and the Prospective Studies Collaboration (PSC).6   RRs for IHD were modeled with 
log (RR) as the dependent variable and median age at event as the independent variable with an age 
intercept (RR equals 1) at age 110. For LDL and ischemic stroke, a similar approach was used, except 
that there was no age intercept at age 110, due to the fact that there was no statistically significant 
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relationship between LDL and stroke after age 70 with a mean RR less than one. We assumed that there 
is not a protective effect of LDL and therefore did not include an RR for ages 80+.  
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High Systolic Blood Pressure Capstone Appendix 
Flowchart 
Input Data & Methodological Summary 
Exposure 
Case Definition 
Brachial systolic blood pressure in mmHg. 
Input Data 
We utilised data on mean systolic blood pressure from literature and from household survey microdata 
and reports (e.g. STEPS, NHANES). Please see the appendix for a full list of included sources. For GBD 
2017, we did not carry out a systematic review of the literature for new data. In total, we have utilised 
934 sources corresponding to 49,690 unique data points. 
Inclusion Criteria 
Studies were included if they were population-based and measured systolic blood pressure using a 
blood test.  We assumed the data is representative of the location if the geography was not selected 
because it was related to the diseases. 
Outliers 
Data was utilised in the modelling process unless an assessment of data strongly suggested that the data 
was biased. A candidate source was excluded if the quality of study did not warrant a valid estimate 
because of selection (non-representative populations) or if the study did not provide methodological 
details for evaluation. In a small number of cases, a data point was considered to be an outlier candidate 
if the level was implausibly low or high based on expert judgement and data from other country data. 
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Data Extraction 
Where possible, individual level data on blood pressure estimates were extracted from survey microdata 
and these were collapsed across individuals and collapsed across demographic groupings to produce 
mean estimates in the standard GBD 5-year age-sex groups. If microdata were unavailable, information 
from survey reports or from literature were extracted along with any available measure of uncertainty 
including standard error, uncertainty intervals, and sample size.  Standard deviations were also 
extracted. Where mean systolic blood pressure was reported split out by groups other than age, sex, 
location, and year (eg, by hypertensive status), a weighted mean was calculated. 
Incorporating United States prevalence data 
Survey reports and literature often report information only about the prevalence, but not the level, of 
hypertension in the population studied.  These sources were not used to model systolic blood pressure, 
with the exception of data from the Behavioral Risk Factors Surveillance System (BRFSS) because of the 
availability of a similarly structured exam survey that is representative of the same population 
(NHANES).  BRFSS is a telephone survey conducted in the United States for all US counties.  It collects 
self-reported diagnosis of hypertension.  These self-reported values of prevalence of raised blood 
pressure were adjusted for self-report bias and tabulated by age group, sex, US state, and year. These 
prevalences were used to predict a mean systolic blood pressure for the same strata with a regression  
using data from the National Health and Nutrition Examination Survey, a nationally representative 
health examination survey of the US adult population.  The regression was run separately by sex, and 
was specified as: 
SBPl,a,t,s =  β0 + β1prevl,a,t,s 
where SBPl,a,t,s is the location, age, time, and sex specific mean systolic blood pressure and prevl,a,t,s is 
the location, age, time, and sex specific prevalence of raised blood pressure.  The coefficients for both 
models are reported in Table 1.   
Table 1.  Coefficients in the sex-specific US states blood pressure prediction models 
Term Male model Female model 
Intercept (𝛽𝛽0) 114.65 108.28 
Prevalence (𝛽𝛽1) 51.86 68.87 
Out of sample RMSE was used to quantify the predictive validity of the model. The regression was 
repeated 10 times for each sex, each time randomly holding out 20% of the data. The RMSEs from each 
holdout analysis were averaged to get the average out of sample RMSE. The results of this holdout 
analysis are reported in Table 2. 
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Table 2. Out of sample RMSEs of the sex-specific US states blood pressure prediction models 
Male model Female model 
Out of sample RMSE 2.37 mmHg 3.27 mmHg 
Age and Sex Splitting 
Prior to modelling, data provided in age groups wider than the GBD 5-year age groups were processed 
using the approach outlined in Ng et al.2 Briefly, an age-sex pattern were identified using 115 sources of 
microdata with multiple age-sex groups, and these patterns were applied to estimate age-sex specific 
levels of mean systolic blood pressure from aggregated results reported in published literature or survey 
reports. In order to incorporate uncertainty into this process and borrow strength across age groups 
when constructing the age-sex pattern, we used a model with auto-regression on the change in mean 
SBP over age groups: 
𝜇𝜇𝑎𝑎 = 𝜇𝜇𝑎𝑎−1 + 𝜔𝜔𝑎𝑎 
𝜔𝜔𝑎𝑎~𝑁𝑁(𝜔𝜔𝑎𝑎−1, 𝜏𝜏) 
Where 𝜇𝜇𝑎𝑎 is the mean predicted value for age group a, 𝜇𝜇𝑎𝑎−1 is the mean predicted value for the age 
group previous to age group a,   𝜔𝜔𝑎𝑎 is the difference in mean between age group a and age group a-1, 
𝜔𝜔𝑎𝑎−1 is the difference between age group a-1 and age group a-2, and 𝜏𝜏 is a user-input prior on how 
quickly the mean SBP changes for each unit increase in age. We used a 𝜏𝜏 of 1.5 mmHg for this model. 
Draws of the age-sex pattern were combined with draws of the input data needing to be split in order to 
calculate the new variance of age-sex split data points. 
Modelling 
Exposure estimates were produced from 1980 to 2016 for each national and subnational location, sex, 
and for each 5-year age group starting from 25+. As in GBD 2016, we used a Spatio-Temporal Gaussian 
Process Regression (ST-GPR) framework to model the mean systolic blood pressure at the location-, 
year-, age-, sex- level. 
Covariate selection 
The first step of the ST-GPR framework requires the creation of a linear model for predicting SBP at the 
location-, year-, age-, sex- level.  Covariates for this model were selected in two stages. First a list of 
variables with an expected causal relationship with SBP was created based on significant association 
found within high-quality prospective cohort studies reported in the published scientific literature.  The 
second stage in covariate selection was to test the predictive validity of every possible combination of 
covariates in the linear model, given the covariates selected above.  This was done separately for each 
sex.  Predictive validity was measured with out of sample root-mean-squared error. 
In GBD 2016, the linear model with the lowest root-mean squared error for each sex was then used in 
the ST-GPR model. In GBD 2017, we used an ensemble model of the 50 models with the lowest root-
mean squared error for each sex. This allows us to utilise covariate information from many plausible 
linear mixed-effects models. The 50 models were each used to predict the mean SBP for every age, sex, 
location, and year, and the inverse-RMSE-weighted average of this set of 50 predictions was used as the 
linear prior. The relative weight in ‘draws’ contributed by each covariate is plotted by sex in Figure 2. 
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Figure 2.  Results of the ensemble linear model covariate selection 
The results of the ensemble linear model were used for the first stage in an ST-GPR model. 
Methodological updates to ST-GPR are reported above. The result of the ST-GPR model are estimates of 
the mean SBP for each age, sex, location, and year. 
Estimate of Standard Deviation  
Currently, the ST-GPR model only produces an estimate of mean exposure level without standard 
deviation. Therefore, the standard deviation of systolic blood pressure within a population was 
estimated for each national and subnational location, sex, and 5-year age group starting from age 25 
using the standard deviation from person-level and some tabulated data sources.  Person-level 
microdata accounted for 10375 of the total 12570 rows of data on standard deviation.  The remaining 
2195 rows came from tabulated data.  Tabulated data was only used to model standard deviation if it 
was sex and 5-year age group specific and reported a population standard deviation of systolic blood 
pressure.  The systolic blood pressure standard deviation function was estimated using a linear 
regression: 




where mean_SBPl,a,t,s is the location, age, time, and sex specific mean SBP estimate from ST-GPR, and IA 
is a dummy variable for a fixed effect on a given 5-year age group. 
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Adjustment for Usual Levels of Blood Pressure 
To account for in-person variation in systolic blood pressure, a ‘usual blood pressure’ adjustment was 
done.  The need for this adjustment has been described elsewhere.5 Briefly, measurements of a risk 
factor taken at a single time point may not accurately capture an individual’s true long-term exposure to 
that risk.  Blood pressure readings are highly variable over time due to measurement error as well as 
diurnal, seasonal, or biological variation.  These sources of variation result in an over-estimation of the 
variation in cross-sectional studies of the distribution of SBP. 
To adjust for this overestimation, we applied a correction factor to each location-, age-, time-, and sex-
specific standard deviation.  These correction factors were age-specific, and represented the proportion 
of the variation in blood pressure within a population that would be observed if there were no within-
person variation across time.  Four longitudinal surveys were used to estimate these factors: the China 
Health and Retirement Longitudinal Survey (CHRLS), the Indonesia Family Life Survey (IFLS), the National 
Health and Nutrition Examination Survey I Epidemiological Follow-up Study (NHANES I/EFS), and the 
South Africa National Income Dynamics Survey (NIDS).  The sample size and number of blood pressure 
measurements at each measurement period for each survey is reported in Table 5.   






CHRLS 2008 3 1967 
2012 3 1419 
IFLS 1997 1 19418 
2000 1 16626 
2007 3 14136 
NIDS 1997 2 14084 
2000 2 9612 
2007 2 9098 
NHANES I/EFS 1971-1976 2 20716 
1982-1984 3 9932 
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For each survey, the following regression was created for each age group: 
SBPi,a =  β0 + β1sex+β3age + +υi 
where SBPi,a is the systolic blood pressure of an individual i at age a, sex is a dummy variable for the sex 
of an individual, age is a continuous variable for the age of an individual, and υi is a random intercept for 
each individual.  Then, a blood pressure value SBP� i,b was predicted for each individual i for his/her age 
at baseline b.  The correction factor cf for each age group within each survey was calculated as variation 






The average of the correction factors was taken over the three surveys to get one set of age-specific 
correction factors, which were then multiplied by the square of the modelled standard deviations to 
estimate standard deviation of the ‘usual blood pressure’ of each age, sex, location, and year.  Because 
of low sample sizes, the correction factors for the 75-79 age group was used for all terminal age groups.  
The final correction factors for each age group are reported in Table 6. Figure 1 shows the correction 
factors by survey and age group ID. 
Table 4. Age-specific usual blood pressure correction factors 













Figure 1: Correction factor by survey and age group id.  The correction factor is equal to the variance of the predictions divided 
by the variance of the raw dataset. In pink  is the average correction factor for each age group, summarised in Table 6.
A visualisation of how the uncorrected blood pressure measurements overestimate the ‘usual’ blood 
pressure variation is shown in Figure 1.  This image shows the density of the distribution of the observed 
blood pressure values SBPi,b in participants in the Indonesian Family Life Study survey in red, and the 
density of the predicted blood pressure values SBP� i,b in blue.  The ratio of the variance of the blue 
distribution to the variance of the red distribution is an example of the scalar adjustment factor being 
applied to the modelled standard deviations. 
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Figure 2: Raw and predicted distributions of blood pressure in the Indonesia Family Life Survey
Estimating the exposure distribution shape 
The shape of the distribution of systolic blood pressure was estimated using all available person-level 
microdata sources, which was a subset of the input data into the modelling process.  The distribution 
shape modelling framework for GBD 2017 is detailed in the appendix.  Briefly, an ensemble distribution 
created from a weighted average of distribution families was fit for each individual microdata source, 
separately by sex. The weights for the distribution families for each individual source were then 
averaged and weighted to create a global ensemble distribution for each sex. 
Theoretical minimum-risk exposure level 
No changes were made to TMREL used in the GBD2015 study. We estimated that the TMREL of SBP 
ranges from 110 to 115 mm Hg based on pooled prospective cohort studies that show risk of mortality 
increases for SBP above that level.3,4 Our selection of a TMREL of 110-115 mmHg is consistent with the 
GBD study approach of estimating all attributable health loss that could be prevented even if current 
interventions do not exist that can achieve such a change in exposure level, for example a tobacco 
smoking prevalence of zero percent. To include the uncertainty in the TMREL, we took a random draw 
from the uniform distribution of the interval between 110 mm and 115 mm Hg each time the population 
attributable burden was calculated. 
- Distribution of unadjusted 
blood pressure measurements




No change was made to RR for blood pressure outcomes used in the GBD2016 study. RRs for chronic 
kidney disease are from the Renal Risk Collaboration meta-analysis of 2.7 million individuals in 106 
cohorts. For other outcomes, we used data from two pooled epidemiological studies: the Asia Pacific 
Cohort Studies Collaboration (APCSC) and the Prospective Studies Collaboration (PSC).4,5 Additional 
estimates of RR for cardiovascular outcomes were used from the CALIBER study, a health-record linkage 
cohort study from the UK.6  
For cardiovascular disease, epidemiological studies have shown that the RR associated with SBP declines 
with age, with the log (RR) having an approximately linear relationship with age and reaching a value of 
1 between the ages of 100 and 120. RRs were reported per 10 mm Hg increase in SBP above the TMREL 




Where 𝑅𝑅𝑅𝑅(𝑥𝑥) is the RR at exposure level x and 𝑅𝑅𝑅𝑅0 is the increase in RR for each 10 mmHg above the 
TMREL. We used Dismod-MR 2.1 to pool effect sizes from included studies and generate a dose-
response curve for each of the outcomes associated with high SBP. The tool enabled us to incorporate 
random effects across studies and include data with different age ranges. RRs were used universally for 
all countries and the meta-regression only helped to pool the three major sources and produce RRs with 
uncertainty and covariance across ages taking into account the uncertainty of the data points. 
References 
1 Bangalore S, Gong Y, Cooper-DeHoff RM, Pepine CJ, Messerli FH. 2014 Eighth Joint National 
Committee panel recommendation for blood pressure targets revisited: results from the 
INVEST study. J Am Coll Cardiol 2014; 64: 784–93. 
2 Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight 
and obesity in children and adults during 1980–2013: a systematic analysis for the Global 
Burden of Disease Study 2013. The Lancet 2014; 384: 766–81. 
3 Singh GM, Danaei G, Farzadfar F, et al. The age-specific quantitative effects of metabolic risk 
factors on cardiovascular diseases and diabetes: a pooled analysis. PloS One 2013; 8: e65174. 
4 Collaboration APCS, others. Blood pressure and cardiovascular disease in the Asia Pacific 
region. J Hypertens 2003; 21: 707–16. 
5 Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular 
mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. 
The Lancet 2002; 360: 1903–13. 
6 Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve 
cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 
1·25 million people. Lancet Lond Engl 2014; 383: 1899–911. 
192




High body-mass index (BMI) for adults (ages 20+) is defined as BMI greater than 20 to 25 kg/m2. High BMI 
for children (ages 1-19) is defined as being overweight or obese based on International Obesity Task Force 
standards. 
Input data and methodological summary 
Data sources 
We systematically searched Medline to identify studies providing nationally or subnationally 
representative estimates of overweight prevalence, obesity prevalence or mean body-mass index (BMI). 
We limited the search to literature published between January 1, 2016 and December 31, 2016 to update 
the systematic literature search previously performed as part of GBD 2015.  
The search for adults was conducted on 4 January 2017 using the following terms: 
((("Body Mass Index"[Mesh] OR "Overweight"[Mesh] OR "Obesity"[Mesh]) AND ("Geographic 
Locations"[Mesh] NOT “United States”[Mesh]) AND ("humans"[Mesh] AND "adult"[MeSH]) AND ("Data 
Collection"[Mesh] OR "Health Services Research"[Mesh] OR "Population Surveillance"[Mesh] OR "Vital 
statistics"[Mesh] OR "Population"[Mesh] OR "Epidemiology"[Mesh] OR "surve*"[TiAb]) NOT 
(Comment[ptyp] OR Case Reports[ptyp] OR "hospital"[TiAb])) AND ("2016/01/01"[Date - Publication] : 
"2016/12/31"[Date - Publication])) 
The search for children was conducted on 4 August 2016 using the following terms: 
((("Body Mass Index"[Mesh] OR "Overweight"[Mesh] OR "Obesity"[Mesh]) AND ("Geographic 
Locations"[Mesh] NOT “United States”[Mesh]) AND ("humans"[Mesh] AND "child"[MeSH]) AND ("Data 
Collection"[Mesh] OR "Health Services Research"[Mesh] OR "Population Surveillance"[Mesh] OR "Vital 
statistics"[Mesh] OR "Population"[Mesh] OR "Epidemiology"[Mesh] OR "surve*"[TiAb]) NOT 
(Comment[ptyp] OR Case Reports[ptyp] OR "hospital"[TiAb])) AND ("2016/01/01"[Date - Publication] : 
"2016/12/31"[Date - Publication])) 
Our search for adult estimates identified 456 abstracts, of which 25 met inclusion criteria and were 
extracted. The search for childhood estimates identified 137 articles, of which 4 were extracted. Including 
sources from the previous GBD systematic literature searches, a total of 11,220 articles were identified, of 
which 845 were included. Additionally, we searched the Global Health Data Exchange (GHDx) database for 
individual-level data from major multinational survey series or country-specific surveys and identified 
5,385 location-year sources meeting the inclusion criteria.  
Eligibility criteria 
We included representative studies providing data on mean BMI or prevalence of overweight or obesity 
among adults or children. For adults, studies were included if they defined overweight as BMI≥25 kg/m2 
and obesity as BMI≥30 kg/m2, or if estimates using those cutoffs could be back-calculated from reported 
categories. For children (children ages 2-18), studies were included if they used International Obesity Task 
Force (IOTF) standards to define overweight and obesity thresholds. We only included studies reporting 
data collected between January 1, 1980 and December 31, 2016. Studies were excluded if they used non-
random samples (e.g. case-control studies or convenience samples), conducted among specific 
subpopulations (e.g. pregnant women, racial or ethnic minorities, immigrants, or individuals with specific 
diseases), used alternative methods to assess adiposity (e.g. waist-circumference, skin-fold thickness, or 
hydrodensitometry), had sample sizes of less than 20 per age-sex group, or provided inadequate 
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information on any of the inclusion criteria. We also excluded review articles and non-English language 
articles.  
Data collection process  
Where individual-level survey data were available, we computed mean BMI using weight and height. We 
then used BMI to determine the prevalence of overweight and obesity. For individuals aged over 18 years, 
we considered them to be overweight if their BMI was greater than or equal to 25 kg/m2, and obese if 
their BMI was greater than or equal to 30 kg/m2. For individuals aged 2 to 18 years, we used monthly IOTF 
cutoffs2 to determine overweight and obese status when age in months was available. When only age in 
years was available, we used the cutoff for the midpoint of that year. Obese individuals were also 
considered to be overweight. We excluded studies using the World Health Organization (WHO) standards 
or country-specific cutoffs to define childhood overweight and obesity. At the individual-level, we 
considered BMI<10 kg/m2 and BMI>70 kg/m2 to be biologically implausible and excluded those 
observations. 
The rationale for choosing to use the IOTF cutoffs over the WHO standards has been described 
elsewhere.1 Briefly, the IOTF cutoffs provide consistent child-specific standards for ages 2-18 derived 
surveys covering multiple countries. On the other hand, the WHO growth standards apply to children 
under age 5 and the WHO growth reference applies to children ages 5 to 19. The WHO growth reference 
for children ages 5 to 19 was derived from United States data which is less representative than the 
multinational data used by IOTF. Additionally, the switch between references at age 5 can produce 
artificial discontinuities. Given that we estimate global childhood overweight and obesity for ages 2-19 
(with ages 19 using standard adult cutoffs), the IOTF cutoffs were preferable. Additionally, we found that 
IOTF cutoffs were more commonly used in scientific literature covering childhood obesity. 
From report and literature data, we extracted data on mean BMI, prevalence of overweight, and 
prevalence of obesity, measures of uncertainty for each, and sample size, by the most granular age and 
sex groups available. Additionally, we extracted the same study-level covariates as were extracted from 
microdata (measurement, urbanicity, and representativeness), as well as location and year.  
In addition to the primary indicators described above, we extracted relevant survey-design variables, 
including primary sampling unit, strata, and survey weights, which were used to tabulate individual-level 
microdata and produce accurate measures of uncertainty. We extracted three study-level covariates: 1) 
whether height and weight data were measured or self-reported; 2) whether the study was 
predominantly conducted in an urban area, rural area or both; and 3) the level of representativeness of 
the study (national or subnational).  
Finally, we extracted relevant demographic indicators, including location, year, age and sex. We estimated 
the standard error of the mean from individual-level data, where available, and used the reported 
standard error of the mean for published data. When multiple data sources were available for the same 
country, we included all of them in our analysis. If data from the same data source were available in 
multiple formats such individual-level data and tabulated data, we used individual-level data.  
Self-report bias adjustment 
We included both measured and self-reported data. We tested for bias in self-report data compared to 
measured data, which is considered to be the gold-standard. There was no clear direction of bias for 
children ages 2 to 14, so for these age groups we only included measured data. For individuals ages 15 
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and above, we adjusted self-reported data for overweight prevalence, obesity prevalence and mean BMI 
using the following nested hierarchical mixed-effects regression models, fit using restricted maximum 
likelihood separately by sex: 






IA[a]IM[m] + αs + αsm + αr + αrm + αc + αcm + αt + αtm + ϵc,a,t 
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IA[a]IM[m] + αs + αsm + αr + αrm + αc + αcm + αt + αtm + ϵc,a,t 
Where m is a fixed effect on measurement (binary, either measured (1) or self-report (0)), IA[a] is an 
indicator variable for specific age group A, IA[a]IM[m] is an interaction term between age and 
measurement, αs, αr, and αc are random effects at the super region, region, and country, respectively, 
and αt is a random effect by time-period (1980-1989, 1990-1999, 2000-2009, 2010-2017). Random effects 
at the country level and time-period level were used to fit the models, but were taken as noise and were 
not used in adjustment of self-reported data. We propagated the uncertainty in the self-report 
adjustment model by adding the variance of each of the regression coefficients used in adjustment to the 
data variance in delta-transformed space. After adjustment, regressions confirmed that self-reported data 
was no longer significantly different from measured data. 
Age and sex splitting 
Any report or literature data provided in age groups wider than the standard 5-year age groups or as both 
sexes combined were split using the approach used by Ng et al.2 Briefly, age-sex patterns were identified 
using sources with data on multiple age-sex groups and these patterns were applied to split aggregated 
report and literature data. Uncertainty in the age-sex split was propagated by multiplying the standard 
error of the data by the square root of the number of splits performed. We did not propagate the 
uncertainty in the age pattern and sex pattern used to split the data as they seemed to have small effect. 
Prevalence estimation for overweight and obesity 
After adjusting for self-report bias and splitting aggregated data into 5-year age-sex groups, we used 
spatiotemporal Gaussian process regression (ST-GPR) to estimate the prevalence of overweight and 
obesity. This modelling approach has been described in detail elsewhere.  
The linear model, which when added to the smoothed residuals forms the mean prior for GPR is as 
follows:  
logit(overweight)c,a,t = β0 + β1energyc,t + β2SDIc,t +  β3vehiclesc,t +  β4agriculturec,t + �βkIA[a]
21
k=5
+ αs + αr + αc
logit(obesity/overweight)c,a,t = β0 + β1energyc,t + β2SDIc,t +  β3vehiclesc,t + �βkIA[a]
21
k=4
+ αs + αr + αc
where 𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 is ten-year lag-distributed energy consumption per capita, 𝑆𝑆𝑆𝑆𝑆𝑆 is a composite index of 
development including lag-distributed income per capita, education, and fertility, 𝑣𝑣𝑒𝑒ℎ𝑖𝑖𝑖𝑖𝑖𝑖𝑒𝑒𝑖𝑖 is is the 
number of two or four-wheel vehicles per capita, and 𝑎𝑎𝑒𝑒𝑒𝑒𝑖𝑖𝑖𝑖𝑟𝑟𝑖𝑖𝑟𝑟𝑟𝑟𝑒𝑒𝑒𝑒 is the proportion of the population 
working in agriculture. IA[a] is a dummy variable indicating specific age group A that the prevalence point 
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captures, and αs, αr, and αc are super region, region, and country random intercepts, respectively. 
Random effects were used in model fitting but were not used in prediction. 
We tested all combinations of the following covariates to see which performed best in terms of in-sample 
AIC for the overweight linear model and the obesity as a proportion of overweight linear model: ten-year 
lag distributed energy per capita, proportion of the population living in urban areas, SDI, lag-distributed 
income per capita, educational attainment (years) per capita, proportion of the population working in 
agriculture, grams of sugar adjusted for energy per capita, grams of sugar not adjusted for energy per 
capita, and the number of two or four-wheeled vehicles per capita. We selected these candidate 
covariates based on theory as well as reviewing covariates used in other publications. The final linear 
model was selected based on: 1) if the direction of covariates matched what is expected from theory, 2) 
all the included covariates were significant, and 3) minimising in-sample AIC. The covariate selection 
process was performed using the dredge package in R. 
The new version of ST-GPR for GBD 2017 incorporates information about data density into the process for 
smoothing over space and time. Estimates in areas/years with few observations have more weight on 
regional observations. To specify the distribution of time weights and space weights, we used values of 
lambda=0.2 and zeta=0.05, respectively. We used a value of omega=1.0 for the distribution of age 
weights. We set the GPR scale parameter to 20, and used the default global cutoff setting for amplitude.  
Estimating mean BMI 
To estimate the mean BMI for adults in each country, age, sex, and time period 1980-2017, we first used 
the following nested hierarchical mixed-effects model, fit using restricted maximum likelihood on data 
from sources containing estimates of all three indicators (prevalence of overweight, prevalence of 
obesity, and mean BMI), in order to characterise the relationship between overweight, obesity, and mean 
BMI:  
log (BMIc,a,s,t) = β0 + β1owc,a,s,t + β2obc,a,s,t + β3sex + �βkIA[a]
20
k=4
+ αs(1 + owc,a,s,t + obc,a,s,t) + αr(1
+ owc,a,s,t + obc,a,s,t) + αc(1 + owc,a,s,t + obc,a,s,t) + ϵc,a,s,t
where owc,a,s,t is the prevalence of overweight in country c, age a, sex s, and year t, obc,a,s,t is the 
prevalence of obesity in country c, age a, sex s, and year t, sex is a fixed effect on sex, IA[a] is an indicator 
variable for age, and αs, αr, and αc are random effects at the super region, region, and country, 
respectively. The model was run in Stata 13. 
We applied 1,000 draws of the regression coefficients to the 1,000 draws of overweight prevalence and 
obesity prevalence produced through ST-GPR to estimate 1,000 draws of mean BMI for each country, 
year, age, and sex. This approach ensured that overweight prevalence, obesity prevalence, and mean BMI 
were correlated at the draw level and uncertainty was propagated. 
Estimating BMI distribution 
We used the ensemble distribution approach described in the manuscript. We fit ensemble weights by 
source and sex, with source- and sex-specific weights averaged across all sources included to produce the 
final global weights. The ensemble weights were fit on measured microdata. The final ensemble weights 
were: exponential = 0.002, gamma = 0.028, inverse gamma = 0.085, log-logistic = 0.187, Gumbel = 0.220, 
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Weibull = 0.011, log-normal = 0.058, normal = 0.012, beta = 0.136, mirror gamma = 0.008, and mirror 
Gumbel = 0.113. 
One thousand draws of BMI distributions for each location, year, age group, and sex estimated were 
produced by fitting an ensemble distribution using 1,000 draws of estimated mean BMI, 1,000 draws of 
estimated standard deviation, and the ensemble weights. Estimated standard deviation was produced by 
optimising a standard deviation to fit estimated overweight prevalence draws and estimated obesity 
prevalence draws. 
Assessment of risk-outcome pairs 
Risk-outcome pairs were defined based on strength of available evidence supporting a causal effect. We 
performed a systematic review of published meta-analyses, pooled analyses, and systematic reviews 
available through PubMed using the following search string: ("Body Mass Index"[Mesh] OR 
"Overweight"[Mesh] OR "Obesity"[Mesh]) AND (Meta-Analysis[ptyp] OR "systematic review"[tiab] OR 
"pooled analysis"[tiab]). Inclusion criteria are 1) the health outcome is included in GBD, 2) at least one 
prospective cohort is included, and 3) that the summary effect size is statistically significant. For outcomes 
meeting inclusion criteria we completed causal criteria tables to evaluate the strength of evidence 
supporting a causal relationship (see Appendix Table 4). Gallbladder disease, cataract, multiple myeloma, 
gout, non-Hodgkin lymphoma, asthma, Alzheimer disease, and atrial fibrillation were added as new 
outcomes in GBD 2016, resulting in a total of 38 outcomes. 
Theoretical minimum risk exposure level  
For adults (ages 20+), the theoretical minimum risk exposure level (TMREL) of BMI (20-25 kg/m2) was 
determined based on the BMI level that was associated with the lowest risk of all-cause mortality in 
prospective cohort studies.3
For children (ages 2-19), the TMREL is “normal weight,” that is, not overweight or obese, based on IOTF 
cutoffs. 
Relative risk 
The relative risk per 5-unit change in BMI for each disease endpoint was obtained from meta-analyses, 
and where available, pooled analyses of prospective observational studies. In cases where a relative risk 
per 5-unit change in BMI was not available we computed our own dose-response meta-analysis using 
two-step generalised least squares for time trends estimation methods.  
For childhood outcomes (ages 2-19), we computed categorical relative risks for overweight and obesity 
using a random effects meta-analysis.  
Relative risks for all 38 outcomes, by age and sex, are reported in Table 6a. 
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Bone Mineral Density Capstone Appendix 
Flowchart 
Input data & methodological summary 
Exposure 
Case definition 
Bone mineral density (BMD) is a continuous variable measured by dual-x-ray-absorptiometry (DXA) at 
the femoral neck (FN) and is presented in g/cm2 after standardizing for the brand of densitometer 
(sBMD). Low BMD is measured in terms of the difference between BMD of a population and the 99th 
percentile of a reference population at the same age and sex (theoretical minimum of risk exposure 
level, TMREL). The burden attributed to low bone mineral density is estimated for adults 20 years and 
older.  
Input data 
A systematic review (search string at the end of document) was conducted in GBD 2015 but it was not 
scheduled for systematic review in GBD 2016 or 2017. Inclusion criteria that informed the search are: 
o Representative, population-based surveys
o Reporting of quantitative BMD
 measured by DXA
 performed at the FN region
 measured in g/cm2
Mean BMD was occasionally reported in stratified groups, e.g. by fracture status but not for total 
sample. In these cases, the stratified means were aggregated to obtain a total mean BMD at population 
level for an age or sex category.  
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The data availability by GBD super-region is shown in table below. 
Super region The number of data points 
Southeast Asia, East Asia, and Oceania 314 
Central Europe, Eastern Europe, and Central Asia 36 
High-income 682 
Latin America and Caribbean 97 
North Africa and Middle East 110 
South Asia 39 
Sub-Saharan Africa 3 
Modelling strategy  
We modelled mean BMD in DisMod-MR 2.1 as a single ‘continuous’ parameter model by age and sex, 
and all GBD locations for years 1990 to 2017. The model had age mesh points at 0 10 20 25 30 40 50 60 
70 80 90 & 100, a time window of 10 years for fitting data, and a minimum coefficient of variation of 0.1 
for global, 0.06 super region and 0.08 for the region level.  
The country covariates of alcohol consumption (litres per capita), tobacco consumption (cigarettes per 
capita), mean BMI, and adjusted calcium intake (g) were included in modelling. The country covariates 
total physical activity and milk consumption did not have a significant effect on BMD so we excluded 
them from our final model.  
The uncertainty of BMD was modelled using various distributions. We tested goodness-of-fit in NHANES 
III data, the only survey for which we had unit record data available. We applied a weighting ensemble 
on those distributions. The weights were calculated in an optimisation model with an objective function 
that minimised Kolmogorov-Smirnov statistics. The weights of the distributions in the ensemble were 
calculated separately for males and females. Distribution weights are shown below.
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Figure 1: Distribution of weights used for Females in GBD 2017 
Figure 2: Distribution of weights used for Males in GBD 2017 
We consider the risk of fatal and non-fatal outcomes for hip non-hip fractures, separately, as relative 
risk data provide different estimates. Thus, there were various steps after DisMod-MR 2.1 exposure 
modelling to arrive at attributable fractions that can be applied to fatal and non-fatal fracture outcomes. 
These osteoporotic non-hip fractures include fractures of vertebrae, clavicle, scapula, humerus, skull, 
sternum, rib, face bone, radius or ulna, femur, patella, tibia, fibula, ankle, pelvis and vertebra.  
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First, we calculated the proportion of injury deaths that are due to fractures. This proportion of death 
caused by fracture is the envelope that we use to attribute death to BMD. In order to do this, we 
assumed that hip fracture and some non-hip fractures (any fractures apart from fingers and toes) are 
potentially fatal fractures. As cause of death data from vital registration and verbal autopsy attributes 
injury deaths to causes of death (e.g. fall or road injury) and not nature of injury (such as fractures), we 
used available hospital data to estimate the proportion of injury deaths during admission that could be 
ascribed to fractures. We restricted our analysis to cases that were dual-coded with both the cause of 
injury (“E-code”) and nature of injury (“N-code”). As injury cases may have multiple forms of trauma, we 
applied a severity hierarchy to the fatal hospital data to determine the proportion of the deaths that 
could be attributed to the chosen fracture types but were not accompanied by more severe fatal trauma 
such as head trauma, spinal cord lesion, and intra-abdominal or thoracic organ damage. We collapsed all 
deaths over E-code to determine the ratio of deaths attributable to fracture versus non-fracture injuries. 
We applied this ratio to the YLL.  
We restricted non-fatal estimates of low BMD to a list of causes that were deemed to cause 
osteoporotic fractures. Below is the list of injuries for which a PAF was calculated: 
• Transport injuries
• Road injuries
• Pedestrian road injuries
• Cyclist road injuries
• Motorcyclist road injuries
• Motor vehicle road injuries
• Other road injuries
• Other transport injuries
• Unintentional injuries
• Falls
• Exposure to mechanical forces
• Other exposure to mechanical forces
• Non-venomous animal contact
• Interpersonal violence
• Assault by other means
We made use of the E to N-code matrix generated from dual-coded (E-code/N-code) patient level data 
in our injury analyses to determine the proportion of each E-code that results in a certain N-code. The 
hip and non-hip fracture population attributable fractions were applied to the appropriate combinations 
of external cause and fracture estimates of YLD and then summed together to produce a single 
estimate. 
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Figure 3: Plot of hospital fractions used by hip and non-hip 
Theoretical minimum-risk exposure level 
The theoretical minimum of risk exposure level or TMREL was chosen as the age-sex specific 99th 
percentile of BMD from 5 cycles of NHANES study as the reference population. Below is a descriptive 
table of the 5 NHANES cycles used. 
NHANES cycle Age range (years) Number of people 
tested 
BMD range (g/cm2) 
1988 20 – 90 14,646 0.23 – 1.84 
2005 20 – 85 3,494 0.40 – 1.50 
2007 20 – 80 4,726 0.34 – 1.46 
2009 20 – 80 5,052 0.33 – 1.63 
2013 40 – 80 3,127 0.39 – 1.36 
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Figure 4: Plot of 99th percentile of BMD at femoral neck in each cycle of NHANES 
Relative risks 
Relative risks must be reported per standard deviation or per unit bone mass density in order for us to 
use the data. Many studies report relative risk based on a z-score or the relative risks in the osteoporotic 
group versus the non-osteoporotic group; neither of these relative risks are usable. 
For GBD 2017, we did not update the systematic review for the RR of BMD that was done in GBD 2013. 
In the GBD 2013 review, twelve prospective observational studies were found, but one meta-analysis of 
12 studies1 reported the dose-response relationship between low BMD and high relative risk of hip and 
other fractures that are prone to osteoporosis, as shown in the below table.  
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#11 Search (#8 AND #10) Filters: Humans 326 12:37:09 
#10 
Search ("Cross-Sectional Studies"[Mesh] OR "cross-sectional"[title/abstract] OR "Health Surveys"[Mesh] 
OR Survey[title/abstract] OR cohort[title/abstract] OR "Diet Surveys"[Mesh] OR "Longitudinal 
Studies"[Mesh] OR "Nutrition Surveys"[Mesh] OR "Surveys and Questionnaires"[Mesh]) Filters: Humans 1324376 12:36:29 
#8 Search (#7 AND #6) Filters: Humans 622 12:33:16 
#7 
Search ("Absorptiometry, Photon"[Mesh] OR "dual-energy x-ray absorptiometry" OR "dual energy x-ray 
absorptiometry") Filters: Humans 21368 12:32:34 
#6 Search (#5 AND ("2010"[Date - Publication] : "3000"[Date - Publication])) Filters: Humans 1387 12:30:26 
#5 Search ((#1 OR #2) AND #3) Filters: Humans 3702 12:29:47 
#4 Search ((#1 OR #2) AND #3) 4015 12:29:33 
#3 
Search (((("bone mineral density"[title/abstract] OR "bone mineral densities"[title/abstract]) OR "Bone 
Density"[Mesh]) AND (mean[title/abstract] OR average[title/abstract]))) 12892 12:29:00 
#2 
Search ((((multinational[TIAB] OR international[TIAB] OR national[TIAB] OR nationwide[TIAB] OR nation-
wide[TIAB] OR equitorial[TIAB] OR equator[TIAB] OR global[TIAB] OR globe[TIAB] OR world[TIAB] OR 
worldwide[TIAB] OR world-wide[TIAB] OR countrywide[TIAB] OR countries[TIAB] OR continental[TIAB] OR 
continent[TIAB] OR continents[TIAB] OR global burden[TIAB] OR burden of disease[TIAB] OR disease 
burden[TIAB] OR tropic[TIAB] OR tropics[TIAB] OR tropical[TIAB] OR Oceania[TIAB] OR South 
America[TIAB] OR Central America[TIAB] OR Mesoamerica[TIAB] OR Americas[TIAB] OR Latin 
America[TIAB] OR paho[TIAB] OR pan-american[TIAB] OR panamerican[TIAB] OR pan-america[TIAB] OR 
Caribbean[TIAB] OR Indies[TIAB] OR Australasia[TIAB] OR Australasian[TIAB] OR developing 
countries[TIAB] OR developing nations[TIAB] OR developed countries[TIAB] OR developed nations[TIAB] 
OR commonwealth[TIAB] OR industrialized[TIAB] OR nonindustrialized[TIAB] OR non-industrialized[TIAB] 
OR underdeveloped countries[TIAB] OR underdeveloped nation[TIAB] OR underdeveloped nations[TIAB] 
OR under-developed country[TIAB] OR under-developed countries[TIAB] OR under-developed 
nation[TIAB] OR under-developed nations[TIAB] OR low-income country[TIAB] OR low-income 
countries[TIAB] OR low-income nation[TIAB] OR low-income nations[TIAB] OR nondeveloped 
country[TIAB] OR nondeveloped countries[TIAB] OR nondeveloped nation[TIAB] OR nondeveloped 
nations[TIAB] OR non-developed country[TIAB] OR non-developed countries[TIAB] OR non-developed 
nation[TIAB] OR non-developed nations[TIAB] OR International Cooperation[TIAB] OR World Health 
Organization[TIAB] OR Asia[TIAB] OR Far East[TIAB] OR Near East[TIAB] OR Middle East[TIAB] OR 
Scandinavia[TIAB] OR Europe[TIAB] OR European[TIAB] OR Eastern Hemisphere[TIAB] OR Western 
Hemisphere[TIAB] OR Northern Hemisphere[TIAB] OR Southern Hemisphere[TIAB] OR North 
America[TIAB] OR island[TIAB] OR islands[TIAB] OR United Nations[TIAB] OR unesco[TIAB] OR 
unicef[TIAB] OR Worldbank[TIAB] OR Benelux[TIAB] OR sub-Saharan[TIAB] OR subsaharan[TIAB] OR 
Sahara[TIAB] OR sub-Sahara[TIAB] OR Amazon[TIAB] OR Amazonian[TIAB] OR valley[TIAB] OR river[TIAB] 3585538 12:28:22 
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OR mountain[TIAB] OR mountains[TIAB] OR forest[TIAB] OR forests[TIAB] OR rainforest[TIAB] OR 
rainforests[TIAB] OR jungle[TIAB] OR jungles[TIAB] OR archipelago[TIAB] OR archipelagos[TIAB] OR 
archipelagoes[TIAB] OR patagonia[TIAB] OR andes[TIAB] OR mediterranean region[TIAB] OR Africa[TIAB] 
OR registry[TIAB] OR North Korea[TIAB] OR Timor[TIAB] OR Palestine[TIAB] OR Syrian Arab Republic[TIAB] 
OR Baltic[TIAB] OR Atlantic Islands[TIAB] OR Indian Ocean[TIAB] OR Pacific[TIAB] OR multicenter[TIAB] OR 
multi-center[TIAB] OR registry[TIAB] OR registries[TIAB] OR Algeria[TIAB] OR Egypt[TIAB] OR Libya[TIAB] 
OR Morocco[TIAB] OR Tunisia[TIAB] OR Cameroon[TIAB] OR Central African Republic[TIAB] OR 
Chad[TIAB] OR Congo[TIAB] OR Congo[TIAB] OR Equatorial Guinea[TIAB] OR Gabon[TIAB] OR 
Burundi[TIAB] OR Djibouti[TIAB] OR Eritrea[TIAB] OR Ethiopia[TIAB] OR Kenya[TIAB] OR Rwanda[TIAB] OR 
Somalia[TIAB] OR Sudan[TIAB] OR Tanzania[TIAB] OR Uganda[TIAB] OR Angola[TIAB] OR Botswana[TIAB] 
OR Lesotho[TIAB] OR Malawi[TIAB] OR Mozambique[TIAB] OR Namibia[TIAB] OR South Africa[TIAB] OR 
Swaziland[TIAB] OR Zambia[TIAB] OR Zimbabwe[TIAB] OR Benin[TIAB] OR Burkina Faso[TIAB] OR Cote 
d'Ivoire[TIAB] OR Gambia[TIAB] OR Ghana[TIAB] OR Guinea[TIAB] OR Guinea-Bissau[TIAB] OR 
Liberia[TIAB] OR Mali[TIAB] OR Mauritania[TIAB] OR Niger[TIAB] OR Nigeria[TIAB] OR Senegal[TIAB] OR 
Sierra Leone[TIAB] OR Togo[TIAB] OR Antigua[TIAB] OR Bahamas[TIAB] OR Barbados[TIAB] OR Cuba[TIAB] 
OR Dominica[TIAB] OR Dominican Republic[TIAB] OR Grenada[TIAB] OR Guadeloupe[TIAB] OR Haiti[TIAB] 
OR Jamaica[TIAB] OR Martinique[TIAB] OR Netherlands Antilles[TIAB] OR Puerto Rico[TIAB] OR Saint Kitts 
and Nevis[TIAB] OR Saint Lucia[TIAB] OR Saint Vincent[TIAB] OR Grenadines[TIAB] OR Trinidad and 
Tobago[TIAB] OR Virgin Islands[TIAB] OR Belize[TIAB] OR Costa Rica[TIAB] OR El Salvador[TIAB] OR 
Guatemala[TIAB] OR Honduras[TIAB] OR Nicaragua[TIAB] OR Panama[TIAB] OR Mexico[TIAB] OR 
Argentina[TIAB] OR Bolivia[TIAB] OR Brazil[TIAB] OR Chile[TIAB] OR Colombia[TIAB] OR Ecuador[TIAB] OR 
French Guiana[TIAB] OR French Guiana[TIAB] OR Paraguay[TIAB] OR Peru[TIAB] OR Suriname[TIAB] OR 
Uruguay[TIAB] OR Venezuela[TIAB] OR Kazakhstan[TIAB] OR Kyrgyzstan[TIAB] OR Tajikistan[TIAB] OR 
Turkmenistan[TIAB] OR Uzbekistan[TIAB] OR Borneo[TIAB] OR Cambodia[TIAB] OR Timor[TIAB] OR 
Indonesia[TIAB] OR Laos[TIAB] OR Malaysia[TIAB] OR Mekong Valley[TIAB] OR Myanmar[TIAB] OR 
Philippines[TIAB] OR Thailand[TIAB] OR Vietnam[TIAB] OR Viet Nam[TIAB] OR Bangladesh[TIAB] OR 
Bhutan[TIAB] OR India[TIAB] OR Afghanistan[TIAB] OR Bahrain[TIAB] OR Iran[TIAB] OR Iraq[TIAB] OR 
Jordan[TIAB] OR Kuwait[TIAB] OR Lebanon[TIAB] OR Oman[TIAB] OR Qatar[TIAB] OR Saudi Arabia[TIAB] 
OR Syria[TIAB] OR Turkey[TIAB] OR United Arab Emirates[TIAB] OR Yemen[TIAB] OR Nepal[TIAB] OR 
Pakistan[TIAB] OR Sri Lanka[TIAB] OR China[TIAB] OR Macao[TIAB] OR Mongolia[TIAB] OR Taiwan[TIAB] 
OR Azores[TIAB] OR Bermuda[TIAB] OR Falkland Islands[TIAB] OR Albania[TIAB] OR Estonia[TIAB] OR 
Latvia[TIAB] OR Lithuania[TIAB] OR Bosnia-Herzegovina[TIAB] OR Bulgaria[TIAB] OR Byelarus[TIAB] OR 
Croatia[TIAB] OR Czech Republic[TIAB] OR Hungary[TIAB] OR Macedonia[TIAB] OR Moldova[TIAB] OR 
Montenegro[TIAB] OR Poland[TIAB] OR Romania[TIAB] OR Russia[TIAB] OR Slovakia[TIAB] OR 
Slovenia[TIAB] OR Ukraine[TIAB] OR Yugoslavia[TIAB] OR Armenia[TIAB] OR Azerbaijan[TIAB] OR 
Georgia[TIAB] OR Comoros[TIAB] OR Madagascar[TIAB] OR Mauritius[TIAB] OR Reunion[TIAB] OR 
Seychelles[TIAB] OR Fiji[TIAB] OR New Caledonia[TIAB] OR Papua New Guinea[TIAB] OR Vanuatu[TIAB] 
OR Guam[TIAB] OR Palau[TIAB] OR Pitcairn Island[TIAB] OR Samoa[TIAB] OR Tonga[TIAB] OR 
Czechoslovakia[TIAB] OR East Germany[TIAB] OR New Guinea[TIAB] OR USSR[TIAB] OR Yugoslavia[TIAB] 
OR Ivory Coast[TIAB] OR Hong Kong[TIAB] OR china[TIAB] OR North Korea[TIAB] OR Palestine[TIAB] OR 
Syrian Arab Republic[TIAB]) AND (hasabstract[text] AND Humans[Mesh] AND middle age[MeSH])) OR 
((International Cooperation[Mesh:noexp] OR developing countries[Mesh] OR developed countries[Mesh] 
OR WORLD HEALTH[Mesh] OR WORLD HEALTH ORGANIZATION[Mesh] OR AFRICA[Mesh] OR 
Americas[Mesh:noexp] OR Caribbean Region[Mesh] OR West Indies[Mesh] OR Central America[Mesh] OR 
Latin America[Mesh:noexp] OR North America[Mesh:noexp] OR South America[Mesh] OR Antarctic 
Regions[Mesh:noexp] OR Arctic Regions[Mesh:noexp] OR Asia[Mesh:noexp] OR Asia, Central[Mesh] OR 
Asia, Southeastern[Mesh:noexp] OR Asia, Western[Mesh:noexp] OR Middle East[Mesh:noexp] OR Far 
East[Mesh:noexp] OR Atlantic Islands[Mesh] OR Europe[Mesh:noexp] OR Europe, Eastern[Mesh] OR 
Scandinavia[Mesh:noexp] OR Transcaucasia[Mesh] OR Indian Ocean Islands[Mesh] OR 
Oceania[Mesh:noexp] OR Australasia[Mesh:noexp] OR Pacific Islands[Mesh:noexp] OR 
Melanesia[Mesh:noexp] OR Micronesia[Mesh:noexp] OR Polynesia[Mesh:noexp] OR Mexico[Mesh] OR 
Borneo[Mesh] OR Cambodia[Mesh] OR East Timor[Mesh] OR Indonesia[Mesh] OR Laos[Mesh] OR 
Malaysia[Mesh] OR Mekong Valley[Mesh] OR Myanmar[Mesh] OR Philippines[Mesh] OR Thailand[Mesh] 
OR Vietnam[Mesh] OR Bangladesh[Mesh] OR Bhutan[Mesh] OR India[Mesh] OR Afghanistan[Mesh] OR 
Bahrain[Mesh] OR Iran[Mesh] OR Iraq[Mesh] OR Jordan[Mesh] OR Kuwait[Mesh] OR Lebanon[Mesh] OR 
Oman[Mesh] OR Qatar[Mesh] OR Saudi Arabia[Mesh] OR Syria[Mesh] OR Turkey[Mesh] OR United Arab 
Emirates[Mesh] OR Yemen[Mesh] OR Nepal[Mesh] OR Pakistan[Mesh] OR Sri Lanka[Mesh] OR 
China[Mesh] OR Macao[Mesh] OR Mongolia[Mesh] OR Taiwan[Mesh] OR Multicenter Studies As 
Topic[Mesh] OR Multicenter Study[PT] OR Algeria[PL] OR Egypt[PL] OR Libya[PL] OR Morocco[PL] OR 
Tunisia[PL] OR Cameroon[PL] OR Central African Republic[PL] OR Chad[PL] OR Congo[PL] OR Congo[PL] 
OR Equatorial Guinea[PL] OR Gabon[PL] OR Burundi[PL] OR Djibouti[PL] OR Eritrea[PL] OR Ethiopia[PL] OR 
Kenya[PL] OR Rwanda[PL] OR Somalia[PL] OR Sudan[PL] OR Tanzania[PL] OR Uganda[PL] OR Angola[PL] 
OR Botswana[PL] OR Lesotho[PL] OR Malawi[PL] OR Mozambique[PL] OR Namibia[PL] OR South Africa[PL] 
OR Swaziland[PL] OR Zambia[PL] OR Zimbabwe[PL] OR Benin[PL] OR Burkina Faso[PL] OR Cote d'Ivoire[PL] 
OR Gambia[PL] OR Ghana[PL] OR Guinea[PL] OR Guinea-Bissau[PL] OR Liberia[PL] OR Mali[PL] OR 
Mauritania[PL] OR Niger[PL] OR Nigeria[PL] OR Senegal[PL] OR Sierra Leone[PL] OR Togo[PL] OR 
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Antigua[PL] OR Bahamas[PL] OR Barbados[PL] OR Cuba[PL] OR Dominica[PL] OR Dominican Republic[PL] 
OR Grenada[PL] OR Guadeloupe[PL] OR Haiti[PL] OR Jamaica[PL] OR Martinique[PL] OR Netherlands 
Antilles[PL] OR Puerto Rico[PL] OR Saint Kitts and Nevis[PL] OR Saint Lucia[PL] OR Saint Vincent[PL] OR 
Grenadines[PL] OR Trinidad and Tobago[PL] OR Virgin Islands[PL] OR Belize[PL] OR Costa Rica[PL] OR El 
Salvador[PL] OR Guatemala[PL] OR Honduras[PL] OR Nicaragua[PL] OR Panama[PL] OR Mexico[PL] OR 
Argentina[PL] OR Bolivia[PL] OR Brazil[PL] OR Chile[PL] OR Colombia[PL] OR Ecuador[PL] OR French 
Guiana[PL] OR French Guiana[PL] OR Paraguay[PL] OR Peru[PL] OR Suriname[PL] OR Uruguay[PL] OR 
Venezuela[PL] OR Kazakhstan[PL] OR Kyrgyzstan[PL] OR Tajikistan[PL] OR Turkmenistan[PL] OR 
Uzbekistan[PL] OR Borneo[PL] OR Cambodia[PL] OR East Timor[PL] OR Indonesia[PL] OR Laos[PL] OR 
Malaysia[PL] OR Mekong Valley[PL] OR Myanmar[PL] OR Philippines[PL] OR Thailand[PL] OR Vietnam[PL] 
OR Bangladesh[PL] OR Bhutan[PL] OR India[PL] OR Afghanistan[PL] OR Bahrain[PL] OR Iran[PL] OR Iraq[PL] 
OR Jordan[PL] OR Kuwait[PL] OR Lebanon[PL] OR Oman[PL] OR Qatar[PL] OR Saudi Arabia[PL] OR 
Syria[PL] OR Turkey[PL] OR United Arab Emirates[PL] OR Yemen[PL] OR Nepal[PL] OR Pakistan[PL] OR Sri 
Lanka[PL] OR China[PL] OR Macao[PL] OR Mongolia[PL] OR Taiwan[PL] OR Azores[PL] OR Bermuda[PL] OR 
Falkland Islands[PL] OR Albania[PL] OR Estonia[PL] OR Latvia[PL] OR Lithuania[PL] OR Bosnia-
Herzegovina[PL] OR Bulgaria[PL] OR Byelarus[PL] OR Croatia[PL] OR Czech Republic[PL] OR Hungary[PL] 
OR Macedonia[PL] OR Moldova[PL] OR Montenegro[PL] OR Poland[PL] OR Romania[PL] OR Russia[PL] OR 
Slovakia[PL] OR Slovenia[PL] OR Ukraine[PL] OR Armenia[PL] OR Azerbaijan[PL] OR Georgia[PL] OR 
Comoros[PL] OR Madagascar[PL] OR Mauritius[PL] OR Reunion[PL] OR Seychelles[PL] OR Fiji[PL] OR New 
Caledonia[PL] OR Papua New Guinea[PL] OR Vanuatu[PL] OR Guam[PL] OR Palau[PL] OR Pitcairn 
Island[PL] OR Samoa[PL] OR Tonga[PL] OR Czechoslovakia[PL] OR Germany, East[PL] OR New Guinea[PL] 
OR USSR[PL] OR Yugoslavia[PL] OR Ivory Coast[PL] OR Hong Kong[PL] OR republic of china[PL]))) 
#1 
Search ((Canada[Mesh] OR Greenland[Mesh] OR United States[Mesh] OR Brunei[Mesh] OR 
Singapore[Mesh] OR Israel[Mesh] OR Japan[Mesh] OR Korea[Mesh] OR Australia[Mesh] OR 
Andorra[Mesh] OR Austria[Mesh] OR Belgium[Mesh] OR Finland[Mesh] OR France[Mesh] OR 
Germany[Mesh] OR Gibraltar[Mesh] OR Great Britain[Mesh] OR Greece[Mesh] OR Iceland[Mesh] OR 
Ireland[Mesh] OR Italy[Mesh] OR Liechtenstein[Mesh] OR Luxembourg[Mesh] OR Mediterranean 
Region[Mesh] OR Monaco[Mesh] OR Netherlands[Mesh] OR Portugal[Mesh] OR San Marino[Mesh] OR 
Scandinavia[Mesh] OR Spain[Mesh] OR Switzerland[Mesh] OR Vatican City[Mesh] OR Australia[Mesh] OR 
New Zealand[Mesh] OR Brunei[TIAB] OR Japan[TIAB] OR South Korea[TIAB] OR Singapore[TIAB] OR 
Andorra[TIAB] OR Austria[TIAB] OR Belgium[TIAB] OR Cyprus[TIAB] OR Denmark[TIAB] OR Finland[TIAB] 
OR France[TIAB] OR Germany[TIAB] OR Gibraltar[TIAB] OR Greece[TIAB] OR Greenland[TIAB] OR 
Vatican[TIAB] OR Iceland[TIAB] OR Ireland[TIAB] OR Israel[TIAB] OR Italy[TIAB] OR Liechtenstein[TIAB] OR 
Luxembourg[TIAB] OR Malta[TIAB] OR Monaco[TIAB] OR Netherlands[TIAB] OR Norway[TIAB] OR 
Portugal[TIAB] OR San Marino[TIAB] OR Spain[TIAB] OR Sweden[TIAB] OR Switzerland[TIAB] OR United 
Kingdom[TIAB] OR England[TIAB] OR Wales[TIAB] OR Scotland[TIAB] OR Canada[TIAB] OR United 
States[TIAB] OR Australia[TIAB] OR New Zealand[TIAB])) 3182449 12:27:20 
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Albuminuria and Stages 3, 4, and 5 chronic 
kidney disease model estimates from 
DisMod-MR 2.1
Calculate PAFs using exposure, 
relative risks, and TMREL
CKD PC1 relative risks on ischemic heart 
disease, stroke, peripheral vascular disease
Literature – relative risks on gout
TMREL




fractions by risk, 




fractions by risk 
aggregate, cause, 
age, sex, and 
geography
Application of mediation 
factors where applicable
Deaths, YLLs, YLDs, 
and DALYs 
attributable to each 
risk by age, sex, 
year, geography
Deaths, YLLs, YLDs, 
DALYs for each 
disease and injury 
by age, sex, year, 
geography
1. The Chronic Kidney Disease Prognosis Consortium collects population-level cohort data on CKD from around the
world for the purpose of collective meta-analyses 
Input Data & Methodological Summary 
Exposure 
Case Definition 
The impaired kidney function risk factor exposure is divided into four categories of renal function 
defined by urinary albumin to creatinine ratio (ACR) and estimated glomerular filtration rate (GFR): 
albuminuria with preserved GFR (ACR >30 mg/g & GFR >=60 ml/min/1.73m2), chronic kidney disease 
(CKD) stage 3 (GFR of 30-59 ml/min/1.73m2), CKD stage 4 (GFR of 15-29 ml/min/1.73m2), and CKD stage 
5 (GFR <15ml/min/1.73m2, not yet on renal replacement therapy).  The modelling of renal function 
prevalence estimates is described in detail in the appendix to the GBD 2017 non-fatal capstone paper as 
these are also disease sequelae. 
Input data 
For GBD 2010, a systematic review of the prevalence of low glomerular filtration rate throughout the 
world was conducted. This search was updated for GBD 2013, GBD 2015, and 2016. Exclusion criteria 
included surveys that were not population-representative, studies not reporting on CKD by stage, and 
studies not reporting on albuminuria with preserved GFR  (GFR >=60 ml/min/1.73m2).   
Disease Number of sources Number of countries Number of  new sources 
for GBD 2016 
Albuminuria 72 31 72 
CKD Stage III 112 47 49 
CKD Stage IV 94 40 45 
CKD Stage V 92 38 49 
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Modeling strategy  
Estimates of exposure to albuminuria and CKD were obtained from the GBD 2017 non-fatal burden of 
disease analysis, which includes stage-specific prevalence estimates at the country level across twenty-
three age-groups for both genders. The modeling strategy for these estimates is detailed in the appendix 
to the GBD 2017 non-fatal capstone paper.   
Relative risks were calculated by the Chronic Kidney Disease Prognosis Consortium, a consortium 
composed of population-level cohorts with prospective data collection from several countries (details 
below).  YLDs and YLLs for cardiovascular diseases and gout were obtained from the GBD 2017 Study for 
the same geographic, time-period, and age-groups as detailed above.  
Theoretical minimum-risk exposure level 
The theoretical minimum risk is a diagnosis of albuminuria or CKD stages 3, 4, or 5. An ACR above 30 
mg/g and eGFR below 60ml/min/1.73m2 have been demonstrated in the literature to be the thresholds 
at which increased cardiovascular and gout events occur secondary to impaired kidney function. (1-10)  
Relative risk 
A two-stage pooled meta-analysis was used to calculate relative risks for ischemic heart disease, stroke, 
and peripheral vascular disease. The relative risk of these conditions was first determined within each 
cohort, and then a pooled analysis of cohort-level relative risks was performed using a random effects 
meta-analysis approach. Uncertainty intervals largely overlapped for the relative risks of fatal and 
nonfatal cardiovascular events from impaired kidney function exposure. Thus, we decided to use the 
relative risks from the combined analysis for fatal and nonfatal cardiovascular outcomes. Gout relative 
risk was determined by meta-analysis of a literature review performed for GBD 2013.  Search terms 
included “gout” and “chronic kidney disease”. Exclusion criteria for search results included special 
populations, reversal of exposure and outcome categories, or unclear exposure category definition. This 
search resulted in four eligible studies; no new studies indicated an increased risk of gout with 
albuminuria. 
Population Attributable Fraction 
We calculated the cardiovascular and gout fatal and nonfatal burden attributable to the categorical 
exposure to impaired kidney function using the following equation: 
Equation 1. PAF based on categorical exposure 
where RRi is the relative risk for exposure level i, Pi is the proportion of the population in that exposure 
category, and n is the number of exposure categories.(11) 
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7 SRs, 6 time periods
Male and Female
Models = 252
21 regions, 6 time 
periods
Male and Female
Models = 2328 
194 countries & 
territories, 6 time 
periods
Male and Female
 Use all data points, all time
periods
 Calculate and apply
covariate coefficient and
random effects
 Determine age pattern
 Consistent fit between
parameters
 Global fit used as prior, modified by
random effects and betas of
country covariates
 Super region data adjusted for
study level covariates and sex ratio
if sex not specified
 Option to use all data over time or
just for specified time window
 Consistent fit between parameters
 Super region fit used as prior;
modified by random effects and
betas of country covariates
 Regional data adjusted for study
level covariates and sex ratio if
sex not specified
 Option to use all data over time
or just for specified time window
 Consistent fit between
parameters
 Regional fit used as prior
modified by random effects and
betas of country covariates
 Country data adjusted for study
level covariates and sex ratio
 Specified time window
 Consistent fit between
parameters
 Country fit used as prior modified
by betas of country covariates plus
adjustment by average of residuals
available data of subnational and
country prior
 Subnational data adjusted for study
level covariates and sex ratio
 Specified time window
 Consistent fit between parameters
Models = 8124
677 subnationals, 6 















checks and assign data id
Appendix Figure 3: Spatiotemporal Gaussian Process Regression
Data






-Continuous (Coeff. of variation mtd)
-Proportion (Wilson score interval)
Data transformations (logit, log)
Prepare knockouts (CODEm method)
Register model




Edit of Tom’s ST: 
zeta_no_data in locations 




Use regression to shift













Combine national and 
subnational draws











Appendix Table 1. GATHER checklist of information that should be included in reports of global 
health estimates, with description of compliance and location of information for GBD 2017. 
# GATHER checklist item Description of 
compliance 
Reference 
Objectives and funding 
1 Define the indicators, populations, and time periods for 
which estimates were made. 
Narrative provided in 





Main text (Methods— 
Overview, Geographic 
units and time periods) 
and methods appendix 




For all data inputs from multiple sources that are synthesized as part of the study: 
3 Describe how the data were identified and how the data 
were accessed. 
Narrative description of 
data seeking 
methods provided 
Main text (Methods) 
and methods appendix 
4 Specify the inclusion and exclusion criteria. Identify all ad-hoc 
exclusions. 
Narrative about 
inclusion and exclusion 
criteria by data type 
provided 
Main text (Methods) 
and methods appendix 
5 Provide information on all included data sources and their 
main characteristics. For each data source used, report 
reference information or contact name/institution, 
population represented, data collection method, year(s) of 
data collection, sex and age range, diagnostic criteria or 
measurement method, and sample size, as relevant.  
An interactive, online 
data source tool that 
provides metadata for 
data sources by 
component, 
geography, cause, risk, 
or impairment has 
been developed 
Online data citation 
tools 
6 Identify and describe any categories of input data that have 
potentially important biases (e.g., based on characteristics 
listed in item 5). 
Summary of known 
biases by cause 
included in methods 
appendix 
Methods appendix 
For data inputs that contribute to the analysis but were not synthesized as part of the study: 




Online data citation 
tools 
For all data inputs: 
8 Provide all data inputs in a file format from which data can be 
efficiently extracted (e.g., a spreadsheet as opposed to a 
PDF), including all relevant meta-data listed in item 5. For any 
data inputs that cannot be shared due to ethical or legal 
reasons, such as third-party ownership, provide a contact 
name or the name of the institution that retains the right to 
the data. 
Downloads of input 
data available through 
online tools, including 
data visualization tools 
and data query tools, 
http://ghdx.healthdata.
Online data 
visualization tools, data 
query tools, and 







available in tools will 
be made available 
upon request 
Data analysis 
9 Provide a conceptual overview of the data analysis method. A 
diagram may be helpful. 
Flow diagrams of the 
overall methodological 
processes, as well as 
cause-specific 
modelling processes, 
have been provided 
Main text (Methods) 
and methods appendix 
10 Provide a detailed description of all steps of the analysis, 
including mathematical formulae. This description should 
cover, as relevant, data cleaning, data pre-processing, data 
adjustments and weighting of data sources, and 
mathematical or statistical model(s).  
Flow diagrams and 
corresponding 
methodological write-
ups for each cause, 
as well as the 
demographics and 
causes of death 
databases and 
modelling processes, 
have been provided 
Main text (Methods) 
and methods appendix 
11 Describe how candidate models were evaluated and how the 
final model(s) were selected. 




12 Provide the results of an evaluation of model performance, if 
done, as well as the results of any relevant sensitivity 
analysis. 




13 Describe methods for calculating uncertainty of the 
estimates. State which sources of uncertainty were, and were 
not, accounted for in the uncertainty analysis. 




14 State how analytic or statistical source code used to generate 
estimates can be accessed. 
Access statement 
provided  
Code is provided in an 
online repository  
Results and Discussion 
15 Provide published estimates in a file format from which data 
can be efficiently extracted. 
Results are available 
through 
online data 
visualization tools, the 
Global Health Data 
Exchange, and the 
online data query tool 
(http://ghdx.healthdata
.org/gbd-2017) 
Main text, methods 
appendix, and online 
data tools (data 
visualization tools, data 
query tools, and the 




16 Report a quantitative measure of the uncertainty of the 
estimates (e.g. uncertainty intervals). 
Uncertainty intervals 
are provided with all 
results 
Main text, methods 
appendix, and online 
data tools (data 
visualization tools, data 
query tools, and the 
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17 Interpret results in light of existing evidence. If updating a 




changes between GBD 
rounds provided in the 
narrative of the Article 
and methods appendix 
Main text (Methods 
and Discussion) and 
methods appendix 
18 Discuss limitations of the estimates. Include a discussion of 
any modelling assumptions or data limitations that affect 
interpretation of the estimates. 
Discussion of 
limitations provided in 
the narrative of the 
main paper, as well as 
in the methodological 
write-ups in the 
methods appendix 
Main text (Limitations) 
and methods appendix 
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Risk factor Level Model type Main data source for exposure
All risk factors 0
Environmental/occupational risks 1
Unsafe water, sanitation, and handwashing 2
Unsafe water source 3 Spatiotemporal Gauissian process regression (ST-GPR) Population surveys and censuses
Unsafe sanitation 3 ST-GPR Population surveys and censuses
No handwashing with soap 3 ST-GPR Population surveys, censuses, and epidemiological studies
Air pollution 2
3
Ambient particulate matter pollution 4 Regression crosswalk between grid-level fusion of 
satellite/chemical transport models and ground level 
monitoring data
Atmospheric chemical transport models, satellite measurements of 
aerosols in the atmosphere, data from ground-level monitoring sites
Household air pollution from solid fuels 4 ST-GPR Population surveys and censuses
Ambient ozone pollution 3 Chemical transport model Atmospheric chemical transport models 
Other environmental risks 2
Residential radon 3 ST-GPR Literature review
Lead exposure 3 ST-GPR Literature review
Occupational risks 2
Occupational carcinogens 3
Occupational exposure to asbestos 4 Asbestos Impact Ratio approach GBD cause-specific mortality data for mesothelioma, epidemiological 
studies
Occupational exposure to arsenic 4 ST-GPR Labor force surveys, censuses, and international information system on 
occupational exposure to carcinogens
Occupational exposure to benzene 4 ST-GPR Labor force surveys, censuses, and international information system on 
occupational exposure to carcinogens
Occupational exposure to beryllium 4 ST-GPR Labor force surveys, censuses, and international information system on 
occupational exposure to carcinogens
Occupational exposure to cadmium 4 ST-GPR Labor force surveys, censuses, and international information system on 
occupational exposure to carcinogens
Occupational exposure to chromium 4 ST-GPR Labor force surveys, censuses, and international information system on 
occupational exposure to carcinogens
Occupational exposure to diesel engine exhaust 4 ST-GPR Labor force surveys, censuses, and international information system on 
occupational exposure to carcinogens
Occupational exposure to formaldehyde 4 ST-GPR Labor force surveys, censuses, and international information system on 
occupational exposure to carcinogens
Occupational exposure to nickel 4 ST-GPR Labor force surveys, censuses, and international information system on 
occupational exposure to carcinogens
Occupational exposure to polycyclic aromatic 
hydrocarbons
4 ST-GPR Labor force surveys, censuses, and international information system on 
occupational exposure to carcinogens
Occupational exposure to silica 4 ST-GPR Labor force surveys, censuses, and international information system on 
occupational exposure to carcinogens
Occupational exposure to sulfphuric acid 4 ST-GPR Labor force surveys, censuses, and international information system on 
occupational exposure to carcinogens
Occupational exposure to trichloroethylene 4 ST-GPR Labor force surveys, censuses, and international information system on 
occupational exposure to carcinogens
Occupational asthmagens 3 ST-GPR Labor force surveys and censuses
3 ST-GPR Labor force surveys and censuses
Occupational noise 3 ST-GPR Labor force surveys and censuses, industry-based surveys of noise 
exposure
Occupational injuries 3 ST-GPR International Labor Organization injury database
Occupational ergonomic factors 3 ST-GPR Labor force surveys and censuses
Behavioural risks 1
Child and maternal malnutrition 2
Suboptimal breastfeeding 3
Non-exclusive breastfeeding 4 ST-GPR Population surveys
Discontinued breastfeeding 4 ST-GPR Population surveys
Childhood undernutrition 3
Childhood underweight 4 ST-GPR Examination surveys and epidemiological studies
Childhood wasting 4 ST-GPR Examination surveys and epidemiological studies
Childhood stunting 4 ST-GPR Examination surveys and epidemiological studies
Iron deficiency 3 Mixed effect regression Examination surveys and epidemiological studies
Vitamin A deficiency 3 DisMod-MR 2.1 Examination surveys and epidemiological studies
Zinc deficiency 3 Mixed effect regression based on stunting prevalence and 
dietary composition
FAO food balance sheets
Tobacco smoke 2
Smoking 3 • Smoking Impact Ratio (SIR) calculated from lung cancer
mortality rates 
• Smoking prevalence estimated using ST-GPR
SIR input data: mortality and cause of death data including vital 
registration and verbal autopsy  
Smoking prevalence input data: nationally representative survey and 
report data
Second-hand smoke 3 DisMod-MR 2.1 Household surveys and national health surveys
Appendix Table 2. GBD 2017 risk factor hierarchy with levels, modeling strategies, and the main type of data sources used to estimate exposure levels
GBD=Global Burden of Disease.
Particulate matter pollution
Occupational particulate matter, gases, and fumes
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Risk factor Level Model type Main data source for exposure
Alcohol use 2 • Alcohol consumption per capita obtained from the FAO 
and the WHO Global Information System on Alcohol and 
Health (GISAH) 
• ST-GPR used to integrate the data and to derive 
coherent time series for each country 
• Prevalence of current alcohol drinkers, lifetime 
abstainers, former drinkers, and binge drinkers estimated 
using DisMod-MR 2.1
• DisMod-MR 2.1 used to estimate the relative sex- and 
age-specific pattern of alcohol consumption in current 
drinkers
Population surveys, alcohol sales, production, and other economic 
statistics
Drug Use 2 DisMod-MR 2.1 Systematic review of published literature, reports from governments and 
international organizations, which include data from: school surveys, 
population surveys, registration data, and indirect estimates of prevalence
Dietary risks 2
Diet low in fruits 3 DisMod-MR 2.1 Nutrition and health surveys, FAO food balance sheets
Diet low in vegetables 3 DisMod-MR 2.1 Nutrition and health surveys, FAO food balance sheets
Diet low in whole grains 3 DisMod-MR 2.1 Nutrition and health surveys
Diet low in nuts and seeds 3 DisMod-MR 2.1 Nutrition and health surveys, FAO food balance sheets
Diet low in milk 3 DisMod-MR 2.1 Nutrition and health surveys, FAO food balance sheets
Diet high in red meat 3 DisMod-MR 2.1 Nutrition and health surveys, FAO food balance sheets
Diet high in processed meat 3 DisMod-MR 2.1 Nutrition and health surveys
3 DisMod-MR 2.1 Nutrition and health surveys
Diet low in fibre 3 DisMod-MR 2.1 Nutrition and health surveys, FAO SUA/USDA
3 DisMod-MR 2.1 Nutrition and health surveys, FAO SUA/USDA
3 DisMod-MR 2.1 Nutrition and health surveys, FAO SUA/USDA
3 DisMod-MR 2.1 Nutrition and health surveys, FAO SUA/USDA
Diet high in trans fatty acids 3 DisMod-MR 2.1 Nutrition and health surveys
Diet high in sodium 3 DisMod-MR 2.1 Nutrition and health surveys
Intimate partner violence 2 DisMod-MR 2.1 Systematic review of published literature, national health surveys, 
violence-specific surveys
Childhood maltreatment 2
Childhood sexual abuse 3 DisMod-MR 2.1 Systematic review of published literature, national health surveys, 
violence-specific surveys
Bullying victimization 3 DisMod-MR 2.1 Systematic review of published literature and surveys reporting bullying 
victimization, including  Global School-based Student Health Survey 
(GSHS), the Health Behavior in School-aged Children (HBSC), and the 
National Crime Victimization Survey – School Crime Supplement 
(NCVS-SCS).
Unsafe sex 2 DisMod-MR 2.1 UNAIDS country progress reports, disease surveillance reports 
Low physical activity 2 DisMod-MR 2.1 Surveys of the adult population that capture reported frequency, duration 
and intensity of physical activity undertaken in the past seven days across 
all domains of life (work, transport, recreation or house/yard work)
Metabolic risks 1
High fasting plasma glucose 2 ST-GPR Examination surveys and epidemiological studies
High LDL cholesterol 2 ST-GPR Examination surveys and epidemiological studies
High systolic blood pressure 2 ST-GPR Examination surveys and epidemiological studies
High body-mass index 2 ST-GPR Examination surveys and epidemiological studies
Low bone mineral density 2 DisMod-MR 2.1 Examination surveys and epidemiological studies
Low glomerular filtration rate 2 DisMod-MR 2.1 Examination surveys and epidemiological studies
Diet low in seafood omega-3 fatty acids 
Diet low in polyunsaturated fatty acids
Diet high in sugar-sweetened beverages
























































































































































































































































































2 Unsafe water, sanitation, and 
handwashing
3 Unsafe water source - chlorination or solar 
(point of use treatment)
Diarrhoeal diseases 25 0 44 6 0 - - Yes - Yes No
3 Unsafe water source - piped Diarrhoeal diseases 1 0 0 9 11 - - Yes - Yes No
3 Unsafe water source - filter Diarrhoeal diseases 11 0 45 2 0 - - Yes - Yes No
3 Unsafe water source - improved water Diarrhoeal diseases 0 - - 5 0 - - Yes - Yes No
3 Unsafe sanitation - piped Diarrhoeal diseases 0 - - 7 0 - - Yes - Yes No
3 Unsafe sanitation - improved sanitation Diarrhoeal diseases 1 - 100 11 0 - - Yes - Yes No
3 No access to handwashing facility Diarrhoeal diseases 19 0 42 0 - - - No - Yes No
3 No access to handwashing facility Lower respiratory infections 8 0 50 11 0 - - No - Yes No
2 Air pollution
3 Particulate matter pollution
4 Ambient particulate matter pollution Lower respiratory infections 0 - - 17 0 - - No Yes Yes No
4 Ambient particulate matter pollution Tracheal, bronchus, and lung cancer 0 - - 30 0 - - No Yes Yes Yes
4 Ambient particulate matter pollution Ischaemic heart disease 0 - - 16 0 - - No Yes Yes Yes
4 Ambient particulate matter pollution Ischaemic stroke 0 - - 30 0 - - No Yes Yes Yes
4 Ambient particulate matter pollution Intracerebral hemorrhage 0 - - 30 0 - - No Yes Yes Yes
4 Ambient particulate matter pollution Subarachnoid hemorrhage 0 - - 30 0 - - No Yes Yes Yes
4 Ambient particulate matter pollution Chronic obstructive pulmonary disease 0 - - 12 0 - - No Yes Yes Yes
4 Ambient particulate matter pollution Diabetes mellitus type 2 0 - - 8 0 - - Yes Yes
4 Household air pollution from solid fuels Lower respiratory infections 2 0 1 8 0 17 0 No Yes Yes No
4 Household air pollution from solid fuels Tracheal, bronchus, and lung cancer 0 - - 0 - 28 0 No Yes Yes Yes
4 Household air pollution from solid fuels Ischaemic heart disease 0 - - 2 - 2 - No Yes Yes Yes
4 Household air pollution from solid fuels Ischaemic stroke 0 - - 1 - - - No Yes Yes Yes
4 Household air pollution from solid fuels Intracerebral hemorrhage 0 - - 1 - - - No Yes Yes Yes
4 Household air pollution from solid fuels Subarachnoid hemorrhage 0 - - 1 - - - No Yes Yes Yes
4 Household air pollution from solid fuels Chronic obstructive pulmonary disease 0 - - 0 - 11 0 No Yes Yes Yes
4 Household air pollution from solid fuels Diabetes mellitus type 2 0 - - 1 - - - Yes Yes
4 Household air pollution from solid fuels Cataract 0 - - 0 - 8 0 No Yes Yes No
3 Ambient ozone pollution Chronic obstructive pulmonary disease 0 - - 3 0 - - No Yes Yes No
2 Other environmental risks
3 Residential radon Tracheal, bronchus, and lung cancer 0 - - 1 0 29 0 No Yes Yes No
3 Lead exposure Idiopathic developmental intellectual 
disability
0 - - 8 0 - - No Yes Yes No
3 Lead exposure Systolic blood pressure 0 - - 3 0 1 0 No Yes Yes No
2 Occupational risks
4 Occupational exposure to asbestos Larynx cancer 0 - - 27 0 - - No - Yes Yes
4 Occupational exposure to asbestos Tracheal, bronchus, and lung cancer 0 - - 18 0 - - Yes - Yes Yes
4 Occupational exposure to asbestos Ovarian cancer 0 - - 15 0 - - No - Yes Yes
4 Occupational exposure to asbestos Mesothelioma 0 - - 5 0 - - Yes - Yes Yes
4 Occupational exposure to arsenic Tracheal, bronchus, and lung cancer 0 - - 9 0 - - No - Yes No
4 Occupational exposure to benzene Leukaemia 0 - - 12 0 - - Yes - Yes No
4 Occupational exposure to beryllium Tracheal, bronchus, and lung cancer 0 - - 3 0 2 0 No - Yes No
4 Occupational exposure to cadmium Tracheal, bronchus, and lung cancer 0 - - 7 0 - - No - Yes No
4 Occupational exposure to chromium Tracheal, bronchus, and lung cancer 0 - - 26 0 - - No - Yes No
4 Occupational exposure to diesel engine 
exhaust
Tracheal, bronchus, and lung cancer 0 - - 17 0 - - No - Yes No
4 Occupational exposure to formaldehyde Nasopharynx cancer 0 - - 2 0 6 0 No - Yes Yes
4 Occupational exposure to formaldehyde Leukaemia 0 - - 13 0 - - No - Yes Yes
4 Occupational exposure to nickel Tracheal, bronchus, and lung cancer 0 - - 6 0 - - No - Yes No
4 Occupational exposure to polycyclic aromatic 
hydrocarbons
Tracheal, bronchus, and lung cancer 0 - - 39 0 - - No - Yes No
4 Occupational exposure to silica Tracheal, bronchus, and lung cancer 0 - - 17 0 - - No - Yes No
4 Occupational exposure to sulfphuric acid Larynx cancer 0 - - 14 0 - - Yes - Yes No
4 Occupational exposure to trichloroethylene Kidney cancer 0 - - 20 0 - - No - Yes No
3 Occupational asthmagens Asthma 0 - - 16 0 - - No - Yes No
3 Occupational particulate matter, gases, and 
fumes
Chronic obstructive pulmonary disease 0 - - 9 0 - - No - Yes No
3 Occupational noise Age-related and other hearing loss 0 - - 5 0 - - Yes - Yes No
3 Occupational ergonomic factors Low back pain 0 - - 10 0 - - No - Yes No
2 Child and maternal malnutrition
4 Non-exclusive breastfeeding Diarrhoeal diseases 0 - - 5 0 7 0 Yes - Yes No
4 Non-exclusive breastfeeding Lower respiratory infections 0 - - 6 0 8 0 Yes - Yes No
4 Discontinued breastfeeding Diarrhoeal diseases 0 - - 2 0 - - No - Yes No
4 Child underweight Diarrhoeal diseases 0 - - 7 0 - - Yes - Yes No
4 Child underweight Lower respiratory infections 0 - - 7 0 - - Yes - Yes No
4 Child underweight Measles 0 - - 7 0 - - Yes - Yes No
4 Child wasting Diarrhoeal diseases 0 - - 7 0 - - Yes - Yes No
4 Child wasting Lower respiratory infections 0 - - 7 0 - - Yes - Yes No
4 Child wasting Measles 0 - - 7 0 - - Yes - Yes No
4 Child stunting Diarrhoeal diseases 0 - - 7 0 - - No - Yes No
4 Child stunting Lower respiratory infections 0 - - 7 0 - - No - Yes No
4 Child stunting Measles 0 - - 7 0 - - No - Yes No
















































































































































































































































4 Short gestation for birth weight Diarrhoeal diseases 0 - - 20 0 - - Yes Yes Yes Yes
4 Short gestation for birth weight Lower respiratory infections 0 - - 20 0 - - Yes Yes Yes Yes
4 Short gestation for birth weight Upper respiratory infections 0 - - 20 0 - - Yes Yes Yes Yes
4 Short gestation for birth weight Otitis media 0 - - 20 0 - - Yes Yes Yes Yes
4 Short gestation for birth weight Pneumococcal meningitis 0 - - 20 0 - - Yes Yes Yes Yes
4 Short gestation for birth weight H influenzae type B meningitis 0 - - 20 0 - - Yes Yes Yes Yes
4 Short gestation for birth weight Meningococcal infection 0 - - 20 0 - - Yes Yes Yes Yes
4 Short gestation for birth weight Other meningitis 0 - - 20 0 - - Yes Yes Yes Yes
4 Short gestation for birth weight Encephalitis 0 - - 20 0 - - Yes Yes Yes Yes
4 Short gestation for birth weight Neonatal preterm birth complications 0 - - 20 0 - - Yes Yes Yes Yes
4 Short gestation for birth weight Neonatal encephalopathy due to birth 
asphyxia and trauma
0 - - 20 0 - - Yes Yes Yes Yes
4 Short gestation for birth weight Neonatal sepsis and other neonatal 
infections
0 - - 20 0 - - Yes Yes Yes Yes
4 Short gestation for birth weight Hemolytic disease and other neonatal 
jaundice
0 - - 20 0 - - Yes Yes Yes Yes
4 Short gestation for birth weight Other n onatal disorders 0 - - 20 0 - - Yes Yes Yes Yes
4 Short gestation for birth weight Sudden infant death syndrome 0 - - 20 0 - - Yes Yes Yes Yes
4 Low birth weight for gestation Diarrhoeal diseases 0 - - 20 0 - - Yes Yes Yes Yes
4 Low birth weight for gestation Lower respiratory infections 0 - - 20 0 - - Yes Yes Yes Yes
4 Low birth weight for gestation Upper respiratory infections 0 - - 20 0 - - Yes Yes Yes Yes
4 Low birth weight for gestation Otitis media 0 - - 20 0 - - Yes Yes Yes Yes
4 Low birth weight for gestation Pneumococcal meningitis 0 - - 20 0 - - Yes Yes Yes Yes
4 Low birth weight for gestation H influenzae type B meningitis 0 - - 20 0 - - Yes Yes Yes Yes
4 Low birth weight for gestation Meningococcal infection 0 - - 20 0 - - Yes Yes Yes Yes
4 Low birth weight for gestation Other meningitis 0 - - 20 0 - - Yes Yes Yes Yes
4 Low birth weight for gestation Encephalitis 0 - - 20 0 - - Yes Yes Yes Yes
4 Low birth weight for gestation Neonatal preterm birth complications 0 - - 20 0 - - Yes Yes Yes Yes
4 Low birth weight for gestation Neonatal encephalopathy due to birth 
asphyxia and trauma
0 - - 20 0 - - Yes Yes Yes Yes
4 Low birth weight for gestation Neonatal sepsis and other neonatal 
infections
0 - - 20 0 - - Yes Yes Yes Yes
4 Low birth weight for gestation Hemolytic disease and other neonatal 
jaundice
0 - - 20 0 - - Yes Yes Yes Yes
4 Low birth weight for gestation Other n onatal disorders 0 - - 20 0 - - Yes Yes Yes Yes
4 Low birth weight for gestation Sudden infant death syndrome 0 - - 20 0 - - Yes Yes Yes Yes
3 Vitamin A deficiency Diarrhoeal diseases 19 0 63 0 - - - No - Yes No
3 Vitamin A deficiency Measles 12 0 83 0 - - - Yes - Yes No
3 Zinc deficiency Diarrhoeal diseases 14 0 29 0 - - - No - Yes No
3 Zinc deficiency Lower respiratory infections 6 0 17 0 - - - No - Yes No
2 Tobacco
3 Smoking Tuberculosis 0 - - 4 0 10 0 No - Yes Yes
3 Smoking Lip and oral cavity cancer 0 - - 5 0 - - Yes - Yes Yes
3 Smoking Nasopharynx cancer 0 - - 4 0 28 0 Yes - Yes Yes
3 Smoking Oesophageal cancer 0 - - 5 0 - - Yes - Yes Yes
3 Smoking Colon and rectum cancer 0 - - 19 0 - - No - Yes Yes
3 Smoking Liver cancer 0 - - 54 0 - - Yes - Yes Yes
3 Smoking Gastric cancer 0 - - 19 0 - - No - Yes Yes
3 Smoking Pancreatic cancer 0 - - 19 0 - - Yes - Yes Yes
3 Smoking Larynx cancer 0 - - 5 0 - - Yes - Yes Yes
3 Smoking Tracheal, bronchus, and lung cancer 0 - - 38 0 - - Yes - Yes Yes
3 Smoking Breast cancer 0 - - 19 0 - - No - Yes Yes
3 Smoking Cervical cancer 0 - - 15 0 - - No - Yes Yes
3 Smoking Prostate cancer 0 - - 19 0 - - No - Yes Yes
3 Smoking Kidney cancer 0 - - 8 0 - - Yes - Yes Yes
3 Smoking Bladder cancer 0 - - 37 0 - - Yes - Yes Yes
3 Smoking Leukaemia 0 - - 22 0 - - No - Yes Yes
3 Smoking Ischaemic heart disease 0 - - 86 - - - No - Yes Yes
3 Smoking Stroke 0 - - 60 - - - No - Yes Yes
3 Smoking Atrial fibrillation and flutter 0 - - 16 0 - - No - Yes Yes
3 Smoking Peripheral vascular disease 0 - - 10 0 - - No - Yes Yes
3 Smoking Chronic obstructive pulmonary disease 0 - - 42 0 - - Yes - Yes Yes
3 Smoking Asthma 0 - - 8 12 - - No - Yes Yes
3 Smoking Peptic ulcer disease 0 - - 7 0 - - No - Yes No
3 Smoking Gallbladder and biliary diseases 0 - - 10 0 - - No - Yes Yes
3 Smoking Alzheimer's disease and other dementias 0 - - 13 8 - - No - Yes Yes
3 Smoking Parkinson's disease 0 - - 8 0 - - Yes - Yes Yes
3 Smoking Multiple sclerosis 0 - - 6 0 - - No - Yes Yes
3 Smoking Diabetes mellitus type 2 0 - - 88 0 - - No - Yes No
3 Smoking Rheumatoid arthritis 0 - - 5 0 - - No - Yes No
3 Smoking Low back pain 0 - - 13 0 - - No - Yes Yes
3 Smoking Cataract 0 - - 13 0 - - No - Yes No
3 Smoking Macular degeneration 0 - - 5 0 - - No - Yes No
3 Smoking Non-Hip Fracture 0 - - 14 14 - - No - Yes Yes
3 Smoking Abdominal aortic aneurysm 0 - - 10 0 - - No - Yes Yes
3 Smoking Hip fracture 0 - - 15 20 - - No - Yes Yes
3 Chewing tobacco Lip and oral cavity cancer 0 - - 4 0 21 5 Yes - Yes Yes
















































































































































































































































3 Second-hand smoke Stroke 0 - - 4 0 3 - No Yes Yes Yes
3 Second-hand smoke Lower respiratory infections 0 - - 18 0 - - No Yes Yes Yes
3 Second-hand smoke Otitis media 0 - - 1 0 4 0 No - Yes Yes
3 Second-hand smoke Tracheal, bronchus, and lung cancer 0 - - 13 0 - - No Yes Yes Yes
3 Second-hand smoke Breast cancer 0 - - 21 0 - - No - Yes Yes
3 Second-hand smoke Ischaemic heart disease 0 - - 5 0 - - No Yes Yes Yes
3 Second-hand smoke Chronic obstructive pulmonary disease 0 - - 2 0 1 0 No Yes Yes Yes
3 Second-hand smoke Diabetes mellitus type 2 0 - - 5 0 - - No - Yes Yes
2 Alcohol use Tuberculosis 0 - - 9 0 18 Yes Yes Yes Yes
2 Alcohol use Lower respiratory infections 0 - - 3 0 2 Yes Yes Yes Yes
2 Alcohol use Lip and oral cavity cancer 0 - - 26 0 - - Yes Yes Yes Yes
2 Alcohol use Nasopharynx cancer 0 - - 6 0 - - Yes Yes Yes Yes
2 Alcohol use Other pharynx cancer 0 - - 19 0 - - Yes Yes Yes Yes
2 Alcohol use Oesophageal cancer 0 - - 57 0 - - Yes Yes Yes Yes
2 Alcohol use Colon and rectum cancer 0 - - 56 0 - - Yes Yes Yes Yes
2 Alcohol use Liver cancer 0 - - 32 0 - - Yes Yes Yes Yes
2 Alcohol use Larynx cancer 0 - - 35 0 - - Yes Yes Yes Yes
2 Alcohol use Breast cancer 0 - - 123 0 - - Yes Yes Yes Yes
2 Alcohol use Ischaemic heart disease 0 - - 93 0 - - Yes Yes Yes Yes
2 Alcohol use Ischaemic stroke 0 - - 24 0 - - Yes Yes Yes Yes
2 Alcohol use Haemorrhagic stroke 0 - - 21 0 - - Yes Yes Yes Yes
2 Alcohol use Hypertensive heart disease 0 - - 13 0 - - Yes Yes Yes Yes
2 Alcohol use Atrial fibrillation and flutter 0 - - 9 0 - - Yes Yes Yes Yes
2 Alcohol use Cirrhosis 0 - - 14 0 - - Yes Yes Yes Yes
2 Alcohol use Pancreatitis 0 - - 4 0 3 0 Yes Yes Yes No
2 Alcohol use Epilepsy 0 - - 2 0 2 0 No Yes Yes No
2 Alcohol use Diabetes mellitus type 2 0 - - 43 0 - - Yes Yes Yes No
2 Alcohol use Motor vehicle road injuries 0 - - 3 0 - - Yes Yes Yes Yes
2 Alcohol use Unintentional injuries 0 - - 4 0 4 0 Yes Yes Yes Yes
2 Alcohol use Self-harm 0 - - 7 0 Yes Yes Yes Yes
2 Alcohol use Interpersonal violence 0 - - 3 0 1 0 Yes Yes Yes Yes
2 Drug use Hepatitis B 1 - - 5 0 - - No - Yes Yes
2 Drug use Hepatitis C 2 - - 10 0 - - No - Yes Yes
2 Drug use Self-harm 0 - - 15 0 0 0 No - Yes No
2 Dietary risks
3 Diet low in fruits Lip and oral cavity cancer 0 - - 2 0 15 0 No Yes Yes Yes
3 Diet low in fruits Nasopharynx cancer 0 - - 2 0 15 0 No Yes Yes Yes
3 Diet low in fruits Other pharynx cancer 0 - - 2 0 15 0 No Yes Yes Yes
3 Diet low in fruits Oesophageal cancer 0 - - 5 0 - - No Yes Yes Yes
3 Diet low in fruits Larynx cancer 0 - - 2 0 15 0 No Yes Yes Yes
3 Diet low in fruits Tracheal, bronchus, and lung cancer 0 - - 22 0 - - No Yes Yes Yes
3 Diet low in fruits Ischaemic heart disease 0 - - 9 0 - - No Yes Yes Yes
3 Diet low in fruits Ischaemic stroke 0 - - 9 0 - - No Yes Yes Yes
3 Diet low in fruits Diabetes mellitus 0 - - 9 0 - - No Yes Yes No
3 Diet low in vegetables Oesophageal cancer 0 - - 5 0 - - No Yes Yes No
3 Diet low in vegetables Ischaemic heart disease 0 - - 9 0 - - No Yes Yes Yes
3 Diet low in vegetables Ischaemic stroke 0 - - 8 0 - - No Yes Yes Yes
3 Diet low in vegetables Haemorrhagic stroke 0 - - 5 0 - - No Yes Yes Yes
3 Diet low in legumes Ischaemic heart disease 0 - - 5 0 - - No Yes Yes No
3 Diet low in whole grains Ischaemic heart disease 0 - - 7 0 - - No Yes Yes Yes
3 Diet low in whole grains Ischaemic stroke 0 - - 6 0 - - No Yes Yes Yes
3 Diet low in whole grains Haemorrhagic stroke 0 - - 6 0 - - No Yes Yes Yes
3 Diet low in whole grains Diabetes mellitus 0 - - 10 0 - - No Yes Yes No
3 Diet low in nuts and seeds Ischaemic heart disease 1 0 100 6 0 - - No Yes Yes No
3 Diet low in nuts and seeds Diabetes mellitus 1 0 100 5 0 - - No Yes Yes No
3 Diet low in milk Colon and rectum cancer 0 - - 7 0 - - No Yes Yes No
3 Diet high in red meat Colon and rectum cancer 0 - - 8 0 - - No Yes Yes No
3 Diet high in red meat Diabetes mellitus 0 - - 9 11 - - No Yes Yes No
3 Diet high in processed meat Colon and rectum cancer 0 - - 9 11 - - No Yes Yes No
3 Diet high in processed meat Ischaemic heart disease 0 - - 5 0 - - No Yes Yes No
3 Diet high in processed meat Diabetes mellitus 0 - - 8 0 - - No Yes Yes No
3 Diet high in sugar-sweetened beverages Diabetes mellitus type 2 0 - - 17 0 - - No Yes Yes No
3 Diet high in sugar-sweetened beverages Ischemic heart disease 0 - - 4 0 - - No Yes Yes No
3 Diet low in fibre Colon and rectum cancer 0 - - 15 0 - - No Yes Yes No
3 Diet low in fibre Ischaemic heart disease 0 - - 12 0 - - No Yes Yes No
3 Diet low in calcium Colon and rectum cancer 0 - - 13 0 - - No Yes Yes No
3 Diet low in seafood omega-3 fatty acids Ischaemic heart disease 17 0 94 16 0 - - No Yes Yes No
3 Diet low in polyunsaturated fatty acids Ischaemic heart disease 8 0 75 11 0 - - No Yes Yes No
3 Diet high in trans fatty acids Ischaemic heart disease 0 - - 13 0 - - No Yes Yes No
3 Diet high in sodium Stomach cancer 0 - - 10 0 - - No Yes Yes No
3 Diet high in sodium Systolic blood pressure 45 0 73 0 - - - No Yes Yes No
2 Child maltreatment
3 Childhood sexual abuse Alcohol use disorders 0 - - 2 0 3 0 No - Yes Yes
3 Childhood sexual abuse Depressive disorders 0 - - 7 0 - - No - Yes Yes
















































































































































































































































3 Bullying victimization Depressive disorders 0 - - 19 0 0 0 No Yes Yes No
2 Intimate partner violence HIV/AIDS 0 - - 2 0 0 0 No - Yes No
2 Intimate partner violence Maternal abortion and miscarriage 0 - - 1 0 3 0 Yes - Yes No
2 Intimate partner violence Depressive disorders 0 - - 4 0 0 0 No - Yes Yes
2 Low physical activity Colon and rectum cancer 0 - - 20 15 - - No Yes Yes Yes
2 Low physical activity Breast cancer 0 - - 35 0 - - No Yes Yes Yes
2 Low physical activity Ischaemic heart disease 0 - - 45 9 - - No Yes Yes Yes
2 Low physical activity Ischaemic stroke 0 - - 27 11 - - No Yes Yes Yes
2 Low physical activity Diabetes mellitus 0 - - 57 7 - - No Yes Yes No
2 High fasting plasma glucose Tuberculosis 0 - - 18 0 - - Yes Yes Yes No
2 High fasting plasma glucose Colon and rectum cancer 0 - - 21 0 - - No - - Yes
2 High fasting plasma glucose Liver cancer 0 - - 28 0 - - Yes - - No
2 High fasting plasma glucose Pancreatic cancer 0 - - 35 0 - - Yes - - Yes
2 High fasting plasma glucose Lung cancer 0 - - 16 6 - - No - - Yes
2 High fasting plasma glucose Breast cancer 0 - - 39 0 - - No - - Yes
2 High fasting plasma glucose Ovarian cancer 0 - - 11 0 - - No - - Yes
2 High fasting plasma glucose Bladder cancer 0 - - 14 0 - - No - - Yes
2 High fasting plasma glucose Ischaemic heart disease 8 0 100 150 - - - Yes Yes Yes Yes
2 High fasting plasma glucose Ischaemic stroke 9 0 100 150 - - - Yes Yes Yes Yes
2 High fasting plasma glucose Subarachnoid hemorrhage 9 0 100 150 - - - Yes Yes Yes Yes
2 High fasting plasma glucose Intracerebral hemorrhage 9 0 100 150 - - - Yes Yes Yes Yes
2 High fasting plasma glucose Alzheimer's disease and other dementias 0 - - 17 0 - - No - - No
2 High fasting plasma glucose Peripheral vascular disease 14 - - 4 0 - - Yes Yes Yes Yes
2 High fasting plasma glucose Chronic kidney disease 5 - - 32 - - - Yes Yes Yes No
2 High fasting plasma glucose Glaucoma 0 - - 5 0 - - No - - Yes
2 High fasting plasma glucose Cataract 0 - - 1 0 1 0 No - - Yes
2 High LDL cholesterol Ischaemic heart disease 21 0 57 88 - - - Yes Yes Yes Yes
2 High LDL cholesterol Ischaemic stroke 21 0 57 88 - - - Yes Yes Yes Yes
2 High systolic blood pressure Rheumatic heart disease 0 - - 62 - - - Yes Yes Yes Yes
2 High systolic blood pressure Ischaemic heart disease 56 0 - 88 - - - Yes Yes Yes Yes
2 High systolic blood pressure Ischaemic stroke 54 0 - 150 - - - Yes Yes Yes Yes
2 High systolic blood pressure Intracerebral hemorrhage 54 0 - 150 - - - Yes Yes Yes Yes
2 High systolic blood pressure Subarachnoid hemorrhage 54 0 - 150 - - - Yes Yes Yes Yes
2 High systolic blood pressure Cardiomyopathy and myocarditis 0 - - 62 - - - Yes Yes Yes Yes
2 High systolic blood pressure Other cardiomyopathy 0 - - 62 - - - Yes Yes Yes Yes
2 High systolic blood pressure Atrial fibrillation and flutter 20 5 60 88 - - - Yes Yes Yes Yes
2 High systolic blood pressure Aortic aneurysm 0 - - 62 - - - Yes Yes Yes Yes
2 High systolic blood pressure Peripheral vascular disease 0 - - 88 - - - Yes Yes Yes Yes
2 High systolic blood pressure Endocarditis 0 - - 62 - - - Yes Yes Yes Yes
3 High systolic blood pressure Other cardiovascular and circulatory diseases 0 - - 88 - - - No Yes Yes Yes
2 High systolic blood pressure Non-rheumatic calcific aortic valve disease 0 - - 2 0 1 0 No Yes Yes Yes
2 High systolic blood pressure Chronic kidney disease 8 - - 88 - - - Yes Yes Yes No
2 High body-mass index (adult) Oesophageal cancer 0 - - 6 0 - - No Yes Yes Yes
2 High body-mass index (adult) Non-hodgkin lymphoma 0 - - 18 0 - - No Yes Yes Yes
2 High body-mass index (adult) Colon and rectum cancer 0 - - 38 0 - - No Yes Yes Yes
2 High body-mass index (adult) Liver cancer 0 - - 34 0 - - No Yes Yes Yes
2 High body-mass index (adult) Gallbladder and biliary tract cancer 0 - - 10 0 - - No Yes Yes Yes
2 High body-mass index (adult) Pancreatic cancer 0 - - 20 0 - - No Yes Yes Yes
2 High body-mass index (adult) Breast cancer (pre-menopausal) 0 - - 44 2 - - No Yes Yes Yes
2 High body-mass index (adult) Breast cancer (post-menopausal) 0 - - 25 8 - - No Yes Yes No
2 High body-mass index (adult) Uterine cancer 0 - - 37 0 - - No Yes Yes Yes
2 High body-mass index (adult) Ovarian cancer 0 - - 31 3 - - No Yes Yes Yes
2 High body-mass index (adult) Kidney cancer 0 - - 28 0 - - No Yes Yes Yes
2 High body-mass index (adult) Thyroid cancer 0 - - 16 0 - - No Yes Yes Yes
2 High body-mass index (adult) Multiple myeloma 0 - - 20 - - - - Yes Yes Yes
2 High body-mass index (adult) Leukaemia 0 - - 17 0 - - No Yes Yes Yes
2 High body-mass index (adult) Ischaemic heart disease 0 - - 129 - - - No Yes Yes Yes
2 High body-mass index (adult) Ischaemic stroke 0 - - 102 - - - No Yes Yes Yes
2 High body-mass index (adult) Haemorrhagic stroke 0 - - 129 - - - No Yes Yes Yes
2 High body-mass index (adult) Hypertensive heart disease 0 - - 85 - - - No Yes Yes Yes
2 High body-mass index (adult) Atrial fibrillation and flutter 0 - - 5 0 - - - No Yes Yes
2 High body-mass index (adult) Asthma 0 - - 7 0 - - - Yes Yes No
2 High body-mass index (adult) Alzheimer's disease and other dementias 0 - - 6 0 - - - No Yes No
2 High body-mass index (adult) Gallbladder disease 0 - - 16 0 - - - Yes Yes Yes
2 High body-mass index (adult) Diabetes mellitus 0 - - 85 - - - Yes Yes Yes No
2 High body-mass index (adult) Chronic kidney disease 0 - - 57 - - - No Yes Yes No
2 High body-mass index (adult) Osteoarthritis 0 - - 32 0 - - No Yes Yes Yes
2 High body-mass index (adult) Low back pain 0 - - 5 0 - - No Yes Yes Yes
2 High body-mass index (adult) Gout 0 - - 10 0 - - - Yes Yes No
2 High body-mass index (adult) Cataract 0 - - 17 0 - - - Yes Yes No
2 High body-mass index (child) Asthma 0 - - 5 0 - - No Yes Yes No
















































































































































































































































2 Impaired kidney function Ischaemic heart disease 0 - - 6 0 - - Yes - Yes Yes
2 Impaired kidney function Ischaemic stroke 0 - - 6 0 - - Yes - Yes Yes
2 Impaired kidney function Intracerebral hemorrhage 0 - - 8 0 - - Yes - Yes Yes
2 Impaired kidney function Peripheral vascular disease 0 - - 5 0 - - Yes - Yes Yes




Unsafe water Diarrhoeal diseases
Cairncross S, Valdmanis V. Water Supply, Sanitation, and Hygiene Promotion. In: Jamison DT, Breman JG, 
Measham AR, et al., eds. Disease Control Priorities in Developing Countries, 2nd edn. Washington (DC): 
World Bank, 2006.
Unsafe water Diarrhoeal diseases
Wolf J, Prüss-Ustün A, Cumming O, et al. Assessing the impact of drinking water and sanitation on 
diarrhoeal disease in low- and middle-income settings: systematic review and meta-regression. Trop Med Int 
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Unsafe water Diarrhoeal diseases
Fewtrell, L., Kaufmann, R. B., Kay, D., Enanoria, W., Haller, L., & Colford, J. M. (2005). Water, sanitation, 
and hygiene interventions to reduce diarrhoea in less developed countries: a systematic review and meta-
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Unsafe sanitation - improved 
sanitation Diarrhoeal diseases
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Unsafe sanitation - improved 
sanitation Diarrhoeal diseases
Fewtrell, L., Kaufmann, R. B., Kay, D., Enanoria, W., Haller, L., & Colford, J. M. (2005). Water, sanitation, 
and hygiene interventions to reduce diarrhoea in less developed countries: a systematic review and meta-
analysis. The Lancet Infectious Diseases, 5(1), 42-52. doi:10.1016/s1473-3099(04)01253-8
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No access to handwashing 
facility Diarrhoeal diseases
Ejemot-Nwadiaro RI, Ehiri JE, Arikpo D, Meremikwu MM, Critchley JA. Hand washing promotion for 
preventing diarrhoea. Cochrane Database Syst Rev 2015; : CD004265.
No access to handwashing 
facility Lower respiratory infections
Rabie T, Curtis V. Handwashing and risk of respiratory infections: a quantitative systematic review. Trop 
Med Int Health Tropical Medicine and International Health. 2006;11(3):258–67.
No access to handwashing 
facility Lower respiratory infections
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Ambient particulate matter 
pollution Lower respiratory infections
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review. Environ Health 2013; 12: 43.
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pollution Lower respiratory infections
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pollution components and risk for lung cancer. Environ Int. 2016 Feb;87:66–73.
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pollution
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Cohen AJ, Brauer M, Burnett R, Anderson HR, Frostad J, Estep K, et al. Estimates and 25-year trends of the 
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Household air pollution from 
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Dherani M, Pope D, Mascarenhas M, Smith KR, Weber M, Bruce N. Indoor air pollution from unprocessed 
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Household air pollution from 
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Tracheal, bronchus and lung 
cancer
Kurmi OP, Arya PH, Lam K-BH, Sorahan T, Ayres JG. Lung cancer risk and solid fuel smoke exposure: a 
systematic review and meta-analysis. Eur Respir J. 2012 Nov;40(5):1228–37.
Household air pollution from 
solid fuels Ischaemic heart disease
Fatmi Z, Coggon D. Coronary heart disease and household air pollution from use of solid fuel: a systematic 
review. Br Med Bull. 2016 Jun;118(1):91–109.
Household air pollution from 
solid fuels Stroke
Fatmi Z, Coggon D. Coronary heart disease and household air pollution from use of solid fuel: a systematic 
review. Br Med Bull. 2016 Jun;118(1):91–109.
Household air pollution from 
solid fuels
Chronic obstructive pulmonary 
disease
Kurmi OP, Arya PH, Lam K-BH, Sorahan T, Ayres JG. Lung cancer risk and solid fuel smoke exposure: a 
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Air Pollution a Risk Factor for Eye Disease? International Journal of Environmental Research and Public 
Health, 10(11), 5378-5398. doi:10.3390/ijerph10115378
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Tracheal, bronchus and lung 
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Tracheal, bronchus and lung 
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Cancer among Never-Smokers in Sweden. Epidemiology. 2001;12(4):396–404.
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Pershagen G, Akerblom G, Axelson O, Clavensjo B, Damber L, Desai G, et al. Residential Radon Exposure 
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Lead exposure Systolic blood pressure
Navas-Acien A, Schwartz BS, Rothenberg SJ, Hu H, Silbergeld EK, Guallar E. Bone lead levels and blood 
pressure endpoints: a meta-analysis. Epidemiology 2008; 19: 496–504.
Lead exposure Systolic blood pressure
Glenn BS, Stewart WF, Links JM, Todd AC, Schwartz BS. The Longitudinal Association of Lead with Blood 
Pressure. Epidemiology. 2003;14(1):30–6.
Lead exposure Systolic blood pressure
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Lead exposure Systolic blood pressure
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Lead exposure Systolic blood pressure
Cheng Y, Schwartz J, Sparrow D, Aro A, Weiss ST, Hu H. Bone Lead and Blood Lead Levels in Relation to 
Baseline Blood Pressure and the Prospective Development of Hypertension The Normative Aging Study. 
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Lead exposure Idiopathic intellectual disability
Lanphear BP, Hornung R, Khoury J, et al. Low-level environmental lead exposure and children’s intellectual 
function: an international pooled analysis. Environ Health Perspect 2005; 113: 894–9.
Lead exposure Idiopathic intellectual disability
Liu J, Li L, Wang Y, Yan C, Liu X. Impact of low blood lead concentrations on IQ and school performance 
in Chinese children. PLoS ONE 2013; 8: e65230.
Lead exposure Idiopathic intellectual disability
Lanphear BP, Hornung R, Khoury J, et al. Low-level environmental lead exposure and children’s intellectual 
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Lead exposure Idiopathic intellectual disability
Needleman HL, Schell A, Bellinger D, Leviton A, Allred EN. The Long-Term Effects of Exposure to Low 
Doses of Lead in Childhood. New England Journal of Medicine. 1990Nov;322(2):83–8.
Occupational exposure to 
asbestos Larynx cancer
Goodman M, Morgan RW, Ray R, Malloy CD, Zhao K. Cancer in asbestos-exposed occupational cohorts: a 
meta-analysis. Cancer Causes Control 1999; 10: 453–65.
Occupational exposure to 
asbestos
Tracheal, bronchus and lung 
cancer
Lenters V, Vermeulen R, Dogger S, et al. A meta-analysis of asbestos and lung cancer: is better quality 
exposure assessment associated with steeper slopes of the exposure-response relationships? Environ Health 
Perspect 2011; 119: 1547–55.
Occupational exposure to 
asbestos Ovarian cancer
Camargo MC, Stayner LT, Straif K, et al. Occupational exposure to asbestos and ovarian cancer: a meta-
analysis. Environ Health Perspect 2011; 119: 1211–7.
Occupational exposure to 
asbestos Mesothelioma
Bourdès V, Boffetta P, Pisani P. Environmental exposure to asbestos and risk of pleural mesothelioma: 
review and meta-analysis. Eur J Epidemiol 2000; 16: 411–7.
Occupational exposure to 
arsenic
Tracheal, bronchus and lung 
cancer
Lenters V, Vermeulen R, Dogger S, et al. A meta-analysis of asbestos and lung cancer: is better quality 
exposure assessment associated with steeper slopes of the exposure-response relationships? Environ Health 
Perspect 2011; 119: 1547–55.
Occupational exposure to 
benzene Leukaemia
Khalade A, Jaakkola MS, Pukkala E, Jaakkola JJK. Exposure to benzene at work and the risk of leukemia: a 
systematic review and meta-analysis. Environ Health 2010; 9: 31.
Occupational exposure to 
beryllium
Tracheal, bronchus and lung 
cancer
Boffetta P, Fryzek JP, Mandel JS. Occupational exposure to beryllium and cancer risk: a review of the 
epidemiologic evidence. Crit Rev Toxicol 2012; 42: 107–18.
Occupational exposure to 
cadmium
Tracheal, bronchus and lung 
cancer
Verougstraete V, Lison D, Hotz P. Cadmium, lung and prostate cancer: a systematic review of recent 
epidemiological data. J Toxicol Environ Health B Crit Rev 2003; 6: 227–55.
Occupational exposure to 
chromium
Tracheal, bronchus and lung 
cancer
Denis Ambroise, Pascal Wild and Jean-Jacques Moulin, Scandinavian Journal of Work, Environment & 
Health, Vol. 32, No. 1 (February 2006), pp. 22-31
Occupational exposure to diesel 
engine exhaust
Tracheal, bronchus and lung 
cancer
Lipsett M, Campleman S. Occupational exposure to diesel exhaust and lung cancer: a meta-analysis. Am J 
Public Health 1999; 89: 1009–17.
Occupational exposure to 
formaldehyde Nasopharynx cancer
Hauptmann M, Lubin JH, Stewart PA, Hayes RB, Blair A. Mortality from solid cancers among workers in 
formaldehyde industries. Am J Epidemiol 2004; 159: 1117–30.
Occupational exposure to 
formaldehyde Leukaemia
Collins JJ, Lineker GA. A review and meta-analysis of formaldehyde exposure and leukemia. Regul Toxicol 
Pharmacol 2004; 40: 81–91.
Occupational exposure to nickel
Tracheal, bronchus and lung 
cancer
Grimsrud TK, Berge SR, Haldorsen T, Andersen A. Can lung cancer risk among nickel refinery workers be 
explained by occupational exposures other than nickel? Epidemiology 2005; 16: 146–54.
Occupational exposure to 
polycyclic aromatic 
hydrocarbons
Tracheal, bronchus and lung 
cancer
Armstrong B, Hutchinson E, Unwin J, Fletcher T. Lung cancer risk after exposure to polycyclic aromatic 
hydrocarbons: a review and meta-analysis. Environ Health Perspect 2004; 112: 970–8.
Occupational exposure to silica
Tracheal, bronchus and lung 
cancer
Liu Y, Steenland K, Rong Y, Hnizdo E, Huang X, Zhang H, et al. Exposure-Response Analysis and Risk 
Assessment for Lung Cancer in Relationship to Silica Exposure: A 44-Year Cohort Study of 34,018 Workers. 
Am J Epidemiol. 2013 Nov 1;178(9):1424–33. 
Occupational exposure to 
sulfuric acid Larynx cancer
Soskolne CL, Jhangri GS, Siemiatycki J, et al. Occupational exposure to sulfuric acid in southern Ontario, 
Canada, in association with laryngeal cancer. Scand J Work Environ Health 1992; 18: 225–32.
Occupational exposure to 
trichloroethylene Kidney cancer
Kelsh MA, Alexander DD, Mink PJ, Mandel JH. Occupational trichloroethylene exposure and kidney cancer: 
a meta-analysis. Epidemiology 2010; 21: 95–102.
Occupational asthmagens Asthma
Karjalainen A, Kurppa K, Martikainen R, Klaukka T, Karjalainen J. Work is related to a substantial portion 
of adult-onset asthma incidence in the Finnish population. Am J Respir Crit Care Med 2001; 164: 565–8.
Occupational particulate matter, 
gases, and fumes
Chronic obstructive pulmonary 
disease
Blanc PD, Iribarren C, Trupin L, et al. Occupational exposures and the risk of COPD: dusty trades revisited. 
Thorax 2009; 64: 6–12.
Occupational noise Age-related and other hearing loss
Agrawal Y, Platz EA, Niparko JK. Prevalence of hearing loss and differences by demographic characteristics 
among US adults: data from the National Health and Nutrition Examination Survey, 1999-2004. Arch Intern 
Med 2008; 168: 1522–30.
Occupational noise Age-related and other hearing loss
Davis A. The prevalence of hearing impairment and reported hearing disability among adults in Great Britain. 
International Journal of Epidemiology 1989,18: 911-917.
Occupational noise Age-related and other hearing loss
Wilson D, Walsh P, Sanchez L, Davis A, Taylor A, Tucker G, Meagher I. The epidemiology of hearing 
impairment in an Australian adult population. International Journal of Epidemiology 1999;28:247-252.
Occupational injuries Injuries
International Labour Organization. Resolution concerning statistics of occupational injuries (resulting from 




Eurostat. Accidents at work statistics. http://ec.europa.eu/eurostat/statistics-
explained/index.php/Accidents_at_work_statistics.
Occupational ergonomic factors Low back pain
Driscoll T, Jacklyn G, Orchard J, et al. The global burden of occupationally related low back pain: estimates 
from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014; 73: 975–81.
Non-exclusive breastfeeding Lower respiratory infections
Horta BL, Victora CG. Short-term effects of breastfeeding: a systematic review on the benefits of 
breastfeeding on diarrhoea and pneumonia mortality. World Health Organization, 2013 
http://allattamento.sip.it/wp-content/uploads/2014/03/WHO_breve-termine.pdf.
Non-exclusive breastfeeding Diarrhoeal diseases
Horta BL, Victora CG. Short-term effects of breastfeeding: a systematic review on the benefits of 
breastfeeding on diarrhoea and pneumonia mortality. World Health Organization, 2013 
http://allattamento.sip.it/wp-content/uploads/2014/03/WHO_breve-termine.pdf.
Discontinued breastfeeding Diarrhoeal diseases
Olofin I, McDonald CM, Ezzati M, et al. Associations of suboptimal growth with all-cause and cause-specific 
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Discontinued breastfeeding Diarrhoeal diseases
Genser, B., Strina, A., Santos, L. A., Teles, C. A., Prado, M. S., Cairncross, S., & Barreto, M. L. (2008). 
Impact of a city-wide sanitation intervention in a large urban centre on social, environmental and behavioural 
determinants of childhood diarrhoea: analysis of two cohort studies. International Journal of Epidemiology, 
37(4), 831-840. doi:10.1093/ije/dyn101
Childhood underweight Diarrhoeal diseases
Olofin I, McDonald CM, Ezzati M, et al. Associations of suboptimal growth with all-cause and cause-specific 
mortality in children under five years: a pooled analysis of ten prospective studies. PLoS ONE 2013; 8: 
e64636.
Childhood underweight Lower respiratory infections
Olofin I, McDonald CM, Ezzati M, et al. Associations of suboptimal growth with all-cause and cause-specific 
mortality in children under five years: a pooled analysis of ten prospective studies. PLoS ONE 2013; 8: 
e64636.
Childhood underweight Measles
Olofin I, McDonald CM, Ezzati M, et al. Associations of suboptimal growth with all-cause and cause-specific 
mortality in children under five years: a pooled analysis of ten prospective studies. PLoS ONE 2013; 8: 
e64636.
Childhood wasting Diarrhoeal diseases
Olofin I, McDonald CM, Ezzati M, et al. Associations of suboptimal growth with all-cause and cause-specific 
mortality in children under five years: a pooled analysis of ten prospective studies. PLoS ONE 2013; 8: 
e64636.
Childhood wasting Lower respiratory infections
Olofin I, McDonald CM, Ezzati M, et al. Associations of suboptimal growth with all-cause and cause-specific 
mortality in children under five years: a pooled analysis of ten prospective studies. PLoS ONE 2013; 8: 
e64636.
Childhood wasting Measles
Olofin I, McDonald CM, Ezzati M, et al. Associations of suboptimal growth with all-cause and cause-specific 
mortality in children under five years: a pooled analysis of ten prospective studies. PLoS ONE 2013; 8: 
e64636.
Childhood stunting Diarrhoeal diseases
Olofin I, McDonald CM, Ezzati M, et al. Associations of suboptimal growth with all-cause and cause-specific 
mortality in children under five years: a pooled analysis of ten prospective studies. PLoS ONE 2013; 8: 
e64636.
Childhood stunting Lower respiratory infections
Olofin I, McDonald CM, Ezzati M, et al. Associations of suboptimal growth with all-cause and cause-specific 
mortality in children under five years: a pooled analysis of ten prospective studies. PLoS ONE 2013; 8: 
e64636.
Childhood stunting Measles
Olofin I, McDonald CM, Ezzati M, et al. Associations of suboptimal growth with all-cause and cause-specific 
mortality in children under five years: a pooled analysis of ten prospective studies. PLoS ONE 2013; 8: 
e64636.
Iron deficiency Maternal hemorrhage
Murray-Kolb LE, Chen L, Chen P, Shapiro M, Caulfield L. CHERG Iron Report: Maternal Mortality, Child 
Mortality, Perinatal Mortality, Child Cognition, and Estimates of Prevalence of Anemia due to Iron 
Deficiency. Baltimore, USA: CHERG, 2012.
Vitamin A deficiency Diarrhoeal diseases
Awasthi S, Peto R, Read S, et al. Vitamin A supplementation every 6 months with retinol in 1 million pre-
school children in north India: DEVTA, a cluster-randomised trial. Lancet 2013; 381: 1469–77.
Vitamin A deficiency Diarrhoeal diseases
Diness BR, Christoffersen D, Pedersen UB, Rodrigues A, Fischer TK, Andersen A, Whittle H, Yazdanbakhsh 
M, Aaby P, Benn CS. The effect of high-dose vitamin A supplementation given with bacille Calmette-Guérin 
vaccine at birth on infant rotavirus infection and diarrhea: a randomized prospective study from Guinea-
Bissau. J Infect Dis. 2010; S243-251.
Vitamin A deficiency Diarrhoeal diseases
Imdad A, Herzer K, Mayo-Wilson E, Yakoob MY, Bhutta ZA. Vitamin A supplementation for preventing 
morbidity and mortality in children from 6 months to 5 years of age. Cochrane Database Syst Rev. 2010; 
CD008524.
Vitamin A deficiency Diarrhoeal diseases
Imdad A, Yakoob MY, Sudfeld C, Haider BA, Black RE, Bhutta ZA. Impact of vitamin A supplementation 
on infant and childhood mortality. BMC Public Health. 2011; S20.
Vitamin A deficiency Measles
Awasthi S, Peto R, Read S, et al. Vitamin A supplementation every 6 months with retinol in 1 million pre-
school children in north India: DEVTA, a cluster-randomised trial. Lancet 2013; 381: 1469–77.
Vitamin A deficiency Measles
Imdad A, Herzer K, Mayo-Wilson E, Yakoob MY, Bhutta ZA. Vitamin A supplementation for preventing 
morbidity and mortality in children from 6 months to 5 years of age. Cochrane Database Syst Rev. 2010; 
CD008524.
Vitamin A deficiency Measles
Imdad A, Yakoob MY, Sudfeld C, Haider BA, Black RE, Bhutta ZA. Impact of vitamin A supplementation 
on infant and childhood mortality. BMC Public Health. 2011; S20.
Zinc deficiency Diarrhoeal diseases
Shankar AH, Prasad AS. Zinc and immune function: the biological basis of altered resistance to infection. 
Am J Clin Nutr 1998; 68: 447S–463S.
Zinc deficiency Diarrhoeal diseases
Yakoob MY, Theodoratou E, Jabeen A, et al. Preventive zinc supplementation in developing countries: 
impact on mortality and morbidity due to diarrhea, pneumonia and malaria. BMC Public Health 2011; 11 
Suppl 3: S23.
Zinc deficiency Lower respiratory infections
Shankar AH, Prasad AS. Zinc and immune function: the biological basis of altered resistance to infection. 
Am J Clin Nutr 1998; 68: 447S–463S.
Zinc deficiency Lower respiratory infections
Yakoob MY, Theodoratou E, Jabeen A, et al. Preventive zinc supplementation in developing countries: 
impact on mortality and morbidity due to diarrhea, pneumonia and malaria. BMC Public Health 2011; 11 
Suppl 3: S23.
Smoking Lower respiratory infections
Surgeon General’s Report - The Health Consequences of Smoking. U.S. Department of Health & Human 
Services, 2004 http://www.cdc.gov/tobacco/data_statistics/sgr/2004/.
Smoking Larynx cancer
Carter BD, Abnet CC, Feskanich D, et al. Smoking and mortality--beyond established causes. N Engl J Med 
2015; 372: 631–40.
Smoking Lip and oral cavity cancer





Appendix Table 5. Epidemiological evidence supporting causality between risk-outcome pairs included in the Global Burden of Disease 2017 study including A. 
Citations and B. Additional information
Smoking
Tracheal, bronchus and lung 
cancer
International Agency for Research on Cancer Working Group on the Evaluation of Carcinogenic Risks to 
Humans. IARC monographs on the evaluation of carcinogenic risks to humans: Tobacco Smoke and 
Involuntary Smoking. Lyon: IARC, 2004.
Smoking Breast cancer
Ordóñez-Mena JM, Schöttker B, Mons U, et al. Quantification of the smoking-associated cancer risk with 
rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES 
consortium. BMC Medicine 2016; 14: 62.
Smoking Cervical cancer
International Agency for Research on Cancer Working Group on the Evaluation of Carcinogenic Risks to 
Humans. IARC monographs on the evaluation of carcinogenic risks to humans: Tobacco Smoke and 
Involuntary Smoking. Lyon: IARC, 2004.
Smoking Prostate cancer
Islami F, Moreira DM, Boffetta P, Freedland SJ. A Systematic Review and Meta-analysis of Tobacco Use and 
Prostate Cancer Mortality and Incidence in Prospective Cohort Studies. European Urology 2014; 66: 
1054–64.
Smoking Kidney cancer
International Agency for Research on Cancer Working Group on the Evaluation of Carcinogenic Risks to 
Humans. IARC monographs on the evaluation of carcinogenic risks to humans: Tobacco Smoke and 
Involuntary Smoking. Lyon: IARC, 2004.
Smoking Nasopharynx cancer
Xue W-Q, Qin H-D, Ruan H-L, Shugart YY, Jia W-H. Quantitative Association of Tobacco Smoking With 
the Risk of Nasopharyngeal Carcinoma: A Comprehensive Meta-Analysis of Studies Conducted Between 
1979 and 2011. Am J Epidemiol 2013; 178: 325–38.
Smoking Bladder cancer
Cumberbatch MG, Rota M, Catto JWF, La Vecchia C. The Role of Tobacco Smoke in Bladder and Kidney 
Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. Eur Urol 
2016; 70: 458–66.
Smoking Leukaemia
Colamesta V, D’Aguanno S, Breccia M, Bruffa S, Cartoni C, Torre GL. Do the smoking intensity and 
duration, the years since quitting, the methodological quality and the year of publication of the studies affect 
the results of the meta-analysis on cigarette smoking and Acute Myeloid Leukemia (AML) in adults? Critical 
Reviews in Oncology / Hematology 2016; 99: 376–88.
Smoking Oesophageal cancer
Surgeon General’s Report - The Health Consequences of Smoking. U.S. Department of Health & Human 
Services, 2004 http://www.cdc.gov/tobacco/data_statistics/sgr/2004/.
Smoking Stomach cancer
Ordóñez-Mena JM, Schöttker B, Mons U, et al. Quantification of the smoking-associated cancer risk with 
rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES 
consortium. BMC Medicine 2016; 14: 62.
Smoking Colon and rectum cancer
Surgeon General’s Report - The Health Consequences of Smoking. U.S. Department of Health & Human 
Services, 2004 http://www.cdc.gov/tobacco/data_statistics/sgr/2004/.
Smoking Liver cancer
Surgeon General’s Report - The Health Consequences of Smoking. U.S. Department of Health & Human 
Services, 2004 http://www.cdc.gov/tobacco/data_statistics/sgr/2004/.
Smoking Pancreatic cancer
Ordóñez-Mena JM, Schöttker B, Mons U, et al. Quantification of the smoking-associated cancer risk with 
rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES 
consortium. BMC Medicine 2016; 14: 62.
Smoking Ischaemic heart disease
Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared 
with men: a systematic review and meta-analysis of prospective cohort studies. Lancet 2011; 378: 1297–305.
Smoking Cerebrovascular disease
Peters SAE, Huxley RR, Woodward M. Smoking as a risk factor for stroke in women compared with men: a 
systematic review and meta-analysis of 81 cohorts, including 3,980,359 individuals and 42,401 strokes. 
Stroke 2013; 44: 2821–8.
Smoking Atrial fibrillation and flutter
Zhu W, Yuan P, Shen Y, Wan R, Hong K. Association of smoking with the risk of incident atrial fibrillation: 
A meta-analysis of prospective studies. Int J Cardiol 2016; 218: 259–66.
Smoking Abdominal aortic aneurysm
Lederle FA, Nelson DB, Joseph AM. Smokers’ relative risk for aortic aneurysm compared with other 
smoking-related diseases: a systematic review. J Vasc Surg 2003; 38: 329–34.
Smoking Peripheral vascular disease
Lu L, Mackay DF, Pell JP. Meta-analysis of the association between cigarette smoking and peripheral arterial 
disease. Heart 2014; 100: 414–23.
Smoking
Chronic obstructive pulmonary 
disease
Forey BA, Thornton AJ, Lee PN. Systematic review with meta-analysis of the epidemiological evidence 
relating smoking to COPD, chronic bronchitis and emphysema. BMC Pulm Med 2011; 11: 36.
Smoking Asthma
Jayes L, Haslam PL, Gratziou CG, et al. SmokeHaz: Systematic Reviews and Meta-analyses of the Effects of 
Smoking on Respiratory Health. Chest 2016; 150: 164–79.
Smoking Peptic ulcer disease
Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, 
Helicobacter pylori, and smoking. J Clin Gastroenterol 1997; 24: 2–17.
Smoking
Gallbladder and biliary tract 
disease
Aune D, Vatten LJ, Boffetta P. Tobacco smoking and the risk of gallbladder disease. Eur J Epidemiol 2016; 
31: 643–53.
Smoking
Alzheimer disease and other 
dimentias
Zhong G, Wang Y, Zhang Y, Guo JJ, Zhao Y. Smoking Is Associated with an Increased Risk of Dementia: A 
Meta-Analysis of Prospective Cohort Studies with Investigation of Potential Effect Modifiers. PLoS One 
2015; 10. DOI:10.1371/journal.pone.0118333.
Smoking Parkinson disease
Li X, Li W, Liu G, Shen X, Tang Y. Association between cigarette smoking and Parkinson’s disease: A meta-
analysis. Arch Gerontol Geriatr 2015; 61: 510–6.
Smoking Multiple sclerosis
O’Gorman C, Broadley SA. Smoking and multiple sclerosis: evidence for latitudinal and temporal variation. J 
Neurol 2014; 261: 1677–83.
Smoking Diabetes mellitus type 2
Pan A, Wang Y, Talaei M, Hu FB, Wu T. Relation of active, passive, and quitting smoking with incident type 
2 diabetes: a systematic review and meta-analysis. The Lancet Diabetes & Endocrinology 2015; 3: 958–67.
Smoking Rheumatoid arthritis
Sugiyama D, Nishimura K, Tamaki K, et al. Impact of smoking as a risk factor for developing rheumatoid 
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Smoking Low back pain
Shiri R, Karppinen J, Leino-Arjas P, Solovieva S, Viikari-Juntura E. The Association between Smoking and 
Low Back Pain: A Meta-analysis. The American Journal of Medicine 2010; 123: 87.e7-87.e35.
Smoking Cataract
Ye J, He J, Wang C, et al. Smoking and risk of age-related cataract: a meta-analysis. Invest Ophthalmol Vis 
Sci 2012; 53: 3885–95.
Smoking Macular degeneration
Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-related macular degeneration: a 
systematic review and meta-analysis. BMC Ophthalmol 2010; 10: 31.
Smoking Injuries
Vestergaard P, Mosekilde L. Fracture risk associated with smoking: a meta-analysis. J Intern Med 2003; 254: 
572–83.
Chewing Tobacco Lip and oral cavity cancer
Siddiqi K, Shah S, Abbas SM, et al. Global burden of disease due to smokeless tobacco consumption in 
adults: analysis of data from 113 countries. BMC Med 2015; 13: 194.
Chewing Tobacco Oesophageal cancer
Siddiqi K, Shah S, Abbas SM, et al. Global burden of disease due to smokeless tobacco consumption in 
adults: analysis of data from 113 countries. BMC Med 2015; 13: 194.
Second-hand smoke Breast cancer
Macacu A, Autier P, Boniol M, Boyle P. Active and passive smoking and risk of breast cancer: a meta-
analysis. Breast Cancer Res Treat 2015; 154: 213–24.
Second-hand smoke
Chronic obstructive pulmonary 
disease
Fischer F, Kraemer A. Meta-analysis of the association between second-hand smoke exposure and ischaemic 
heart diseases, COPD and stroke. BMC Public Health 2015; 15: 1202.
Second-hand smoke Diabetes mellitus type 2
Zhu B, Wu X, Wang X, Zheng Q, Sun G. The association between passive smoking and type 2 diabetes: a 
meta-analysis. Asia Pac J Public Health 2014; 26: 226–37.
Second-hand smoke Tuberculosis
Dogar OF, Pillai N, Safdar N, Shah SK, Zahid R, Siddiqi K. Second-hand smoke and the risk of tuberculosis: 
a systematic review and a meta-analysis. Epidemiol Infect 2015; 143: 3158–72.
Second-hand smoke Lower respiratory infections
Baker RJ, Hertz-Picciotto I, Dostal M, Keller JA, Nozicka J, Kotesovec F, Dejmek J, Loomis D, Sram RJ. 
Coal home heating and environmental tobacco smoke in relation to lower respiratory illness in Czech 
children, from birth to 3 years of age. Environ Health Perspect. 2006; 1126-32.
Second-hand smoke Lower respiratory infections
Blizzard L, Ponsonby A-L, Dwyer T, Venn A, Cochrane JA. Parental smoking and infant respiratory 
infection: how important is not smoking in the same room with the baby?. Am J Public Health. 2003; 482-8.
Second-hand smoke Lower respiratory infections
Bonu S, Rani M, Jha P, Peters DH, Nguyen SN. Household tobacco and alcohol use, and child health: an 
exploratory study from India. Health Policy. 2004; 67-83.
Second-hand smoke Lower respiratory infections
Broor S, Pandey RM, Ghosh M, Maitreyi RS, Lodha R, Singhal T, Kabra SK. Risk factors for severe acute 
lower respiratory tract infection in under-five children. Indian Pediatr. 2001; 1361-9.
Second-hand smoke Lower respiratory infections
Chen Y, Li WX, Yu SZ, Qian WH. Chang-Ning epidemiological study of children's health: I: Passive 
smoking and children's respiratory diseases. Int J Epidemiol. 1988; 348-55.
Second-hand smoke Lower respiratory infections
Duijts L, Jaddoe VWV, Hofman A, Steegers EAP, Mackenbach JP, de Jongste JC, Moll HA. Maternal 
smoking in pre-natal and early post-natal life and the risk of respiratory tract infections in infancy. The 
Generation R study. Eur J Epidemiol. 2008; 547-55.
Second-hand smoke Lower respiratory infections
Ekwo EE, Weinberger MM, Lachenbruch PA, Huntley WH. Relationship of parental smoking and gas 
cooking to respiratory disease in children. Chest. 1983; 662-8.
Second-hand smoke Lower respiratory infections
Etiler N, Velipasaoglu S, Aktekin M. Incidence of acute respiratory infections and the relationship with some 
factors in infancy in Antalya, Turkey. Pediatr Int 2002; 44: 64–9.
Second-hand smoke Lower respiratory infections
Ferris BG, Ware JH, Berkey CS, Dockery DW, Spiro A, Speizer FE. Effects of passive smoking on health of 
children. Environ Health Perspect. 1985; 289-95.
Second-hand smoke Lower respiratory infections
Forastiere F, Corbo GM, Michelozzi P, Pistelli R, Agabiti N, Brancato G, Ciappi G, Perucci CA. Effects of 
environment and passive smoking on the respiratory health of children. Int J Epidemiol. 1992; 66-73.
Second-hand smoke Lower respiratory infections
Gardner G, Frank AL, Taber LH. Effects of social and family factors on viral respiratory infection and illness 
in the first year of life. J Epidemiol Community Health. 1984; 42-8.
Second-hand smoke Lower respiratory infections Hassan MK, Al-Sadoon I. Risk factors for severe pneumonia in children in Basrah. Trop Doct. 2001; 139-41.
Second-hand smoke Lower respiratory infections
Koch A, Molbak K, Homoe P, Sorensen P, Hjuler T, Olesen ME, Pejl J, Pedersen FK, Olsen OR, Melbye M. 
Risk factors for acute respiratory tract infections in young Greenlandic children. Am J Epidemiol. 2003; 374-
84.
Second-hand smoke Lower respiratory infections
Kristensen IA, Olsen J. Determinants of acute respiratory infections in Soweto--a population-based birth 
cohort. S Afr Med J. 2006; 633-40.
Second-hand smoke Lower respiratory infections
Margolis PA, Keyes LL, Greenberg RA, Bauman KE, LaVange LM. Urinary cotinine and parent history 
(questionnaire) as indicators of passive smoking and predictors of lower respiratory illness in infants. Pediatr 
Pulmonol. 1997; 417-23.
Second-hand smoke Lower respiratory infections
Nuesslein TG, Beckers D, Rieger CH. Cotinine in meconium indicates risk for early respiratory tract 
infections. Hum Exp Toxicol. 1999; 283-90.
Second-hand smoke Lower respiratory infections
Ogston SA, Florey CD, Walker CH. The Tayside infant morbidity and mortality study: effect on health of 
using gas for cooking. BMJ. 1985; 957-60.
Second-hand smoke Lower respiratory infections
Ogston SA, Florey CD, Walker CH. Association of infant alimentary and respiratory illness with parental 
smoking and other environmental factors. J Epidemiol Community Health. 1987; 21-5.
Second-hand smoke Lower respiratory infections
Pedreira FA, Guandolo VL, Feroli EJ, Mella GW, Weiss IP. Involuntary smoking and incidence of respiratory 
illness during the first year of life. Pediatrics. 1985; 594-7.
Second-hand smoke Lower respiratory infections
Rylander E, Pershagen G, Eriksson M, Bermann G. Parental smoking, urinary cotinine, and wheezing 
bronchitis in children. Epidemiology. 1995; 289-93.
Second-hand smoke Lower respiratory infections
Suzuki M, Thiem VD, Yanai H, Matsubayashi T, Yoshida LM, Tho LH, Minh TT, Anh DD, Kilgore PE, 
Ariyoshi K. Association of environmental tobacco smoking exposure with an increased risk of hospital 
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Second-hand smoke Lower respiratory infections
Taylor B, Wadsworth J. Maternal smoking during pregnancy and lower respiratory tract illness in early life. 
Arch Dis Child. 1987; 786-91.
Second-hand smoke Lower respiratory infections
Victora CG, Fuchs SC, Flores JA, Fonseca W, Kirkwood B. Risk factors for pneumonia among children in a 
Brazilian metropolitan area. Pediatrics. 1994; 977-85.
Second-hand smoke Otitis media
Jones LL, Hassanien A, Cook DG, Britton J, Leonardi-Bee J. Parental smoking and the risk of middle ear 
disease in children: a systematic review and meta-analysis. Arch Pediatr Adolesc Med 2012; 166: 18–27.
Second-hand smoke
Tracheal, bronchus, and lung 
cancer
Jayes L, Haslam PL, Gratziou CG, et al. SmokeHaz: Systematic Reviews and Meta-analyses of the Effects of 
Smoking on Respiratory Health. Chest 2016; 150: 164–79.
Second-hand smoke Ischaemic heart disease
Fischer F, Kraemer A. Meta-analysis of the association between second-hand smoke exposure and ischaemic 
heart diseases, COPD and stroke. BMC Public Health 2015; 15: 1202.
Second-hand smoke Ischaemic stroke
Oono IP, Mackay DF, Pell JP. Meta-analysis of the association between secondhand smoke exposure and 
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Psychiatry. 2000; 57(10): 953–9.
Childhood sexual abuse Depressive disorders
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psychosocial outcomes: results from a twin study. Arch Gen Psychiatry. 2002; 59(2): 139-45.
Childhood sexual abuse Depressive disorders
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Dube, S.R., Anda, R.F., Whitfield, C.L., Brown, D.W., Felitti, V.J., Dong, M. and Giles, W.H., 2005. Long-
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systematic review and meta-analysis in 2.7 million participants (unpublished).
High systolic blood pressure
Chronic kidney disease due to 
diabetes mellitus
Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal 
outcomes: updated systematic review and meta-analysis. Lancet Lond Engl 2016; 387: 435–43.
High systolic blood pressure
Chronic kidney disease due to 
hypertension
The Renal Risk Collaboration, Foote C, Lin J, et al. The effect of Blood Pressure on Kidney Failure: a 
systematic review and meta-analysis in 2.7 million participants (unpublished).
High systolic blood pressure
Chronic kidney disease due to 
hypertension
Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal 
outcomes: updated systematic review and meta-analysis. Lancet Lond Engl 2016; 387: 435–43.
High systolic blood pressure
Chronic kidney disease due to 
glomerulonephritis
The Renal Risk Collaboration, Foote C, Lin J, et al. The effect of Blood Pressure on Kidney Failure: a 
systematic review and meta-analysis in 2.7 million participants (unpublished).
High systolic blood pressure
Chronic kidney disease due to 
glomerulonephritis
Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal 
outcomes: updated systematic review and meta-analysis. Lancet Lond Engl 2016; 387: 435–43.
High systolic blood pressure
Chronic kidney disease due to 
other causes
The Renal Risk Collaboration, Foote C, Lin J, et al. The effect of Blood Pressure on Kidney Failure: a 
systematic review and meta-analysis in 2.7 million participants (unpublished).
High systolic blood pressure
Chronic kidney disease due to 
other causes
Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal 
outcomes: updated systematic review and meta-analysis. Lancet Lond Engl 2016; 387: 435–43.
High systolic blood pressure
Non-rheumatic calcific aortic 
valve disease
Bahler RC, Desser DR, Finkelhor RS, Brener SJ, Youssefi M. Factors leading to progression of valvular 
aortic stenosis. Am J Cardiol. 1999;84(9):1044-8.
High systolic blood pressure
Non-rheumatic calcific aortic 
valve disease
Hoagland PM, Cook EF, Flatley M, Walker C, Goldman L. Case-control analysis of risk factors for presence 
of aortic stenosis in adults (age 50 years or older). Am J Cardiol. 1985;55(6):744-7.
High systolic blood pressure
Non-rheumatic calcific aortic 
valve disease
Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. 
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High body-mass index Colon and rectum cancer
Schlesinger S, Lieb W, Koch M, et al. Body weight gain and risk of colorectal cancer: a systematic review 
and meta-analysis of observational studies. Obes Rev 2015; 16: 607–19.
High body-mass index Liver cancer
Chen Y, Wang X, Wang J, Yan Z, Luo J. Excess body weight and the risk of primary liver cancer: an updated 
meta-analysis of prospective studies. Eur J Cancer 2012; 48: 2137–45.
High body-mass index Liver cancer
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a 
systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569–78.
High body-mass index Liver cancer
Rui R, Lou J, Zou L, et al. Excess body mass index and risk of liver cancer: a nonlinear dose-response meta-
analysis of prospective studies. PLoS ONE 2012; 7: e44522.
High body-mass index Liver cancer
Tanaka K, Tsuji I, Tamakoshi A, et al. Obesity and liver cancer risk: an evaluation based on a systematic 
review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol 2012; 42: 212–21.
High body-mass index Liver cancer
Wang Y, Wang B, Shen F, Fan J, Cao H. Body mass index and risk of primary liver cancer: a meta-analysis 
of prospective studies. Oncologist 2012; 17: 1461–8.
High body-mass index
Gallbladder and biliary tract 
cancer
Park M, Song DY, Je Y, Lee JE. Body mass index and biliary tract disease: a systematic review and meta-
analysis of prospective studies. Prev Med 2014; 65: 13–22.
High body-mass index
Gallbladder and biliary tract 
cancer
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a 
systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569–78.
High body-mass index Pancreatic cancer
Alsamarrai A, Das SLM, Windsor JA, Petrov MS. Factors that affect risk for pancreatic disease in the general 
population: a systematic review and meta-analysis of prospective cohort studies. Clin Gastroenterol Hepatol 
2014; 12: 1635–1644.e5; quiz e103.
High body-mass index Pancreatic cancer
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a 
systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569–78.
High body-mass index Breast cancer (Pre-menopause)
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a 
systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569–78.
High body-mass index Breast cancer (Pre-menopause)
Xia X, Chen W, Li J, et al. Body mass index and risk of breast cancer: a nonlinear dose-response meta-
analysis of prospective studies. Sci Rep 2014; 4: 7480.
High body-mass index Breast cancer (Post-menopause)
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a 
systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569–78.
High body-mass index Breast cancer (Post-menopause)
Xia X, Chen W, Li J, et al. Body mass index and risk of breast cancer: a nonlinear dose-response meta-
analysis of prospective studies. Sci Rep 2014; 4: 7480.
High body-mass index Uterine cancer
Aune D, Greenwood DC, Chan DSM, et al. Body mass index, abdominal fatness and pancreatic cancer risk: a 
systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol 2012; 23: 
843–52.
High body-mass index Uterine cancer
Jenabi E, Poorolajal J. The effect of body mass index on endometrial cancer: a meta-analysis. Public Health 
2015; 129: 872–80.
High body-mass index Uterine cancer
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a 
systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569–78.
High body-mass index Ovarian cancer
Aune D, Navarro Rosenblatt DA, Chan DSM, et al. Anthropometric factors and ovarian cancer risk: a 
systematic review and nonlinear dose-response meta-analysis of prospective studies. Int J Cancer 2015; 136: 
1888–98.
High body-mass index Ovarian cancer
Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and body size: individual 
participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. 
PLoS Med 2012; 9: e1001200.
High body-mass index Ovarian cancer
Liu Z, Zhang T-T, Zhao J-J, et al. The association between overweight, obesity and ovarian cancer: a meta-
analysis. Jpn J Clin Oncol 2015; 45: 1107–15.
High body-mass index Ovarian cancer
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a 
systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569–78.
High body-mass index Kidney cancer
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a 
systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569–78.
High body-mass index Kidney cancer
Wang F, Xu Y. Body mass index and risk of renal cell cancer: a dose-response meta-analysis of published 
cohort studies. Int J Cancer 2014; 135: 1673–86.
High body-mass index Thyroid cancer
Ma J, Huang M, Wang L, Ye W, Tong Y, Wang H. Obesity and risk of thyroid cancer: evidence from a meta-
analysis of 21 observational studies. Med Sci Monit 2015; 21: 283–91.
High body-mass index Thyroid cancer
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a 
systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371(9612): 569-78.
High body-mass index Non-hodgkin lymphoma
Larsson SC, Wolk A. Body mass index and risk of non-Hodgkin’s and Hodgkin’s lymphoma: A meta-
analysis of prospective studies. European Journal of Cancer 2011; 47: 2422–30.
High body-mass index Leukaemia
Castillo JJ, Reagan JL, Ingham RR, et al. Obesity but not overweight increases the incidence and mortality of 
leukemia in adults: a meta-analysis of prospective cohort studies. Leuk Res 2012; 36: 868–75.
High body-mass index Leukaemia
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a 
systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371(9612): 569-78.
High body-mass index Multiple myeloma
Teras LR, Kitahara CM, Birmann BM, et al. Body Size and Multiple Myeloma Mortality: a pooled analysis of 
20 prospective studies. Br J Haematol 2014; 166: 667–76.
High body-mass index Ischaemic heart disease
Singh GM, Danaei G, Farzadfar F, et al. The age-specific quantitative effects of metabolic risk factors on 
cardiovascular diseases and diabetes: a pooled analysis. PLoS ONE 2013; 8: e65174.
High body-mass index Cerebrovascular disease
Singh GM, Danaei G, Farzadfar F, et al. The age-specific quantitative effects of metabolic risk factors on 
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High body-mass index Hypertensive heart disease
Singh GM, Danaei G, Farzadfar F, et al. The age-specific quantitative effects of metabolic risk factors on 
cardiovascular diseases and diabetes: a pooled analysis. PLoS ONE 2013; 8: e65174.
High body-mass index Atrial fibrillation and flutter
Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS. Atrial fibrillation and 
obesity—results of a meta-analysis. American Heart Journal 2008; 155: 310–5.
High body-mass index Asthma
Beuther DA, Sutherland ER. Overweight, Obesity, and Incident Asthma. Am J Respir Crit Care Med 2007; 
175: 661–6.
High body-mass index Gallbladder diseases
Aune D, Norat T, Vatten LJ. Body mass index, abdominal fatness and the risk of gallbladder disease. Eur J 
Epidemiol 2015; 30: 1009–19.
High body-mass index
Alzheimer disease and other 
dementias
Profenno LA, Porsteinsson AP, Faraone SV. Meta-Analysis of Alzheimer’s Disease Risk with Obesity, 
Diabetes, and Related Disorders. Biological Psychiatry 2010; 67: 505–12.
High body-mass index Diabetes mellitus
Singh GM, Danaei G, Farzadfar F, et al. The age-specific quantitative effects of metabolic risk factors on 
cardiovascular diseases and diabetes: a pooled analysis. PLoS ONE 2013; 8: e65174.
High body-mass index Chronic kidney disease
Emerging Risk Factors Collaboration, Wormser D, Kaptoge S, et al. Separate and combined associations of 
body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 
prospective studies. Lancet 2011; 377: 1085–95.
High body-mass index Chronic kidney disease
Ni Mhurchu C, Rodgers A, Pan WH, Gu DF, Woodward M, Asia Pacific Cohort Studies Collaboration. Body 
mass index and cardiovascular disease in the Asia-Pacific Region: an overview of 33 cohorts involving 310 
000 participants. Int J Epidemiol 2004; 33: 751–8.
High body-mass index Chronic kidney disease
Prospective Studies Collaboration, Whitlock G, Lewington S, et al. Body-mass index and cause-specific 
mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373: 1083–96.
High body-mass index Osteoarthritis
Jiang L, Rong J, Wang Y, et al. The relationship between body mass index and hip osteoarthritis: a systematic 
review and meta-analysis. Joint Bone Spine 2011; 78: 150–5.
High body-mass index Osteoarthritis
Jiang L, Tian W, Wang Y, et al. Body mass index and susceptibility to knee osteoarthritis: a systematic 
review and meta-analysis. Joint Bone Spine 2012; 79: 291–7.
High body-mass index Osteoarthritis
Silverwood V, Blagojevic-Bucknall M, Jinks C, Jordan JL, Protheroe J, Jordan KP. Current evidence on risk 
factors for knee osteoarthritis in older adults: a systematic review and meta-analysis. Osteoarthr Cartil 2015; 
23: 507–15.
High body-mass index Low back pain
Shiri R, Karppinen J, Leino-Arjas P, Solovieva S, Viikari-Juntura E. The association between obesity and low 
back pain: a meta-analysis. Am J Epidemiol 2010; 171: 135–54.
High body-mass index Gout
Aune D, Norat T, Vatten LJ. Body mass index and the risk of gout: a systematic review and dose-response 
meta-analysis of prospective studies. Eur J Nutr 2014; 53: 1591–601.
High body-mass index Cataract
Ye J, Lou L-X, He J-J, Xu Y-F. Body Mass Index and Risk of Age-Related Cataract: A Meta-Analysis of 
Prospective Cohort Studies. PLOS ONE 2014; 9: e89923.
High body-mass index (child) Asthma
Mebrahtu TF, Feltbower RG, Greenwood DC, Parslow RC. Childhood body mass index and wheezing 
disorders: a systematic review and meta-analysis. Pediatr Allergy Immunol 2015; 26: 62–72.
Low bone mineral density Injuries
Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 
2005; 20: 1185–94.
Impaired kidney function Ischaemic heart disease
Chronic Kidney Disease Prognosis Consortium (CKD-PC). Chronic Kidney Disease Prognosis Consortium 
GBD 2016 Impaired Kidney Function Relative Risk Meta-Analysis.
Impaired kidney function Ischaemic heart disease
National Heart, Lung, and Blood Institute, National Institutes of Health (NIH). United States Atherosclerosis 
Risk in Communities Study. Bethesda, United States: National Heart, Lung, and Blood Institute, National 
Institutes of Health (NIH).
Impaired kidney function Ischaemic heart disease
International Diabetes Institute (IDI). Australia Diabetes, Obesity and Lifestyle Study 1999-2000. Melbourne, 
Australia: International Diabetes Institute (IDI).
Impaired kidney function Ischaemic heart disease
Boston University, School of Medicine, Framingham Heart Study, National Heart, Lung, and Blood Institute, 
National Institutes of Health (NIH). United States Framingham Heart Study .
Impaired kidney function Ischaemic heart disease Association for Cardiac Research, Rome (Italy). The Gubbio Population Study.
Impaired kidney function Ischaemic heart disease
National Heart, Lung, and Blood Institute, National Institutes of Health, University of California, Los Angeles 
(UCLA), University of Minnesota. United States Multi-Ethnic Study of Atherosclerosis First Examination 
2000-2002. Bethesda, United States: National Heart, Lung, and Blood Institute, National Institutes of Health.
Impaired kidney function Ischaemic heart disease Uppsala University. Sweden Uppsala Longitudinal Study of Adult Men.
Impaired kidney function Cerebrovascular disease
Chronic Kidney Disease Prognosis Consortium (CKD-PC). Chronic Kidney Disease Prognosis Consortium 
GBD 2016 Impaired Kidney Function Relative Risk Meta-Analysis.
Impaired kidney function Cerebrovascular disease
National Heart, Lung, and Blood Institute, National Institutes of Health (NIH). United States Atherosclerosis 
Risk in Communities Study. Bethesda, United States: National Heart, Lung, and Blood Institute, National 
Institutes of Health (NIH).
Impaired kidney function Cerebrovascular disease
International Diabetes Institute (IDI). Australia Diabetes, Obesity and Lifestyle Study 1999-2000. Melbourne, 
Australia: International Diabetes Institute (IDI).
Impaired kidney function Cerebrovascular disease
National Heart, Lung, and Blood Institute, National Institutes of Health, University of California, Los Angeles 
(UCLA), University of Minnesota. United States Multi-Ethnic Study of Atherosclerosis First Examination 
2000-2002. Bethesda, United States: National Heart, Lung, and Blood Institute, National Institutes of Health.
Impaired kidney function Cerebrovascular disease Uppsala University. Sweden Uppsala Longitudinal Study of Adult Men.
Impaired kidney function Peripheral vascular disease
Chronic Kidney Disease Prognosis Consortium (CKD-PC). Chronic Kidney Disease Prognosis Consortium 
GBD 2016 Impaired Kidney Function Relative Risk Meta-Analysis.
Impaired kidney function Peripheral vascular disease
National Heart, Lung, and Blood Institute, National Institutes of Health (NIH). United States Atherosclerosis 
Risk in Communities Study. Bethesda, United States: National Heart, Lung, and Blood Institute, National 
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Impaired kidney function Peripheral vascular disease Association for Cardiac Research, Rome (Italy). The Gubbio Population Study.
Impaired kidney function Peripheral vascular disease
National Heart, Lung, and Blood Institute, National Institutes of Health, University of California, Los Angeles 
(UCLA), University of Minnesota. United States Multi-Ethnic Study of Atherosclerosis First Examination 
2000-2002. Bethesda, United States: National Heart, Lung, and Blood Institute, National Institutes of Health.
Impaired kidney function Gout
Cea Soriano L, Rothenbacher D, Choi HK, García Rodríguez LA. Contemporary epidemiology of gout in the 
UK general population. Arthritis Res Ther 2011; 13: R39.
Impaired kidney function Gout
Krishnan E. Chronic kidney disease and the risk of incident gout among middle-aged men: a seven-year 
prospective observational study. Arthritis Rheum 2013; 65: 3271–8.
Impaired kidney function Gout
McAdams-DeMarco MA, Maynard JW, Baer AN, Coresh J. Hypertension and the risk of incident gout in a 
population-based study: the atherosclerosis risk in communities cohort. J Clin Hypertens (Greenwich) 2012; 
14: 675–9.
Impaired kidney function Gout
Trifirò G, Morabito P, Cavagna L, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 
2005-2009: a nationwide population-based study. Ann Rheum Dis 2013; 72: 694–700.
Short gestation for birth weight Diarrheal diseases
Katz J, Lee AC, Kozuki N, Lawn JE, Cousens S, Blencowe H, Ezzati M, Bhutta ZA, Marchant T, Willey BA, 
Adair L, Barros F, Baqui AH, Christian P, Fawzi W, Gonzalez R, Humphrey J, Huybregts L, Kolsteren P, 
Mongkolchati A, Mullany LC, Ndyomugyenyi R, Nien JK, Osrin D, Roberfroid D, Sania A, Schmiegelow C, 
Silveira MF, Tielsch J, Vaidya A, Velaphi SC, Victora CG, Watson-Jones D, Black RE; CHERG Small-for-
Gestational-Age-Preterm Birth Working Group. Mortality risk in preterm and small-for-gestational-age 
infants in low-income and middle-income countries: a pooled country analysis. Lancet. 2013; 382(9890): 417-
25.
Short gestation for birth weight Lower respiratory infections
Katz J, Lee AC, Kozuki N, Lawn JE, Cousens S, Blencowe H, Ezzati M, Bhutta ZA, Marchant T, Willey BA, 
Adair L, Barros F, Baqui AH, Christian P, Fawzi W, Gonzalez R, Humphrey J, Huybregts L, Kolsteren P, 
Mongkolchati A, Mullany LC, Ndyomugyenyi R, Nien JK, Osrin D, Roberfroid D, Sania A, Schmiegelow C, 
Silveira MF, Tielsch J, Vaidya A, Velaphi SC, Victora CG, Watson-Jones D, Black RE; CHERG Small-for-
Gestational-Age-Preterm Birth Working Group. Mortality risk in preterm and small-for-gestational-age 
infants in low-income and middle-income countries: a pooled country analysis. Lancet. 2013; 382(9890): 417-
25.
Short gestation for birth weight Upper respiratory infections
Katz J, Lee AC, Kozuki N, Lawn JE, Cousens S, Blencowe H, Ezzati M, Bhutta ZA, Marchant T, Willey BA, 
Adair L, Barros F, Baqui AH, Christian P, Fawzi W, Gonzalez R, Humphrey J, Huybregts L, Kolsteren P, 
Mongkolchati A, Mullany LC, Ndyomugyenyi R, Nien JK, Osrin D, Roberfroid D, Sania A, Schmiegelow C, 
Silveira MF, Tielsch J, Vaidya A, Velaphi SC, Victora CG, Watson-Jones D, Black RE; CHERG Small-for-
Gestational-Age-Preterm Birth Working Group. Mortality risk in preterm and small-for-gestational-age 
infants in low-income and middle-income countries: a pooled country analysis. Lancet. 2013; 382(9890): 417-
25.
Short gestation for birth weight Otitis media
Katz J, Lee AC, Kozuki N, Lawn JE, Cousens S, Blencowe H, Ezzati M, Bhutta ZA, Marchant T, Willey BA, 
Adair L, Barros F, Baqui AH, Christian P, Fawzi W, Gonzalez R, Humphrey J, Huybregts L, Kolsteren P, 
Mongkolchati A, Mullany LC, Ndyomugyenyi R, Nien JK, Osrin D, Roberfroid D, Sania A, Schmiegelow C, 
Silveira MF, Tielsch J, Vaidya A, Velaphi SC, Victora CG, Watson-Jones D, Black RE; CHERG Small-for-
Gestational-Age-Preterm Birth Working Group. Mortality risk in preterm and small-for-gestational-age 
infants in low-income and middle-income countries: a pooled country analysis. Lancet. 2013; 382(9890): 417-
25.
Short gestation for birth weight Pneumococcal meningitis
Katz J, Lee AC, Kozuki N, Lawn JE, Cousens S, Blencowe H, Ezzati M, Bhutta ZA, Marchant T, Willey BA, 
Adair L, Barros F, Baqui AH, Christian P, Fawzi W, Gonzalez R, Humphrey J, Huybregts L, Kolsteren P, 
Mongkolchati A, Mullany LC, Ndyomugyenyi R, Nien JK, Osrin D, Roberfroid D, Sania A, Schmiegelow C, 
Silveira MF, Tielsch J, Vaidya A, Velaphi SC, Victora CG, Watson-Jones D, Black RE; CHERG Small-for-
Gestational-Age-Preterm Birth Working Group. Mortality risk in preterm and small-for-gestational-age 
infants in low-income and middle-income countries: a pooled country analysis. Lancet. 2013; 382(9890): 417-
25.
Short gestation for birth weight H influenzae type B meningitis
Katz J, Lee AC, Kozuki N, Lawn JE, Cousens S, Blencowe H, Ezzati M, Bhutta ZA, Marchant T, Willey BA, 
Adair L, Barros F, Baqui AH, Christian P, Fawzi W, Gonzalez R, Humphrey J, Huybregts L, Kolsteren P, 
Mongkolchati A, Mullany LC, Ndyomugyenyi R, Nien JK, Osrin D, Roberfroid D, Sania A, Schmiegelow C, 
Silveira MF, Tielsch J, Vaidya A, Velaphi SC, Victora CG, Watson-Jones D, Black RE; CHERG Small-for-
Gestational-Age-Preterm Birth Working Group. Mortality risk in preterm and small-for-gestational-age 
infants in low-income and middle-income countries: a pooled country analysis. Lancet. 2013; 382(9890): 417-
25.
Short gestation for birth weight Meningococcal meningitis
Katz J, Lee AC, Kozuki N, Lawn JE, Cousens S, Blencowe H, Ezzati M, Bhutta ZA, Marchant T, Willey BA, 
Adair L, Barros F, Baqui AH, Christian P, Fawzi W, Gonzalez R, Humphrey J, Huybregts L, Kolsteren P, 
Mongkolchati A, Mullany LC, Ndyomugyenyi R, Nien JK, Osrin D, Roberfroid D, Sania A, Schmiegelow C, 
Silveira MF, Tielsch J, Vaidya A, Velaphi SC, Victora CG, Watson-Jones D, Black RE; CHERG Small-for-
Gestational-Age-Preterm Birth Working Group. Mortality risk in preterm and small-for-gestational-age 
infants in low-income and middle-income countries: a pooled country analysis. Lancet. 2013; 382(9890): 417-
25.
Short gestation for birth weight Other meningitis
Katz J, Lee AC, Kozuki N, Lawn JE, Cousens S, Blencowe H, Ezzati M, Bhutta ZA, Marchant T, Willey BA, 
Adair L, Barros F, Baqui AH, Christian P, Fawzi W, Gonzalez R, Humphrey J, Huybregts L, Kolsteren P, 
Mongkolchati A, Mullany LC, Ndyomugyenyi R, Nien JK, Osrin D, Roberfroid D, Sania A, Schmiegelow C, 
Silveira MF, Tielsch J, Vaidya A, Velaphi SC, Victora CG, Watson-Jones D, Black RE; CHERG Small-for-
Gestational-Age-Preterm Birth Working Group. Mortality risk in preterm and small-for-gestational-age 
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Short gestation for birth weight Encephalitis
Katz J, Lee AC, Kozuki N, Lawn JE, Cousens S, Blencowe H, Ezzati M, Bhutta ZA, Marchant T, Willey BA, 
Adair L, Barros F, Baqui AH, Christian P, Fawzi W, Gonzalez R, Humphrey J, Huybregts L, Kolsteren P, 
Mongkolchati A, Mullany LC, Ndyomugyenyi R, Nien JK, Osrin D, Roberfroid D, Sania A, Schmiegelow C, 
Silveira MF, Tielsch J, Vaidya A, Velaphi SC, Victora CG, Watson-Jones D, Black RE; CHERG Small-for-
Gestational-Age-Preterm Birth Working Group. Mortality risk in preterm and small-for-gestational-age 
infants in low-income and middle-income countries: a pooled country analysis. Lancet. 2013; 382(9890): 417-
25.
Short gestation for birth weight
Neonatal preterm birth 
complications
Katz J, Lee AC, Kozuki N, Lawn JE, Cousens S, Blencowe H, Ezzati M, Bhutta ZA, Marchant T, Willey BA, 
Adair L, Barros F, Baqui AH, Christian P, Fawzi W, Gonzalez R, Humphrey J, Huybregts L, Kolsteren P, 
Mongkolchati A, Mullany LC, Ndyomugyenyi R, Nien JK, Osrin D, Roberfroid D, Sania A, Schmiegelow C, 
Silveira MF, Tielsch J, Vaidya A, Velaphi SC, Victora CG, Watson-Jones D, Black RE; CHERG Small-for-
Gestational-Age-Preterm Birth Working Group. Mortality risk in preterm and small-for-gestational-age 
infants in low-income and middle-income countries: a pooled country analysis. Lancet. 2013; 382(9890): 417-
25.
Short gestation for birth weight
Neonatal encephalopathy due to 
birth asphyxia and trauma
Katz J, Lee AC, Kozuki N, Lawn JE, Cousens S, Blencowe H, Ezzati M, Bhutta ZA, Marchant T, Willey BA, 
Adair L, Barros F, Baqui AH, Christian P, Fawzi W, Gonzalez R, Humphrey J, Huybregts L, Kolsteren P, 
Mongkolchati A, Mullany LC, Ndyomugyenyi R, Nien JK, Osrin D, Roberfroid D, Sania A, Schmiegelow C, 
Silveira MF, Tielsch J, Vaidya A, Velaphi SC, Victora CG, Watson-Jones D, Black RE; CHERG Small-for-
Gestational-Age-Preterm Birth Working Group. Mortality risk in preterm and small-for-gestational-age 
infants in low-income and middle-income countries: a pooled country analysis. Lancet. 2013; 382(9890): 417-
25.
Short gestation for birth weight
Neonatal sepsis and other neonatal 
infections
Katz J, Lee AC, Kozuki N, Lawn JE, Cousens S, Blencowe H, Ezzati M, Bhutta ZA, Marchant T, Willey BA, 
Adair L, Barros F, Baqui AH, Christian P, Fawzi W, Gonzalez R, Humphrey J, Huybregts L, Kolsteren P, 
Mongkolchati A, Mullany LC, Ndyomugyenyi R, Nien JK, Osrin D, Roberfroid D, Sania A, Schmiegelow C, 
Silveira MF, Tielsch J, Vaidya A, Velaphi SC, Victora CG, Watson-Jones D, Black RE; CHERG Small-for-
Gestational-Age-Preterm Birth Working Group. Mortality risk in preterm and small-for-gestational-age 
infants in low-income and middle-income countries: a pooled country analysis. Lancet. 2013; 382(9890): 417-
25.
Short gestation for birth weight
Hemolytic disease and other 
neonatal jaundice
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Appendix Table 5. Epidemiological evidence supporting causality between risk-outcome pairs included in the Global Burden of Disease 2017 study including A. 
Citations and B. Additional information
6B. Supplemental information
Unsafe water, sanitation, and 
handwashing
Typhoid and paratyphoid fever Typhoid and paratyphoid were included as outcome for unsafe water and sanitation by analogy to diarrhoeal diseases
Household air pollution from solid 
fuels
Cataract Evidence on the relationship between household air pollution and cataract was from 6 case-control and 1 cross-sectional 
studies
Air pollution -- The relationships of cerebrovascular disease, chronic obstructive pulmonary disease, ischaemic heart disease, and lung 
cancer with ambient air pollution, second-hand smoke, and active smoking were used to interpolate their relationship 
with household air pollution. We considered the biological pathway for health impact of all four sources to be PM2.5 
exposure, with the effect size being a function of the level of PM2.5. As such, we presented data from cohorts reporting 
on ambient PM2.5 and the outcome was used to inform the strength of evidence for household air pollution.
Other environmental risks and 
dietary risks
Cardiovascular diseases and chronic 
kidney disease
The health effects of lead and sodium on cardiovascular outcomes and chronic kidney disease were assessed through 
systolic blood pressure and the health effects of sugar sweetened beverages were assessed through body mass index.
Residential Radon Tracheal, bronchus, and lung cancer In evaluation of evidence on the relationship of residential radon and lung cancer, we excluded evidence from cohorts of 
miners as they were not from a representative population. Evidence on this risk-outcome pair mostly comes from case-
control studies
Occupational injuries Injuries Evidence from International Labour Organization Safety and Health and Eurostat Safety and Health was used to 
establish causality between occupational injuries and injuries
Child and maternal malnutrition -- Evidence on the causal relationship of childhood stunting, underweight, and wasting was from a pooled analysis of 7 
prospective cohorts
Child and maternal malnutrition -- For the following risk-outcome pairs, the risk factor was considered as the necessary cause: childhood underweight and 
protein-energy malnutrition; childhood wasting and protein-energy malnutrition; vitamin A deficiency and vitamin A 
deficiency; alcohol use and cirrhosis due to alcohol use; alcohol use and alcohol use disorders; alcohol use and liver 
cancer due to alcohol use; drug use and amphetamine use disorders; drug use and cannabis use disorders; drug use and 
cocaine use disorders; drug use and opioid use disorders; drug use and other drug use disorders; iron deficiency and iron-
deficiency anemia; unsafe sex and cervical cancer; unsafe sex and syphilis; unsafe sex and chlamydial infection; unsafe 
sex and gonococcal infection; unsafe sex and trichomoniasis; unsafe sex and genital herpes; unsafe sex and other 
sexually transmitted diseases; high systolic blood pressure and hypertensive heart disease; high systolic blood pressure 
and chronic kidney disease due to hypertension; high fasting plasma glucose and chronic kidney disease due to diabetes 
mellitus; high fasting plasma glucose and diabetes mellitus; low glomerular filtration rate and chronic kidney disease
Iron deficiency Maternal haemorrhage Evidence on the relationship of iron deficiency with maternal haemorrhage and maternal sepsis mainly came 10 
observational studies evaluating the association between low hemoglobin and maternal mortality using hospital records
Smoking, alcohol use, and high 
body mass index
-- For smoking, alcohol use, and high body mass index evidence from risk reduction trials has not been included
Smoking, alcohol use, and high 
body mass index
Liver cancer Liver cancer included liver cancer due to alcohol use, hepatitis B, hepatitis C, and other causes
Smoking Lower respiratory infections Evidence on the relationship between smoking and lower respiratory infections comes 10 case-control or cross-sectional 
studies
Smoking, alcohol use Nasopharynx cancer The evidence on causal relationship of alcohol and smoking with nasopharynx cancer was from the studies evaluating 
oral cavity and pharyngeal cancers as outcome
Smoking Bladder cancer The evidence on causal relationship of smoking and bladder cancer was based on the studies evaluating the lower urinary 
tract as outcome
Smoking Asbestosis Asbestosis, coal workers pneumoconiosis, other pneumoconiosis, silicosis were included as outcomes for smoking as 
they were included in the other chronic respiratory diseases category
Alcohol use Ischaemic heart disease, 
cerebrovascular disease, hypertensive 
heart disease, and diabetes mellitus
Alcohol was included as both a protective and harmful risk factor for ischaemic heart disease, cerebrovascular disease, 
hypertensive heart disease, and diabetes mellitus
Alcohol use Cirrhosis Cirrhosis included cirrhosis due to alcohol use, hepatitis B, hepatitis C, and other causes
Alcohol use Self-harm Self-harm was included as an outcome for alcohol use by analogy to injury
Alcohol use Injuries Injuries included pedestrian road injuries, cyclist road injuries, motorcyclist road injuries, motor vehicle road injuries, 
drowning, falls, fire, heat, hot substances, poisonings, unintentional firearm injuries, unintentional suffocation, other 
exposure to mechanical forces
Alcohol use Interpersonal violence Interpersonal violence included assault by firearm, sharp object, other means
Diet low in nuts and seeds Ischaemic heart disease and diabetes 
mellitus
Experimental evidence on the relationship of nuts with ischaemic heart disease and diabetes mellitus come from the 
PREDIMED trial; a randomized trial consisting of three arms: a Mediterranean diet with extra-virgin olive oil, a 
Mediterranean diet with nuts, and a control diet. Given that the intake of dietary factors other than nuts changed in the 
intervention arms of this trial, the observed effect might be fully attributable to nuts.
“RCTs (Number)” represents the total number of independent randomized controlled trials evaluating the relationship of each risk-outcome pair. “RCTs with significant effect in 
the opposite direction (%)” represents the percentage of randomized controlled trials showing a significant effect in the opposite direction. “Prospective observational studies 
(Number)” shows the total number of independent prospective cohort studies or non-randomized interventions evaluating the relationship of the risk-outcome pair. “Prospective 
observational studies with significant association in the opposite direction (%)” represents the percentage of prospective cohort studies or non-randomized interventions reporting a 
significant association in the opposite direction. “Lower limit of RR > 1.5” shows whether the lower limit of the 95% confidence interval for the relative risk of the risk-outcome 
pair is greater than 1.5. “Dose-response relationship” shows whether there is any evidence of linear or non-linear dose-response relationship between the risk and the outcome. 
“Biologic plausibility” shows whether there is any biologic or mechanistic pathway that could potentially explain the relationship of the risk-outcome pair. “Analogy” shows 
whether the risk is associated with another outcome from the same category and there is evidence that it can cause the current outcome through the same pathway. The numbers in 
the table represent the independent RCTs and prospective observational studies evaluated the relationship between each risk-outcome pairs. If there were multiple reports from one 
study, they were counted as one study. Dose-response relationship was only assessed for continuous risks. To evaluate the magnitude of the effect size for continuous risks, we 
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Diet high in sugar sweetened 
beverages and body mass index
-- Evidence on the relationship between sugar-sweetened beverages and body mass index comes from the interventional 
and prospective observational studies evaluating the relationship of sugar-sweetened beverages with weight change 
among children and adults.
Diet high in sodium Cardiovascular diseases Evidence on the direct effect of sodium on cardiovascular disease mainly comes from prospective cohort studies. 
Considering that, in GBD, we have only evaluated the effect of sodium mediated through systolic blood pressure, we did 
not present epidemiologic evidence on the direct effect of sodium on cardiovascular disease in this table. Evidence on 
the effect of sodium on systolic blood pressure mostly comes from randomized controlled trials. While some cohort 
studies evaluated the relationship between sodium and systolic blood pressure, we did not identify a systematic 
evaluation of these studies.
Drug use Hepatitis B and C We included liver cancer due to Hepatitis B and Hepatitis C and cirrhosis due to Hepatitis B and Hepatitis C as 
outcomes for drug use because these were considered secondary outcomes of Hepatitis B and Hepatitis C.
Drug use, unsafe sex HIV/AIDS For the following risk-outcome pairs, the risk factor was considered as the sufficient cause: drug use and HIV/AIDS and 
unsafe sex and HIV/AIDS
Metabolic risks Chronic kidney disease Chronic kidney disease included chronic kidney disease due to diabetes mellitus, hypertension, glomerulonephritis, or 
other causes
High fasting plasma glucose Cerebrovascular disease, chronic 
kidney disease, ischaemic heart 
disease
Evidence on the relationship of high fasting plasma glucose with stroke (DECODE, APCSC, ERFC); chronic kidney 
disease (APCSC), and ischaemic heart disease (DECODE, APCSC, ERFC) was from pooled analysis of cohorts
High systolic blood pressure Atrial fibrillation and flutter, 
peripheral vascular disease
Evidence on the relationship of high systolic blood pressure with atrial fibrillation and peripheral vascular disease was 
from two pooled cohort analysis (APCSC and PSC)
High systolic blood pressure Rheumatic heart disease, 
cardiomyopathy and myocarditis, 
aortic aneurysm, endocarditis, and 
other cardiovascular diseases
Evidence on the relationship of high systolic blood pressure with rheumatic heart disease, cardiomyopathy and 
myocarditis, aortic aneurysm, endocarditis, and other cardiovascular diseases came from a pooled cohort analysis (PSC)
High body-mass index Ischaemic heart disease Evidence on the relationship of high body-mass index with ischaemic heart disease (APCSC, ERFC, PSC) and stroke 
(ischaemic: APCSC, ERFC, PSC; hemorrhagic: PSC and ERFC) came from three pooled cohort analysis
High body-mass index Diabetes mellitus, hypertensive heart 
disease
Evidence on the relationship of high body-mass index with diabetes mellitus and hypertensive heart disease came from 
two pooled cohort analysis (APCSC and PSC)
High body-mass index Chronic kidney disease Evidence on the relationship of high body-mass index with chronic kidney disease was from a pooled cohort analysis 
(PSC)
High LDL cholesterol Ischaemic heart disease, ischaemic 
stroke
Evidence on the relationship of high LDL cholesterol with ischaemic heart disease and ischaemic stroke came from two 
pooled cohort analysis (APCSC and PSC)
Impaired kidney function Tuberculosis Glycemic Control and the Risk of Tuberculosis: A Cohort Study.
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Cataract Exposed morbidity Both 2.47
(1.61 to 3.73)
Chronic obstructive pulmonary 
disease












































































IQ shift 10 µg/dL Morbidity Both 4.688
(1.719 to 7.656)
IQ shift 12 µg/dL Morbidity Both 5.014
(1.839 to 8.19)
IQ shift 15 µg/dL Morbidity Both 5.42
(1.988 to 8.853)
IQ shift 2 µg/dL Morbidity Both 0.0
(0.0 to 0.0)
IQ shift 20 µg/dL Morbidity Both 5.952
(2.183 to 9.721)
IQ shift 25 µg/dL Morbidity Both 6.37
(2.336 to 10.403)
IQ shift 30 µg/dL Morbidity Both 6.713
(2.462 to 10.965)
IQ shift 35 µg/dL Morbidity Both 7.006
(2.569 to 11.442)
IQ shift 4 µg/dL Morbidity Both 3.146
(1.154 to 5.139)
IQ shift 40 µg/dL Morbidity Both 7.26
(2.662 to 11.857)
IQ shift 6 µg/dL Morbidity Both 3.804
(1.395 to 6.213)
IQ shift 8 µg/dL Morbidity Both 4.296
(1.575 to 7.016)




















































































































































































Non-rheumatic calcific aortic valve 
disease




















































































































































































Other cardiovascular and circulatory 
diseases






























Chronic kidney disease due to 
diabetes mellitus type 1






























Chronic kidney disease due to 
diabetes mellitus type 2






























Appendix Table 6a. Relative risks used by age and sex for each outcome for all risk factors except for ambient air pollution alcohol, and smoking.




No access to handwashing facility
Household air pollution from solid fuels
Ambient ozone pollution
Residential radon
Lead exposure in blood
Lead exposure in bone
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Risk - Outcome Category / Units Morbidity / Mortality Sex
Ages
Chronic kidney disease due to 
hypertension






























Chronic kidney disease due to 
glomerulonephritis






























Chronic kidney disease due to other 
and unspecified causes




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Occupational exposure to arsenic
Occupational exposure to benzene
Occupational exposure to beryllium
Occupational exposure to cadmium
Occupational exposure to chromium
Occupational exposure to asbestos
Occupational exposure to diesel engine exhaust
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Occupational exposure to formaldehyde
Occupational exposure to nickel
Occupational exposure to polycyclic aromatic hydrocarbons
Occupational exposure to silica
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Chronic obstructive pulmonary 
disease


































Chronic obstructive pulmonary 
disease


































Chronic obstructive pulmonary 
disease


































Chronic obstructive pulmonary 
disease


































Chronic obstructive pulmonary 
disease


































Chronic obstructive pulmonary 
disease


































Mild hearing loss due to age-related 
and other hearing loss


































Mild hearing loss with ringing due 
to age-related and other hearing loss


































Moderate hearing loss due to age-
related and other hearing loss


































Moderate hearing loss with ringing 
due to age-related and other hearing 
loss


































Moderately severe hearing loss due 
to age-related and other hearing loss


































Moderately severe hearing loss with 
ringing due to age-related and other 
hearing loss


































Severe hearing loss with ringing due 
to age-related and other hearing loss


































Severe hearing loss due to age-
related and other hearing loss


































Profound hearing loss due to age-
related and other hearing loss


































Profound hearing loss with ringing 
due to age-related and other hearing 
loss


































Complete hearing loss due to age-
related and other hearing loss


































Complete hearing loss with ringing 
due to age-related and other hearing 
loss


































Mild hearing loss due to age-related 
and other hearing loss


































Mild hearing loss with ringing due 
to age-related and other hearing loss


































Moderate hearing loss due to age-
related and other hearing loss


































Moderate hearing loss with ringing 
due to age-related and other hearing 
loss


































Moderately severe hearing loss due 
to age-related and other hearing loss


































Moderately severe hearing loss with 
ringing due to age-related and other 
hearing loss


































Severe hearing loss with ringing due 
to age-related and other hearing loss


































Severe hearing loss due to age-
related and other hearing loss


































Profound hearing loss due to age-
related and other hearing loss


































Profound hearing loss with ringing 
due to age-related and other hearing 
loss


































Occupational exposure to sulphuric acid
Occupational exposure to trichloroethylene
Occupational asthmagens
Occupational particulate matter, gases, and fumes
Occupational noise *
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Risk - Outcome Category / Units Morbidity / Mortality Sex
Ages
Complete hearing loss due to age-
related and other hearing loss


































Complete hearing loss with ringing 
due to age-related and other hearing 
loss


































Mild hearing loss due to age-related 
and other hearing loss


































Mild hearing loss with ringing due 
to age-related and other hearing loss


































Moderate hearing loss due to age-
related and other hearing loss


































Moderate hearing loss with ringing 
due to age-related and other hearing 
loss


































Moderately severe hearing loss due 
to age-related and other hearing loss


































Moderately severe hearing loss with 
ringing due to age-related and other 
hearing loss


































Severe hearing loss with ringing due 
to age-related and other hearing loss


































Severe hearing loss due to age-
related and other hearing loss


































Profound hearing loss due to age-
related and other hearing loss


































Profound hearing loss with ringing 
due to age-related and other hearing 
loss


































Complete hearing loss due to age-
related and other hearing loss


































Complete hearing loss with ringing 
due to age-related and other hearing 
loss














































































































































































Low back pain Agriculture,  animal husbandry and forestry 





























Low back pain Production and related workers,  transport 
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Low birth weight and short gestation
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Appendix Table 6a. Relative risks used by age and sex for each outcome for all risk factors except for ambient air pollution alcohol, and smoking.
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Maternal sepsis and other pregnancy 
related infections




































Maternal obstructed labour and 
uterine rupture


























































































Maternal deaths aggravated by 
HIV/AIDS




























































Lower respiratory infections Zinc deficient Morbidity Both 1.837
(1.275 to 2.523)
Lower respiratory infections Zinc deficient Mortality Both 1.672
(0.458 to 4.135)
Lower respiratory infections Not deficient Both Both 1.0
(1.0 to 1.0)
Diarrhoeal diseases Zinc deficient Morbidity Both 1.903
(1.517 to 2.335)
Diarrhoeal diseases Zinc deficient Mortality Both 1.951
(0.905 to 3.909)
Diarrhoeal diseases Not deficient Both Both 1.0
(1.0 to 1.0)
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Diet low in vegetables
Diet low in legumes
Diet low in whole grains
Diet low in nuts and seeds
Diet low in milk
Diet high in red meat
Diet high in processed meat
Diet high in trans fatty acids
Diet high in sodium **
Diet high in sugar-sweetened beverages
Diet low in fibre
Diet low in calcium
Diet low in seafood omega-3 fatty acids
Diet low in polyunsaturated fatty acids
295
All-age 0-6 days 7-27 days 28-364 days 1-4 years 5-9 years 10-14 years 15-19 years 20-24 years 25-29 years 30-34 years 35-39 years 40-44 years 45-49 years 50-54 years 55-59 years 60-64 years 65-69 years 70-74 years 75-79 years 80-84 years 85-89 years 90-94 years 95+ years
Appendix Table 6a. Relative risks used by age and sex for each outcome for all risk factors except for ambient air pollution alcohol, and smoking.
Risk - Outcome Category / Units Morbidity / Mortality Sex
Ages






























HIV/AIDS - Drug-susceptible 
Tuberculosis
Exposed morbidity Both 1.59
(1.3 to 1.94)
HIV/AIDS - Drug-susceptible 
Tuberculosis
Exposed mortality Both 1.59
(1.3 to 1.94)
HIV/AIDS - Drug-susceptible 
Tuberculosis
Not exposed morbidity Both 1.0
(1.0 to 1.0)
HIV/AIDS - Drug-susceptible 
Tuberculosis
Not exposed mortality Both 1.0
(1.0 to 1.0)
HIV/AIDS - Multidrug-resistant 
Tuberculosis without extensive drug 
resistance
Exposed morbidity Both 1.59
(1.3 to 1.94)
HIV/AIDS - Multidrug-resistant 
Tuberculosis without extensive drug 
resistance
Exposed mortality Both 1.59
(1.3 to 1.94)
HIV/AIDS - Multidrug-resistant 
Tuberculosis without extensive drug 
resistance
Not exposed morbidity Both 1.0
(1.0 to 1.0)
HIV/AIDS - Multidrug-resistant 
Tuberculosis without extensive drug 
resistance
Not exposed mortality Both 1.0
(1.0 to 1.0)
HIV/AIDS - Extensively drug-
resistant Tuberculosis
Exposed morbidity Both 1.59
(1.3 to 1.94)
HIV/AIDS - Extensively drug-
resistant Tuberculosis
Exposed mortality Both 1.59
(1.3 to 1.94)
HIV/AIDS - Extensively drug-
resistant Tuberculosis
Not exposed morbidity Both 1.0
(1.0 to 1.0)
HIV/AIDS - Extensively drug-
resistant Tuberculosis
Not exposed mortality Both 1.0
(1.0 to 1.0)
HIV/AIDS resulting in other 
diseases
Exposed morbidity Both 1.59
(1.3 to 1.94)
HIV/AIDS resulting in other 
diseases
Exposed mortality Both 1.59
(1.3 to 1.94)
HIV/AIDS resulting in other 
diseases
Not exposed morbidity Both 1.0
(1.0 to 1.0)
HIV/AIDS resulting in other 
diseases
Not exposed mortality Both 1.0
(1.0 to 1.0)
















































































































































































































































































































































































Major depressive disorder First exposed to bullying in current year morbidity Both 2.016
( 1.488 to 2.731)
Major depressive disorder First exposed to bullying 1 year prior morbidity Both 1.955
(1.481 to 2.579)
Major depressive disorder First exposed to bullying 2 years prior morbidity Both 1.895
(1.471 to 2.441)
Major depressive disorder First exposed to bullying 3 years prior morbidity Both 1.838
(1.457 to 2.318)
Major depressive disorder First exposed to bullying 4 years prior morbidity Both 1.782
(1.437 to 2.21)
Major depressive disorder First exposed to bullying 5 years prior morbidity Both 1.728
(1.41 to 2.117)
Major depressive disorder First exposed to bullying 6 years prior morbidity Both 1.675
(1.376 to 2.04)
Major depressive disorder First exposed to bullying 7 years prior morbidity Both 1.624
(1.333 to 1.979)
Major depressive disorder First exposed to bullying 8 years prior morbidity Both 1.575
(1.284 to 1.932)
Major depressive disorder First exposed to bullying 9 years prior morbidity Both 1.527
(1.229 to 1.898)
Major depressive disorder First exposed to bullying 10 years prior morbidity Both 1.481
(1.171 to 1.873)
Major depressive disorder First exposed to bullying 11 years prior morbidity Both 1.436
(1.112 to 1.855)
Major depressive disorder First exposed to bullying 12 years prior morbidity Both 1.392
(1.052 to 1.843)
Major depressive disorder First exposed to bullying 13 years prior morbidity Both 1.35
(0.993 to 1.836)
Major depressive disorder First exposed to bullying 14 years prior morbidity Both 1.309
(0.936 to 1.832)
Major depressive disorder First exposed to bullying 15 years prior morbidity Both 1.269
(0.881 to 1.83)
Major depressive disorder First exposed to bullying 16 years prior morbidity Both 1.231
(0.828 to 1.83)
Major depressive disorder First exposed to bullying 17 years prior morbidity Both 1.193
(0.778 to 1.831)
Major depressive disorder First exposed to bullying 18 years prior morbidity Both 1.157
(0.73 to 1.834)
Major depressive disorder First exposed to bullying 19 years prior morbidity Both 1.122
(0.685 to 1.837)
Major depressive disorder First exposed to bullying 20 years prior morbidity Both 1.088
(0.643 to 1.842)
Major depressive disorder First exposed to bullying 21 years prior morbidity Both 1.055
(0.603 to 1.847)
Major depressive disorder First exposed to bullying 22 years prior morbidity Both 1.023
(0.565 to 1.852)
Major depressive disorder Never exposed to bullying or first exposed 
over 22 years prior
morbidity Both 1.0
(1.0 to 1.0)
Anxiety disorders First exposed to bullying in current year morbidity Both 2.016
(1.488 to 2.731)
Anxiety disorders First exposed to bullying 1 year prior morbidity Both 1.955
(1.481 to 2.579)
Anxiety disorders First exposed to bullying 2 years prior morbidity Both 1.895
(1.471 to 2.441)
Anxiety disorders First exposed to bullying 3 years prior morbidity Both 1.838
(1.457 to 2.318)
Bullying victimization
Intimate partner violence (HIV PAF approach)
Intimate partner violence (exposure approach)
Childhood sexual abuse
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Anxiety disorders First exposed to bullying 4 years prior morbidity Both 1.782
(1.437 to 2.21)
Anxiety disorders First exposed to bullying 5 years prior morbidity Both 1.728
(1.41 to 2.117)
Anxiety disorders First exposed to bullying 6 years prior morbidity Both 1.675
(1.376 to 2.04)
Anxiety disorders First exposed to bullying 7 years prior morbidity Both 1.624
(1.333 to 1.979)
Anxiety disorders First exposed to bullying 8 years prior morbidity Both 1.575
(1.284 to 1.932)
Anxiety disorders First exposed to bullying 9 years prior morbidity Both 1.527
(1.229 to 1.898)
Anxiety disorders First exposed to bullying 10 years prior morbidity Both 1.481
(1.171 to 1.873)
Anxiety disorders First exposed to bullying 11 years prior morbidity Both 1.436
(1.112 to 1.855)
Anxiety disorders First exposed to bullying 12 years prior morbidity Both 1.392
(1.052 to 1.843)
Anxiety disorders First exposed to bullying 13 years prior morbidity Both 1.35
(0.993 to 1.836)
Anxiety disorders First exposed to bullying 14 years prior morbidity Both 1.309
(0.936 to 1.832)
Anxiety disorders First exposed to bullying 15 years prior morbidity Both 1.269
(0.881 to 1.83)
Anxiety disorders First exposed to bullying 16 years prior morbidity Both 1.231
(0.828 to 1.83)
Anxiety disorders First exposed to bullying 17 years prior morbidity Both 1.193
(0.778 to 1.831)
Anxiety disorders First exposed to bullying 18 years prior morbidity Both 1.157
(0.73 to 1.834)
Anxiety disorders First exposed to bullying 19 years prior morbidity Both 1.122
(0.685 to 1.837)
Anxiety disorders First exposed to bullying 20 years prior morbidity Both 1.088
(0.643 to 1.842)
Anxiety disorders First exposed to bullying 21 years prior morbidity Both 1.055
(0.603 to 1.847)
Anxiety disorders First exposed to bullying 22 years prior morbidity Both 1.023
(0.565 to 1.852)
Anxiety disorders Never exposed to bullying or first exposed 
over 22 years prior
morbidity Both 1.0
(1.0 to 1.0)
Colon and rectum cancer 0 METs Both Both 1.0
(1.0 to 1.0)
Colon and rectum cancer 10200 METs Both Both 0.811
(0.758 to 0.864)
Colon and rectum cancer 10800 METs Both Both 0.809
(0.757 to 0.862)
Colon and rectum cancer 11400 METs Both Both 0.807
(0.756 to 0.86)
Colon and rectum cancer 1200 METs Both Both 0.956
(0.88 to 1.032)
Colon and rectum cancer 12000 METs Both Both 0.805
(0.754 to 0.858)
Colon and rectum cancer 12600 METs Both Both 0.804
(0.753 to 0.856)
Colon and rectum cancer 13200 METs Both Both 0.802
(0.752 to 0.855)
Colon and rectum cancer 13800 METs Both Both 0.8
(0.75 to 0.854)
Colon and rectum cancer 14400 METs Both Both 0.798
(0.749 to 0.851)
Colon and rectum cancer 15000 METs Both Both 0.796
(0.747 to 0.85)
Colon and rectum cancer 15600 METs Both Both 0.795
(0.744 to 0.849)
Colon and rectum cancer 16200 METs Both Both 0.793
(0.742 to 0.849)
Colon and rectum cancer 16800 METs Both Both 0.791
(0.739 to 0.848)
Colon and rectum cancer 17400 METs Both Both 0.789
(0.736 to 0.847)
Colon and rectum cancer 1800 METs Both Both 0.933
(0.821 to 1.048)
Colon and rectum cancer 18000 METs Both Both 0.787
(0.733 to 0.847)
Colon and rectum cancer 18600 METs Both Both 0.786
(0.729 to 0.846)
Colon and rectum cancer 19200 METs Both Both 0.784
(0.726 to 0.846)
Colon and rectum cancer 19800 METs Both Both 0.782
(0.723 to 0.845)
Colon and rectum cancer 20400 METs Both Both 0.78
(0.72 to 0.845)
Colon and rectum cancer 21000 METs Both Both 0.778
(0.717 to 0.845)
Colon and rectum cancer 21600 METs Both Both 0.777
(0.713 to 0.846)
Colon and rectum cancer 22200 METs Both Both 0.775
(0.709 to 0.847)
Colon and rectum cancer 22800 METs Both Both 0.773
(0.706 to 0.848)
Colon and rectum cancer 23400 METs Both Both 0.771
(0.702 to 0.849)
Colon and rectum cancer 2400 METs Both Both 0.883
(0.806 to 0.958)
Colon and rectum cancer 24000 METs Both Both 0.769
(0.698 to 0.849)
Colon and rectum cancer 24600 METs Both Both 0.767
(0.694 to 0.85)
Colon and rectum cancer 25200 METs Both Both 0.766
(0.689 to 0.85)
Colon and rectum cancer 25800 METs Both Both 0.764
(0.685 to 0.849)
Colon and rectum cancer 26400 METs Both Both 0.762
(0.679 to 0.851)
Colon and rectum cancer 27000 METs Both Both 0.76
(0.675 to 0.853)
Colon and rectum cancer 27600 METs Both Both 0.758
(0.671 to 0.853)
Colon and rectum cancer 28200 METs Both Both 0.757
(0.668 to 0.856)
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Colon and rectum cancer 29400 METs Both Both 0.753
(0.659 to 0.856)
Colon and rectum cancer 3000 METs Both Both 0.833
(0.76 to 0.907)
Colon and rectum cancer 30000 METs Both Both 0.751
(0.654 to 0.856)
Colon and rectum cancer 30600 METs Both Both 0.749
(0.649 to 0.857)
Colon and rectum cancer 31200 METs Both Both 0.748
(0.644 to 0.858)
Colon and rectum cancer 31800 METs Both Both 0.746
(0.64 to 0.859)
Colon and rectum cancer 32400 METs Both Both 0.744
(0.635 to 0.86)
Colon and rectum cancer 33000 METs Both Both 0.743
(0.632 to 0.86)
Colon and rectum cancer 3600 METs Both Both 0.831
(0.761 to 0.903)
Colon and rectum cancer 4200 METs Both Both 0.829
(0.761 to 0.898)
Colon and rectum cancer 4800 METs Both Both 0.827
(0.761 to 0.893)
Colon and rectum cancer 5400 METs Both Both 0.825
(0.763 to 0.89)
Colon and rectum cancer 600 METs Both Both 0.978
(0.94 to 1.016)
Colon and rectum cancer 6000 METs Both Both 0.824
(0.763 to 0.887)
Colon and rectum cancer 6600 METs Both Both 0.822
(0.762 to 0.884)
Colon and rectum cancer 7200 METs Both Both 0.82
(0.762 to 0.88)
Colon and rectum cancer 7800 METs Both Both 0.818
(0.761 to 0.877)
Colon and rectum cancer 8400 METs Both Both 0.816
(0.76 to 0.872)
Colon and rectum cancer 9000 METs Both Both 0.815
(0.758 to 0.871)
Colon and rectum cancer 9600 METs Both Both 0.813
(0.758 to 0.868)
Breast cancer 0 METs Both Both 1.0
(1.0 to 1.0)
Breast cancer 10200 METs Both Both 0.908
(0.861 to 0.961)
Breast cancer 10800 METs Both Both 0.904
(0.859 to 0.952)
Breast cancer 11400 METs Both Both 0.9
(0.855 to 0.948)
Breast cancer 1200 METs Both Both 0.974
(0.942 to 1.005)
Breast cancer 12000 METs Both Both 0.895
(0.85 to 0.946)
Breast cancer 12600 METs Both Both 0.891
(0.842 to 0.946)
Breast cancer 13200 METs Both Both 0.887
(0.832 to 0.948)
Breast cancer 13800 METs Both Both 0.883
(0.819 to 0.949)
Breast cancer 14400 METs Both Both 0.879
(0.807 to 0.952)
Breast cancer 15000 METs Both Both 0.874
(0.796 to 0.957)
Breast cancer 15600 METs Both Both 0.872
(0.797 to 0.951)
Breast cancer 16200 METs Both Both 0.87
(0.799 to 0.946)
Breast cancer 16800 METs Both Both 0.868
(0.801 to 0.941)
Breast cancer 17400 METs Both Both 0.865
(0.804 to 0.933)
Breast cancer 1800 METs Both Both 0.96
(0.914 to 1.008)
Breast cancer 18000 METs Both Both 0.863
(0.807 to 0.927)
Breast cancer 18600 METs Both Both 0.861
(0.807 to 0.919)
Breast cancer 19200 METs Both Both 0.859
(0.808 to 0.912)
Breast cancer 19800 METs Both Both 0.856
(0.809 to 0.909)
Breast cancer 20400 METs Both Both 0.854
(0.809 to 0.906)
Breast cancer 21000 METs Both Both 0.852
(0.809 to 0.9)
Breast cancer 21600 METs Both Both 0.85
(0.808 to 0.896)
Breast cancer 22200 METs Both Both 0.847
(0.805 to 0.893)
Breast cancer 22800 METs Both Both 0.845
(0.804 to 0.891)
Breast cancer 23400 METs Both Both 0.843
(0.801 to 0.888)
Breast cancer 2400 METs Both Both 0.957
(0.914 to 1.001)
Breast cancer 24000 METs Both Both 0.841
(0.797 to 0.888)
Breast cancer 24600 METs Both Both 0.839
(0.793 to 0.889)
Breast cancer 25200 METs Both Both 0.836
(0.789 to 0.891)
Breast cancer 25800 METs Both Both 0.834
(0.784 to 0.892)
Breast cancer 26400 METs Both Both 0.832
(0.779 to 0.892)
Breast cancer 27000 METs Both Both 0.83
(0.773 to 0.892)
Breast cancer 27600 METs Both Both 0.827
(0.77 to 0.894)
Breast cancer 28200 METs Both Both 0.825
(0.766 to 0.897)
Breast cancer 28800 METs Both Both 0.823
(0.759 to 0.9)
Breast cancer 29400 METs Both Both 0.821
(0.752 to 0.903)
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Breast cancer 3000 METs Both Both 0.953
(0.913 to 0.994)
Breast cancer 30000 METs Both Both 0.818
(0.745 to 0.904)
Breast cancer 30600 METs Both Both 0.816
(0.738 to 0.906)
Breast cancer 31200 METs Both Both 0.814
(0.731 to 0.907)
Breast cancer 31800 METs Both Both 0.812
(0.724 to 0.909)
Breast cancer 32400 METs Both Both 0.809
(0.717 to 0.911)
Breast cancer 33000 METs Both Both 0.808
(0.713 to 0.912)
Breast cancer 3600 METs Both Both 0.949
(0.912 to 0.99)
Breast cancer 4200 METs Both Both 0.946
(0.909 to 0.985)
Breast cancer 4800 METs Both Both 0.942
(0.907 to 0.982)
Breast cancer 5400 METs Both Both 0.938
(0.903 to 0.979)
Breast cancer 600 METs Both Both 0.987
(0.971 to 1.003)
Breast cancer 6000 METs Both Both 0.935
(0.897 to 0.979)
Breast cancer 6600 METs Both Both 0.931
(0.889 to 0.978)
Breast cancer 7200 METs Both Both 0.928
(0.883 to 0.978)
Breast cancer 7800 METs Both Both 0.924
(0.875 to 0.979)
Breast cancer 8400 METs Both Both 0.92
(0.867 to 0.979)
Breast cancer 9000 METs Both Both 0.917
(0.858 to 0.979)
Breast cancer 9600 METs Both Both 0.912
(0.862 to 0.97)
Ischaemic heart disease 0 METs Both Both 1.0
(1.0 to 1.0)
Ischaemic heart disease 10200 METs Both Both 0.73
(0.668 to 0.793)
Ischaemic heart disease 10800 METs Both Both 0.73
(0.669 to 0.791)
Ischaemic heart disease 11400 METs Both Both 0.729
(0.671 to 0.789)
Ischaemic heart disease 1200 METs Both Both 0.819
(0.714 to 0.928)
Ischaemic heart disease 12000 METs Both Both 0.728
(0.672 to 0.787)
Ischaemic heart disease 12600 METs Both Both 0.728
(0.672 to 0.786)
Ischaemic heart disease 13200 METs Both Both 0.727
(0.671 to 0.785)
Ischaemic heart disease 13800 METs Both Both 0.727
(0.67 to 0.784)
Ischaemic heart disease 14400 METs Both Both 0.726
(0.671 to 0.782)
Ischaemic heart disease 15000 METs Both Both 0.725
(0.67 to 0.781)
Ischaemic heart disease 15600 METs Both Both 0.725
(0.671 to 0.781)
Ischaemic heart disease 16200 METs Both Both 0.724
(0.671 to 0.779)
Ischaemic heart disease 16800 METs Both Both 0.724
(0.669 to 0.779)
Ischaemic heart disease 17400 METs Both Both 0.723
(0.669 to 0.78)
Ischaemic heart disease 1800 METs Both Both 0.808
(0.739 to 0.886)
Ischaemic heart disease 18000 METs Both Both 0.722
(0.668 to 0.78)
Ischaemic heart disease 18600 METs Both Both 0.722
(0.667 to 0.781)
Ischaemic heart disease 19200 METs Both Both 0.721
(0.666 to 0.781)
Ischaemic heart disease 19800 METs Both Both 0.721
(0.665 to 0.781)
Ischaemic heart disease 20400 METs Both Both 0.72
(0.664 to 0.781)
Ischaemic heart disease 21000 METs Both Both 0.72
(0.663 to 0.782)
Ischaemic heart disease 21600 METs Both Both 0.719
(0.662 to 0.782)
Ischaemic heart disease 22200 METs Both Both 0.718
(0.66 to 0.783)
Ischaemic heart disease 22800 METs Both Both 0.718
(0.659 to 0.784)
Ischaemic heart disease 23400 METs Both Both 0.717
(0.657 to 0.786)
Ischaemic heart disease 2400 METs Both Both 0.796
(0.711 to 0.895)
Ischaemic heart disease 24000 METs Both Both 0.717
(0.655 to 0.787)
Ischaemic heart disease 24600 METs Both Both 0.716
(0.653 to 0.788)
Ischaemic heart disease 25200 METs Both Both 0.715
(0.65 to 0.789)
Ischaemic heart disease 25800 METs Both Both 0.715
(0.648 to 0.79)
Ischaemic heart disease 26400 METs Both Both 0.714
(0.646 to 0.792)
Ischaemic heart disease 27000 METs Both Both 0.714
(0.643 to 0.794)
Ischaemic heart disease 27600 METs Both Both 0.713
(0.64 to 0.796)
Ischaemic heart disease 28200 METs Both Both 0.712
(0.636 to 0.798)
Ischaemic heart disease 28800 METs Both Both 0.712
(0.633 to 0.8)
Ischaemic heart disease 29400 METs Both Both 0.711
(0.63 to 0.801)
Ischaemic heart disease 3000 METs Both Both 0.776
(0.713 to 0.844)
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Ischaemic heart disease 30000 METs Both Both 0.711
(0.626 to 0.801)
Ischaemic heart disease 30600 METs Both Both 0.71
(0.623 to 0.802)
Ischaemic heart disease 31200 METs Both Both 0.709
(0.62 to 0.804)
Ischaemic heart disease 31800 METs Both Both 0.709
(0.616 to 0.806)
Ischaemic heart disease 32400 METs Both Both 0.708
(0.615 to 0.808)
Ischaemic heart disease 33000 METs Both Both 0.708
(0.613 to 0.81)
Ischaemic heart disease 3600 METs Both Both 0.756
(0.692 to 0.816)
Ischaemic heart disease 4200 METs Both Both 0.736
(0.652 to 0.821)
Ischaemic heart disease 4800 METs Both Both 0.736
(0.653 to 0.818)
Ischaemic heart disease 5400 METs Both Both 0.735
(0.654 to 0.815)
Ischaemic heart disease 600 METs Both Both 0.909
(0.857 to 0.964)
Ischaemic heart disease 6000 METs Both Both 0.734
(0.656 to 0.811)
Ischaemic heart disease 6600 METs Both Both 0.734
(0.657 to 0.808)
Ischaemic heart disease 7200 METs Both Both 0.733
(0.659 to 0.806)
Ischaemic heart disease 7800 METs Both Both 0.733
(0.66 to 0.803)
Ischaemic heart disease 8400 METs Both Both 0.732
(0.662 to 0.801)
Ischaemic heart disease 9000 METs Both Both 0.731
(0.664 to 0.799)
Ischaemic heart disease 9600 METs Both Both 0.731
(0.666 to 0.796)
Ischaemic stroke 0 METs Both Both 1.0
(1.0 to 1.0)
Ischaemic stroke 10200 METs Both Both 0.753
(0.653 to 0.864)
Ischaemic stroke 10800 METs Both Both 0.75
(0.653 to 0.858)
Ischaemic stroke 11400 METs Both Both 0.747
(0.653 to 0.851)
Ischaemic stroke 1200 METs Both Both 0.819
(0.662 to 0.999)
Ischaemic stroke 12000 METs Both Both 0.744
(0.651 to 0.845)
Ischaemic stroke 12600 METs Both Both 0.741
(0.65 to 0.84)
Ischaemic stroke 13200 METs Both Both 0.738
(0.65 to 0.833)
Ischaemic stroke 13800 METs Both Both 0.735
(0.65 to 0.828)
Ischaemic stroke 14400 METs Both Both 0.732
(0.647 to 0.825)
Ischaemic stroke 15000 METs Both Both 0.729
(0.644 to 0.82)
Ischaemic stroke 15600 METs Both Both 0.727
(0.642 to 0.813)
Ischaemic stroke 16200 METs Both Both 0.724
(0.639 to 0.809)
Ischaemic stroke 16800 METs Both Both 0.721
(0.639 to 0.806)
Ischaemic stroke 17400 METs Both Both 0.718
(0.636 to 0.802)
Ischaemic stroke 1800 METs Both Both 0.802
(0.702 to 0.915)
Ischaemic stroke 18000 METs Both Both 0.715
(0.633 to 0.797)
Ischaemic stroke 18600 METs Both Both 0.712
(0.63 to 0.793)
Ischaemic stroke 19200 METs Both Both 0.709
(0.626 to 0.791)
Ischaemic stroke 19800 METs Both Both 0.706
(0.623 to 0.789)
Ischaemic stroke 20400 METs Both Both 0.703
(0.62 to 0.79)
Ischaemic stroke 21000 METs Both Both 0.7
(0.615 to 0.787)
Ischaemic stroke 21600 METs Both Both 0.697
(0.611 to 0.787)
Ischaemic stroke 22200 METs Both Both 0.694
(0.606 to 0.787)
Ischaemic stroke 22800 METs Both Both 0.691
(0.602 to 0.785)
Ischaemic stroke 23400 METs Both Both 0.688
(0.595 to 0.783)
Ischaemic stroke 2400 METs Both Both 0.785
(0.643 to 0.943)
Ischaemic stroke 24000 METs Both Both 0.685
(0.593 to 0.78)
Ischaemic stroke 24600 METs Both Both 0.682
(0.586 to 0.779)
Ischaemic stroke 25200 METs Both Both 0.679
(0.579 to 0.778)
Ischaemic stroke 25800 METs Both Both 0.677
(0.572 to 0.776)
Ischaemic stroke 26400 METs Both Both 0.674
(0.566 to 0.777)
Ischaemic stroke 27000 METs Both Both 0.671
(0.56 to 0.779)
Ischaemic stroke 27600 METs Both Both 0.668
(0.554 to 0.781)
Ischaemic stroke 28200 METs Both Both 0.665
(0.547 to 0.781)
Ischaemic stroke 28800 METs Both Both 0.662
(0.541 to 0.783)
Ischaemic stroke 29400 METs Both Both 0.659
(0.534 to 0.785)
Ischaemic stroke 3000 METs Both Both 0.784
(0.701 to 0.888)
Ischaemic stroke 30000 METs Both Both 0.656
(0.527 to 0.787)
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All-age 0-6 days 7-27 days 28-364 days 1-4 years 5-9 years 10-14 years 15-19 years 20-24 years 25-29 years 30-34 years 35-39 years 40-44 years 45-49 years 50-54 years 55-59 years 60-64 years 65-69 years 70-74 years 75-79 years 80-84 years 85-89 years 90-94 years 95+ years
Appendix Table 6a. Relative risks used by age and sex for each outcome for all risk factors except for ambient air pollution alcohol, and smoking.
Risk - Outcome Category / Units Morbidity / Mortality Sex
Ages
Ischaemic stroke 30600 METs Both Both 0.653
(0.521 to 0.789)
Ischaemic stroke 31200 METs Both Both 0.65
(0.514 to 0.791)
Ischaemic stroke 31800 METs Both Both 0.647
(0.506 to 0.792)
Ischaemic stroke 32400 METs Both Both 0.644
(0.498 to 0.792)
Ischaemic stroke 33000 METs Both Both 0.643
(0.493 to 0.792)
Ischaemic stroke 3600 METs Both Both 0.783
(0.695 to 0.883)
Ischaemic stroke 4200 METs Both Both 0.782
(0.644 to 0.934)
Ischaemic stroke 4800 METs Both Both 0.779
(0.647 to 0.926)
Ischaemic stroke 5400 METs Both Both 0.776
(0.648 to 0.918)
Ischaemic stroke 600 METs Both Both 0.91
(0.831 to 0.999)
Ischaemic stroke 6000 METs Both Both 0.774
(0.649 to 0.913)
Ischaemic stroke 6600 METs Both Both 0.771
(0.65 to 0.905)
Ischaemic stroke 7200 METs Both Both 0.768
(0.652 to 0.898)
Ischaemic stroke 7800 METs Both Both 0.765
(0.65 to 0.891)
Ischaemic stroke 8400 METs Both Both 0.762
(0.651 to 0.884)
Ischaemic stroke 9000 METs Both Both 0.759
(0.652 to 0.878)
Ischaemic stroke 9600 METs Both Both 0.756
(0.652 to 0.87)
Diabetes mellitus type 2 0 METs Both Both 1.0
(1.0 to 1.0)
Diabetes mellitus type 2 10200 METs Both Both 0.727
(0.684 to 0.774)
Diabetes mellitus type 2 10800 METs Both Both 0.726
(0.683 to 0.772)
Diabetes mellitus type 2 11400 METs Both Both 0.725
(0.682 to 0.77)
Diabetes mellitus type 2 1200 METs Both Both 0.961
(0.933 to 0.992)
Diabetes mellitus type 2 12000 METs Both Both 0.723
(0.682 to 0.771)
Diabetes mellitus type 2 12600 METs Both Both 0.722
(0.682 to 0.768)
Diabetes mellitus type 2 13200 METs Both Both 0.721
(0.681 to 0.766)
Diabetes mellitus type 2 13800 METs Both Both 0.72
(0.68 to 0.765)
Diabetes mellitus type 2 14400 METs Both Both 0.719
(0.678 to 0.764)
Diabetes mellitus type 2 15000 METs Both Both 0.718
(0.678 to 0.762)
Diabetes mellitus type 2 15600 METs Both Both 0.717
(0.677 to 0.761)
Diabetes mellitus type 2 16200 METs Both Both 0.716
(0.676 to 0.76)
Diabetes mellitus type 2 16800 METs Both Both 0.715
(0.674 to 0.759)
Diabetes mellitus type 2 17400 METs Both Both 0.714
(0.673 to 0.759)
Diabetes mellitus type 2 1800 METs Both Both 0.921
(0.867 to 0.985)
Diabetes mellitus type 2 18000 METs Both Both 0.713
(0.67 to 0.759)
Diabetes mellitus type 2 18600 METs Both Both 0.712
(0.668 to 0.759)
Diabetes mellitus type 2 19200 METs Both Both 0.711
(0.665 to 0.758)
Diabetes mellitus type 2 19800 METs Both Both 0.709
(0.663 to 0.758)
Diabetes mellitus type 2 20400 METs Both Both 0.708
(0.66 to 0.759)
Diabetes mellitus type 2 21000 METs Both Both 0.707
(0.658 to 0.759)
Diabetes mellitus type 2 21600 METs Both Both 0.706
(0.656 to 0.759)
Diabetes mellitus type 2 22200 METs Both Both 0.705
(0.654 to 0.759)
Diabetes mellitus type 2 22800 METs Both Both 0.704
(0.651 to 0.759)
Diabetes mellitus type 2 23400 METs Both Both 0.703
(0.65 to 0.759)
Diabetes mellitus type 2 2400 METs Both Both 0.882
(0.8 to 0.977)
Diabetes mellitus type 2 24000 METs Both Both 0.702
(0.648 to 0.76)
Diabetes mellitus type 2 24600 METs Both Both 0.701
(0.646 to 0.76)
Diabetes mellitus type 2 25200 METs Both Both 0.7
(0.643 to 0.76)
Diabetes mellitus type 2 25800 METs Both Both 0.699
(0.64 to 0.76)
Diabetes mellitus type 2 26400 METs Both Both 0.698
(0.638 to 0.76)
Diabetes mellitus type 2 27000 METs Both Both 0.697
(0.635 to 0.76)
Diabetes mellitus type 2 27600 METs Both Both 0.696
(0.631 to 0.761)
Diabetes mellitus type 2 28200 METs Both Both 0.694
(0.628 to 0.762)
Diabetes mellitus type 2 28800 METs Both Both 0.693
(0.624 to 0.762)
Diabetes mellitus type 2 29400 METs Both Both 0.692
(0.621 to 0.763)
Diabetes mellitus type 2 3000 METs Both Both 0.834
(0.773 to 0.904)
Diabetes mellitus type 2 30000 METs Both Both 0.691
(0.618 to 0.764)
Diabetes mellitus type 2 30600 METs Both Both 0.69
(0.615 to 0.765)
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Appendix Table 6a. Relative risks used by age and sex for each outcome for all risk factors except for ambient air pollution alcohol, and smoking.
Risk - Outcome Category / Units Morbidity / Mortality Sex
Ages
Diabetes mellitus type 2 31200 METs Both Both 0.689
(0.612 to 0.766)
Diabetes mellitus type 2 31800 METs Both Both 0.688
(0.609 to 0.768)
Diabetes mellitus type 2 32400 METs Both Both 0.687
(0.607 to 0.768)
Diabetes mellitus type 2 33000 METs Both Both 0.686
(0.605 to 0.769)
Diabetes mellitus type 2 3600 METs Both Both 0.786
(0.735 to 0.841)
Diabetes mellitus type 2 4200 METs Both Both 0.737
(0.684 to 0.794)
Diabetes mellitus type 2 4800 METs Both Both 0.736
(0.685 to 0.791)
Diabetes mellitus type 2 5400 METs Both Both 0.735
(0.684 to 0.789)
Diabetes mellitus type 2 600 METs Both Both 0.98
(0.967 to 0.996)
Diabetes mellitus type 2 6000 METs Both Both 0.734
(0.684 to 0.786)
Diabetes mellitus type 2 6600 METs Both Both 0.733
(0.685 to 0.784)
Diabetes mellitus type 2 7200 METs Both Both 0.732
(0.685 to 0.782)
Diabetes mellitus type 2 7800 METs Both Both 0.731
(0.684 to 0.78)
Diabetes mellitus type 2 8400 METs Both Both 0.73
(0.684 to 0.779)
Diabetes mellitus type 2 9000 METs Both Both 0.729
(0.684 to 0.777)
Diabetes mellitus type 2 9600 METs Both Both 0.728
(0.684 to 0.776)
























































































































Chronic kidney disease due to 
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Chronic kidney disease due to 
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Chronic kidney disease due to other 
and unspecified causes
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High fasting plasma glucose (continuous)
High fasting plasma glucose (categorical)
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Appendix Table 6a. Relative risks used by age and sex for each outcome for all risk factors except for ambient air pollution alcohol, and smoking.
Risk - Outcome Category / Units Morbidity / Mortality Sex
Ages




















































































































































































Alzheimer's disease and other 
dementias






























Alzheimer's disease and other 
dementias






























Alzheimer's disease and other 
dementias






























Alzheimer's disease and other 
dementias






























































































































































































































































































































































































































































































































Non-rheumatic calcific aortic valve 
disease
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High body-mass index in adults
High systolic blood pressure
High LDL cholesterol
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Appendix Table 6a. Relative risks used by age and sex for each outcome for all risk factors except for ambient air pollution alcohol, and smoking.
Risk - Outcome Category / Units Morbidity / Mortality Sex
Ages
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Alzheimer's disease and other 
dementias
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dementias
































































Chronic kidney disease due to 
diabetes mellitus type 2
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hypertension


























Chronic kidney disease due to 
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Chronic kidney disease due to other 
and unspecified causes










































































































































































































































































































































































































High body-mass index in children
Low bone mineral density
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Appendix Table 6a. Relative risks used by age and sex for each outcome for all risk factors except for ambient air pollution alcohol, and smoking.
Risk - Outcome Category / Units Morbidity / Mortality Sex
Ages































































































































































































































































































































































































































































































































































































































































































































































































































Risk-outcome pairs with 100% attribution
Alcohol use High fasting plasma glucose Occupational particulate matter, gases, and fumes
Liver cancer due to alcohol use Diabetes mellitus Coal workers pneumoconiosis
* Occupational noise relative risk values are for sequela
** Shifts are reported for diet high in sodium as the estimation is based on mediation through high systolic blood pressure.
Childhood underweight Hypertensive heart disease Chlamydial infection
Protein-energy malnutrition Chronic kidney disease due to hypertension Gonococcal infection
Cirrhosis due to alcohol use Chronic kidney disease due to diabetes mellitus Unsafe sex
Alcohol use disorders High systolic blood pressure Syphilis
Drug use Low glomerular filtration rate Other sexually transmitted diseases
Opiod use disorders Chronic kidney disease due to diabetes mellitus Cervical cancer
Childhood wasting Iron deficiency Trichomoniasis
Protein-energy malnutrition Iron-deficiency anaemia Genital herpes
Cannabis use disorders Chronic kidney disease due to other causes Vitamin A deficiency
Other drug use disorders
Cocaine use disorders Chronic kidney disease due to hypertension Sexually transmitted diseases excluding HIV
Amphetamine use disorders Chronic kidney disease due to glomerulonephritis Vitamin A deficiency
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All ages 25-29 years 30-34 years 35-39 years 40-44 years 45-49 years 50-54 years 55-59 years 60-64 years 65-69 years 70-74 years 75-79 years 80-84 years 85-89 years 90-94 years 95+ years
Lower respiratory infections 600 µg/m³ Both Both 2.38(1.968 to 2.776)
Lower respiratory infections 500 µg/m³ Both Both 2.347(1.936 to 2.735)
Lower respiratory infections 400 µg/m³ Both Both 2.297(1.883 to 2.687)
Lower respiratory infections 300 µg/m³ Both Both 2.213(1.809 to 2.615)
Lower respiratory infections 200 µg/m³ Both Both 2.062(1.702 to 2.44)
Lower respiratory infections 150 µg/m³ Both Both 1.938(1.629 to 2.281)
Lower respiratory infections 135 µg/m³ Both Both 1.891(1.6 to 2.209)
Lower respiratory infections 120 µg/m³ Both Both 1.838(1.571 to 2.129)
Lower respiratory infections 105 µg/m³ Both Both 1.778(1.54 to 2.05)
Lower respiratory infections 90 µg/m³ Both Both 1.711(1.505 to 1.945)
Lower respiratory infections 75 µg/m³ Both Both 1.634(1.455 to 1.827)
Lower respiratory infections 60 µg/m³ Both Both 1.546(1.4 to 1.711)
Lower respiratory infections 45 µg/m³ Both Both 1.443(1.323 to 1.576)
Lower respiratory infections 30 µg/m³ Both Both 1.322(1.225 to 1.428)
Lower respiratory infections 25 µg/m³ Both Both 1.276(1.184 to 1.379)
Lower respiratory infections 20 µg/m³ Both Both 1.226(1.14 to 1.335)
Lower respiratory infections 15 µg/m³ Both Both 1.171(1.093 to 1.282)
Lower respiratory infections 10 µg/m³ Both Both 1.108(1.046 to 1.219)
Lower respiratory infections 5 µg/m³ Both Both 1.025(1.0 to 1.119)
Lower respiratory infections 0 µg/m³ Both Both 1.0(1.0 to 1.0)
Tracheal, bronchus, and lung cancer 600 µg/m³ Both Both 2.541(2.222 to 2.868)
Tracheal, bronchus, and lung cancer 500 µg/m³ Both Both 2.369(2.074 to 2.675)
Tracheal, bronchus, and lung cancer 400 µg/m³ Both Both 2.185(1.919 to 2.469)
Tracheal, bronchus, and lung cancer 300 µg/m³ Both Both 1.982(1.748 to 2.229)
Tracheal, bronchus, and lung cancer 200 µg/m³ Both Both 1.753(1.56 to 1.958)
Tracheal, bronchus, and lung cancer 150 µg/m³ Both Both 1.622(1.454 to 1.802)
Tracheal, bronchus, and lung cancer 135 µg/m³ Both Both 1.58(1.421 to 1.754)
Tracheal, bronchus, and lung cancer 120 µg/m³ Both Both 1.536(1.385 to 1.701)
Tracheal, bronchus, and lung cancer 105 µg/m³ Both Both 1.49(1.348 to 1.648)
Ambient particulate matter pollution (PM2.5)








All ages 25-29 years 30-34 years 35-39 years 40-44 years 45-49 years 50-54 years 55-59 years 60-64 years 65-69 years 70-74 years 75-79 years 80-84 years 85-89 years 90-94 years 95+ years
Ambient particulate matter pollution (PM2.5)







Tracheal, bronchus, and lung cancer 90 µg/m³ Both Both 1.442(1.309 to 1.588)
Tracheal, bronchus, and lung cancer 75 µg/m³ Both Both 1.39(1.269 to 1.526)
Tracheal, bronchus, and lung cancer 60 µg/m³ Both Both 1.335(1.227 to 1.458)
Tracheal, bronchus, and lung cancer 45 µg/m³ Both Both 1.273(1.18 to 1.383)
Tracheal, bronchus, and lung cancer 30 µg/m³ Both Both 1.203(1.128 to 1.295)
Tracheal, bronchus, and lung cancer 25 µg/m³ Both Both 1.177(1.109 to 1.261)
Tracheal, bronchus, and lung cancer 20 µg/m³ Both Both 1.148(1.089 to 1.223)
Tracheal, bronchus, and lung cancer 15 µg/m³ Both Both 1.116(1.067 to 1.178)
Tracheal, bronchus, and lung cancer 10 µg/m³ Both Both 1.077(1.041 to 1.126)
Tracheal, bronchus, and lung cancer 5 µg/m³ Both Both 1.02(1.0 to 1.056)
Tracheal, bronchus, and lung cancer 0 µg/m³ Both Both 1.0(1.0 to 1.0)











































































































































































































































































































































































































































































































































All ages 25-29 years 30-34 years 35-39 years 40-44 years 45-49 years 50-54 years 55-59 years 60-64 years 65-69 years 70-74 years 75-79 years 80-84 years 85-89 years 90-94 years 95+ years
Ambient particulate matter pollution (PM2.5)





































































































































































































































































































































































































































































































































































































































































Chronic obstructive pulmonary disease 600 µg/m³ Both Both 2.335(1.956 to 2.701)
Chronic obstructive pulmonary disease 500 µg/m³ Both Both 2.231(1.864 to 2.585)
Chronic obstructive pulmonary disease 400 µg/m³ Both Both 2.114(1.767 to 2.447)
Chronic obstructive pulmonary disease 300 µg/m³ Both Both 1.979(1.653 to 2.292)
Chronic obstructive pulmonary disease 200 µg/m³ Both Both 1.815(1.52 to 2.099)
Chronic obstructive pulmonary disease 150 µg/m³ Both Both 1.714(1.441 to 1.976)
Chronic obstructive pulmonary disease 135 µg/m³ Both Both 1.681(1.415 to 1.94)
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All ages 25-29 years 30-34 years 35-39 years 40-44 years 45-49 years 50-54 years 55-59 years 60-64 years 65-69 years 70-74 years 75-79 years 80-84 years 85-89 years 90-94 years 95+ years
Ambient particulate matter pollution (PM2.5)







Chronic obstructive pulmonary disease 120 µg/m³ Both Both 1.645(1.388 to 1.899)
Chronic obstructive pulmonary disease 105 µg/m³ Both Both 1.606(1.359 to 1.854)
Chronic obstructive pulmonary disease 90 µg/m³ Both Both 1.564(1.328 to 1.804)
Chronic obstructive pulmonary disease 75 µg/m³ Both Both 1.518(1.294 to 1.745)
Chronic obstructive pulmonary disease 60 µg/m³ Both Both 1.466(1.258 to 1.68)
Chronic obstructive pulmonary disease 45 µg/m³ Both Both 1.405(1.217 to 1.607)
Chronic obstructive pulmonary disease 30 µg/m³ Both Both 1.33(1.168 to 1.512)
Chronic obstructive pulmonary disease 25 µg/m³ Both Both 1.3(1.149 to 1.473)
Chronic obstructive pulmonary disease 20 µg/m³ Both Both 1.266(1.126 to 1.426)
Chronic obstructive pulmonary disease 15 µg/m³ Both Both 1.224(1.101 to 1.371)
Chronic obstructive pulmonary disease 10 µg/m³ Both Both 1.17(1.07 to 1.296)
Chronic obstructive pulmonary disease 5 µg/m³ Both Both 1.06(1.0 to 1.17)
Chronic obstructive pulmonary disease 0 µg/m³ Both Both 1.0(1.0 to 1.0)
Diabetes mellitus type 2 600 µg/m³ Both Both 1.448(1.33 to 1.545)
Diabetes mellitus type 2 500 µg/m³ Both Both 1.447(1.324 to 1.545)
Diabetes mellitus type 2 400 µg/m³ Both Both 1.446(1.317 to 1.545)
Diabetes mellitus type 2 300 µg/m³ Both Both 1.445(1.306 to 1.545)
Diabetes mellitus type 2 200 µg/m³ Both Both 1.443(1.292 to 1.545)
Diabetes mellitus type 2 150 µg/m³ Both Both 1.441(1.281 to 1.545)
Diabetes mellitus type 2 135 µg/m³ Both Both 1.44(1.276 to 1.545)
Diabetes mellitus type 2 120 µg/m³ Both Both 1.439(1.272 to 1.544)
Diabetes mellitus type 2 105 µg/m³ Both Both 1.438(1.266 to 1.538)
Diabetes mellitus type 2 90 µg/m³ Both Both 1.436(1.26 to 1.533)
Diabetes mellitus type 2 75 µg/m³ Both Both 1.433(1.253 to 1.53)
Diabetes mellitus type 2 60 µg/m³ Both Both 1.429(1.245 to 1.526)
Diabetes mellitus type 2 45 µg/m³ Both Both 1.422(1.234 to 1.52)
Diabetes mellitus type 2 30 µg/m³ Both Both 1.405(1.219 to 1.504)
Diabetes mellitus type 2 25 µg/m³ Both Both 1.393(1.213 to 1.501)
Diabetes mellitus type 2 20 µg/m³ Both Both 1.375(1.197 to 1.494)
Diabetes mellitus type 2 15 µg/m³ Both Both 1.345(1.177 to 1.489)
Diabetes mellitus type 2 10 µg/m³ Both Both 1.282(1.116 to 1.466)
Diabetes mellitus type 2 5 µg/m³ Both Both 1.089(1.0 to 1.346)
Diabetes mellitus type 2 0 µg/m³ Both Both 1.0(1.0 to 1.0)
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Tuberculosis 72 g/day Both Both
3.507
(2.596 to 4.474)
Tuberculosis 60 g/day Both Both
2.994
(1.972 to 4.204)
Tuberculosis 48 g/day Both Both
2.535
(1.701 to 3.51)
Tuberculosis 36 g/day Both Both
2.058
(1.485 to 2.795)
Tuberculosis 24 g/day Both Both
1.531
(1.165 to 1.98)
Tuberculosis 12 g/day Both Both
1.101
(0.815 to 1.425)
Tuberculosis 0 g/day Both Both
1.0
(1.0 to 1.0)
Lower respiratory infections 72 g/day Both Both
1.357
(1.113 to 1.648)
Lower respiratory infections 60 g/day Both Both
1.226
(1.036 to 1.423)
Lower respiratory infections 48 g/day Both Both
1.127
(0.936 to 1.327)
Lower respiratory infections 36 g/day Both Both
1.064
(0.928 to 1.219)
Lower respiratory infections 24 g/day Both Both
1.026
(0.901 to 1.167)
Lower respiratory infections 12 g/day Both Both
1.013
(0.951 to 1.084)
Lower respiratory infections 0 g/day Both Both
1.0
(1.0 to 1.0)
Oesophageal cancer 72 g/day Both Both
2.669
(2.074 to 3.348)
Oesophageal cancer 60 g/day Both Both
2.452
(1.905 to 3.094)
Oesophageal cancer 48 g/day Both Both
2.202
(1.73 to 2.703)
Oesophageal cancer 36 g/day Both Both
1.815
(1.468 to 2.222)
Oesophageal cancer 24 g/day Both Both
1.466
(1.209 to 1.764)
Oesophageal cancer 12 g/day Both Both
1.212
(1.031 to 1.439)
Oesophageal cancer 0 g/day Both Both
1.0
(1.0 to 1.0)
Liver cancer due to alcohol use 72 g/day Both Both
1.424
(1.088 to 1.855)
Liver cancer due to alcohol use 60 g/day Both Both
1.372
(1.093 to 1.692)
Liver cancer due to alcohol use 48 g/day Both Both
1.31
(1.036 to 1.639)
Liver cancer due to alcohol use 36 g/day Both Both
1.225
(1.009 to 1.455)
Liver cancer due to alcohol use 24 g/day Both Both
1.14
(0.934 to 1.359)
Liver cancer due to alcohol use 12 g/day Both Both
1.067
(0.936 to 1.207)
Liver cancer due to alcohol use 0 g/day Both Both
1.0
(1.0 to 1.0)
Larynx cancer 72 g/day Both Both
2.461
(1.758 to 3.228)
Larynx cancer 60 g/day Both Both
2.144
(1.46 to 2.935)
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Risk - Outcome Category / Units Morbidity / Mortality Sex
Larynx cancer 36 g/day Both Both
1.531
(1.126 to 2.061)
Larynx cancer 24 g/day Both Both
1.304
(1.006 to 1.659)
Larynx cancer 12 g/day Both Both
1.12
(0.903 to 1.386)
Larynx cancer 0 g/day Both Both
1.0
(1.0 to 1.0)
Breast cancer 72 g/day Both Both
1.476
(1.282 to 1.691)
Breast cancer 60 g/day Both Both
1.452
(1.312 to 1.599)
Breast cancer 48 g/day Both Both
1.443
(1.348 to 1.542)
Breast cancer 36 g/day Both Both
1.433
(1.311 to 1.551)
Breast cancer 24 g/day Both Both
1.329
(1.237 to 1.419)
Breast cancer 12 g/day Both Both
1.17
(1.081 to 1.265)
Breast cancer 0 g/day Both Both
1.0
(1.0 to 1.0)
Colon and rectum cancer 72 g/day Both Both
1.616
(1.38 to 1.861)
Colon and rectum cancer 60 g/day Both Both
1.468
(1.329 to 1.615)
Colon and rectum cancer 48 g/day Both Both
1.323
(1.156 to 1.501)
Colon and rectum cancer 36 g/day Both Both
1.237
(1.148 to 1.336)
Colon and rectum cancer 24 g/day Both Both
1.156
(1.067 to 1.248)
Colon and rectum cancer 12 g/day Both Both
1.078
(1.034 to 1.124)
Colon and rectum cancer 0 g/day Both Both
1.0
(1.0 to 1.0)
Lip and oral cavity cancer 72 g/day Both Both
4.858
(3.74 to 6.076)
Lip and oral cavity cancer 60 g/day Both Both
3.766
(2.839 to 4.9)
Lip and oral cavity cancer 48 g/day Both Both
2.991
(2.283 to 3.896)
Lip and oral cavity cancer 36 g/day Both Both
2.311
(1.757 to 2.929)
Lip and oral cavity cancer 24 g/day Both Both
1.738
(1.383 to 2.161)
Lip and oral cavity cancer 12 g/day Both Both
1.293
(1.076 to 1.551)
Lip and oral cavity cancer 0 g/day Both Both
1.0
(1.0 to 1.0)
Nasopharynx cancer 72 g/day Both Both
4.545
(4.1 to 4.982)
Nasopharynx cancer 60 g/day Both Both
3.803
(3.509 to 4.102)
Nasopharynx cancer 48 g/day Both Both
3.062
(2.873 to 3.258)
Nasopharynx cancer 36 g/day Both Both
2.385
(2.25 to 2.552)
Nasopharynx cancer 24 g/day Both Both
1.839
(1.77 to 1.907)
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Risk - Outcome Category / Units Morbidity / Mortality Sex
Nasopharynx cancer 0 g/day Both Both
1.0
(1.0 to 1.0)
Other pharynx cancer 72 g/day Both Both
4.764
(3.315 to 6.576)
Other pharynx cancer 60 g/day Both Both
3.972
(2.813 to 5.354)
Other pharynx cancer 48 g/day Both Both
3.199
(2.202 to 4.407)
Other pharynx cancer 36 g/day Both Both
2.519
(1.843 to 3.299)
Other pharynx cancer 24 g/day Both Both
1.943
(1.467 to 2.484)
Other pharynx cancer 12 g/day Both Both
1.472
(1.234 to 1.742)
Other pharynx cancer 0 g/day Both Both
1.0
(1.0 to 1.0)
Ischaemic heart disease 72 g/day Both Male
1.091
(0.933 to 1.271)
Ischaemic heart disease 60 g/day Both Male
0.993
(0.883 to 1.105)
Ischaemic heart disease 48 g/day Both Male
0.906
(0.797 to 1.035)
Ischaemic heart disease 36 g/day Both Male
0.871
(0.788 to 0.964)
Ischaemic heart disease 24 g/day Both Male
0.857
(0.779 to 0.943)
Ischaemic heart disease 12 g/day Both Male
0.865
(0.79 to 0.948)
Ischaemic heart disease 0 g/day Both Male
1.0
(1.0 to 1.0)
Ischaemic heart disease 72 g/day Both Female
1.107
(0.894 to 1.341)
Ischaemic heart disease 60 g/day Both Female
1.012
(0.869 to 1.174)
Ischaemic heart disease 48 g/day Both Female
0.932
(0.786 to 1.113)
Ischaemic heart disease 36 g/day Both Female
0.882
(0.781 to 0.997)
Ischaemic heart disease 24 g/day Both Female
0.846
(0.749 to 0.948)
Ischaemic heart disease 12 g/day Both Female
0.823
(0.733 to 0.926)
Ischaemic heart disease 0 g/day Both Female
1.0
(1.0 to 1.0)
Ischaemic stroke 72 g/day Both Male
1.451
(1.228 to 1.69)
Ischaemic stroke 60 g/day Both Male
1.312
(1.167 to 1.471)
Ischaemic stroke 48 g/day Both Male
1.159
(0.98 to 1.353)
Ischaemic stroke 36 g/day Both Male
1.057
(0.931 to 1.192)
Ischaemic stroke 24 g/day Both Male
0.97
(0.862 to 1.088)
Ischaemic stroke 12 g/day Both Male
0.938
(0.83 to 1.054)
Ischaemic stroke 0 g/day Both Male
1.0
(1.0 to 1.0)
Ischaemic stroke 72 g/day Both Female
1.43
(1.147 to 1.771)
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Risk - Outcome Category / Units Morbidity / Mortality Sex
Ischaemic stroke 48 g/day Both Female
1.145
(0.946 to 1.359)
Ischaemic stroke 36 g/day Both Female
0.985
(0.834 to 1.149)
Ischaemic stroke 24 g/day Both Female
0.85
(0.726 to 0.985)
Ischaemic stroke 12 g/day Both Female
0.824
(0.718 to 0.939)
Ischaemic stroke 0 g/day Both Female
1.0
(1.0 to 1.0)
Intracerebral hemorrhage 72 g/day Both Male
1.971
(1.663 to 2.316)
Intracerebral hemorrhage 60 g/day Both Male
1.705
(1.45 to 1.991)
Intracerebral hemorrhage 48 g/day Both Male
1.458
(1.182 to 1.768)
Intracerebral hemorrhage 36 g/day Both Male
1.31
(1.105 to 1.539)
Intracerebral hemorrhage 24 g/day Both Male
1.162
(0.973 to 1.385)
Intracerebral hemorrhage 12 g/day Both Male
1.068
(0.945 to 1.214)
Intracerebral hemorrhage 0 g/day Both Male
1.0
(1.0 to 1.0)
Intracerebral hemorrhage 72 g/day Both Female
2.276
(1.701 to 2.934)
Intracerebral hemorrhage 60 g/day Both Female
1.964
(1.536 to 2.464)
Intracerebral hemorrhage 48 g/day Both Female
1.614
(1.245 to 2.048)
Intracerebral hemorrhage 36 g/day Both Female
1.337
(1.065 to 1.664)
Intracerebral hemorrhage 24 g/day Both Female
1.11
(0.884 to 1.367)
Intracerebral hemorrhage 12 g/day Both Female
1.031
(0.897 to 1.18)
Intracerebral hemorrhage 0 g/day Both Female
1.0
(1.0 to 1.0)
Hypertensive heart disease 72 g/day Both Both
1.86
(1.445 to 2.358)
Hypertensive heart disease 60 g/day Both Both
1.705
(1.297 to 2.175)
Hypertensive heart disease 48 g/day Both Both
1.614
(1.25 to 2.049)
Hypertensive heart disease 36 g/day Both Both
1.479
(1.232 to 1.759)
Hypertensive heart disease 24 g/day Both Both
1.315
(1.136 to 1.526)
Hypertensive heart disease 12 g/day Both Both
1.046
(0.913 to 1.198)
Hypertensive heart disease 0 g/day Both Both
1.0
(1.0 to 1.0)
Atrial fibrillation and flutter 72 g/day Both Both
1.535
(1.348 to 1.728)
Atrial fibrillation and flutter 60 g/day Both Both
1.411
(1.26 to 1.569)
Atrial fibrillation and flutter 48 g/day Both Both
1.312
(1.218 to 1.407)
Atrial fibrillation and flutter 36 g/day Both Both
1.214
(1.145 to 1.29)
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Risk - Outcome Category / Units Morbidity / Mortality Sex
Atrial fibrillation and flutter 12 g/day Both Both
1.066
(1.034 to 1.102)
Atrial fibrillation and flutter 0 g/day Both Both
1.0
(1.0 to 1.0)
Cirrhosis and other chronic liver diseases due to alcohol use 72 g/day Both Both
9.427
(6.131 to 13.804)
Cirrhosis and other chronic liver diseases due to alcohol use 60 g/day Both Both
6.274
(3.958 to 9.319)
Cirrhosis and other chronic liver diseases due to alcohol use 48 g/day Both Both
4.673
(3.25 to 6.717)
Cirrhosis and other chronic liver diseases due to alcohol use 36 g/day Both Both
3.274
(2.309 to 4.485)
Cirrhosis and other chronic liver diseases due to alcohol use 24 g/day Both Both
2.055
(1.521 to 2.688)
Cirrhosis and other chronic liver diseases due to alcohol use 12 g/day Both Both
1.243
(0.943 to 1.611)
Cirrhosis and other chronic liver diseases due to alcohol use 0 g/day Both Both
1.0
(1.0 to 1.0)
Pancreatitis 72 g/day Both Both
3.298
(2.473 to 4.458)
Pancreatitis 60 g/day Both Both
2.217
(1.415 to 3.389)
Pancreatitis 48 g/day Both Both
1.717
(1.199 to 2.477)
Pancreatitis 36 g/day Both Both
1.471
(1.062 to 2.021)
Pancreatitis 24 g/day Both Both
1.228
(0.874 to 1.67)
Pancreatitis 12 g/day Both Both
1.073
(0.791 to 1.481)
Pancreatitis 0 g/day Both Both
1.0
(1.0 to 1.0)
Epilepsy 72 g/day Both Both
2.48
(1.929 to 3.144)
Epilepsy 60 g/day Both Both
2.186
(1.781 to 2.622)
Epilepsy 48 g/day Both Both
1.872
(1.438 to 2.369)
Epilepsy 36 g/day Both Both
1.585
(1.303 to 1.898)
Epilepsy 24 g/day Both Both
1.353
(1.118 to 1.633)
Epilepsy 12 g/day Both Both
1.177
(1.059 to 1.316)
Epilepsy 0 g/day Both Both
1.0
(1.0 to 1.0)
Diabetes mellitus 72 g/day Both Male
1.198
(1.065 to 1.337)
Diabetes mellitus 60 g/day Both Male
1.165
(0.998 to 1.342)
Diabetes mellitus 48 g/day Both Male
1.084
(0.933 to 1.239)
Diabetes mellitus 36 g/day Both Male
1.0
(0.891 to 1.119)
Diabetes mellitus 24 g/day Both Male
0.932
(0.841 to 1.03)
Diabetes mellitus 12 g/day Both Male
0.921
(0.833 to 1.015)
Diabetes mellitus 0 g/day Both Male
1.0
(1.0 to 1.0)
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Risk - Outcome Category / Units Morbidity / Mortality Sex
Diabetes mellitus 60 g/day Both Female
1.074
(0.765 to 1.443)
Diabetes mellitus 48 g/day Both Female
0.945
(0.737 to 1.173)
Diabetes mellitus 36 g/day Both Female
0.836
(0.702 to 0.981)
Diabetes mellitus 24 g/day Both Female
0.76
(0.66 to 0.872)
Diabetes mellitus 12 g/day Both Female
0.733
(0.658 to 0.826)
Diabetes mellitus 0 g/day Both Female
1.0
(1.0 to 1.0)
Transport injuries 72 g/day Both Both
1.552
(1.201 to 2.032)
Transport injuries 60 g/day Both Both
1.456
(1.186 to 1.818)
Transport injuries 48 g/day Both Both
1.366
(1.101 to 1.692)
Transport injuries 36 g/day Both Both
1.288
(1.089 to 1.534)
Transport injuries 24 g/day Both Both
1.22
(1.062 to 1.4)
Transport injuries 12 g/day Both Both
1.163
(1.021 to 1.346)
Transport injuries 0 g/day Both Both
1.0
(1.0 to 1.0)
Unintentional injuries 72 g/day Both Both
1.266
(1.063 to 1.555)
Unintentional injuries 60 g/day Both Both
1.221
(1.059 to 1.46)
Unintentional injuries 48 g/day Both Both
1.182
(1.024 to 1.428)
Unintentional injuries 36 g/day Both Both
1.168
(1.054 to 1.347)
Unintentional injuries 24 g/day Both Both
1.154
(1.046 to 1.319)
Unintentional injuries 12 g/day Both Both
1.09
(1.016 to 1.187)
Unintentional injuries 0 g/day Both Both
1.0
(1.0 to 1.0)
Self‐harm 72 g/day Both Both
1.927
(1.398 to 2.665)
Self‐harm 60 g/day Both Both
1.734
(1.29 to 2.308)
Self‐harm 48 g/day Both Both
1.545
(1.132 to 2.048)
Self‐harm 36 g/day Both Both
1.376
(1.05 to 1.751)
Self‐harm 24 g/day Both Both
1.23
(0.972 to 1.533)
Self‐harm 12 g/day Both Both
1.107
(0.908 to 1.343)
Self‐harm 0 g/day Both Both
1.0
(1.0 to 1.0)
Interpersonal violence 72 g/day Both Both
1.516
(1.255 to 1.867)
Interpersonal violence 60 g/day Both Both
1.452
(1.215 to 1.719)
Interpersonal violence 48 g/day Both Both
1.396
(1.118 to 1.739)
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Risk - Outcome Category / Units Morbidity / Mortality Sex
Interpersonal violence 24 g/day Both Both
1.256
(1.055 to 1.46)
Interpersonal violence 12 g/day Both Both
1.129
(0.963 to 1.317)
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Kensington and Chelsea 6






















Newcastle upon Tyne 6
North Tyneside 6
Northumberland 6




North West England 5
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Wigan 6
Wirral 6
South East England 5
Bracknell Forest 6
















Windsor and Maidenhead 6
Wokingham 6
South West England 5
Bath and North East Somerset 6
Bournemouth 6




































East Riding of Yorkshire 6
Kingston upon Hull, City of 6
Kirklees 6
Leeds 6










Latin America and Caribbean 1



















Appendix Table 7. GBD location hierarchy with levels
Puerto Rico 3
Saint Lucia 3
Saint Vincent and the Grenadines 3
Suriname 3
Trinidad and Tobago 3
Virgin Islands 3

































































Rio de Janeiro 4
Rio Grande do Norte 4








North Africa and Middle East 1





























































Appendix Table 7. GBD location hierarchy with levels
West Bengal 4
Union Territories other than Delhi 4
Nepal 3
Pakistan 3




Taiwan (Province of China) 3
Oceania 2
American Samoa 3





Northern Mariana Islands 3




















Central sub-Saharan Africa 2
Angola 3





Eastern sub-Saharan Africa 2
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Risk Factor Mediator Cause Mediation Factor
Lead exposure in bone High systolic blood pressure Rheumatic heart disease 1(1 to 1)
Lead exposure in bone High systolic blood pressure Ischaemic heart disease 1(1 to 1)
Lead exposure in bone High systolic blood pressure Ischaemic stroke 1(1 to 1)
Lead exposure in bone High systolic blood pressure Intracerebral hemorrhage 1(1 to 1)
Lead exposure in bone High systolic blood pressure Subarachnoid hemorrhage 1(1 to 1)
Lead exposure in bone High systolic blood pressure Hypertensive heart disease 1(1 to 1)
Lead exposure in bone High systolic blood pressure Other cardiomyopathy 1(1 to 1)
Lead exposure in bone High systolic blood pressure Atrial fibrillation and flutter 1(1 to 1)
Lead exposure in bone High systolic blood pressure Aortic aneurysm 1(1 to 1)
Lead exposure in bone High systolic blood pressure Peripheral vascular disease 1(1 to 1)
Lead exposure in bone High systolic blood pressure Other cardiovascular and circulatory diseases 1(1 to 1)
Lead exposure in bone High systolic blood pressure Chronic kidney disease due to diabetes mellitus type 1 1(1 to 1)
Lead exposure in bone High systolic blood pressure Chronic kidney disease due to diabetes mellitus type 2 1(1 to 1)
Lead exposure in bone High systolic blood pressure Chronic kidney disease due to hypertension 1(1 to 1)
Lead exposure in bone High systolic blood pressure Chronic kidney disease due to glomerulonephritis 1(1 to 1)
Lead exposure in bone High systolic blood pressure Chronic kidney disease due to other and unspecified causes 1(1 to 1)
Lead exposure in bone Impaired kidney function Chronic kidney disease due to diabetes mellitus type 1 1(1 to 1)
Lead exposure in bone Impaired kidney function Chronic kidney disease due to diabetes mellitus type 2 1(1 to 1)
Lead exposure in bone Impaired kidney function Chronic kidney disease due to hypertension 1(1 to 1)
Lead exposure in bone Impaired kidney function Chronic kidney disease due to glomerulonephritis 1(1 to 1)
Lead exposure in bone Impaired kidney function Chronic kidney disease due to other and unspecified causes 1(1 to 1)
Smoking High fasting plasma glucose Diabetes mellitus type 2 1(1 to 1)
Smoking Low bone mineral density Pedestrian road injuries 1(1 to 1)
Smoking Low bone mineral density Cyclist road injuries 1(1 to 1)
Smoking Low bone mineral density Motor vehicle road injuries 1(1 to 1)
Smoking Low bone mineral density Other road injuries 1(1 to 1)
Smoking Low bone mineral density Other transport injuries 1(1 to 1)
Smoking Low bone mineral density Falls 1(1 to 1)
Smoking Low bone mineral density Other exposure to mechanical forces 1(1 to 1)
Smoking Low bone mineral density Non-venomous animal contact 1(1 to 1)
Smoking Low bone mineral density Assault by other means 1(1 to 1)
Diet low in fruits High fasting plasma glucose Ischaemic stroke 0.05(0.04 to 0.06)
Appendix Table 8. Mediation factors
For IHD, stroke, and diabetes we pooled all available cohorts and estimated relative risks with and without adjustment across all combinations 
of metabolic risk factors. We then computed the excess attenuated risk for each mediation‐risk‐cause set.
347
Risk Factor Mediator Cause Mediation Factor
Appendix Table 8. Mediation factors
For IHD, stroke, and diabetes we pooled all available cohorts and estimated relative risks with and without adjustment across all combinations 
of metabolic risk factors. We then computed the excess attenuated risk for each mediation‐risk‐cause set.
Diet low in fruits High fasting plasma glucose Diabetes mellitus type 2 0.99(0.99 to 0.99)
Diet low in fruits High LDL cholesterol Ischaemic heart disease 0.06(0.05 to 0.08)
Diet low in fruits High LDL cholesterol Ischaemic stroke 0.05(0.04 to 0.06)
Diet low in fruits High systolic blood pressure Ischaemic heart disease 0.06(0.05 to 0.08)
Diet low in fruits High systolic blood pressure Ischaemic stroke 0.05(0.04 to 0.06)
Diet low in fruits High systolic blood pressure Intracerebral hemorrhage 0.02(0.02 to 0.03)
Diet low in fruits High systolic blood pressure Subarachnoid hemorrhage 0.02(0.02 to 0.03)
Diet low in vegetables High fasting plasma glucose Ischaemic heart disease 0.06(0.01 to 0.2)
Diet low in vegetables High fasting plasma glucose Ischaemic stroke 0.08(0.04 to 0.16)
Diet low in vegetables High fasting plasma glucose Intracerebral hemorrhage 0.08(0.04 to 0.16)
Diet low in vegetables High fasting plasma glucose Subarachnoid hemorrhage 0.08(0.04 to 0.16)
Diet low in vegetables High LDL cholesterol Ischaemic heart disease 0.04(0.03 to 0.05)
Diet low in vegetables High LDL cholesterol Ischaemic stroke 0.09(0.04 to 0.16)
Diet low in vegetables High systolic blood pressure Ischaemic heart disease 0.04(0.03 to 0.05)
Diet low in vegetables High systolic blood pressure Ischaemic stroke 0.03(0.02 to 0.04)
Diet low in vegetables High systolic blood pressure Intracerebral hemorrhage 0.04(0.02 to 0.05)
Diet low in vegetables High systolic blood pressure Subarachnoid hemorrhage 0.04(0.02 to 0.05)
Diet low in whole grains High fasting plasma glucose Diabetes mellitus type 2 1(1 to 1)
Diet low in whole grains High LDL cholesterol Ischaemic heart disease 0.39(0.17 to 0.54)
Diet low in whole grains High LDL cholesterol Ischaemic stroke 0.16(0.05 to 0.37)
Diet low in nuts and seeds High fasting plasma glucose Ischaemic heart disease 0.03(0.02 to 0.06)
Diet low in nuts and seeds High fasting plasma glucose Diabetes mellitus type 2 0.99(0.99 to 0.99)
Diet low in nuts and seeds High LDL cholesterol Ischaemic heart disease 0.28(0.01 to 1.62)
Diet low in nuts and seeds High systolic blood pressure Ischaemic heart disease 0.34(0.24 to 0.47)
Diet low in milk Diet low in calcium Colon and rectum cancer 1(1 to 1)
Diet high in red meat High fasting plasma glucose Diabetes mellitus type 2 1(1 to 1)
Diet high in processed meat High fasting plasma glucose Ischaemic heart disease 0.01(0.01 to 0.02)
Diet high in processed meat High fasting plasma glucose Diabetes mellitus type 2 1(1 to 1)
Diet high in sugar-sweetened beverages High fasting plasma glucose Ischaemic heart disease 0.15(0.1 to 0.2)
Diet high in sugar-sweetened beverages High fasting plasma glucose Diabetes mellitus type 2 1(1 to 1)
Diet high in sugar-sweetened beverages High LDL cholesterol Ischaemic heart disease 0.1(0.05 to 0.15)
Diet high in sugar-sweetened beverages High systolic blood pressure Ischaemic heart disease 0.31(0.28 to 0.34)
348
Risk Factor Mediator Cause Mediation Factor
Appendix Table 8. Mediation factors
For IHD, stroke, and diabetes we pooled all available cohorts and estimated relative risks with and without adjustment across all combinations 
of metabolic risk factors. We then computed the excess attenuated risk for each mediation‐risk‐cause set.
Diet high in sugar-sweetened beverages High body-mass index Ischaemic heart disease 1(1 to 1)
Diet high in sugar-sweetened beverages High body-mass index Diabetes mellitus type 2 1(1 to 1)
Diet low in fibre Diet low in fruits Ischaemic heart disease 1(1 to 1)
Diet low in fibre Diet low in vegetables Ischaemic heart disease 1(1 to 1)
Diet low in fibre Diet low in whole grains Ischaemic heart disease 1(1 to 1)
Diet low in seafood omega-3 fatty acids High systolic blood pressure Ischaemic heart disease 0.01(0 to 0.02)
Diet low in polyunsaturated fatty acids High fasting plasma glucose Ischaemic heart disease 0.57(0.39 to 0.77)
Diet low in polyunsaturated fatty acids High systolic blood pressure Ischaemic heart disease 0.72(0.57 to 0.89)
Diet high in trans fatty acids High LDL cholesterol Ischaemic heart disease 0.15(0.02 to 0.24)
Diet high in trans fatty acids High systolic blood pressure Ischaemic heart disease 0.15(0.02 to 0.24)
Diet high in sodium High systolic blood pressure Rheumatic heart disease 1(1 to 1)
Diet high in sodium High systolic blood pressure Ischaemic heart disease 1(1 to 1)
Diet high in sodium High systolic blood pressure Ischaemic stroke 1(1 to 1)
Diet high in sodium High systolic blood pressure Intracerebral hemorrhage 1(1 to 1)
Diet high in sodium High systolic blood pressure Subarachnoid hemorrhage 1(1 to 1)
Diet high in sodium High systolic blood pressure Hypertensive heart disease 1(1 to 1)
Diet high in sodium High systolic blood pressure Other cardiomyopathy 1(1 to 1)
Diet high in sodium High systolic blood pressure Atrial fibrillation and flutter 1(1 to 1)
Diet high in sodium High systolic blood pressure Aortic aneurysm 1(1 to 1)
Diet high in sodium High systolic blood pressure Peripheral vascular disease 1(1 to 1)
Diet high in sodium High systolic blood pressure Other cardiovascular and circulatory diseases 1(1 to 1)
Diet high in sodium High systolic blood pressure Chronic kidney disease due to diabetes mellitus type 1 1(1 to 1)
Diet high in sodium High systolic blood pressure Chronic kidney disease due to diabetes mellitus type 2 1(1 to 1)
Diet high in sodium High systolic blood pressure Chronic kidney disease due to hypertension 1(1 to 1)
Diet high in sodium High systolic blood pressure Chronic kidney disease due to glomerulonephritis 1(1 to 1)
Diet high in sodium High systolic blood pressure Chronic kidney disease due to other and unspecified causes 1(1 to 1)
Diet high in sodium Impaired kidney function Chronic kidney disease due to diabetes mellitus type 1 1(1 to 1)
Diet high in sodium Impaired kidney function Chronic kidney disease due to diabetes mellitus type 2 1(1 to 1)
Diet high in sodium Impaired kidney function Chronic kidney disease due to hypertension 1(1 to 1)
Diet high in sodium Impaired kidney function Chronic kidney disease due to glomerulonephritis 1(1 to 1)
Diet high in sodium Impaired kidney function Chronic kidney disease due to other and unspecified causes 1(1 to 1)
Childhood sexual abuse Alcohol use Alcohol use disorders 1(1 to 1)
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For IHD, stroke, and diabetes we pooled all available cohorts and estimated relative risks with and without adjustment across all combinations 
of metabolic risk factors. We then computed the excess attenuated risk for each mediation‐risk‐cause set.
Low physical activity High fasting plasma glucose Ischaemic heart disease 0.14(0.11 to 0.18)
Low physical activity High fasting plasma glucose Ischaemic stroke 0.08(0.03 to 0.14)
Low physical activity High fasting plasma glucose Diabetes mellitus type 2 1(1 to 1)
High fasting plasma glucose High LDL cholesterol Ischaemic heart disease 0.04(0.02 to 0.05)
High fasting plasma glucose High LDL cholesterol Ischaemic stroke 0.04(0.03 to 0.06)
High fasting plasma glucose High systolic blood pressure Ischaemic heart disease 0.1(0.08 to 0.11)
High fasting plasma glucose High systolic blood pressure Ischaemic stroke 0.15(0.14 to 0.17)
High fasting plasma glucose High systolic blood pressure Intracerebral hemorrhage 0.15(0.14 to 0.17)
High fasting plasma glucose High systolic blood pressure Subarachnoid hemorrhage 0.15(0.14 to 0.17)
High fasting plasma glucose Impaired kidney function Chronic kidney disease due to diabetes mellitus type 1 1(1 to 1)
High fasting plasma glucose Impaired kidney function Chronic kidney disease due to diabetes mellitus type 2 1(1 to 1)
High fasting plasma glucose Impaired kidney function Chronic kidney disease due to hypertension 1(1 to 1)
High fasting plasma glucose Impaired kidney function Chronic kidney disease due to glomerulonephritis 1(1 to 1)
High fasting plasma glucose Impaired kidney function Chronic kidney disease due to other and unspecified causes 1(1 to 1)
High LDL cholesterol High systolic blood pressure Ischaemic heart disease 0.09(0.07 to 0.11)
High LDL cholesterol High systolic blood pressure Ischaemic stroke 0.16(0.14 to 0.18)
High systolic blood pressure Impaired kidney function Chronic kidney disease due to diabetes mellitus type 1 1(1 to 1)
High systolic blood pressure Impaired kidney function Chronic kidney disease due to diabetes mellitus type 2 1(1 to 1)
High systolic blood pressure Impaired kidney function Chronic kidney disease due to hypertension 1(1 to 1)
High systolic blood pressure Impaired kidney function Chronic kidney disease due to glomerulonephritis 1(1 to 1)
High systolic blood pressure Impaired kidney function Chronic kidney disease due to other and unspecified causes 1(1 to 1)
High body-mass index High fasting plasma glucose Ischaemic heart disease 0.15(0.1 to 0.2)
High body-mass index High fasting plasma glucose Ischaemic stroke 0.22(0.12 to 0.31)
High body-mass index High fasting plasma glucose Intracerebral hemorrhage 0.22(0.13 to 0.32)
High body-mass index High fasting plasma glucose Subarachnoid hemorrhage 0.22(0.13 to 0.32)
High body-mass index High fasting plasma glucose Diabetes mellitus type 2 1(1 to 1)
High body-mass index High LDL cholesterol Ischaemic heart disease 0.1(0.05 to 0.15)
High body-mass index High LDL cholesterol Ischaemic stroke 0.03(0 to 0.08)
High body-mass index High systolic blood pressure Ischaemic heart disease 0.31(0.28 to 0.34)
High body-mass index High systolic blood pressure Ischaemic stroke 0.65(0.57 to 0.72)
High body-mass index High systolic blood pressure Intracerebral hemorrhage 0.65(0.58 to 0.73)
High body-mass index High systolic blood pressure Subarachnoid hemorrhage 0.65(0.58 to 0.73)
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For IHD, stroke, and diabetes we pooled all available cohorts and estimated relative risks with and without adjustment across all combinations 
of metabolic risk factors. We then computed the excess attenuated risk for each mediation‐risk‐cause set.
High body-mass index High systolic blood pressure Hypertensive heart disease 1(1 to 1)
High body-mass index High systolic blood pressure Atrial fibrillation and flutter 0.31(0.28 to 0.34)
High body-mass index Impaired kidney function Chronic kidney disease due to diabetes mellitus type 2 1(1 to 1)
High body-mass index Impaired kidney function Chronic kidney disease due to hypertension 1(1 to 1)
High body-mass index Impaired kidney function Chronic kidney disease due to glomerulonephritis 1(1 to 1)
High body-mass index Impaired kidney function Chronic kidney disease due to other and unspecified causes 1(1 to 1)
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Global 0.652
Central Europe, Eastern Europe, and Central Asia 0.766
Central Asia 0.673
Armenia 0.702 High-middle SDI
Azerbaijan 0.701 High-middle SDI
Georgia 0.7 High-middle SDI
Kazakhstan 0.735 High-middle SDI
Kyrgyzstan 0.607 Low-middle SDI
Mongolia 0.662 Middle SDI
Tajikistan 0.523 Low-middle SDI
Turkmenistan 0.696 Middle SDI
Uzbekistan 0.63 Middle SDI
Central Europe 0.814
Albania 0.685 Middle SDI
Bosnia and Herzegovina 0.713 High-middle SDI
Bulgaria 0.792 High-middle SDI
Croatia 0.825 High SDI
Czech Republic 0.851 High SDI
Hungary 0.817 High-middle SDI
Macedonia 0.754 High-middle SDI
Montenegro 0.788 High-middle SDI
Poland 0.844 High SDI
Romania 0.784 High-middle SDI
Serbia 0.752 High-middle SDI
Slovakia 0.842 High SDI
Slovenia 0.86 High SDI
Eastern Europe 0.785
Belarus 0.773 High-middle SDI
Estonia 0.858 High SDI
Latvia 0.825 High SDI
Lithuania 0.841 High SDI
Moldova 0.676 Middle SDI
Russian Federation 0.792 High-middle SDI
Ukraine 0.74 High-middle SDI
High-income 0.854
Australasia 0.869
Australia 0.873 High SDI
New Zealand 0.842 High SDI
High-income Asia-Pacific 0.869
Brunei 0.856 High SDI
Japan 0.865 High SDI
Aichi 0.875 High SDI
Akita 0.829 High SDI
Aomori 0.825 High SDI
Chiba 0.859 High SDI
Appendix Table 9. Socio-Demographic Index groupings by geography, based on 2017 values
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Ehime 0.838 High SDI
Fukui 0.852 High SDI
Fukuoka 0.855 High SDI
Fukushima 0.831 High SDI
Gifu 0.849 High SDI
Gunma 0.851 High SDI
Hiroshima 0.863 High SDI
Hokkaidō 0.842 High SDI
Hyōgo 0.86 High SDI
Ibaraki 0.851 High SDI
Ishikawa 0.856 High SDI
Iwate 0.825 High SDI
Kagawa 0.85 High SDI
Kagoshima 0.83 High SDI
Kanagawa 0.875 High SDI
Kōchi 0.825 High SDI
Kumamoto 0.832 High SDI
Kyōto 0.873 High SDI
Mie 0.854 High SDI
Miyagi 0.85 High SDI
Miyazaki 0.823 High SDI
Nagano 0.851 High SDI
Nagasaki 0.826 High SDI
Nara 0.848 High SDI
Niigata 0.843 High SDI
Ōita 0.846 High SDI
Okayama 0.856 High SDI
Okinawa 0.818 High SDI
Ōsaka 0.872 High SDI
Saga 0.834 High SDI
Saitama 0.852 High SDI
Shiga 0.871 High SDI
Shimane 0.831 High SDI
Shizuoka 0.859 High SDI
Tochigi 0.853 High SDI
Tokushima 0.845 High SDI
Tōkyō 0.924 High SDI
Tottori 0.834 High SDI
Toyama 0.86 High SDI
Wakayama 0.84 High SDI
Yamagata 0.832 High SDI
Yamaguchi 0.849 High SDI
Yamanashi 0.854 High SDI
South Korea 0.872 High SDI
Singapore 0.872 High SDI
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High-income North America 0.868
Canada 0.882 High SDI
Greenland 0.76 High-middle SDI
USA 0.867 High SDI
Alabama 0.837 High SDI
Alaska 0.861 High SDI
Arizona 0.845 High SDI
Arkansas 0.826 High SDI
California 0.872 High SDI
Colorado 0.882 High SDI
Connecticut 0.906 High SDI
Delaware 0.874 High SDI
Washington, DC 0.89 High SDI
Florida 0.864 High SDI
Georgia 0.848 High SDI
Hawaii 0.872 High SDI
Idaho 0.841 High SDI
Illinois 0.879 High SDI
Indiana 0.848 High SDI
Iowa 0.87 High SDI
Kansas 0.864 High SDI
Kentucky 0.831 High SDI
Louisiana 0.835 High SDI
Maine 0.872 High SDI
Maryland 0.896 High SDI
Massachusetts 0.913 High SDI
Michigan 0.868 High SDI
Minnesota 0.893 High SDI
Mississippi 0.819 High SDI
Missouri 0.853 High SDI
Montana 0.863 High SDI
Nebraska 0.873 High SDI
Nevada 0.847 High SDI
New Hampshire 0.904 High SDI
New Jersey 0.899 High SDI
New Mexico 0.835 High SDI
New York 0.893 High SDI
North Carolina 0.85 High SDI
North Dakota 0.88 High SDI
Ohio 0.858 High SDI
Oklahoma 0.838 High SDI
Oregon 0.871 High SDI
Pennsylvania 0.879 High SDI
Rhode Island 0.89 High SDI
South Carolina 0.846 High SDI
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South Dakota 0.86 High SDI
Tennessee 0.837 High SDI
Texas 0.838 High SDI
Utah 0.856 High SDI
Vermont 0.896 High SDI
Virginia 0.885 High SDI
Washington 0.884 High SDI
West Virginia 0.825 High SDI
Wisconsin 0.878 High SDI
Wyoming 0.869 High SDI
Southern Latin America 0.72
Argentina 0.71 High-middle SDI
Chile 0.748 High-middle SDI
Uruguay 0.707 High-middle SDI
Western Europe 0.857
Andorra 0.902 High SDI
Austria 0.866 High SDI
Belgium 0.886 High SDI
Cyprus 0.865 High SDI
Denmark 0.918 High SDI
Finland 0.893 High SDI
France 0.865 High SDI
Germany 0.87 High SDI
Greece 0.817 High SDI
Iceland 0.907 High SDI
Ireland 0.882 High SDI
Israel 0.816 High-middle SDI
Italy 0.843 High SDI
Luxembourg 0.916 High SDI
Malta 0.836 High SDI
Netherlands 0.912 High SDI
Norway 0.911 High SDI
Portugal 0.778 High-middle SDI
Spain 0.825 High SDI
Sweden 0.883 High SDI
Stockholm 0.914 High SDI
Sweden except Stockholm 0.873 High SDI
Switzerland 0.889 High SDI
United Kingdom 0.843 High SDI
England 0.849 High SDI
East Midlands 0.83 High SDI
Derby 0.846 High SDI
Derbyshire 0.817 High SDI
Leicester 0.839 High SDI
Leicestershire 0.846 High SDI
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Lincolnshire 0.812 High SDI
Northamptonshire 0.829 High SDI
Nottingham 0.863 High SDI
Nottinghamshire 0.814 High SDI
Rutland 0.833 High SDI
East of England 0.84 High SDI
Bedford 0.838 High SDI
Cambridgeshire 0.871 High SDI
Central Bedfordshire 0.834 High SDI
Essex 0.832 High SDI
Hertfordshire 0.87 High SDI
Luton 0.833 High SDI
Norfolk 0.826 High SDI
Peterborough 0.818 High SDI
Southend-on-Sea 0.811 High SDI
Suffolk 0.821 High SDI
Thurrock 0.807 High SDI
Greater London 0.894 High SDI
Barking and Dagenham 0.802 High SDI
Barnet 0.865 High SDI
Bexley 0.826 High SDI
Brent 0.849 High SDI
Bromley 0.848 High SDI
Camden 0.93 High SDI
Croydon 0.833 High SDI
Ealing 0.865 High SDI
Enfield 0.839 High SDI
Greenwich 0.833 High SDI
Hackney 0.887 High SDI
Hammersmith and Fulham 0.927 High SDI
Haringey 0.854 High SDI
Harrow 0.848 High SDI
Havering 0.824 High SDI
Hillingdon 0.882 High SDI
Hounslow 0.879 High SDI
Islington 0.922 High SDI
Kensington and Chelsea 0.932 High SDI
Kingston upon Thames 0.89 High SDI
Lambeth 0.9 High SDI
Lewisham 0.843 High SDI
Merton 0.873 High SDI
Newham 0.838 High SDI
Redbridge 0.831 High SDI
Richmond upon Thames 0.902 High SDI
Southwark 0.912 High SDI
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Sutton 0.843 High SDI
Tower Hamlets 0.905 High SDI
Waltham Forest 0.819 High SDI
Wandsworth 0.911 High SDI
Westminster 0.927 High SDI
North East England 0.821 High SDI
County Durham 0.81 High SDI
Darlington 0.825 High SDI
Gateshead 0.826 High SDI
Hartlepool 0.793 High SDI
Middlesbrough 0.808 High SDI
Newcastle upon Tyne 0.872 High SDI
North Tyneside 0.825 High SDI
Northumberland 0.808 High SDI
Redcar and Cleveland 0.79 High SDI
South Tyneside 0.794 High SDI
Stockton-on-Tees 0.823 High SDI
Sunderland 0.815 High SDI
North West England 0.834 High SDI
Blackburn with Darwen 0.802 High SDI
Blackpool 0.781 High SDI
Bolton 0.805 High SDI
Bury 0.815 High SDI
Cheshire East 0.864 High SDI
Cheshire West and Chester 0.855 High SDI
Cumbria 0.828 High SDI
Halton 0.824 High SDI
Knowsley 0.816 High SDI
Lancashire 0.831 High SDI
Liverpool 0.852 High SDI
Manchester 0.885 High SDI
Oldham 0.79 High SDI
Rochdale 0.795 High SDI
Salford 0.838 High SDI
Sefton 0.812 High SDI
St Helens 0.803 High SDI
Stockport 0.843 High SDI
Tameside 0.797 High SDI
Trafford 0.873 High SDI
Warrington 0.86 High SDI
Wigan 0.798 High SDI
Wirral 0.803 High SDI
South East England 0.856 High SDI
Bracknell Forest 0.869 High SDI
Brighton and Hove 0.885 High SDI
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Buckinghamshire 0.865 High SDI
East Sussex 0.814 High SDI
Hampshire 0.85 High SDI
Isle of Wight 0.814 High SDI
Kent 0.828 High SDI
Medway 0.809 High SDI
Milton Keynes 0.86 High SDI
Oxfordshire 0.879 High SDI
Portsmouth 0.86 High SDI
Reading 0.895 High SDI
Slough 0.859 High SDI
Southampton 0.858 High SDI
Surrey 0.883 High SDI
West Berkshire 0.872 High SDI
West Sussex 0.843 High SDI
Windsor and Maidenhead 0.889 High SDI
Wokingham 0.885 High SDI
South West England 0.841 High SDI
Bath and North East Somerset 0.875 High SDI
Bournemouth 0.858 High SDI
Bristol, City of 0.884 High SDI
Cornwall 0.817 High SDI
Devon 0.837 High SDI
Dorset 0.825 High SDI
Gloucestershire 0.85 High SDI
North Somerset 0.832 High SDI
Plymouth 0.836 High SDI
Poole 0.842 High SDI
Somerset 0.816 High SDI
South Gloucestershire 0.867 High SDI
Swindon 0.847 High SDI
Torbay 0.79 High SDI
Wiltshire 0.829 High SDI
West Midlands 0.829 High SDI
Birmingham 0.84 High SDI
Coventry 0.848 High SDI
Dudley 0.799 High SDI
Herefordshire, County of 0.828 High SDI
Sandwell 0.797 High SDI
Shropshire 0.832 High SDI
Solihull 0.855 High SDI
Staffordshire 0.826 High SDI
Stoke-on-Trent 0.804 High SDI
Telford and Wrekin 0.822 High SDI
Walsall 0.791 High SDI
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Warwickshire 0.857 High SDI
Wolverhampton 0.811 High SDI
Worcestershire 0.833 High SDI
Yorkshire and the Humber 0.83 High SDI
Barnsley 0.787 High SDI
Bradford 0.807 High SDI
Calderdale 0.827 High SDI
Doncaster 0.791 High SDI
East Riding of Yorkshire 0.822 High SDI
Kingston upon Hull, City of 0.813 High SDI
Kirklees 0.816 High SDI
Leeds 0.868 High SDI
North East Lincolnshire 0.804 High SDI
North Lincolnshire 0.811 High SDI
North Yorkshire 0.839 High SDI
Rotherham 0.796 High SDI
Sheffield 0.853 High SDI
Wakefield 0.806 High SDI
York 0.879 High SDI
Northern Ireland 0.835 High SDI
Scotland 0.805 High SDI
Wales 0.806 High SDI
Latin America and Caribbean 0.64
Andean Latin America 0.628
Bolivia 0.587 Low-middle SDI
Ecuador 0.636 Middle SDI
Peru 0.636 Middle SDI
Caribbean 0.638
Antigua and Barbuda 0.715 High-middle SDI
The Bahamas 0.756 High-middle SDI
Barbados 0.739 High-middle SDI
Belize 0.602 Low-middle SDI
Bermuda 0.805 High-middle SDI
Cuba 0.688 Middle SDI
Dominica 0.687 Middle SDI
Dominican Republic 0.593 Low-middle SDI
Grenada 0.64 Middle SDI
Guyana 0.584 Low-middle SDI
Haiti 0.442 Low SDI
Jamaica 0.679 Middle SDI
Puerto Rico 0.813 High-middle SDI
Saint Lucia 0.653 Middle SDI
Saint Vincent and the Grenadines 0.608 Middle SDI
Suriname 0.641 Middle SDI
Trinidad and Tobago 0.698 Middle SDI
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Virgin Islands 0.807 High-middle SDI
Central Latin America 0.623
Colombia 0.634 Middle SDI
Costa Rica 0.662 Middle SDI
El Salvador 0.593 Low-middle SDI
Guatemala 0.524 Low-middle SDI
Honduras 0.512 Low-middle SDI
Mexico 0.628 Middle SDI
Aguascalientes 0.659 Middle SDI
Baja California 0.657 Middle SDI
Baja California Sur 0.659 Middle SDI
Campeche 0.616 Middle SDI
Chiapas 0.533 Middle SDI
Chihuahua 0.639 Middle SDI
Coahuila 0.645 Middle SDI
Colima 0.654 Middle SDI
Mexico City 0.716 Middle SDI
Durango 0.624 Middle SDI
Guanajuato 0.621 Middle SDI
Guerrero 0.562 Middle SDI
Hidalgo 0.587 Middle SDI
Jalisco 0.649 Middle SDI
México 0.635 Middle SDI
Michoacán de Ocampo 0.586 Middle SDI
Morelos 0.635 Middle SDI
Nayarit 0.62 Middle SDI
Nuevo León 0.677 Middle SDI
Oaxaca 0.561 Middle SDI
Puebla 0.584 Middle SDI
Querétaro 0.639 Middle SDI
Quintana Roo 0.626 Middle SDI
San Luis Potosí 0.621 Middle SDI
Sinaloa 0.649 Middle SDI
Sonora 0.65 Middle SDI
Tabasco 0.611 Middle SDI
Tamaulipas 0.647 Middle SDI
Tlaxcala 0.604 Middle SDI
Veracruz de Ignacio de la Llave 0.592 Middle SDI
Yucatán 0.63 Middle SDI
Zacatecas 0.608 Middle SDI
Nicaragua 0.53 Low-middle SDI
Panama 0.677 Middle SDI
Venezuela 0.655 Middle SDI
Tropical Latin America 0.662
Brazil 0.663 Middle SDI
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Acre 0.602 Low-middle SDI
Alagoas 0.556 Low-middle SDI
Amapá 0.659 Middle SDI
Amazonas 0.629 Middle SDI
Bahia 0.591 Low-middle SDI
Ceará 0.6 Low-middle SDI
Distrito Federal 0.792 High-middle SDI
Espírito Santo 0.677 Middle SDI
Goiás 0.65 Middle SDI
Maranhão 0.507 Low-middle SDI
Mato Grosso 0.662 Middle SDI
Mato Grosso do Sul 0.65 Middle SDI
Minas Gerais 0.661 Middle SDI
Pará 0.579 Low-middle SDI
Paraíba 0.574 Low-middle SDI
Paraná 0.682 Middle SDI
Pernambuco 0.594 Low-middle SDI
Piauí 0.552 Low-middle SDI
Rio de Janeiro 0.709 High-middle SDI
Rio Grande do Norte 0.605 Low-middle SDI
Rio Grande do Sul 0.693 Middle SDI
Rondônia 0.622 Middle SDI
Roraima 0.646 Middle SDI
Santa Catarina 0.702 High-middle SDI
São Paulo 0.72 High-middle SDI
Sergipe 0.616 Middle SDI
Tocantins 0.611 Middle SDI
Paraguay 0.619 Middle SDI
North Africa and Middle East 0.639
North Africa and Middle East 0.639
Afghanistan 0.29 Low SDI
Algeria 0.696 Middle SDI
Bahrain 0.712 High-middle SDI
Egypt 0.604 Low-middle SDI
Iran 0.7 High-middle SDI
Iraq 0.585 Low-middle SDI
Jordan 0.697 Middle SDI
Kuwait 0.786 High-middle SDI
Lebanon 0.73 High-middle SDI
Libya 0.761 High-middle SDI
Morocco 0.579 Low-middle SDI
Palestine 0.541 Low-middle SDI
Oman 0.744 High-middle SDI
Qatar 0.766 High-middle SDI
Saudi Arabia 0.779 High-middle SDI
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Sudan 0.478 Low-middle SDI
Syria 0.611 Middle SDI
Tunisia 0.675 Middle SDI
Turkey 0.729 High-middle SDI
United Arab Emirates 0.795 High-middle SDI
Yemen 0.43 Low SDI
South Asia 0.534
South Asia 0.534
Bangladesh 0.458 Low SDI
Bhutan 0.57 Low-middle SDI
India 0.55 Low-middle SDI
Andhra Pradesh 0.536 Low-middle SDI
Arunachal Pradesh 0.556 Low-middle SDI
Assam 0.53 Low-middle SDI
Bihar 0.433 Low SDI
Chhattisgarh 0.512 Low-middle SDI
Delhi 0.715 High-middle SDI
Goa 0.74 High-middle SDI
Gujarat 0.584 Low-middle SDI
Haryana 0.6 Low-middle SDI
Himachal Pradesh 0.633 Middle SDI
Jammu and Kashmir 0.59 Low-middle SDI
Jharkhand 0.487 Low-middle SDI
Karnataka 0.574 Low-middle SDI
Kerala 0.659 Middle SDI
Madhya Pradesh 0.487 Low-middle SDI
Maharashtra 0.618 Middle SDI
Manipur 0.59 Low-middle SDI
Meghalaya 0.565 Low-middle SDI
Mizoram 0.616 Middle SDI
Nagaland 0.633 Middle SDI
Odisha 0.524 Low-middle SDI
Punjab 0.622 Middle SDI
Rajasthan 0.492 Low-middle SDI
Sikkim 0.628 Middle SDI
Tamil Nadu 0.615 Middle SDI
Telangana 0.575 Low-middle SDI
Tripura 0.543 Low-middle SDI
Uttar Pradesh 0.488 Low-middle SDI
Uttarakhand 0.607 Middle SDI
West Bengal 0.538 Low-middle SDI
Union Territories other than Delhi 0.653 Middle SDI
Nepal 0.429 Low SDI
Pakistan 0.492 Low-middle SDI
Southeast Asia, East Asia, and Oceania 0.685
362
Geography 2017 SDI SDI Quintile
Appendix Table 9. Socio-Demographic Index groupings by geography, based on 2017 values
East Asia 0.709
China 0.707 High-middle SDI
North Korea 0.538 Low-middle SDI
Taiwan (Province of China) 0.864 High SDI
Oceania 0.471
American Samoa 0.702 High-middle SDI
Federated States of Micronesia 0.575 Low-middle SDI
Fiji 0.641 Middle SDI
Guam 0.794 High-middle SDI
Kiribati 0.427 Low SDI
Marshall Islands 0.55 Low-middle SDI
Northern Mariana Islands 0.758 High-middle SDI
Papua New Guinea 0.419 Low SDI
Samoa 0.576 Low-middle SDI
Solomon Islands 0.425 Low SDI
Tonga 0.625 Middle SDI
Vanuatu 0.475 Low-middle SDI
Southeast Asia 0.641
Cambodia 0.482 Low-middle SDI
Indonesia 0.648 Middle SDI
Laos 0.519 Low-middle SDI
Malaysia 0.759 High-middle SDI
Maldives 0.655 Middle SDI
Mauritius 0.72 High-middle SDI
Myanmar 0.556 Low-middle SDI
Philippines 0.617 Middle SDI
Sri Lanka 0.68 Middle SDI
Seychelles 0.692 Middle SDI
Thailand 0.684 Middle SDI
Timor-Leste 0.505 Low-middle SDI
Vietnam 0.607 Middle SDI
Sub-Saharan Africa 0.446
Central sub-Saharan Africa 0.457
Angola 0.461 Low-middle SDI
Central African Republic 0.334 Low SDI
Congo (Brazzaville) 0.574 Low-middle SDI
DR Congo 0.364 Low SDI
Equatorial Guinea 0.625 Middle SDI
Gabon 0.651 Middle SDI
Eastern sub-Saharan Africa 0.387
Burundi 0.31 Low SDI
Comoros 0.434 Low SDI
Djibouti 0.485 Low-middle SDI
Eritrea 0.409 Low SDI
Ethiopia 0.334 Low SDI
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Kenya 0.499 Low-middle SDI
Baringo 0.444 Low-middle SDI
Bomet 0.496 Low-middle SDI
Bungoma 0.463 Low-middle SDI
Busia 0.438 Low-middle SDI
Elgeyo Marakwet 0.496 Low-middle SDI
Embu 0.533 Low-middle SDI
Garissa 0.334 Low-middle SDI
Homa Bay 0.425 Low-middle SDI
Isiolo 0.385 Low-middle SDI
Kajiado 0.534 Low-middle SDI
Kakamega 0.45 Low-middle SDI
Kericho 0.5 Low-middle SDI
Kiambu 0.58 Low-middle SDI
Kilifi 0.456 Low-middle SDI
Kirinyaga 0.533 Low-middle SDI
Kisii 0.522 Low-middle SDI
Kisumu 0.503 Low-middle SDI
Kitui 0.461 Low-middle SDI
Kwale 0.457 Low-middle SDI
Laikipia 0.556 Low-middle SDI
Lamu 0.453 Low-middle SDI
Machakos 0.518 Low-middle SDI
Makueni 0.469 Low-middle SDI
Mandera 0.295 Low-middle SDI
Marsabit 0.34 Low-middle SDI
Meru 0.508 Low-middle SDI
Migori 0.419 Low-middle SDI
Mombasa 0.568 Low-middle SDI
Murang’a 0.528 Low-middle SDI
Nairobi 0.674 Low-middle SDI
Nakuru 0.545 Low-middle SDI
Nandi 0.501 Low-middle SDI
Narok 0.402 Low-middle SDI
Nyamira 0.544 Low-middle SDI
Nyandarua 0.534 Low-middle SDI
Nyeri 0.554 Low-middle SDI
Samburu 0.308 Low-middle SDI
Siaya 0.46 Low-middle SDI
Taita Taveta 0.529 Low-middle SDI
Tana River 0.379 Low-middle SDI
Tharaka Nithi 0.528 Low-middle SDI
Trans Nzoia 0.496 Low-middle SDI
Turkana 0.295 Low-middle SDI
Uasin Gishu 0.545 Low-middle SDI
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Vihiga 0.477 Low-middle SDI
Wajir 0.243 Low-middle SDI
West Pokot 0.382 Low-middle SDI
Madagascar 0.331 Low SDI
Malawi 0.349 Low SDI
Mozambique 0.34 Low SDI
Rwanda 0.407 Low SDI
Somalia 0.235 Low SDI
South Sudan 0.275 Low SDI
Tanzania 0.412 Low SDI
Uganda 0.388 Low SDI
Zambia 0.472 Low-middle SDI
Southern sub-Saharan Africa 0.64
Botswana 0.663 Middle SDI
Lesotho 0.493 Low-middle SDI
Namibia 0.616 Middle SDI
South Africa 0.677 Middle SDI
Swaziland 0.578 Low-middle SDI
Zimbabwe 0.463 Low-middle SDI
Western sub-Saharan Africa 0.441
Benin 0.373 Low SDI
Burkina Faso 0.284 Low SDI
Cameroon 0.482 Low-middle SDI
Cape Verde 0.549 Low-middle SDI
Chad 0.253 Low SDI
Cote d'Ivoire 0.412 Low SDI
The Gambia 0.405 Low SDI
Ghana 0.537 Low-middle SDI
Guinea 0.325 Low SDI
Guinea-Bissau 0.349 Low SDI
Liberia 0.328 Low SDI
Mali 0.267 Low SDI
Mauritania 0.471 Low-middle SDI
Niger 0.191 Low SDI
Nigeria 0.493 Low-middle SDI
Sao Tome and Principe 0.488 Low-middle SDI
Senegal 0.373 Low SDI
Sierra Leone 0.357 Low SDI
Togo 0.413 Low SDI
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Location 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Global 0.523 0.529 0.534 0.539 0.543 0.548 0.553 0.557 0.561 0.566 0.571 0.576 0.581 0.585 0.59 0.595 0.601 0.606 0.611 0.616 0.62 0.624 0.628 0.633 0.639 0.644 0.647 0.652
Central Europe, Eastern Europe, and Central Asia 0.656 0.662 0.67 0.674 0.677 0.682 0.686 0.689 0.691 0.694 0.698 0.701 0.705 0.709 0.715 0.72 0.725 0.73 0.735 0.739 0.743 0.747 0.75 0.753 0.757 0.76 0.763 0.766
Central Asia 0.563 0.567 0.57 0.573 0.575 0.577 0.578 0.579 0.58 0.582 0.585 0.588 0.593 0.598 0.603 0.609 0.615 0.621 0.627 0.633 0.639 0.644 0.649 0.654 0.659 0.664 0.669 0.673
Armenia 0.555 0.559 0.56 0.562 0.565 0.567 0.57 0.573 0.577 0.581 0.586 0.592 0.6 0.61 0.619 0.629 0.639 0.65 0.66 0.667 0.673 0.678 0.683 0.687 0.691 0.695 0.699 0.702
Azerbaijan 0.611 0.614 0.616 0.617 0.616 0.613 0.61 0.607 0.604 0.601 0.6 0.6 0.602 0.605 0.608 0.615 0.625 0.635 0.645 0.654 0.664 0.672 0.678 0.684 0.689 0.694 0.698 0.701
Georgia 0.654 0.66 0.661 0.658 0.653 0.645 0.639 0.634 0.63 0.625 0.621 0.62 0.622 0.624 0.628 0.633 0.638 0.644 0.649 0.654 0.659 0.665 0.671 0.676 0.682 0.688 0.695 0.7
Kazakhstan 0.613 0.615 0.619 0.625 0.632 0.638 0.643 0.645 0.646 0.647 0.651 0.656 0.661 0.666 0.671 0.677 0.683 0.689 0.696 0.702 0.705 0.707 0.708 0.711 0.716 0.723 0.73 0.735
Kyrgyzstan 0.565 0.571 0.576 0.578 0.577 0.572 0.569 0.567 0.564 0.562 0.56 0.559 0.56 0.562 0.565 0.566 0.567 0.569 0.572 0.575 0.576 0.581 0.584 0.589 0.594 0.598 0.603 0.607
Mongolia 0.537 0.545 0.55 0.555 0.559 0.564 0.569 0.573 0.577 0.581 0.585 0.589 0.594 0.598 0.603 0.608 0.614 0.619 0.624 0.628 0.632 0.636 0.641 0.646 0.65 0.654 0.658 0.662
Tajikistan 0.474 0.481 0.485 0.487 0.486 0.481 0.474 0.468 0.463 0.459 0.455 0.454 0.456 0.462 0.465 0.466 0.472 0.479 0.483 0.488 0.494 0.501 0.506 0.51 0.514 0.517 0.52 0.523
Turkmenistan 0.588 0.592 0.594 0.599 0.602 0.604 0.606 0.606 0.606 0.607 0.61 0.613 0.617 0.622 0.628 0.635 0.638 0.641 0.644 0.647 0.651 0.657 0.663 0.669 0.678 0.685 0.691 0.696
Uzbekistan 0.481 0.484 0.487 0.493 0.497 0.502 0.508 0.513 0.52 0.526 0.532 0.537 0.543 0.549 0.555 0.56 0.565 0.57 0.575 0.581 0.587 0.592 0.598 0.604 0.611 0.618 0.624 0.63
Central Europe 0.665 0.671 0.677 0.683 0.69 0.698 0.705 0.711 0.717 0.723 0.731 0.738 0.745 0.751 0.757 0.762 0.767 0.772 0.776 0.782 0.788 0.793 0.797 0.802 0.805 0.808 0.811 0.814
Albania 0.548 0.545 0.542 0.541 0.542 0.546 0.552 0.558 0.566 0.577 0.584 0.593 0.602 0.611 0.619 0.627 0.635 0.642 0.648 0.653 0.658 0.661 0.665 0.668 0.672 0.676 0.681 0.685
Bosnia and Herzegovina 0.497 0.499 0.5 0.5 0.501 0.507 0.525 0.549 0.571 0.592 0.607 0.619 0.63 0.639 0.647 0.654 0.66 0.667 0.673 0.679 0.685 0.69 0.694 0.699 0.703 0.706 0.71 0.713
Bulgaria 0.658 0.668 0.676 0.684 0.693 0.699 0.705 0.706 0.704 0.703 0.708 0.715 0.721 0.726 0.731 0.736 0.741 0.746 0.751 0.757 0.765 0.771 0.775 0.778 0.781 0.784 0.788 0.792
Croatia 0.725 0.73 0.732 0.732 0.731 0.731 0.732 0.737 0.743 0.749 0.755 0.762 0.768 0.773 0.778 0.782 0.787 0.792 0.797 0.801 0.805 0.809 0.813 0.816 0.818 0.821 0.823 0.825
Czech Republic 0.711 0.717 0.726 0.74 0.757 0.769 0.777 0.783 0.788 0.794 0.799 0.804 0.809 0.814 0.819 0.823 0.827 0.83 0.833 0.836 0.84 0.843 0.846 0.847 0.848 0.848 0.849 0.851
Hungary 0.678 0.683 0.691 0.699 0.707 0.716 0.724 0.732 0.739 0.745 0.751 0.758 0.764 0.77 0.776 0.781 0.786 0.791 0.795 0.799 0.803 0.806 0.807 0.808 0.809 0.811 0.814 0.817
Macedonia 0.626 0.629 0.63 0.631 0.632 0.635 0.64 0.647 0.654 0.661 0.665 0.67 0.677 0.685 0.693 0.699 0.704 0.709 0.715 0.719 0.724 0.729 0.734 0.739 0.744 0.748 0.751 0.754
Montenegro 0.705 0.706 0.705 0.701 0.698 0.696 0.696 0.698 0.7 0.703 0.706 0.711 0.716 0.721 0.726 0.731 0.737 0.743 0.75 0.756 0.761 0.767 0.771 0.775 0.779 0.782 0.785 0.788
Poland 0.662 0.668 0.678 0.686 0.697 0.707 0.714 0.724 0.733 0.741 0.75 0.759 0.767 0.773 0.779 0.784 0.789 0.792 0.797 0.804 0.811 0.818 0.823 0.829 0.833 0.837 0.841 0.844
Romania 0.652 0.66 0.663 0.666 0.671 0.678 0.682 0.685 0.689 0.694 0.7 0.707 0.713 0.718 0.724 0.73 0.734 0.739 0.745 0.751 0.758 0.763 0.768 0.772 0.774 0.777 0.78 0.784
Serbia 0.632 0.638 0.643 0.642 0.641 0.641 0.643 0.648 0.653 0.655 0.661 0.665 0.669 0.675 0.684 0.692 0.699 0.705 0.709 0.713 0.718 0.723 0.729 0.736 0.742 0.747 0.75 0.752
Slovakia 0.684 0.69 0.699 0.71 0.722 0.732 0.74 0.748 0.756 0.764 0.772 0.779 0.784 0.788 0.793 0.798 0.804 0.809 0.814 0.818 0.823 0.828 0.832 0.834 0.836 0.838 0.839 0.842
Slovenia 0.741 0.747 0.753 0.759 0.764 0.769 0.775 0.781 0.788 0.794 0.801 0.808 0.814 0.819 0.824 0.828 0.833 0.837 0.841 0.843 0.846 0.848 0.85 0.852 0.854 0.856 0.858 0.86
Eastern Europe 0.678 0.685 0.694 0.698 0.7 0.704 0.708 0.708 0.71 0.711 0.712 0.713 0.715 0.72 0.727 0.734 0.739 0.745 0.751 0.756 0.761 0.764 0.767 0.772 0.776 0.779 0.783 0.785
Belarus 0.625 0.631 0.636 0.641 0.645 0.647 0.65 0.654 0.657 0.661 0.665 0.67 0.676 0.682 0.689 0.696 0.704 0.712 0.72 0.727 0.733 0.74 0.747 0.753 0.759 0.764 0.769 0.773
Estonia 0.711 0.719 0.728 0.736 0.742 0.746 0.75 0.755 0.761 0.766 0.772 0.778 0.783 0.788 0.794 0.799 0.806 0.813 0.82 0.826 0.832 0.838 0.843 0.847 0.851 0.854 0.856 0.858
Latvia 0.696 0.703 0.712 0.721 0.727 0.731 0.733 0.734 0.735 0.738 0.741 0.745 0.75 0.757 0.763 0.769 0.776 0.783 0.792 0.8 0.806 0.81 0.814 0.816 0.817 0.819 0.822 0.825
Lithuania 0.707 0.71 0.717 0.725 0.728 0.731 0.733 0.736 0.74 0.746 0.753 0.76 0.765 0.772 0.779 0.785 0.79 0.796 0.802 0.808 0.815 0.822 0.828 0.833 0.836 0.838 0.839 0.841
Moldova 0.575 0.578 0.58 0.582 0.583 0.584 0.584 0.582 0.58 0.577 0.574 0.574 0.577 0.582 0.588 0.595 0.602 0.61 0.618 0.624 0.632 0.64 0.647 0.654 0.66 0.666 0.671 0.676
Russian Federation 0.683 0.692 0.704 0.708 0.708 0.714 0.718 0.719 0.72 0.722 0.722 0.722 0.724 0.728 0.734 0.742 0.747 0.752 0.757 0.763 0.768 0.77 0.772 0.777 0.781 0.785 0.789 0.792
Ukraine 0.664 0.667 0.67 0.673 0.675 0.676 0.676 0.675 0.673 0.672 0.672 0.673 0.675 0.68 0.687 0.694 0.7 0.707 0.714 0.717 0.721 0.725 0.729 0.732 0.735 0.736 0.738 0.74
High-income 0.769 0.774 0.779 0.783 0.787 0.792 0.796 0.798 0.801 0.804 0.807 0.811 0.814 0.817 0.82 0.822 0.823 0.826 0.829 0.832 0.836 0.839 0.842 0.845 0.848 0.851 0.853 0.854
Australasia 0.783 0.786 0.79 0.794 0.797 0.801 0.805 0.809 0.813 0.817 0.821 0.825 0.828 0.832 0.835 0.837 0.838 0.84 0.842 0.845 0.848 0.851 0.855 0.859 0.862 0.864 0.867 0.869
Australia 0.786 0.79 0.793 0.797 0.801 0.805 0.81 0.814 0.818 0.822 0.825 0.829 0.833 0.837 0.84 0.843 0.844 0.845 0.848 0.851 0.854 0.856 0.86 0.864 0.867 0.869 0.871 0.873
New Zealand 0.765 0.768 0.771 0.774 0.777 0.78 0.783 0.786 0.79 0.794 0.798 0.802 0.805 0.807 0.809 0.811 0.811 0.811 0.813 0.816 0.819 0.823 0.828 0.832 0.835 0.838 0.84 0.842
High-income Asia-Pacific 0.783 0.789 0.794 0.799 0.804 0.809 0.813 0.817 0.82 0.823 0.826 0.83 0.833 0.836 0.839 0.842 0.844 0.846 0.849 0.851 0.853 0.856 0.858 0.861 0.863 0.865 0.867 0.869
Brunei 0.728 0.733 0.739 0.745 0.751 0.757 0.763 0.769 0.774 0.779 0.784 0.789 0.795 0.802 0.808 0.814 0.819 0.824 0.828 0.831 0.835 0.838 0.842 0.845 0.848 0.851 0.854 0.856
Japan 0.803 0.807 0.812 0.816 0.82 0.823 0.826 0.829 0.831 0.833 0.834 0.836 0.838 0.84 0.842 0.844 0.846 0.847 0.849 0.851 0.853 0.855 0.857 0.859 0.861 0.862 0.863 0.865
Aichi 0.812 0.816 0.821 0.825 0.829 0.833 0.836 0.839 0.841 0.843 0.844 0.846 0.847 0.85 0.852 0.854 0.855 0.856 0.858 0.86 0.862 0.864 0.866 0.869 0.871 0.872 0.873 0.875
Akita 0.766 0.77 0.775 0.778 0.781 0.785 0.788 0.791 0.793 0.795 0.796 0.798 0.8 0.802 0.805 0.806 0.808 0.81 0.812 0.814 0.816 0.818 0.821 0.823 0.825 0.826 0.827 0.829
Aomori 0.761 0.765 0.77 0.773 0.777 0.78 0.783 0.786 0.788 0.79 0.791 0.793 0.795 0.798 0.801 0.803 0.805 0.807 0.809 0.81 0.812 0.815 0.817 0.819 0.821 0.822 0.823 0.825
Chiba 0.803 0.807 0.812 0.816 0.82 0.823 0.827 0.829 0.831 0.832 0.833 0.834 0.836 0.837 0.839 0.841 0.842 0.843 0.845 0.846 0.848 0.85 0.852 0.854 0.856 0.857 0.858 0.859
Ehime 0.776 0.78 0.785 0.788 0.792 0.796 0.799 0.802 0.804 0.806 0.808 0.809 0.811 0.814 0.816 0.818 0.819 0.82 0.822 0.824 0.825 0.828 0.83 0.832 0.834 0.835 0.836 0.838
Fukui 0.784 0.789 0.794 0.798 0.802 0.806 0.81 0.813 0.815 0.818 0.819 0.821 0.823 0.826 0.828 0.83 0.832 0.834 0.836 0.837 0.839 0.842 0.844 0.846 0.848 0.849 0.85 0.852
Fukuoka 0.797 0.801 0.806 0.809 0.813 0.816 0.819 0.822 0.824 0.826 0.828 0.83 0.832 0.834 0.836 0.837 0.838 0.839 0.841 0.842 0.843 0.845 0.847 0.849 0.851 0.853 0.854 0.855
Fukushima 0.769 0.773 0.778 0.781 0.784 0.788 0.791 0.793 0.794 0.795 0.797 0.798 0.8 0.803 0.807 0.809 0.811 0.813 0.814 0.816 0.819 0.821 0.823 0.825 0.827 0.828 0.829 0.831
Gifu 0.786 0.79 0.795 0.799 0.803 0.807 0.81 0.813 0.815 0.817 0.818 0.82 0.821 0.824 0.826 0.828 0.829 0.831 0.833 0.835 0.837 0.839 0.841 0.843 0.845 0.846 0.847 0.849
Gunma 0.787 0.791 0.796 0.8 0.803 0.807 0.81 0.813 0.815 0.816 0.818 0.819 0.821 0.824 0.827 0.829 0.831 0.833 0.835 0.837 0.839 0.841 0.843 0.845 0.847 0.848 0.849 0.851
Hiroshima 0.8 0.805 0.809 0.813 0.817 0.821 0.825 0.828 0.83 0.832 0.833 0.835 0.836 0.839 0.841 0.842 0.843 0.844 0.846 0.847 0.849 0.852 0.854 0.856 0.858 0.86 0.861 0.863
Hokkaidō 0.783 0.788 0.792 0.796 0.799 0.803 0.806 0.808 0.809 0.811 0.812 0.813 0.815 0.818 0.82 0.822 0.824 0.825 0.827 0.828 0.83 0.832 0.834 0.836 0.838 0.839 0.84 0.842
Hyōgo 0.798 0.803 0.807 0.811 0.815 0.819 0.822 0.825 0.827 0.829 0.831 0.833 0.835 0.837 0.839 0.841 0.842 0.843 0.845 0.846 0.848 0.85 0.852 0.854 0.856 0.857 0.858 0.86
Ibaraki 0.789 0.793 0.798 0.802 0.805 0.809 0.813 0.815 0.817 0.819 0.82 0.821 0.823 0.826 0.828 0.83 0.831 0.833 0.835 0.837 0.839 0.841 0.843 0.845 0.847 0.848 0.849 0.851
Ishikawa 0.789 0.795 0.8 0.804 0.808 0.812 0.815 0.818 0.82 0.822 0.824 0.826 0.828 0.831 0.833 0.835 0.837 0.839 0.84 0.842 0.844 0.846 0.848 0.85 0.852 0.853 0.854 0.856
Iwate 0.76 0.764 0.768 0.772 0.775 0.779 0.782 0.785 0.787 0.788 0.79 0.791 0.793 0.796 0.799 0.801 0.803 0.806 0.808 0.81 0.812 0.815 0.817 0.819 0.821 0.823 0.823 0.825
Kagawa 0.787 0.792 0.797 0.801 0.804 0.808 0.811 0.814 0.816 0.817 0.819 0.82 0.822 0.825 0.827 0.829 0.831 0.832 0.834 0.835 0.837 0.839 0.842 0.844 0.846 0.847 0.848 0.85
Kagoshima 0.768 0.772 0.777 0.781 0.784 0.788 0.791 0.793 0.795 0.797 0.798 0.799 0.801 0.804 0.806 0.808 0.809 0.81 0.812 0.814 0.816 0.818 0.82 0.823 0.825 0.827 0.828 0.83
Kanagawa 0.818 0.823 0.827 0.831 0.835 0.838 0.842 0.844 0.846 0.848 0.849 0.85 0.852 0.854 0.856 0.857 0.859 0.86 0.862 0.863 0.865 0.866 0.868 0.87 0.871 0.873 0.873 0.875
Kōchi 0.759 0.763 0.767 0.771 0.775 0.779 0.783 0.786 0.788 0.791 0.793 0.795 0.797 0.8 0.803 0.805 0.806 0.808 0.81 0.812 0.813 0.816 0.818 0.82 0.822 0.823 0.824 0.825
Kumamoto 0.77 0.774 0.778 0.782 0.785 0.789 0.792 0.794 0.796 0.798 0.799 0.801 0.803 0.805 0.808 0.81 0.811 0.812 0.814 0.815 0.817 0.82 0.822 0.825 0.827 0.829 0.83 0.832
Kyōto 0.813 0.817 0.822 0.826 0.83 0.833 0.837 0.839 0.841 0.843 0.845 0.847 0.849 0.851 0.853 0.854 0.856 0.857 0.859 0.86 0.862 0.863 0.865 0.867 0.869 0.87 0.871 0.873
Mie 0.787 0.792 0.797 0.801 0.805 0.81 0.813 0.815 0.818 0.819 0.821 0.823 0.825 0.827 0.83 0.832 0.833 0.835 0.836 0.838 0.84 0.842 0.845 0.847 0.849 0.851 0.852 0.854
Miyagi 0.788 0.793 0.798 0.801 0.805 0.809 0.812 0.814 0.816 0.817 0.818 0.819 0.821 0.824 0.827 0.829 0.831 0.833 0.835 0.836 0.838 0.841 0.843 0.845 0.847 0.848 0.849 0.85
Miyazaki 0.764 0.768 0.772 0.775 0.778 0.781 0.784 0.786 0.788 0.79 0.791 0.793 0.795 0.797 0.8 0.801 0.802 0.804 0.805 0.807 0.809 0.812 0.814 0.816 0.819 0.82 0.821 0.823
Nagano 0.792 0.797 0.801 0.805 0.808 0.811 0.814 0.817 0.818 0.82 0.821 0.823 0.824 0.827 0.829 0.831 0.832 0.834 0.836 0.838 0.839 0.842 0.844 0.845 0.847 0.849 0.849 0.851
Nagasaki 0.766 0.77 0.774 0.777 0.781 0.784 0.787 0.79 0.792 0.794 0.795 0.797 0.799 0.801 0.803 0.805 0.806 0.808 0.809 0.811 0.813 0.815 0.817 0.82 0.822 0.823 0.824 0.826
Nara 0.789 0.794 0.799 0.803 0.807 0.811 0.814 0.817 0.819 0.821 0.822 0.824 0.825 0.827 0.829 0.831 0.832 0.834 0.835 0.836 0.838 0.839 0.841 0.843 0.844 0.845 0.846 0.848
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Niigata 0.776 0.78 0.784 0.788 0.792 0.795 0.799 0.801 0.804 0.806 0.808 0.81 0.813 0.815 0.818 0.82 0.822 0.824 0.826 0.828 0.83 0.832 0.835 0.837 0.839 0.84 0.842 0.843
Ōita 0.785 0.789 0.795 0.802 0.808 0.809 0.809 0.81 0.812 0.813 0.815 0.816 0.819 0.821 0.824 0.825 0.827 0.828 0.83 0.831 0.833 0.835 0.838 0.84 0.842 0.843 0.844 0.846
Okayama 0.79 0.794 0.799 0.803 0.807 0.811 0.814 0.817 0.819 0.821 0.823 0.824 0.827 0.829 0.832 0.834 0.836 0.837 0.839 0.841 0.843 0.846 0.848 0.85 0.852 0.853 0.854 0.856
Okinawa 0.753 0.757 0.764 0.772 0.778 0.779 0.777 0.777 0.778 0.78 0.781 0.783 0.786 0.789 0.793 0.795 0.797 0.799 0.8 0.802 0.804 0.807 0.809 0.812 0.814 0.815 0.816 0.818
Ōsaka 0.815 0.819 0.823 0.827 0.831 0.834 0.837 0.84 0.842 0.844 0.845 0.847 0.849 0.851 0.853 0.854 0.855 0.856 0.858 0.859 0.861 0.863 0.865 0.867 0.868 0.87 0.871 0.872
Saga 0.773 0.777 0.782 0.785 0.788 0.792 0.795 0.797 0.799 0.8 0.801 0.803 0.805 0.808 0.81 0.812 0.814 0.815 0.817 0.819 0.821 0.823 0.825 0.827 0.83 0.831 0.832 0.834
Saitama 0.793 0.798 0.802 0.806 0.81 0.814 0.818 0.82 0.822 0.824 0.825 0.826 0.827 0.829 0.831 0.833 0.835 0.836 0.838 0.839 0.841 0.843 0.845 0.847 0.848 0.849 0.85 0.852
Shiga 0.804 0.809 0.814 0.819 0.823 0.827 0.83 0.833 0.836 0.838 0.84 0.841 0.843 0.846 0.848 0.85 0.852 0.853 0.855 0.857 0.858 0.861 0.863 0.865 0.867 0.868 0.869 0.871
Shimane 0.762 0.766 0.771 0.775 0.779 0.783 0.787 0.79 0.793 0.795 0.797 0.798 0.801 0.803 0.806 0.808 0.81 0.812 0.814 0.816 0.818 0.82 0.823 0.825 0.827 0.828 0.829 0.831
Shizuoka 0.798 0.802 0.807 0.81 0.814 0.818 0.821 0.823 0.825 0.826 0.827 0.828 0.83 0.833 0.835 0.837 0.838 0.84 0.842 0.843 0.846 0.848 0.85 0.853 0.855 0.856 0.857 0.859
Tochigi 0.787 0.792 0.797 0.801 0.805 0.809 0.813 0.815 0.817 0.819 0.82 0.821 0.823 0.826 0.829 0.831 0.832 0.834 0.836 0.838 0.84 0.842 0.845 0.847 0.849 0.85 0.851 0.853
Tokushima 0.776 0.781 0.786 0.79 0.794 0.798 0.802 0.805 0.807 0.809 0.812 0.814 0.816 0.819 0.822 0.824 0.826 0.828 0.83 0.831 0.833 0.835 0.837 0.839 0.841 0.842 0.843 0.845
Tōkyō 0.87 0.875 0.879 0.883 0.887 0.892 0.896 0.899 0.901 0.903 0.905 0.906 0.908 0.91 0.911 0.913 0.914 0.915 0.916 0.917 0.918 0.919 0.92 0.921 0.922 0.923 0.923 0.924
Tottori 0.77 0.775 0.78 0.783 0.787 0.791 0.794 0.797 0.799 0.801 0.802 0.804 0.806 0.808 0.811 0.813 0.814 0.816 0.818 0.819 0.821 0.824 0.826 0.828 0.831 0.832 0.833 0.834
Toyama 0.79 0.795 0.8 0.805 0.808 0.812 0.816 0.818 0.821 0.823 0.825 0.827 0.829 0.832 0.835 0.837 0.839 0.841 0.843 0.845 0.847 0.849 0.852 0.854 0.856 0.857 0.858 0.86
Wakayama 0.775 0.78 0.785 0.789 0.792 0.796 0.8 0.802 0.805 0.806 0.808 0.81 0.812 0.815 0.817 0.819 0.821 0.822 0.824 0.825 0.827 0.829 0.831 0.833 0.836 0.837 0.838 0.84
Yamagata 0.766 0.77 0.775 0.778 0.782 0.785 0.788 0.791 0.792 0.794 0.795 0.796 0.799 0.802 0.805 0.807 0.809 0.812 0.814 0.816 0.819 0.821 0.824 0.826 0.828 0.829 0.83 0.832
Yamaguchi 0.79 0.794 0.799 0.802 0.806 0.809 0.812 0.815 0.817 0.819 0.82 0.822 0.824 0.826 0.828 0.83 0.831 0.832 0.834 0.835 0.837 0.839 0.841 0.843 0.846 0.847 0.848 0.849
Yamanashi 0.791 0.796 0.8 0.804 0.808 0.812 0.815 0.818 0.82 0.822 0.823 0.825 0.827 0.829 0.832 0.834 0.836 0.837 0.839 0.841 0.842 0.844 0.846 0.848 0.85 0.851 0.853 0.854
South Korea 0.713 0.724 0.733 0.742 0.751 0.76 0.768 0.777 0.783 0.79 0.799 0.806 0.814 0.82 0.825 0.83 0.834 0.839 0.843 0.846 0.85 0.853 0.857 0.86 0.864 0.867 0.869 0.872
Singapore 0.736 0.744 0.75 0.758 0.765 0.772 0.78 0.786 0.79 0.79 0.797 0.808 0.815 0.82 0.824 0.827 0.832 0.838 0.844 0.849 0.854 0.857 0.86 0.863 0.865 0.868 0.87 0.872
High-income North America 0.784 0.786 0.789 0.793 0.796 0.8 0.805 0.807 0.809 0.812 0.815 0.82 0.824 0.827 0.829 0.83 0.829 0.832 0.837 0.843 0.848 0.852 0.856 0.859 0.861 0.865 0.867 0.868
Canada 0.802 0.805 0.808 0.811 0.814 0.818 0.823 0.828 0.832 0.836 0.841 0.846 0.85 0.853 0.857 0.859 0.861 0.862 0.864 0.867 0.871 0.874 0.877 0.878 0.879 0.88 0.881 0.882
Greenland 0.671 0.67 0.67 0.671 0.672 0.675 0.679 0.683 0.687 0.691 0.695 0.699 0.703 0.708 0.713 0.717 0.722 0.726 0.731 0.737 0.743 0.747 0.751 0.754 0.756 0.757 0.759 0.76
USA 0.781 0.784 0.787 0.79 0.793 0.798 0.803 0.804 0.806 0.809 0.812 0.817 0.821 0.823 0.826 0.826 0.826 0.829 0.834 0.84 0.846 0.85 0.853 0.857 0.859 0.863 0.866 0.867
Alabama 0.745 0.749 0.753 0.757 0.76 0.765 0.769 0.769 0.771 0.773 0.777 0.783 0.787 0.791 0.794 0.794 0.793 0.796 0.801 0.809 0.816 0.82 0.824 0.827 0.83 0.834 0.837 0.837
Alaska 0.755 0.757 0.761 0.767 0.772 0.781 0.788 0.79 0.793 0.795 0.799 0.804 0.808 0.811 0.814 0.813 0.811 0.813 0.818 0.826 0.833 0.838 0.843 0.847 0.851 0.857 0.86 0.861
Arizona 0.751 0.753 0.755 0.758 0.76 0.764 0.769 0.77 0.771 0.772 0.775 0.781 0.784 0.787 0.79 0.791 0.791 0.797 0.806 0.815 0.823 0.828 0.832 0.836 0.839 0.842 0.845 0.845
Arkansas 0.723 0.727 0.733 0.738 0.741 0.746 0.751 0.751 0.753 0.754 0.757 0.763 0.767 0.77 0.773 0.772 0.77 0.774 0.78 0.789 0.797 0.802 0.807 0.811 0.816 0.821 0.825 0.826
California 0.771 0.771 0.773 0.776 0.78 0.787 0.794 0.798 0.803 0.807 0.812 0.819 0.823 0.826 0.829 0.83 0.831 0.835 0.84 0.846 0.852 0.856 0.859 0.863 0.865 0.869 0.871 0.872
Colorado 0.798 0.801 0.804 0.807 0.81 0.815 0.818 0.819 0.82 0.821 0.824 0.83 0.833 0.836 0.839 0.84 0.84 0.844 0.849 0.855 0.861 0.865 0.869 0.872 0.875 0.879 0.881 0.882
Connecticut 0.841 0.844 0.847 0.85 0.853 0.856 0.859 0.861 0.863 0.866 0.869 0.874 0.877 0.879 0.881 0.881 0.881 0.883 0.886 0.89 0.894 0.896 0.899 0.901 0.903 0.905 0.906 0.906
Delaware 0.801 0.804 0.808 0.811 0.813 0.816 0.819 0.819 0.82 0.822 0.825 0.83 0.833 0.836 0.838 0.839 0.838 0.841 0.846 0.852 0.858 0.861 0.864 0.866 0.868 0.871 0.873 0.874
Washington, DC 0.797 0.801 0.806 0.812 0.818 0.826 0.834 0.839 0.845 0.85 0.855 0.861 0.865 0.868 0.869 0.868 0.866 0.866 0.868 0.871 0.874 0.876 0.877 0.88 0.883 0.887 0.89 0.89
Florida 0.774 0.778 0.782 0.786 0.789 0.794 0.799 0.8 0.802 0.804 0.808 0.813 0.817 0.82 0.823 0.824 0.825 0.828 0.834 0.84 0.846 0.85 0.853 0.855 0.858 0.861 0.863 0.864
Georgia 0.755 0.759 0.764 0.769 0.772 0.778 0.782 0.783 0.784 0.785 0.788 0.793 0.796 0.798 0.801 0.801 0.8 0.804 0.81 0.818 0.825 0.83 0.834 0.837 0.841 0.845 0.848 0.848
Hawaii 0.781 0.784 0.788 0.792 0.797 0.805 0.811 0.813 0.815 0.817 0.82 0.824 0.828 0.83 0.833 0.833 0.832 0.834 0.839 0.845 0.851 0.854 0.858 0.861 0.864 0.868 0.871 0.872
Idaho 0.756 0.76 0.764 0.769 0.773 0.778 0.783 0.783 0.784 0.785 0.787 0.791 0.794 0.796 0.799 0.798 0.797 0.801 0.807 0.814 0.821 0.824 0.827 0.83 0.832 0.836 0.84 0.841
Illinois 0.787 0.789 0.792 0.796 0.799 0.805 0.81 0.812 0.816 0.818 0.823 0.828 0.833 0.837 0.84 0.841 0.841 0.845 0.85 0.855 0.861 0.864 0.867 0.87 0.873 0.876 0.879 0.879
Indiana 0.772 0.774 0.778 0.781 0.783 0.787 0.791 0.791 0.793 0.794 0.797 0.802 0.806 0.808 0.81 0.809 0.807 0.809 0.813 0.819 0.825 0.829 0.832 0.836 0.839 0.844 0.847 0.848
Iowa 0.794 0.797 0.8 0.803 0.806 0.809 0.813 0.814 0.816 0.818 0.821 0.825 0.828 0.829 0.832 0.831 0.83 0.832 0.837 0.843 0.848 0.852 0.856 0.86 0.863 0.867 0.87 0.87
Kansas 0.782 0.785 0.788 0.791 0.794 0.798 0.802 0.803 0.804 0.806 0.809 0.814 0.817 0.819 0.821 0.819 0.817 0.819 0.823 0.83 0.837 0.842 0.847 0.852 0.856 0.861 0.864 0.864
Kentucky 0.743 0.747 0.751 0.755 0.759 0.763 0.768 0.769 0.77 0.772 0.776 0.782 0.786 0.789 0.791 0.79 0.787 0.789 0.793 0.799 0.806 0.81 0.814 0.817 0.821 0.827 0.83 0.831
Louisiana 0.735 0.739 0.743 0.748 0.752 0.758 0.762 0.764 0.765 0.767 0.771 0.777 0.782 0.786 0.789 0.788 0.787 0.79 0.796 0.803 0.811 0.815 0.819 0.823 0.826 0.831 0.835 0.835
Maine 0.789 0.795 0.8 0.805 0.809 0.814 0.817 0.819 0.821 0.823 0.826 0.83 0.834 0.837 0.84 0.84 0.84 0.842 0.846 0.851 0.856 0.859 0.861 0.864 0.866 0.869 0.871 0.872
Maryland 0.813 0.817 0.821 0.825 0.828 0.833 0.836 0.838 0.839 0.841 0.845 0.85 0.854 0.857 0.86 0.861 0.861 0.864 0.868 0.874 0.879 0.883 0.886 0.889 0.891 0.894 0.896 0.896
Massachusetts 0.843 0.847 0.85 0.853 0.856 0.86 0.864 0.866 0.869 0.871 0.875 0.88 0.883 0.886 0.888 0.889 0.89 0.893 0.896 0.899 0.902 0.904 0.907 0.909 0.91 0.912 0.913 0.913
Michigan 0.788 0.791 0.795 0.799 0.803 0.808 0.813 0.815 0.817 0.82 0.823 0.829 0.832 0.835 0.838 0.838 0.837 0.839 0.841 0.845 0.849 0.852 0.854 0.857 0.86 0.864 0.867 0.868
Minnesota 0.818 0.821 0.825 0.828 0.83 0.834 0.837 0.839 0.841 0.843 0.845 0.849 0.852 0.855 0.857 0.858 0.858 0.86 0.865 0.87 0.874 0.877 0.881 0.884 0.886 0.89 0.892 0.893
Mississippi 0.719 0.722 0.727 0.732 0.736 0.741 0.746 0.747 0.748 0.75 0.753 0.758 0.762 0.764 0.765 0.764 0.76 0.763 0.77 0.779 0.789 0.794 0.8 0.804 0.809 0.814 0.818 0.819
Missouri 0.77 0.773 0.777 0.781 0.784 0.789 0.793 0.795 0.797 0.799 0.802 0.806 0.81 0.812 0.813 0.812 0.811 0.813 0.818 0.825 0.831 0.835 0.839 0.842 0.846 0.85 0.853 0.853
Montana 0.775 0.779 0.783 0.789 0.793 0.799 0.804 0.805 0.807 0.808 0.81 0.814 0.816 0.819 0.822 0.822 0.821 0.823 0.827 0.833 0.839 0.843 0.847 0.851 0.855 0.859 0.862 0.863
Nebraska 0.795 0.798 0.802 0.805 0.808 0.813 0.817 0.817 0.819 0.819 0.821 0.824 0.827 0.829 0.831 0.831 0.83 0.832 0.836 0.842 0.848 0.853 0.857 0.861 0.865 0.869 0.872 0.873
Nevada 0.76 0.761 0.762 0.765 0.767 0.773 0.779 0.781 0.784 0.787 0.791 0.798 0.802 0.805 0.808 0.809 0.81 0.814 0.82 0.827 0.833 0.836 0.838 0.84 0.842 0.845 0.847 0.847
New Hampshire 0.827 0.832 0.835 0.838 0.84 0.844 0.847 0.849 0.852 0.856 0.86 0.865 0.869 0.872 0.874 0.875 0.876 0.878 0.881 0.885 0.889 0.891 0.894 0.897 0.899 0.902 0.904 0.904
New Jersey 0.828 0.831 0.834 0.838 0.841 0.845 0.849 0.85 0.852 0.854 0.857 0.861 0.864 0.867 0.87 0.87 0.871 0.873 0.876 0.881 0.885 0.888 0.89 0.893 0.895 0.897 0.899 0.899
New Mexico 0.733 0.735 0.739 0.743 0.748 0.755 0.76 0.762 0.764 0.765 0.767 0.773 0.777 0.779 0.782 0.781 0.779 0.783 0.79 0.799 0.808 0.814 0.819 0.823 0.828 0.832 0.835 0.835
New York 0.816 0.819 0.822 0.825 0.828 0.832 0.836 0.838 0.841 0.843 0.847 0.852 0.855 0.858 0.86 0.861 0.861 0.864 0.868 0.872 0.877 0.88 0.883 0.886 0.889 0.892 0.893 0.893
North Carolina 0.763 0.766 0.77 0.774 0.777 0.781 0.785 0.785 0.786 0.788 0.791 0.796 0.8 0.802 0.805 0.805 0.805 0.809 0.815 0.822 0.829 0.833 0.836 0.84 0.843 0.846 0.849 0.85
North Dakota 0.79 0.792 0.796 0.799 0.802 0.807 0.813 0.816 0.82 0.823 0.827 0.83 0.833 0.834 0.835 0.835 0.833 0.835 0.839 0.844 0.85 0.854 0.859 0.864 0.87 0.875 0.879 0.88
Ohio 0.78 0.783 0.787 0.79 0.793 0.797 0.801 0.802 0.804 0.806 0.809 0.814 0.818 0.82 0.822 0.822 0.821 0.822 0.826 0.832 0.837 0.841 0.844 0.847 0.85 0.854 0.857 0.858
Oklahoma 0.749 0.751 0.755 0.758 0.76 0.764 0.768 0.768 0.768 0.769 0.772 0.777 0.781 0.784 0.786 0.785 0.784 0.786 0.792 0.8 0.808 0.813 0.818 0.824 0.829 0.835 0.838 0.838
Oregon 0.785 0.788 0.791 0.794 0.797 0.802 0.806 0.808 0.811 0.814 0.818 0.824 0.827 0.83 0.833 0.833 0.833 0.836 0.841 0.847 0.852 0.855 0.858 0.861 0.864 0.867 0.87 0.871
Pennsylvania 0.8 0.804 0.808 0.812 0.816 0.821 0.824 0.826 0.828 0.83 0.833 0.837 0.84 0.842 0.845 0.845 0.845 0.847 0.851 0.856 0.86 0.863 0.866 0.869 0.871 0.875 0.878 0.879
Rhode Island 0.815 0.818 0.822 0.825 0.827 0.831 0.834 0.835 0.838 0.84 0.843 0.848 0.851 0.854 0.857 0.858 0.859 0.862 0.866 0.87 0.875 0.877 0.88 0.882 0.885 0.887 0.889 0.89
South Carolina 0.752 0.757 0.762 0.768 0.772 0.777 0.781 0.782 0.783 0.785 0.787 0.793 0.796 0.799 0.801 0.8 0.799 0.802 0.808 0.815 0.822 0.826 0.83 0.834 0.838 0.842 0.845 0.846
South Dakota 0.769 0.772 0.777 0.783 0.788 0.794 0.799 0.801 0.804 0.805 0.808 0.811 0.813 0.814 0.816 0.814 0.812 0.814 0.819 0.826 0.833 0.838 0.842 0.847 0.851 0.856 0.859 0.86
Tennessee 0.749 0.752 0.757 0.761 0.765 0.77 0.774 0.775 0.777 0.779 0.781 0.786 0.788 0.789 0.79 0.789 0.786 0.789 0.795 0.803 0.81 0.815 0.819 0.823 0.827 0.832 0.836 0.837
Texas 0.743 0.745 0.747 0.75 0.752 0.757 0.761 0.763 0.764 0.766 0.769 0.775 0.779 0.782 0.784 0.783 0.782 0.785 0.792 0.801 0.809 0.815 0.82 0.824 0.829 0.834 0.837 0.838
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Appendix Table 10: Socio-Demographic Index values for all estimated GBD 2017 locations, 1990-2017
Utah 0.761 0.765 0.769 0.773 0.776 0.781 0.786 0.787 0.79 0.792 0.795 0.8 0.803 0.806 0.808 0.808 0.807 0.811 0.817 0.825 0.832 0.837 0.841 0.845 0.848 0.852 0.855 0.856
Vermont 0.815 0.819 0.823 0.827 0.83 0.833 0.837 0.839 0.841 0.844 0.848 0.853 0.857 0.86 0.864 0.866 0.866 0.869 0.872 0.876 0.88 0.882 0.885 0.887 0.89 0.893 0.895 0.896
Virginia 0.8 0.803 0.807 0.81 0.814 0.818 0.822 0.823 0.824 0.826 0.829 0.834 0.838 0.841 0.845 0.846 0.847 0.851 0.856 0.862 0.867 0.871 0.874 0.877 0.88 0.883 0.885 0.885
Washington 0.797 0.8 0.804 0.807 0.811 0.816 0.821 0.823 0.827 0.83 0.834 0.84 0.844 0.846 0.849 0.848 0.848 0.85 0.855 0.86 0.865 0.868 0.871 0.874 0.877 0.881 0.883 0.884
West Virginia 0.749 0.752 0.756 0.761 0.764 0.769 0.773 0.774 0.775 0.776 0.778 0.783 0.786 0.787 0.789 0.787 0.784 0.784 0.787 0.793 0.799 0.802 0.806 0.81 0.814 0.82 0.824 0.825
Wisconsin 0.801 0.804 0.808 0.812 0.815 0.819 0.823 0.825 0.826 0.828 0.831 0.835 0.839 0.841 0.843 0.843 0.843 0.845 0.849 0.853 0.858 0.862 0.865 0.868 0.871 0.874 0.877 0.878
Wyoming 0.766 0.771 0.777 0.782 0.786 0.792 0.796 0.797 0.799 0.801 0.804 0.809 0.813 0.816 0.818 0.819 0.819 0.823 0.831 0.838 0.846 0.851 0.855 0.858 0.862 0.866 0.869 0.869
Southern Latin America 0.594 0.6 0.607 0.613 0.619 0.626 0.632 0.638 0.643 0.648 0.652 0.655 0.658 0.662 0.667 0.673 0.677 0.679 0.682 0.685 0.69 0.695 0.7 0.704 0.707 0.713 0.717 0.72
Argentina 0.59 0.595 0.604 0.61 0.617 0.624 0.63 0.635 0.64 0.644 0.647 0.649 0.65 0.653 0.658 0.665 0.669 0.672 0.675 0.677 0.681 0.686 0.691 0.693 0.696 0.702 0.707 0.71
Chile 0.6 0.608 0.615 0.62 0.626 0.633 0.64 0.647 0.654 0.661 0.667 0.674 0.681 0.687 0.692 0.696 0.698 0.701 0.704 0.708 0.714 0.721 0.727 0.732 0.738 0.742 0.746 0.748
Uruguay 0.592 0.597 0.6 0.602 0.606 0.609 0.613 0.618 0.625 0.632 0.637 0.64 0.643 0.647 0.652 0.656 0.659 0.661 0.663 0.666 0.671 0.675 0.68 0.685 0.691 0.697 0.702 0.707
Western Europe 0.764 0.77 0.776 0.782 0.787 0.791 0.795 0.798 0.801 0.805 0.809 0.813 0.817 0.82 0.822 0.825 0.828 0.83 0.833 0.836 0.838 0.842 0.845 0.848 0.851 0.853 0.855 0.857
Andorra 0.85 0.854 0.856 0.857 0.858 0.859 0.86 0.863 0.866 0.868 0.871 0.873 0.875 0.878 0.881 0.883 0.885 0.886 0.888 0.89 0.891 0.894 0.896 0.897 0.899 0.9 0.901 0.902
Austria 0.776 0.778 0.78 0.785 0.79 0.795 0.8 0.805 0.809 0.813 0.818 0.822 0.825 0.828 0.831 0.834 0.838 0.841 0.845 0.847 0.85 0.854 0.857 0.859 0.862 0.863 0.865 0.866
Belgium 0.803 0.808 0.813 0.818 0.822 0.826 0.829 0.832 0.835 0.837 0.84 0.843 0.847 0.849 0.852 0.854 0.856 0.858 0.861 0.863 0.867 0.871 0.875 0.879 0.882 0.884 0.885 0.886
Cyprus 0.724 0.73 0.74 0.75 0.758 0.765 0.771 0.778 0.784 0.789 0.795 0.803 0.81 0.817 0.824 0.83 0.837 0.842 0.847 0.851 0.854 0.857 0.859 0.861 0.862 0.863 0.864 0.865
Denmark 0.846 0.849 0.852 0.855 0.858 0.862 0.866 0.87 0.874 0.877 0.881 0.884 0.888 0.891 0.893 0.895 0.897 0.898 0.9 0.902 0.904 0.907 0.91 0.912 0.914 0.915 0.916 0.918
Finland 0.813 0.813 0.814 0.817 0.821 0.825 0.828 0.831 0.835 0.84 0.844 0.847 0.851 0.854 0.857 0.859 0.862 0.865 0.869 0.871 0.875 0.878 0.881 0.884 0.887 0.889 0.891 0.893
France 0.769 0.776 0.783 0.79 0.793 0.795 0.802 0.806 0.808 0.813 0.816 0.819 0.824 0.827 0.83 0.833 0.836 0.838 0.84 0.842 0.845 0.848 0.851 0.854 0.857 0.86 0.863 0.865
Germany 0.787 0.796 0.801 0.805 0.809 0.811 0.812 0.813 0.813 0.814 0.818 0.823 0.827 0.829 0.832 0.835 0.838 0.842 0.846 0.848 0.851 0.855 0.858 0.861 0.864 0.866 0.868 0.87
Greece 0.717 0.723 0.731 0.738 0.744 0.75 0.755 0.761 0.767 0.773 0.778 0.782 0.787 0.792 0.796 0.8 0.803 0.806 0.809 0.812 0.815 0.818 0.819 0.82 0.819 0.818 0.817 0.817
Iceland 0.814 0.818 0.821 0.825 0.828 0.83 0.833 0.835 0.839 0.843 0.848 0.854 0.859 0.862 0.865 0.869 0.872 0.876 0.88 0.883 0.886 0.889 0.892 0.895 0.899 0.902 0.905 0.907
Ireland 0.756 0.762 0.768 0.774 0.779 0.785 0.79 0.795 0.802 0.808 0.814 0.821 0.827 0.834 0.84 0.844 0.846 0.849 0.851 0.855 0.858 0.862 0.865 0.867 0.87 0.874 0.878 0.882
Israel 0.734 0.738 0.743 0.748 0.752 0.757 0.76 0.764 0.768 0.772 0.776 0.78 0.783 0.786 0.789 0.793 0.796 0.798 0.798 0.799 0.801 0.803 0.805 0.808 0.81 0.812 0.814 0.816
Italy 0.767 0.772 0.778 0.783 0.788 0.793 0.797 0.8 0.804 0.807 0.81 0.814 0.817 0.819 0.821 0.823 0.825 0.827 0.829 0.83 0.832 0.834 0.836 0.838 0.839 0.841 0.842 0.843
Luxembourg 0.845 0.849 0.851 0.854 0.858 0.862 0.866 0.869 0.873 0.876 0.878 0.88 0.881 0.883 0.885 0.888 0.891 0.894 0.896 0.899 0.901 0.904 0.906 0.909 0.912 0.913 0.915 0.916
Malta 0.729 0.733 0.737 0.743 0.748 0.752 0.756 0.761 0.766 0.773 0.779 0.784 0.788 0.792 0.796 0.799 0.802 0.805 0.808 0.811 0.814 0.817 0.82 0.823 0.826 0.829 0.833 0.836
Netherlands 0.827 0.832 0.837 0.841 0.845 0.849 0.852 0.855 0.858 0.862 0.866 0.87 0.873 0.876 0.879 0.882 0.885 0.887 0.89 0.892 0.895 0.898 0.901 0.904 0.906 0.908 0.91 0.912
Norway 0.811 0.816 0.821 0.827 0.831 0.835 0.84 0.846 0.85 0.855 0.86 0.866 0.87 0.873 0.876 0.878 0.88 0.882 0.885 0.888 0.892 0.896 0.9 0.903 0.906 0.909 0.91 0.911
Portugal 0.642 0.65 0.659 0.667 0.675 0.682 0.688 0.694 0.699 0.705 0.71 0.716 0.722 0.727 0.732 0.736 0.741 0.744 0.748 0.751 0.755 0.76 0.764 0.768 0.771 0.773 0.775 0.778
Spain 0.715 0.723 0.731 0.738 0.745 0.752 0.758 0.763 0.768 0.773 0.778 0.782 0.786 0.79 0.794 0.797 0.799 0.802 0.805 0.809 0.812 0.815 0.818 0.819 0.82 0.822 0.823 0.825
Sweden 0.784 0.789 0.795 0.802 0.808 0.815 0.82 0.825 0.831 0.835 0.838 0.841 0.844 0.847 0.85 0.853 0.855 0.857 0.86 0.862 0.865 0.868 0.871 0.874 0.876 0.879 0.881 0.883
Stockholm 0.825 0.83 0.835 0.84 0.845 0.85 0.854 0.859 0.864 0.867 0.871 0.873 0.876 0.879 0.882 0.885 0.888 0.891 0.893 0.896 0.899 0.902 0.904 0.907 0.909 0.911 0.913 0.914
Sweden except Stockholm 0.773 0.778 0.785 0.792 0.798 0.805 0.811 0.816 0.821 0.825 0.829 0.832 0.834 0.838 0.841 0.843 0.845 0.848 0.85 0.852 0.854 0.858 0.86 0.863 0.866 0.868 0.87 0.873
Switzerland 0.841 0.842 0.844 0.846 0.847 0.848 0.849 0.85 0.851 0.852 0.854 0.857 0.859 0.86 0.862 0.863 0.865 0.868 0.871 0.873 0.875 0.877 0.88 0.882 0.884 0.886 0.887 0.889
United Kingdom 0.723 0.729 0.736 0.743 0.749 0.754 0.758 0.762 0.767 0.774 0.78 0.786 0.791 0.794 0.797 0.801 0.804 0.807 0.81 0.813 0.817 0.821 0.826 0.832 0.836 0.839 0.841 0.843
England 0.732 0.738 0.745 0.752 0.758 0.763 0.766 0.77 0.776 0.782 0.788 0.794 0.798 0.801 0.804 0.807 0.81 0.813 0.816 0.819 0.823 0.827 0.832 0.838 0.842 0.845 0.847 0.849
East Midlands 0.71 0.716 0.723 0.73 0.737 0.741 0.745 0.75 0.755 0.762 0.768 0.773 0.778 0.781 0.785 0.788 0.791 0.794 0.797 0.8 0.804 0.808 0.813 0.819 0.823 0.826 0.828 0.83
Derby 0.715 0.722 0.73 0.738 0.745 0.75 0.754 0.758 0.764 0.771 0.778 0.785 0.79 0.793 0.797 0.801 0.803 0.806 0.809 0.811 0.815 0.82 0.826 0.832 0.837 0.841 0.844 0.846
Derbyshire 0.698 0.703 0.71 0.716 0.723 0.727 0.731 0.735 0.74 0.747 0.753 0.758 0.762 0.765 0.768 0.771 0.774 0.777 0.779 0.782 0.785 0.79 0.796 0.803 0.808 0.812 0.815 0.817
Leicester 0.708 0.715 0.723 0.73 0.737 0.743 0.747 0.751 0.756 0.763 0.769 0.775 0.78 0.785 0.79 0.794 0.798 0.802 0.805 0.809 0.813 0.817 0.822 0.828 0.832 0.835 0.837 0.839
Leicestershire 0.727 0.733 0.74 0.748 0.754 0.759 0.763 0.767 0.773 0.778 0.784 0.789 0.794 0.798 0.802 0.806 0.81 0.814 0.817 0.82 0.823 0.827 0.831 0.836 0.839 0.842 0.844 0.846
Lincolnshire 0.699 0.705 0.711 0.718 0.724 0.729 0.732 0.737 0.742 0.748 0.754 0.76 0.764 0.768 0.77 0.772 0.774 0.776 0.779 0.781 0.784 0.788 0.793 0.8 0.804 0.808 0.81 0.812
Northamptonshire 0.714 0.72 0.728 0.735 0.741 0.746 0.749 0.753 0.757 0.764 0.77 0.775 0.779 0.781 0.784 0.787 0.79 0.792 0.796 0.798 0.802 0.806 0.812 0.818 0.822 0.825 0.828 0.829
Nottingham 0.735 0.742 0.749 0.757 0.763 0.769 0.774 0.78 0.786 0.793 0.8 0.806 0.812 0.817 0.822 0.826 0.829 0.832 0.835 0.839 0.842 0.847 0.852 0.856 0.859 0.861 0.862 0.863
Nottinghamshire 0.696 0.702 0.708 0.715 0.722 0.726 0.73 0.734 0.74 0.747 0.754 0.76 0.765 0.768 0.771 0.775 0.778 0.781 0.783 0.785 0.788 0.792 0.797 0.803 0.807 0.81 0.812 0.814
Rutland 0.73 0.735 0.741 0.746 0.752 0.756 0.759 0.762 0.767 0.772 0.777 0.781 0.784 0.787 0.79 0.793 0.797 0.8 0.804 0.806 0.81 0.814 0.818 0.823 0.826 0.829 0.831 0.833
East of England 0.724 0.73 0.737 0.744 0.75 0.755 0.759 0.763 0.768 0.774 0.78 0.786 0.79 0.793 0.796 0.799 0.802 0.805 0.808 0.811 0.814 0.818 0.824 0.83 0.834 0.837 0.839 0.84
Bedford 0.73 0.736 0.743 0.749 0.756 0.76 0.764 0.768 0.774 0.78 0.785 0.79 0.794 0.797 0.8 0.803 0.805 0.807 0.81 0.812 0.816 0.82 0.825 0.83 0.833 0.836 0.837 0.838
Cambridgeshire 0.75 0.757 0.764 0.771 0.777 0.782 0.786 0.791 0.797 0.803 0.809 0.815 0.82 0.823 0.827 0.83 0.833 0.836 0.84 0.842 0.846 0.85 0.855 0.86 0.864 0.867 0.869 0.871
Central Bedfordshire 0.723 0.729 0.736 0.743 0.749 0.753 0.757 0.76 0.765 0.771 0.776 0.781 0.785 0.787 0.79 0.793 0.795 0.797 0.8 0.803 0.806 0.81 0.816 0.822 0.827 0.83 0.833 0.834
Essex 0.713 0.719 0.726 0.734 0.74 0.745 0.748 0.753 0.758 0.764 0.77 0.775 0.78 0.783 0.787 0.79 0.793 0.796 0.8 0.802 0.806 0.81 0.816 0.821 0.825 0.828 0.83 0.832
Hertfordshire 0.749 0.755 0.762 0.769 0.776 0.781 0.784 0.789 0.795 0.802 0.81 0.816 0.821 0.825 0.829 0.832 0.835 0.837 0.84 0.843 0.846 0.85 0.855 0.86 0.863 0.866 0.868 0.87
Luton 0.71 0.716 0.723 0.731 0.737 0.742 0.745 0.749 0.754 0.76 0.766 0.771 0.775 0.778 0.781 0.785 0.79 0.795 0.8 0.805 0.809 0.814 0.819 0.825 0.828 0.83 0.832 0.833
Norfolk 0.712 0.717 0.724 0.731 0.737 0.741 0.745 0.749 0.754 0.761 0.767 0.772 0.776 0.779 0.781 0.784 0.787 0.79 0.792 0.795 0.798 0.803 0.808 0.814 0.819 0.822 0.824 0.826
Peterborough 0.713 0.718 0.724 0.731 0.737 0.741 0.743 0.746 0.751 0.757 0.761 0.765 0.768 0.77 0.772 0.774 0.776 0.778 0.779 0.781 0.784 0.788 0.795 0.803 0.808 0.813 0.816 0.818
Southend-on-Sea 0.696 0.701 0.707 0.714 0.72 0.724 0.727 0.731 0.736 0.743 0.75 0.755 0.761 0.765 0.768 0.77 0.773 0.775 0.778 0.781 0.785 0.79 0.795 0.801 0.805 0.808 0.81 0.811
Suffolk 0.713 0.719 0.726 0.732 0.738 0.742 0.745 0.748 0.753 0.758 0.763 0.767 0.771 0.773 0.775 0.777 0.78 0.782 0.785 0.788 0.792 0.797 0.803 0.81 0.814 0.817 0.819 0.821
Thurrock 0.71 0.716 0.723 0.73 0.737 0.741 0.745 0.749 0.754 0.759 0.763 0.767 0.769 0.77 0.772 0.774 0.775 0.776 0.778 0.781 0.784 0.789 0.793 0.799 0.802 0.804 0.806 0.807
Greater London 0.78 0.786 0.793 0.8 0.806 0.81 0.814 0.818 0.823 0.83 0.836 0.842 0.846 0.849 0.852 0.855 0.858 0.861 0.863 0.866 0.87 0.875 0.88 0.885 0.889 0.891 0.893 0.894
Barking and Dagenham 0.704 0.709 0.716 0.723 0.73 0.734 0.737 0.741 0.746 0.752 0.756 0.76 0.762 0.762 0.763 0.763 0.763 0.763 0.764 0.765 0.768 0.773 0.78 0.787 0.793 0.797 0.8 0.802
Barnet 0.759 0.765 0.771 0.777 0.783 0.788 0.792 0.796 0.802 0.809 0.814 0.82 0.824 0.827 0.829 0.831 0.834 0.835 0.838 0.84 0.843 0.847 0.852 0.856 0.859 0.862 0.864 0.865
Bexley 0.721 0.727 0.734 0.74 0.746 0.75 0.753 0.757 0.761 0.767 0.772 0.777 0.781 0.784 0.787 0.789 0.791 0.793 0.796 0.798 0.801 0.804 0.809 0.815 0.819 0.822 0.824 0.826
Brent 0.753 0.758 0.764 0.771 0.777 0.781 0.785 0.789 0.795 0.801 0.806 0.811 0.814 0.816 0.818 0.819 0.821 0.821 0.822 0.823 0.825 0.828 0.833 0.839 0.842 0.845 0.847 0.849
Bromley 0.751 0.756 0.762 0.768 0.774 0.778 0.782 0.786 0.791 0.798 0.804 0.809 0.814 0.817 0.82 0.822 0.825 0.827 0.829 0.83 0.831 0.833 0.837 0.84 0.843 0.845 0.847 0.848
Camden 0.838 0.843 0.848 0.854 0.858 0.862 0.866 0.869 0.873 0.88 0.885 0.889 0.892 0.895 0.898 0.901 0.904 0.906 0.908 0.911 0.913 0.917 0.92 0.924 0.926 0.927 0.929 0.93
Croydon 0.741 0.747 0.754 0.761 0.767 0.771 0.774 0.777 0.782 0.788 0.794 0.799 0.803 0.805 0.808 0.81 0.812 0.813 0.815 0.816 0.818 0.82 0.824 0.827 0.83 0.831 0.832 0.833
Ealing 0.764 0.77 0.776 0.783 0.789 0.794 0.797 0.801 0.807 0.814 0.82 0.825 0.828 0.831 0.833 0.834 0.835 0.836 0.837 0.837 0.839 0.843 0.848 0.853 0.857 0.86 0.863 0.865
Enfield 0.737 0.742 0.749 0.755 0.761 0.765 0.768 0.772 0.777 0.783 0.788 0.793 0.797 0.799 0.801 0.802 0.804 0.806 0.809 0.811 0.814 0.818 0.824 0.829 0.833 0.836 0.838 0.839
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Greenwich 0.725 0.732 0.74 0.747 0.754 0.758 0.762 0.766 0.771 0.777 0.783 0.788 0.791 0.793 0.795 0.797 0.799 0.801 0.803 0.805 0.809 0.813 0.819 0.824 0.828 0.83 0.832 0.833
Hackney 0.767 0.774 0.781 0.789 0.795 0.798 0.8 0.801 0.805 0.811 0.817 0.822 0.825 0.828 0.831 0.834 0.838 0.843 0.848 0.853 0.858 0.864 0.871 0.877 0.882 0.884 0.886 0.887
Hammersmith and Fulham 0.825 0.833 0.839 0.845 0.851 0.856 0.86 0.864 0.869 0.875 0.879 0.883 0.887 0.889 0.892 0.895 0.898 0.901 0.904 0.907 0.91 0.914 0.917 0.921 0.923 0.924 0.925 0.927
Haringey 0.755 0.761 0.766 0.773 0.778 0.782 0.785 0.788 0.792 0.798 0.804 0.809 0.813 0.815 0.818 0.821 0.823 0.825 0.828 0.829 0.832 0.835 0.84 0.845 0.848 0.851 0.852 0.854
Harrow 0.747 0.754 0.76 0.767 0.773 0.777 0.78 0.784 0.79 0.796 0.802 0.808 0.812 0.815 0.819 0.821 0.824 0.825 0.827 0.829 0.83 0.832 0.835 0.839 0.842 0.844 0.846 0.848
Havering 0.719 0.725 0.731 0.737 0.743 0.747 0.75 0.754 0.759 0.765 0.77 0.775 0.78 0.783 0.786 0.789 0.792 0.794 0.797 0.8 0.802 0.805 0.809 0.814 0.817 0.82 0.823 0.824
Hillingdon 0.781 0.787 0.794 0.801 0.807 0.811 0.815 0.818 0.822 0.828 0.832 0.836 0.84 0.842 0.845 0.846 0.848 0.85 0.852 0.854 0.857 0.862 0.867 0.872 0.876 0.879 0.881 0.882
Hounslow 0.769 0.775 0.781 0.788 0.793 0.797 0.801 0.805 0.811 0.818 0.824 0.83 0.834 0.837 0.84 0.842 0.844 0.845 0.848 0.849 0.852 0.856 0.862 0.868 0.872 0.875 0.877 0.879
Islington 0.812 0.818 0.825 0.832 0.838 0.843 0.847 0.851 0.856 0.862 0.867 0.872 0.876 0.879 0.882 0.885 0.888 0.891 0.895 0.898 0.902 0.906 0.91 0.914 0.917 0.919 0.921 0.922
Kensington and Chelsea 0.839 0.845 0.851 0.857 0.861 0.865 0.869 0.873 0.877 0.884 0.889 0.894 0.897 0.899 0.902 0.905 0.907 0.909 0.912 0.915 0.918 0.921 0.924 0.927 0.929 0.93 0.931 0.932
Kingston upon Thames 0.787 0.794 0.8 0.807 0.812 0.817 0.821 0.826 0.831 0.838 0.844 0.849 0.854 0.858 0.861 0.864 0.867 0.869 0.872 0.874 0.876 0.879 0.882 0.885 0.887 0.888 0.889 0.89
Lambeth 0.775 0.783 0.791 0.797 0.804 0.808 0.812 0.816 0.821 0.828 0.835 0.84 0.845 0.848 0.852 0.856 0.86 0.864 0.869 0.873 0.877 0.882 0.887 0.892 0.895 0.897 0.899 0.9
Lewisham 0.733 0.74 0.746 0.753 0.759 0.763 0.766 0.77 0.775 0.781 0.787 0.793 0.797 0.799 0.802 0.804 0.806 0.808 0.811 0.813 0.816 0.821 0.826 0.832 0.836 0.839 0.841 0.843
Merton 0.758 0.765 0.771 0.779 0.785 0.79 0.795 0.799 0.805 0.812 0.819 0.824 0.828 0.83 0.833 0.835 0.837 0.839 0.841 0.843 0.845 0.849 0.855 0.86 0.865 0.868 0.871 0.873
Newham 0.716 0.722 0.728 0.734 0.74 0.743 0.746 0.748 0.753 0.76 0.765 0.771 0.775 0.777 0.78 0.781 0.783 0.785 0.788 0.792 0.799 0.806 0.815 0.823 0.829 0.833 0.836 0.838
Redbridge 0.728 0.733 0.739 0.746 0.751 0.756 0.759 0.763 0.768 0.774 0.78 0.785 0.789 0.791 0.794 0.796 0.798 0.801 0.803 0.805 0.807 0.811 0.816 0.821 0.825 0.827 0.83 0.831
Richmond upon Thames 0.794 0.801 0.807 0.813 0.819 0.824 0.827 0.832 0.837 0.844 0.85 0.856 0.86 0.864 0.867 0.87 0.872 0.874 0.876 0.878 0.88 0.883 0.887 0.891 0.895 0.897 0.9 0.902
Southwark 0.793 0.8 0.807 0.815 0.821 0.827 0.83 0.835 0.84 0.847 0.852 0.857 0.86 0.863 0.866 0.869 0.872 0.875 0.879 0.883 0.887 0.893 0.898 0.904 0.907 0.909 0.911 0.912
Sutton 0.735 0.74 0.747 0.754 0.761 0.765 0.769 0.774 0.78 0.787 0.793 0.798 0.802 0.805 0.808 0.809 0.811 0.813 0.815 0.817 0.819 0.823 0.828 0.833 0.836 0.839 0.841 0.843
Tower Hamlets 0.766 0.773 0.78 0.788 0.795 0.801 0.805 0.81 0.817 0.825 0.832 0.839 0.844 0.848 0.852 0.857 0.861 0.866 0.871 0.876 0.881 0.886 0.891 0.896 0.9 0.902 0.904 0.905
Waltham Forest 0.712 0.718 0.724 0.731 0.738 0.742 0.745 0.749 0.754 0.76 0.765 0.77 0.773 0.775 0.777 0.778 0.78 0.781 0.783 0.784 0.787 0.792 0.798 0.805 0.81 0.814 0.817 0.819
Wandsworth 0.793 0.8 0.807 0.814 0.82 0.825 0.83 0.835 0.84 0.848 0.855 0.862 0.867 0.87 0.873 0.876 0.879 0.881 0.885 0.887 0.889 0.893 0.897 0.901 0.905 0.907 0.909 0.911
Westminster 0.831 0.837 0.843 0.849 0.854 0.858 0.862 0.865 0.87 0.875 0.881 0.885 0.889 0.891 0.895 0.898 0.901 0.903 0.905 0.907 0.91 0.913 0.916 0.92 0.922 0.924 0.925 0.927
North East England 0.697 0.703 0.711 0.718 0.725 0.73 0.733 0.738 0.744 0.75 0.757 0.763 0.767 0.771 0.774 0.778 0.781 0.784 0.787 0.79 0.794 0.798 0.804 0.81 0.814 0.817 0.819 0.821
County Durham 0.69 0.696 0.703 0.71 0.717 0.721 0.725 0.73 0.735 0.742 0.748 0.754 0.758 0.762 0.765 0.767 0.77 0.772 0.776 0.778 0.782 0.786 0.792 0.798 0.802 0.806 0.808 0.81
Darlington 0.703 0.709 0.716 0.723 0.73 0.734 0.737 0.74 0.745 0.752 0.758 0.764 0.769 0.773 0.777 0.78 0.783 0.785 0.788 0.791 0.795 0.8 0.806 0.812 0.817 0.821 0.823 0.825
Gateshead 0.7 0.706 0.713 0.72 0.727 0.732 0.735 0.739 0.745 0.751 0.758 0.764 0.769 0.773 0.777 0.781 0.784 0.787 0.791 0.794 0.798 0.803 0.808 0.814 0.818 0.821 0.824 0.826
Hartlepool 0.677 0.683 0.69 0.697 0.703 0.707 0.71 0.714 0.719 0.726 0.732 0.737 0.74 0.742 0.744 0.747 0.749 0.752 0.755 0.758 0.762 0.767 0.773 0.78 0.785 0.788 0.791 0.793
Middlesbrough 0.688 0.695 0.702 0.709 0.716 0.72 0.723 0.727 0.732 0.74 0.746 0.751 0.755 0.758 0.762 0.766 0.769 0.772 0.775 0.778 0.781 0.786 0.792 0.797 0.801 0.804 0.806 0.808
Newcastle upon Tyne 0.736 0.743 0.751 0.759 0.765 0.771 0.776 0.781 0.787 0.794 0.801 0.808 0.814 0.82 0.825 0.831 0.835 0.84 0.843 0.846 0.85 0.854 0.858 0.863 0.866 0.869 0.87 0.872
North Tyneside 0.696 0.703 0.71 0.718 0.724 0.729 0.733 0.737 0.743 0.749 0.756 0.762 0.768 0.772 0.776 0.78 0.784 0.787 0.79 0.793 0.797 0.802 0.807 0.813 0.817 0.821 0.823 0.825
Northumberland 0.697 0.703 0.709 0.716 0.722 0.727 0.73 0.735 0.74 0.746 0.752 0.757 0.761 0.764 0.767 0.77 0.773 0.776 0.779 0.781 0.784 0.787 0.793 0.798 0.802 0.805 0.807 0.808
Redcar and Cleveland 0.67 0.675 0.682 0.689 0.696 0.701 0.704 0.708 0.714 0.721 0.727 0.732 0.736 0.738 0.741 0.743 0.745 0.747 0.75 0.752 0.756 0.76 0.767 0.775 0.78 0.784 0.787 0.79
South Tyneside 0.664 0.671 0.678 0.685 0.692 0.697 0.7 0.705 0.711 0.718 0.725 0.731 0.737 0.74 0.744 0.748 0.751 0.754 0.757 0.759 0.762 0.767 0.773 0.78 0.785 0.789 0.792 0.794
Stockton-on-Tees 0.705 0.712 0.72 0.728 0.735 0.74 0.744 0.748 0.754 0.761 0.767 0.772 0.775 0.777 0.779 0.781 0.784 0.785 0.788 0.791 0.794 0.798 0.804 0.811 0.815 0.818 0.821 0.823
Sunderland 0.689 0.696 0.704 0.713 0.72 0.725 0.729 0.733 0.739 0.746 0.752 0.758 0.763 0.766 0.77 0.773 0.776 0.779 0.782 0.784 0.787 0.791 0.797 0.803 0.808 0.811 0.813 0.815
North West England 0.716 0.723 0.729 0.736 0.742 0.747 0.751 0.755 0.76 0.766 0.772 0.778 0.782 0.786 0.789 0.792 0.795 0.798 0.801 0.804 0.807 0.812 0.817 0.823 0.827 0.83 0.832 0.834
Blackburn with Darwen 0.691 0.695 0.701 0.707 0.713 0.717 0.719 0.723 0.728 0.734 0.74 0.745 0.748 0.75 0.753 0.756 0.758 0.761 0.764 0.766 0.769 0.774 0.78 0.788 0.793 0.797 0.8 0.802
Blackpool 0.68 0.685 0.691 0.698 0.703 0.707 0.71 0.713 0.718 0.724 0.729 0.733 0.737 0.738 0.741 0.743 0.745 0.747 0.748 0.75 0.752 0.756 0.762 0.768 0.773 0.776 0.779 0.781
Bolton 0.701 0.707 0.714 0.72 0.726 0.73 0.733 0.736 0.741 0.746 0.751 0.756 0.759 0.761 0.763 0.765 0.768 0.769 0.772 0.774 0.777 0.781 0.787 0.794 0.798 0.801 0.803 0.805
Bury 0.703 0.709 0.716 0.723 0.73 0.734 0.738 0.742 0.747 0.752 0.758 0.762 0.766 0.768 0.771 0.774 0.777 0.779 0.781 0.783 0.786 0.791 0.797 0.803 0.807 0.81 0.813 0.815
Cheshire East 0.748 0.754 0.76 0.767 0.773 0.778 0.782 0.787 0.792 0.798 0.803 0.809 0.813 0.817 0.82 0.823 0.826 0.829 0.832 0.834 0.836 0.84 0.845 0.851 0.856 0.859 0.861 0.864
Cheshire West and Chester 0.74 0.747 0.754 0.761 0.768 0.772 0.776 0.78 0.785 0.792 0.797 0.803 0.807 0.811 0.815 0.818 0.822 0.825 0.828 0.831 0.834 0.838 0.842 0.847 0.85 0.852 0.854 0.855
Cumbria 0.719 0.724 0.731 0.737 0.743 0.748 0.751 0.755 0.76 0.765 0.77 0.774 0.777 0.779 0.782 0.784 0.787 0.789 0.792 0.794 0.798 0.802 0.808 0.815 0.819 0.823 0.826 0.828
Halton 0.702 0.708 0.715 0.723 0.729 0.734 0.737 0.74 0.745 0.75 0.756 0.762 0.766 0.769 0.772 0.775 0.778 0.78 0.784 0.787 0.791 0.797 0.803 0.81 0.815 0.819 0.822 0.824
Knowsley 0.691 0.696 0.702 0.708 0.714 0.718 0.722 0.726 0.731 0.737 0.743 0.749 0.754 0.757 0.76 0.764 0.767 0.77 0.774 0.777 0.782 0.787 0.793 0.8 0.806 0.81 0.813 0.816
Lancashire 0.72 0.726 0.734 0.741 0.747 0.752 0.756 0.76 0.765 0.77 0.775 0.78 0.784 0.786 0.789 0.792 0.794 0.797 0.799 0.802 0.805 0.809 0.815 0.82 0.824 0.827 0.829 0.831
Liverpool 0.721 0.728 0.735 0.742 0.748 0.753 0.757 0.762 0.768 0.775 0.783 0.789 0.795 0.801 0.806 0.811 0.815 0.819 0.823 0.828 0.831 0.835 0.84 0.844 0.847 0.849 0.851 0.852
Manchester 0.746 0.753 0.76 0.768 0.775 0.78 0.785 0.79 0.796 0.804 0.812 0.819 0.825 0.83 0.835 0.84 0.844 0.849 0.853 0.856 0.86 0.864 0.869 0.874 0.878 0.88 0.883 0.885
Oldham 0.685 0.69 0.697 0.703 0.708 0.711 0.713 0.715 0.719 0.724 0.729 0.733 0.737 0.739 0.741 0.744 0.746 0.749 0.752 0.754 0.758 0.763 0.77 0.778 0.782 0.786 0.788 0.79
Rochdale 0.686 0.692 0.698 0.705 0.711 0.715 0.717 0.721 0.726 0.732 0.738 0.742 0.746 0.748 0.75 0.753 0.755 0.757 0.76 0.762 0.765 0.77 0.777 0.783 0.787 0.791 0.793 0.795
Salford 0.708 0.714 0.721 0.728 0.735 0.74 0.743 0.747 0.753 0.761 0.768 0.775 0.781 0.785 0.79 0.794 0.797 0.8 0.803 0.806 0.809 0.814 0.819 0.826 0.83 0.834 0.836 0.838
Sefton 0.706 0.713 0.72 0.727 0.733 0.738 0.741 0.746 0.751 0.757 0.763 0.768 0.773 0.776 0.78 0.783 0.786 0.788 0.79 0.792 0.794 0.796 0.8 0.803 0.806 0.809 0.81 0.812
St Helens 0.684 0.69 0.696 0.703 0.709 0.713 0.716 0.72 0.725 0.731 0.738 0.744 0.749 0.753 0.756 0.759 0.762 0.765 0.768 0.771 0.774 0.779 0.785 0.791 0.795 0.798 0.801 0.803
Stockport 0.727 0.734 0.741 0.748 0.755 0.759 0.763 0.767 0.772 0.779 0.785 0.791 0.796 0.799 0.803 0.806 0.809 0.812 0.814 0.817 0.82 0.823 0.828 0.833 0.837 0.839 0.841 0.843
Tameside 0.691 0.697 0.703 0.71 0.716 0.721 0.724 0.728 0.734 0.74 0.746 0.751 0.755 0.758 0.76 0.762 0.763 0.764 0.766 0.768 0.77 0.774 0.779 0.785 0.79 0.793 0.795 0.797
Trafford 0.751 0.757 0.764 0.771 0.778 0.782 0.786 0.79 0.795 0.802 0.809 0.815 0.82 0.824 0.829 0.832 0.836 0.839 0.842 0.844 0.848 0.852 0.856 0.862 0.865 0.868 0.871 0.873
Warrington 0.739 0.745 0.752 0.759 0.765 0.769 0.773 0.776 0.782 0.788 0.795 0.801 0.807 0.811 0.814 0.818 0.822 0.825 0.827 0.83 0.833 0.838 0.843 0.849 0.853 0.856 0.858 0.86
Wigan 0.691 0.697 0.703 0.71 0.716 0.72 0.723 0.727 0.731 0.737 0.742 0.747 0.75 0.753 0.755 0.757 0.76 0.762 0.764 0.766 0.769 0.774 0.78 0.786 0.79 0.793 0.796 0.798
Wirral 0.695 0.701 0.708 0.714 0.721 0.725 0.728 0.732 0.737 0.743 0.749 0.753 0.757 0.761 0.763 0.766 0.768 0.77 0.773 0.775 0.777 0.781 0.786 0.792 0.796 0.799 0.801 0.803
South East England 0.749 0.755 0.761 0.767 0.773 0.777 0.781 0.784 0.789 0.795 0.801 0.806 0.809 0.812 0.815 0.818 0.821 0.823 0.826 0.828 0.831 0.836 0.841 0.846 0.85 0.852 0.855 0.856
Bracknell Forest 0.759 0.764 0.77 0.776 0.781 0.785 0.788 0.791 0.797 0.804 0.811 0.817 0.822 0.825 0.829 0.832 0.835 0.838 0.841 0.843 0.845 0.849 0.854 0.859 0.862 0.865 0.867 0.869
Brighton and Hove 0.766 0.772 0.779 0.785 0.791 0.796 0.801 0.806 0.811 0.816 0.822 0.827 0.833 0.838 0.843 0.847 0.851 0.855 0.859 0.863 0.865 0.868 0.872 0.876 0.879 0.881 0.883 0.885
Buckinghamshire 0.764 0.769 0.775 0.782 0.788 0.792 0.795 0.799 0.804 0.81 0.815 0.82 0.824 0.826 0.829 0.832 0.834 0.836 0.838 0.84 0.842 0.846 0.851 0.855 0.859 0.861 0.863 0.865
East Sussex 0.712 0.718 0.724 0.73 0.736 0.74 0.742 0.745 0.749 0.754 0.759 0.763 0.766 0.769 0.771 0.773 0.776 0.778 0.781 0.783 0.787 0.791 0.797 0.803 0.807 0.81 0.812 0.814
Hampshire 0.744 0.75 0.756 0.762 0.768 0.772 0.775 0.778 0.782 0.788 0.793 0.798 0.802 0.804 0.807 0.81 0.812 0.815 0.818 0.82 0.824 0.828 0.834 0.839 0.843 0.846 0.848 0.85
Isle of Wight 0.704 0.709 0.715 0.722 0.727 0.732 0.735 0.739 0.744 0.749 0.756 0.761 0.765 0.767 0.768 0.771 0.773 0.776 0.779 0.781 0.784 0.788 0.794 0.801 0.806 0.809 0.812 0.814
Kent 0.723 0.728 0.734 0.74 0.746 0.75 0.752 0.756 0.76 0.765 0.77 0.774 0.777 0.779 0.782 0.785 0.787 0.79 0.793 0.796 0.8 0.805 0.811 0.817 0.822 0.824 0.826 0.828
Medway 0.703 0.709 0.715 0.722 0.728 0.731 0.734 0.737 0.742 0.747 0.752 0.756 0.76 0.762 0.765 0.768 0.771 0.773 0.776 0.778 0.781 0.785 0.791 0.797 0.802 0.805 0.807 0.809
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Milton Keynes 0.754 0.76 0.767 0.774 0.78 0.784 0.786 0.789 0.793 0.798 0.802 0.806 0.81 0.812 0.815 0.817 0.819 0.821 0.823 0.825 0.829 0.834 0.84 0.847 0.852 0.856 0.859 0.86
Oxfordshire 0.769 0.775 0.781 0.788 0.794 0.798 0.801 0.805 0.81 0.816 0.822 0.827 0.831 0.835 0.838 0.841 0.844 0.847 0.849 0.852 0.855 0.859 0.864 0.869 0.872 0.875 0.878 0.879
Portsmouth 0.75 0.756 0.763 0.77 0.776 0.781 0.785 0.79 0.795 0.8 0.805 0.81 0.815 0.818 0.822 0.824 0.827 0.829 0.832 0.835 0.838 0.842 0.846 0.851 0.854 0.857 0.858 0.86
Reading 0.785 0.791 0.797 0.803 0.809 0.813 0.817 0.821 0.827 0.834 0.84 0.847 0.852 0.856 0.86 0.864 0.866 0.868 0.87 0.872 0.874 0.877 0.882 0.887 0.89 0.892 0.894 0.895
Slough 0.764 0.77 0.777 0.784 0.79 0.793 0.796 0.799 0.802 0.806 0.81 0.813 0.815 0.816 0.817 0.818 0.819 0.82 0.822 0.825 0.829 0.834 0.841 0.848 0.852 0.855 0.858 0.859
Southampton 0.752 0.758 0.765 0.772 0.779 0.784 0.789 0.794 0.8 0.805 0.81 0.815 0.819 0.823 0.826 0.829 0.831 0.834 0.836 0.837 0.839 0.842 0.845 0.849 0.852 0.855 0.856 0.858
Surrey 0.773 0.779 0.785 0.791 0.797 0.801 0.805 0.809 0.814 0.821 0.827 0.833 0.838 0.841 0.845 0.847 0.85 0.853 0.856 0.858 0.861 0.864 0.868 0.873 0.876 0.879 0.881 0.883
West Berkshire 0.774 0.78 0.786 0.793 0.799 0.803 0.805 0.808 0.813 0.819 0.824 0.829 0.832 0.835 0.836 0.836 0.837 0.838 0.84 0.842 0.846 0.851 0.857 0.863 0.867 0.869 0.871 0.872
West Sussex 0.74 0.745 0.751 0.757 0.763 0.767 0.77 0.773 0.777 0.783 0.788 0.793 0.796 0.799 0.802 0.804 0.807 0.809 0.812 0.814 0.818 0.822 0.827 0.833 0.837 0.84 0.842 0.843
Windsor and Maidenhead 0.778 0.783 0.789 0.795 0.8 0.805 0.808 0.811 0.816 0.823 0.829 0.835 0.839 0.843 0.847 0.851 0.854 0.857 0.86 0.863 0.866 0.87 0.874 0.88 0.883 0.885 0.887 0.889
Wokingham 0.778 0.784 0.79 0.797 0.802 0.806 0.81 0.814 0.82 0.826 0.832 0.837 0.842 0.845 0.849 0.853 0.856 0.858 0.861 0.863 0.865 0.868 0.871 0.876 0.879 0.882 0.883 0.885
South West England 0.729 0.735 0.741 0.748 0.754 0.758 0.762 0.766 0.771 0.777 0.783 0.788 0.792 0.796 0.799 0.802 0.805 0.807 0.81 0.813 0.816 0.82 0.825 0.831 0.835 0.838 0.84 0.841
Bath and North East Somerset 0.752 0.758 0.764 0.77 0.777 0.782 0.786 0.79 0.796 0.803 0.809 0.816 0.822 0.828 0.833 0.838 0.842 0.846 0.85 0.853 0.856 0.859 0.863 0.867 0.869 0.872 0.874 0.875
Bournemouth 0.736 0.743 0.75 0.757 0.763 0.768 0.773 0.778 0.784 0.79 0.797 0.803 0.808 0.812 0.816 0.821 0.824 0.828 0.831 0.834 0.836 0.839 0.843 0.848 0.851 0.853 0.856 0.858
Bristol, City of 0.763 0.77 0.777 0.784 0.791 0.796 0.8 0.805 0.81 0.817 0.823 0.828 0.833 0.836 0.839 0.843 0.846 0.849 0.853 0.856 0.859 0.863 0.868 0.873 0.877 0.88 0.882 0.884
Cornwall 0.7 0.706 0.713 0.721 0.727 0.731 0.734 0.738 0.743 0.749 0.755 0.76 0.764 0.768 0.771 0.774 0.777 0.78 0.783 0.786 0.789 0.793 0.799 0.806 0.81 0.813 0.815 0.817
Devon 0.72 0.726 0.733 0.74 0.746 0.75 0.753 0.757 0.762 0.769 0.775 0.78 0.785 0.789 0.793 0.796 0.8 0.803 0.806 0.808 0.811 0.816 0.821 0.826 0.83 0.833 0.835 0.837
Dorset 0.716 0.721 0.727 0.734 0.74 0.744 0.747 0.751 0.756 0.762 0.769 0.773 0.777 0.779 0.781 0.783 0.786 0.788 0.791 0.793 0.797 0.802 0.808 0.814 0.818 0.821 0.823 0.825
Gloucestershire 0.735 0.741 0.747 0.754 0.76 0.765 0.768 0.772 0.777 0.783 0.79 0.795 0.8 0.804 0.808 0.811 0.813 0.816 0.818 0.82 0.824 0.828 0.833 0.839 0.843 0.846 0.848 0.85
North Somerset 0.714 0.72 0.727 0.733 0.739 0.743 0.746 0.75 0.755 0.76 0.766 0.771 0.776 0.78 0.783 0.786 0.789 0.792 0.795 0.798 0.801 0.806 0.813 0.819 0.824 0.827 0.83 0.832
Plymouth 0.724 0.73 0.737 0.744 0.75 0.754 0.758 0.762 0.767 0.772 0.778 0.783 0.787 0.79 0.793 0.796 0.799 0.802 0.805 0.807 0.81 0.814 0.819 0.825 0.829 0.832 0.834 0.836
Poole 0.727 0.733 0.74 0.746 0.753 0.758 0.761 0.765 0.771 0.777 0.783 0.789 0.793 0.796 0.798 0.801 0.804 0.806 0.809 0.811 0.814 0.818 0.824 0.83 0.835 0.838 0.84 0.842
Somerset 0.713 0.718 0.724 0.731 0.737 0.741 0.744 0.748 0.752 0.757 0.763 0.767 0.77 0.772 0.775 0.777 0.78 0.782 0.785 0.787 0.789 0.794 0.799 0.805 0.809 0.812 0.814 0.816
South Gloucestershire 0.747 0.752 0.758 0.765 0.771 0.775 0.779 0.783 0.789 0.796 0.802 0.808 0.813 0.817 0.821 0.824 0.827 0.831 0.834 0.837 0.84 0.844 0.849 0.855 0.859 0.862 0.865 0.867
Swindon 0.747 0.753 0.76 0.767 0.773 0.776 0.778 0.781 0.786 0.792 0.797 0.801 0.805 0.806 0.807 0.809 0.811 0.813 0.815 0.818 0.82 0.825 0.831 0.837 0.841 0.844 0.846 0.847
Torbay 0.699 0.705 0.711 0.717 0.723 0.727 0.73 0.733 0.736 0.741 0.745 0.749 0.75 0.751 0.753 0.755 0.757 0.759 0.761 0.762 0.764 0.767 0.773 0.779 0.783 0.786 0.789 0.79
Wiltshire 0.726 0.731 0.737 0.743 0.749 0.753 0.756 0.759 0.763 0.769 0.775 0.78 0.784 0.786 0.789 0.791 0.793 0.795 0.797 0.799 0.803 0.808 0.813 0.819 0.823 0.826 0.828 0.829
West Midlands 0.707 0.713 0.72 0.727 0.734 0.739 0.743 0.747 0.752 0.759 0.765 0.771 0.776 0.779 0.783 0.786 0.789 0.792 0.795 0.798 0.802 0.806 0.812 0.818 0.822 0.825 0.828 0.829
Birmingham 0.707 0.714 0.721 0.728 0.735 0.739 0.743 0.747 0.753 0.76 0.766 0.773 0.778 0.782 0.787 0.791 0.794 0.798 0.803 0.807 0.811 0.817 0.823 0.829 0.834 0.837 0.839 0.84
Coventry 0.722 0.729 0.737 0.745 0.751 0.757 0.762 0.766 0.772 0.779 0.785 0.791 0.796 0.8 0.803 0.807 0.81 0.812 0.815 0.818 0.821 0.825 0.831 0.837 0.841 0.844 0.847 0.848
Dudley 0.692 0.698 0.704 0.71 0.716 0.721 0.724 0.728 0.733 0.739 0.746 0.751 0.756 0.759 0.762 0.765 0.767 0.77 0.772 0.774 0.776 0.779 0.784 0.789 0.793 0.795 0.797 0.799
Herefordshire, County of 0.706 0.712 0.719 0.726 0.733 0.738 0.742 0.747 0.752 0.759 0.766 0.771 0.776 0.779 0.783 0.786 0.789 0.792 0.795 0.798 0.801 0.806 0.812 0.818 0.822 0.825 0.827 0.828
Sandwell 0.682 0.688 0.695 0.702 0.708 0.712 0.715 0.719 0.724 0.729 0.735 0.74 0.744 0.747 0.75 0.752 0.754 0.756 0.759 0.761 0.765 0.769 0.776 0.783 0.788 0.792 0.795 0.797
Shropshire 0.708 0.714 0.721 0.728 0.734 0.739 0.743 0.747 0.752 0.759 0.766 0.771 0.776 0.781 0.785 0.789 0.793 0.795 0.799 0.802 0.806 0.811 0.816 0.821 0.825 0.828 0.83 0.832
Solihull 0.733 0.74 0.747 0.755 0.762 0.767 0.771 0.776 0.783 0.789 0.795 0.801 0.807 0.811 0.815 0.818 0.822 0.825 0.828 0.83 0.832 0.835 0.84 0.845 0.848 0.851 0.853 0.855
Staffordshire 0.708 0.714 0.722 0.729 0.736 0.74 0.744 0.749 0.755 0.761 0.767 0.772 0.777 0.78 0.783 0.787 0.79 0.793 0.796 0.799 0.802 0.806 0.811 0.816 0.819 0.822 0.824 0.826
Stoke-on-Trent 0.689 0.696 0.703 0.71 0.716 0.721 0.724 0.728 0.733 0.738 0.743 0.747 0.75 0.751 0.753 0.754 0.756 0.757 0.76 0.763 0.767 0.772 0.78 0.788 0.794 0.798 0.801 0.804
Telford and Wrekin 0.713 0.719 0.726 0.733 0.74 0.745 0.749 0.754 0.759 0.764 0.769 0.773 0.776 0.777 0.779 0.781 0.783 0.784 0.787 0.789 0.791 0.796 0.802 0.809 0.814 0.817 0.82 0.822
Walsall 0.681 0.686 0.692 0.698 0.704 0.707 0.709 0.712 0.717 0.723 0.729 0.734 0.738 0.74 0.743 0.746 0.749 0.752 0.755 0.757 0.761 0.766 0.772 0.779 0.783 0.787 0.789 0.791
Warwickshire 0.732 0.738 0.746 0.753 0.76 0.765 0.769 0.774 0.779 0.786 0.792 0.798 0.802 0.806 0.809 0.812 0.816 0.819 0.823 0.826 0.83 0.834 0.84 0.845 0.85 0.853 0.855 0.857
Wolverhampton 0.691 0.697 0.704 0.712 0.719 0.723 0.727 0.731 0.737 0.744 0.751 0.757 0.761 0.764 0.768 0.771 0.774 0.776 0.779 0.781 0.784 0.788 0.794 0.8 0.804 0.807 0.809 0.811
Worcestershire 0.707 0.713 0.72 0.727 0.733 0.738 0.742 0.747 0.754 0.762 0.771 0.778 0.782 0.786 0.791 0.794 0.798 0.8 0.803 0.805 0.808 0.811 0.816 0.822 0.826 0.829 0.831 0.833
Yorkshire and the Humber 0.711 0.717 0.724 0.731 0.737 0.742 0.745 0.75 0.755 0.762 0.768 0.773 0.778 0.781 0.785 0.788 0.791 0.794 0.797 0.8 0.803 0.808 0.813 0.819 0.823 0.826 0.828 0.83
Barnsley 0.675 0.68 0.686 0.692 0.698 0.702 0.705 0.709 0.715 0.721 0.726 0.731 0.735 0.738 0.741 0.743 0.746 0.748 0.75 0.752 0.755 0.759 0.765 0.772 0.778 0.781 0.785 0.787
Bradford 0.693 0.699 0.705 0.712 0.718 0.721 0.723 0.725 0.729 0.736 0.741 0.747 0.751 0.753 0.756 0.759 0.762 0.765 0.768 0.771 0.775 0.78 0.787 0.794 0.799 0.803 0.805 0.807
Calderdale 0.708 0.714 0.721 0.729 0.735 0.739 0.743 0.746 0.751 0.758 0.763 0.768 0.771 0.774 0.777 0.78 0.783 0.785 0.788 0.791 0.795 0.8 0.807 0.814 0.819 0.823 0.825 0.827
Doncaster 0.674 0.679 0.685 0.692 0.697 0.701 0.704 0.707 0.712 0.718 0.724 0.729 0.733 0.736 0.74 0.743 0.746 0.749 0.752 0.755 0.759 0.764 0.771 0.778 0.783 0.786 0.789 0.791
East Riding of Yorkshire 0.714 0.72 0.727 0.734 0.741 0.745 0.749 0.753 0.758 0.764 0.769 0.774 0.778 0.781 0.784 0.787 0.79 0.792 0.794 0.797 0.799 0.802 0.807 0.812 0.815 0.818 0.82 0.822
Kingston upon Hull, City of 0.689 0.695 0.702 0.71 0.717 0.722 0.726 0.73 0.736 0.742 0.749 0.755 0.76 0.763 0.767 0.77 0.773 0.776 0.779 0.782 0.785 0.789 0.795 0.801 0.806 0.809 0.811 0.813
Kirklees 0.703 0.709 0.716 0.723 0.73 0.734 0.737 0.741 0.746 0.752 0.758 0.763 0.767 0.77 0.773 0.776 0.779 0.781 0.783 0.785 0.788 0.793 0.798 0.805 0.809 0.812 0.814 0.816
Leeds 0.739 0.746 0.753 0.761 0.768 0.773 0.778 0.783 0.789 0.797 0.803 0.81 0.816 0.82 0.825 0.83 0.834 0.837 0.841 0.843 0.846 0.849 0.854 0.858 0.862 0.864 0.867 0.868
North East Lincolnshire 0.698 0.705 0.712 0.72 0.727 0.731 0.733 0.737 0.741 0.745 0.749 0.753 0.755 0.757 0.758 0.761 0.763 0.767 0.77 0.775 0.779 0.784 0.79 0.796 0.799 0.802 0.803 0.804
North Lincolnshire 0.702 0.707 0.714 0.72 0.727 0.731 0.734 0.737 0.742 0.748 0.752 0.757 0.76 0.762 0.764 0.766 0.768 0.77 0.773 0.776 0.78 0.785 0.792 0.799 0.803 0.807 0.809 0.811
North Yorkshire 0.724 0.73 0.737 0.743 0.75 0.754 0.758 0.762 0.767 0.774 0.78 0.785 0.79 0.794 0.798 0.801 0.803 0.806 0.808 0.81 0.813 0.817 0.822 0.827 0.831 0.834 0.836 0.839
Rotherham 0.681 0.687 0.693 0.7 0.707 0.711 0.714 0.717 0.722 0.728 0.734 0.739 0.744 0.747 0.75 0.753 0.756 0.759 0.761 0.763 0.766 0.77 0.776 0.782 0.787 0.791 0.794 0.796
Sheffield 0.727 0.733 0.74 0.747 0.753 0.758 0.762 0.767 0.773 0.78 0.786 0.792 0.798 0.803 0.807 0.811 0.815 0.819 0.823 0.826 0.83 0.834 0.839 0.843 0.847 0.849 0.852 0.853
Wakefield 0.692 0.698 0.705 0.712 0.718 0.722 0.726 0.729 0.734 0.741 0.747 0.752 0.755 0.758 0.76 0.763 0.765 0.766 0.768 0.769 0.772 0.777 0.784 0.791 0.797 0.801 0.804 0.806
York 0.762 0.769 0.776 0.783 0.789 0.795 0.799 0.804 0.81 0.816 0.822 0.829 0.834 0.839 0.844 0.848 0.851 0.854 0.857 0.859 0.862 0.865 0.868 0.872 0.874 0.876 0.878 0.879
Northern Ireland 0.71 0.718 0.726 0.735 0.742 0.747 0.751 0.755 0.761 0.767 0.774 0.78 0.786 0.79 0.795 0.798 0.801 0.805 0.808 0.812 0.815 0.818 0.822 0.825 0.828 0.831 0.833 0.835
Scotland 0.672 0.678 0.686 0.693 0.701 0.706 0.711 0.716 0.722 0.73 0.737 0.743 0.748 0.752 0.757 0.761 0.764 0.768 0.772 0.777 0.781 0.785 0.789 0.793 0.797 0.8 0.803 0.805
Wales 0.642 0.65 0.659 0.668 0.676 0.683 0.688 0.694 0.702 0.711 0.719 0.727 0.734 0.739 0.745 0.75 0.755 0.76 0.765 0.77 0.774 0.78 0.786 0.792 0.797 0.8 0.803 0.806
Latin America and Caribbean 0.497 0.502 0.508 0.514 0.521 0.527 0.534 0.54 0.546 0.552 0.557 0.563 0.567 0.571 0.576 0.581 0.587 0.592 0.598 0.603 0.608 0.613 0.618 0.624 0.628 0.633 0.637 0.64
Andean Latin America 0.483 0.486 0.49 0.495 0.501 0.507 0.512 0.518 0.526 0.533 0.539 0.546 0.552 0.558 0.563 0.567 0.572 0.577 0.581 0.585 0.59 0.595 0.601 0.606 0.612 0.618 0.624 0.628
Bolivia 0.403 0.408 0.416 0.424 0.431 0.438 0.447 0.456 0.466 0.475 0.485 0.494 0.504 0.513 0.52 0.526 0.532 0.536 0.539 0.543 0.547 0.551 0.555 0.559 0.565 0.573 0.581 0.587
Ecuador 0.506 0.51 0.515 0.52 0.524 0.524 0.522 0.521 0.526 0.532 0.539 0.548 0.557 0.564 0.57 0.575 0.581 0.585 0.588 0.59 0.594 0.603 0.611 0.618 0.623 0.628 0.632 0.636
Peru 0.493 0.495 0.497 0.501 0.509 0.517 0.526 0.534 0.542 0.549 0.555 0.56 0.564 0.568 0.571 0.575 0.578 0.584 0.59 0.594 0.6 0.604 0.608 0.614 0.62 0.626 0.632 0.636
Caribbean 0.531 0.536 0.539 0.543 0.546 0.549 0.552 0.555 0.559 0.563 0.568 0.573 0.578 0.583 0.589 0.596 0.602 0.607 0.61 0.613 0.617 0.621 0.624 0.626 0.628 0.631 0.635 0.638
Antigua and Barbuda 0.61 0.616 0.622 0.627 0.631 0.633 0.636 0.64 0.644 0.649 0.653 0.657 0.661 0.666 0.67 0.675 0.68 0.685 0.69 0.694 0.696 0.698 0.7 0.703 0.706 0.709 0.712 0.715
The Bahamas 0.674 0.669 0.665 0.667 0.671 0.676 0.681 0.687 0.695 0.703 0.71 0.715 0.718 0.721 0.723 0.727 0.732 0.737 0.742 0.746 0.751 0.753 0.755 0.755 0.755 0.755 0.755 0.756
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Appendix Table 10: Socio-Demographic Index values for all estimated GBD 2017 locations, 1990-2017
Barbados 0.65 0.655 0.661 0.667 0.672 0.675 0.678 0.68 0.682 0.683 0.686 0.689 0.693 0.698 0.703 0.707 0.71 0.713 0.717 0.72 0.723 0.726 0.729 0.732 0.734 0.736 0.738 0.739
Belize 0.402 0.414 0.429 0.445 0.458 0.471 0.482 0.49 0.496 0.501 0.506 0.511 0.518 0.525 0.533 0.541 0.549 0.557 0.563 0.569 0.576 0.581 0.586 0.59 0.594 0.598 0.6 0.602
Bermuda 0.73 0.732 0.734 0.737 0.738 0.74 0.741 0.743 0.746 0.749 0.752 0.754 0.757 0.761 0.765 0.769 0.773 0.777 0.782 0.786 0.79 0.794 0.797 0.8 0.803 0.804 0.805 0.805
Cuba 0.592 0.6 0.604 0.605 0.604 0.603 0.601 0.6 0.601 0.604 0.607 0.611 0.617 0.623 0.629 0.636 0.644 0.646 0.647 0.649 0.652 0.656 0.663 0.668 0.671 0.676 0.683 0.688
Dominica 0.534 0.535 0.539 0.546 0.555 0.563 0.57 0.577 0.584 0.592 0.599 0.606 0.614 0.621 0.63 0.636 0.641 0.645 0.65 0.656 0.662 0.668 0.673 0.677 0.68 0.682 0.684 0.687
Dominican Republic 0.442 0.443 0.445 0.449 0.454 0.459 0.464 0.469 0.475 0.48 0.484 0.49 0.495 0.499 0.511 0.525 0.536 0.547 0.555 0.562 0.568 0.572 0.575 0.576 0.578 0.583 0.589 0.593
Grenada 0.46 0.472 0.485 0.497 0.508 0.519 0.529 0.54 0.55 0.558 0.566 0.573 0.578 0.584 0.589 0.594 0.599 0.604 0.608 0.612 0.615 0.618 0.62 0.624 0.628 0.632 0.637 0.64
Guyana 0.442 0.446 0.45 0.454 0.458 0.465 0.472 0.481 0.489 0.497 0.503 0.51 0.516 0.521 0.526 0.53 0.533 0.537 0.542 0.547 0.552 0.557 0.563 0.568 0.573 0.576 0.58 0.584
Haiti 0.328 0.332 0.336 0.339 0.342 0.345 0.35 0.355 0.361 0.367 0.373 0.379 0.384 0.389 0.393 0.397 0.401 0.405 0.409 0.413 0.416 0.42 0.423 0.427 0.431 0.435 0.439 0.442
Jamaica 0.547 0.553 0.56 0.565 0.571 0.578 0.585 0.591 0.596 0.6 0.607 0.615 0.621 0.626 0.63 0.635 0.639 0.644 0.649 0.653 0.658 0.663 0.667 0.671 0.673 0.676 0.677 0.679
Puerto Rico 0.684 0.689 0.693 0.698 0.703 0.708 0.714 0.719 0.724 0.729 0.736 0.745 0.752 0.756 0.759 0.762 0.766 0.77 0.774 0.778 0.782 0.786 0.791 0.797 0.805 0.811 0.813 0.813
Saint Lucia 0.509 0.516 0.524 0.532 0.54 0.549 0.558 0.566 0.573 0.58 0.585 0.589 0.593 0.598 0.603 0.606 0.609 0.613 0.618 0.623 0.628 0.633 0.636 0.64 0.643 0.646 0.65 0.653
Saint Vincent and the Grenadines 0.465 0.472 0.479 0.486 0.492 0.499 0.506 0.512 0.518 0.524 0.53 0.537 0.543 0.549 0.553 0.557 0.561 0.566 0.571 0.575 0.579 0.584 0.588 0.593 0.597 0.601 0.605 0.608
Suriname 0.529 0.534 0.538 0.541 0.543 0.543 0.544 0.547 0.551 0.555 0.56 0.568 0.576 0.585 0.592 0.597 0.601 0.604 0.608 0.612 0.616 0.62 0.625 0.628 0.632 0.636 0.639 0.641
Trinidad and Tobago 0.601 0.604 0.608 0.611 0.615 0.619 0.624 0.629 0.634 0.64 0.646 0.652 0.657 0.663 0.669 0.675 0.68 0.685 0.689 0.691 0.693 0.694 0.695 0.696 0.697 0.698 0.698 0.698
Virgin Islands 0.673 0.683 0.691 0.699 0.706 0.713 0.719 0.725 0.73 0.734 0.737 0.74 0.748 0.755 0.762 0.768 0.774 0.78 0.786 0.79 0.795 0.799 0.802 0.804 0.805 0.806 0.806 0.807
Central Latin America 0.492 0.496 0.501 0.507 0.515 0.521 0.528 0.534 0.54 0.545 0.551 0.557 0.561 0.564 0.567 0.571 0.577 0.583 0.588 0.593 0.597 0.601 0.606 0.61 0.614 0.617 0.621 0.623
Colombia 0.482 0.483 0.485 0.49 0.496 0.503 0.511 0.518 0.524 0.528 0.533 0.537 0.541 0.544 0.548 0.553 0.558 0.565 0.573 0.581 0.588 0.596 0.604 0.611 0.617 0.624 0.629 0.634
Costa Rica 0.524 0.53 0.536 0.54 0.545 0.55 0.555 0.56 0.566 0.573 0.581 0.589 0.594 0.598 0.603 0.607 0.609 0.612 0.616 0.623 0.629 0.634 0.64 0.645 0.649 0.654 0.658 0.662
El Salvador 0.406 0.409 0.413 0.418 0.424 0.431 0.44 0.449 0.459 0.47 0.481 0.491 0.5 0.508 0.515 0.523 0.531 0.539 0.545 0.55 0.556 0.561 0.567 0.573 0.578 0.584 0.589 0.593
Guatemala 0.313 0.318 0.326 0.338 0.353 0.363 0.371 0.381 0.397 0.411 0.42 0.427 0.433 0.44 0.449 0.458 0.465 0.47 0.476 0.482 0.489 0.496 0.501 0.507 0.513 0.517 0.521 0.524
Honduras 0.34 0.344 0.347 0.352 0.358 0.365 0.372 0.381 0.39 0.4 0.41 0.419 0.428 0.437 0.445 0.452 0.459 0.465 0.47 0.475 0.481 0.486 0.49 0.495 0.499 0.504 0.508 0.512
Mexico 0.513 0.517 0.521 0.529 0.537 0.543 0.549 0.555 0.561 0.566 0.572 0.577 0.581 0.586 0.59 0.595 0.598 0.602 0.606 0.608 0.611 0.613 0.616 0.619 0.622 0.624 0.626 0.628
Aguascalientes 0.558 0.561 0.565 0.571 0.577 0.583 0.591 0.597 0.603 0.606 0.609 0.612 0.615 0.621 0.626 0.632 0.636 0.64 0.643 0.644 0.645 0.647 0.649 0.651 0.653 0.655 0.657 0.659
Baja California 0.57 0.572 0.575 0.579 0.582 0.585 0.589 0.594 0.599 0.604 0.608 0.611 0.615 0.618 0.622 0.626 0.63 0.634 0.639 0.642 0.644 0.646 0.649 0.651 0.653 0.654 0.656 0.657
Baja California Sur 0.569 0.573 0.577 0.582 0.586 0.589 0.593 0.598 0.602 0.605 0.609 0.612 0.614 0.617 0.621 0.624 0.628 0.633 0.637 0.641 0.644 0.647 0.649 0.652 0.654 0.656 0.657 0.659
Campeche 0.485 0.49 0.496 0.504 0.511 0.517 0.525 0.534 0.543 0.551 0.558 0.564 0.569 0.573 0.577 0.581 0.585 0.589 0.593 0.595 0.597 0.599 0.602 0.605 0.608 0.611 0.614 0.616
Chiapas 0.403 0.407 0.413 0.422 0.43 0.436 0.444 0.452 0.459 0.465 0.47 0.475 0.48 0.484 0.489 0.494 0.498 0.503 0.508 0.512 0.514 0.517 0.52 0.522 0.525 0.528 0.531 0.533
Chihuahua 0.546 0.549 0.552 0.555 0.558 0.559 0.562 0.566 0.57 0.574 0.577 0.581 0.585 0.589 0.594 0.599 0.604 0.61 0.615 0.619 0.622 0.625 0.628 0.63 0.633 0.635 0.637 0.639
Coahuila 0.549 0.555 0.561 0.567 0.573 0.576 0.581 0.587 0.592 0.597 0.601 0.604 0.607 0.611 0.616 0.62 0.624 0.628 0.631 0.633 0.634 0.635 0.637 0.638 0.64 0.642 0.644 0.645
Colima 0.538 0.543 0.549 0.556 0.561 0.565 0.571 0.577 0.583 0.588 0.594 0.598 0.603 0.607 0.611 0.616 0.621 0.626 0.631 0.634 0.637 0.64 0.643 0.645 0.648 0.65 0.652 0.654
Mexico City 0.602 0.606 0.61 0.617 0.629 0.64 0.65 0.656 0.661 0.666 0.671 0.676 0.681 0.685 0.689 0.693 0.696 0.698 0.7 0.701 0.702 0.704 0.706 0.708 0.71 0.712 0.714 0.716
Durango 0.506 0.508 0.511 0.516 0.52 0.523 0.528 0.535 0.542 0.55 0.556 0.562 0.568 0.574 0.581 0.586 0.592 0.597 0.602 0.605 0.607 0.609 0.612 0.614 0.617 0.619 0.622 0.624
Guanajuato 0.494 0.499 0.504 0.511 0.519 0.527 0.534 0.541 0.546 0.551 0.558 0.565 0.571 0.575 0.579 0.583 0.587 0.591 0.595 0.598 0.601 0.604 0.607 0.611 0.614 0.616 0.619 0.621
Guerrero 0.426 0.429 0.433 0.44 0.445 0.45 0.456 0.465 0.473 0.48 0.487 0.492 0.498 0.505 0.511 0.517 0.523 0.529 0.535 0.539 0.542 0.545 0.548 0.552 0.555 0.558 0.56 0.562
Hidalgo 0.417 0.424 0.433 0.444 0.454 0.462 0.471 0.481 0.491 0.501 0.511 0.52 0.527 0.531 0.535 0.538 0.543 0.548 0.554 0.558 0.562 0.567 0.572 0.576 0.58 0.583 0.585 0.587
Jalisco 0.532 0.538 0.545 0.552 0.558 0.563 0.569 0.576 0.582 0.588 0.593 0.598 0.602 0.606 0.611 0.615 0.619 0.624 0.628 0.63 0.632 0.635 0.637 0.64 0.642 0.645 0.647 0.649
México 0.529 0.524 0.525 0.539 0.558 0.568 0.574 0.577 0.58 0.585 0.59 0.596 0.6 0.603 0.607 0.611 0.613 0.614 0.614 0.614 0.615 0.617 0.621 0.625 0.628 0.631 0.633 0.635
Michoacán de Ocampo 0.464 0.47 0.476 0.483 0.489 0.494 0.501 0.508 0.515 0.522 0.527 0.532 0.537 0.542 0.546 0.551 0.555 0.559 0.563 0.566 0.568 0.571 0.573 0.576 0.579 0.581 0.584 0.586
Morelos 0.525 0.532 0.539 0.547 0.553 0.558 0.564 0.571 0.577 0.582 0.587 0.591 0.595 0.598 0.601 0.605 0.608 0.612 0.615 0.617 0.619 0.622 0.624 0.627 0.629 0.631 0.634 0.635
Nayarit 0.495 0.5 0.506 0.512 0.518 0.523 0.529 0.537 0.545 0.553 0.56 0.566 0.571 0.576 0.581 0.585 0.59 0.594 0.598 0.6 0.602 0.604 0.607 0.61 0.613 0.615 0.618 0.62
Nuevo León 0.598 0.602 0.606 0.611 0.615 0.617 0.62 0.625 0.63 0.635 0.64 0.644 0.647 0.65 0.653 0.656 0.659 0.662 0.665 0.666 0.667 0.669 0.67 0.672 0.673 0.675 0.676 0.677
Oaxaca 0.431 0.435 0.441 0.447 0.452 0.455 0.459 0.466 0.473 0.479 0.485 0.49 0.496 0.501 0.507 0.512 0.517 0.523 0.529 0.533 0.537 0.541 0.545 0.549 0.552 0.555 0.558 0.561
Puebla 0.456 0.463 0.47 0.478 0.487 0.493 0.496 0.497 0.498 0.499 0.504 0.509 0.516 0.524 0.532 0.538 0.544 0.549 0.554 0.558 0.563 0.567 0.571 0.575 0.577 0.58 0.582 0.584
Querétaro 0.497 0.502 0.508 0.518 0.53 0.543 0.556 0.566 0.575 0.583 0.591 0.597 0.602 0.606 0.609 0.612 0.616 0.619 0.623 0.624 0.626 0.629 0.631 0.633 0.635 0.636 0.638 0.639
Quintana Roo 0.52 0.526 0.533 0.541 0.548 0.555 0.562 0.57 0.577 0.582 0.587 0.591 0.594 0.596 0.599 0.601 0.605 0.608 0.612 0.614 0.616 0.618 0.62 0.621 0.623 0.624 0.625 0.626
San Luis Potosí 0.482 0.486 0.492 0.5 0.508 0.514 0.522 0.53 0.538 0.545 0.551 0.556 0.561 0.566 0.571 0.575 0.58 0.586 0.591 0.595 0.599 0.602 0.606 0.61 0.613 0.616 0.619 0.621
Sinaloa 0.523 0.528 0.533 0.539 0.544 0.549 0.555 0.562 0.57 0.577 0.583 0.589 0.594 0.599 0.604 0.609 0.614 0.619 0.623 0.627 0.63 0.633 0.636 0.639 0.642 0.644 0.646 0.649
Sonora 0.553 0.557 0.562 0.566 0.57 0.573 0.578 0.583 0.588 0.593 0.597 0.601 0.605 0.608 0.612 0.616 0.621 0.625 0.629 0.632 0.635 0.637 0.64 0.643 0.645 0.647 0.649 0.65
Tabasco 0.474 0.479 0.486 0.493 0.5 0.507 0.515 0.524 0.533 0.541 0.548 0.553 0.558 0.563 0.568 0.573 0.578 0.583 0.588 0.591 0.594 0.596 0.599 0.602 0.604 0.607 0.609 0.611
Tamaulipas 0.548 0.553 0.558 0.564 0.568 0.571 0.574 0.579 0.586 0.592 0.598 0.602 0.606 0.609 0.613 0.616 0.62 0.624 0.628 0.63 0.633 0.635 0.637 0.64 0.642 0.643 0.645 0.647
Tlaxcala 0.478 0.482 0.487 0.495 0.506 0.515 0.524 0.531 0.536 0.541 0.545 0.55 0.556 0.561 0.567 0.573 0.578 0.583 0.587 0.59 0.591 0.594 0.596 0.598 0.6 0.601 0.603 0.604
Veracruz de Ignacio de la Llave 0.461 0.463 0.467 0.472 0.477 0.48 0.485 0.492 0.5 0.509 0.517 0.523 0.529 0.534 0.54 0.546 0.551 0.557 0.563 0.567 0.571 0.574 0.578 0.581 0.584 0.587 0.59 0.592
Yucatán 0.497 0.502 0.508 0.516 0.524 0.531 0.54 0.548 0.556 0.562 0.569 0.575 0.581 0.587 0.592 0.596 0.599 0.602 0.605 0.608 0.61 0.613 0.617 0.62 0.623 0.626 0.628 0.63
Zacatecas 0.483 0.489 0.495 0.502 0.509 0.514 0.52 0.527 0.534 0.54 0.546 0.551 0.555 0.56 0.564 0.568 0.572 0.577 0.581 0.584 0.586 0.589 0.592 0.595 0.598 0.602 0.605 0.608
Nicaragua 0.357 0.363 0.368 0.374 0.381 0.389 0.397 0.406 0.415 0.424 0.432 0.439 0.446 0.453 0.46 0.466 0.47 0.475 0.481 0.486 0.492 0.499 0.504 0.509 0.514 0.52 0.525 0.53
Panama 0.542 0.546 0.55 0.555 0.56 0.565 0.569 0.573 0.578 0.583 0.589 0.595 0.6 0.604 0.608 0.611 0.614 0.618 0.622 0.626 0.63 0.635 0.641 0.648 0.656 0.664 0.671 0.677
Venezuela 0.528 0.536 0.553 0.559 0.566 0.578 0.587 0.592 0.591 0.587 0.591 0.602 0.602 0.588 0.576 0.579 0.594 0.61 0.621 0.625 0.629 0.633 0.64 0.646 0.648 0.651 0.654 0.655
Tropical Latin America 0.494 0.5 0.507 0.514 0.521 0.529 0.537 0.544 0.55 0.556 0.561 0.566 0.571 0.577 0.582 0.588 0.594 0.601 0.608 0.614 0.621 0.628 0.635 0.642 0.648 0.654 0.659 0.662
Brazil 0.494 0.501 0.508 0.515 0.522 0.53 0.537 0.545 0.551 0.556 0.562 0.567 0.572 0.577 0.583 0.589 0.595 0.602 0.608 0.615 0.622 0.629 0.636 0.643 0.649 0.655 0.66 0.663
Acre 0.376 0.386 0.395 0.405 0.415 0.424 0.435 0.445 0.453 0.46 0.466 0.472 0.479 0.485 0.492 0.5 0.508 0.517 0.527 0.536 0.546 0.556 0.565 0.575 0.583 0.591 0.597 0.602
Alagoas 0.355 0.363 0.371 0.379 0.387 0.395 0.404 0.412 0.419 0.425 0.431 0.436 0.442 0.448 0.455 0.462 0.47 0.478 0.487 0.496 0.505 0.514 0.523 0.531 0.539 0.546 0.552 0.556
Amapá 0.467 0.475 0.483 0.491 0.5 0.508 0.517 0.526 0.534 0.54 0.546 0.552 0.558 0.564 0.57 0.576 0.583 0.591 0.598 0.605 0.613 0.621 0.629 0.636 0.643 0.65 0.655 0.659
Amazonas 0.438 0.447 0.457 0.466 0.475 0.483 0.492 0.499 0.505 0.51 0.514 0.519 0.523 0.528 0.533 0.539 0.546 0.553 0.561 0.568 0.577 0.585 0.594 0.602 0.611 0.618 0.625 0.629
Bahia 0.402 0.41 0.419 0.427 0.435 0.443 0.451 0.459 0.465 0.47 0.475 0.48 0.485 0.491 0.496 0.503 0.51 0.518 0.526 0.534 0.542 0.551 0.559 0.567 0.575 0.582 0.587 0.591
Ceará 0.411 0.419 0.426 0.433 0.44 0.448 0.455 0.463 0.469 0.475 0.48 0.486 0.492 0.498 0.505 0.512 0.52 0.528 0.536 0.544 0.553 0.561 0.569 0.577 0.584 0.591 0.596 0.6
Distrito Federal 0.63 0.636 0.642 0.649 0.656 0.663 0.671 0.679 0.685 0.691 0.696 0.702 0.707 0.713 0.719 0.725 0.731 0.738 0.744 0.75 0.756 0.763 0.769 0.775 0.78 0.785 0.789 0.792
Espírito Santo 0.499 0.507 0.515 0.524 0.532 0.54 0.549 0.557 0.564 0.57 0.576 0.582 0.588 0.593 0.599 0.606 0.612 0.618 0.625 0.631 0.638 0.644 0.651 0.657 0.663 0.669 0.673 0.677
Goiás 0.46 0.468 0.476 0.484 0.493 0.501 0.51 0.518 0.526 0.532 0.538 0.545 0.551 0.558 0.564 0.571 0.579 0.586 0.594 0.601 0.608 0.616 0.623 0.63 0.636 0.642 0.647 0.65
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Appendix Table 10: Socio-Demographic Index values for all estimated GBD 2017 locations, 1990-2017
Maranhão 0.313 0.322 0.33 0.339 0.347 0.355 0.364 0.371 0.377 0.38 0.383 0.386 0.389 0.392 0.396 0.402 0.409 0.418 0.427 0.436 0.446 0.456 0.467 0.477 0.486 0.495 0.502 0.507
Mato Grosso 0.475 0.484 0.492 0.501 0.509 0.518 0.527 0.535 0.543 0.548 0.554 0.559 0.564 0.57 0.576 0.582 0.589 0.596 0.604 0.611 0.618 0.626 0.633 0.641 0.648 0.654 0.659 0.662
Mato Grosso do Sul 0.465 0.473 0.481 0.489 0.497 0.506 0.515 0.523 0.531 0.537 0.543 0.549 0.555 0.56 0.566 0.573 0.58 0.587 0.594 0.6 0.607 0.614 0.622 0.629 0.636 0.642 0.647 0.65
Minas Gerais 0.491 0.498 0.506 0.513 0.521 0.53 0.538 0.545 0.551 0.557 0.562 0.567 0.573 0.579 0.585 0.591 0.598 0.604 0.611 0.618 0.624 0.631 0.637 0.643 0.649 0.654 0.658 0.661
Pará 0.41 0.418 0.425 0.432 0.44 0.447 0.454 0.461 0.466 0.47 0.473 0.476 0.48 0.483 0.488 0.493 0.499 0.506 0.514 0.521 0.529 0.538 0.546 0.554 0.562 0.569 0.575 0.579
Paraíba 0.399 0.406 0.413 0.42 0.427 0.434 0.441 0.447 0.453 0.457 0.461 0.465 0.469 0.474 0.48 0.486 0.493 0.501 0.509 0.517 0.526 0.535 0.543 0.551 0.559 0.565 0.571 0.574
Paraná 0.513 0.519 0.525 0.532 0.539 0.548 0.556 0.564 0.572 0.578 0.585 0.591 0.597 0.603 0.609 0.615 0.622 0.628 0.634 0.64 0.646 0.652 0.658 0.664 0.67 0.675 0.679 0.682
Pernambuco 0.416 0.423 0.43 0.437 0.444 0.451 0.458 0.466 0.472 0.477 0.481 0.486 0.492 0.497 0.503 0.51 0.517 0.525 0.533 0.54 0.548 0.556 0.564 0.572 0.579 0.585 0.59 0.594
Piauí 0.365 0.372 0.379 0.386 0.393 0.4 0.408 0.415 0.42 0.425 0.429 0.434 0.439 0.444 0.45 0.457 0.465 0.473 0.482 0.491 0.5 0.51 0.518 0.527 0.535 0.542 0.548 0.552
Rio de Janeiro 0.576 0.581 0.585 0.59 0.595 0.601 0.608 0.614 0.619 0.624 0.628 0.632 0.637 0.641 0.645 0.65 0.655 0.66 0.665 0.67 0.675 0.681 0.686 0.692 0.697 0.702 0.706 0.709
Rio Grande do Norte 0.415 0.422 0.429 0.436 0.444 0.451 0.46 0.467 0.474 0.48 0.485 0.491 0.497 0.503 0.509 0.516 0.524 0.532 0.541 0.549 0.558 0.567 0.575 0.583 0.59 0.597 0.602 0.605
Rio Grande do Sul 0.543 0.549 0.555 0.561 0.567 0.574 0.581 0.587 0.593 0.598 0.603 0.608 0.614 0.619 0.624 0.63 0.635 0.641 0.647 0.653 0.659 0.665 0.67 0.676 0.681 0.686 0.69 0.693
Rondônia 0.423 0.433 0.441 0.45 0.458 0.467 0.475 0.484 0.491 0.497 0.502 0.508 0.515 0.521 0.528 0.535 0.543 0.551 0.559 0.567 0.575 0.584 0.592 0.599 0.606 0.613 0.618 0.622
Roraima 0.428 0.438 0.447 0.456 0.465 0.474 0.483 0.492 0.499 0.504 0.509 0.514 0.521 0.527 0.534 0.543 0.552 0.562 0.572 0.581 0.591 0.601 0.611 0.62 0.628 0.636 0.642 0.646
Santa Catarina 0.541 0.548 0.554 0.56 0.567 0.574 0.582 0.589 0.595 0.601 0.606 0.612 0.618 0.623 0.629 0.635 0.641 0.647 0.653 0.659 0.665 0.672 0.678 0.684 0.69 0.695 0.699 0.702
São Paulo 0.558 0.565 0.572 0.579 0.587 0.595 0.603 0.611 0.618 0.624 0.63 0.636 0.641 0.646 0.652 0.657 0.663 0.669 0.674 0.68 0.685 0.691 0.697 0.703 0.708 0.713 0.717 0.72
Sergipe 0.425 0.433 0.441 0.448 0.456 0.464 0.473 0.481 0.488 0.494 0.5 0.506 0.512 0.518 0.524 0.531 0.538 0.546 0.554 0.562 0.57 0.578 0.586 0.594 0.601 0.607 0.612 0.616
Tocantins 0.396 0.404 0.412 0.42 0.428 0.436 0.445 0.453 0.46 0.466 0.471 0.477 0.484 0.491 0.498 0.507 0.517 0.527 0.537 0.547 0.558 0.568 0.577 0.586 0.594 0.601 0.607 0.611
Paraguay 0.467 0.471 0.475 0.48 0.485 0.491 0.497 0.504 0.512 0.519 0.525 0.532 0.538 0.544 0.548 0.553 0.558 0.562 0.566 0.569 0.573 0.577 0.582 0.589 0.598 0.606 0.613 0.619
North Africa and Middle East 0.456 0.464 0.472 0.478 0.485 0.492 0.499 0.506 0.513 0.521 0.531 0.539 0.547 0.553 0.561 0.568 0.574 0.582 0.589 0.596 0.602 0.607 0.612 0.617 0.622 0.628 0.635 0.639
North Africa and Middle East 0.456 0.464 0.472 0.478 0.485 0.492 0.499 0.506 0.513 0.521 0.531 0.539 0.547 0.553 0.561 0.568 0.574 0.582 0.589 0.596 0.602 0.607 0.612 0.617 0.622 0.628 0.635 0.639
Afghanistan 0.149 0.15 0.151 0.152 0.151 0.151 0.152 0.152 0.154 0.155 0.157 0.159 0.164 0.171 0.177 0.184 0.191 0.199 0.208 0.218 0.228 0.238 0.248 0.258 0.267 0.276 0.284 0.29
Algeria 0.495 0.504 0.513 0.522 0.531 0.54 0.549 0.558 0.567 0.574 0.583 0.591 0.599 0.608 0.617 0.625 0.633 0.641 0.648 0.653 0.659 0.665 0.67 0.675 0.68 0.685 0.691 0.696
Bahrain 0.612 0.618 0.624 0.63 0.635 0.639 0.644 0.648 0.653 0.657 0.662 0.668 0.673 0.677 0.68 0.684 0.687 0.69 0.693 0.695 0.696 0.697 0.698 0.7 0.702 0.706 0.709 0.712
Egypt 0.441 0.451 0.461 0.47 0.477 0.485 0.493 0.5 0.507 0.514 0.52 0.526 0.532 0.537 0.542 0.547 0.55 0.553 0.556 0.559 0.563 0.565 0.564 0.566 0.572 0.584 0.596 0.604
Iran 0.503 0.513 0.522 0.532 0.541 0.548 0.553 0.556 0.56 0.572 0.589 0.604 0.616 0.626 0.634 0.641 0.649 0.656 0.662 0.667 0.672 0.677 0.68 0.683 0.687 0.691 0.696 0.7
Iraq 0.433 0.433 0.437 0.441 0.444 0.446 0.45 0.455 0.463 0.473 0.481 0.488 0.494 0.496 0.502 0.507 0.512 0.517 0.522 0.528 0.535 0.542 0.551 0.559 0.566 0.572 0.58 0.585
Jordan 0.552 0.556 0.561 0.566 0.57 0.574 0.578 0.584 0.589 0.594 0.597 0.6 0.603 0.607 0.612 0.616 0.621 0.626 0.633 0.643 0.653 0.662 0.671 0.679 0.685 0.69 0.694 0.697
Kuwait 0.656 0.651 0.642 0.637 0.633 0.632 0.638 0.651 0.665 0.674 0.681 0.683 0.685 0.687 0.693 0.701 0.711 0.721 0.73 0.737 0.743 0.748 0.754 0.762 0.769 0.776 0.781 0.786
Lebanon 0.519 0.528 0.536 0.544 0.552 0.56 0.569 0.578 0.588 0.597 0.604 0.611 0.618 0.626 0.635 0.643 0.65 0.658 0.667 0.676 0.686 0.694 0.702 0.711 0.717 0.722 0.726 0.73
Libya 0.645 0.657 0.669 0.679 0.688 0.696 0.705 0.713 0.72 0.725 0.729 0.732 0.736 0.742 0.747 0.753 0.759 0.765 0.771 0.777 0.783 0.781 0.784 0.783 0.779 0.773 0.766 0.761
Morocco 0.389 0.397 0.404 0.411 0.419 0.426 0.434 0.442 0.449 0.456 0.463 0.47 0.477 0.484 0.49 0.496 0.503 0.51 0.517 0.525 0.532 0.54 0.547 0.554 0.561 0.567 0.574 0.579
Palestine 0.362 0.366 0.371 0.377 0.384 0.39 0.397 0.405 0.413 0.421 0.427 0.431 0.433 0.435 0.439 0.444 0.448 0.453 0.46 0.468 0.479 0.491 0.503 0.513 0.521 0.528 0.536 0.541
Oman 0.473 0.485 0.497 0.509 0.521 0.533 0.546 0.558 0.57 0.582 0.594 0.606 0.618 0.629 0.639 0.649 0.659 0.668 0.678 0.686 0.695 0.703 0.711 0.72 0.727 0.734 0.739 0.744
Qatar 0.603 0.615 0.626 0.637 0.647 0.656 0.665 0.674 0.681 0.688 0.695 0.701 0.706 0.712 0.717 0.721 0.725 0.728 0.731 0.735 0.738 0.743 0.747 0.751 0.755 0.759 0.762 0.766
Saudi Arabia 0.436 0.457 0.477 0.496 0.514 0.53 0.545 0.56 0.573 0.586 0.598 0.61 0.621 0.633 0.645 0.658 0.67 0.682 0.695 0.706 0.716 0.728 0.738 0.748 0.757 0.765 0.773 0.779
Sudan 0.221 0.228 0.236 0.244 0.252 0.26 0.267 0.275 0.283 0.291 0.3 0.308 0.317 0.326 0.336 0.346 0.357 0.367 0.378 0.389 0.401 0.414 0.425 0.437 0.448 0.46 0.47 0.478
Syria 0.389 0.394 0.401 0.409 0.419 0.429 0.439 0.448 0.458 0.466 0.474 0.481 0.489 0.496 0.506 0.518 0.527 0.536 0.545 0.556 0.566 0.576 0.584 0.589 0.595 0.601 0.606 0.611
Tunisia 0.453 0.463 0.473 0.482 0.491 0.501 0.511 0.521 0.532 0.543 0.553 0.563 0.572 0.582 0.592 0.6 0.609 0.617 0.625 0.632 0.639 0.645 0.65 0.656 0.661 0.666 0.671 0.675
Turkey 0.507 0.516 0.524 0.533 0.54 0.548 0.556 0.564 0.572 0.579 0.587 0.594 0.601 0.608 0.616 0.625 0.633 0.643 0.652 0.66 0.669 0.678 0.688 0.697 0.706 0.715 0.723 0.729
United Arab Emirates 0.621 0.637 0.651 0.663 0.675 0.686 0.696 0.707 0.716 0.726 0.734 0.742 0.749 0.755 0.76 0.765 0.77 0.776 0.781 0.784 0.788 0.79 0.791 0.793 0.791 0.794 0.794 0.795
Yemen 0.203 0.208 0.214 0.22 0.228 0.238 0.247 0.256 0.266 0.275 0.284 0.294 0.304 0.313 0.324 0.336 0.349 0.362 0.373 0.382 0.393 0.401 0.408 0.415 0.422 0.426 0.429 0.43
South Asia 0.312 0.317 0.324 0.331 0.338 0.345 0.352 0.358 0.363 0.371 0.38 0.388 0.395 0.403 0.412 0.421 0.43 0.438 0.446 0.455 0.462 0.468 0.476 0.489 0.504 0.517 0.526 0.534
South Asia 0.312 0.317 0.324 0.331 0.338 0.345 0.352 0.358 0.363 0.371 0.38 0.388 0.395 0.403 0.412 0.421 0.43 0.438 0.446 0.455 0.462 0.468 0.476 0.489 0.504 0.517 0.526 0.534
Bangladesh 0.256 0.264 0.272 0.281 0.289 0.298 0.306 0.314 0.322 0.329 0.335 0.34 0.345 0.35 0.356 0.362 0.369 0.377 0.385 0.393 0.401 0.41 0.418 0.427 0.435 0.443 0.451 0.458
Bhutan 0.324 0.333 0.343 0.352 0.362 0.372 0.382 0.392 0.402 0.412 0.422 0.432 0.442 0.452 0.461 0.47 0.479 0.489 0.498 0.507 0.516 0.525 0.534 0.542 0.549 0.557 0.564 0.57
India 0.32 0.324 0.331 0.339 0.346 0.353 0.36 0.365 0.37 0.378 0.387 0.395 0.403 0.412 0.422 0.431 0.44 0.448 0.457 0.465 0.472 0.477 0.485 0.5 0.517 0.532 0.542 0.55
Andhra Pradesh 0.28 0.286 0.294 0.303 0.312 0.322 0.331 0.337 0.344 0.352 0.363 0.374 0.384 0.395 0.406 0.415 0.424 0.434 0.442 0.451 0.459 0.466 0.473 0.487 0.503 0.517 0.528 0.536
Arunachal Pradesh 0.311 0.317 0.323 0.33 0.336 0.345 0.354 0.36 0.366 0.374 0.381 0.388 0.395 0.405 0.416 0.424 0.432 0.44 0.447 0.458 0.467 0.473 0.479 0.498 0.52 0.536 0.548 0.556
Assam 0.327 0.332 0.339 0.345 0.351 0.358 0.363 0.367 0.371 0.379 0.389 0.397 0.406 0.415 0.424 0.431 0.439 0.446 0.453 0.459 0.464 0.467 0.472 0.485 0.5 0.513 0.523 0.53
Bihar 0.29 0.293 0.297 0.298 0.298 0.298 0.298 0.297 0.292 0.291 0.292 0.294 0.296 0.299 0.303 0.308 0.316 0.324 0.334 0.342 0.349 0.355 0.365 0.382 0.4 0.414 0.425 0.433
Chhattisgarh 0.292 0.294 0.298 0.303 0.306 0.311 0.316 0.319 0.322 0.328 0.336 0.344 0.352 0.362 0.372 0.382 0.392 0.403 0.413 0.421 0.427 0.431 0.438 0.455 0.474 0.49 0.503 0.512
Delhi 0.486 0.493 0.504 0.516 0.522 0.526 0.531 0.535 0.537 0.545 0.555 0.565 0.575 0.584 0.593 0.602 0.612 0.62 0.628 0.637 0.644 0.649 0.656 0.67 0.686 0.7 0.709 0.715
Goa 0.499 0.505 0.512 0.519 0.526 0.534 0.542 0.55 0.56 0.571 0.58 0.588 0.597 0.606 0.616 0.626 0.634 0.643 0.655 0.665 0.674 0.683 0.691 0.702 0.714 0.724 0.733 0.74
Gujarat 0.35 0.353 0.361 0.37 0.379 0.388 0.396 0.402 0.409 0.418 0.426 0.433 0.438 0.447 0.457 0.469 0.478 0.487 0.496 0.506 0.515 0.521 0.528 0.541 0.556 0.569 0.577 0.584
Haryana 0.342 0.348 0.356 0.364 0.372 0.38 0.388 0.394 0.398 0.405 0.414 0.423 0.431 0.44 0.451 0.462 0.472 0.481 0.491 0.5 0.508 0.512 0.521 0.54 0.564 0.582 0.593 0.6
Himachal Pradesh 0.34 0.347 0.356 0.366 0.376 0.386 0.397 0.408 0.418 0.431 0.445 0.457 0.468 0.479 0.491 0.502 0.513 0.524 0.534 0.544 0.553 0.562 0.571 0.585 0.601 0.614 0.625 0.633
Jammu and Kashmir 0.334 0.337 0.341 0.349 0.356 0.363 0.37 0.38 0.389 0.402 0.417 0.43 0.442 0.454 0.466 0.476 0.485 0.493 0.503 0.511 0.519 0.527 0.535 0.547 0.562 0.574 0.582 0.59
Jharkhand 0.281 0.283 0.286 0.29 0.293 0.297 0.3 0.304 0.307 0.312 0.319 0.325 0.333 0.342 0.353 0.362 0.371 0.38 0.388 0.397 0.405 0.411 0.419 0.434 0.451 0.466 0.478 0.487
Karnataka 0.323 0.331 0.339 0.349 0.357 0.366 0.375 0.38 0.386 0.396 0.406 0.415 0.424 0.434 0.444 0.454 0.463 0.472 0.481 0.49 0.498 0.504 0.512 0.526 0.542 0.556 0.566 0.574
Kerala 0.404 0.408 0.418 0.429 0.438 0.447 0.456 0.463 0.472 0.483 0.496 0.506 0.515 0.525 0.536 0.548 0.557 0.565 0.574 0.581 0.587 0.592 0.599 0.612 0.629 0.642 0.652 0.659
Madhya Pradesh 0.284 0.288 0.293 0.299 0.303 0.309 0.315 0.317 0.319 0.326 0.334 0.342 0.348 0.355 0.363 0.369 0.373 0.378 0.384 0.39 0.394 0.398 0.406 0.425 0.447 0.465 0.477 0.487
Maharashtra 0.363 0.369 0.379 0.39 0.399 0.41 0.419 0.426 0.431 0.44 0.451 0.459 0.468 0.478 0.489 0.5 0.51 0.52 0.529 0.538 0.546 0.552 0.559 0.572 0.588 0.602 0.611 0.618
Manipur 0.381 0.387 0.393 0.4 0.405 0.411 0.417 0.421 0.427 0.436 0.445 0.454 0.461 0.469 0.479 0.49 0.498 0.505 0.512 0.52 0.526 0.532 0.539 0.549 0.561 0.572 0.582 0.59
Meghalaya 0.334 0.339 0.345 0.352 0.357 0.364 0.37 0.376 0.382 0.39 0.401 0.411 0.42 0.43 0.441 0.45 0.46 0.469 0.478 0.487 0.495 0.501 0.507 0.52 0.534 0.547 0.557 0.565
Mizoram 0.392 0.399 0.408 0.417 0.424 0.433 0.443 0.449 0.456 0.465 0.475 0.483 0.492 0.502 0.511 0.52 0.526 0.531 0.537 0.545 0.55 0.552 0.557 0.57 0.587 0.6 0.609 0.616
Nagaland 0.395 0.399 0.406 0.414 0.421 0.429 0.435 0.441 0.445 0.452 0.462 0.472 0.482 0.492 0.503 0.513 0.522 0.532 0.543 0.552 0.56 0.567 0.574 0.587 0.602 0.614 0.625 0.633
Odisha 0.283 0.287 0.292 0.299 0.305 0.314 0.32 0.325 0.331 0.34 0.349 0.357 0.364 0.373 0.384 0.393 0.404 0.415 0.425 0.434 0.441 0.447 0.456 0.472 0.49 0.504 0.515 0.524
Punjab 0.383 0.388 0.396 0.404 0.413 0.422 0.429 0.435 0.441 0.449 0.459 0.468 0.475 0.483 0.492 0.501 0.511 0.52 0.53 0.539 0.547 0.554 0.563 0.576 0.592 0.605 0.614 0.622
372
Location 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Appendix Table 10: Socio-Demographic Index values for all estimated GBD 2017 locations, 1990-2017
Rajasthan 0.263 0.268 0.274 0.28 0.287 0.295 0.303 0.309 0.314 0.322 0.332 0.342 0.349 0.359 0.369 0.377 0.385 0.391 0.398 0.404 0.41 0.415 0.421 0.438 0.458 0.473 0.484 0.492
Sikkim 0.343 0.349 0.355 0.362 0.368 0.375 0.382 0.388 0.395 0.403 0.413 0.421 0.431 0.442 0.453 0.463 0.473 0.482 0.492 0.512 0.528 0.541 0.555 0.574 0.593 0.608 0.619 0.628
Tamil Nadu 0.35 0.354 0.363 0.373 0.383 0.391 0.399 0.406 0.414 0.424 0.436 0.446 0.455 0.465 0.475 0.486 0.497 0.506 0.514 0.522 0.529 0.535 0.543 0.559 0.579 0.595 0.607 0.615
Telangana 0.288 0.294 0.3 0.307 0.315 0.323 0.331 0.337 0.344 0.352 0.363 0.373 0.383 0.395 0.407 0.418 0.429 0.441 0.454 0.465 0.478 0.488 0.5 0.517 0.536 0.552 0.565 0.575
Tripura 0.333 0.336 0.34 0.346 0.35 0.356 0.363 0.368 0.373 0.385 0.398 0.409 0.419 0.43 0.44 0.449 0.457 0.462 0.469 0.476 0.48 0.483 0.488 0.5 0.515 0.527 0.536 0.543
Uttar Pradesh 0.272 0.276 0.281 0.286 0.291 0.297 0.303 0.307 0.31 0.317 0.325 0.333 0.34 0.348 0.358 0.366 0.374 0.382 0.39 0.398 0.404 0.41 0.419 0.436 0.454 0.469 0.48 0.488
Uttarakhand 0.304 0.306 0.31 0.315 0.321 0.329 0.336 0.341 0.347 0.355 0.367 0.378 0.391 0.405 0.42 0.434 0.449 0.463 0.478 0.494 0.509 0.522 0.535 0.552 0.57 0.586 0.598 0.607
West Bengal 0.321 0.322 0.329 0.338 0.345 0.353 0.36 0.366 0.371 0.38 0.389 0.398 0.406 0.416 0.425 0.434 0.441 0.448 0.455 0.462 0.467 0.471 0.476 0.49 0.506 0.519 0.53 0.538
Union Territories other than Delhi 0.406 0.408 0.412 0.417 0.423 0.43 0.439 0.446 0.453 0.463 0.474 0.486 0.498 0.511 0.524 0.537 0.548 0.559 0.569 0.579 0.586 0.591 0.597 0.61 0.624 0.636 0.646 0.653
Nepal 0.216 0.222 0.228 0.235 0.242 0.249 0.257 0.265 0.273 0.281 0.29 0.298 0.307 0.315 0.323 0.331 0.339 0.347 0.355 0.364 0.373 0.382 0.39 0.399 0.407 0.415 0.422 0.429
Pakistan 0.305 0.31 0.314 0.319 0.324 0.33 0.337 0.343 0.35 0.359 0.367 0.375 0.382 0.389 0.396 0.404 0.412 0.42 0.428 0.436 0.443 0.449 0.458 0.466 0.474 0.48 0.486 0.492
Southeast Asia, East Asia, and Oceania 0.468 0.479 0.489 0.498 0.506 0.517 0.528 0.538 0.546 0.553 0.561 0.568 0.574 0.58 0.588 0.596 0.606 0.615 0.624 0.632 0.641 0.649 0.656 0.662 0.67 0.673 0.675 0.685
East Asia 0.463 0.476 0.486 0.495 0.504 0.516 0.528 0.54 0.55 0.559 0.568 0.577 0.584 0.591 0.599 0.61 0.621 0.632 0.642 0.652 0.663 0.672 0.679 0.685 0.694 0.696 0.696 0.709
China 0.456 0.469 0.479 0.489 0.498 0.51 0.523 0.535 0.545 0.554 0.563 0.573 0.58 0.587 0.595 0.606 0.618 0.63 0.64 0.65 0.661 0.671 0.678 0.683 0.693 0.695 0.694 0.707
North Korea 0.512 0.517 0.52 0.524 0.524 0.522 0.519 0.515 0.51 0.506 0.503 0.5 0.498 0.498 0.499 0.501 0.503 0.506 0.508 0.511 0.514 0.517 0.52 0.524 0.527 0.531 0.535 0.538
Taiwan (Province of China) 0.691 0.7 0.708 0.715 0.723 0.731 0.739 0.75 0.759 0.764 0.77 0.778 0.786 0.793 0.8 0.807 0.813 0.821 0.827 0.833 0.838 0.842 0.846 0.85 0.854 0.858 0.861 0.864
Oceania 0.406 0.408 0.41 0.412 0.415 0.418 0.421 0.423 0.426 0.428 0.43 0.431 0.432 0.433 0.435 0.436 0.438 0.44 0.442 0.444 0.446 0.449 0.452 0.455 0.459 0.463 0.467 0.471
American Samoa 0.609 0.612 0.615 0.62 0.624 0.629 0.633 0.636 0.639 0.643 0.647 0.651 0.655 0.659 0.662 0.666 0.668 0.671 0.673 0.675 0.678 0.682 0.687 0.691 0.694 0.697 0.7 0.702
Federated States of Micronesia 0.462 0.469 0.476 0.483 0.489 0.496 0.501 0.505 0.509 0.514 0.518 0.523 0.527 0.532 0.536 0.54 0.543 0.547 0.549 0.552 0.555 0.559 0.562 0.565 0.567 0.57 0.573 0.575
Fiji 0.533 0.537 0.542 0.547 0.552 0.558 0.563 0.568 0.574 0.58 0.585 0.589 0.594 0.598 0.602 0.604 0.607 0.61 0.611 0.613 0.615 0.617 0.619 0.623 0.627 0.632 0.637 0.641
Guam 0.698 0.695 0.693 0.694 0.698 0.703 0.709 0.717 0.727 0.739 0.75 0.759 0.765 0.768 0.77 0.77 0.769 0.77 0.771 0.774 0.776 0.78 0.784 0.788 0.792 0.794 0.794 0.794
Kiribati 0.355 0.357 0.359 0.361 0.363 0.365 0.368 0.37 0.373 0.376 0.379 0.382 0.385 0.388 0.39 0.393 0.395 0.397 0.398 0.399 0.401 0.403 0.406 0.41 0.414 0.418 0.423 0.427
Marshall Islands 0.413 0.421 0.429 0.436 0.444 0.451 0.457 0.462 0.465 0.469 0.473 0.477 0.482 0.485 0.489 0.493 0.498 0.503 0.507 0.512 0.518 0.523 0.528 0.533 0.538 0.542 0.547 0.55
Northern Mariana Islands 0.738 0.744 0.748 0.75 0.752 0.754 0.756 0.757 0.758 0.759 0.763 0.766 0.767 0.767 0.767 0.766 0.765 0.764 0.763 0.761 0.759 0.758 0.757 0.756 0.756 0.756 0.757 0.758
Papua New Guinea 0.318 0.321 0.324 0.33 0.335 0.34 0.344 0.348 0.351 0.354 0.356 0.358 0.36 0.361 0.363 0.365 0.368 0.371 0.375 0.379 0.383 0.388 0.393 0.398 0.404 0.409 0.415 0.419
Samoa 0.538 0.539 0.538 0.536 0.535 0.536 0.536 0.537 0.538 0.54 0.542 0.544 0.546 0.548 0.55 0.552 0.554 0.556 0.558 0.559 0.561 0.563 0.56 0.558 0.562 0.567 0.572 0.576
Solomon Islands 0.316 0.32 0.326 0.331 0.337 0.344 0.35 0.355 0.36 0.364 0.365 0.366 0.366 0.366 0.367 0.369 0.371 0.375 0.38 0.384 0.388 0.394 0.4 0.406 0.411 0.416 0.421 0.425
Tonga 0.522 0.528 0.533 0.538 0.544 0.549 0.553 0.557 0.56 0.564 0.566 0.569 0.573 0.577 0.581 0.584 0.587 0.589 0.592 0.595 0.599 0.603 0.607 0.61 0.614 0.617 0.621 0.625
Vanuatu 0.38 0.384 0.388 0.391 0.395 0.398 0.402 0.406 0.409 0.413 0.416 0.419 0.421 0.423 0.425 0.428 0.431 0.435 0.44 0.445 0.449 0.453 0.458 0.462 0.465 0.469 0.472 0.475
Southeast Asia 0.467 0.477 0.486 0.495 0.504 0.513 0.521 0.529 0.534 0.538 0.543 0.548 0.552 0.557 0.562 0.567 0.572 0.578 0.584 0.589 0.595 0.602 0.609 0.616 0.622 0.629 0.635 0.641
Cambodia 0.259 0.266 0.273 0.279 0.286 0.294 0.302 0.31 0.317 0.326 0.335 0.344 0.353 0.362 0.372 0.382 0.392 0.401 0.411 0.42 0.427 0.435 0.443 0.451 0.459 0.467 0.475 0.482
Indonesia 0.465 0.476 0.487 0.499 0.51 0.52 0.53 0.537 0.542 0.546 0.55 0.554 0.558 0.562 0.566 0.571 0.576 0.581 0.587 0.594 0.6 0.608 0.615 0.622 0.629 0.636 0.642 0.648
Laos 0.307 0.313 0.32 0.326 0.332 0.339 0.345 0.352 0.358 0.364 0.371 0.378 0.385 0.392 0.4 0.407 0.416 0.425 0.434 0.444 0.453 0.463 0.473 0.483 0.493 0.502 0.511 0.519
Malaysia 0.57 0.575 0.581 0.589 0.598 0.606 0.616 0.626 0.638 0.654 0.661 0.664 0.671 0.679 0.684 0.689 0.697 0.704 0.709 0.714 0.721 0.727 0.733 0.739 0.744 0.749 0.754 0.759
Maldives 0.386 0.399 0.412 0.424 0.435 0.446 0.46 0.477 0.493 0.507 0.518 0.528 0.537 0.545 0.554 0.56 0.567 0.575 0.584 0.593 0.602 0.611 0.62 0.629 0.636 0.643 0.65 0.655
Mauritius 0.554 0.561 0.568 0.576 0.585 0.595 0.603 0.609 0.613 0.616 0.621 0.627 0.633 0.639 0.646 0.651 0.657 0.663 0.669 0.675 0.68 0.687 0.694 0.701 0.708 0.713 0.717 0.72
Myanmar 0.33 0.333 0.337 0.341 0.347 0.353 0.36 0.367 0.375 0.383 0.392 0.402 0.412 0.423 0.434 0.446 0.458 0.47 0.481 0.492 0.501 0.51 0.518 0.527 0.535 0.542 0.549 0.556
Philippines 0.511 0.516 0.521 0.525 0.53 0.534 0.539 0.542 0.545 0.547 0.55 0.553 0.555 0.557 0.559 0.561 0.563 0.566 0.568 0.569 0.572 0.579 0.586 0.593 0.599 0.605 0.612 0.617
Sri Lanka 0.49 0.495 0.501 0.508 0.516 0.524 0.532 0.54 0.547 0.553 0.559 0.565 0.571 0.578 0.584 0.59 0.597 0.604 0.611 0.618 0.626 0.634 0.642 0.65 0.658 0.666 0.673 0.68
Seychelles 0.549 0.557 0.565 0.573 0.582 0.589 0.597 0.605 0.613 0.62 0.626 0.631 0.636 0.64 0.643 0.646 0.65 0.653 0.656 0.658 0.66 0.663 0.667 0.671 0.675 0.68 0.686 0.692
Thailand 0.502 0.514 0.525 0.534 0.542 0.552 0.561 0.567 0.569 0.572 0.579 0.587 0.594 0.6 0.605 0.61 0.616 0.623 0.629 0.635 0.641 0.647 0.654 0.66 0.667 0.673 0.679 0.684
Timor-Leste 0.276 0.283 0.29 0.296 0.302 0.307 0.314 0.321 0.325 0.321 0.32 0.325 0.332 0.345 0.362 0.379 0.4 0.419 0.437 0.449 0.46 0.471 0.481 0.49 0.495 0.5 0.504 0.505
Vietnam 0.406 0.413 0.42 0.427 0.435 0.444 0.452 0.461 0.469 0.477 0.483 0.49 0.497 0.504 0.511 0.518 0.525 0.532 0.54 0.547 0.554 0.562 0.57 0.578 0.585 0.593 0.6 0.607
Sub-Saharan Africa 0.304 0.307 0.311 0.314 0.317 0.32 0.324 0.328 0.332 0.335 0.339 0.343 0.348 0.353 0.359 0.365 0.371 0.379 0.386 0.393 0.4 0.407 0.414 0.421 0.428 0.435 0.441 0.446
Central sub-Saharan Africa 0.298 0.303 0.307 0.309 0.311 0.313 0.316 0.318 0.32 0.323 0.325 0.328 0.332 0.336 0.341 0.348 0.355 0.364 0.373 0.382 0.391 0.402 0.413 0.423 0.433 0.443 0.452 0.457
Angola 0.235 0.24 0.245 0.249 0.253 0.258 0.263 0.269 0.276 0.282 0.288 0.293 0.299 0.305 0.312 0.32 0.329 0.34 0.351 0.363 0.375 0.389 0.401 0.414 0.428 0.441 0.453 0.461
Central African Republic 0.22 0.225 0.228 0.232 0.236 0.24 0.242 0.245 0.249 0.254 0.257 0.261 0.265 0.268 0.271 0.275 0.28 0.285 0.29 0.296 0.304 0.313 0.323 0.325 0.328 0.33 0.333 0.334
Congo (Brazzaville) 0.382 0.39 0.398 0.405 0.41 0.416 0.421 0.426 0.43 0.434 0.439 0.444 0.449 0.455 0.46 0.467 0.475 0.482 0.49 0.499 0.509 0.52 0.531 0.542 0.552 0.561 0.569 0.574
DR Congo 0.293 0.296 0.298 0.298 0.296 0.294 0.291 0.288 0.283 0.279 0.274 0.269 0.265 0.263 0.262 0.264 0.264 0.265 0.267 0.27 0.278 0.288 0.3 0.315 0.33 0.344 0.356 0.364
Equatorial Guinea 0.2 0.204 0.212 0.22 0.229 0.241 0.26 0.292 0.316 0.339 0.363 0.388 0.41 0.429 0.449 0.467 0.483 0.499 0.516 0.53 0.544 0.559 0.573 0.587 0.599 0.61 0.62 0.625
Gabon 0.433 0.443 0.453 0.462 0.472 0.481 0.49 0.498 0.506 0.514 0.522 0.529 0.535 0.542 0.549 0.556 0.562 0.569 0.576 0.582 0.589 0.598 0.607 0.616 0.625 0.634 0.644 0.651
Eastern sub-Saharan Africa 0.23 0.233 0.236 0.239 0.241 0.245 0.249 0.254 0.259 0.262 0.266 0.271 0.276 0.282 0.288 0.294 0.301 0.308 0.316 0.324 0.332 0.34 0.348 0.356 0.365 0.373 0.381 0.387
Burundi 0.247 0.252 0.257 0.258 0.263 0.265 0.265 0.266 0.268 0.268 0.268 0.267 0.268 0.269 0.271 0.272 0.274 0.276 0.278 0.282 0.286 0.29 0.295 0.299 0.303 0.306 0.308 0.31
Comoros 0.272 0.279 0.286 0.293 0.298 0.303 0.306 0.31 0.314 0.319 0.325 0.331 0.338 0.344 0.351 0.358 0.365 0.372 0.378 0.384 0.39 0.396 0.403 0.41 0.417 0.423 0.429 0.434
Djibouti 0.313 0.317 0.32 0.322 0.325 0.329 0.333 0.337 0.339 0.341 0.342 0.347 0.359 0.374 0.388 0.4 0.407 0.412 0.419 0.425 0.432 0.439 0.446 0.454 0.462 0.47 0.478 0.485
Eritrea 0.202 0.214 0.223 0.234 0.247 0.26 0.272 0.285 0.296 0.306 0.315 0.323 0.331 0.337 0.343 0.348 0.353 0.357 0.36 0.364 0.368 0.372 0.378 0.383 0.39 0.396 0.403 0.409
Ethiopia 0.138 0.141 0.143 0.146 0.148 0.15 0.155 0.161 0.166 0.169 0.172 0.177 0.183 0.189 0.195 0.202 0.21 0.221 0.233 0.245 0.257 0.268 0.28 0.292 0.303 0.314 0.325 0.334
Kenya 0.341 0.349 0.357 0.364 0.372 0.377 0.382 0.387 0.392 0.398 0.401 0.403 0.406 0.411 0.416 0.42 0.425 0.432 0.438 0.445 0.452 0.459 0.465 0.473 0.481 0.488 0.494 0.499
Baringo 0.254 0.266 0.278 0.289 0.299 0.307 0.313 0.319 0.326 0.333 0.338 0.341 0.345 0.352 0.358 0.362 0.368 0.376 0.384 0.393 0.401 0.408 0.414 0.421 0.428 0.434 0.439 0.444
Bomet 0.306 0.315 0.325 0.333 0.341 0.347 0.351 0.355 0.361 0.367 0.371 0.373 0.378 0.385 0.392 0.398 0.406 0.414 0.423 0.433 0.442 0.449 0.456 0.465 0.475 0.483 0.49 0.496
Bungoma 0.316 0.325 0.333 0.341 0.348 0.353 0.357 0.36 0.365 0.37 0.373 0.373 0.376 0.38 0.384 0.387 0.391 0.397 0.403 0.41 0.417 0.423 0.429 0.436 0.445 0.451 0.458 0.463
Busia 0.297 0.304 0.312 0.32 0.327 0.332 0.336 0.339 0.344 0.349 0.352 0.353 0.356 0.361 0.367 0.37 0.375 0.381 0.386 0.393 0.4 0.404 0.409 0.415 0.423 0.428 0.434 0.438
Elgeyo Marakwet 0.292 0.302 0.312 0.321 0.329 0.336 0.342 0.348 0.355 0.362 0.368 0.372 0.378 0.386 0.394 0.4 0.408 0.417 0.425 0.435 0.443 0.451 0.458 0.467 0.475 0.483 0.49 0.496
Embu 0.375 0.384 0.393 0.4 0.407 0.413 0.417 0.422 0.427 0.431 0.434 0.437 0.44 0.444 0.449 0.452 0.458 0.464 0.47 0.478 0.486 0.493 0.499 0.507 0.514 0.521 0.527 0.533
Garissa 0.153 0.16 0.168 0.177 0.184 0.19 0.195 0.201 0.207 0.213 0.217 0.219 0.223 0.228 0.233 0.237 0.242 0.249 0.255 0.263 0.272 0.28 0.288 0.298 0.309 0.318 0.326 0.334
Homa Bay 0.214 0.222 0.232 0.243 0.253 0.26 0.265 0.271 0.279 0.288 0.292 0.293 0.297 0.305 0.313 0.319 0.328 0.338 0.346 0.356 0.366 0.374 0.382 0.392 0.403 0.411 0.419 0.425
Isiolo 0.264 0.27 0.276 0.282 0.288 0.292 0.295 0.298 0.301 0.305 0.307 0.308 0.31 0.314 0.318 0.321 0.326 0.331 0.337 0.343 0.35 0.355 0.36 0.365 0.372 0.377 0.381 0.385
Kajiado 0.384 0.392 0.4 0.407 0.414 0.42 0.425 0.429 0.434 0.438 0.442 0.445 0.448 0.452 0.456 0.46 0.464 0.47 0.475 0.481 0.486 0.492 0.498 0.506 0.514 0.521 0.528 0.534
Kakamega 0.295 0.303 0.311 0.319 0.326 0.332 0.337 0.342 0.348 0.356 0.36 0.361 0.365 0.37 0.375 0.378 0.383 0.389 0.394 0.4 0.407 0.412 0.417 0.425 0.433 0.439 0.445 0.45
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Kericho 0.266 0.277 0.288 0.299 0.309 0.317 0.324 0.331 0.339 0.348 0.353 0.356 0.362 0.37 0.378 0.385 0.394 0.404 0.414 0.425 0.436 0.445 0.454 0.464 0.475 0.485 0.493 0.5
Kiambu 0.435 0.443 0.45 0.457 0.464 0.469 0.473 0.476 0.48 0.484 0.487 0.489 0.492 0.496 0.5 0.504 0.509 0.516 0.521 0.528 0.535 0.541 0.548 0.555 0.562 0.569 0.575 0.58
Kilifi 0.292 0.3 0.307 0.314 0.321 0.327 0.331 0.336 0.34 0.346 0.348 0.349 0.352 0.357 0.361 0.365 0.371 0.378 0.385 0.392 0.4 0.408 0.415 0.424 0.434 0.442 0.45 0.456
Kirinyaga 0.389 0.396 0.402 0.407 0.411 0.415 0.418 0.422 0.425 0.429 0.432 0.434 0.437 0.442 0.447 0.451 0.457 0.464 0.471 0.479 0.486 0.493 0.5 0.507 0.514 0.521 0.527 0.533
Kisii 0.34 0.35 0.36 0.368 0.377 0.383 0.389 0.395 0.401 0.407 0.411 0.414 0.418 0.424 0.429 0.434 0.44 0.448 0.454 0.463 0.471 0.479 0.486 0.495 0.503 0.51 0.517 0.522
Kisumu 0.315 0.325 0.334 0.342 0.349 0.355 0.36 0.364 0.37 0.376 0.381 0.384 0.388 0.395 0.402 0.407 0.415 0.424 0.432 0.442 0.451 0.459 0.466 0.475 0.484 0.491 0.497 0.503
Kitui 0.28 0.288 0.297 0.304 0.311 0.317 0.322 0.327 0.332 0.338 0.343 0.346 0.351 0.357 0.363 0.369 0.376 0.383 0.391 0.399 0.408 0.416 0.423 0.432 0.44 0.448 0.455 0.461
Kwale 0.294 0.301 0.308 0.314 0.321 0.326 0.33 0.334 0.338 0.342 0.344 0.346 0.348 0.352 0.357 0.36 0.366 0.374 0.381 0.39 0.399 0.407 0.414 0.424 0.433 0.442 0.45 0.457
Laikipia 0.346 0.354 0.361 0.368 0.375 0.38 0.385 0.389 0.395 0.401 0.405 0.409 0.415 0.423 0.433 0.442 0.451 0.462 0.472 0.483 0.494 0.502 0.511 0.521 0.531 0.54 0.549 0.556
Lamu 0.295 0.303 0.312 0.321 0.328 0.334 0.338 0.343 0.347 0.352 0.355 0.356 0.359 0.364 0.369 0.373 0.378 0.384 0.39 0.397 0.405 0.411 0.417 0.425 0.434 0.441 0.448 0.453
Machakos 0.352 0.362 0.372 0.38 0.389 0.396 0.403 0.411 0.418 0.426 0.431 0.435 0.44 0.444 0.449 0.452 0.456 0.461 0.465 0.471 0.476 0.482 0.487 0.493 0.5 0.507 0.512 0.518
Makueni 0.3 0.307 0.314 0.322 0.328 0.333 0.336 0.339 0.343 0.348 0.35 0.351 0.354 0.36 0.367 0.373 0.381 0.391 0.401 0.413 0.423 0.432 0.439 0.447 0.454 0.46 0.465 0.469
Mandera 0.102 0.109 0.118 0.126 0.135 0.142 0.149 0.156 0.164 0.172 0.178 0.181 0.187 0.194 0.201 0.206 0.212 0.218 0.224 0.231 0.238 0.244 0.251 0.261 0.271 0.28 0.288 0.295
Marsabit 0.22 0.223 0.227 0.231 0.236 0.239 0.241 0.244 0.247 0.252 0.255 0.256 0.259 0.264 0.268 0.271 0.276 0.281 0.286 0.293 0.299 0.304 0.309 0.315 0.323 0.329 0.335 0.34
Meru 0.338 0.346 0.354 0.362 0.369 0.376 0.381 0.387 0.393 0.399 0.403 0.407 0.411 0.417 0.423 0.428 0.434 0.441 0.447 0.454 0.462 0.469 0.475 0.482 0.49 0.496 0.503 0.508
Migori 0.229 0.237 0.246 0.255 0.262 0.267 0.27 0.274 0.279 0.285 0.287 0.286 0.289 0.296 0.303 0.307 0.315 0.325 0.333 0.344 0.355 0.364 0.372 0.383 0.395 0.404 0.412 0.419
Mombasa 0.396 0.405 0.414 0.422 0.43 0.437 0.443 0.449 0.455 0.461 0.465 0.468 0.471 0.475 0.478 0.481 0.486 0.491 0.496 0.502 0.51 0.517 0.525 0.534 0.543 0.552 0.561 0.568
Murang’a 0.381 0.389 0.396 0.402 0.408 0.413 0.418 0.424 0.429 0.436 0.441 0.444 0.449 0.454 0.46 0.465 0.47 0.476 0.482 0.488 0.494 0.499 0.504 0.51 0.515 0.52 0.524 0.528
Nairobi 0.499 0.506 0.513 0.519 0.525 0.53 0.534 0.539 0.544 0.549 0.553 0.556 0.56 0.566 0.572 0.577 0.585 0.593 0.602 0.611 0.619 0.627 0.634 0.643 0.652 0.66 0.667 0.674
Nakuru 0.337 0.347 0.357 0.367 0.375 0.383 0.389 0.394 0.399 0.405 0.409 0.413 0.417 0.423 0.43 0.436 0.445 0.454 0.464 0.474 0.484 0.493 0.502 0.511 0.521 0.53 0.538 0.545
Nandi 0.323 0.333 0.344 0.354 0.362 0.369 0.375 0.381 0.388 0.394 0.399 0.402 0.406 0.412 0.418 0.422 0.428 0.435 0.441 0.449 0.456 0.462 0.468 0.475 0.483 0.49 0.496 0.501
Narok 0.217 0.225 0.234 0.242 0.25 0.255 0.259 0.264 0.272 0.28 0.284 0.285 0.289 0.297 0.305 0.31 0.318 0.326 0.333 0.342 0.35 0.356 0.362 0.371 0.381 0.389 0.396 0.402
Nyamira 0.361 0.37 0.379 0.387 0.395 0.401 0.406 0.41 0.414 0.419 0.421 0.423 0.426 0.431 0.437 0.443 0.451 0.46 0.468 0.478 0.488 0.496 0.504 0.513 0.523 0.531 0.538 0.544
Nyandarua 0.353 0.361 0.369 0.376 0.382 0.388 0.392 0.397 0.402 0.409 0.413 0.416 0.421 0.428 0.436 0.442 0.449 0.458 0.466 0.475 0.484 0.491 0.498 0.506 0.514 0.521 0.528 0.534
Nyeri 0.407 0.414 0.421 0.427 0.434 0.439 0.444 0.449 0.454 0.459 0.463 0.466 0.47 0.475 0.479 0.484 0.489 0.496 0.502 0.509 0.516 0.522 0.527 0.533 0.539 0.544 0.549 0.554
Samburu 0.205 0.21 0.215 0.221 0.225 0.228 0.23 0.232 0.235 0.239 0.24 0.239 0.24 0.243 0.247 0.249 0.253 0.258 0.262 0.267 0.273 0.277 0.28 0.287 0.294 0.299 0.304 0.308
Siaya 0.227 0.236 0.246 0.255 0.265 0.272 0.279 0.287 0.294 0.303 0.309 0.313 0.318 0.326 0.334 0.34 0.349 0.359 0.368 0.379 0.39 0.4 0.409 0.421 0.432 0.443 0.452 0.46
Taita Taveta 0.352 0.362 0.371 0.38 0.389 0.396 0.403 0.409 0.416 0.422 0.427 0.43 0.434 0.438 0.443 0.447 0.452 0.458 0.464 0.472 0.48 0.487 0.494 0.502 0.509 0.516 0.523 0.529
Tana River 0.231 0.237 0.244 0.25 0.255 0.26 0.263 0.267 0.27 0.274 0.276 0.276 0.278 0.281 0.285 0.288 0.292 0.298 0.304 0.311 0.319 0.326 0.333 0.342 0.353 0.362 0.371 0.379
Tharaka Nithi 0.342 0.35 0.357 0.364 0.371 0.377 0.382 0.387 0.392 0.397 0.402 0.405 0.41 0.417 0.423 0.429 0.437 0.445 0.453 0.463 0.472 0.48 0.488 0.497 0.506 0.514 0.522 0.528
Trans Nzoia 0.318 0.328 0.337 0.346 0.353 0.359 0.363 0.368 0.373 0.38 0.384 0.388 0.392 0.399 0.406 0.411 0.418 0.426 0.433 0.441 0.448 0.454 0.46 0.468 0.477 0.484 0.491 0.496
Turkana 0.211 0.216 0.221 0.226 0.231 0.234 0.237 0.239 0.242 0.245 0.247 0.247 0.248 0.25 0.252 0.252 0.253 0.255 0.257 0.26 0.264 0.266 0.269 0.274 0.281 0.286 0.291 0.295
Uasin Gishu 0.363 0.373 0.382 0.391 0.399 0.405 0.41 0.416 0.421 0.428 0.433 0.436 0.441 0.447 0.453 0.458 0.465 0.472 0.48 0.488 0.496 0.503 0.51 0.517 0.526 0.533 0.539 0.545
Vihiga 0.328 0.337 0.346 0.355 0.362 0.367 0.371 0.374 0.376 0.378 0.378 0.378 0.379 0.382 0.387 0.392 0.399 0.408 0.417 0.427 0.437 0.444 0.45 0.457 0.464 0.469 0.474 0.477
Wajir 0.104 0.111 0.12 0.128 0.136 0.142 0.146 0.151 0.156 0.162 0.165 0.166 0.168 0.172 0.176 0.178 0.181 0.185 0.189 0.195 0.201 0.206 0.21 0.218 0.226 0.233 0.238 0.243
West Pokot 0.213 0.219 0.226 0.233 0.24 0.245 0.249 0.253 0.258 0.265 0.268 0.27 0.274 0.28 0.286 0.291 0.298 0.305 0.312 0.319 0.327 0.333 0.34 0.349 0.359 0.368 0.376 0.382
Madagascar 0.262 0.264 0.265 0.265 0.265 0.265 0.266 0.268 0.27 0.272 0.274 0.278 0.282 0.286 0.291 0.294 0.295 0.295 0.298 0.3 0.302 0.303 0.306 0.31 0.315 0.321 0.326 0.331
Malawi 0.199 0.202 0.204 0.206 0.208 0.212 0.216 0.221 0.225 0.23 0.234 0.238 0.244 0.249 0.256 0.262 0.27 0.279 0.288 0.296 0.305 0.313 0.32 0.327 0.333 0.339 0.345 0.349
Mozambique 0.133 0.135 0.136 0.138 0.14 0.142 0.147 0.154 0.162 0.169 0.175 0.182 0.189 0.197 0.206 0.215 0.224 0.235 0.246 0.257 0.268 0.279 0.29 0.301 0.311 0.322 0.332 0.34
Rwanda 0.267 0.269 0.272 0.274 0.268 0.267 0.269 0.272 0.276 0.28 0.284 0.29 0.297 0.304 0.311 0.319 0.327 0.334 0.342 0.349 0.356 0.363 0.371 0.378 0.386 0.393 0.401 0.407
Somalia 0.153 0.156 0.157 0.159 0.16 0.161 0.162 0.163 0.163 0.164 0.165 0.167 0.169 0.172 0.176 0.179 0.183 0.188 0.193 0.198 0.203 0.208 0.212 0.217 0.222 0.227 0.231 0.235
South Sudan 0.179 0.18 0.182 0.183 0.184 0.186 0.187 0.189 0.191 0.194 0.197 0.2 0.204 0.207 0.211 0.215 0.22 0.225 0.229 0.234 0.239 0.244 0.249 0.254 0.259 0.265 0.27 0.275
Tanzania 0.275 0.28 0.285 0.289 0.291 0.294 0.297 0.3 0.304 0.307 0.311 0.315 0.32 0.325 0.33 0.334 0.339 0.344 0.35 0.355 0.36 0.366 0.373 0.381 0.388 0.397 0.405 0.412
Uganda 0.163 0.164 0.166 0.169 0.173 0.178 0.185 0.193 0.202 0.212 0.222 0.232 0.243 0.254 0.265 0.276 0.287 0.298 0.31 0.32 0.33 0.339 0.348 0.357 0.366 0.374 0.382 0.388
Zambia 0.312 0.314 0.316 0.319 0.321 0.324 0.326 0.329 0.332 0.335 0.338 0.343 0.348 0.353 0.358 0.365 0.373 0.382 0.392 0.402 0.412 0.421 0.431 0.44 0.449 0.458 0.466 0.472
Southern sub-Saharan Africa 0.521 0.525 0.53 0.535 0.539 0.543 0.546 0.55 0.555 0.56 0.565 0.569 0.574 0.578 0.582 0.585 0.59 0.596 0.603 0.607 0.612 0.616 0.619 0.622 0.627 0.633 0.637 0.64
Botswana 0.463 0.473 0.483 0.492 0.501 0.509 0.517 0.524 0.532 0.539 0.546 0.553 0.56 0.567 0.574 0.581 0.588 0.597 0.605 0.612 0.619 0.626 0.633 0.639 0.646 0.652 0.658 0.663
Lesotho 0.333 0.34 0.347 0.354 0.362 0.369 0.376 0.383 0.389 0.396 0.402 0.407 0.413 0.417 0.422 0.426 0.431 0.436 0.441 0.446 0.452 0.458 0.464 0.47 0.476 0.482 0.488 0.493
Namibia 0.454 0.459 0.465 0.471 0.477 0.483 0.489 0.495 0.501 0.507 0.512 0.516 0.521 0.525 0.53 0.534 0.54 0.546 0.552 0.558 0.565 0.572 0.579 0.587 0.595 0.603 0.61 0.616
South Africa 0.557 0.56 0.565 0.57 0.574 0.576 0.579 0.583 0.587 0.593 0.598 0.602 0.607 0.611 0.615 0.619 0.624 0.631 0.639 0.644 0.649 0.653 0.655 0.658 0.664 0.669 0.674 0.677
Swaziland 0.426 0.435 0.444 0.452 0.459 0.466 0.473 0.478 0.483 0.489 0.494 0.499 0.503 0.508 0.513 0.518 0.523 0.528 0.533 0.538 0.543 0.547 0.552 0.557 0.563 0.569 0.574 0.578
Zimbabwe 0.408 0.417 0.424 0.43 0.436 0.44 0.446 0.45 0.453 0.456 0.457 0.459 0.458 0.456 0.453 0.449 0.443 0.438 0.43 0.426 0.424 0.425 0.43 0.436 0.444 0.451 0.458 0.463
Western sub-Saharan Africa 0.293 0.296 0.299 0.303 0.306 0.309 0.313 0.316 0.32 0.324 0.328 0.333 0.337 0.343 0.35 0.357 0.365 0.373 0.381 0.389 0.396 0.403 0.411 0.417 0.424 0.43 0.437 0.441
Benin 0.218 0.223 0.228 0.233 0.238 0.243 0.248 0.253 0.258 0.263 0.268 0.273 0.278 0.284 0.29 0.296 0.301 0.307 0.313 0.32 0.326 0.332 0.338 0.345 0.353 0.36 0.367 0.373
Burkina Faso 0.139 0.143 0.147 0.151 0.154 0.158 0.163 0.168 0.173 0.179 0.184 0.19 0.195 0.201 0.208 0.214 0.22 0.226 0.232 0.237 0.242 0.248 0.253 0.259 0.266 0.272 0.279 0.284
Cameroon 0.332 0.338 0.343 0.347 0.35 0.352 0.355 0.357 0.359 0.36 0.361 0.361 0.361 0.362 0.366 0.373 0.38 0.388 0.396 0.405 0.414 0.423 0.433 0.443 0.453 0.464 0.474 0.482
Cape Verde 0.307 0.315 0.322 0.329 0.337 0.347 0.357 0.367 0.377 0.387 0.399 0.41 0.42 0.431 0.441 0.451 0.461 0.472 0.482 0.491 0.5 0.509 0.517 0.524 0.531 0.538 0.544 0.549
Chad 0.119 0.123 0.128 0.131 0.135 0.138 0.141 0.144 0.146 0.148 0.15 0.152 0.154 0.156 0.161 0.166 0.171 0.178 0.185 0.192 0.2 0.207 0.216 0.224 0.232 0.24 0.248 0.253
Cote d'Ivoire 0.273 0.28 0.287 0.292 0.297 0.301 0.306 0.312 0.317 0.322 0.326 0.33 0.334 0.338 0.342 0.346 0.349 0.353 0.357 0.361 0.367 0.371 0.377 0.384 0.391 0.398 0.406 0.412
The Gambia 0.245 0.251 0.257 0.263 0.269 0.275 0.282 0.288 0.294 0.3 0.307 0.314 0.319 0.325 0.332 0.338 0.343 0.349 0.355 0.361 0.367 0.372 0.378 0.384 0.389 0.395 0.401 0.405
Ghana 0.38 0.386 0.392 0.396 0.4 0.403 0.408 0.413 0.416 0.418 0.422 0.425 0.43 0.435 0.439 0.443 0.45 0.459 0.467 0.474 0.482 0.49 0.498 0.505 0.513 0.521 0.53 0.537
Guinea 0.164 0.168 0.171 0.175 0.178 0.183 0.188 0.194 0.2 0.206 0.211 0.217 0.222 0.228 0.234 0.24 0.246 0.252 0.26 0.266 0.273 0.281 0.288 0.295 0.303 0.31 0.318 0.325
Guinea-Bissau 0.183 0.189 0.194 0.199 0.205 0.211 0.217 0.224 0.229 0.235 0.241 0.246 0.252 0.257 0.263 0.268 0.274 0.28 0.286 0.293 0.3 0.308 0.315 0.322 0.329 0.336 0.343 0.349
Liberia 0.207 0.209 0.21 0.206 0.199 0.19 0.178 0.174 0.175 0.183 0.198 0.214 0.228 0.234 0.239 0.245 0.251 0.257 0.264 0.27 0.276 0.284 0.292 0.301 0.31 0.318 0.324 0.328
Mali 0.13 0.134 0.137 0.141 0.145 0.148 0.152 0.157 0.161 0.166 0.171 0.176 0.181 0.187 0.192 0.198 0.203 0.209 0.215 0.22 0.226 0.232 0.238 0.243 0.249 0.255 0.262 0.267
Mauritania 0.299 0.307 0.314 0.321 0.328 0.335 0.341 0.346 0.351 0.356 0.359 0.363 0.367 0.371 0.377 0.382 0.39 0.398 0.406 0.412 0.42 0.427 0.435 0.442 0.45 0.458 0.465 0.471
Niger 0.092 0.097 0.101 0.105 0.108 0.111 0.113 0.115 0.118 0.121 0.123 0.125 0.127 0.13 0.134 0.137 0.14 0.144 0.147 0.151 0.156 0.16 0.165 0.17 0.176 0.181 0.186 0.191
Nigeria 0.344 0.346 0.347 0.349 0.352 0.355 0.358 0.362 0.365 0.369 0.374 0.379 0.385 0.391 0.4 0.41 0.419 0.429 0.437 0.445 0.452 0.459 0.466 0.473 0.478 0.484 0.49 0.493
Sao Tome and Principe 0.287 0.292 0.296 0.3 0.305 0.309 0.314 0.32 0.326 0.332 0.338 0.345 0.353 0.362 0.371 0.381 0.39 0.399 0.408 0.416 0.426 0.435 0.444 0.453 0.463 0.472 0.481 0.488
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Senegal 0.244 0.25 0.257 0.262 0.267 0.272 0.277 0.281 0.286 0.291 0.295 0.299 0.303 0.307 0.311 0.316 0.319 0.324 0.328 0.333 0.338 0.342 0.347 0.352 0.357 0.362 0.368 0.373
Sierra Leone 0.202 0.205 0.207 0.211 0.216 0.219 0.222 0.225 0.226 0.228 0.23 0.233 0.238 0.244 0.249 0.256 0.262 0.27 0.278 0.286 0.294 0.302 0.312 0.325 0.336 0.344 0.351 0.357
Togo 0.263 0.27 0.276 0.281 0.286 0.292 0.297 0.303 0.307 0.311 0.315 0.318 0.321 0.325 0.329 0.333 0.337 0.343 0.348 0.353 0.36 0.366 0.373 0.381 0.39 0.398 0.406 0.413
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